Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Habitual
Association between PD-1/PD-L1 and T regulate cells in early recurrent miscarriage.
Abortion, Spontaneous
Expression and significance of PD-1 and PD-L1 in patients with recurrent spontaneous abortion: A protocol for systematic review and meta-analysis.
Abortion, Spontaneous
Immunization with BLS-Stx2B chimera totally protects dams from early pregnancy loss induced by Shiga toxin type 2 (Stx2) and confers anti-Stx2 immunity to the offspring.
Abortion, Spontaneous
Involvement of hypoxia and inflammation in early pregnancy loss mediated by Shiga toxin type 2.
Abortion, Spontaneous
Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway.
Acidosis
Cellular Localization of Acid-Sensing Ion Channel 1 in Rat Nucleus Tractus Solitarii.
Acquired Immunodeficiency Syndrome
A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents.
Acquired Immunodeficiency Syndrome
Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors.
Acquired Immunodeficiency Syndrome
Brain-Resident T Cells Following Viral Infection.
Acquired Immunodeficiency Syndrome
Comparative lectinhistochemical studies on paraffin- and glycol methacrylate-embedded CNS tissue specimens from AIDS autopsies. Mistletoe lectin I (ML I) as cell-marker.
Acquired Immunodeficiency Syndrome
Differential Molecular Expression Patterns Associated with Metastasis in Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Acquired Immunodeficiency Syndrome
Emerging enteropathogenic Escherichia coli strains?
Acquired Immunodeficiency Syndrome
Engineering of a mini-trichosanthin that has lower antigenicity by deleting its C-terminal amino acid residues.
Acquired Immunodeficiency Syndrome
Immunocytochemical identification of T-cells in HIV-1 encephalitis: implications for pathogenesis of CNS disease.
Acquired Immunodeficiency Syndrome
Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type.
Acquired Immunodeficiency Syndrome
Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection.
Acquired Immunodeficiency Syndrome
Spectroscopic characterization of gelonin--assignments secondary structure and thermal denaturation.
Acquired Immunodeficiency Syndrome
The anti-viral protein of trichosanthin penetrates into human immunodeficiency virus type 1.
Acquired Immunodeficiency Syndrome
The complete amino acid sequence of an abortifacient protein, karasurin.
Acquired Immunodeficiency Syndrome
Trichosanthin treatment of HIV-induced immune dysregulation.
Acquired Immunodeficiency Syndrome
Truncations of gelonin lead to a reduction in its cytotoxicity.
Acquired Immunodeficiency Syndrome
X-ray structure of gelonin at 1.8 A resolution.
Acute Coronary Syndrome
Expression of coinhibitory PD-L1 on CD4?CD25?FOXP3? regulatory T cells is elevated in patients with acute coronary syndrome.
Acute Kidney Injury
Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
Acute Kidney Injury
Acute renal failure and proximal tubule lesions after trichosanthin injection in rats.
Acute Kidney Injury
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Acute Kidney Injury
Characterisation of STEC and other diarrheic E. coli isolated on CHROMagarSTEC at a tertiary referral hospital, Cape Town.
Acute Kidney Injury
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
Acute Kidney Injury
Chemokine Receptor CCR1 Disruption Limits Renal Damage in a Murine Model of Hemolytic Uremic Syndrome.
Acute Kidney Injury
Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Acute Kidney Injury
Crosstalk between Human Microvascular Endothelial Cells and Tubular Epithelial Cells Modulates Pro-Inflammatory Responses Induced by Shiga Toxin Type 2 and Subtilase Cytotoxin.
Acute Kidney Injury
Detection of Shiga-Like Toxin-Producing Escherichia coli in Ground Beef and Milk by Commercial Enzyme Immunoassay.
Acute Kidney Injury
Development and Evaluation of a Novel VHH-Based Immunocapture Assay for High-Sensitivity Detection of Shiga Toxin Type 2 (Stx2) in Stool Samples.
Acute Kidney Injury
Development and Validation of Shiga Toxin-Producing Escherichia coli Immunodiagnostic Assay.
Acute Kidney Injury
Development of a Mouse Model of Shiga Toxin 2 (STX2) Intoxication for Testing Therapeutic Agents against Hemolytic Uremic Syndrome (HUS).
Acute Kidney Injury
Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines.
Acute Kidney Injury
Effects of Escherichia coli subtilase cytotoxin and Shiga toxin 2 on primary cultures of human renal tubular epithelial cells.
Acute Kidney Injury
Effects of shiga toxin 2 on cellular regeneration mechanisms in primary and three-dimensional cultures of human renal tubular epithelial cells.
Acute Kidney Injury
Genetic makeup of Shiga toxin-producing Escherichia coli in relation to clinical symptoms and duration of shedding: a microarray analysis of isolates from Swedish children.
Acute Kidney Injury
Genetics of hemolytic uremic syndromes.
Acute Kidney Injury
Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo.
Acute Kidney Injury
Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls.
Acute Kidney Injury
Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.
Acute Kidney Injury
Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Acute Kidney Injury
Ingested Shiga Toxin 2 (Stx2) Causes Histopathological Changes in Kidney, Spleen, and Thymus Tissues and Mortality in Mice.
Acute Kidney Injury
Interactions between Shiga toxins and human polymorphonuclear leukocytes.
Acute Kidney Injury
Involvement of high-mobility group box 1 in the pathogenesis of severe hemolytic uremic syndrome in a murine model.
Acute Kidney Injury
Is immune cell activation the missing link in the pathogenesis of post-diarrhoeal HUS?
Acute Kidney Injury
Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice.
Acute Kidney Injury
Lactate up-regulates the expression of PD-L1 in kidney and causes immunosuppression in septic Acute Renal Injury.
Acute Kidney Injury
Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report.
Acute Kidney Injury
Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.
Acute Kidney Injury
Norovirus: a novel etiologic agent in hemolytic uremic syndrome in an infant.
Acute Kidney Injury
Ouabain Protects against Shiga Toxin-Triggered Apoptosis by Reversing the Imbalance between Bax and Bcl-xL.
Acute Kidney Injury
Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1.
Acute Kidney Injury
Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.
Acute Kidney Injury
Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.
Acute Kidney Injury
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
Acute Kidney Injury
Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome.
Acute Kidney Injury
Shiga toxin associated hemolytic uremic syndrome.
Acute Kidney Injury
Shiga toxin binds to activated platelets.
Acute Kidney Injury
Shiga toxin of enterohemorrhagic Escherichia coli type O157:H7 promotes intestinal colonization.
Acute Kidney Injury
Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
Acute Kidney Injury
Shiga toxin-1 affects nitric oxide production by human glomerular endothelial and mesangial cells.
Acute Kidney Injury
Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1.
Acute Kidney Injury
Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.
Acute Kidney Injury
Shiga toxin-induced tumor necrosis factor alpha expression: requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases.
Acute Kidney Injury
Shiga Toxin-Producing Escherichia coli in Diarrheal Stool of Swedish Children: Evaluation of Polymerase Chain Reaction Screening and Duration of Shiga Toxin Shedding.
Acute Kidney Injury
Shiga toxin-producing Escherichia coli O157:H7 show an increased pathogenicity in mice after the passage through the gastrointestinal tract of the same host.
Acute Kidney Injury
The A1 Subunit of Shiga Toxin 2 Has Higher Affinity for Ribosomes and Higher Catalytic Activity than the A1 Subunit of Shiga Toxin 1.
Acute Kidney Injury
The MAP kinase-activated protein kinase 2 (MK2) contributes to the Shiga toxin-induced inflammatory response.
Acute Kidney Injury
The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome.
Acute Kidney Injury
The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury.
Acute Kidney Injury
Treatment options for HUS secondary to Escherichia coli O157:H7.
Acute Kidney Injury
Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin.
Acute Kidney Injury
Usefulness of serum fibrinogen degradation product-E in sporadic cases of classical hemolytic uremic syndrome.
Acute Lung Injury
BLOCKADE OF ENDOTHELIAL, BUT NOT EPITHELIAL, CELL EXPRESSION OF PD-L1 FOLLOWING SEVERE SHOCK ATTENUATES THE DEVELOPMENT OF INDIRECT ACUTE LUNG INJURY IN MICE.
Acute Lung Injury
Mice with induced pulmonary morbidities display severe lung inflammation and mortality following exposure to SARS-CoV-2.
Acute Lung Injury
Proinflammatory responses of human airway cells to ricin involve stress-activated protein kinases and NF-kappaB.
Acute Lung Injury
Pulmonary inflammation triggered by ricin toxin requires macrophages and IL-1 signaling.
Acute Lung Injury
[Blockade of programmed death-ligand 1 attenuates indirect acute lung injury in mice through targeting endothelial cells but not epithelial cells].
adamts13 endopeptidase deficiency
Hemolytic uremic syndrome with Mycoplasma pneumoniae infection and membrane cofactor protein mutation case report.
adamts13 endopeptidase deficiency
The thrombotic microangiopathies.
Addison Disease
Programmed Death Ligand 1 (PD-L1) Gene Variants Contribute to Autoimmune Addison's Disease and Graves' Disease Susceptibility.
Adenocarcinoma
2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
Adenocarcinoma
A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
Adenocarcinoma
A case of severe Pembrolizumab-induced neutropenia.
Adenocarcinoma
A Mismatch Repair-Deficient Hepatoid Adenocarcinoma of the Lung Responding to Anti-PD-L1 Durvalumab Therapy Despite no PD-L1 Expression.
Adenocarcinoma
A novel case of endometrial dedifferentiated adenocarcinoma associated with MLH1 promotor hypermethylation and microsatellite instability.
Adenocarcinoma
A Rare Case of Moderately Differentiated Adenocarcinoma With PD-L1 Overexpression and a Heterogeneous LELC Component in the Ascending Colon.
Adenocarcinoma
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Adenocarcinoma
A Space-Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer?
Adenocarcinoma
A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.
Adenocarcinoma
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Adenocarcinoma
Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
Adenocarcinoma
Analysis of PD-L1 expression in trophoblastic tissues and tumors.
Adenocarcinoma
Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
Adenocarcinoma
Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.
Adenocarcinoma
Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.
Adenocarcinoma
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Adenocarcinoma
Association of histologic subtypes with genetic alteration and PD-L1 expression in pulmonary adenocarcinoma.
Adenocarcinoma
Association of Immunostaining of Galectin-3 and Sambucus nigra Agglutinin with Invasion, Metastasis and Poor Progression of Gallbladder Adenocarcinoma.
Adenocarcinoma
Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.
Adenocarcinoma
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Adenocarcinoma
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Adenocarcinoma
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation.
Adenocarcinoma
Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation.
Adenocarcinoma
Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Adenocarcinoma
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-? and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
Adenocarcinoma
Carcinosarcoma of the prostate: case report with molecular and histological characterization.
Adenocarcinoma
Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.
Adenocarcinoma
CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma.
Adenocarcinoma
Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.
Adenocarcinoma
Changes in the therapeutic landscape of oesophago-gastric cancers.
Adenocarcinoma
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression.
Adenocarcinoma
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Adenocarcinoma
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Adenocarcinoma
Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Adenocarcinoma
Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Adenocarcinoma
Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.
Adenocarcinoma
Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma.
Adenocarcinoma
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
Adenocarcinoma
Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
Adenocarcinoma
Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Adenocarcinoma
Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.
Adenocarcinoma
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
Adenocarcinoma
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Adenocarcinoma
Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.
Adenocarcinoma
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
Adenocarcinoma
Comparative cytotoxicity of purified Shiga-like toxin-IIe on porcine and bovine aortic endothelial and human colonic adenocarcinoma cells.
Adenocarcinoma
Comparison of growth inhibition of a human ovarian adenocarcinoma cell line by free monoclonal antibodies and their corresponding antibody-recombinant ricin A chain immunotoxins.
Adenocarcinoma
Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens.
Adenocarcinoma
Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.
Adenocarcinoma
Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores.
Adenocarcinoma
Comprehensive evaluation of PD-L1 expression in primary and metastatic prostate cancer.
Adenocarcinoma
Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component.
Adenocarcinoma
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Adenocarcinoma
Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer.
Adenocarcinoma
Correction: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability.
Adenocarcinoma
Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort.
Adenocarcinoma
Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.
Adenocarcinoma
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?
Adenocarcinoma
Critical appraisal of PD-L1 reflex diagnostic testing: current standards and future opportunities.
Adenocarcinoma
Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-? signalling pathway.
Adenocarcinoma
Cutaneous Toxicity After Chemoradiotherapy and PD-L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye.
Adenocarcinoma
Cyclic AMP-response element regulated cell cycle arrests in cancer cells.
Adenocarcinoma
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
Adenocarcinoma
Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater.
Adenocarcinoma
Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Adenocarcinoma
EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Adenocarcinoma
Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo.
Adenocarcinoma
Effects of gelonin immunoconjugate of monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vitro.
Adenocarcinoma
Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
Adenocarcinoma
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1? and STAT3.
Adenocarcinoma
Endoscopic Ultrasound-Guided Fine-Needle Biopsies From Pancreatic Ductal Adenocarcinomas Can Be Used to Quantify PD-L1.
Adenocarcinoma
Enhancement of the cytotoxic effect of anti-carcinoembryonic antigen immunotoxins by adenovirus and carboxylic ionophores.
Adenocarcinoma
Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma.
Adenocarcinoma
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.
Adenocarcinoma
Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Adenocarcinoma
Evidence that dysplasia related microRNAs in Barrett's esophagus target PD-L1 expression and contribute to the development of esophageal adenocarcinoma.
Adenocarcinoma
Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor.
Adenocarcinoma
Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer.
Adenocarcinoma
Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.
Adenocarcinoma
Expression of PD-L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion.
Adenocarcinoma
Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Adenocarcinoma
Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung.
Adenocarcinoma
Expression of PD-L1, cancer stem cell and epithelial-mesenchymal transition phenotype in non-small cell lung cancer.
Adenocarcinoma
Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
Adenocarcinoma
Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma.
Adenocarcinoma
Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Adenocarcinoma
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Adenocarcinoma
Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.
Adenocarcinoma
Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma.
Adenocarcinoma
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Adenocarcinoma
Free alpha subunits of glycoprotein hormone with dissimilar carbohydrates produced by pathologically different carcinomas.
Adenocarcinoma
Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Adenocarcinoma
Gastric adenocarcinomas express the glycosphingolipid Gb3/CD77: Targeting of gastric cancer cells with Shiga toxin B-subunit.
Adenocarcinoma
Gastrointestinal tract metastasis of lung cancer: The PD-L1 expression and correlated clinicopathological variables.
Adenocarcinoma
Genomic Characteristics of Invasive Mucinous Adenocarcinomas of the Lung and Potential Therapeutic Targets of B7-H3.
Adenocarcinoma
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early-Invasive Lung Adenocarcinoma.
Adenocarcinoma
GNG12 regulates PD-L1 expression by activating NF-?B signaling in pancreatic ductal adenocarcinoma.
Adenocarcinoma
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
Adenocarcinoma
Hepatoid adenocarcinoma of lung: A diagnostic challenge - Series of six cases with histopathological, predictive molecular and PD.L1 assessment.
Adenocarcinoma
Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas.
Adenocarcinoma
Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas.
Adenocarcinoma
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.
Adenocarcinoma
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
Adenocarcinoma
High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
Adenocarcinoma
High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas.
Adenocarcinoma
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Adenocarcinoma
Histopathological Subtypes and PD-L1 Expression in Primary Urethral Adenocarcinoma: A Series of 5 Cases.
Adenocarcinoma
Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Adenocarcinoma
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Co-expression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung.
Adenocarcinoma
Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC.
Adenocarcinoma
Identification of a human pancreatic duct tissue-specific antigen.
Adenocarcinoma
Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.
Adenocarcinoma
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.
Adenocarcinoma
Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Adenocarcinoma
Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis.
Adenocarcinoma
Immune Microenvironment in Gallbladder Adenocarcinomas.
Adenocarcinoma
Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities.
Adenocarcinoma
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Adenocarcinoma
Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Adenocarcinoma
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
Adenocarcinoma
In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.
Adenocarcinoma
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Adenocarcinoma
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Adenocarcinoma
Induced apoptotic action of recombinant trichosanthin in human stomach adenocarcinoma MCG803 cells.
Adenocarcinoma
Induction of T cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma.
Adenocarcinoma
Inhibition of human tumor growth by intraperitoneal immunotoxins in nude mice.
Adenocarcinoma
Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer.
Adenocarcinoma
Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer.
Adenocarcinoma
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Adenocarcinoma
Intratumoral Heterogeneity in PD-L1 Immunoreactivity is Associated with Variation in Non-Small Cell Lung Carcinoma Histotype.
Adenocarcinoma
Lectin histochemistry of resected adenocarcinoma of the lung: helix pomatia agglutinin binding is an independent prognostic factor.
Adenocarcinoma
Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice.
Adenocarcinoma
Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis.
Adenocarcinoma
Lymph nodes may be a source for immunetherapy in gastric cancer.
Adenocarcinoma
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.
Adenocarcinoma
miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Adenocarcinoma
Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features.
Adenocarcinoma
Molecular Characterization of Appendiceal Goblet Cell Carcinoid.
Adenocarcinoma
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Adenocarcinoma
Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report.
Adenocarcinoma
Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
Adenocarcinoma
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Adenocarcinoma
Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Adenocarcinoma
Novel mechanism of immune evasion in cancer via structural variations of the PD-L1 gene.
Adenocarcinoma
Pancreatic undifferentiated carcinoma with osteoclast-like giant cells curatively resected after pembrolizumab therapy for lung metastases: a case report.
Adenocarcinoma
Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.
Adenocarcinoma
Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability.
Adenocarcinoma
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
Adenocarcinoma
PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.
Adenocarcinoma
PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma.
Adenocarcinoma
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Adenocarcinoma
PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
Adenocarcinoma
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.
Adenocarcinoma
PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate.
Adenocarcinoma
PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Adenocarcinoma
PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
Adenocarcinoma
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Adenocarcinoma
PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions.
Adenocarcinoma
PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-? leads to poor pancreatic cancer prognosis.
Adenocarcinoma
PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival.
Adenocarcinoma
PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes.
Adenocarcinoma
PD-L1 expression in gastroesophageal dysplastic lesions.
Adenocarcinoma
PD-L1 expression in HPV-independent cervical adenocarcinoma and its prognostic significance.
Adenocarcinoma
PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
Adenocarcinoma
PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study.
Adenocarcinoma
PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component.
Adenocarcinoma
PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Adenocarcinoma
PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.
Adenocarcinoma
PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy.
Adenocarcinoma
PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung.
Adenocarcinoma
PD-L1 expression increased by IFN-? via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer.
Adenocarcinoma
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Adenocarcinoma
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.
Adenocarcinoma
PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
Adenocarcinoma
PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.
Adenocarcinoma
PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay.
Adenocarcinoma
PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability.
Adenocarcinoma
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Adenocarcinoma
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
Adenocarcinoma
PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry.
Adenocarcinoma
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Adenocarcinoma
PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions.
Adenocarcinoma
PD-L1 promotes tumor growth and progression by activating WIP and ?-catenin signaling pathways and predicts poor prognosis in lung cancer.
Adenocarcinoma
PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
Adenocarcinoma
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Adenocarcinoma
Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report.
Adenocarcinoma
Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma.
Adenocarcinoma
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
Adenocarcinoma
Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics.
Adenocarcinoma
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
Adenocarcinoma
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Adenocarcinoma
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.
Adenocarcinoma
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Adenocarcinoma
Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma.
Adenocarcinoma
Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma.
Adenocarcinoma
Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
Adenocarcinoma
Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Adenocarcinoma
Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
Adenocarcinoma
Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Adenocarcinoma
Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
Adenocarcinoma
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
Adenocarcinoma
Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Adenocarcinoma
Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
Adenocarcinoma
Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Adenocarcinoma
Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma.
Adenocarcinoma
Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer.
Adenocarcinoma
Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Adenocarcinoma
Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.
Adenocarcinoma
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Adenocarcinoma
Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC.
Adenocarcinoma
Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in colorectal adenocarcinoma.
Adenocarcinoma
Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.
Adenocarcinoma
Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer.
Adenocarcinoma
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Adenocarcinoma
Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
Adenocarcinoma
Relationship Between Tumor Immune Markers and Fluorine-18-?-Methyltyrosine ([18F]FAMT) Uptake in Patients with Lung Cancer.
Adenocarcinoma
Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma.
Adenocarcinoma
Response to: 'Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma'.
Adenocarcinoma
Retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients.
Adenocarcinoma
Riproximin Exhibits Diversity in Sugar Binding, and Modulates some Metastasis-Related Proteins with Lectin like Properties in Pancreatic Ductal Adenocarcinoma.
Adenocarcinoma
Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL.
Adenocarcinoma
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.
Adenocarcinoma
Role of TGF-? in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Adenocarcinoma
Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors.
Adenocarcinoma
Shiga toxin glycosphingolipid receptor expression and toxin susceptibility of human pancreatic ductal adenocarcinomas of differing origin and differentiation.
Adenocarcinoma
Small heterodimer partner as a predictor of neoadjuvant radiochemotherapy response and survival in patients with rectal cancer: A preliminary study.
Adenocarcinoma
Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy.
Adenocarcinoma
STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNF? mediated immune responses in a model of NSCLC.
Adenocarcinoma
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Adenocarcinoma
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
Adenocarcinoma
The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.
Adenocarcinoma
The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma.
Adenocarcinoma
The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.
Adenocarcinoma
The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Adenocarcinoma
The emerging role of immunotherapy for esophageal cancer.
Adenocarcinoma
The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
Adenocarcinoma
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Adenocarcinoma
The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?
Adenocarcinoma
The PD-L1 metabolic interactome intersects with choline metabolism and inflammation.
Adenocarcinoma
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.
Adenocarcinoma
The prognostic effect of neoadjuvant chemoradiotherapy on the change of PD-L1 expression in patients with locally advanced rectal adenocarcinoma.
Adenocarcinoma
The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis.
Adenocarcinoma
The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
Adenocarcinoma
The role of genetic polymorphism within PD-L1 gene in cancer. Review.
Adenocarcinoma
The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma.
Adenocarcinoma
The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation.
Adenocarcinoma
Tissue and Blood Biomarkers in Lung Cancer: A Review.
Adenocarcinoma
Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ? 50.
Adenocarcinoma
Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma.
Adenocarcinoma
Tumor-specific targeting of pancreatic cancer with Shigatoxin B-subunit.
Adenocarcinoma
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Adenocarcinoma
Update on Immunohistochemistry for the Diagnosis of Lung Cancer.
Adenocarcinoma
[Concomitant use of nivolumab and immunosuppressants in a renal transplant patient].
Adenocarcinoma
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Adenocarcinoma
[Glycoproteins associated with metastatic potential of cancer]
Adenocarcinoma
[New molecular classification of colorectal cancer, pancreatic cancer and stomach cancer: Towards "à la carte" treatment?].
Adenocarcinoma
[Ribosome Inactivation and the Integrity of the Intestinal Epithelial Barrier].
Adenocarcinoma in Situ
Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma.
Adenocarcinoma of Lung
A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma.
Adenocarcinoma of Lung
A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas.
Adenocarcinoma of Lung
A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.
Adenocarcinoma of Lung
A Positive Correlation Between the EZH2 and PD-L1 Expression in Resected Lung Adenocarcinomas.
Adenocarcinoma of Lung
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.
Adenocarcinoma of Lung
A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.
Adenocarcinoma of Lung
About PD-L1 Immunohistochemistry and RNA In Situ Hybridization in Lung Adenocarcinoma.
Adenocarcinoma of Lung
Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Adenocarcinoma of Lung
Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients.
Adenocarcinoma of Lung
An orally active galectin-3 antagonist inhibits lung adenocarcinoma growth and augments response to PD-L1 blockade.
Adenocarcinoma of Lung
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Adenocarcinoma of Lung
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Adenocarcinoma of Lung
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Adenocarcinoma of Lung
Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Adenocarcinoma of Lung
B7-H4 and HHLA2, members of B7 family, are aberrantly expressed in EGFR mutated lung adenocarcinoma.
Adenocarcinoma of Lung
Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Adenocarcinoma of Lung
Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers.
Adenocarcinoma of Lung
Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma.
Adenocarcinoma of Lung
CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma.
Adenocarcinoma of Lung
Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma.
Adenocarcinoma of Lung
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
Adenocarcinoma of Lung
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Adenocarcinoma of Lung
Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression.
Adenocarcinoma of Lung
Clinical importance of VEGFC and PD-L1 co-expression in lung adenocarcinoma patients.
Adenocarcinoma of Lung
Clinical significance of PD-L1 expression in patients with surgically resected non-small cell lung cancer.
Adenocarcinoma of Lung
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Adenocarcinoma of Lung
Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
Adenocarcinoma of Lung
Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Adenocarcinoma of Lung
Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Adenocarcinoma of Lung
Comparative expression analysis of PD-1, PD-L1, and CD8A in lung adenocarcinoma.
Adenocarcinoma of Lung
Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas.
Adenocarcinoma of Lung
Complete Response Achieved 1 Year after a Single Administration of Nivolumab in a Patient with Lung Adenocarcinoma with Negative Expression of PD-L1.
Adenocarcinoma of Lung
Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component.
Adenocarcinoma of Lung
Computed Tomography Features of Lung Adenocarcinomas With Programmed Death Ligand 1 Expression.
Adenocarcinoma of Lung
Construction of an anti-programmed death-ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells.
Adenocarcinoma of Lung
Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report.
Adenocarcinoma of Lung
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Adenocarcinoma of Lung
Correction: PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma.
Adenocarcinoma of Lung
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma.
Adenocarcinoma of Lung
Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma.
Adenocarcinoma of Lung
Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma.
Adenocarcinoma of Lung
Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA In Situ Hybridization.
Adenocarcinoma of Lung
Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma.
Adenocarcinoma of Lung
Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer.
Adenocarcinoma of Lung
Differential expression of PD-L1 and IDO1 in association with the immune microenvironment in resected lung adenocarcinomas.
Adenocarcinoma of Lung
Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27kip1 /CDK4 axis in non-small cell lung cancer.
Adenocarcinoma of Lung
Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.
Adenocarcinoma of Lung
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report.
Adenocarcinoma of Lung
Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.
Adenocarcinoma of Lung
Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
Adenocarcinoma of Lung
Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.
Adenocarcinoma of Lung
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.
Adenocarcinoma of Lung
Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case report.
Adenocarcinoma of Lung
Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma.
Adenocarcinoma of Lung
Exploring a Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells.
Adenocarcinoma of Lung
Expression of AKT and p-AKT protein in lung adenocarcinoma and its correlation with PD-L1 protein and prognosis.
Adenocarcinoma of Lung
Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
Adenocarcinoma of Lung
Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.
Adenocarcinoma of Lung
FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Adenocarcinoma of Lung
Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1.
Adenocarcinoma of Lung
Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Adenocarcinoma of Lung
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Adenocarcinoma of Lung
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Adenocarcinoma of Lung
Ginsenoside Rh2 improves the cisplatin anti-tumor effect in lung adenocarcinoma A549 cells via superoxide and PD-L1.
Adenocarcinoma of Lung
Ginsenoside Rk1 induces apoptosis and downregulates the expression of PD-L1 by targeting the NF-?B pathway in lung adenocarcinoma.
Adenocarcinoma of Lung
Hepatoid adenocarcinoma of lung: A diagnostic challenge - Series of six cases with histopathological, predictive molecular and PD.L1 assessment.
Adenocarcinoma of Lung
Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas.
Adenocarcinoma of Lung
Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
Adenocarcinoma of Lung
Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
Adenocarcinoma of Lung
High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma.
Adenocarcinoma of Lung
High expression of programmed cell death 1 ligand 1 in lung adenocarcinoma is a poor prognostic factor particularly in smokers and wild-type epidermal growth-factor receptor cases.
Adenocarcinoma of Lung
High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas.
Adenocarcinoma of Lung
High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.
Adenocarcinoma of Lung
High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy.
Adenocarcinoma of Lung
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Adenocarcinoma of Lung
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Co-expression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung.
Adenocarcinoma of Lung
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.
Adenocarcinoma of Lung
Identification of chemical compounds regulating PD-L1 by introducing HiBiT-tagged cells.
Adenocarcinoma of Lung
Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma.
Adenocarcinoma of Lung
Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.
Adenocarcinoma of Lung
Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
Adenocarcinoma of Lung
Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma.
Adenocarcinoma of Lung
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Adenocarcinoma of Lung
Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Adenocarcinoma of Lung
Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.
Adenocarcinoma of Lung
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Adenocarcinoma of Lung
Is there any correlation between spectral CT imaging parameters and PD-L1 expression of lung adenocarcinoma?
Adenocarcinoma of Lung
Knockdown of CDK5 down-regulates PD-L1 via the ubiquitination-proteasome pathway and improves antitumor immunity in lung adenocarcinoma.
Adenocarcinoma of Lung
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Adenocarcinoma of Lung
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas.
Adenocarcinoma of Lung
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (?50%) lung adenocarcinoma.
Adenocarcinoma of Lung
Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes.
Adenocarcinoma of Lung
MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
Adenocarcinoma of Lung
MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
Adenocarcinoma of Lung
MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3.
Adenocarcinoma of Lung
mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Adenocarcinoma of Lung
Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
Adenocarcinoma of Lung
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.
Adenocarcinoma of Lung
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression.
Adenocarcinoma of Lung
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration.
Adenocarcinoma of Lung
PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.
Adenocarcinoma of Lung
PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.
Adenocarcinoma of Lung
PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
Adenocarcinoma of Lung
PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation.
Adenocarcinoma of Lung
PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Adenocarcinoma of Lung
PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy.
Adenocarcinoma of Lung
PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.
Adenocarcinoma of Lung
PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy.
Adenocarcinoma of Lung
PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival.
Adenocarcinoma of Lung
PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Adenocarcinoma of Lung
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Adenocarcinoma of Lung
PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT.
Adenocarcinoma of Lung
PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells.
Adenocarcinoma of Lung
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer.
Adenocarcinoma of Lung
PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry.
Adenocarcinoma of Lung
PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
Adenocarcinoma of Lung
PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
Adenocarcinoma of Lung
Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report.
Adenocarcinoma of Lung
PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma.
Adenocarcinoma of Lung
Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression.
Adenocarcinoma of Lung
Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung.
Adenocarcinoma of Lung
Prognostic Immune Cell Profiling of Malignant Pleural Effusion Patients by Computerized Immunohistochemical and Transcriptional Analysis.
Adenocarcinoma of Lung
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
Adenocarcinoma of Lung
Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: a systematic review and meta-analysis.
Adenocarcinoma of Lung
Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Adenocarcinoma of Lung
Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
Adenocarcinoma of Lung
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Adenocarcinoma of Lung
Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms.
Adenocarcinoma of Lung
Prognostic value of programmed cell death ligand-1 expression in the tumor-infiltrating immune cells of patients with lung cancer: A meta-analysis.
Adenocarcinoma of Lung
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Adenocarcinoma of Lung
Programmed Cell Death Ligand 1 (PD-L1) Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
Adenocarcinoma of Lung
Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Adenocarcinoma of Lung
Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Adenocarcinoma of Lung
Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients.
Adenocarcinoma of Lung
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.
Adenocarcinoma of Lung
Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
Adenocarcinoma of Lung
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma.
Adenocarcinoma of Lung
Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
Adenocarcinoma of Lung
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Adenocarcinoma of Lung
Regulation of PD-L1 expression by matrix stiffness in lung cancer cells.
Adenocarcinoma of Lung
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Adenocarcinoma of Lung
Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.
Adenocarcinoma of Lung
Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort.
Adenocarcinoma of Lung
Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy.
Adenocarcinoma of Lung
ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report.
Adenocarcinoma of Lung
Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation.
Adenocarcinoma of Lung
Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma.
Adenocarcinoma of Lung
Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy.
Adenocarcinoma of Lung
Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.
Adenocarcinoma of Lung
Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden.
Adenocarcinoma of Lung
The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.
Adenocarcinoma of Lung
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
Adenocarcinoma of Lung
The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma.
Adenocarcinoma of Lung
The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series.
Adenocarcinoma of Lung
The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?
Adenocarcinoma of Lung
The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Adenocarcinoma of Lung
The mechanism of ABL1 upregulating the expression of PD-L1 and the therapeutic effect of PD-L1 and STAT3 inhibitors in lung adenocarcinoma.
Adenocarcinoma of Lung
The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Adenocarcinoma of Lung
The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Adenocarcinoma of Lung
The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
Adenocarcinoma of Lung
The significance of Siglec-15 expression in resectable non-small cell lung cancer.
Adenocarcinoma of Lung
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis.
Adenocarcinoma of Lung
Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.
Adenocarcinoma of Lung
Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression.
Adenocarcinoma of Lung
UBE2V2 Positively Correlates With PD-L1 Expression and Confers Poor Patient Survival in Lung Adenocarcinoma.
Adenocarcinoma of Lung
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Adenocarcinoma of Lung
Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
Adenocarcinoma of Lung
Upregulation of PD-L1 by SPP1 mediates macrophage polarization and facilitates immune escape in lung adenocarcinoma.
Adenocarcinoma of Lung
Utility of CT radiomics for prediction of PD-L1 expression in advanced lung adenocarcinomas.
Adenocarcinoma of Lung
Validation of the QR1 Antibody for the Evaluation of PD-L1 Expression in Non-Small Cell Lung Adenocarcinomas.
Adenocarcinoma of Lung
[A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Adenocarcinoma of Lung
[Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
Adenocarcinoma of Lung
[Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Adenocarcinoma of Lung
[Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].
Adenocarcinoma of Lung
[McAb LC-1 against human lung cancer]
Adenocarcinoma of Lung
[Pericardial Fenestration and Multidisciplinary Treatment to Improve the Prognosis of the Malignant Pericarditis Due to Lung Cancer].
Adenocarcinoma of Lung
[Self defense instead of offense - Immunotherapy in lung cancer].
Adenocarcinoma of Lung
[The expression of PD-L1 in the non-small cell lung cancer and the correlation with the novel lung adenocarcinoma classification].
Adenocarcinoma, Bronchiolo-Alveolar
Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype.
Adenocarcinoma, Clear Cell
Histopathological Subtypes and PD-L1 Expression in Primary Urethral Adenocarcinoma: A Series of 5 Cases.
Adenocarcinoma, Follicular
Comprehensive screening for PD-L1 expression in thyroid cancer.
Adenocarcinoma, Mucinous
Clinical Relevance of PD-L1 Expression and CD8+ T Cells' Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma.
Adenocarcinoma, Mucinous
Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.
Adenocarcinoma, Mucinous
Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Adenocarcinoma, Mucinous
PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Adenocarcinoma, Mucinous
PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.
Adenocarcinoma, Mucinous
[Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Adenocarcinoma, Papillary
Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
Adenoma
Expression of PD-L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion.
Adenoma
Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
Adenoma
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.
Adenoma
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Adenoma
Myoepithelial Carcinoma Ex-Pleomorphic Adenoma: A Rare Pathology Misdiagnosed as Pleomorphic Adenoma; With a Novel TERT Promoter Mutation and High PD-L1 Expression.
Adenoma
PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies.
Adenoma
The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes.
Adenoma
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Adenoma, Pleomorphic
Myoepithelial Carcinoma Ex-Pleomorphic Adenoma: A Rare Pathology Misdiagnosed as Pleomorphic Adenoma; With a Novel TERT Promoter Mutation and High PD-L1 Expression.
Adenomatous Polyposis Coli
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer.
Adenomatous Polyposis Coli
The prognostic and clinicopathological roles of microsatellite instability, PD-L1 expression and tumor-infiltrating leukocytes in familial adenomatous polyposis.
Adrenocortical Carcinoma
The Prognostic Role of CD8+ T Lymphocytes in Childhood Adrenocortical Carcinomas Compared to Ki-67, PD-1, PD-L1, and the Weiss Score.
AIDS-Related Complex
A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents.
AIDS-Related Complex
Trichosanthin treatment of HIV-induced immune dysregulation.
Alopecia
Detoxification of Abrus precatorius L. seeds by Ayurvedic Shodhana process and anti-inflammatory potential of the detoxified extract.
Alopecia Areata
Increased expression of PD-L1 and PD-L2 in dermal fibroblasts from alopecia areata mice.
Alzheimer Disease
Basal forebrain cholinergic immunolesion by 192IgG-saporin: evidence for a presynaptic location of subpopulations of alpha 2- and beta-adrenergic as well as 5-HT2A receptors on cortical cholinergic terminals.
Alzheimer Disease
Change in nomenclature for the immunologic synapse from Troxis Necrosis to trogocytosis.
Alzheimer Disease
Comparison of site specific injections into the basal forebrain on water maze and radial arm maze performance in the male rat after immunolesioning with 192 IgG saporin.
Alzheimer Disease
Comparison of site-specific injections into the basal forebrain on water maze and radial arm maze performance in the male rat after immunolesioning with 192 IgG saporin.
Alzheimer Disease
The involvement of the Golgi apparatus in the pathogenesis of amyotrophic lateral sclerosis, Alzheimer's disease, and ricin intoxication.
Amyotrophic Lateral Sclerosis
Quantification of motor neuron loss and muscular atrophy in ricin-induced focal nerve injury.
Amyotrophic Lateral Sclerosis
The involvement of the Golgi apparatus in the pathogenesis of amyotrophic lateral sclerosis, Alzheimer's disease, and ricin intoxication.
Anaphylaxis
Engineering of a mini-trichosanthin that has lower antigenicity by deleting its C-terminal amino acid residues.
Anaphylaxis
PD-L1 Blockade During Allergen Sensitization Inhibits the Synthesis of Specific Antibodies and Decreases Mast Cell Activation in a Murine Model of Active Cutaneous Anaphylaxis.
Anaphylaxis
[Rat model of passive lung anaphylaxis induced by trichosanthin]
Anemia
Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome.
Anemia
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
Anemia
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Anemia
PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes.
Anemia, Hemolytic
Absence of interleukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome.
Anemia, Hemolytic
Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
Anemia, Hemolytic
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Anemia, Hemolytic
Chemokine Receptor CCR1 Disruption Limits Renal Damage in a Murine Model of Hemolytic Uremic Syndrome.
Anemia, Hemolytic
Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Anemia, Hemolytic
Development and Evaluation of a Novel VHH-Based Immunocapture Assay for High-Sensitivity Detection of Shiga Toxin Type 2 (Stx2) in Stool Samples.
Anemia, Hemolytic
Development of a Mouse Model of Shiga Toxin 2 (STX2) Intoxication for Testing Therapeutic Agents against Hemolytic Uremic Syndrome (HUS).
Anemia, Hemolytic
Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo.
Anemia, Hemolytic
Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Anemia, Hemolytic
Ingested Shiga Toxin 2 (Stx2) Causes Histopathological Changes in Kidney, Spleen, and Thymus Tissues and Mortality in Mice.
Anemia, Hemolytic
Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice.
Anemia, Hemolytic
Norovirus: a novel etiologic agent in hemolytic uremic syndrome in an infant.
Anemia, Hemolytic
Postoperative hemolytic uremic syndrome with renal cortical necrosis following laparoscopic hemicolectomy.
Anemia, Hemolytic
Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.
Anemia, Hemolytic
Rifaximin does not induce toxin production or phage-mediated lysis of Shiga toxin-producing Escherichia coli.
Anemia, Hemolytic
Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
Anemia, Hemolytic
Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.
Anemia, Hemolytic
Shiga toxin-producing Escherichia coli O157:H7 show an increased pathogenicity in mice after the passage through the gastrointestinal tract of the same host.
Anemia, Hemolytic
Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells.
Anemia, Hemolytic
The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome.
Anemia, Megaloblastic
Nucleic acid composition of bone marrow mononuclear cells in cobalamin deficiency.
Angina, Stable
Expression of coinhibitory PD-L1 on CD4?CD25?FOXP3? regulatory T cells is elevated in patients with acute coronary syndrome.
Angina, Unstable
Expression of coinhibitory PD-L1 on CD4?CD25?FOXP3? regulatory T cells is elevated in patients with acute coronary syndrome.
Angiomyolipoma
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.
Anthrax
Biological and chemical terrorism: recognition and management.
Anthrax
Bioterrorism for the respiratory physician.
Anthrax
Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus.
Anthrax
Combination of two candidate subunit vaccine antigens elicits protective immunity to ricin and anthrax toxin in mice.
Anthrax
Forensic DNA Analysis of Wheat Flour as Commonly Used in White Powder Cases.
Anthrax
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.
Anthrax
Heterogeneous Family of Cyclomodulins: Smart Weapons That Allow Bacteria to Hijack the Eukaryotic Cell Cycle and Promote Infections.
Anthrax
Issues in preparedness for biologic terrorism: a perspective for critical care nursing.
Anthrax
Mass spectrometric detection of protein-based toxins.
Anthrax
Mechanisms of Ricin Toxin Neutralization Revealed through Engineered Homodimeric and Heterodimeric Camelid Antibodies.
Anthrax
Metabolic discrimination of select list agents by monitoring cellular responses in a multianalyte microphysiometer.
Anthrax
Monoclonal antibodies and toxins--a perspective on function and isotype.
Anthrax
Mosquito inoculation: an alternative bioassay for toxins.
Anthrax
Peptide toxins directed at the matrix dissolution systems of cancer cells.
Anthrax
Perceptions of state public health officers and state veterinarians regarding risks of bioterrorism in the United States.
Anthrax
Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates.
Anthrax
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.
Anthrax
Prospects of Bacterial and Plant Protein-based Immunotoxins for Treatment of Cancer.
Anthrax
Recovery efficiencies of anthrax spores and ricin from nonporous or nonabsorbent and porous or absorbent surfaces by a variety of sampling methods*.
Anthrax
Ricin: mechanism of toxicity, clinical manifestations, and vaccine development. A review.
Anthrax
Strategies for the prevention of a successful biological warfare aerosol attack.
Anthrax
Terrorism-Related Chemical, Biological, Radiation, and Nuclear Attacks: A Historical Global Comparison Influencing the Emergence of Counter-Terrorism Medicine.
Anthrax
The medicinal chemistry of botulinum, ricin and anthrax toxins.
Anthrax
Toxins of concern to animals and people.
Anthrax
Uniform, Large-Area, Highly Ordered Peptoid Monolayer and Bilayer Films for Sensing Applications.
Anthrax
[Bioterrorism and pathogenic microorganisms].
Anthrax
[Molecular cloning, expression, and characterization of human mini-antibodies against enterotoxin C1 of Staphylococcus aureus]
Anthrax
[Preparation and characterization of monoclonal antibodies to the cholera toxin]
Anthrax
[Production and characteristics of monoclonal antibodies to the diphtheria toxin]
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1.
Antiphospholipid Syndrome
Thrombotic microangiopathies: Similar presentations, different therapies.
Aortic Aneurysm
[Dissecting aneurysm of the aorta: histochemical study using a set of lectins with different carbohydrate specificity]
Arrhythmias, Cardiac
Ablation of brainstem C1 neurons improves cardiac function in volume overload heart failure.
Arrhythmias, Cardiac
The cardiovascular effects of ricin in rabbits.
Arthralgia
Loss of N-acetylglucosamine-1-phosphotransferase gamma subunit due to intronic mutation in GNPTG causes mucolipidosis type III gamma: Implications for molecular and cellular diagnostics.
Arthralgia
Ricin poisoning: a comprehensive review.
Arthritis
Anti-rheumatoid arthritis effect of the Kochia scoparia fruits and activity comparison of momordin lc, its prosapogenin and sapogenin.
Arthritis, Experimental
Programmed Cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for Rheumatoid Arthritis.
Arthritis, Reactive
Immunological detection assays for recombinant Shiga toxin & Shigella dysenteriae.
Arthritis, Rheumatoid
Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity.
Arthritis, Rheumatoid
Administration of an anti-CD5 immunoconjugate to patients with rheumatoid arthritis: effect on peripheral blood mononuclear cells and in vitro immune function.
Arthritis, Rheumatoid
Anti-rheumatoid arthritis effect of the Kochia scoparia fruits and activity comparison of momordin lc, its prosapogenin and sapogenin.
Arthritis, Rheumatoid
Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis.
Arthritis, Rheumatoid
Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group.
Arthritis, Rheumatoid
Immunologic assessment during treatment of rheumatoid arthritis with anti-CD5 immunoconjugate.
Arthritis, Rheumatoid
PD-L1 signaling on human memory CD4+ T cells induces a regulatory phenotype.
Arthritis, Rheumatoid
Programmed Cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for Rheumatoid Arthritis.
Arthritis, Rheumatoid
Smoking Is Associated With Low Levels of Soluble PD-L1 in Rheumatoid Arthritis.
Arthritis, Rheumatoid
Transgene delivery and gelonin cytotoxicity enhanced by photochemical internalization in fibroblast-like synoviocytes (FLS) from rheumatoid arthritis patients.
Arthritis, Rheumatoid
Treatment of malignant disease and rheumatoid arthritis using ricin A-chain immunotoxins.
Asbestosis
Downregulation of the PD-1/PD-Ls pathway in peripheral cells correlates with asbestosis severity.
Asperger Syndrome
STX1A and Asperger syndrome: a replication study.
Asthma
Correlation of PD-1/PD-L1 Signaling Pathway with Treg/Th17 Imbalance from Asthmatic Children.
Asthma
Differential regulation of PD-1 and its ligands in allergic asthma.
Asthma
Inhibition of PI3K? Enhances Poly I:C-Induced Antiviral Responses and Inhibits Replication of Human Metapneumovirus in Murine Lungs and Human Bronchial Epithelial Cells.
Asthma
Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism.
Asthma
PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
Asthma
Respiratory infections regulated blood cells IFN-?-PD-L1 pathway in pediatric asthma.
Asthma
Role of PD-L1 and PD-L2 in allergic diseases and asthma.
Asthma
[Asthma from ricin.]
Asthma
[Preliminary data on specific desensitization treatment in asthma caused by ricin in workers cultivating the castor oil plant.]
Astrocytoma
Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.
Astrocytoma
Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progress.
Astrocytoma
Lectins as differentiation markers of human gliomas.
Astrocytoma
Mismatch repair proteins PMS2 and MLH1 can further refine molecular stratification of IDH-mutant lower grade astrocytomas.
Astrocytoma
Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression.
Ataxia
Diphtheria toxin mutant selectively kills cerebellar Purkinje neurons.
Ataxia Telangiectasia
High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells.
Ataxia Telangiectasia
Human uracil DNA N-glycosidase: studies in normal and repair defective cultured fibroblasts.
Atherosclerosis
Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.
Atherosclerosis
PD-1/PD-L1 in cardiovascular disease.
Atrial Fibrillation
PD-1/PD-L1 expression on CD(4+) T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation.
Atypical Hemolytic Uremic Syndrome
Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
Atypical Hemolytic Uremic Syndrome
Post-traumatic thrombotic microangiopathy: What trauma surgeons need to know?
Atypical Hemolytic Uremic Syndrome
Thrombotic microangiopathies: Similar presentations, different therapies.
Autoimmune Diseases
A peptide tetramer Tk-tPN induces tolerance of cardiac allografting by conversion of type 1 to type 2 immune responses via the Toll-like receptor 2 signal-promoted activation of the MCP1 gene.
Autoimmune Diseases
Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity.
Autoimmune Diseases
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Autoimmune Diseases
Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
Autoimmune Diseases
Capillary leak syndrome: etiologies, pathophysiology, and management.
Autoimmune Diseases
Differential Role of Programmed Death-1 Ligand and Programmed Death-2 Ligand in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis.
Autoimmune Diseases
Etiology and Outcomes of Thrombotic Microangiopathies.
Autoimmune Diseases
Expression of programed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol.
Autoimmune Diseases
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
Autoimmune Diseases
High body mass index and pre-existing autoimmune disease are associated with an increased risk of immune-related adverse events in cancer patients treated with PD-(L)1 inhibitors across different solid tumors.
Autoimmune Diseases
Immune modulatory mesenchymal stem cells derived from human embryonic stem cells through a trophoblast-like stage.
Autoimmune Diseases
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Autoimmune Diseases
Lack of an association of PD-1 and its ligand genes with Behcet's disease in a Chinese Han population.
Autoimmune Diseases
Making antigen invisible: a coinhibitory molecule regulates the interaction between T cells and dendritic cells.
Autoimmune Diseases
PD-L1- and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease.
Autoimmune Diseases
PD-L1hi B cells are critical regulators of humoral immunity.
Autoimmune Diseases
Preproricin expressed in Nicotiana tabacum cells in vitro is fully processed and biologically active.
Autoimmune Diseases
Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.
Autoimmune Diseases
Programmed Cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem Cells as Targeted Therapy for Rheumatoid Arthritis.
Autoimmune Diseases
Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus.
Autoimmune Diseases
Recombinant VAA-I from Viscum album induces apoptotic cell death of hepatocellular carcinoma SMMC7721 cells.
Autoimmune Diseases
Varicella Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex 1 in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells and Lung Fibroblasts.
Autoimmune Hypophysitis
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
Autoimmune Pancreatitis
Autoimmune Pancreatitis Type 2: Diagnostic Utility of PD-L1 Immunohistochemistry.
Bacteremia
Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection.
Bacteremia
Emerging Multidrug-Resistant Hybrid Pathotype Shiga Toxin-Producing Escherichia coli O80 and Related Strains of Clonal Complex 165, Europe.
Bacteremia
Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates.
Bacterial Infections
A Putative Microcin Amplifies Shiga Toxin 2a Production of Escherichia coli O157:H7.
Bacterial Infections
Effects of Lonicera japonica Flower Bud Extract on Citrobacter rodentium-Induced Digestive Tract Infection.
Bacterial Infections
Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection.
Bacterial Infections
Lettuce-based production of an oral vaccine against porcine edema disease for the seed lot system.
Bacterial Infections
Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
Bacterial Infections
Serum proteins associated with periodontitis relapse post-surgery: A pilot study.
Bacterial Infections
Studies on the mode of action of bacterial AB5 toxins.
Bacterial Infections
Transgenic lettuce producing a candidate protein for vaccine against edema disease.
Bacterial Infections
Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-? by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection.
Barrett Esophagus
Evidence that dysplasia related microRNAs in Barrett's esophagus target PD-L1 expression and contribute to the development of esophageal adenocarcinoma.
Bile Duct Neoplasms
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Bile Duct Neoplasms
Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies.
Biliary Fistula
THE PATHOGENESIS OF EXPERIMENTAL COLITIS, AND THE RELATION OF COLITIS IN ANIMALS AND MAN.
Biliary Tract Neoplasms
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.
Biliary Tract Neoplasms
Graft PD-L1 expression as a marker for transplant rejection following anti-PD1 immunotherapy for recurrent liver tumors.
Biliary Tract Neoplasms
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.
Biliary Tract Neoplasms
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.
Biliary Tract Neoplasms
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
Biliary Tract Neoplasms
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in patients with pretreated biliary tract cancer.
Biliary Tract Neoplasms
The prognostic role of soluble transforming growth factor-? and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
Bone Cysts, Aneurysmal
Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone.
Bone Neoplasms
Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia.
Bone Resorption
Overexpression of PD-L1 in gingival basal keratinocytes reduces periodontal inflammation in a ligature-induced periodontitis model.
Botulism
Comparison of ovalbumin quantification using forward-phase protein microarrays and suspension arrays.
Botulism
Electrochemical Aptamer Scaffold Biosensors for Detection of Botulism and Ricin Proteins.
Botulism
Electrochemical aptamer scaffold biosensors for detection of botulism and ricin toxins.
Botulism
Medical aspects of bio-terrorism.
Botulism
Strategies for the prevention of a successful biological warfare aerosol attack.
Botulism
[Bioterrorism and pathogenic microorganisms].
Brain Diseases
Affinity-Based Screening of Tetravalent Peptides Identifies Subtype-Selective Neutralizers of Shiga Toxin 2d, a Highly Virulent Subtype, by Targeting a Unique Amino Acid Involved in Its Receptor Recognition.
Brain Diseases
Anti-inflammatory agents reduce microglial response, demyelinating process and neuronal toxin uptake in a model of encephalopathy produced by Shiga Toxin 2.
Brain Diseases
Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionization quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1.
Brain Diseases
Brainstem mechanisms of autonomic dysfunction in encephalopathy-associated Shiga toxin 2 intoxication.
Brain Diseases
Dexamethasone rescues neurovascular unit integrity from cell damage caused by systemic administration of shiga toxin 2 and lipopolysaccharide in mice motor cortex.
Brain Diseases
Encephalopathy and exposure to Shiga toxin without evidence of haemolytic uraemic syndrome.
Brain Diseases
Enhancement of pentylenetetrazole-induced seizures by Shigella dysenteriae in LPS-resistant C3H/HeJ mice: role of the host response.
Brain Diseases
Environmental Cues Modulate Microglial Cell Behavior Upon Shiga Toxin 2 From Enterohemorrhagic Escherichia coli Exposure.
Brain Diseases
Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains.
Brain Diseases
Investigation of Encephalopathy Caused by Shiga Toxin 2c-Producing Escherichia coli Infection in Mice.
Brain Diseases
Massive fatal overdose of abrin with progressive encephalopathy
Brain Diseases
Shiga toxin 2 from enterohemorrhagic Escherichia coli induces reactive glial cells and neurovascular disarrangements including edema and lipid peroxidation in the murine brain hippocampus.
Brain Diseases
The involvement of the cerebral cortex in human immunodeficiency virus encephalopathy: a morphological and immunohistochemical study.
Brain Diseases
Transcriptomic profile of host response in mouse brain after exposure to plant toxin abrin.
Brain Edema
Enhanced Expression of PD-L1 on Microglia After Surgical Brain Injury Exerts Self-Protection from Inflammation and Promotes Neurological Repair.
Brain Edema
PD-L1 (Programmed Death Ligand 1) Protects Against Experimental Intracerebral Hemorrhage-Induced Brain Injury.
Brain Infarction
Multiple cavitations in posterior reversible leukoencephalopathy syndrome associated with hemolytic-uremic syndrome.
Brain Injuries
Enhanced Expression of PD-L1 on Microglia After Surgical Brain Injury Exerts Self-Protection from Inflammation and Promotes Neurological Repair.
Brain Injuries
PD-L1 (Programmed Death Ligand 1) Protects Against Experimental Intracerebral Hemorrhage-Induced Brain Injury.
Brain Neoplasms
18F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.
Brain Neoplasms
Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications.
Brain Neoplasms
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Brain Neoplasms
Characterization of the immune microenvironment in brain metastases from different solid tumors.
Brain Neoplasms
Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
Brain Neoplasms
Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
Brain Neoplasms
Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.
Brain Neoplasms
Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
Brain Neoplasms
Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation.
Brain Neoplasms
Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases.
Brain Neoplasms
Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors.
Brain Neoplasms
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Brain Neoplasms
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors.
Brain Neoplasms
Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
Brain Neoplasms
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ?50.
Brain Neoplasms
Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy.
Brain Neoplasms
GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors.
Brain Neoplasms
Glial TIM-3 modulates immune responses in the brain tumor microenvironment.
Brain Neoplasms
Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Brain Neoplasms
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Brain Neoplasms
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Brain Neoplasms
Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab.
Brain Neoplasms
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Brain Neoplasms
Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma.
Brain Neoplasms
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade.
Brain Neoplasms
Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors: A Single Institutional Experience.
Brain Neoplasms
Outcomes to first-line pembrolizumab in patients with PD-L1-high (?50%) non-small cell lung cancer and a poor performance status.
Brain Neoplasms
Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression.
Brain Neoplasms
PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.
Brain Neoplasms
PD-L1 expression in medulloblastoma: an evaluation by subgroup.
Brain Neoplasms
PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Brain Neoplasms
PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
Brain Neoplasms
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (? 50%) NSCLC: Real-world Results with Special Focus on PS ? 2, Brain Metastases, and Steroids.
Brain Neoplasms
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Brain Neoplasms
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
Brain Neoplasms
Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy.
Brain Neoplasms
Relationship with programmed cell death ligand 1 (PD-L1) and DTI features in brain metastases of non-small cell lung cancer; Preliminary study.
Brain Neoplasms
Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours.
Brain Neoplasms
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
Brain Neoplasms
Subgroup-specific immune and stromal microenvironment in medulloblastoma.
Brain Neoplasms
Targeting PD-1/PD-L1 interactions for cancer immunotherapy.
Brain Neoplasms
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
Brain Neoplasms
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Brain Neoplasms
Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting a treatment outcomes of non-small cell lung cancer.
Breast Neoplasms
A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
Breast Neoplasms
A flow-proteometric platform for analyzing protein concentration (FAP): Proof of concept for quantification of PD-L1 protein in cells and tissues.
Breast Neoplasms
A gelonin-containing immunotoxin directed against human breast carcinoma.
Breast Neoplasms
A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Breast Neoplasms
A Potential Predictive Biomarker for Miller/Payne Grading: PD-L1 Expression before Neoadjuvant Chemotherapy in Breast Cancer.
Breast Neoplasms
A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
Breast Neoplasms
A Staphylococcus aureus Coinfection on a COVID-19 Pneumonia in a Breast Cancer Patient.
Breast Neoplasms
A tumor microenvironment (TME)-responsive nanoplatform for systemic saporin delivery and effective breast cancer therapy.
Breast Neoplasms
A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
Breast Neoplasms
Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.
Breast Neoplasms
Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.
Breast Neoplasms
Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.
Breast Neoplasms
ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation.
Breast Neoplasms
Alpha-momorcharin (?-MMC) exerts effective anti-human breast tumor activities but has a narrow therapeutic window in vivo.
Breast Neoplasms
An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma.
Breast Neoplasms
An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.
Breast Neoplasms
Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
Breast Neoplasms
Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
Breast Neoplasms
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Breast Neoplasms
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.
Breast Neoplasms
Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Breast Neoplasms
Atezolizumab Combo Approved for PD-L1-positive TNBC.
Breast Neoplasms
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.
Breast Neoplasms
Aurintricarboxylic acid induces a distinct activation of the IGF-I receptor signaling within MDA-231 cells.
Breast Neoplasms
Author Correction: Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination.
Breast Neoplasms
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer.
Breast Neoplasms
Balsamin induces apoptosis in breast cancer cells via DNA fragmentation and cell cycle arrest.
Breast Neoplasms
BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.
Breast Neoplasms
Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
Breast Neoplasms
Bifunctional and Bioreducible Dendrimer Bearing a Fluoroalkyl Tail for Efficient Protein Delivery Both In Vitro and In Vivo.
Breast Neoplasms
Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Breast Neoplasms
Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells.
Breast Neoplasms
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Breast Neoplasms
Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.
Breast Neoplasms
Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
Breast Neoplasms
BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.
Breast Neoplasms
Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages.
Breast Neoplasms
Cancer-associated oxidoreductase ERO1-? promotes immune escape through up-regulation of PD-L1 in human breast cancer.
Breast Neoplasms
Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
Breast Neoplasms
Characterization of translational inhibitors from Phytolacca americana. Amino-terminal sequence determination and antibody-inhibitor conjugates.
Breast Neoplasms
Checkpoint Inhibitors and Their Application in Breast Cancer.
Breast Neoplasms
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
Breast Neoplasms
Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma.
Breast Neoplasms
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy.
Breast Neoplasms
Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.
Breast Neoplasms
Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer.
Breast Neoplasms
Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
Breast Neoplasms
Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis.
Breast Neoplasms
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Breast Neoplasms
Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
Breast Neoplasms
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Breast Neoplasms
Cognate Non-Lytic Interactions between CD8+ T cells and Breast Cancer Cells Induce Cancer Stem Cell-like Properties.
Breast Neoplasms
Combination of Balsamin and Flavonoids Induce Apoptotic Effects in Liver and Breast Cancer Cells.
Breast Neoplasms
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
Breast Neoplasms
Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Breast Neoplasms
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Breast Neoplasms
Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Breast Neoplasms
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Breast Neoplasms
Coordination and Redox Dual-Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy.
Breast Neoplasms
Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.
Breast Neoplasms
Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system.
Breast Neoplasms
Decreased levels of circulating cytokines VEGF, TNF-? and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients.
Breast Neoplasms
Defining the immunogram of breast cancer: a focus on clinical trials.
Breast Neoplasms
Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.
Breast Neoplasms
Designing and Analyzing the Structure of DT-STXB Fusion Protein as an Anti-tumor Agent: An in Silico Approach.
Breast Neoplasms
Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
Breast Neoplasms
Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1.
Breast Neoplasms
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Breast Neoplasms
Differences of the Immune Phenotype of Breast Cancer Cells after Ex Vivo Hyperthermia by Warm-Water or Microwave Radiation in a Closed-Loop System Alone or in Combination with Radiotherapy.
Breast Neoplasms
Differential expression of neurogenes among breast cancer subtypes identifies high risk patients.
Breast Neoplasms
Differential inhibitory potencies and mechanisms of the type I ribosome inactivating protein marmorin on estrogen receptor (ER)-positive and ER-negative breast cancer cells.
Breast Neoplasms
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis.
Breast Neoplasms
Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer.
Breast Neoplasms
DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.
Breast Neoplasms
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy.
Breast Neoplasms
Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells.
Breast Neoplasms
Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination.
Breast Neoplasms
Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.
Breast Neoplasms
Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.
Breast Neoplasms
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.
Breast Neoplasms
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Breast Neoplasms
Effect of interstitial chemotherapy with ricin temperature-responsive gel for anti-breast cancer and immune regulation in rat.
Breast Neoplasms
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Breast Neoplasms
Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer.
Breast Neoplasms
Effects of BCL-2 overexpression on the sensitivity of MCF-7 breast cancer cells to ricin, diphtheria and Pseudomonas toxin and immunotoxins.
Breast Neoplasms
Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence.
Breast Neoplasms
Efficiently restoring the tumoricidal immunity against resistant malignancies via an immune nanomodulator.
Breast Neoplasms
Endoplasmic reticulum stress-induced exosomal miR-27a-3p promotes immune escape in breast cancer via regulating PD-L1 expression in macrophages.
Breast Neoplasms
Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines.
Breast Neoplasms
Enhancement of the specific cytotoxicity of a breast cancer-associated antigen immunotoxin by the carboxylic ionophore monensin.
Breast Neoplasms
Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer.
Breast Neoplasms
Epithelial/Mesenchymal Characteristics and PD-L1 Co-Expression in CTCs of Metastatic Breast Cancer Patients Treated with Eribulin: Correlation with Clinical Outcome.
Breast Neoplasms
ER? is a negative regulator of PD-L1 gene transcription in breast cancer.
Breast Neoplasms
Erratum to: Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Breast Neoplasms
Estrogen Receptor Downregulates Expression of PD-1/PD-L1 and Infiltration of CD8+ T Cells by Inhibiting IL-17 Signaling Transduction in Breast Cancer.
Breast Neoplasms
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.
Breast Neoplasms
Evaluating the Possible Association between PD-1 (Rs11568821, Rs2227981, Rs2227982) and PD-L1 (Rs4143815, Rs2890658) Polymorphisms and Susceptibility to Breast Cancer in a Sample of Southeast Iranian Women.
Breast Neoplasms
Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Breast Neoplasms
Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+?and FOXP3+?immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Breast Neoplasms
Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.
Breast Neoplasms
Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Breast Neoplasms
Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters.
Breast Neoplasms
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Breast Neoplasms
Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
Breast Neoplasms
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
Breast Neoplasms
Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
Breast Neoplasms
Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.
Breast Neoplasms
Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.
Breast Neoplasms
FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
Breast Neoplasms
Formulation and Cytotoxicity of Ribosome-Inactivating Protein Mirabilis Jalapa L. Nanoparticles Using Alginate-Low Viscosity Chitosan Conjugated with Anti-Epcam Antibodies in the T47D Breast Cancer Cell Line.
Breast Neoplasms
Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Breast Neoplasms
Frequent expression of PD-L1 on circulating breast cancer cells.
Breast Neoplasms
GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer.
Breast Neoplasms
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
Breast Neoplasms
Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1.
Breast Neoplasms
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
Breast Neoplasms
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Breast Neoplasms
High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
Breast Neoplasms
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.
Breast Neoplasms
Higher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Paraffin-Embedded Formalin-Fixed Tissues.
Breast Neoplasms
Higher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.
Breast Neoplasms
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Breast Neoplasms
How can artificial intelligence models assist PD-L1 expression scoring in breast cancer: results of multi-institutional ring studies.
Breast Neoplasms
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
Breast Neoplasms
Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer.
Breast Neoplasms
Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.
Breast Neoplasms
Immune checkpoint inhibitors in the treatment of cancer.
Breast Neoplasms
Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
Breast Neoplasms
Immune checkpoints in aggressive breast cancer subtypes.
Breast Neoplasms
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Breast Neoplasms
Immunoconjugate generation between the ribosome inactivating protein restrictocin and an anti-human breast carcinoma MAB.
Breast Neoplasms
Immunotherapy for early breast cancer: too soon, too superficial, or just right?
Breast Neoplasms
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
Breast Neoplasms
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
Breast Neoplasms
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Breast Neoplasms
In situ Tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Breast Neoplasms
In vitro potentiation by lonidamine of the sc-RIP saporin 6 effect in a human metastatic breast cancer cell line.
Breast Neoplasms
In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with 89Zr-labeled avelumab.
Breast Neoplasms
Inhibition of growth of breast cancer cells in vitro by the ribosome-inactivating protein saporin 6.
Breast Neoplasms
Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Breast Neoplasms
Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer.
Breast Neoplasms
Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.
Breast Neoplasms
Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Breast Neoplasms
Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.
Breast Neoplasms
Internalized ricin and the plasma membrane glycoprotein MAM-6 colocalize in the trans-Golgi network of T47D human breast carcinoma cells.
Breast Neoplasms
Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging.
Breast Neoplasms
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Breast Neoplasms
Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy.
Breast Neoplasms
Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem.
Breast Neoplasms
ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer.
Breast Neoplasms
Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Breast Neoplasms
LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
Breast Neoplasms
Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes.
Breast Neoplasms
Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth.
Breast Neoplasms
Marmorin, a new ribosome inactivating protein with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from the mushroom Hypsizigus marmoreus.
Breast Neoplasms
MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression.
Breast Neoplasms
Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells.
Breast Neoplasms
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Breast Neoplasms
MicroRNA -383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1.
Breast Neoplasms
MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
Breast Neoplasms
miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint.
Breast Neoplasms
miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.
Breast Neoplasms
Mistletoe lectin is not the only cytotoxic component in fermented preparations of Viscum album from white fir (Abies pectinata).
Breast Neoplasms
Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
Breast Neoplasms
Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
Breast Neoplasms
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
Breast Neoplasms
Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1.
Breast Neoplasms
Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions.
Breast Neoplasms
Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.
Breast Neoplasms
Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.
Breast Neoplasms
Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms.
Breast Neoplasms
Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model.
Breast Neoplasms
Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.
Breast Neoplasms
NR4A1 Ligands as Potent Inhibitors of Breast Cancer Cell and Tumor Growth.
Breast Neoplasms
Nuclear localization of PD-L1: artifact or reality?
Breast Neoplasms
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.
Breast Neoplasms
Oleuropin controls miR-194/XIST/PD-L1 loop in triple negative breast cancer: New role of nutri-epigenetics in immune-oncology.
Breast Neoplasms
Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
Breast Neoplasms
Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study.
Breast Neoplasms
Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment.
Breast Neoplasms
Palmitoylation stabilizes PD-L1 to promote breast tumor growth.
Breast Neoplasms
Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.
Breast Neoplasms
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression.
Breast Neoplasms
PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer.
Breast Neoplasms
PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer.
Breast Neoplasms
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.
Breast Neoplasms
PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.
Breast Neoplasms
PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
Breast Neoplasms
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Breast Neoplasms
PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Breast Neoplasms
PD-L1 and intratumoral immune response in breast cancer.
Breast Neoplasms
PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.
Breast Neoplasms
PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.
Breast Neoplasms
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.
Breast Neoplasms
PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Breast Neoplasms
PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
Breast Neoplasms
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.
Breast Neoplasms
PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Breast Neoplasms
PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old.
Breast Neoplasms
PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer.
Breast Neoplasms
PD-L1 expression by circulating breast cancer cells.
Breast Neoplasms
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
Breast Neoplasms
PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review.
Breast Neoplasms
PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications.
Breast Neoplasms
PD-L1 expression in human cancers and its association with clinical outcomes.
Breast Neoplasms
PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.
Breast Neoplasms
PD-L1 expression in triple-negative breast cancer.
Breast Neoplasms
PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
Breast Neoplasms
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
Breast Neoplasms
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.
Breast Neoplasms
PD-L1 expression is increased in a subset of basal type breast cancer cells.
Breast Neoplasms
PD-L1 expression levels on tumor cells affect their immunosuppressive activity.
Breast Neoplasms
PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Breast Neoplasms
PD-L1 Glycosylation and Its Impact on Binding to Clinical Antibodies.
Breast Neoplasms
PD-L1 in Breast Cancer: Comparative Analysis of Three Different Antibodies.
Breast Neoplasms
PD-L1 in Breast Cancer: The Road to the Perfect BiomarkerIs Fraught With Uncertainty.
Breast Neoplasms
PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer.
Breast Neoplasms
PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis.
Breast Neoplasms
PD-L1 mediated the differentiation of tumor-infiltrating CD19(+) B lymphocytes and T cells in Invasive breast cancer.
Breast Neoplasms
PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells.
Breast Neoplasms
PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
Breast Neoplasms
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.
Breast Neoplasms
PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer.
Breast Neoplasms
PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Breast Neoplasms
PD-L1 status in breast cancer: Current view and perspectives.
Breast Neoplasms
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Breast Neoplasms
PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
Breast Neoplasms
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Breast Neoplasms
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.
Breast Neoplasms
Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies.
Breast Neoplasms
Phosphorylation of HSF1 by PIM2 induces PD-L1 expression and promotes tumor growth in breast cancer.
Breast Neoplasms
Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer.
Breast Neoplasms
Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.
Breast Neoplasms
Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Breast Neoplasms
Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.
Breast Neoplasms
Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression.
Breast Neoplasms
Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.
Breast Neoplasms
Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis.
Breast Neoplasms
Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
Breast Neoplasms
Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
Breast Neoplasms
Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
Breast Neoplasms
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.
Breast Neoplasms
Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
Breast Neoplasms
Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
Breast Neoplasms
Prognostic significance of PD-L1 and PD-L2 in breast cancer.
Breast Neoplasms
Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.
Breast Neoplasms
Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.
Breast Neoplasms
Programmed cell death 1 (PD-1) receptor and programmed death ligand 1 (PD-L1) gene expression in primary breast cancer.
Breast Neoplasms
Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value.
Breast Neoplasms
Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome.
Breast Neoplasms
Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
Breast Neoplasms
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Breast Neoplasms
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Breast Neoplasms
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
Breast Neoplasms
Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting.
Breast Neoplasms
Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion.
Breast Neoplasms
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
Breast Neoplasms
Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.
Breast Neoplasms
Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Breast Neoplasms
Refining patient selection for breast cancer immunotherapy: beyond PD-L1.
Breast Neoplasms
Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice.
Breast Neoplasms
Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma.
Breast Neoplasms
Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features.
Breast Neoplasms
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
Breast Neoplasms
Response of primary human mammary tumor cell cultures to a monoclonal antibody-recombinant ricin A chain immunotoxin.
Breast Neoplasms
Rho-associated protein kinase-dependent moesin phosphorylation is required for PD-L1 stabilization in breast cancer.
Breast Neoplasms
Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells.
Breast Neoplasms
Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
Breast Neoplasms
Saporin 6 and lonidamine in primary cell cultures from human breast carcinomas: a synergistic effect.
Breast Neoplasms
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.
Breast Neoplasms
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Breast Neoplasms
Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes.
Breast Neoplasms
Small-molecule inhibitors of breast cancer-related targets: Potential therapeutic agents for breast cancer.
Breast Neoplasms
SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
Breast Neoplasms
Structures of the oligosaccharide chains of two forms of alpha 1-acid glycoprotein purified from liver metastases of lung, colon, and breast tumors.
Breast Neoplasms
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Breast Neoplasms
T cell coinhibition and immunotherapy in human breast cancer.
Breast Neoplasms
Targeted and intracellular delivery of protein therapeutics by a boronated polymer for the treatment of bone tumors.
Breast Neoplasms
Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer.
Breast Neoplasms
TET2 Inhibits PD-L1 Gene Expression in Breast Cancer Cells through Histone Deacetylation.
Breast Neoplasms
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.
Breast Neoplasms
The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level.
Breast Neoplasms
The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer.
Breast Neoplasms
The expression of programmed death-ligand 1 and its association with histopathological grade, stage of disease, and occurrence of metastasis in breast cancer.
Breast Neoplasms
The expression of programmed death-ligand 1 in patients with invasive breast cancer.
Breast Neoplasms
The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Breast Neoplasms
The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.
Breast Neoplasms
The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.
Breast Neoplasms
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
Breast Neoplasms
The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth.
Breast Neoplasms
The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Breast Neoplasms
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice.
Breast Neoplasms
The PD-L1 metabolic interactome intersects with choline metabolism and inflammation.
Breast Neoplasms
The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Breast Neoplasms
The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.
Breast Neoplasms
The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
Breast Neoplasms
The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
Breast Neoplasms
The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer.
Breast Neoplasms
The value of maspin and PD-L1 expression and peritumoral lymphocytic infiltration in breast tumors.
Breast Neoplasms
Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.
Breast Neoplasms
Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Breast Neoplasms
TIM-3 expression in breast cancer.
Breast Neoplasms
Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer.
Breast Neoplasms
Transforming growth factor beta orchestrates PD-L1 enrichment in tumor derived exosomes and mediates CD8 T cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Breast Neoplasms
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN? secretion.
Breast Neoplasms
Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis.
Breast Neoplasms
Triple negative breast cancer - prognostic role of immune-related factors: a systematic review.
Breast Neoplasms
Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells.
Breast Neoplasms
Triptolide reverses helper T cell inhibition and down-regulates IFN-? induced PD-L1 expression in glioma cell lines.
Breast Neoplasms
Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer.
Breast Neoplasms
Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Breast Neoplasms
Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancer.
Breast Neoplasms
Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components.
Breast Neoplasms
Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.
Breast Neoplasms
Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers.
Breast Neoplasms
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.
Breast Neoplasms
Type I? phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-?B.
Breast Neoplasms
Understanding PD-L1 Testing in Breast Cancer: A Practical Approach.
Breast Neoplasms
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
Breast Neoplasms
Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions.
Breast Neoplasms
VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer.
Breast Neoplasms
Voluntary wheel running can lead to modulation of immune checkpoint molecule expression.
Breast Neoplasms
XIST and TSIX: Novel Cancer Immune Biomarkers in PD-L1-Overexpressing Breast Cancer Patients.
Breast Neoplasms
[Blocking programmed death-ligand 1 attenuates maturation inhibition of dendritic cells by co-cultured breast cancer cells].
Breast Neoplasms
[Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
Breast Neoplasms
[Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
Breast Neoplasms
[IFN-? induces overexpression of PD-L1 and epithelialmesenchymal transformation of breast cancer cells through activating ERK/Jak2-STAT signaling pathways].
Breast Neoplasms
[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
Breast Neoplasms
[PD-L1 status in breast cancer].
Breast Neoplasms
[Role of PD-1/PD-L1 in microenvironment of breast cancer].
Breast Neoplasms
[Study of the PD-L1 status in breast cancer, by using the SP142 monoclonal antibody, and the prospects for determining treatment policy].
Breast Neoplasms
[The first experience of PD-L1 testing of triple negative breast cancer with marker SP142 in Russia].
Breast Neoplasms, Male
PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer.
Bronchiolitis
Rescue of rhesus macaques from the lethality of aerosolized ricin toxin.
Bronchiolitis Obliterans
Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans.
Bronchiolitis Obliterans
Protective effect of two recombinant ricin subunit vaccines in the new zealand white rabbit subjected to a lethal aerosolized ricin challenge: survival, immunological response, and histopathological findings.
Brucellosis
Perceptions of state public health officers and state veterinarians regarding risks of bioterrorism in the United States.
Burkitt Lymphoma
A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines.
Burkitt Lymphoma
Activation of the caspase cascade during Stx1-induced apoptosis in Burkitt's lymphoma cells.
Burkitt Lymphoma
An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Burkitt Lymphoma
Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen.
Burkitt Lymphoma
Cloned Shiga toxin 2 B subunit induces apoptosis in Ramos Burkitt's lymphoma B cells.
Burkitt Lymphoma
Correction to: Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program.
Burkitt Lymphoma
Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling.
Burkitt Lymphoma
Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Burkitt Lymphoma
Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Burkitt Lymphoma
Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program.
Burkitt Lymphoma
Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxin in vitro and in a disseminated human Burkitt's lymphoma model in SCID mice.
Burkitt Lymphoma
The binding of the B-chain of ricin to Burkitt lymphoma cells. A new approach to ligand-receptor interaction studies.
Calcinosis
T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.
Campylobacter Infections
Foodborne disease in Australia: incidence, notifications and outbreaks. Annual report of the OzFoodNet network, 2002.
Candidiasis
Anti-PD-L1 peptide improves survival in sepsis.
Capillary Leak Syndrome
Capillary leak syndrome: etiologies, pathophysiology, and management.
Carcinogenesis
A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung.
Carcinogenesis
APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Carcinogenesis
Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
Carcinogenesis
Association of Immunostaining of Galectin-3 and Sambucus nigra Agglutinin with Invasion, Metastasis and Poor Progression of Gallbladder Adenocarcinoma.
Carcinogenesis
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Carcinogenesis
Carcinogenesis response modulation induced by gelonin encapsulated in liposome.
Carcinogenesis
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
Carcinogenesis
CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Carcinogenesis
Clinicopathological and prognostic significance of PD-L1 in oral cancer: A preliminary retrospective immunohistochemistry study.
Carcinogenesis
Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.
Carcinogenesis
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
Carcinogenesis
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
Carcinogenesis
Evaluation of p16 in Epithelial Ovarian Cancer for a 10-Year Study in Northeast China: Significance of HPV in Correlation with PD-L1 Expression.
Carcinogenesis
Expression of Concern: PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.
Carcinogenesis
Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
Carcinogenesis
Expression of PD-L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion.
Carcinogenesis
Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma.
Carcinogenesis
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
Carcinogenesis
HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis.
Carcinogenesis
Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer.
Carcinogenesis
IL-17A Secreted from Lymphatic Endothelial Cells Promotes Tumorigenesis by Up-regulation of PD-L1 in Hepatoma Stem Cells.
Carcinogenesis
Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.
Carcinogenesis
Interleukin-1?-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression.
Carcinogenesis
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
Carcinogenesis
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Carcinogenesis
Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Carcinogenesis
LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Carcinogenesis
LncRNA NUTM2A-AS1 positively modulates TET1 and HIF-1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR-376a.
Carcinogenesis
MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Carcinogenesis
MicroRNA-519 inhibits hypoxia-induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD-L1.
Carcinogenesis
MYC Promotes Tumorigenesis via Activation of CD47 and PD-L1.
Carcinogenesis
Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.
Carcinogenesis
Novel thioredoxin reductase inhibitor butaselen inhibits tumorigenesis by down-regulating programmed death-ligand 1 expression.
Carcinogenesis
Oleic acid and oleoylethanolamide decrease interferon-?-induced expression of PD-L1 and induce apoptosis in human lung carcinoma cells.
Carcinogenesis
Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate.
Carcinogenesis
PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Carcinogenesis
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.
Carcinogenesis
PD-L1 expression in colon cancer and its relationship with clinical prognosis.
Carcinogenesis
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Carcinogenesis
PD-L1 Expression, T-lymphocyte Subpopulations and Langerhans Cells in Cutaneous Squamous Cell Carcinoma and Precursor Lesions.
Carcinogenesis
PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer.
Carcinogenesis
PD-L1 inhibitors for the treatment of prostate cancer.
Carcinogenesis
PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.
Carcinogenesis
PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer.
Carcinogenesis
Phospho-?-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2.
Carcinogenesis
PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma.
Carcinogenesis
Polymorphisms of co-inhibitory molecules (CTLA-4/PD-1/PD-L1) and the risk of non-small cell lung cancer in a Chinese population.
Carcinogenesis
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer.
Carcinogenesis
Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Carcinogenesis
Programmed Death Ligand-1 (PD-L1) regulated by NRF- 2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Carcinogenesis
Proinflammatory S100A8 Induces PD-L1 Expression in Macrophages, Mediating Tumor Immune Escape.
Carcinogenesis
Prostasin regulates PD-L1 expression in human lung cancer cells.
Carcinogenesis
Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects.
Carcinogenesis
RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis.
Carcinogenesis
The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
Carcinogenesis
The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
Carcinogenesis
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
Carcinogenesis
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.
Carcinogenesis
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.
Carcinogenesis
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.
Carcinogenesis
[The clinical significance of the expression of costimulatory molecule PD-L1 in nasopharyngeal carcinoma]
Carcinoid Tumor
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Carcinoid Tumor
Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors.
Carcinoid Tumor
PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread.
Carcinoid Tumor
PD-L1 expression in neuroendocrine tumors of the lung.
Carcinoid Tumor
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours.
Carcinoma
A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Carcinoma
A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Carcinoma
A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma.
Carcinoma
A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis.
Carcinoma
A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review.
Carcinoma
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.
Carcinoma
A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung.
Carcinoma
A nomogram incorporating PD-L1, NLR, and clinicopathologic features to predict inguinal lymph node metastasis in penile squamous cell carcinoma.
Carcinoma
A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non-Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen.
Carcinoma
A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.
Carcinoma
A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.
Carcinoma
A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.
Carcinoma
Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.
Carcinoma
Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy.
Carcinoma
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.
Carcinoma
Administration of Dendritic Cells and Anti-PD-1 Antibody Converts X-ray Irradiated Tumors Into Effective In situ Vaccines.
Carcinoma
Advances in cancer immunology and cancer immunotherapy.
Carcinoma
Advances in targeted therapy for esophageal cancer.
Carcinoma
Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Carcinoma
Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.
Carcinoma
Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
Carcinoma
Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
Carcinoma
An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.
Carcinoma
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.
Carcinoma
Analysis of radiotherapy-induced alteration of CD8+ T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinoma.
Carcinoma
Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review.
Carcinoma
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
Carcinoma
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
Carcinoma
Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).
Carcinoma
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
Carcinoma
Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials.
Carcinoma
Anti-PD-L1/TGF?R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Carcinoma
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen.
Carcinoma
Antitumor effects of abrin and ricin used singly and in combination with cisplatin.
Carcinoma
Antitumour effect of abrin on transplanted tumours in mice.
Carcinoma
Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells.
Carcinoma
Aralin, a new cytotoxic protein from Aralia elata, inducing apoptosis in human cancer cells.
Carcinoma
Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.
Carcinoma
Assessment of circularized E7 RNA, GLUT1, and PD-L1 in anal squamous cell carcinoma.
Carcinoma
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
Carcinoma
Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.
Carcinoma
Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma.
Carcinoma
Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland.
Carcinoma
Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
Carcinoma
Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications.
Carcinoma
Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.
Carcinoma
Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Carcinoma
Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma.
Carcinoma
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
Carcinoma
Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
Carcinoma
Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade.
Carcinoma
Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
Carcinoma
Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Carcinoma
Association of PD-L1 expression in oral squamous cell carcinoma with smoking, sex, and p53 expression.
Carcinoma
Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma.
Carcinoma
Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens.
Carcinoma
Association of Programmed Death Ligand-1 Overexpression with the Grade and Stage of Oral Squamous Cell Carcinoma.
Carcinoma
Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
Carcinoma
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation.
Carcinoma
Associations among pretreatment tumor necrosis and the expression of HIF-1? and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.
Carcinoma
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Carcinoma
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
Carcinoma
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Carcinoma
Attempts to express the A1-GMCSF immunotoxin in the baculovirus expression vector system.
Carcinoma
Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens.
Carcinoma
Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software.
Carcinoma
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma.
Carcinoma
Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.
Carcinoma
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Carcinoma
Avelumab in gastric cancer.
Carcinoma
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Carcinoma
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
Carcinoma
B7-H1 and a Mathematical Model for Cytotoxic T Cell and Tumor Cell Interaction.
Carcinoma
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.
Carcinoma
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Carcinoma
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.
Carcinoma
Binding of Ricinus communis agglutinin on non-tumorigenic variants of mouse mammary carcinoma cells in culture.
Carcinoma
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Carcinoma
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF? and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Carcinoma
Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.
Carcinoma
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Carcinoma
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
Carcinoma
Bisdemethoxycurcumin in combination with ?-PD-L1 antibody boosts immune response against bladder cancer.
Carcinoma
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Carcinoma
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Carcinoma
BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
Carcinoma
Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Carcinoma
c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer.
Carcinoma
C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma.
Carcinoma
Capture of recombinant ricin A chain by a bispecific anti-RTA:anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice.
Carcinoma
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
Carcinoma
Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma.
Carcinoma
Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.
Carcinoma
Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma.
Carcinoma
Case Report: Squamous Cell Carcinoma of Pancreas With High PD-L1 Expression: A Rare Presentation.
Carcinoma
Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab.
Carcinoma
CD163(+)CD204(+) tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma.
Carcinoma
CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
Carcinoma
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
Carcinoma
CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance.
Carcinoma
CD44+ cells in head and neck squamous cell carcinoma suppress T cell-mediated immunity by selective constitutive and inducible expression of PD-L1.
Carcinoma
CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma.
Carcinoma
Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency.
Carcinoma
Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma.
Carcinoma
Change in binding reactivity of an anti-tumor monoclonal antibody after the introduction of 2-pyridyl disulphide groups.
Carcinoma
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.
Carcinoma
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
Carcinoma
Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.
Carcinoma
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Carcinoma
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Carcinoma
Checkpoint cluster: biomarkers of response.
Carcinoma
Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Carcinoma
Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation.
Carcinoma
Cinnamomin: a multifunctional type II ribosome-inactivating protein.
Carcinoma
Cinnamomin: separation, crystallization and preliminary X-ray diffraction study.
Carcinoma
Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
Carcinoma
Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Carcinoma
Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis.
Carcinoma
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Carcinoma
Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series.
Carcinoma
Clinical comments on prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma (OSCC).
Carcinoma
Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor.
Carcinoma
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
Carcinoma
Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma.
Carcinoma
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.
Carcinoma
Clinical significance of PD-L1 (CD274) enhanced expression in cervical squamous cell carcinoma.
Carcinoma
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.
Carcinoma
Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Carcinoma
Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Carcinoma
Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.
Carcinoma
Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
Carcinoma
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Carcinoma
Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.
Carcinoma
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
Carcinoma
Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Carcinoma
Clinicopathological and prognostic significance of PD-L1 in oral cancer: A preliminary retrospective immunohistochemistry study.
Carcinoma
Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Carcinoma
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.
Carcinoma
Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.
Carcinoma
Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma.
Carcinoma
Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.
Carcinoma
Clonality analysis of synchronous gastro-oesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing.
Carcinoma
CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma.
Carcinoma
Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Carcinoma
Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.
Carcinoma
Cochinin B, a novel ribosome-inactivating protein from the seeds of Momordica cochinchinensis.
Carcinoma
Colon carcinoma glycoproteins carrying alpha 2,6-linked sialic acid reactive with Sambucus nigra agglutinin are not constitutively expressed in normal human colon mucosa and are distinct from sialyl-Tn antigen.
Carcinoma
Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Carcinoma
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
Carcinoma
Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
Carcinoma
Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
Carcinoma
Comparative Analysis of Programmed Cell Death Ligand 1 Assays in Renal Cell Carcinoma.
Carcinoma
Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small cell lung cancer in clinical practice.
Carcinoma
Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.
Carcinoma
Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
Carcinoma
Complete remission in a patient with advanced renal pelvis carcinoma with lung metastasis treated with durvalumab immunotherapy: a case report.
Carcinoma
Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
Carcinoma
Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.
Carcinoma
Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Carcinoma
Comprehensive analysis of PD-L1 expression, HER2 amplification, ALK/EML4 fusion, and mismatch repair deficiency as putative predictive and prognostic factors in ovarian carcinoma.
Carcinoma
Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Carcinoma
Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Carcinoma
Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma.
Carcinoma
Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
Carcinoma
Comprehensive evaluation of PD-L1 expression in primary and metastatic prostate cancer.
Carcinoma
Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.
Carcinoma
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Carcinoma
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Carcinoma
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Carcinoma
Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Carcinoma
Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
Carcinoma
Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
Carcinoma
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
Carcinoma
Construction of an anti-programmed death-ligand 1 chimeric antigen receptor and determination of its antitumor function with transduced cells.
Carcinoma
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Carcinoma
Correction to: PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.
Carcinoma
Correction to: PD-L1 expression in tongue squamous cell carcinoma.
Carcinoma
Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Carcinoma
Correction: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Carcinoma
Correction: Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Carcinoma
Correction: COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
Carcinoma
Correction: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Carcinoma
Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma.
Carcinoma
Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort.
Carcinoma
Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Carcinoma
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.
Carcinoma
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Carcinoma
Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder.
Carcinoma
Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma.
Carcinoma
Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial.
Carcinoma
Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.
Carcinoma
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Carcinoma
Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
Carcinoma
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
Carcinoma
Cutaneous metastasis of PD-L1 positive ovarian carcinoma.
Carcinoma
CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway.
Carcinoma
Cytotoxicity of two new ribosome-inactivating proteins, cinnamomin and camphorin, to carcinoma cells.
Carcinoma
Delivery of ricin and abrin A-chains to human carcinoma cells in culture following covalent linkage to monoclonal antibody LICR-LOND-Fib 75.
Carcinoma
Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo.
Carcinoma
Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder.
Carcinoma
Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma.
Carcinoma
Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
Carcinoma
Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma.
Carcinoma
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Carcinoma
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Carcinoma
Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma.
Carcinoma
Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma.
Carcinoma
Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade.
Carcinoma
Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder.
Carcinoma
Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
Carcinoma
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.
Carcinoma
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Carcinoma
Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Carcinoma
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Carcinoma
Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.
Carcinoma
Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma.
Carcinoma
Differential Molecular Expression Patterns Associated with Metastasis in Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Carcinoma
Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Carcinoma
Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers.
Carcinoma
Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas.
Carcinoma
Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions.
Carcinoma
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Carcinoma
Distribution and Expression of Programmed Death Ligand -1 (PD-L1) in Non-Small Cell Carcinomas of the Lung in a Tertiary Care Centre in South India.
Carcinoma
Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Carcinoma
Disulfonated tetraphenyl chlorin (TPCS(2a)), a novel photosensitizer developed for clinical utilization of photochemical internalization.
Carcinoma
DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU).
Carcinoma
Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?
Carcinoma
Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer.
Carcinoma
Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation.
Carcinoma
Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells.
Carcinoma
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Carcinoma
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ?25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Carcinoma
Dynamic host immune response in virus-associated cancers.
Carcinoma
EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.
Carcinoma
Effect of lectins on 3H-uridine and 3H-thymidine uptake by cultured renal cell carcinoma and normal renal cells.
Carcinoma
Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States.
Carcinoma
Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis.
Carcinoma
Effects of brefeldin A on endocytosis, transcytosis and transport to the Golgi complex in polarized MDCK cells.
Carcinoma
Effects of Tussilago farfara L. Polysaccharides on the Expression of PD-1 (CD279) and PD-L1 (CD274) in Peripheral Blood and Tumor Tissue Lymphocytes in Mice with Lewis Lung Carcinoma.
Carcinoma
Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report.
Carcinoma
Efficacy of immune-checkpoint inhibitors in PD-L1 selected or unselected patients vs. control group in patients with advanced or metastatic urothelial carcinoma.
Carcinoma
Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review.
Carcinoma
EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells.
Carcinoma
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV?201): a multicentre, single-arm, phase 2 trial.
Carcinoma
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Carcinoma
Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.
Carcinoma
Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.
Carcinoma
Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
Carcinoma
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Carcinoma
Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas.
Carcinoma
Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
Carcinoma
Erratum: Five-Factor Prognostic Model for Survival of Post-Platinum Patients withMetastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Carcinoma
Esophageal squamous cell carcinoma metachronous to head and neck cancers.
Carcinoma
Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Carcinoma
Evaluating PD-L1 in Head & Neck Squamous Cell Carcinoma: concordance between 22C3 PharmaDx and SP263 assays on whole sections from a multicenter study.
Carcinoma
Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Carcinoma
Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes.
Carcinoma
Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance.
Carcinoma
Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis.
Carcinoma
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Carcinoma
Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma.
Carcinoma
Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.
Carcinoma
Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
Carcinoma
Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure.
Carcinoma
Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Carcinoma
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
Carcinoma
Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma.
Carcinoma
Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Carcinoma
Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma.
Carcinoma
Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Carcinoma
Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer.
Carcinoma
Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Carcinoma
Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
Carcinoma
Expression of Nectin-4 and PD-L1 in Upper Tract Urothelial Carcinoma.
Carcinoma
Expression of PD-L1 and CTLA-4 in female urethral carcinoma.
Carcinoma
Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome.
Carcinoma
Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Carcinoma
Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis.
Carcinoma
Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung.
Carcinoma
Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression.
Carcinoma
Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
Carcinoma
Expression of PD-L1 on canine tumor cells and enhancement of IFN-? production from tumor-infiltrating cells by PD-L1 blockade.
Carcinoma
Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.
Carcinoma
Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
Carcinoma
Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus.
Carcinoma
Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma.
Carcinoma
Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Carcinoma
Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status.
Carcinoma
Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration.
Carcinoma
Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
Carcinoma
Expression of the RIP-1 gene and its role in growth and invasion of human gallbladder carcinoma.
Carcinoma
Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions.
Carcinoma
Expressions of Immune Negative Regulator FoxP3+Treg and PD-L1 Protein in the Immune Microenvironment of Cervical Lesion.
Carcinoma
Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti-PD-1 Immunotherapy.
Carcinoma
Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma.
Carcinoma
First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK): a systematic review and network meta-analysis.
Carcinoma
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Carcinoma
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.
Carcinoma
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Carcinoma
FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma.
Carcinoma
Free alpha subunits of glycoprotein hormone with dissimilar carbohydrates produced by pathologically different carcinomas.
Carcinoma
Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated.
Carcinoma
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
Carcinoma
Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma.
Carcinoma
Functional Diversity of p53 in Human and Wild Animals.
Carcinoma
Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.
Carcinoma
GATA1-induced upregulation of LINC01503 promotes carboplatin resistance in ovarian carcinoma by upregulating PD-L1 via sponging miR-766-5p.
Carcinoma
GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.
Carcinoma
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
Carcinoma
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Carcinoma
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Carcinoma
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Carcinoma
Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
Carcinoma
Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.
Carcinoma
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
Carcinoma
HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines.
Carcinoma
Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
Carcinoma
Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas.
Carcinoma
Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas.
Carcinoma
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.
Carcinoma
HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Carcinoma
HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status.
Carcinoma
High co-expression of PD-L1 and HIF-1? correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Carcinoma
High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.
Carcinoma
High Expression of PD-L1 and PD-L2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
Carcinoma
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Carcinoma
High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.
Carcinoma
High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy.
Carcinoma
High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Carcinoma
High sensitivity of cultured human trophoblasts to ribosome-inactivating proteins.
Carcinoma
High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.
Carcinoma
Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Carcinoma
Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Carcinoma
Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
Carcinoma
Histochemical expression of sialoglycoconjugates in carcinoma of the papilla of Vater.
Carcinoma
Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
Carcinoma
HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.
Carcinoma
Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds.
Carcinoma
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Carcinoma
Identification and characterization of an alternative cancer-derived PD-L1 splice variant.
Carcinoma
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.
Carcinoma
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
Carcinoma
Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer.
Carcinoma
IFN-?-related mRNA profile predicts clinical response to PD-1 blockade.
Carcinoma
IFN? induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
Carcinoma
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Carcinoma
Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients.
Carcinoma
Immune checkpoint analysis in lip cancer.
Carcinoma
Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?
Carcinoma
Immune checkpoint inhibitors in the treatment of cancer.
Carcinoma
Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing.
Carcinoma
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
Carcinoma
Immune checkpoints: A therapeutic target in triple negative breast cancer.
Carcinoma
Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma.
Carcinoma
Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.
Carcinoma
Immune Infiltrates of m6A RNA Methylation-Related lncRNAs and Identification of PD-L1 in Patients With Primary Head and Neck Squamous Cell Carcinoma.
Carcinoma
Immune microenvironment and expression of PD-L1, PD-1, cancer testis antigen PRAME and MHC I in salivary duct carcinoma.
Carcinoma
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
Carcinoma
Immune-related signature predicts the prognosis and immunotherapy benefit in bladder cancer.
Carcinoma
Immunohistochemical Analysis of Foxp3(+), CD4(+), CD8(+) Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma.
Carcinoma
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience.
Carcinoma
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.
Carcinoma
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Carcinoma
Immunotherapy for squamous cell carcinoma of the head and neck.
Carcinoma
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
Carcinoma
Immunotoxins in cancer therapy: Review and update.
Carcinoma
Immunotoxins to human small-cell lung cancer.
Carcinoma
Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Carcinoma
Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma.
Carcinoma
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
Carcinoma
Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Carcinoma
Impact of PD-L1 Protein Expression on Renal Cell Carcinoma Histo-differentiation.
Carcinoma
Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma.
Carcinoma
In vitro and in vivo cytotoxic activity of native and ricin conjugated monoclonal antibodies to HBs antigen for Alexander primary liver cell carcinoma cells and tumours.
Carcinoma
In vitro and in vivo efficacy of heat shock protein specific immunotoxins on human tumor cells.
Carcinoma
In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: relevance to immunotherapy of prostate carcinoma.
Carcinoma
Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma.
Carcinoma
Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
Carcinoma
Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Carcinoma
Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study.
Carcinoma
Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Carcinoma
Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
Carcinoma
Increased PD-L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation.
Carcinoma
Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200.
Carcinoma
Independent association of PD-L1 expression with non-inactivated VHL clear cell renal cell carcinoma - a finding with therapeutic potential.
Carcinoma
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Carcinoma
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Carcinoma
Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells: B7-H1 induction by Porphyromonas gingivalis fractions.
Carcinoma
Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma.
Carcinoma
Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors.
Carcinoma
Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma.
Carcinoma
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Carcinoma
iNOS Expression by Tumor-Infiltrating Lymphocytes, PD-L1 and Prognosis in Non-Small-Cell Lung Cancer.
Carcinoma
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Carcinoma
Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Carcinoma
Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Carcinoma
Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study.
Carcinoma
Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
Carcinoma
Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC.
Carcinoma
Interpretation According to Clone-Specific PD-L1 Cutoffs Reveals Better Concordance in Muscle-Invasive Urothelial Carcinoma.
Carcinoma
Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease.
Carcinoma
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Carcinoma
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.
Carcinoma
Intratumoral Heterogeneity in PD-L1 Immunoreactivity is Associated with Variation in Non-Small Cell Lung Carcinoma Histotype.
Carcinoma
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
Carcinoma
Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
Carcinoma
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.
Carcinoma
JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Carcinoma
KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
Carcinoma
Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint Inhibitor.
Carcinoma
Lack of efficacy of radiation therapy plus PD-L1 blockade for Merkel cell carcinoma arising in a patient with chronic active Epstein-Barr virus infection.
Carcinoma
Lactate induces PD-L1 in HRASG12V-positive oropharyngeal squamous cell carcinoma.
Carcinoma
Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1.
Carcinoma
LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
Carcinoma
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
Carcinoma
Lectin-resistant variants of mouse Lewis lung carcinoma cells. II. Altered glycosylation of membrane glycoproteins.
Carcinoma
Letter to the Editor regarding, "The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis".
Carcinoma
Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics.
Carcinoma
LncRNA SNHG1 regulates immune escape of renal cell carcinoma by targeting miR-129-3p to activate STAT3 and PD-L1.
Carcinoma
Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report.
Carcinoma
Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Carcinoma
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.
Carcinoma
Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Carcinoma
Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma.
Carcinoma
Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Carcinoma
Macrophages in Oral Carcinomas: Relationship with Cancer Stem Cell Markers and PD-L1 Expression.
Carcinoma
Major DNA fragmentation is a late event in apoptosis.
Carcinoma
Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1.
Carcinoma
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
Carcinoma
Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.
Carcinoma
Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Carcinoma
Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.
Carcinoma
Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma.
Carcinoma
MET is overexpressed in microsatellite instability-high gastric carcinoma.
Carcinoma
MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.
Carcinoma
Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.
Carcinoma
Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.
Carcinoma
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Carcinoma
Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus.
Carcinoma
Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral ?? T cell equilibrium via tumor-derived exosomes.
Carcinoma
MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma.
Carcinoma
Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.
Carcinoma
miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells.
Carcinoma
miR-375 inhibits IFN-?-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
Carcinoma
MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Carcinoma
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Carcinoma
Mixed large cell neuroendocrine carcinoma and squamous cell carcinoma of the colon: detailed molecular characterisation of two cases indicates a distinct colorectal cancer entity.
Carcinoma
MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Carcinoma
Molecular diagnostics of lung cancer in the clinic.
Carcinoma
Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
Carcinoma
MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.
Carcinoma
Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report.
Carcinoma
Myoepithelial Carcinoma Ex-Pleomorphic Adenoma: A Rare Pathology Misdiagnosed as Pleomorphic Adenoma; With a Novel TERT Promoter Mutation and High PD-L1 Expression.
Carcinoma
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
Carcinoma
Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.
Carcinoma
Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma.
Carcinoma
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
Carcinoma
New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles.
Carcinoma
NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Carcinoma
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Carcinoma
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Carcinoma
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Carcinoma
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Carcinoma
NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma.
Carcinoma
Nods for Atezolizumab and Nivolumab from FDA.
Carcinoma
Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
Carcinoma
Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Carcinoma
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Carcinoma
Oleic acid and oleoylethanolamide decrease interferon-?-induced expression of PD-L1 and induce apoptosis in human lung carcinoma cells.
Carcinoma
Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.
Carcinoma
Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.
Carcinoma
Optimized PD-L1 scoring of gastric cancer.
Carcinoma
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
Carcinoma
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Carcinoma
Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
Carcinoma
Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma.
Carcinoma
Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck.
Carcinoma
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration.
Carcinoma
Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.
Carcinoma
Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
Carcinoma
PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters.
Carcinoma
PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Carcinoma
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Carcinoma
PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Carcinoma
PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Carcinoma
PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma.
Carcinoma
PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications.
Carcinoma
PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
Carcinoma
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Carcinoma
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Carcinoma
PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
Carcinoma
PD-L1 and LAG-3 expression in advanced cutaneous squamous cell carcinomas.
Carcinoma
PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Carcinoma
PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.
Carcinoma
PD-L1 and PD-L2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Carcinoma
PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications.
Carcinoma
PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy.
Carcinoma
PD-L1 Antibody Comparison in Urothelial Carcinoma.
Carcinoma
PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification.
Carcinoma
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
Carcinoma
PD-L1 assessment in urothelial carcinoma: a practical approach.
Carcinoma
PD-L1 blockade for urothelial carcinoma.
Carcinoma
PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Carcinoma
PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma.
Carcinoma
PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC.
Carcinoma
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response.
Carcinoma
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Carcinoma
PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
Carcinoma
PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report.
Carcinoma
PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies.
Carcinoma
PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
Carcinoma
PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Carcinoma
PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis.
Carcinoma
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
Carcinoma
PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8.
Carcinoma
PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.
Carcinoma
PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Carcinoma
PD-L1 expression and infiltration by CD4+ and FoxP3+ T cells are increased in Xp11 translocation renal cell carcinoma and indicate poor prognosis.
Carcinoma
PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
Carcinoma
PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Carcinoma
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Carcinoma
PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
Carcinoma
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.
Carcinoma
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Carcinoma
PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer.
Carcinoma
PD-L1 expression at tumor invasive front is associated with EMT and poor prognosis in esophageal squamous cell carcinoma.
Carcinoma
PD-L1 expression by immunohistochemistry in salivary duct carcinoma.
Carcinoma
PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263.
Carcinoma
PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
Carcinoma
PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma.
Carcinoma
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Carcinoma
PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
Carcinoma
PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
Carcinoma
PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1(+) and CD8(+) tumor-infiltrating T cells and outcome.
Carcinoma
PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.
Carcinoma
PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival.
Carcinoma
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.
Carcinoma
PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis.
Carcinoma
PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Carcinoma
PD-L1 expression in HNPCC-associated colorectal cancer.
Carcinoma
PD-L1 expression in human cancers and its association with clinical outcomes.
Carcinoma
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
Carcinoma
PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes.
Carcinoma
PD-L1 expression in meningiomas.
Carcinoma
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
Carcinoma
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Carcinoma
PD-L1 Expression in Muscle Invasive Urothelial Carcinomas as Assessed via Immunohistochemistry: Correlations with Specific Clinical and Pathological Features, with Emphasis on Prognosis after Radical Cystectomy.
Carcinoma
PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype.
Carcinoma
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Carcinoma
PD-L1 expression in nonclear-cell renal cell carcinoma.
Carcinoma
PD-L1 expression in NSCLC: Role of cell blocks and concordance between samples.
Carcinoma
PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component.
Carcinoma
PD-L1 expression in papillary renal cell carcinoma.
Carcinoma
PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.
Carcinoma
PD-L1 expression in recurrent head and neck squamous cell carcinoma.
Carcinoma
PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.
Carcinoma
PD-L1 expression in sebaceous carcinomas.
Carcinoma
PD-L1 expression in small cell neuroendocrine carcinomas.
Carcinoma
PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung.
Carcinoma
PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival.
Carcinoma
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Carcinoma
PD-L1 expression in tongue squamous cell carcinoma.
Carcinoma
PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Carcinoma
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
Carcinoma
PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma.
Carcinoma
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents.
Carcinoma
PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology: Concordance Among 3 Commonly Used and Commercially Available Antibodies.
Carcinoma
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Carcinoma
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Carcinoma
PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma.
Carcinoma
PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy.
Carcinoma
PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
Carcinoma
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Carcinoma
PD-L1 expression is associated with p16
Carcinoma
PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma.
Carcinoma
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.
Carcinoma
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Carcinoma
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
Carcinoma
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases: Erratum.
Carcinoma
PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.
Carcinoma
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.
Carcinoma
PD-L1 Expression Is Regulated By NF-?B During EMT Signaling In Gastric Carcinoma.
Carcinoma
PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.
Carcinoma
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Carcinoma
PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Carcinoma
PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma.
Carcinoma
PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.
Carcinoma
PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma.
Carcinoma
PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins.
Carcinoma
PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
Carcinoma
PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma.
Carcinoma
PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma.
Carcinoma
PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases.
Carcinoma
PD-L1 Expression, T-lymphocyte Subpopulations and Langerhans Cells in Cutaneous Squamous Cell Carcinoma and Precursor Lesions.
Carcinoma
PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
Carcinoma
PD-L1 hotspot in tumor-infiltrating lymphocytes of radically treated esophageal squamous cell carcinoma: Pattern of recurrence and long-term clinical outcomes.
Carcinoma
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Carcinoma
PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
Carcinoma
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Carcinoma
PD-L1 in Combination with CD8+TIL and HIF-1? are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma.
Carcinoma
PD-L1 in squamous cell carcinoma of the oral tongue shows gender-specific association with prognosis.
Carcinoma
PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma.
Carcinoma
PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells.
Carcinoma
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Carcinoma
PD-L1 Interpretation in Cervical Carcinomas: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting.
Carcinoma
PD-L1 is a positive prognostic factor in squamous cell carcinoma of the nasal vestibule.
Carcinoma
PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level.
Carcinoma
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Carcinoma
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
Carcinoma
PD-L1 is prognostic factor in esophageal squamous cell carcinoma and is associated with EGFR.
Carcinoma
PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival.
Carcinoma
PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
Carcinoma
PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions.
Carcinoma
PD-L1 Positivity Associated with Presence of Tertiary Lymphoid Structures and High-Stage Disease in Upper Tract Urothelial Carcinoma.
Carcinoma
PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma.
Carcinoma
PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
Carcinoma
PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols.
Carcinoma
PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives.
Carcinoma
PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
Carcinoma
PD-L1 testing in urothelial carcinoma: are we there yet?
Carcinoma
PD-L1 Tumor Cell Expression in Upper Tract Urothelial Carcinomas is Associated With Higher Pathologic Stage.
Carcinoma
PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients.
Carcinoma
PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
Carcinoma
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Carcinoma
PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Carcinoma
PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type of the uterine cervix.
Carcinoma
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Carcinoma
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Carcinoma
PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
Carcinoma
PD1 blockage delays murine squamous cell carcinoma development.
Carcinoma
PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood.
Carcinoma
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Carcinoma
Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective.
Carcinoma
Pembrolizumab as a first-line therapy in spinocellular esophageal cancer.
Carcinoma
Pembrolizumab for the treatment of esophageal cancer.
Carcinoma
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.
Carcinoma
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Carcinoma
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Carcinoma
Penile Lymphoepithelioma-Like Carcinoma: A Rare Case With PD-L1 Expression.
Carcinoma
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Carcinoma
Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma.
Carcinoma
Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
Carcinoma
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.
Carcinoma
Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
Carcinoma
Photochemical internalisation increases the cytotoxic effect of the immunotoxin MOC31-gelonin.
Carcinoma
Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta.
Carcinoma
PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.
Carcinoma
PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma.
Carcinoma
Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC.
Carcinoma
Porphyromonas gingivalis cell wall components induce PD-L1 expression on human oral carcinoma cells by a RIP2-dependent mechanism.
Carcinoma
Porphyromonas gingivalis induced up-regulation of PD-L1 in colon carcinoma cells.
Carcinoma
Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy.
Carcinoma
Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
Carcinoma
Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
Carcinoma
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
Carcinoma
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma.
Carcinoma
Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
Carcinoma
Predictive value of CD8/FOXP3 ratio combined with PD-L1 expression for radiosensitivity in patients with squamous cell carcinoma of the larynx receiving definitive radiation therapy.
Carcinoma
Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma.
Carcinoma
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Carcinoma
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Carcinoma
Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.
Carcinoma
Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis.
Carcinoma
Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis.
Carcinoma
Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report.
Carcinoma
Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.
Carcinoma
Primary pulmonary lymphoepithelioma-like carcinoma with positive expression of Epstein-Barr virus and PD-L1: A case report.
Carcinoma
Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
Carcinoma
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
Carcinoma
Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
Carcinoma
Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
Carcinoma
Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.
Carcinoma
Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.
Carcinoma
Prognostic and Therapeutic Implications of Immune Classification by CD8+ Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma.
Carcinoma
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Carcinoma
Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Carcinoma
Prognostic factor analysis for patient outcome of PD-L1 expression in thoracic oesophageal squamous cell carcinoma.
Carcinoma
Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.
Carcinoma
Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.
Carcinoma
Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung.
Carcinoma
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.
Carcinoma
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Carcinoma
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Carcinoma
Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Carcinoma
Prognostic Relevance of CD4+, CD8+ and FOXP3+ TILs in Oral Squamous Cell Carcinoma and Correlations with PD-L1 and Cancer Stem Cell Markers.
Carcinoma
Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma.
Carcinoma
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.
Carcinoma
Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.
Carcinoma
Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Carcinoma
Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma.
Carcinoma
Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.
Carcinoma
Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
Carcinoma
Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
Carcinoma
Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Carcinoma
Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.
Carcinoma
Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma.
Carcinoma
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Carcinoma
Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.
Carcinoma
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.
Carcinoma
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
Carcinoma
Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Carcinoma
Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Carcinoma
Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy.
Carcinoma
Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
Carcinoma
Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Carcinoma
Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas.
Carcinoma
Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.
Carcinoma
Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Carcinoma
Prognostic value of PD-L1 combined positive score in patients with upper tract urothelial carcinoma.
Carcinoma
Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies.
Carcinoma
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
Carcinoma
Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis.
Carcinoma
Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
Carcinoma
Prognostic value of programmed cell death ligand-1 expression in the tumor-infiltrating immune cells of patients with lung cancer: A meta-analysis.
Carcinoma
Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
Carcinoma
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.
Carcinoma
Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer.
Carcinoma
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
Carcinoma
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Carcinoma
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Carcinoma
Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.
Carcinoma
Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer.
Carcinoma
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Carcinoma
Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Carcinoma
Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms.
Carcinoma
Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers.
Carcinoma
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
Carcinoma
Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin ?4/SNAI1/SIRT3 signaling pathway.
Carcinoma
Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Carcinoma
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Carcinoma
Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Carcinoma
Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.
Carcinoma
Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas.
Carcinoma
Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma.
Carcinoma
Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma.
Carcinoma
Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Carcinoma
Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma.
Carcinoma
Programmed death-1 ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squamous cell carcinoma in smokers.
Carcinoma
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Carcinoma
Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
Carcinoma
Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
Carcinoma
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Carcinoma
Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC.
Carcinoma
Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Carcinoma
Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.
Carcinoma
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.
Carcinoma
Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression.
Carcinoma
Publisher Correction: Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder.
Carcinoma
Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report.
Carcinoma
Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab.
Carcinoma
Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: A case report on the therapeutic regimen.
Carcinoma
Radioimmunoimaging and targeting treatment in an immunocompetent murine model of triple-negative breast cancer using radiolabeled anti-programmed death-ligand 1 monoclonal antibody.
Carcinoma
Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab.
Carcinoma
Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells.
Carcinoma
Re: Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications: S. A. M. Wankowicz, L. Werner, A. Orsola, J. Novak, M. Bowden, T. K. Choueiri, I. de Torres, J. Morote, G. J. Freeman, S. Signoretti and J. Bellmunt J Urol 2017;198:817-823.
Carcinoma
Re: Five-factor Prognostic Model for Survival of Post-platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Carcinoma
Re: Frequent PD-L1 Expression in Primary and Metastatic Penile Squamous Cell Carcinoma: Potential Opportunities for Immunotherapeutic Approaches.
Carcinoma
Re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.11.002.
Carcinoma
Re: PD-L1 Expression in Tumor Cells and the Immunologic Milieu of Bladder Carcinomas: A Pathologic Review of 165 Cases.
Carcinoma
Re: Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma: L. M. Krabbe, B. Heitplatz, S. Preuss, R. C. Hutchinson, S. L. Woldu, N. Singla, M. Boegemann, C. G. Wood, J. A. Karam, A. Z. Weizer, J. D. Raman, M. Remzi, N. Rioux-Leclercq, A. Haitel, L. M. Rapoport, P. V. Glybochko, M. Roscigno, C. Bolenz, K. Bensalah, A. I. Sagalowsky, S. F. Shariat, Y. Lotan, E. Xylinas and V. Margulis J Urol 2017;198:1253-1262.
Carcinoma
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Carcinoma
Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells.
Carcinoma
Relationship between IL-10 and PD-L1 in esophageal carcinoma tissues and IL-10 down-regulates PD-L1 expression via Met signaling pathway.
Carcinoma
Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines.
Carcinoma
Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
Carcinoma
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Carcinoma
Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort.
Carcinoma
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.
Carcinoma
Reply to Thomas Gevaert, Markus Eckstein, Rodolfo Montironi, and Antonio Lopez-Beltran's Letter to the Editor re: Maud Rijnders, Astrid A.M. van der Veldt, Tahlita C.M. Zuiverloon, et al. PD-L1 Antibody Comparison in Urothelial Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.11.002.
Carcinoma
Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
Carcinoma
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Carcinoma
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Carcinoma
Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report.
Carcinoma
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
Carcinoma
Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification.
Carcinoma
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
Carcinoma
Ribotoxins and their applications in probing the topographical structure of ribosomes.
Carcinoma
Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro.
Carcinoma
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Carcinoma
Role of Checkpoint Inhibition in Localized Bladder Cancer.
Carcinoma
Role of HPV status and PD-L1 expression in prognosis of laryngeal squamous cell carcinoma.
Carcinoma
Role of PD-L1 in radio-sensitivity of esophageal squamous cell carcinoma.
Carcinoma
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Carcinoma
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
Carcinoma
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Carcinoma
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Carcinoma
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).
Carcinoma
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
Carcinoma
Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis.
Carcinoma
Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates.
Carcinoma
Selective killing of laryngeal carcinoma cells by a monoclonal immunotoxin.
Carcinoma
Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes.
Carcinoma
Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes.
Carcinoma
Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma.
Carcinoma
Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
Carcinoma
Significance of PD-L1 Expression in Tongue Cancer Development.
Carcinoma
Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Carcinoma
Simultaneous blockade of multiple immune inhibitory checkpoints enhance anti-tumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Carcinoma
Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas.
Carcinoma
SNP-SNP Interaction in Genes Encoding PD-1/PD-L1 Axis as a Potential Risk Factor for Clear Cell Renal Cell Carcinoma.
Carcinoma
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Carcinoma
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Carcinoma
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.
Carcinoma
Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.
Carcinoma
Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression.
Carcinoma
Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
Carcinoma
Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma.
Carcinoma
Specific adsorption of functionalized colloids at the surface of living cells: A quantitative kinetic analysis of the receptor-mediated binding.
Carcinoma
Standardizing immunohistochemistry methodology for evaluation of PD-1 and PDL-1 expression in upper tract urothelial carcinoma.
Carcinoma
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
Carcinoma
Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?
Carcinoma
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Carcinoma
Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer.
Carcinoma
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Carcinoma
Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Carcinoma
Targeted Therapies in Advanced Gastric Cancer.
Carcinoma
Targeted therapy for upper gastrointestinal tract cancer: current and future prospects.
Carcinoma
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Carcinoma
Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.
Carcinoma
Targeting the TGF? pathway with galunisertib, a TGF?RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Carcinoma
TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1.
Carcinoma
The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Carcinoma
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.
Carcinoma
The clinical benefits of immune checkpoint inhibitor for thymic carcinomas ?experience of single public hospital in Japan?.
Carcinoma
The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Carcinoma
The conundrum of the Epstein-Barr virus-associated gastric carcinoma in the Americas.
Carcinoma
The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis.
Carcinoma
The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma.
Carcinoma
The effect of ricin B chain on the intracellular trafficking of an A chain immunotoxin.
Carcinoma
The emerging role of immunotherapy for esophageal cancer.
Carcinoma
The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma.
Carcinoma
The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.
Carcinoma
The expression of PD-L1 in salivary gland carcinomas.
Carcinoma
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Carcinoma
The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
Carcinoma
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Carcinoma
The immune microenvironment of breast ductal carcinoma in situ.
Carcinoma
The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
Carcinoma
The intracellular movement and cycling of ricin.
Carcinoma
The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.
Carcinoma
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.
Carcinoma
The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Carcinoma
The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Carcinoma
The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
Carcinoma
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Carcinoma
The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Carcinoma
The oncocytic variant of poorly differentiated thyroid carcinoma shows a specific immune-related gene expression profile.
Carcinoma
The Pattern and Clinicopathological Correlates of PD-L1 Expression in Cutaneous Squamous Cell Carcinoma.
Carcinoma
The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
Carcinoma
The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.
Carcinoma
The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis.
Carcinoma
The Positive Relationship Between ?H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma.
Carcinoma
The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Carcinoma
The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis.
Carcinoma
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.
Carcinoma
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Carcinoma
The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.
Carcinoma
The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer.
Carcinoma
The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
Carcinoma
The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count.
Carcinoma
The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma.
Carcinoma
The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma.
Carcinoma
The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma.
Carcinoma
The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
Carcinoma
The Role of PD-L1 Testing in Advanced Genitourinary Malignancies.
Carcinoma
The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma.
Carcinoma
The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
Carcinoma
The significance of Siglec-15 expression in resectable non-small cell lung cancer.
Carcinoma
The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
Carcinoma
The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma.
Carcinoma
The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Carcinoma
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Carcinoma
Three Drugs Approved for Urothelial Carcinoma by FDA.
Carcinoma
Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database.
Carcinoma
TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Carcinoma
Toll-like receptor 4 facilitates binding of Shiga toxin to colon carcinoma and primary umbilical vein endothelial cells.
Carcinoma
Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review.
Carcinoma
Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line.
Carcinoma
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Carcinoma
TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas.
Carcinoma
Treatment of micrometastases from Lewis lung carcinoma with abrin and cyclophosphamide, given singly and in combination.
Carcinoma
Trial watch: TLR3 agonists in cancer therapy.
Carcinoma
Trichosanthin cooperates with Granzyme B to restrain tumor formation in tongue squamous cell carcinoma.
Carcinoma
Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Carcinoma
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.
Carcinoma
Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
Carcinoma
Tumor mutation burden: from comprehensive mutational screening to the clinic.
Carcinoma
Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.
Carcinoma
Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma.
Carcinoma
Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma.
Carcinoma
Tumor PD-L1 status and CD8
Carcinoma
Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.
Carcinoma
Tumor-Associated CD163+ M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer.
Carcinoma
Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
Carcinoma
Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer.
Carcinoma
Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.
Carcinoma
Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology.
Carcinoma
Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.
Carcinoma
Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.
Carcinoma
Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
Carcinoma
Uncovering PD-L1 and CD8+ TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma.
Carcinoma
Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells.
Carcinoma
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Carcinoma
Update on Immunohistochemistry for the Diagnosis of Lung Cancer.
Carcinoma
Update on the Treatment of Metastatic Urothelial Carcinoma.
Carcinoma
Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.
Carcinoma
Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
Carcinoma
Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study.
Carcinoma
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Carcinoma
Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma.
Carcinoma
XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
Carcinoma
YAP/STAT3 promotes the immune escape of larynx carcinoma by activating VEGFR1-TGF? signaling to facilitate PD-L1 expression in M2-like TAMs.
Carcinoma
[A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
Carcinoma
[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1?Antibody-Safety and Effectiveness of Pirfenidone].
Carcinoma
[Assessment of PD-L1 expression using the neural network analysis algorithm in non-small cell lung carcinoma biopsy specimens].
Carcinoma
[Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
Carcinoma
[Clinical relevance of common inhibitory immune checkpoint genes in esophageal squamous cell carcinoma].
Carcinoma
[Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis].
Carcinoma
[Concordance of PD-L1 expression detected by two immunohistochemical platforms and antibodies].
Carcinoma
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Carcinoma
[Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Carcinoma
[Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Carcinoma
[Late-Onset Acute Pneumonitis Caused by Pembrolizumab Used to Treat Postoperative Recurrence of Squamous Cell Carcinoma-A Case Report].
Carcinoma
[Mode of action, new targets and potential biomarkers in modern immunotherapy].
Carcinoma
[PD-L1 status in breast cancer].
Carcinoma
[Predictive value of PD-L1 diagnostics].
Carcinoma
[Preparation of an anti-human immunotoxin against bladder carcinoma and its in vitro targeting cytotoxicity]
Carcinoma
[Preparation of anticolon carcinoma vaccine with rich chaperone peptides and study on its anticancer efficacy.]
Carcinoma
[Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].
Carcinoma
[Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Carcinoma
[Synergistic antitumor activity of human breast cancer immunotoxins]
Carcinoma
[Systemic treatment of metastatic tumors of the upper urinary tract].
Carcinoma
[The Immune Checkpoints Inhibitors for Head and Neck Cancer].
Carcinoma
[The role of immunotherapy in the modern treatment of urothelial carcinoma].
Carcinoma in Situ
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Carcinoma in Situ
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Carcinoma, Acinar Cell
Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report.
Carcinoma, Acinar Cell
Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.
Carcinoma, Adenoid Cystic
Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland.
Carcinoma, Adenoid Cystic
EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells.
Carcinoma, Adenoid Cystic
PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications.
Carcinoma, Adenoid Cystic
Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms.
Carcinoma, Adenosquamous
Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
Carcinoma, Adenosquamous
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Carcinoma, Adenosquamous
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma.
Carcinoma, Adenosquamous
Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas.
Carcinoma, Adenosquamous
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Carcinoma, Adenosquamous
PD-L1 expression and surgical outcomes of adenosquamous carcinoma of the pancreas in a single-centre study of 56 lesions.
Carcinoma, Adenosquamous
PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.
Carcinoma, Adenosquamous
PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component.
Carcinoma, Adenosquamous
Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms.
Carcinoma, Adenosquamous
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Carcinoma, Adenosquamous
The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma.
Carcinoma, Basal Cell
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
Carcinoma, Basal Cell
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
Carcinoma, Basal Cell
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.
Carcinoma, Basal Cell
Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
Carcinoma, Basal Cell
Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy.
Carcinoma, Basal Cell
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Carcinoma, Basal Cell
Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study.
Carcinoma, Ductal
Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Carcinoma, Ductal
Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Carcinoma, Ductal
Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
Carcinoma, Ductal
In vitro potentiation by lonidamine of the sc-RIP saporin 6 effect in a human metastatic breast cancer cell line.
Carcinoma, Ductal
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.
Carcinoma, Ductal
PD-L1 in Breast Cancer: Comparative Analysis of Three Different Antibodies.
Carcinoma, Ductal
Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
Carcinoma, Ductal
Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma.
Carcinoma, Ductal
Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features.
Carcinoma, Ductal
T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.
Carcinoma, Ductal
The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
Carcinoma, Ductal
[Expression of PD-L1 and clinicopathologic correlation in invasive ductal carcinoma of breast with nodal metastasis].
Carcinoma, Ehrlich Tumor
Differential response of human melanoma and Ehrlich ascites cells in vitro to the ribosome-inactivating protein luffin.
Carcinoma, Ehrlich Tumor
Inhibitory effect of abrin on Ehrlich ascites tumor.
Carcinoma, Ehrlich Tumor
Nature of lectin-induced alteration of potassium transfer in Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
The binding of abrin and ricin by Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
The cytotoxic effects of abrin and ricin on Ehrlich ascites tumor cells.
Carcinoma, Ehrlich Tumor
The inhibitory effect of crystalline ricin in Ehrlich ascites tumor.
Carcinoma, Embryonal
Fibroblast growth factor complexed to the cytotoxin saporin is growth inhibitory but not cytotoxic for embryonal carcinoma cells.
Carcinoma, Embryonal
Mutants of embryonal carcinoma cells defective in the expression of embryoglycan.
Carcinoma, Embryonal
Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Carcinoma, Embryonal
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Carcinoma, Embryonal
Variant embryonal carcinoma cells lacking SSEA-1 and Forsmann antigens remain developmentally pluripotent.
Carcinoma, Endometrioid
Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.
Carcinoma, Endometrioid
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Carcinoma, Endometrioid
PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Carcinoma, Endometrioid
PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases.
Carcinoma, Endometrioid
The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
Carcinoma, Endometrioid
[Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Carcinoma, Giant Cell
PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.
Carcinoma, Hepatocellular
2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
Carcinoma, Hepatocellular
A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
A quantitative assay for concanavalin A- and Ricinus communis agglutinin-mediated agglutinations of rat ascites hepatoma cells. Relationship between concanavalin A binding and cell agglutination.
Carcinoma, Hepatocellular
Action on ricin and its polypeptide chains on cultured hepatoma cells.
Carcinoma, Hepatocellular
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.
Carcinoma, Hepatocellular
Adipocytes promote tumor progression and induce PD-L1 expression via TNF-?/IL-6 signaling.
Carcinoma, Hepatocellular
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
Carcinoma, Hepatocellular
An insight into the mechanism of cytotoxicity of ricin to hepatoma cell: roles of Bcl-2 family proteins, caspases, Ca(2+)-dependent proteases and protein kinase C.
Carcinoma, Hepatocellular
Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Association of PD-L1 and HIF-1? Coexpression with Poor Prognosis in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells.
Carcinoma, Hepatocellular
Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation.
Carcinoma, Hepatocellular
Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels.
Carcinoma, Hepatocellular
Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
Carcinoma, Hepatocellular
Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
Carcinoma, Hepatocellular
CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage.
Carcinoma, Hepatocellular
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study.
Carcinoma, Hepatocellular
Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma: Where does it come from?
Carcinoma, Hepatocellular
CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
Carcinoma, Hepatocellular
Combined Inhibition of TGF-?1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment.
Carcinoma, Hepatocellular
Comparative studies by scanning electron microscopy of the effect of ricin on the cell membrane of hepatoma cells and isolated hepatocytes.
Carcinoma, Hepatocellular
Comparison of the peptide and saccharide moieties of gamma-glutamyltransferase isolated from neoplastic and non-neoplastic human liver tissue.
Carcinoma, Hepatocellular
Comprehensive Analysis of the Immune Infiltrates and PD-L1 of m6A RNA Methylation Regulators in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients.
Carcinoma, Hepatocellular
Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population.
Carcinoma, Hepatocellular
Delivery of ricin toxin a-chain by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.
Carcinoma, Hepatocellular
Dendritic cells with an increased PD-L1 by TGF-? induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Differential entry of ricin into malignant and normal rat hepatocytes.
Carcinoma, Hepatocellular
Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression.
Carcinoma, Hepatocellular
Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?
Carcinoma, Hepatocellular
Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis.
Carcinoma, Hepatocellular
Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
Carcinoma, Hepatocellular
Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Carcinoma, Hepatocellular
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages.
Carcinoma, Hepatocellular
Frizzled-7 promoter is highly active in tumors and promoter-driven Shiga-like toxin I inhibits hepatocellular carcinoma growth.
Carcinoma, Hepatocellular
GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Graft PD-L1 expression as a marker for transplant rejection following anti-PD1 immunotherapy for recurrent liver tumors.
Carcinoma, Hepatocellular
Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.
Carcinoma, Hepatocellular
Hepatitis B virus-triggered PTEN/?-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Carcinoma, Hepatocellular
Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Carcinoma, Hepatocellular
Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer.
Carcinoma, Hepatocellular
IL-17A Secreted from Lymphatic Endothelial Cells Promotes Tumorigenesis by Up-regulation of PD-L1 in Hepatoma Stem Cells.
Carcinoma, Hepatocellular
IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Carcinoma, Hepatocellular
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
Carcinoma, Hepatocellular
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Immune checkpoint inhibitors in the treatment of cancer.
Carcinoma, Hepatocellular
In vitro and in vivo cytotoxic activity of native and ricin conjugated monoclonal antibodies to HBs antigen for Alexander primary liver cell carcinoma cells and tumours.
Carcinoma, Hepatocellular
Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
Carcinoma, Hepatocellular
Insulin-ricin B chain conjugate has enhanced biological activity in insulin-insensitive cells.
Carcinoma, Hepatocellular
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Carcinoma, Hepatocellular
Interferon regulatory factor 1 (IRF-1) downregulates Checkpoint kinase 1 (CHK1) through miR-195 to upregulate apoptosis and PD-L1 expression in Hepatocellular carcinoma (HCC) cells.
Carcinoma, Hepatocellular
Interstitial chemotherapy using thermosensitive gel-coated ricin in nude mice bearing a human hepatoma.
Carcinoma, Hepatocellular
Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression.
Carcinoma, Hepatocellular
Investigation on the effects of soluble programmed death-1 (sPD-1) enhancing anti-tumor immune response.
Carcinoma, Hepatocellular
KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Carcinoma, Hepatocellular
Killing efficiency affected by mutually modulated PD-1 and PD-L1 expression via NKT-hepatoma cell interactions.
Carcinoma, Hepatocellular
Lectin-binding proteins in nuclear preparations from rat liver and malignant tumors.
Carcinoma, Hepatocellular
Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Carcinoma, Hepatocellular
LINC00657 knockdown suppresses hepatocellular carcinoma progression by sponging miR-424 to regulate PD-L1 expression.
Carcinoma, Hepatocellular
Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Carcinoma, Hepatocellular
M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1? Signaling.
Carcinoma, Hepatocellular
Marmorin, a new ribosome inactivating protein with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from the mushroom Hypsizigus marmoreus.
Carcinoma, Hepatocellular
MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Carcinoma, Hepatocellular
Modulation of HCV-specific CD8 effector T-cell function with antiviral effect in infectious hepatitis C virus co-culture model.
Carcinoma, Hepatocellular
Momordin Ic induces HepG2 cell apoptosis through MAPK and PI3K/Akt-mediated mitochondrial pathways.
Carcinoma, Hepatocellular
MYC inhibition increases PD-L1 expression induced by IFN-? in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Observational Study of PD-L1, TGF-?, and Immune Cell Infiltrates in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion.
Carcinoma, Hepatocellular
Overexpression of PD-L1 and PD-L2 is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
Carcinoma, Hepatocellular
PD-1 expression is elevated in monocytes from hepatocellular carcinoma patients and contributes to CD8 T cell suppression.
Carcinoma, Hepatocellular
PD-L1 and Immune Infiltration of m6A RNA Methylation Regulators and Its miRNA Regulators in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
PD-L1 and Survival in Solid Tumors: A Meta-Analysis.
Carcinoma, Hepatocellular
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
PD-L1 expression in hepatocellular carcinoma: A prognostic marker and therapeutic target for liver cancer?
Carcinoma, Hepatocellular
PD-L1 expression in human cancers and its association with clinical outcomes.
Carcinoma, Hepatocellular
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.
Carcinoma, Hepatocellular
PD-L1, fibrosis, and immunotherapy in hepatocellular carcinoma: the importance of a scientific method to explore observations and answer questions.
Carcinoma, Hepatocellular
PD-L1, Galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?
Carcinoma, Hepatocellular
Pd-ligand 1 is expressed in inflammatory cells but not in neoplastic cells in hepatocellular carcinoma: An immunohistochemical study.
Carcinoma, Hepatocellular
Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-? Signaling.
Carcinoma, Hepatocellular
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Carcinoma, Hepatocellular
Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.
Carcinoma, Hepatocellular
Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Carcinoma, Hepatocellular
Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
Carcinoma, Hepatocellular
Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma.
Carcinoma, Hepatocellular
Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma.
Carcinoma, Hepatocellular
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Carcinoma, Hepatocellular
Programmed Death Ligand-1 (PD-L1) regulated by NRF- 2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Carcinoma, Hepatocellular
Promotion effects of DEHP on hepatocellular carcinoma models: up-regulation of PD-L1 by activating the JAK2/STAT3 pathway.
Carcinoma, Hepatocellular
Purification and characterization of a novel type i ribosome inactivating protein, pachyerosin, from Pachyrhizus erosus seeds, and preparation of its immunotoxin against human hepatoma cells.
Carcinoma, Hepatocellular
Recent developments with immunotherapy for hepatocellular carcinoma.
Carcinoma, Hepatocellular
Recombinant VAA-I from Viscum album induces apoptotic cell death of hepatocellular carcinoma SMMC7721 cells.
Carcinoma, Hepatocellular
Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines.
Carcinoma, Hepatocellular
Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Ricin B-chain promotes the internalisation of liposomal contents into rat hepatoma cells.
Carcinoma, Hepatocellular
Ricinus communis agglutinin II-reactive glycoproteins from the ascites of patients with hepatocellular carcinoma and their use in enzyme-linked immunosorbent assay.
Carcinoma, Hepatocellular
Role of MAPK activity in PD-L1 expression in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Selective antitumor effect of thioether-linked immunotoxins composed of gelonin and monoclonal antibody to alpha-fetoprotein or its F(ab')2 fragment.
Carcinoma, Hepatocellular
Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Soluble forms of gamma-glutamyltransferase in human adult liver, fetal liver, and primary hepatoma compared.
Carcinoma, Hepatocellular
Soluble PD-L1 and prognosis of patients with hepatocellular carcinoma.
Carcinoma, Hepatocellular
Suppression of furin by interferon-? and the impact on hepatitis B virus antigen biosynthesis in human hepatocytes.
Carcinoma, Hepatocellular
Suppression of hepatoma tumor growth by systemic administration of the phytotoxin gelonin driven by the survivin promoter.
Carcinoma, Hepatocellular
Synthesis of green fluorescent protein-ricin and monitoring of its intracellular trafficking.
Carcinoma, Hepatocellular
The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
Carcinoma, Hepatocellular
The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Carcinoma, Hepatocellular
Transcriptional activation of PD-L1 by Sox2 contributes to the proliferation of hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Trichosanthin-monoclonal antibody conjugate specifically cytotoxic to human hepatoma cells in vitro.
Carcinoma, Hepatocellular
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Upregulation of PD-L1 expression promotes epithelial-to-mesenchymal transition in sorafenib-resistant hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Use of quantitative image microfluorometry to follow fluorescent ricin internalization in single living cells.
Carcinoma, Hepatocellular
WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
Carcinoma, Hepatocellular
[A study of ricinus communis agglutinin I receptors in liver cancer tissues]
Carcinoma, Hepatocellular
[Effects of interstitial chemotherapy using thermosensitive gel-coated ricin on hepatoma H22-bearing mice.]
Carcinoma, Hepatocellular
[Interaction between ricin and Zajdela ascitic hepatoma cells]
Carcinoma, Hepatocellular
Metastatic lymphoepithelioma-like hepatocellular carcinoma: a potential diagnostic pitfall and demonstration of PD-L1 expression.
Carcinoma, Intraductal, Noninfiltrating
Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Carcinoma, Intraductal, Noninfiltrating
Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast.
Carcinoma, Intraductal, Noninfiltrating
Higher Densities of Tumour-Infiltrating Lymphocytes and CD4+ T Cells Predict Recurrence and Progression of Ductal Carcinoma in Situ of the Breast.
Carcinoma, Intraductal, Noninfiltrating
Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.
Carcinoma, Intraductal, Noninfiltrating
Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features.
Carcinoma, Intraductal, Noninfiltrating
The immune microenvironment of breast ductal carcinoma in situ.
Carcinoma, Intraductal, Noninfiltrating
The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
Carcinoma, Large Cell
Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.
Carcinoma, Large Cell
Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors.
Carcinoma, Large Cell
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Carcinoma, Large Cell
Pulmonary large cell carcinoma, highly positive for PD-L1, shows marked response to pembrolizumab: A case report.
Carcinoma, Large Cell
Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort.
Carcinoma, Lewis Lung
Administration of Dendritic Cells and Anti-PD-1 Antibody Converts X-ray Irradiated Tumors Into Effective In situ Vaccines.
Carcinoma, Lewis Lung
Design, Synthesis, and Evaluation of o-(Biphenyl-3-ylmethoxy)nitrophenyl Derivatives as PD-1/PD-L1 Inhibitors with Potent Anticancer Efficacy In Vivo.
Carcinoma, Lewis Lung
Effects of Tussilago farfara L. Polysaccharides on the Expression of PD-1 (CD279) and PD-L1 (CD274) in Peripheral Blood and Tumor Tissue Lymphocytes in Mice with Lewis Lung Carcinoma.
Carcinoma, Lewis Lung
Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti-PD-1 Immunotherapy.
Carcinoma, Lewis Lung
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Carcinoma, Lewis Lung
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Carcinoma, Lewis Lung
Lectin-resistant variants of mouse Lewis lung carcinoma cells. II. Altered glycosylation of membrane glycoproteins.
Carcinoma, Lewis Lung
MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.
Carcinoma, Lewis Lung
Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
Carcinoma, Lewis Lung
Treatment of micrometastases from Lewis lung carcinoma with abrin and cyclophosphamide, given singly and in combination.
Carcinoma, Lobular
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Carcinoma, Lobular
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.
Carcinoma, Medullary
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?
Carcinoma, Medullary
PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.
Carcinoma, Medullary
Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.
Carcinoma, Merkel Cell
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Carcinoma, Merkel Cell
Avelumab in gastric cancer.
Carcinoma, Merkel Cell
Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.
Carcinoma, Merkel Cell
Expression and prognostic significance of programmed death-ligand 1 (PD-L1) in Merkel cell carcinoma.
Carcinoma, Merkel Cell
Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
Carcinoma, Merkel Cell
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
Carcinoma, Merkel Cell
Lack of efficacy of radiation therapy plus PD-L1 blockade for Merkel cell carcinoma arising in a patient with chronic active Epstein-Barr virus infection.
Carcinoma, Merkel Cell
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Carcinoma, Merkel Cell
Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma.
Carcinoma, Merkel Cell
PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters.
Carcinoma, Merkel Cell
PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Carcinoma, Merkel Cell
PD-L1 blockade with avelumab: A new paradigm for treating Merkel cell carcinoma.
Carcinoma, Merkel Cell
PD-L1 expression in human cancers and its association with clinical outcomes.
Carcinoma, Merkel Cell
PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival.
Carcinoma, Merkel Cell
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Carcinoma, Merkel Cell
PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type of the uterine cervix.
Carcinoma, Merkel Cell
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Carcinoma, Merkel Cell
Prognostic Impact of MCPyV and TIL Subtyping in Merkel Cell Carcinoma: Evidence from a Large European Cohort of 95 Patients.
Carcinoma, Merkel Cell
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Carcinoma, Merkel Cell
The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.
Carcinoma, Mucoepidermoid
Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms.
Carcinoma, Neuroendocrine
Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
Carcinoma, Neuroendocrine
Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix.
Carcinoma, Neuroendocrine
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Carcinoma, Neuroendocrine
Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Carcinoma, Neuroendocrine
Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
Carcinoma, Neuroendocrine
High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression.
Carcinoma, Neuroendocrine
Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors.
Carcinoma, Neuroendocrine
PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity.
Carcinoma, Neuroendocrine
PD-L1 expression in large cell neuroendocrine carcinoma of the lung.
Carcinoma, Neuroendocrine
PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Carcinoma, Neuroendocrine
PD-L1 expression in small cell neuroendocrine carcinomas.
Carcinoma, Neuroendocrine
PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type of the uterine cervix.
Carcinoma, Neuroendocrine
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
Carcinoma, Neuroendocrine
Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.
Carcinoma, Neuroendocrine
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.
Carcinoma, Neuroendocrine
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours.
Carcinoma, Neuroendocrine
Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
Carcinoma, Neuroendocrine
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Carcinoma, Neuroendocrine
[Basic and translational research progress of gastrointestinal neuroendocrine neoplasmas].
Carcinoma, Non-Small-Cell Lung
155P: PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Carcinoma, Non-Small-Cell Lung
18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
A Case Series of Two Patients Presenting With Pericardial Effusion as First Manifestation of Non-Small Cell Lung Cancer With BRAF Mutation and Expression Of PD-L1.
Carcinoma, Non-Small-Cell Lung
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland.
Carcinoma, Non-Small-Cell Lung
A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Carcinoma, Non-Small-Cell Lung
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Carcinoma, Non-Small-Cell Lung
A novel bifunctional anti-PD-L1/TGF-? Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.
Carcinoma, Non-Small-Cell Lung
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Carcinoma, Non-Small-Cell Lung
A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Carcinoma, Non-Small-Cell Lung
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.
Carcinoma, Non-Small-Cell Lung
A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.
Carcinoma, Non-Small-Cell Lung
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
Carcinoma, Non-Small-Cell Lung
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFN? signaling in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Accurate PD-L1 Protocols for Non-Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3.
Carcinoma, Non-Small-Cell Lung
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Carcinoma, Non-Small-Cell Lung
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Carcinoma, Non-Small-Cell Lung
Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell-block specimens.
Carcinoma, Non-Small-Cell Lung
Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence.
Carcinoma, Non-Small-Cell Lung
Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.
Carcinoma, Non-Small-Cell Lung
Advances in cancer immunology and cancer immunotherapy.
Carcinoma, Non-Small-Cell Lung
Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy.
Carcinoma, Non-Small-Cell Lung
Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors: A protocol for systematic review and meta-analysis.
Carcinoma, Non-Small-Cell Lung
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cut-Offs in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Carcinoma, Non-Small-Cell Lung
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Carcinoma, Non-Small-Cell Lung
An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Carcinoma, Non-Small-Cell Lung
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
Carcinoma, Non-Small-Cell Lung
Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.
Carcinoma, Non-Small-Cell Lung
Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials.
Carcinoma, Non-Small-Cell Lung
Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Carcinoma, Non-Small-Cell Lung
Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Carcinoma, Non-Small-Cell Lung
Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Assays for predicting and monitoring responses to lung cancer immunotherapy.
Carcinoma, Non-Small-Cell Lung
Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Carcinoma, Non-Small-Cell Lung
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Carcinoma, Non-Small-Cell Lung
Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Carcinoma, Non-Small-Cell Lung
Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
Carcinoma, Non-Small-Cell Lung
Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Carcinoma, Non-Small-Cell Lung
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Carcinoma, Non-Small-Cell Lung
Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
Carcinoma, Non-Small-Cell Lung
Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications.
Carcinoma, Non-Small-Cell Lung
Association Between PD-L1 Expression and Metabolic Activity on
Carcinoma, Non-Small-Cell Lung
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Carcinoma, Non-Small-Cell Lung
Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population.
Carcinoma, Non-Small-Cell Lung
Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Carcinoma, Non-Small-Cell Lung
Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
Carcinoma, Non-Small-Cell Lung
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy.
Carcinoma, Non-Small-Cell Lung
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Carcinoma, Non-Small-Cell Lung
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Carcinoma, Non-Small-Cell Lung
Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software.
Carcinoma, Non-Small-Cell Lung
Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Carcinoma, Non-Small-Cell Lung
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation.
Carcinoma, Non-Small-Cell Lung
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial.
Carcinoma, Non-Small-Cell Lung
Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells.
Carcinoma, Non-Small-Cell Lung
Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
Carcinoma, Non-Small-Cell Lung
Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Blockade of PD-1 decreases neutrophilic inflammation and lung damage in experimental COPD.
Carcinoma, Non-Small-Cell Lung
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Carcinoma, Non-Small-Cell Lung
Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Carcinoma, Non-Small-Cell Lung
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Carcinoma, Non-Small-Cell Lung
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
Carcinoma, Non-Small-Cell Lung
CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
Carcinoma, Non-Small-Cell Lung
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
Carcinoma, Non-Small-Cell Lung
Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.
Carcinoma, Non-Small-Cell Lung
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
Carcinoma, Non-Small-Cell Lung
Challenges of PD-L1 testing in non-small cell lung cancer and beyond.
Carcinoma, Non-Small-Cell Lung
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Carcinoma, Non-Small-Cell Lung
Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
Carcinoma, Non-Small-Cell Lung
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.
Carcinoma, Non-Small-Cell Lung
Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images.
Carcinoma, Non-Small-Cell Lung
Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-? induced epithelial mesenchymal transition in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Circular RNA circ_0000284 plays an oncogenic role in the progression of non-small cell lung cancer through the miR-377-3p-mediated PD-L1 promotion.
Carcinoma, Non-Small-Cell Lung
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Carcinoma, Non-Small-Cell Lung
Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics.
Carcinoma, Non-Small-Cell Lung
Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study.
Carcinoma, Non-Small-Cell Lung
Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
Carcinoma, Non-Small-Cell Lung
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Carcinoma, Non-Small-Cell Lung
Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Carcinoma, Non-Small-Cell Lung
Clinical significance of ? 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Clinical significance of PD-L1 expression in patients with surgically resected non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Carcinoma, Non-Small-Cell Lung
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.
Carcinoma, Non-Small-Cell Lung
Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.
Carcinoma, Non-Small-Cell Lung
Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
Carcinoma, Non-Small-Cell Lung
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Co-expression of PD-L1 and HIF-1? predicts poor prognosis in Patients with Non-small Cell Lung Cancer after surgery.
Carcinoma, Non-Small-Cell Lung
Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ?50% treated with front-line pembrolizumab'.
Carcinoma, Non-Small-Cell Lung
Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Comparability of PD-L1 immunohistochemistry assays for non-small cell lung cancer: a systematic review.
Carcinoma, Non-Small-Cell Lung
Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients.
Carcinoma, Non-Small-Cell Lung
Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Carcinoma, Non-Small-Cell Lung
Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Carcinoma, Non-Small-Cell Lung
Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
Carcinoma, Non-Small-Cell Lung
Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
Carcinoma, Non-Small-Cell Lung
Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small cell lung cancer in clinical practice.
Carcinoma, Non-Small-Cell Lung
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Carcinoma, Non-Small-Cell Lung
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Carcinoma, Non-Small-Cell Lung
Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Carcinoma, Non-Small-Cell Lung
Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Concordance of PD-L1 Expression Detection in Non-Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC).
Carcinoma, Non-Small-Cell Lung
Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Correction of acknowledgments: PD-L1 testing in non-small cell lung cancer: past, present, and future.
Carcinoma, Non-Small-Cell Lung
Correction to: High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Carcinoma, Non-Small-Cell Lung
Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort.
Carcinoma, Non-Small-Cell Lung
Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver.
Carcinoma, Non-Small-Cell Lung
Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Carcinoma, Non-Small-Cell Lung
Correlation of
Carcinoma, Non-Small-Cell Lung
Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
Carcinoma, Non-Small-Cell Lung
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
Carcinoma, Non-Small-Cell Lung
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
Carcinoma, Non-Small-Cell Lung
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Carcinoma, Non-Small-Cell Lung
Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels.
Carcinoma, Non-Small-Cell Lung
CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study.
Carcinoma, Non-Small-Cell Lung
CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
Carcinoma, Non-Small-Cell Lung
Current PD-L1 immunohistochemistry for non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Carcinoma, Non-Small-Cell Lung
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
Carcinoma, Non-Small-Cell Lung
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Carcinoma, Non-Small-Cell Lung
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.
Carcinoma, Non-Small-Cell Lung
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Carcinoma, Non-Small-Cell Lung
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
Carcinoma, Non-Small-Cell Lung
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
Carcinoma, Non-Small-Cell Lung
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.
Carcinoma, Non-Small-Cell Lung
Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas.
Carcinoma, Non-Small-Cell Lung
Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27kip1 /CDK4 axis in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report.
Carcinoma, Non-Small-Cell Lung
Durvalumab Promising for NSCLC.
Carcinoma, Non-Small-Cell Lung
Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
Carcinoma, Non-Small-Cell Lung
E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features.
Carcinoma, Non-Small-Cell Lung
EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Carcinoma, Non-Small-Cell Lung
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Carcinoma, Non-Small-Cell Lung
Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Carcinoma, Non-Small-Cell Lung
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Carcinoma, Non-Small-Cell Lung
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ?50.
Carcinoma, Non-Small-Cell Lung
Efficiency of Cytology Samples for PD-L1 Evaluation and Comparison with Tissue Samples.
Carcinoma, Non-Small-Cell Lung
EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative.
Carcinoma, Non-Small-Cell Lung
EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Carcinoma, Non-Small-Cell Lung
Eliminating Radiation Resistance of Non-Small Cell Lung Cancer by Dihydroartemisinin Through Abrogating Immunity Escaping and Promoting Radiation Sensitivity by Inhibiting PD-L1 Expression.
Carcinoma, Non-Small-Cell Lung
Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report.
Carcinoma, Non-Small-Cell Lung
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Carcinoma, Non-Small-Cell Lung
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis.
Carcinoma, Non-Small-Cell Lung
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor.
Carcinoma, Non-Small-Cell Lung
Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Carcinoma, Non-Small-Cell Lung
Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung.
Carcinoma, Non-Small-Cell Lung
Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Expression of PD-L1, cancer stem cell and epithelial-mesenchymal transition phenotype in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay.
Carcinoma, Non-Small-Cell Lung
Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.
Carcinoma, Non-Small-Cell Lung
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.
Carcinoma, Non-Small-Cell Lung
External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different.
Carcinoma, Non-Small-Cell Lung
EZH2 regulates PD-L1 expression via HIF-1? in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Carcinoma, Non-Small-Cell Lung
Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
First Anti-PD-L1 Drug Approved for NSCLC.
Carcinoma, Non-Small-Cell Lung
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
Carcinoma, Non-Small-Cell Lung
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ?50% in a multicenter real-life cohort: The PEMBREIZH study.
Carcinoma, Non-Small-Cell Lung
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Carcinoma, Non-Small-Cell Lung
First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Carcinoma, Non-Small-Cell Lung
Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1.
Carcinoma, Non-Small-Cell Lung
FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenter PGxLUNG study.
Carcinoma, Non-Small-Cell Lung
Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report.
Carcinoma, Non-Small-Cell Lung
Harmonization across programmed death ligand 1 (PD-L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing.
Carcinoma, Non-Small-Cell Lung
Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1.
Carcinoma, Non-Small-Cell Lung
Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Carcinoma, Non-Small-Cell Lung
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Carcinoma, Non-Small-Cell Lung
HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status.
Carcinoma, Non-Small-Cell Lung
High co-expression of PD-L1 and HIF-1? correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Carcinoma, Non-Small-Cell Lung
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
Carcinoma, Non-Small-Cell Lung
High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer.
Carcinoma, Non-Small-Cell Lung
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.
Carcinoma, Non-Small-Cell Lung
High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-?B signaling pathway in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Histology versus cytology: PD-L1 testing in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.
Carcinoma, Non-Small-Cell Lung
Identifying optimal first-line interventions for advanced non-small cell lung carcinoma according to PD-L1 expression: a systematic review and network meta-analysis.
Carcinoma, Non-Small-Cell Lung
Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients.
Carcinoma, Non-Small-Cell Lung
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Carcinoma, Non-Small-Cell Lung
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.
Carcinoma, Non-Small-Cell Lung
Immune checkpoint inhibitors in the treatment of cancer.
Carcinoma, Non-Small-Cell Lung
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
Carcinoma, Non-Small-Cell Lung
Immune checkpoints and their inhibition in cancer and infectious diseases.
Carcinoma, Non-Small-Cell Lung
Immune checkpoints: A therapeutic target in triple negative breast cancer.
Carcinoma, Non-Small-Cell Lung
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.
Carcinoma, Non-Small-Cell Lung
Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis.
Carcinoma, Non-Small-Cell Lung
Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Carcinoma, Non-Small-Cell Lung
Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.
Carcinoma, Non-Small-Cell Lung
Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features.
Carcinoma, Non-Small-Cell Lung
Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities.
Carcinoma, Non-Small-Cell Lung
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Carcinoma, Non-Small-Cell Lung
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
Carcinoma, Non-Small-Cell Lung
Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Carcinoma, Non-Small-Cell Lung
Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines.
Carcinoma, Non-Small-Cell Lung
Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.
Carcinoma, Non-Small-Cell Lung
Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center.
Carcinoma, Non-Small-Cell Lung
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Carcinoma, Non-Small-Cell Lung
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
Carcinoma, Non-Small-Cell Lung
Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
Carcinoma, Non-Small-Cell Lung
Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation.
Carcinoma, Non-Small-Cell Lung
Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Increased PD-L1 expression in erlotinib-resistant NSCLC cells with
Carcinoma, Non-Small-Cell Lung
Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Carcinoma, Non-Small-Cell Lung
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
iNOS Expression by Tumor-Infiltrating Lymphocytes, PD-L1 and Prognosis in Non-Small-Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Interlaboratory-concordance of PD-L1 immunohistochemistry for non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists.
Carcinoma, Non-Small-Cell Lung
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Carcinoma, Non-Small-Cell Lung
Intrathoracic core needle biopsy and repeat biopsy for PD-L1 evaluation in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Intratumoral Heterogeneity in PD-L1 Immunoreactivity is Associated with Variation in Non-Small Cell Lung Carcinoma Histotype.
Carcinoma, Non-Small-Cell Lung
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
Carcinoma, Non-Small-Cell Lung
Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker.
Carcinoma, Non-Small-Cell Lung
KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.
Carcinoma, Non-Small-Cell Lung
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (?50%) lung adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint Inhibitor.
Carcinoma, Non-Small-Cell Lung
Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
Carcinoma, Non-Small-Cell Lung
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
Carcinoma, Non-Small-Cell Lung
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression.
Carcinoma, Non-Small-Cell Lung
Liquid Biopsy and Lung Cancer.
Carcinoma, Non-Small-Cell Lung
LncRNA SOX2-OT/miR-30d-5p/PDK1 Regulates PD-L1 Checkpoint Through the mTOR Signaling Pathway to Promote Non-small Cell Lung Cancer Progression and Immune Escape.
Carcinoma, Non-Small-Cell Lung
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Carcinoma, Non-Small-Cell Lung
Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Carcinoma, Non-Small-Cell Lung
Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.
Carcinoma, Non-Small-Cell Lung
Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway.
Carcinoma, Non-Small-Cell Lung
Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis.
Carcinoma, Non-Small-Cell Lung
Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
Carcinoma, Non-Small-Cell Lung
Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images.
Carcinoma, Non-Small-Cell Lung
Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports.
Carcinoma, Non-Small-Cell Lung
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Carcinoma, Non-Small-Cell Lung
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Carcinoma, Non-Small-Cell Lung
NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Carcinoma, Non-Small-Cell Lung
Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ?50.
Carcinoma, Non-Small-Cell Lung
Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report.
Carcinoma, Non-Small-Cell Lung
Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC.
Carcinoma, Non-Small-Cell Lung
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Carcinoma, Non-Small-Cell Lung
Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates.
Carcinoma, Non-Small-Cell Lung
Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
Carcinoma, Non-Small-Cell Lung
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
Carcinoma, Non-Small-Cell Lung
Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.
Carcinoma, Non-Small-Cell Lung
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ?50% who progress on first-line immunotherapy: real-world data from a European cohort.
Carcinoma, Non-Small-Cell Lung
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.
Carcinoma, Non-Small-Cell Lung
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.
Carcinoma, Non-Small-Cell Lung
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Carcinoma, Non-Small-Cell Lung
PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
Carcinoma, Non-Small-Cell Lung
PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system
Carcinoma, Non-Small-Cell Lung
PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging.
Carcinoma, Non-Small-Cell Lung
PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
Carcinoma, Non-Small-Cell Lung
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Carcinoma, Non-Small-Cell Lung
PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype.
Carcinoma, Non-Small-Cell Lung
PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.
Carcinoma, Non-Small-Cell Lung
PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC.
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression in a Non-Small Cell Lung Cancer Specimen Obtained by EBUS-TBNA.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation.
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in NSCLC: Role of cell blocks and concordance between samples.
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression in Patients with Non-small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression in tumour buds of colorectal carcinoma.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression is associated with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression testing in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
Carcinoma, Non-Small-Cell Lung
PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study.
Carcinoma, Non-Small-Cell Lung
PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
Carcinoma, Non-Small-Cell Lung
PD-L1 immunohistochemistry in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.
Carcinoma, Non-Small-Cell Lung
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics.
Carcinoma, Non-Small-Cell Lung
PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
Carcinoma, Non-Small-Cell Lung
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Carcinoma, Non-Small-Cell Lung
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies.
Carcinoma, Non-Small-Cell Lung
PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
Carcinoma, Non-Small-Cell Lung
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Carcinoma, Non-Small-Cell Lung
PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.
Carcinoma, Non-Small-Cell Lung
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future.
Carcinoma, Non-Small-Cell Lung
PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
Carcinoma, Non-Small-Cell Lung
PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
Carcinoma, Non-Small-Cell Lung
PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
Carcinoma, Non-Small-Cell Lung
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ?50%: real-world data.
Carcinoma, Non-Small-Cell Lung
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.
Carcinoma, Non-Small-Cell Lung
Pembrolizumab Monotherapy for NSCLC Extends Survival.
Carcinoma, Non-Small-Cell Lung
Pembrolizumab monotherapy for PD-L1 ?50% non-small cell lung cancer, undisputed first choice?
Carcinoma, Non-Small-Cell Lung
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Carcinoma, Non-Small-Cell Lung
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Carcinoma, Non-Small-Cell Lung
Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
Carcinoma, Non-Small-Cell Lung
Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of???1% by the U.S. Food and Drug Administration.
Carcinoma, Non-Small-Cell Lung
Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Carcinoma, Non-Small-Cell Lung
Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin.
Carcinoma, Non-Small-Cell Lung
Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ?50% on first-line pembrolizumab.
Carcinoma, Non-Small-Cell Lung
Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
Carcinoma, Non-Small-Cell Lung
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Carcinoma, Non-Small-Cell Lung
Predictive potential and need for standardization of PD-L1 immunohistochemistry.
Carcinoma, Non-Small-Cell Lung
Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Carcinoma, Non-Small-Cell Lung
Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
Carcinoma, Non-Small-Cell Lung
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Carcinoma, Non-Small-Cell Lung
Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Carcinoma, Non-Small-Cell Lung
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance.
Carcinoma, Non-Small-Cell Lung
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Carcinoma, Non-Small-Cell Lung
Prognostic and predictive role of the tumor immune landscape.
Carcinoma, Non-Small-Cell Lung
Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience.
Carcinoma, Non-Small-Cell Lung
Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
Carcinoma, Non-Small-Cell Lung
Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Carcinoma, Non-Small-Cell Lung
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
Carcinoma, Non-Small-Cell Lung
Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1.
Carcinoma, Non-Small-Cell Lung
Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.
Carcinoma, Non-Small-Cell Lung
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Carcinoma, Non-Small-Cell Lung
Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Programmed death ligand 1 expression in EBUS aspirates of non-small cell lung cancer: Is interpretation affected by type of fixation?
Carcinoma, Non-Small-Cell Lung
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.
Carcinoma, Non-Small-Cell Lung
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Carcinoma, Non-Small-Cell Lung
Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.
Carcinoma, Non-Small-Cell Lung
Programmed death ligand-1 expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Programmed Death Ligand-1 Immunohistochemistry- A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Carcinoma, Non-Small-Cell Lung
Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
Carcinoma, Non-Small-Cell Lung
Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
Carcinoma, Non-Small-Cell Lung
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
Carcinoma, Non-Small-Cell Lung
Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Carcinoma, Non-Small-Cell Lung
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
Carcinoma, Non-Small-Cell Lung
Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
Carcinoma, Non-Small-Cell Lung
Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
Carcinoma, Non-Small-Cell Lung
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
Carcinoma, Non-Small-Cell Lung
Relationship Between Programmed Death-ligand 1 and Clinicopathological Characteristics in Non-small Cell Lung Cancer Patients.
Carcinoma, Non-Small-Cell Lung
Relationship Between Tumor Immune Markers and Fluorine-18-?-Methyltyrosine ([18F]FAMT) Uptake in Patients with Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Reliability of PD-L1 assays using small tissue samples compared with surgical specimens.
Carcinoma, Non-Small-Cell Lung
Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression.
Carcinoma, Non-Small-Cell Lung
Retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Carcinoma, Non-Small-Cell Lung
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.
Carcinoma, Non-Small-Cell Lung
Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Carcinoma, Non-Small-Cell Lung
ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Carcinoma, Non-Small-Cell Lung
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Carcinoma, Non-Small-Cell Lung
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).
Carcinoma, Non-Small-Cell Lung
Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors.
Carcinoma, Non-Small-Cell Lung
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
Carcinoma, Non-Small-Cell Lung
Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
Carcinoma, Non-Small-Cell Lung
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Carcinoma, Non-Small-Cell Lung
Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.
Carcinoma, Non-Small-Cell Lung
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations.
Carcinoma, Non-Small-Cell Lung
Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.
Carcinoma, Non-Small-Cell Lung
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Squamous NSCLC Improves with Atezolizumab Plus Chemo.
Carcinoma, Non-Small-Cell Lung
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Carcinoma, Non-Small-Cell Lung
Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression.
Carcinoma, Non-Small-Cell Lung
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Carcinoma, Non-Small-Cell Lung
Targeting PD-L1 in non-small cell lung cancer using CAR T cells.
Carcinoma, Non-Small-Cell Lung
Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
Carcinoma, Non-Small-Cell Lung
The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials.
Carcinoma, Non-Small-Cell Lung
The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Carcinoma, Non-Small-Cell Lung
The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.
Carcinoma, Non-Small-Cell Lung
The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study.
Carcinoma, Non-Small-Cell Lung
The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Carcinoma, Non-Small-Cell Lung
The effect of PD-L1 status on survival outcomes in patients with stage II-III non-small cell lung cancer treated with chemotherapy.
Carcinoma, Non-Small-Cell Lung
The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.
Carcinoma, Non-Small-Cell Lung
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Carcinoma, Non-Small-Cell Lung
The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.
Carcinoma, Non-Small-Cell Lung
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.
Carcinoma, Non-Small-Cell Lung
The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis.
Carcinoma, Non-Small-Cell Lung
The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
Carcinoma, Non-Small-Cell Lung
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Carcinoma, Non-Small-Cell Lung
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Carcinoma, Non-Small-Cell Lung
The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Carcinoma, Non-Small-Cell Lung
The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy.
Carcinoma, Non-Small-Cell Lung
The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
The Value of PD-L1 Expression in Metastatic Lymph Nodes of Advanced Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.
Carcinoma, Non-Small-Cell Lung
Three-Drug Regimen Bests Chemo in NSCLC.
Carcinoma, Non-Small-Cell Lung
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature.
Carcinoma, Non-Small-Cell Lung
Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells.
Carcinoma, Non-Small-Cell Lung
Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway.
Carcinoma, Non-Small-Cell Lung
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.
Carcinoma, Non-Small-Cell Lung
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Carcinoma, Non-Small-Cell Lung
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.
Carcinoma, Non-Small-Cell Lung
Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.
Carcinoma, Non-Small-Cell Lung
Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC).
Carcinoma, Non-Small-Cell Lung
Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature.
Carcinoma, Non-Small-Cell Lung
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
Carcinoma, Non-Small-Cell Lung
Use of an Additional 19-G EBUS-TBNA Needle Increases the Diagnostic Yield of EBUS-TBNA.
Carcinoma, Non-Small-Cell Lung
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Carcinoma, Non-Small-Cell Lung
Utility of PD-L1 testing on non-small cell lung cancer cytology specimens: An institutional experience with interobserver variability analysis.
Carcinoma, Non-Small-Cell Lung
Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses.
Carcinoma, Non-Small-Cell Lung
Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers.
Carcinoma, Non-Small-Cell Lung
YAP regulates PD-L1 expression in human NSCLC cells.
Carcinoma, Non-Small-Cell Lung
Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
[A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Carcinoma, Non-Small-Cell Lung
[Assessment of PD-L1 expression using the neural network analysis algorithm in non-small cell lung carcinoma biopsy specimens].
Carcinoma, Non-Small-Cell Lung
[Concordance of PD-L1 expression detected by two immunohistochemical platforms and antibodies].
Carcinoma, Non-Small-Cell Lung
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Carcinoma, Non-Small-Cell Lung
[Detection of PD-L1 expression in non-small cell lung cancer: current status].
Carcinoma, Non-Small-Cell Lung
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or ?Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Carcinoma, Non-Small-Cell Lung
[Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
Carcinoma, Non-Small-Cell Lung
[Immuno-Oncology: A Brief Overview].
Carcinoma, Non-Small-Cell Lung
[Immunotherapy for lung cancer].
Carcinoma, Non-Small-Cell Lung
[Immunotherapy of lung cancer].
Carcinoma, Non-Small-Cell Lung
[Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].
Carcinoma, Non-Small-Cell Lung
[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
Carcinoma, Non-Small-Cell Lung
[Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
Carcinoma, Non-Small-Cell Lung
[Research Progress on Heterogeneity of Tumor Mutation Burden in Patients with ?Non-small Cell Lung Cancer].
Carcinoma, Non-Small-Cell Lung
[Status of PD-L1 testing in non-small cell lung cancer in China].
Carcinoma, Non-Small-Cell Lung
[The expression of PD-L1 in the non-small cell lung cancer and the correlation with the novel lung adenocarcinoma classification].
Carcinoma, Ovarian Epithelial
Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors.
Carcinoma, Ovarian Epithelial
Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.
Carcinoma, Ovarian Epithelial
Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation.
Carcinoma, Ovarian Epithelial
Evaluation of p16 in Epithelial Ovarian Cancer for a 10-Year Study in Northeast China: Significance of HPV in Correlation with PD-L1 Expression.
Carcinoma, Ovarian Epithelial
Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.
Carcinoma, Ovarian Epithelial
Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200.
Carcinoma, Ovarian Epithelial
MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of ?-Catenin and c-Myc.
Carcinoma, Ovarian Epithelial
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Carcinoma, Ovarian Epithelial
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Carcinoma, Ovarian Epithelial
PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases.
Carcinoma, Ovarian Epithelial
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
[Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Carcinoma, Papillary
Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma.
Carcinoma, Renal Cell
A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with metastatic and unresectable renal cell carcinoma.
Carcinoma, Renal Cell
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Carcinoma, Renal Cell
Advances in cancer immunology and cancer immunotherapy.
Carcinoma, Renal Cell
Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Carcinoma, Renal Cell
Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade.
Carcinoma, Renal Cell
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Carcinoma, Renal Cell
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
Carcinoma, Renal Cell
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Carcinoma, Renal Cell
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Carcinoma, Renal Cell
BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
Carcinoma, Renal Cell
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Carcinoma, Renal Cell
Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study.
Carcinoma, Renal Cell
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Carcinoma, Renal Cell
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Carcinoma, Renal Cell
Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Carcinoma, Renal Cell
Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis.
Carcinoma, Renal Cell
Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor.
Carcinoma, Renal Cell
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Carcinoma, Renal Cell
Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Carcinoma, Renal Cell
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.
Carcinoma, Renal Cell
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Carcinoma, Renal Cell
Comparative Analysis of Programmed Cell Death Ligand 1 Assays in Renal Cell Carcinoma.
Carcinoma, Renal Cell
Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Correction: Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Carcinoma, Renal Cell
Correction: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Carcinoma, Renal Cell
Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial.
Carcinoma, Renal Cell
Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma.
Carcinoma, Renal Cell
Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.
Carcinoma, Renal Cell
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Carcinoma, Renal Cell
Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.
Carcinoma, Renal Cell
Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Carcinoma, Renal Cell
Effect of lectins on 3H-uridine and 3H-thymidine uptake by cultured renal cell carcinoma and normal renal cells.
Carcinoma, Renal Cell
Expression of PD-L1 on canine tumor cells and enhancement of IFN-? production from tumor-infiltrating cells by PD-L1 blockade.
Carcinoma, Renal Cell
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts.
Carcinoma, Renal Cell
Genomic and immunologic correlates of LAG-3 expression in cancer.
Carcinoma, Renal Cell
Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment.
Carcinoma, Renal Cell
Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.
Carcinoma, Renal Cell
HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Carcinoma, Renal Cell
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Carcinoma, Renal Cell
Immune Checkpoint Inhibitors in Metastatic Clear-cell Renal Cell Carcinoma: Is PD-L1 Expression Useful?
Carcinoma, Renal Cell
Immune checkpoints: A therapeutic target in triple negative breast cancer.
Carcinoma, Renal Cell
Immunotoxins in cancer therapy: Review and update.
Carcinoma, Renal Cell
Impact of PD-L1 Protein Expression on Renal Cell Carcinoma Histo-differentiation.
Carcinoma, Renal Cell
In vitro assessment of a chemically synthesized Shiga toxin receptor analog attached to chromosorb P (Synsorb Pk) as a specific absorbing agent of Shiga toxin 1 and 2.
Carcinoma, Renal Cell
Independent association of PD-L1 expression with non-inactivated VHL clear cell renal cell carcinoma - a finding with therapeutic potential.
Carcinoma, Renal Cell
JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Carcinoma, Renal Cell
LncRNA SNHG1 regulates immune escape of renal cell carcinoma by targeting miR-129-3p to activate STAT3 and PD-L1.
Carcinoma, Renal Cell
Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report.
Carcinoma, Renal Cell
Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Carcinoma, Renal Cell
Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.
Carcinoma, Renal Cell
Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus.
Carcinoma, Renal Cell
MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells.
Carcinoma, Renal Cell
New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.
Carcinoma, Renal Cell
NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Carcinoma, Renal Cell
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Carcinoma, Renal Cell
Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Carcinoma, Renal Cell
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Carcinoma, Renal Cell
PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation.
Carcinoma, Renal Cell
PD-L1 and VEGFR-2 expression in synchronous metastatic renal cell carcinoma treated with targeted therapy following cytoreductive nephrectomy.
Carcinoma, Renal Cell
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
Carcinoma, Renal Cell
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response.
Carcinoma, Renal Cell
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
Carcinoma, Renal Cell
PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8.
Carcinoma, Renal Cell
PD-L1 expression and infiltration by CD4+ and FoxP3+ T cells are increased in Xp11 translocation renal cell carcinoma and indicate poor prognosis.
Carcinoma, Renal Cell
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.
Carcinoma, Renal Cell
PD-L1 expression in human cancers and its association with clinical outcomes.
Carcinoma, Renal Cell
PD-L1 expression in meningiomas.
Carcinoma, Renal Cell
PD-L1 expression in nonclear-cell renal cell carcinoma.
Carcinoma, Renal Cell
PD-L1 expression in papillary renal cell carcinoma.
Carcinoma, Renal Cell
PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.
Carcinoma, Renal Cell
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Carcinoma, Renal Cell
PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
Carcinoma, Renal Cell
PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma.
Carcinoma, Renal Cell
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma.
Carcinoma, Renal Cell
PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma.
Carcinoma, Renal Cell
PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
Carcinoma, Renal Cell
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.
Carcinoma, Renal Cell
Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
Carcinoma, Renal Cell
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma.
Carcinoma, Renal Cell
Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
Carcinoma, Renal Cell
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.
Carcinoma, Renal Cell
Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.
Carcinoma, Renal Cell
Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Carcinoma, Renal Cell
Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies.
Carcinoma, Renal Cell
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.
Carcinoma, Renal Cell
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Carcinoma, Renal Cell
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
Carcinoma, Renal Cell
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
Carcinoma, Renal Cell
Significance of PD-L1 Expression in Tongue Cancer Development.
Carcinoma, Renal Cell
SNP-SNP Interaction in Genes Encoding PD-1/PD-L1 Axis as a Potential Risk Factor for Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Carcinoma, Renal Cell
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Carcinoma, Renal Cell
Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
Somatic mutations in renal cell carcinomas from Chinese patients revealed by targeted gene panel sequencing and their associations with prognosis and PD-L1 expression.
Carcinoma, Renal Cell
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
Carcinoma, Renal Cell
TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1.
Carcinoma, Renal Cell
The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
Carcinoma, Renal Cell
The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.
Carcinoma, Renal Cell
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Carcinoma, Renal Cell
The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Carcinoma, Renal Cell
The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients.
Carcinoma, Renal Cell
The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry.
Carcinoma, Renal Cell
The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma.
Carcinoma, Renal Cell
The Role of PD-L1 Testing in Advanced Genitourinary Malignancies.
Carcinoma, Renal Cell
The significance of lectin receptors in the kidney and in hypernephroma (renal adenocarcinoma).
Carcinoma, Renal Cell
The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Carcinoma, Renal Cell
Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database.
Carcinoma, Renal Cell
Toxicity of Checkpoint Inhibition in Advanced RCC: A Systematic Review.
Carcinoma, Renal Cell
Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Carcinoma, Renal Cell
Updated European Association of Urology Guidelines Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer.
Carcinoma, Renal Cell
[Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Carcinoma, Renal Cell
[Mode of action, new targets and potential biomarkers in modern immunotherapy].
Carcinoma, Small Cell
Case Report: Re-Sensitization to Gefitinib in Lung Adenocarcinoma Harboring EGFR Mutation and High PD-L1 Expression After Immunotherapy Resistance, Which Finally Transform Into Small Cell Carcinoma.
Carcinoma, Small Cell
Comprehensive evaluation of PD-L1 expression in primary and metastatic prostate cancer.
Carcinoma, Small Cell
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Carcinoma, Small Cell
Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience.
Carcinoma, Small Cell
PD-L1 expression in small cell neuroendocrine carcinomas.
Carcinoma, Small Cell
Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.
Carcinoma, Squamous Cell
A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Carcinoma, Squamous Cell
A nomogram incorporating PD-L1, NLR, and clinicopathologic features to predict inguinal lymph node metastasis in penile squamous cell carcinoma.
Carcinoma, Squamous Cell
A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non-Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen.
Carcinoma, Squamous Cell
A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.
Carcinoma, Squamous Cell
Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Carcinoma, Squamous Cell
Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
Carcinoma, Squamous Cell
Analysis of radiotherapy-induced alteration of CD8+ T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinoma.
Carcinoma, Squamous Cell
Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review.
Carcinoma, Squamous Cell
Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).
Carcinoma, Squamous Cell
Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.
Carcinoma, Squamous Cell
Assessment of circularized E7 RNA, GLUT1, and PD-L1 in anal squamous cell carcinoma.
Carcinoma, Squamous Cell
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
Carcinoma, Squamous Cell
Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma.
Carcinoma, Squamous Cell
Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Carcinoma, Squamous Cell
Association of PD-L1 expression in oral squamous cell carcinoma with smoking, sex, and p53 expression.
Carcinoma, Squamous Cell
Association of Programmed Death Ligand-1 Overexpression with the Grade and Stage of Oral Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
Carcinoma, Squamous Cell
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation.
Carcinoma, Squamous Cell
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Carcinoma, Squamous Cell
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.
Carcinoma, Squamous Cell
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Carcinoma, Squamous Cell
beta-Momorcharin, a plant glycoprotein, inhibits synthesis of macromolecules in embryos, splenocytes and tumor cells.
Carcinoma, Squamous Cell
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Carcinoma, Squamous Cell
Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Carcinoma, Squamous Cell
Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Case Report: A Case Report of a Histological Transformation of ALK-Rearranged Adenocarcinoma With High Expression of PD-L1 to Squamous Cell Carcinoma After Treatment With Alectinib.
Carcinoma, Squamous Cell
Case Report: Squamous Cell Carcinoma of Pancreas With High PD-L1 Expression: A Rare Presentation.
Carcinoma, Squamous Cell
Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab.
Carcinoma, Squamous Cell
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
Carcinoma, Squamous Cell
CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance.
Carcinoma, Squamous Cell
CD44+ cells in head and neck squamous cell carcinoma suppress T cell-mediated immunity by selective constitutive and inducible expression of PD-L1.
Carcinoma, Squamous Cell
Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Checkpoint cluster: biomarkers of response.
Carcinoma, Squamous Cell
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Carcinoma, Squamous Cell
Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series.
Carcinoma, Squamous Cell
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.
Carcinoma, Squamous Cell
Clinical significance of PD-L1 (CD274) enhanced expression in cervical squamous cell carcinoma.
Carcinoma, Squamous Cell
Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma.
Carcinoma, Squamous Cell
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Carcinoma, Squamous Cell
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
Carcinoma, Squamous Cell
Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Clinicopathological and prognostic significance of PD-L1 in oral cancer: A preliminary retrospective immunohistochemistry study.
Carcinoma, Squamous Cell
CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Carcinoma, Squamous Cell
Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Carcinoma, Squamous Cell
Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Carcinoma, Squamous Cell
Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
Carcinoma, Squamous Cell
Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.
Carcinoma, Squamous Cell
Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
Carcinoma, Squamous Cell
Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Carcinoma, Squamous Cell
Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Carcinoma, Squamous Cell
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Carcinoma, Squamous Cell
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Carcinoma, Squamous Cell
Correction to: PD-L1 expression in tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
Correction: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Carcinoma, Squamous Cell
Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort.
Carcinoma, Squamous Cell
Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
Carcinoma, Squamous Cell
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Carcinoma, Squamous Cell
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Differences of tumor-recruiting myeloid cells in murine squamous cell carcinoma influence the efficacy of immunotherapy combined with a TLR7 agonist and PD-L1 blockade.
Carcinoma, Squamous Cell
Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Differential Molecular Expression Patterns Associated with Metastasis in Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Carcinoma, Squamous Cell
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Carcinoma, Squamous Cell
Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Carcinoma, Squamous Cell
DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU).
Carcinoma, Squamous Cell
Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?
Carcinoma, Squamous Cell
Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer.
Carcinoma, Squamous Cell
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ?25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Carcinoma, Squamous Cell
Dynamic host immune response in virus-associated cancers.
Carcinoma, Squamous Cell
Efficacy of Liposomal Monensin on the Enhancement of the Antitumour Activity of Liposomal Ricin in Human Epidermoid Carcinoma (KB) Cells.
Carcinoma, Squamous Cell
Enhanced killing of human epidermoid carcinoma (KB) cells by treatment with ricin encapsulated into sterically stabilized liposomes in combination with monensin.
Carcinoma, Squamous Cell
Enhancement of the activity of immunotoxins made with either ricin A chain or Pseudomonas exotoxin in human ovarian and epidermoid carcinoma cell lines.
Carcinoma, Squamous Cell
Evaluating PD-L1 in Head & Neck Squamous Cell Carcinoma: concordance between 22C3 PharmaDx and SP263 assays on whole sections from a multicenter study.
Carcinoma, Squamous Cell
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Carcinoma, Squamous Cell
Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer.
Carcinoma, Squamous Cell
Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.
Carcinoma, Squamous Cell
Expressions of Immune Negative Regulator FoxP3+Treg and PD-L1 Protein in the Immune Microenvironment of Cervical Lesion.
Carcinoma, Squamous Cell
Folate receptor mediated targeted delivery of ricin entrapped into sterically stabilized liposomes to human epidermoid carcinoma (KB) cells: effect of monensin intercalated into folate-tagged liposomes.
Carcinoma, Squamous Cell
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
Carcinoma, Squamous Cell
Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.
Carcinoma, Squamous Cell
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Carcinoma, Squamous Cell
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Carcinoma, Squamous Cell
Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.
Carcinoma, Squamous Cell
HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines.
Carcinoma, Squamous Cell
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.
Carcinoma, Squamous Cell
High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.
Carcinoma, Squamous Cell
Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
Carcinoma, Squamous Cell
Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC.
Carcinoma, Squamous Cell
Identification and characterization of an alternative cancer-derived PD-L1 splice variant.
Carcinoma, Squamous Cell
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.
Carcinoma, Squamous Cell
Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer.
Carcinoma, Squamous Cell
IFN-?-related mRNA profile predicts clinical response to PD-1 blockade.
Carcinoma, Squamous Cell
Immune checkpoint analysis in lip cancer.
Carcinoma, Squamous Cell
Immune checkpoint inhibitors in the treatment of cancer.
Carcinoma, Squamous Cell
Immune Escape Is an Early Event in Pre-Invasive Lesions of Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Immune Infiltrates of m6A RNA Methylation-Related lncRNAs and Identification of PD-L1 in Patients With Primary Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Immune microenvironment and expression of PD-L1, PD-1, cancer testis antigen PRAME and MHC I in salivary duct carcinoma.
Carcinoma, Squamous Cell
Immunotherapy for squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
Carcinoma, Squamous Cell
Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Carcinoma, Squamous Cell
Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells.
Carcinoma, Squamous Cell
Increased PD-L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation.
Carcinoma, Squamous Cell
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Carcinoma, Squamous Cell
Induction of B7-H1 receptor by bacterial cells fractions of Porphyromonas gingivalis on human oral epithelial cells: B7-H1 induction by Porphyromonas gingivalis fractions.
Carcinoma, Squamous Cell
Inflammation promotes oral squamous carcinoma immune evasion via induced programmed death ligand-1 surface expression.
Carcinoma, Squamous Cell
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Carcinoma, Squamous Cell
Interferon-?-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Carcinoma, Squamous Cell
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Carcinoma, Squamous Cell
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
Carcinoma, Squamous Cell
Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
Carcinoma, Squamous Cell
Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1.
Carcinoma, Squamous Cell
Letter to the Editor regarding, "The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis".
Carcinoma, Squamous Cell
Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Carcinoma, Squamous Cell
Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression.
Carcinoma, Squamous Cell
Loss of MHC Class I Expression in HPV-associated Cervical and Vulvar Neoplasia: A Potential Mechanism of Resistance to Checkpoint Inhibition.
Carcinoma, Squamous Cell
Low concentrations of trichosanthin induce apoptosis and cell cycle arrest via c-Jun N-terminal protein kinase/mitogen-activated protein kinase activation.
Carcinoma, Squamous Cell
Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.
Carcinoma, Squamous Cell
Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
miR-375 inhibits IFN-?-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
Carcinoma, Squamous Cell
Molecular diagnostics of lung cancer in the clinic.
Carcinoma, Squamous Cell
Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
Carcinoma, Squamous Cell
Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report.
Carcinoma, Squamous Cell
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
Carcinoma, Squamous Cell
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Carcinoma, Squamous Cell
NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma.
Carcinoma, Squamous Cell
Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Carcinoma, Squamous Cell
Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.
Carcinoma, Squamous Cell
Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck.
Carcinoma, Squamous Cell
Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.
Carcinoma, Squamous Cell
PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Carcinoma, Squamous Cell
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Carcinoma, Squamous Cell
PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
Carcinoma, Squamous Cell
PD-L1 and LAG-3 expression in advanced cutaneous squamous cell carcinomas.
Carcinoma, Squamous Cell
PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.
Carcinoma, Squamous Cell
PD-L1 and PD-L2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Carcinoma, Squamous Cell
PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
Carcinoma, Squamous Cell
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Carcinoma, Squamous Cell
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Carcinoma, Squamous Cell
PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
Carcinoma, Squamous Cell
PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1(+) and CD8(+) tumor-infiltrating T cells and outcome.
Carcinoma, Squamous Cell
PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis.
Carcinoma, Squamous Cell
PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes.
Carcinoma, Squamous Cell
PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component.
Carcinoma, Squamous Cell
PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.
Carcinoma, Squamous Cell
PD-L1 expression in recurrent head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival.
Carcinoma, Squamous Cell
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1 expression in tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Carcinoma, Squamous Cell
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents.
Carcinoma, Squamous Cell
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Carcinoma, Squamous Cell
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1 expression is associated with p16
Carcinoma, Squamous Cell
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
Carcinoma, Squamous Cell
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases: Erratum.
Carcinoma, Squamous Cell
PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.
Carcinoma, Squamous Cell
PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1 Expression, T-lymphocyte Subpopulations and Langerhans Cells in Cutaneous Squamous Cell Carcinoma and Precursor Lesions.
Carcinoma, Squamous Cell
PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Carcinoma, Squamous Cell
PD-L1 in Combination with CD8+TIL and HIF-1? are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
PD-L1 in squamous cell carcinoma of the oral tongue shows gender-specific association with prognosis.
Carcinoma, Squamous Cell
PD-L1 is a positive prognostic factor in squamous cell carcinoma of the nasal vestibule.
Carcinoma, Squamous Cell
PD-L1 is a Prognostic Biomarker in Resected NSCLC Patients with Moderate/high Smoking History and Elevated Serum SCCA Level.
Carcinoma, Squamous Cell
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Carcinoma, Squamous Cell
PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
Carcinoma, Squamous Cell
PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
Carcinoma, Squamous Cell
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Carcinoma, Squamous Cell
PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols.
Carcinoma, Squamous Cell
PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Carcinoma, Squamous Cell
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
PD1 blockage delays murine squamous cell carcinoma development.
Carcinoma, Squamous Cell
Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective.
Carcinoma, Squamous Cell
Pembrolizumab as a first-line therapy in spinocellular esophageal cancer.
Carcinoma, Squamous Cell
Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Photophysical and photobiological properties of a sulfonated chlorin photosensitiser TPCS(2a) for photochemical internalisation (PCI).
Carcinoma, Squamous Cell
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
Carcinoma, Squamous Cell
Predictive value of CD8/FOXP3 ratio combined with PD-L1 expression for radiosensitivity in patients with squamous cell carcinoma of the larynx receiving definitive radiation therapy.
Carcinoma, Squamous Cell
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Carcinoma, Squamous Cell
Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis.
Carcinoma, Squamous Cell
Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report.
Carcinoma, Squamous Cell
Prognostic and Therapeutic Implications of Immune Classification by CD8+ Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Carcinoma, Squamous Cell
Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung.
Carcinoma, Squamous Cell
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.
Carcinoma, Squamous Cell
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Carcinoma, Squamous Cell
Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Carcinoma, Squamous Cell
Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.
Carcinoma, Squamous Cell
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer.
Carcinoma, Squamous Cell
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
Carcinoma, Squamous Cell
Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
Carcinoma, Squamous Cell
Prognostic value of programmed cell death ligand-1 expression in the tumor-infiltrating immune cells of patients with lung cancer: A meta-analysis.
Carcinoma, Squamous Cell
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.
Carcinoma, Squamous Cell
Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer.
Carcinoma, Squamous Cell
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Carcinoma, Squamous Cell
Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Carcinoma, Squamous Cell
Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.
Carcinoma, Squamous Cell
Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma.
Carcinoma, Squamous Cell
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Carcinoma, Squamous Cell
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Carcinoma, Squamous Cell
Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC.
Carcinoma, Squamous Cell
Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.
Carcinoma, Squamous Cell
Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab.
Carcinoma, Squamous Cell
Re: Frequent PD-L1 Expression in Primary and Metastatic Penile Squamous Cell Carcinoma: Potential Opportunities for Immunotherapeutic Approaches.
Carcinoma, Squamous Cell
Relevance of PD-L1 Non-Coding Polymorphisms on the Prognosis of a Genetically Admixed NSCLC Cohort.
Carcinoma, Squamous Cell
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Carcinoma, Squamous Cell
Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification.
Carcinoma, Squamous Cell
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Carcinoma, Squamous Cell
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Carcinoma, Squamous Cell
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Carcinoma, Squamous Cell
Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma.
Carcinoma, Squamous Cell
Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Significance of PD-L1 Expression in Tongue Cancer Development.
Carcinoma, Squamous Cell
Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
Carcinoma, Squamous Cell
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer.
Carcinoma, Squamous Cell
Synthesis of green fluorescent protein-ricin and monitoring of its intracellular trafficking.
Carcinoma, Squamous Cell
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Carcinoma, Squamous Cell
Targeted Therapies in Advanced Gastric Cancer.
Carcinoma, Squamous Cell
The clinical benefits of immune checkpoint inhibitor for thymic carcinomas ?experience of single public hospital in Japan?.
Carcinoma, Squamous Cell
The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis.
Carcinoma, Squamous Cell
The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Carcinoma, Squamous Cell
The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Carcinoma, Squamous Cell
The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Carcinoma, Squamous Cell
The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Carcinoma, Squamous Cell
The Pattern and Clinicopathological Correlates of PD-L1 Expression in Cutaneous Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis.
Carcinoma, Squamous Cell
The Positive Relationship Between ?H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Carcinoma, Squamous Cell
The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
The significance of Siglec-15 expression in resectable non-small cell lung cancer.
Carcinoma, Squamous Cell
TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Carcinoma, Squamous Cell
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
TRAIL promotes epithelial-to-mesenchymal transition by inducing PD-L1 expression in esophageal squamous cell carcinomas.
Carcinoma, Squamous Cell
Trial watch: TLR3 agonists in cancer therapy.
Carcinoma, Squamous Cell
Trichosanthin cooperates with Granzyme B to restrain tumor formation in tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma.
Carcinoma, Squamous Cell
Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma.
Carcinoma, Squamous Cell
Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Tumor-Associated CD163+ M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer.
Carcinoma, Squamous Cell
Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Uncovering PD-L1 and CD8+ TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma.
Carcinoma, Squamous Cell
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Carcinoma, Squamous Cell
Update on Immunohistochemistry for the Diagnosis of Lung Cancer.
Carcinoma, Squamous Cell
Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Carcinoma, Squamous Cell
XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
Carcinoma, Squamous Cell
[A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
Carcinoma, Squamous Cell
[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1?Antibody-Safety and Effectiveness of Pirfenidone].
Carcinoma, Squamous Cell
[Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
Carcinoma, Squamous Cell
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Carcinoma, Squamous Cell
[Expression and significance of PD-L1 in laryngocarcinoma]
Carcinoma, Squamous Cell
[Late-Onset Acute Pneumonitis Caused by Pembrolizumab Used to Treat Postoperative Recurrence of Squamous Cell Carcinoma-A Case Report].
Carcinoma, Squamous Cell
[The Immune Checkpoints Inhibitors for Head and Neck Cancer].
Carcinoma, Verrucous
Pembrolizumab in FIGO IVB Verrucous Carcinoma of the Vulva: A Case Report.
Carcinosarcoma
An immunohistochemical analysis of CD3, PD-L1, and CTLA-4 expression in carcinosarcomas of the gynecological tract and their metastases.
Carcinosarcoma
Carcinosarcoma of the prostate: case report with molecular and histological characterization.
Carcinosarcoma
Landscape of Immune Checkpoint Inhibition in Carcinosarcoma (MMMT): Analysis of IDO-1, PD-L1 and PD-1.
Carcinosarcoma
Lectin-binding proteins in nuclear preparations from rat liver and malignant tumors.
Carcinosarcoma
PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas.
Carcinosarcoma
PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Carcinosarcoma
PD-L1 pathway as a novel target in carcinosarcoma of the kidney and renal pelvis.
Carcinosarcoma
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Carcinosarcoma
Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma.
Carcinosarcoma
Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review.
Cardiomyopathies
Trypanosoma cruzi Induces Regulatory B Cell Alterations in Patients With Chronic Chagas Disease.
Cardiomyopathy, Dilated
Dilated cardiomyopathy in mucolipidosis type 2.
Cardiotoxicity
Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors: A protocol for systematic review and meta-analysis.
Cardiotoxicity
How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Cardiotoxicity
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
Cardiotoxicity
Ricin disturbs calcium homeostasis in the rabbit heart.
Cardiotoxicity
Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation.
Cardiotoxicity
Vibrio parahaemolyticus, enterotoxigenic Escherichia coli, enterohemorrhagic Escherichia coli and Vibrio cholerae.
Celiac Disease
PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability.
Cellulitis
Infectious and toxic cellulitis due to suicide attempt by subcutaneous injection of ricin.
Central Nervous System Diseases
Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
Central Nervous System Diseases
Influence of Escherichia coli shiga toxin on the mammalian central nervous system.
Central Nervous System Diseases
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice.
Cervical Intraepithelial Neoplasia
Increased expression of PD-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk HPV-related cervical intraepithelial neoplasia.
Cervical Intraepithelial Neoplasia
Positive Surgical Margin, HPV Persistence, and Expression of Both TPX2 and PD-L1 Are Associated with Persistence/Recurrence of Cervical Intraepithelial Neoplasia after Cervical Conization.
Cheilitis
Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.
Chickenpox
Atypical hemolytic uremic syndrome triggered by varicella infection.
Chickenpox
Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function.
Cholangiocarcinoma
Actionability evaluation of biliary tract cancer by genome transcriptome analysis and Asian cancer knowledgebase.
Cholangiocarcinoma
ASO Author Reflections: Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells in Cholangiocarcinoma Patients.
Cholangiocarcinoma
Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
Cholangiocarcinoma
Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.
Cholangiocarcinoma
Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Cholangiocarcinoma
Identification of Mutator-Derived Alternative Splicing Signatures of Genomic Instability for Improving the Clinical Outcome of Cholangiocarcinoma.
Cholangiocarcinoma
Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Cholangiocarcinoma
Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma.
Cholangiocarcinoma
LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
Cholangiocarcinoma
Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade.
Cholangiocarcinoma
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma.
Cholangiocarcinoma
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma.
Cholangiocarcinoma
PD-L1 expression in extrahepatic cholangiocarcinoma.
Cholangiocarcinoma
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis.
Cholangiocarcinoma
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Cholangiocarcinoma
Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.
Cholangiocarcinoma
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Cholangiocarcinoma
Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.
Cholangiocarcinoma
Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression.
Cholangiocarcinoma
Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
Cholangiocarcinoma
The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis.
Cholangiocarcinoma
The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.
Cholangiocarcinoma
Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.
Cholangiocarcinoma
[A study of ricinus communis agglutinin I receptors in liver cancer tissues]
Cholangitis
IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.
Cholangitis
Immune tolerance: What is unique about the liver.
Cholecystitis
Association of Immunostaining of Galectin-3 and Sambucus nigra Agglutinin with Invasion, Metastasis and Poor Progression of Gallbladder Adenocarcinoma.
Cholera
A Metagenomic Approach to Evaluating Surface Water Quality in Haiti.
Cholera
A microarray immunoassay for simultaneous detection of proteins and bacteria.
Cholera
A small molecule inhibitor of ER-to-cytosol protein dislocation exhibits anti-dengue and anti-Zika virus activity.
Cholera
A yeast killer toxin screen provides insights into a/b toxin entry, trafficking, and killing mechanisms.
Cholera
Abundance in sewage of bacteriophages infecting Escherichia coli O157:H7.
Cholera
Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II.
Cholera
Adenosine 2A receptor inhibition protects phrenic motor neurons from cell death induced by protein synthesis inhibition.
Cholera
AGAP2 regulates retrograde transport between early endosomes and the TGN.
Cholera
Amplification of microsphere-based microarrays using catalyzed reporter deposition.
Cholera
An approach for analysis of protein toxins based on thin films of lipid mixtures in an optical biosensor.
Cholera
Antibody-mediated inhibition of ricin toxin retrograde transport.
Cholera
Antigenic cross reactivity among the venoms and toxins from unrelated diverse sources.
Cholera
Applications in Stimulated Emission Depletion Microscopy: Localization of a Protein Toxin in the Endoplasmic Reticulum Following Retrograde Transport.
Cholera
Array biosensor for detection of toxins.
Cholera
Bacterial and plant enterotoxin B subunit-autoantigen fusion proteins suppress diabetes insulitis.
Cholera
Bacterial type AB? enterotoxins--structure, function and mechanism of action.
Cholera
BiP negatively affects ricin transport.
Cholera
Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus.
Cholera
Carbohydrate-dependent binding of the cell-free hemagglutinin of Vibrio cholerae to glycoprotein and glycolipid.
Cholera
Cerebrospinal fluid-contacting neurons affect the expression of endogenous neural progenitor cells and the recovery of neural function after spinal cord injury.
Cholera
Characterization of the cholera toxin receptor on Balb/c 3T3 cells as a ganglioside similar to, or identical with, ganglioside GM1. No evidence for galactoproteins with receptor activity.
Cholera
Cholera and Shiga toxin B-subunits: thermodynamic and structural considerations for function and biomedical applications.
Cholera
Cholera toxin B-subunit protects mammalian cells from ricin and abrin toxicity.
Cholera
Clathrin-dependent trafficking of subtilase cytotoxin, a novel AB5 toxin that targets the endoplasmic reticulum chaperone BiP.
Cholera
Comparison of Shiga-like toxin I B-subunit expression and localization in Escherichia coli and Vibrio cholerae by using trc or iron-regulated promoter systems.
Cholera
Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli.
Cholera
CSF-CN contributes to cancer-induced bone pain via the MKP-1-mediated MAPK pathway.
Cholera
Detecting Protein-Glycolipid Interactions Using Glycomicelles and CaR-ESI-MS.
Cholera
Development of a highly sensitive bead-ELISA to detect bacterial protein toxins.
Cholera
Development of xMAP Assay for Detection of Six Protein Toxins.
Cholera
Differential expression of receptors for Shiga and Cholera toxin is regulated by the cell cycle.
Cholera
Differential mechanisms are required for phrenic long-term facilitation over the course of motor neuron loss following CTB-SAP intrapleural injections.
Cholera
Discrimination between lectins with similar specificities by ratiometric profiling of binding to glycosylated surfaces; a chemical 'tongue' approach.
Cholera
Divergent receptor utilization is necessary for phrenic long-term facilitation over the course of motor neuron loss following CTB-SAP intrapleural injections.
Cholera
Evidence that the transport of ricin to the cytoplasm is independent of both Rab6A and COPI.
Cholera
Exercise is neuroprotective on the morphology of somatic motoneurons following the death of neighboring motoneurons via androgen action at the target muscle.
Cholera
Exogenous testosterone prevents motoneuron atrophy induced by contralateral motoneuron depletion.
Cholera
Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines.
Cholera
Expression of cell fate determinants and plastic changes after neurotoxic lesion of adult mice spinal cord by cholera toxin-B saporin.
Cholera
Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library.
Cholera
Facilitated production of secretory IgA against Shiga toxin B subunits by intranasal application of antigen-coated polystyrene microspheres.
Cholera
Fate and action of ricin in rat liver in vivo: translocation of endocytosed ricin into cytosol and induction of intrinsic apoptosis by ricin B-chain.
Cholera
Heterogeneous Family of Cyclomodulins: Smart Weapons That Allow Bacteria to Hijack the Eukaryotic Cell Cycle and Promote Infections.
Cholera
How Ricin and Shiga Toxin Reach the Cytosol of Target Cells: Retrotranslocation from the Endoplasmic Reticulum.
Cholera
Hypoglossal Motor Neuron Death Via Intralingual CTB-saporin (CTB-SAP) Injections Mimic Aspects of Amyotrophic Lateral Sclerosis (ALS) Related to Dysphagia.
Cholera
Identification and characterization of small molecules that inhibit intracellular toxin transport.
Cholera
Immunogenicity and antigenic relationship of Salmonella enterotoxin with other enterotoxins.
Cholera
Inhibition of endoplasmic reticulum-associated degradation in CHO cells resistant to cholera toxin, Pseudomonas aeruginosa exotoxin A, and ricin.
Cholera
Intracellular transport and processing of protein toxins produced by enteric bacteria.
Cholera
Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Cholera
Involvement of brain-derived neurotrophic factor and sonic hedgehog in the spinal cord plasticity after neurotoxic partial removal of lumbar motoneurons.
Cholera
Localized surface plasmon resonance detection of biological toxins using cell surface oligosaccharides on glyco chips.
Cholera
Localizing Carbohydrate Binding Sites in Proteins Using Hydrogen/Deuterium Exchange Mass Spectrometry.
Cholera
Membrane Lipids Define Small Extracellular Vesicle Subtypes Secreted By Mesenchymal Stromal Cell.
Cholera
Metabolic discrimination of select list agents by monitoring cellular responses in a multianalyte microphysiometer.
Cholera
Modulation of toxin stability by 4-phenylbutyric acid and negatively charged phospholipids.
Cholera
Multiplexed toxin analysis using four colors of quantum dot fluororeagents.
Cholera
Neuromuscular Plasticity in a Mouse Neurotoxic Model of Spinal Motoneuronal Loss.
Cholera
Neuroplasticity and Repair in Rodent Neurotoxic Models of Spinal Motoneuron Disease.
Cholera
Neuroprotective effect of testosterone treatment on motoneuron recruitment following the death of nearby motoneurons.
Cholera
Neuroprotective Effects of Exercise on the Morphology of Somatic Motoneurons Following the Death of Neighboring Motoneurons.
Cholera
Neuroprotective effects of testosterone metabolites and dependency on receptor action on the morphology of somatic motoneurons following the death of neighboring motoneurons.
Cholera
Neuroprotective effects of testosterone on dendritic morphology following partial motoneuron depletion: efficacy in female rats.
Cholera
Neuroprotective effects of testosterone on the morphology and function of somatic motoneurons following the death of neighboring motoneurons.
Cholera
Neuroprotective Effects on the Morphology of Somatic Motoneurons Following the Death of Neighboring Motoneurons: A Role for Microglia?
Cholera
Nine-analyte detection using an array-based biosensor.
Cholera
Noggin and Sonic hedgehog are involved in compensatory changes within the motoneuron-depleted mouse spinal cord.
Cholera
Non-natural cell surface receptors: synthetic peptides capped with N-cholesterylglycine efficiently deliver proteins into Mammalian cells.
Cholera
Novel Mechanisms of Spinal Cord Plasticity in a Mouse Model of Motoneuron Disease.
Cholera
p97 Is in a complex with cholera toxin and influences the transport of cholera toxin and related toxins to the cytoplasm.
Cholera
Pathways followed by protein toxins into cells.
Cholera
Phage regulatory circuits and virulence gene expression.
Cholera
Phrenic long-term facilitation following intrapleural CTB-SAP-induced respiratory motor neuron death.
Cholera
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.
Cholera
Protein-Glycosphingolipid Interactions Revealed Using Catch-and-Release Mass Spectrometry.
Cholera
Purification & antigenicity of Salmonella newport enterotoxin.
Cholera
Purification and characterization of an extracellular secretogenic non-membrane-damaging cytotoxin produced by clinical strains of Vibrio cholerae non-O1.
Cholera
Purification and characterization of enterotoxic moiety present in cell-free culture supernatant of Salmonella typhimurium.
Cholera
Putative virulence traits and pathogenicity of Vibrio cholerae Non-O1, Non-O139 isolates from surface waters in Kolkata, India.
Cholera
Rapid cycling of lipid raft markers between the cell surface and Golgi complex.
Cholera
Recognition of human milk oligosaccharides by bacterial exotoxins.
Cholera
Redox diversity in ERAD-mediated protein retrotranslocation from the endoplasmic reticulum: a complex puzzle.
Cholera
Respiratory function after selective respiratory motor neuron death from intrapleural CTB-saporin injections.
Cholera
Retrograde axonal transport of specific macromolecules as a tool for characterizing nerve terminal membranes.
Cholera
Retrograde transport of protein toxins through the Golgi apparatus.
Cholera
Retrograde transport pathways utilised by viruses and protein toxins.
Cholera
Retrogradely transported CTB-saporin kills sympathetic preganglionic neurons.
Cholera
Review of the inhibition of biological activities of food-related selected toxins by natural compounds.
Cholera
Salmonella cytotonic and cytolytic factors: their detection in Chinese hamster ovary cells and antigenic relatedness.
Cholera
Salmonellosis: in retrospect and prospect.
Cholera
Schwann cells are removed from the spinal cord after effecting recovery from paraplegia.
Cholera
Selective regulation of apical endocytosis in polarized Madin-Darby canine kidney cells by mastoparan and cAMP.
Cholera
Sensitive detection of biotoxoids and bacterial spores using an immunomagnetic electrochemiluminescence sensor.
Cholera
Sensitive detection of multiplex toxins using antibody microarray.
Cholera
Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3.
Cholera
Studies on the mode of action of bacterial AB5 toxins.
Cholera
Syntaxin 16 and syntaxin 5 are required for efficient retrograde transport of several exogenous and endogenous cargo proteins.
Cholera
Targeted ablation of cardiac sympathetic neurons reduces resting, reflex and exercise-induced sympathetic activation in conscious rats.
Cholera
Targeted ablation of cardiac sympathetic neurons reduces the susceptibility to ischemia-induced sustained ventricular tachycardia in conscious rats.
Cholera
Targeted Ablation of Distal Cerebrospinal Fluid-Contacting Nucleus Alleviates Renal Fibrosis in Chronic Kidney Disease.
Cholera
Targeted Ablation of Mesenteric Projecting Sympathetic Neurons Reduces the Hemodynamic Response to Pain in Conscious Spinal Cord Transected Rats.
Cholera
Testosterone manipulation protects motoneurons from dendritic atrophy after contralateral motoneuron depletion.
Cholera
The crystal structure of pertussis toxin.
Cholera
The CSF-contacting nucleus regulates learning and memory through synaptic connections with the hippocampus.
Cholera
The enteric immune response to shigella antigens.
Cholera
The Establishment of a CSF-Contacting Nucleus "Knockout" Model Animal.
Cholera
The retromer component sorting nexin-1 is required for efficient retrograde transport of Shiga toxin from early endosome to the trans Golgi network.
Cholera
The secretion inhibitor Exo2 perturbs trafficking of Shiga toxin between endosomes and the trans-Golgi network.
Cholera
The use of lectins and cholera toxin for the detection of surface carbohydrates of cultured neurons and neuroblastoma.
Cholera
Tongue and hypoglossal morphology after intralingual cholera toxin B-saporin injection.
Cholera
Toxigenic Characterization of Vibrios Isolated from Foods Available in Taiwan.
Cholera
Transport of protein toxins into cells: pathways used by ricin, cholera toxin and Shiga toxin.
Cholera
Vibrio parahaemolyticus, enterotoxigenic Escherichia coli, enterohemorrhagic Escherichia coli and Vibrio cholerae.
Cholera
[Molecular cloning, expression, and characterization of human mini-antibodies against enterotoxin C1 of Staphylococcus aureus]
Chondrosarcoma
Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype.
Chondrosarcoma
Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.
Chondrosarcoma
Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma.
Chondrosarcoma
Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.
Chondrosarcoma
PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Chondrosarcoma
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Chondrosarcoma, Mesenchymal
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
Chordoma
Clinicopathologic implications of CD8
Chordoma
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
Chordoma
Erratum to: PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.
Chordoma
Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.
Chordoma
Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.
Chordoma
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
Chordoma
Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors.
Chordoma
PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.
Chordoma
The Immune Microenvironment of Chordomas: An Immunohistochemical Analysis.
Choriocarcinoma
A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab.
Choriocarcinoma
Analysis of PD-L1 expression in trophoblastic tissues and tumors.
Choriocarcinoma
Biosynthesis and bioactivity of trichosanthin in cultured crown gall tissues of Trichosanthes kirilowii Maximowicz.
Choriocarcinoma
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Choriocarcinoma
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.
Choriocarcinoma
Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Choriocarcinoma
Enhanced green fluorescence protein tracks trichosanthin in human choriocarcinoma cells as a feasible and stable reporter.
Choriocarcinoma
High sensitivity of cultured human trophoblasts to ribosome-inactivating proteins.
Choriocarcinoma
Important Chinese herbal remedies.
Choriocarcinoma
Kinetic analysis of choriocarcinoma cell intoxication induced by ricin and ricin A chain immunotoxin.
Choriocarcinoma
Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics.
Choriocarcinoma
Low-density lipoprotein receptor-related protein 1 is an essential receptor for trichosanthin in 2 choriocarcinoma cell lines.
Choriocarcinoma
PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.
Choriocarcinoma
PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.
Choriocarcinoma
Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Choriocarcinoma
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Choriocarcinoma
Receptor-mediated endocytosis of trichosanthin in choriocarcinoma cells.
Choriocarcinoma
Selective killing of choriocarcinoma cells in vitro by trichosanthin, a plant protein purified from root tubers of the Chinese medicinal herb Trichosanthes kirilowii.
Choriocarcinoma
Smac is another pathway in the anti-tumour activity of Trichosanthin and reverses Trichosanthin resistance in CaSki cervical cancer cells.
Choriocarcinoma
Successful treatment of metastatic refractory gestational choriocarcinoma with pembrolizumab: A case for immune checkpoint salvage therapy in trophoblastic tumors.
Choriocarcinoma
Trichosanthin induced calcium-dependent generation of reactive oxygen species in human choriocarcinoma cells.
Choriocarcinoma
Two novel proteins bind specifically to trichosanthin on choriocarcinoma cell membrane.
Choriocarcinoma
TYchi, a novel chitinase with RNA N-glycosidase and anti-tumor activities.
Choriocarcinoma
[Studies on injury-mechanism of trichosanthin on trophoblast cells and choriocarcinoma cells in culture]
Choroidal Neovascularization
Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.
Chronic Periodontitis
[Programmed death ligand 1 negatively regulates inflammatory response of chronic periodontitis].
Coinfection
Hemolytic uremic syndrome: co-infection with two different serotypes of Shiga-like toxin producing Escherichia coli.
Coinfection
PD-L1, TIM-3, and CTLA-4 blockade fail to promote resistance to secondary infection with virulent strains of Toxoplasma gondii.
Coinfection
The CI repressors of Shiga toxin-converting prophages are involved in coinfection of Escherichia coli strains, which causes a down regulation in the production of Shiga toxin 2.
Coinfection
The PD-L1/CD86 ratio is increased in dendritic cells co-infected with porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus, and the PD-L1/PD-1 axis is associated with anergy, apoptosis, and the induction of regulatory T-cells in porcine lymphocytes.
Colitis
A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin.
Colitis
A New Immunoassay for Detecting All Subtypes of Shiga Toxins Produced by Shiga Toxin-Producing E. coli in Ground Beef.
Colitis
A Novel Tail-Associated O91-Specific Polysaccharide Depolymerase from Podophage Reveals Lytic Efficacy of Shiga Toxin-Producing E. coli.
Colitis
A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.
Colitis
Acquired Resistance to Shiga Toxin-Induced Apoptosis by Loss of CD77 Expression in Human Myelogenous Leukemia Cell Line, THP-1.
Colitis
Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods.
Colitis
Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte proliferation.
Colitis
Attaching-effacing Escherichia coli infections in cattle.
Colitis
Cattle lack vascular receptors for Escherichia coli O157:H7 Shiga toxins.
Colitis
Characterization of a Shiga toxin 1-neutralizing recombinant Fab fragment isolated by phage display system.
Colitis
Characterization of Shiga-toxigenic Escherichia coli isolated from cases of diarrhoea & haemolytic uremic syndrome in north India.
Colitis
Charged and hydrophobic surfaces on the a chain of shiga-like toxin 1 recognize the C-terminal domain of ribosomal stalk proteins.
Colitis
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Colitis
Clonal relatedness of Shiga-like toxin-producing Escherichia coli O101 strains of human and porcine origin.
Colitis
Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome.
Colitis
Combining Mass Spectrometry, Surface Acoustic Wave Interaction Analysis, and Cell Viability Assays for Characterization of Shiga Toxin Subtypes of Pathogenic Escherichia coli Bacteria.
Colitis
Comparative toxicity and virulence of Escherichia coli clones expressing variant and chimeric Shiga-like toxin type II operons.
Colitis
Comparisons of Native Shiga Toxins (Stxs) Type 1 and 2 with Chimeric Toxins Indicate that the Source of the Binding Subunit Dictates Degree of Toxicity.
Colitis
Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Colitis
Crohn's disease is facilitated by a disturbance of programmed death-1 ligand 2 on blood dendritic cells.
Colitis
Degradation and inactivation of Shiga toxins by nitrogen gas plasma.
Colitis
Detection of E. coli O157:H7 and Shigella dysenteriae toxins in clinical samples by PCR-ELISA.
Colitis
Detection of Shiga toxin-producing Escherichia coli by sandwich enzyme-linked immunosorbent assay using chicken egg yolk IgY antibodies.
Colitis
Detection of VTEC using specific DNA probes and complex typing of Escherichia coli O157.
Colitis
Development and evaluation of enzyme-linked immunosorbent assays for detection of shiga-like toxin I and shiga-like toxin II.
Colitis
Development and Validation of Shiga Toxin-Producing Escherichia coli Immunodiagnostic Assay.
Colitis
Dexamethasone rescues neurovascular unit integrity from cell damage caused by systemic administration of shiga toxin 2 and lipopolysaccharide in mice motor cortex.
Colitis
Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2.
Colitis
Direct cytotoxic action of Shiga toxin on human vascular endothelial cells.
Colitis
Direct detection of Shiga toxin: a necessary step for improved diagnosis of enterohemorrhagic colitis.
Colitis
Do the A subunits contribute to the differences in the toxicity of Shiga toxin 1 and Shiga toxin 2?
Colitis
Duplication and diversification of a unique chromosomal virulence island hosting the subtilase cytotoxin in Escherichia coli ST58.
Colitis
Effects of human intravenous immune globulin on diarrhea caused by Shiga-like toxin I and Shiga-like toxin II in infant rabbits.
Colitis
Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli.
Colitis
Enhanced virulence of the Escherichia coli O157:H7 spinach-associated outbreak strain in two animal models is associated with higher levels of Stx2 production after induction with ciprofloxacin.
Colitis
Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in a Shiga toxin independent manner.
Colitis
Epidemic of gastrointestinal tract infection including hemorrhagic colitis attributable to Shiga toxin 1-producing Escherichia coli O118:H2 at a junior high school in Japan.
Colitis
Escherichia coli strains producing a novel Shiga toxin 2 subtype circulate in China.
Colitis
Failure of manganese to protect from Shiga toxin.
Colitis
First Detection of Shiga Toxin-Producing Escherichia coli in Shellfish and Coastal Environments of Morocco.
Colitis
From the National Institute of Allergy and Infectious Diseases. Summary of the 19th United States-Japan Joint Cholera Conference.
Colitis
Genetic makeup of Shiga toxin-producing Escherichia coli in relation to clinical symptoms and duration of shedding: a microarray analysis of isolates from Swedish children.
Colitis
Hemorrhagic colitis due to a novel Escherichia coli serotype (O121:H19) in a transplant patient.
Colitis
Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide.
Colitis
Identification and distribution of the enterohemorrhagic Escherichia coli factor for adherence (efa1) gene in sorbitol-fermenting Escherichia coli O157: H-.
Colitis
Immune modulatory mesenchymal stem cells derived from human embryonic stem cells through a trophoblast-like stage.
Colitis
Immunity profiles of wild-type and recombinant shiga-like toxin-encoding bacteriophages and characterization of novel double lysogens.
Colitis
Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
Colitis
Interactions between Shiga toxins and human polymorphonuclear leukocytes.
Colitis
Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains.
Colitis
Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: an ultrastructural study.
Colitis
M-COPA, a novel Golgi system disruptor, suppresses apoptosis induced by Shiga toxin.
Colitis
Neutral glycosphingolipids in human blood: a precise mass spectrometry analysis with special reference to lipoprotein-associated Shiga toxin receptors.
Colitis
Nitrobenzylthioinosine (NBT), a nucleoside transport inhibitor, protects against Shiga toxin cytotoxicity in human microvascular endothelial cells.
Colitis
Oral intoxication of mice with Shiga toxin type 2a (Stx2a) and protection by anti-Stx2a monoclonal antibody 11E10.
Colitis
Overview and Historical Perspectives.
Colitis
Pathogenesis of Shiga-Toxin Producing Escherichia coli.
Colitis
PD-L1 is required for human endometrial regenerative cells-associated attenuation of experimental colitis in mice.
Colitis
Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.
Colitis
Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection.
Colitis
Prevalence, quantification and isolation of pathogenic shiga toxin Escherichia coli O157:H7 along the production and supply chain of pork around Hubei Province of China.
Colitis
Procalcitonin in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome.
Colitis
Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.
Colitis
Protective effects of Fc-fused PD-L1 on two different animal models of colitis.
Colitis
Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice.
Colitis
Purification and some properties of Shiga-like toxin from Escherichia coli O157:H7 that is immunologically identical to Shiga toxin.
Colitis
Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli.
Colitis
Retinoid levels influence enterohemorrhagic Escherichia coli infection and Shiga toxin 2 susceptibility in mice.
Colitis
Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis.
Colitis
Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment.
Colitis
Safety and Pharmacokinetics of Chimeric Anti-Shiga Toxin 1 and Anti-Shiga Toxin 2 Monoclonal Antibodies in Healthy Volunteers.
Colitis
Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.
Colitis
Shiga toxin-converting phages and the emergence of new pathogenic Escherichia coli: a world in motion.
Colitis
Shiga Toxin-Producing Escherichiacoli in Feces of Finisher Pigs: Isolation, Identification and Public Health Implications of Major and Minor Serogroups.
Colitis
Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells.
Colitis
Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea.
Colitis
Soluble Toll-Like Receptor 4 Impairs the Interaction of Shiga Toxin 2a with Human Serum Amyloid P Component.
Colitis
Spread of a Distinct Stx2-Encoding Phage Prototype among Escherichia coli O104:H4 Strains from Outbreaks in Germany, Norway, and Georgia.
Colitis
Structural basis for the interaction of Shiga toxin 2a with a C-terminal peptide of ribosomal P stalk proteins.
Colitis
Synthesis and Assessment of Globotriose-Chitosan Conjugate, a Novel Inhibitor of Shiga Toxins Produced by Escherichia coli.
Colitis
The A1 Subunit of Shiga Toxin 2 Has Higher Affinity for Ribosomes and Higher Catalytic Activity than the A1 Subunit of Shiga Toxin 1.
Colitis
The crystal structure of shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor.
Colitis
The Effects of Shiga Toxin 1, 2 and Their Subunits on Cytokine and Chemokine Expression by Human Macrophage-Like THP-1 Cells.
Colitis
The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Colitis
The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Colitis
The role of Tir, EspA, and NleB in the colonization of cattle by Shiga toxin producing Escherichia coli O26:H11.
Colitis
Therapeutic strategies for Shiga toxin-producing Escherichia coli infections.
Colitis
Transcription of the subtilase cytotoxin gene subAB1 in Shiga toxin-producing Escherichia coli is dependent on hfq and hns.
Colitis
Tumor necrosis factor-? modifies the effects of Shiga toxin on glial cells.
Colitis
Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511.
Colitis
Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities.
Colitis
Use of comparative genomics as a tool to assess the clinical and public health significance of emerging Shiga toxin-producing Escherichia coli serotypes.
Colitis
[A case of hemolytic uremic syndrome with hemorrhagic colitis due to Escherichia coli O111 infection]
Colitis
[Cytotoxic effect of Shiga toxin type 2 and its B subunit on human renal tubular epithelial cell cultures]
Colitis
[Enterohemorrhagic Escherichia coli and its infection: from 1977 to 1995]
Colitis
[Isolation and characterization of Shiga-toxin-producing Escherichia coli from frozen hamburgers and soft cheeses]
Colitis
[Pathogenesis of enterohaemorrhagic Escherichia coli infection].
Colitis
[Shiga toxin and tetanus toxin as a potential biologic weapon].
Colitis
[Shiga toxin producing Escherichia coli infection]
Colitis
[The occurrence of Shiga toxin-producing Escherichia coli in humans and animals]
Colitis, Ulcerative
Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease.
Colitis, Ulcerative
Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
Colitis, Ulcerative
Over-Expression of Immunosuppressive Molecules, PD-L1 and PD-L2, in Ulcerative Colitis Patients.
Colitis, Ulcerative
Shiga Toxin Producing Escherichia coli-Hemolytic Uremic Syndrome Mimicking Acute Severe Ulcerative Colitis in a Child With Bloody Diarrhea.
Colitis, Ulcerative
Shiga-like toxin production and connective tissue protein binding of Escherichia coli isolated from a patient with ulcerative colitis.
Colitis, Ulcerative
Surface properties, connective tissue protein binding and Shiga-like toxin production of Escherichia coli isolated from patients with ulcerative colitis.
Colitis-Associated Neoplasms
The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM/DSS Model of Colitis-Associated Cancer.
Collagen Diseases
Quetiapine-induced thrombotic microangiopathy in a patient on maintenance dialysis.
Colonic Neoplasms
89Zr Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression.
Colonic Neoplasms
A novel histological examination with dynamic 3D reconstruction from multiple immunohistochemically stained sections of a programmed cell death ligand 1-positive colon cancer.
Colonic Neoplasms
A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
Colonic Neoplasms
Abrin P2 suppresses proliferation and induces apoptosis of colon cancer cells via mitochondrial membrane depolarization and caspase activation.
Colonic Neoplasms
Analysis of the transcriptomic features of microsatellite instability subtype colon cancer.
Colonic Neoplasms
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Colonic Neoplasms
Beta-galactoside alpha2,6 sialyltransferase in human colon cancer: contribution of multiple transcripts to regulation of enzyme activity and reactivity with Sambucus nigra agglutinin.
Colonic Neoplasms
Biostimulating Gut Microbiome with Bilberry Anthocyanin Combo to Enhance Anti-PD-L1 Efficiency against Murine Colon Cancer.
Colonic Neoplasms
BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts.
Colonic Neoplasms
Camptothecin Induces PD-L1 and Immunomodulatory Cytokines in Colon Cancer Cells.
Colonic Neoplasms
Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer.
Colonic Neoplasms
Correction: Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer.
Colonic Neoplasms
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Colonic Neoplasms
Efficiently restoring the tumoricidal immunity against resistant malignancies via an immune nanomodulator.
Colonic Neoplasms
Expression of alpha 2,6-sialylated sugar chains in normal and neoplastic colon tissues. Detection by digoxigenin-conjugated Sambucus nigra agglutinin.
Colonic Neoplasms
High Affinity of Chlorin e6 to Immunoglobulin G for Intraoperative Fluorescence Image-Guided Cancer Photodynamic and Checkpoint Blockade Therapy.
Colonic Neoplasms
Human colon cancer cell lines permanently expressing alpha 2,6-sialylated sugar chains by transfection with rat beta-galactoside alpha 2,6 sialyltransferase cDNA.
Colonic Neoplasms
In vitro cytotoxicity of recombinant ricin A chain-antitransferrin receptor immunotoxin against human adenocarcinomas of the colon and pancreas.
Colonic Neoplasms
In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles.
Colonic Neoplasms
Increased PD-L1 Expression in Breast and Colon Cancer Stem Cells.
Colonic Neoplasms
Inflammatory cytokines IL-17 and TNF-? up-regulate PD-L1 expression in human prostate and colon cancer cells.
Colonic Neoplasms
Inhibition to Epithelial-Mesenchymal Transition and Metastatic Potential In Colorectal Cancer Cell By Combination of Traditional Chinese Medicine Formulation Jiedu Sangen Decoction and PD-L1 Inhibitor.
Colonic Neoplasms
Interleukin-22 promotes PD-L1 expression via STAT3 in colon cancer cells.
Colonic Neoplasms
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Colonic Neoplasms
KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the ?-catenin/STT3 signaling pathway.
Colonic Neoplasms
Loss of tumor intrinsic PD-L1 confers resistance to drug-induced apoptosis in human colon cancer.
Colonic Neoplasms
Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression.
Colonic Neoplasms
Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
Colonic Neoplasms
Momordin Ic induces G0/1 phase arrest and apoptosis in colon cancer cells by suppressing SENP1/c-MYC signaling pathway.
Colonic Neoplasms
Novel Complex of PD-L1 Aptamer and Holliday Junction Enhances Antitumor Efficacy in Vivo.
Colonic Neoplasms
Orexin A Suppresses the Expression of Exosomal PD-L1 in Colon Cancer and Promotes T Cell Activity by Inhibiting JAK2/STAT3 Signaling Pathway.
Colonic Neoplasms
PD-L1 as a Prognostic Factor in Early-Stage Colon Carcinoma within the Immunohistochemical Molecular Subtype Classification.
Colonic Neoplasms
PD-L1 expression in colon cancer and its relationship with clinical prognosis.
Colonic Neoplasms
PD-L1 Targeting Immune-Microbubble Complex Enhances Therapeutic Index in Murine Colon Cancer Models.
Colonic Neoplasms
PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer.
Colonic Neoplasms
PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth.
Colonic Neoplasms
Porphyromonas gingivalis induced up-regulation of PD-L1 in colon carcinoma cells.
Colonic Neoplasms
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
Colonic Neoplasms
Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer.
Colonic Neoplasms
Preclinical Toxicity and Safety of MM-129-First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer.
Colonic Neoplasms
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Colonic Neoplasms
Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort.
Colonic Neoplasms
Protein-inorganic hybrid nanoflowers as ultrasensitive electrochemical cytosensing Interfaces for evaluation of cell surface sialic acid.
Colonic Neoplasms
Recombinant hybrid protein, Shiga toxin and granulocyte macrophage colony stimulating factor effectively induce apoptosis of colon cancer cells.
Colonic Neoplasms
Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity.
Colonic Neoplasms
Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis.
Colonic Neoplasms
RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells.
Colonic Neoplasms
Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo.
Colonic Neoplasms
Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
Colonic Neoplasms
Selective cytotoxicity of a ricin A-chain-anti-carcinoembryonic antigen antibody conjugate for a human colon adenocarcinoma cell line.
Colonic Neoplasms
Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation.
Colonic Neoplasms
Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer.
Colonic Neoplasms
Specific dose-dependent damage of Lieberkühn crypts promoted by large doses of type 2 ribosome-inactivating protein nigrin b intravenous injection to mice.
Colonic Neoplasms
Stromal cell PD-L1 inhibits CD8+ T-cell antitumor immune responses and promotes colon cancer.
Colonic Neoplasms
Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
Colonic Neoplasms
The Combination Therapy of Fluorouracil and Oxaliplatin Suppress the Progression of Colon Cancer Through miR-183-5p/SOCS3 Axis and Downregulating PD-L1.
Colonic Neoplasms
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.
Colonic Neoplasms
The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer.
Colonic Neoplasms
The novel EpCAM-targeting monoclonal antibody 3-17I linked to saporin is highly cytotoxic after photochemical internalization in breast, pancreas and colon cancer cell lines.
Colonic Neoplasms
The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Colonic Neoplasms
The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3.
Colonic Neoplasms
The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation.
Colonic Neoplasms
Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice.
Colonic Neoplasms
Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma.
Colonic Neoplasms
ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer.
Colonic Neoplasms
[Expression of Bcl-2, PD-L1 and its clinical significance in colorectal cancer].
Colonic Neoplasms
[Purification and anti-cancer activity of ricin]
Colorectal Neoplasms
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.
Colorectal Neoplasms
Activated human primary NK cells efficiently kill colorectal cancer cells in 3D spheroid cultures irrespectively of the level of PD-L1 expression.
Colorectal Neoplasms
Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
Colorectal Neoplasms
An update: circulating tumor cells in head and neck cancer.
Colorectal Neoplasms
Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.
Colorectal Neoplasms
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression.
Colorectal Neoplasms
ASO Author Reflections: Analysis of PD-L1 Expression and Immunoscore in Colorectal Cancer.
Colorectal Neoplasms
B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.
Colorectal Neoplasms
BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts.
Colorectal Neoplasms
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Colorectal Neoplasms
Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.
Colorectal Neoplasms
Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo.
Colorectal Neoplasms
Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
Colorectal Neoplasms
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
Colorectal Neoplasms
Clinical retrospective study on the expression of the PD-L1 molecule in sporadic colorectal cancer and its correlation with K-ras gene mutations in Chinese patients.
Colorectal Neoplasms
Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.
Colorectal Neoplasms
Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis.
Colorectal Neoplasms
Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
Colorectal Neoplasms
Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression.
Colorectal Neoplasms
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Colorectal Neoplasms
Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
Colorectal Neoplasms
Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
Colorectal Neoplasms
Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models.
Colorectal Neoplasms
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer.
Colorectal Neoplasms
Correlation of pd-l1 staining in tumor cells and tumor infiltrate between primary tumors and matched metastasis in advanced colorectal cancer patients.
Colorectal Neoplasms
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement.
Colorectal Neoplasms
Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Colorectal Neoplasms
Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer.
Colorectal Neoplasms
Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Colorectal Neoplasms
Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer.
Colorectal Neoplasms
DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer.
Colorectal Neoplasms
Doxorubicin and Anti-PD-L1 Antibody Conjugated Gold Nanoparticles for Colorectal Cancer Photochemotherapy.
Colorectal Neoplasms
Erratum: miR-140-3p Suppresses Cell Growth and Induces Apoptosis in Colorectal Cancer by Targeting PD-L1 [Corrigendum].
Colorectal Neoplasms
Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis.
Colorectal Neoplasms
Expression of STING and PD-L1 in colorectal cancer and their correlation with clinical prognosis.
Colorectal Neoplasms
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Colorectal Neoplasms
Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens.
Colorectal Neoplasms
Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer.
Colorectal Neoplasms
High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Colorectal Neoplasms
Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression.
Colorectal Neoplasms
HNRNPL affects the proliferation and apoptosis of colorectal cancer cells by regulating PD-L1.
Colorectal Neoplasms
Hsa_circ_0020397 regulates colorectal cancer cell viability, apoptosis and invasion by promoting the expression of the miR-138 targets TERT and PD-L1.
Colorectal Neoplasms
Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497/PD-L1 pathway.
Colorectal Neoplasms
Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.
Colorectal Neoplasms
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Colorectal Neoplasms
Identification and characterization of riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana.
Colorectal Neoplasms
IFN?/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.
Colorectal Neoplasms
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
Colorectal Neoplasms
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Colorectal Neoplasms
Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
Colorectal Neoplasms
Immunosuppression Factors PD-1, PD-L1, and IDO1 and Colorectal Cancer.
Colorectal Neoplasms
Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand
Colorectal Neoplasms
In vitro and in vivo antitumor activity of ZENECA ZD0490, a recombinant ricin A-chain immunotoxin for the treatment of colorectal cancer.
Colorectal Neoplasms
Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Colorectal Neoplasms
Inhibition to Epithelial-Mesenchymal Transition and Metastatic Potential In Colorectal Cancer Cell By Combination of Traditional Chinese Medicine Formulation Jiedu Sangen Decoction and PD-L1 Inhibitor.
Colorectal Neoplasms
Integrated Analysis of the Immune Infiltrates and PD-L1 Expression of N6-Methyladenosine-Related Long Non-Coding RNAs in Colorectal Cancer.
Colorectal Neoplasms
Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Colorectal Neoplasms
Inverse correlation between PD-L1 expression and LGR5 expression in tumor budding of stage II/III colorectal cancer.
Colorectal Neoplasms
Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.
Colorectal Neoplasms
Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer.
Colorectal Neoplasms
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Colorectal Neoplasms
Krill oil extract inhibits the migration of human colorectal cancer cells and down-regulates EGFR signalling and PD-L1 expression.
Colorectal Neoplasms
LncRNA KCNQ1OT1 Secreted by Tumor Cell-Derived Exosomes Mediates Immune Escape in Colorectal Cancer by Regulating PD-L1 Ubiquitination via MiR-30a-5p/USP22.
Colorectal Neoplasms
Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8+ T-cell Responses.
Colorectal Neoplasms
Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells.
Colorectal Neoplasms
MEK and PD-L1 inhibition in colorectal cancer: a burning blaze turning into a flash in the pan.
Colorectal Neoplasms
Met inhibition revokes IFN?-induction of PD-1 ligands in MET-amplified tumours.
Colorectal Neoplasms
Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells.
Colorectal Neoplasms
MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Colorectal Neoplasms
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
Colorectal Neoplasms
miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1.
Colorectal Neoplasms
miREIA - an immunoassay method in assessment of microRNA levels in tumor tissue-pilot study. The impact of miR-93-5p, miR-142-5p and IFN? on PD-L1 level in colorectal cancer.
Colorectal Neoplasms
miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
Colorectal Neoplasms
Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.
Colorectal Neoplasms
Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Colorectal Neoplasms
MM-129 as a Novel Inhibitor Targeting PI3K/AKT/mTOR and PD-L1 in Colorectal Cancer.
Colorectal Neoplasms
Molecular profiling analysis for colorectal cancer patients with Pi-Xu or Shi-Re syndrome.
Colorectal Neoplasms
Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial).
Colorectal Neoplasms
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer.
Colorectal Neoplasms
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Colorectal Neoplasms
Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice.
Colorectal Neoplasms
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Colorectal Neoplasms
OX40 as a novel target for the reversal of immune escape in colorectal cancer.
Colorectal Neoplasms
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Colorectal Neoplasms
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
Colorectal Neoplasms
PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
Colorectal Neoplasms
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
Colorectal Neoplasms
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
Colorectal Neoplasms
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.
Colorectal Neoplasms
PD-L1 and Survival in Solid Tumors: A Meta-Analysis.
Colorectal Neoplasms
PD-L1 expression in colorectal cancer and its relationship with TLR-4 expression.
Colorectal Neoplasms
PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments.
Colorectal Neoplasms
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Colorectal Neoplasms
PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation.
Colorectal Neoplasms
PD-L1 expression in HNPCC-associated colorectal cancer.
Colorectal Neoplasms
PD-L1 expression in human cancers and its association with clinical outcomes.
Colorectal Neoplasms
PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer.
Colorectal Neoplasms
PD-L1 expression in tumour buds of colorectal carcinoma.
Colorectal Neoplasms
PD-L1 expression increased by IFN-? via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer.
Colorectal Neoplasms
PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers.
Colorectal Neoplasms
PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.
Colorectal Neoplasms
PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins.
Colorectal Neoplasms
PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1.
Colorectal Neoplasms
PD-L1 Overexpression on Tumor-Infiltrating Lymphocytes Related to Better Prognosis of Colorectal Cancer.
Colorectal Neoplasms
PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
Colorectal Neoplasms
PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
Colorectal Neoplasms
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
Colorectal Neoplasms
Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
Colorectal Neoplasms
PPAR? induces PD-L1 expression in MSS+ colorectal cancer cells.
Colorectal Neoplasms
Predictive Potential of PD-L1, TYMS, and DCC Expressions in Treatment Outcome of Colorectal Carcinoma.
Colorectal Neoplasms
Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Colorectal Neoplasms
Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
Colorectal Neoplasms
Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer.
Colorectal Neoplasms
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Colorectal Neoplasms
Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients.
Colorectal Neoplasms
Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.
Colorectal Neoplasms
Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin.
Colorectal Neoplasms
Prognostic Significance of Immune Checkpoints HLA-G/ILT-2/4 and PD-L1 in Colorectal Cancer.
Colorectal Neoplasms
Prognostic Value of Immunoscore and PD-L1 Expression in Metastatic Colorectal Cancer Patients with Different RAS Status after Palliative Operation.
Colorectal Neoplasms
Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer.
Colorectal Neoplasms
Prognostic value of tumor infiltrating lymphocytes combined with PD-L1 expression for patients with solitary colorectal cancer liver metastasis.
Colorectal Neoplasms
Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer.
Colorectal Neoplasms
Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis.
Colorectal Neoplasms
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Colorectal Neoplasms
Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis.
Colorectal Neoplasms
PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.
Colorectal Neoplasms
Quantitative lectin-histochemical and immunohistochemical studies on the occurrence of alpha(2,3)- and alpha(2,6)-linked sialic acid residues in colorectal carcinomas. Relation to clinicopathologic features.
Colorectal Neoplasms
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Colorectal Neoplasms
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity.
Colorectal Neoplasms
Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Colorectal Neoplasms
Retrospective analysis of the prognostic value of PD-L1 expression and 18F-FDG PET/CT metabolic parameters in colorectal cancer.
Colorectal Neoplasms
Riproximin: A type II ribosome inactivating protein with anti-neoplastic potential induces IL24/MDA-7 and GADD genes in colorectal cancer cell lines.
Colorectal Neoplasms
Rise of PD-L1 expression during metastasis of colorectal cancer: implications for immunotherapy.
Colorectal Neoplasms
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Colorectal Neoplasms
Sialoglycoconjugate expression in primary colorectal cancer and metastatic lymph node tissues.
Colorectal Neoplasms
Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer.
Colorectal Neoplasms
STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability.
Colorectal Neoplasms
Stromal cell PD-L1 inhibits CD8+ T-cell antitumor immune responses and promotes colon cancer.
Colorectal Neoplasms
Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
Colorectal Neoplasms
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy.
Colorectal Neoplasms
The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer.
Colorectal Neoplasms
The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Colorectal Neoplasms
The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
Colorectal Neoplasms
The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study.
Colorectal Neoplasms
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.
Colorectal Neoplasms
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Colorectal Neoplasms
The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy.
Colorectal Neoplasms
The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Colorectal Neoplasms
The roles of microbial products in the development of colorectal cancer: a review.
Colorectal Neoplasms
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.
Colorectal Neoplasms
Trial watch: TLR3 agonists in cancer therapy.
Colorectal Neoplasms
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Colorectal Neoplasms
Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
Colorectal Neoplasms
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes.
Colorectal Neoplasms
ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer.
Colorectal Neoplasms, Hereditary Nonpolyposis
A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
Colorectal Neoplasms, Hereditary Nonpolyposis
Immunology of Lynch Syndrome.
Colorectal Neoplasms, Hereditary Nonpolyposis
Immunoprofiles of colorectal cancer from Lynch syndrome.
Colorectal Neoplasms, Hereditary Nonpolyposis
[Enhancing Antitumor Effects Using Hyperthermia(Including Immune Checkpoint Inhibitor)].
Communicable Diseases
A quantitative PCR assay for the detection and quantification of Shiga toxin-producing Escherichia coli (STEC) in minced beef and dairy products.
Communicable Diseases
Anti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm.
Communicable Diseases
Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
Communicable Diseases
Development of an o-pthalaldehyde (OPA) assay to measure protein content in Ricin Vaccine E. coli (RVEc).
Communicable Diseases
EL4 cell-based colorimetric toxin neutralization activity assays for determination of neutralizing anti-ricin antibodies.
Communicable Diseases
Evaluation of Recombinant Forms of the Shiga Toxin Variant Stx2eB Subunit and Non-Toxic Mutant Stx2e as Vaccine Candidates against Porcine Edema Disease.
Communicable Diseases
Inclusion of PD-L1 into a recombinant profilin antigen enhances immunity against Babesia microti in a murine model.
Communicable Diseases
Inhibitory effect of tyrphostin 47 on Shiga toxin-induced cell death.
Communicable Diseases
Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.
Communicable Diseases
Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli.
Communicable Diseases, Emerging
Antibody-mediated inhibition of ricin toxin retrograde transport.
Confusion
The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Connective Tissue Diseases
Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
Corneal Neovascularization
A novel function for programmed death ligand-1 regulation of angiogenesis.
Coronary Artery Disease
Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis.
Coronary Artery Disease
Expression of coinhibitory PD-L1 on CD4?CD25?FOXP3? regulatory T cells is elevated in patients with acute coronary syndrome.
Coronary Artery Disease
Expression of PD-L1 in mononuclear cells, multinucleated cells, and foam cells in tenosynovial giant cell tumors.
Coronary Artery Disease
Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography.
Coronary Disease
PD-L1 expression on peripheral T-cells and association with coronary heart disease patients: A protocol for systematic reviews and meta-analysis.
Cough
Ricin poisoning: a comprehensive review.
COVID-19
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer.
COVID-19
Blood neutrophils from children with COVID-19 exhibit both inflammatory and anti-inflammatory markers.
COVID-19
Correction: COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
COVID-19
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
COVID-19
Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns.
COVID-19
Deep RNA Sequencing of Intensive Care Unit Patients with COVID-19.
COVID-19
Disharmonic Inflammatory Signatures in COVID-19: Augmented Neutrophils' but Impaired Monocytes' and Dendritic Cells' Responsiveness.
COVID-19
Increased PD-L1 Expression May Be Associated With the Cytokine Storm and CD8+ T-Cell Exhaustion in Severe COVID-19.
COVID-19
Mice with induced pulmonary morbidities display severe lung inflammation and mortality following exposure to SARS-CoV-2.
COVID-19
Morphoproteomics and Etiopathogenic Features of Pulmonary COVID-19 with Therapeutic Implications: A Case Study.
COVID-19
Novel Binding Mechanisms of Fusion Broad Range Anti-Infective Protein Ricin A Chain Mutant-Pokeweed Antiviral Protein 1 (RTAM-PAP1) against SARS-CoV-2 Key Proteins in Silico.
COVID-19
PD-L1 Dysregulation in COVID-19 Patients.
COVID-19
Saporin, a Polynucleotide-Adenosine Nucleosidase, May Be an Efficacious Therapeutic Agent for SARS-CoV-2 Infection.
COVID-19
SARS-CoV-2 infection: The role of PD-1/PD-L1 and CTLA-4 axis.
Craniopharyngioma
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and VISTA in craniopharyngioma.
Craniopharyngioma
Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma.
Craniopharyngioma
Immune Microenvironment of Primary and Recurrent Craniopharyngiomas: A Study of the Differences and Clinical Significance.
Craniopharyngioma
Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities in Craniopharyngioma.
Crohn Disease
A case of severe Pembrolizumab-induced neutropenia.
Crohn Disease
Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy.
Crohn Disease
Immuno-inhibitory PD-L1 can be induced by a Peptidoglycan/NOD2 mediated pathway in primary monocytic cells and is deficient in Crohn's patients with homozygous NOD2 mutations.
Crohn Disease
Intestinal APCs of the endogenous nanomineral pathway fail to express PD-L1 in Crohn's disease.
Crohn Disease
Matrix metalloproteinases cleave membrane-bound PD-L1 on CD90+ (myo-)fibroblasts in Crohn's disease and regulate Th1/Th17 cell responses.
Crohn Disease
Pathotypes and probiotics: response to a commentary on the detection of a Shiga toxin producing Escherichia coli in a Crohn's disease patient.
Crohn Disease
PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability.
Crohn Disease
T-bet interferes with PD-1/PD-L1-mediated suppression of CD4+ T cell inflammation and survival in Crohn's disease.
Cross Infection
Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.
Cystic Fibrosis
Cucurmosin induces the apoptosis of human pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-? signalling pathway.
Cystic Fibrosis
Pseudomonas aeruginosa colonization causes PD-L1 overexpression on monocytes, impairing the adaptive immune response in patients with cystic fibrosis.
Cystitis
Inflammation and nerve injury induce expression of pancreatitis-associated protein-II in primary sensory neurons.
Cysts
Colloid cyst of the third ventricle. A comparative immunohistochemical study of neuraxis cysts and choroid plexus epithelium.
Cysts
In vitro assessment of PD-L1+ microvesicles in the cyst fluid of non-syndromic odontogenic keratocysts.
Cysts
Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.
Deglutition Disorders
Tongue and hypoglossal morphology after intralingual cholera toxin B-saporin injection.
Dehydration
Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
Dehydration
Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study.
Dehydration
Rare Jatropha multifida intoxication in two children.
Deltaretrovirus Infections
Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.
Demyelinating Diseases
Acute demyelinating encephalitis due to Abrus precatorius poisoning - complete recovery after steroid therapy.
Demyelinating Diseases
Axonal injury heralds virus-induced demyelination.
Demyelinating Diseases
Plant toxin abrin induced oxidative stress mediated neurodegenerative changes in mice.
Demyelinating Diseases
Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune Neuritis by Controlling Peripheral Nervous System Inflammation of Rats.
Dendritic Cell Sarcoma, Follicular
Follicular dendritic cell sarcoma: clinicopathologic study of 15 cases with emphasis on novel expression of MDM2, somatostatin receptor 2A, and PD-L1.
Dendritic Cell Sarcoma, Follicular
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Dendritic Cell Sarcoma, Interdigitating
Neoplastic PD-L1 expression on interdigitating dendritic cell sarcoma: A supplementary study of a case report.
Dengue
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Dermatitis
Immunohistochemical Analysis of Lichenoid Reactions in Patients Treated with Anti-PD-L1 and Anti-PD-1 Therapy.
Dermatitis
Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events.
Dermatitis, Allergic Contact
Human Langerhans cells control Th cells via programmed death-ligand 1 in response to bacterial stimuli and nickel-induced contact allergy.
Dermatitis, Contact
Inactivation of the PD-1-Dependent Immunoregulation in Mice Exacerbates Contact Hypersensitivity Resembling Immune-Related Adverse Events.
Dermatitis, Contact
PD-L1 on mast cells suppresses effector CD8+ T-cell activation in the skin in murine contact hypersensitivity.
Dermatofibrosarcoma
Dermatofibrosarcoma protuberans: A retrospective study of clinicopathologic features and related Akt/mTOR, STAT3, ERK, cyclin D1, and PD-L1 expression.
Diabetes Mellitus
Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
Diabetes Mellitus
Getting with the program in type 1 diabetes mellitus.
Diabetes Mellitus
Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management.
Diabetes Mellitus
PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
Diabetes Mellitus, Type 1
A Missing PD-L1/PD-1 Coinhibition Regulates Diabetes Induction by Preproinsulin-Specific CD8 T-Cells in an Epitope-Specific Manner.
Diabetes Mellitus, Type 1
Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
Diabetes Mellitus, Type 1
Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility.
Diabetes Mellitus, Type 1
Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.
Diabetes Mellitus, Type 1
Cutting Edge: Identification of Autoreactive CD4+ and CD8+ T Cell Subsets Resistant to PD-1 Pathway Blockade.
Diabetes Mellitus, Type 1
Enhanced STAT3 phosphorylation and PD-L1 expression in myeloid dendritic cells indicate impaired IL-27Ralpha signaling in type 1 diabetes.
Diabetes Mellitus, Type 1
Getting with the program in type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management.
Diabetes Mellitus, Type 1
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
Diabetes Mellitus, Type 1
Making antigen invisible: a coinhibitory molecule regulates the interaction between T cells and dendritic cells.
Diabetes Mellitus, Type 1
News.
Diabetes Mellitus, Type 1
PD-1 and PD-L1 Expression in Peripheral CD4/CD8+ T Cells Is Restored in the Partial Remission Phase in Type 1 Diabetes.
Diabetes Mellitus, Type 1
PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes.
Diabetes Mellitus, Type 1
PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes.
Diabetes Mellitus, Type 1
Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models.
Diabetes Mellitus, Type 1
Tissue expression of PD-L1 mediates peripheral T cell tolerance.
Diabetes Mellitus, Type 2
Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation.
Diabetes Mellitus, Type 2
Insulin-receptor tyrosine kinase activity is decreased in erythrocytes from non-obese patients with NIDDM.
Diabetes Mellitus, Type 2
PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain.
Diabetes Mellitus, Type 2
Programmed death ligand 1 on Burkholderia pseudomallei-infected human polymorphonuclear neutrophils impairs T cell functions.
Diabetes Mellitus, Type 2
Unlike PD-L1, PD-1 Is Downregulated on Partial Immune Cells in Type 2 Diabetes.
Digestive System Neoplasms
Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.
Diphtheria
A Chinese hamster ovary cell mutant with a heat-sensitive, conditional-lethal defect in vacuolar function.
Diphtheria
A comparative study of ricin and diphtheria toxin-antibody-conjugate kinetics on protein synthesis inactivation.
Diphtheria
A novel method to purify immunotoxins from free antibodies using modified recombinant toxins.
Diphtheria
A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model.
Diphtheria
A quantitative and highly sensitive luciferase-based assay for bacterial toxins that inhibit protein synthesis.
Diphtheria
A single mutation in Chinese hamster ovary cells impairs both Golgi and endosomal functions.
Diphtheria
Active target cell processes, possibly involving receptor-mediated endocytosis, are critical for expression of cytotoxicity by natural killer cell-derived cytolytic factor.
Diphtheria
An approach for analysis of protein toxins based on thin films of lipid mixtures in an optical biosensor.
Diphtheria
Anion requirement and effect of anion transport inhibitors on the response of vero cells to diphtheria toxin and modeccin.
Diphtheria
Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells.
Diphtheria
Benzyl alcohol induces a reversible fragmentation of the Golgi apparatus and inhibits membrane trafficking between endosomes and the trans-Golgi network.
Diphtheria
Bithionol blocks pathogenicity of bacterial toxins, ricin, and Zika virus.
Diphtheria
Brefeldin A protects ricin-induced cytotoxicity in human cancer KB cell line, but not in its resistant counterpart with altered Golgi structures.
Diphtheria
Cell surface sulfhydryls are required for the cytotoxicity of diphtheria toxin but not of ricin in Chinese hamster ovary cells.
Diphtheria
Cellular recovery from exposure to sub-optimal concentrations of AB toxins that inhibit protein synthesis.
Diphtheria
Cerulenin inhibits the cytotoxicity of ricin, modeccin, Pseudomonas toxin, and diphtheria toxin in brefeldin A-resistant cell lines.
Diphtheria
Characterization of 3'-azido-3'-deoxythymidine inhibition of ricin and Pseudomonas exotoxin A toxicity in CHO and Vero cells.
Diphtheria
Characterization of hybrid molecules containing fragment A from diphtheria toxin linked to concanavalin A or the binding subunit of ricin toxin.
Diphtheria
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
Diphtheria
Chinese hamster ovary cell mutants with temperature-sensitive defects in endocytosis. I. Loss of function on shifting to the nonpermissive temperature.
Diphtheria
Comparison of protein synthesis inhibition kinetics and cell killing induced by immunotoxins.
Diphtheria
Comparison of the apoptosis-inducing abilities of various protein synthesis inhibitors in U937 cells.
Diphtheria
Cytotoxic effect of diphtheria toxin used alone or in combination with other agents on human renal cell carcinoma cell lines.
Diphtheria
Delivery into cells: lessons learned from plant and bacterial toxins.
Diphtheria
Delivery of internalized ricin from endosomes to cisternal Golgi elements is a discontinuous, temperature-sensitive process.
Diphtheria
Differential toxicity of ricin and diphtheria toxin for bloodstream forms of Trypanosoma brucei.
Diphtheria
Diisopropylfluorophosphate (DFP) inhibits ricin-induced apoptosis of MDCK cells.
Diphtheria
Diphtheria fusion protein therapy of chemoresistant malignancies.
Diphtheria
Diphtheria toxin mutant selectively kills cerebellar Purkinje neurons.
Diphtheria
Disruption of the Golgi apparatus by brefeldin A inhibits the cytotoxicity of ricin, modeccin, and Pseudomonas toxin.
Diphtheria
DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis.
Diphtheria
Dual effects of the ricin A chain on protein synthesis in rabbit reticulocyte lysate. Inhibition of initiation and translocation.
Diphtheria
Effect of helicobacter pylori vacuolating toxin on maturation and extracellular release of procathepsin D and on epidermal growth factor degradation.
Diphtheria
Effect of lovastatin on the cytotoxicity of ricin, modeccin, Pseudomonas toxin, and diphtheria toxin in brefeldin A-sensitive and -resistant cell lines.
Diphtheria
Effects of BCL-2 overexpression on the sensitivity of MCF-7 breast cancer cells to ricin, diphtheria and Pseudomonas toxin and immunotoxins.
Diphtheria
Effects of mepanipyrim on intracellular trafficking: a comparative study on its effects on exocytic and endocytic trafficking of proteins, sphingolipids, and cholesterol.
Diphtheria
Effects of retinoids and phorbol esters on the sensitivity of different cell lines to the polypeptide toxins modeccin, abrin, ricin and diphtheria toxin.
Diphtheria
Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice.
Diphtheria
Efrapeptins block exocytic but not endocytic trafficking of proteins.
Diphtheria
Energy requirements for diphtheria toxin translocation are coupled to the maintenance of a plasma membrane potential and a proton gradient.
Diphtheria
Engineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.
Diphtheria
Enhancement of cytotoxicity of modeccin by nigericin in modeccin-resistant mutant cell lines.
Diphtheria
Enhancement of diphtheria toxin-induced apoptosis in Vero cells by combination treatment with brefeldin A and okadaic acid.
Diphtheria
Enhancement of ricin cytotoxicity in Chinese hamster ovary cells by depletion of intracellular K+: evidence for an Na+/H+ exchange system in Chinese hamster ovary cells.
Diphtheria
Enhancement of the cytotoxicity of mistletoe lectin-1 (ML-1) by high pH or perturbation in Golgi functions.
Diphtheria
Enhancement of toxicity of saporin-based toxins by Gypsophila saponins--kinetic of the saponin.
Diphtheria
Entry of the toxic proteins abrin, modeccin, ricin, and diphtheria toxin into cells. I. Requirement for calcium.
Diphtheria
Entry of the toxic proteins abrin, modeccin, ricin, and diphtheria toxin into cells. II. Effect of pH, metabolic inhibitors, and ionophores and evidence for toxin penetration from endocytotic vesicles.
Diphtheria
Epidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxic.
Diphtheria
Evidence that diphtheria toxin and modeccin enter the cytosol from different vesicular compartments.
Diphtheria
Expression cloning of cDNAs that render cancer cells resistant to Pseudomonas and diphtheria toxin and immunotoxins.
Diphtheria
Expression of mutant dynamin protects cells against diphtheria toxin but not against ricin.
Diphtheria
Fate and action of ricin in rat liver in vivo: translocation of endocytosed ricin into cytosol and induction of intrinsic apoptosis by ricin B-chain.
Diphtheria
FOCAL OR INSULAR NECROSIS PRODUCED BY THE BACILLUS OF TUBERCULOSIS.
Diphtheria
Formation of a hybrid toxin from ricin agglutinin and a non-toxic mutant protein of diphtheria toxin.
Diphtheria
Functional expression of the human transferrin receptor cDNA in Chinese hamster ovary cells deficient in endogenous transferrin receptor.
Diphtheria
Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells.
Diphtheria
HeLa cell mutants resistant to epidermal growth factor ricin A-chain conjugate.
Diphtheria
Hybrid toxin of the A chain of ricin toxin and a subunit of Wistaria floribunda lectin. Possible importance of the hydrophobic region for entry of toxin into the cell.
Diphtheria
Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics.
Diphtheria
Ilimaquinone inhibits the cytotoxicities of ricin, diphtheria toxin, and other protein toxins in Vero cells.
Diphtheria
Immunotherapy of experimental animal tumors with antitumor antibodies conjugated to diphtheria toxin or ricin.
Diphtheria
Immunotoxins and recombinant toxins in the treatment of solid carcinomas.
Diphtheria
Immunotoxins in cancer therapy: Review and update.
Diphtheria
Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen.
Diphtheria
Immunotoxins: is there a clinical value?
Diphtheria
In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme.
Diphtheria
Increased cytotoxicity of ricin in a putative Golgi-defective mutant of Chinese hamster ovary cell.
Diphtheria
Induction of cytokines by toxins that have an identical RNA N-glycosidase activity: Shiga toxin, ricin, and modeccin.
Diphtheria
Inhibition of Cholera Toxin and Other AB Toxins by Polyphenolic Compounds.
Diphtheria
Inhibition of coated pit formation in Hep2 cells blocks the cytotoxicity of diphtheria toxin but not that of ricin toxin.
Diphtheria
Inhibition of mouse spleen cell function by diphtheria toxin fragment A coupled to anti-mouse Thy-1.2 and by ricin A chain coupled to anti-mouse IgM.
Diphtheria
Inhibition of the cytotoxicity of protein toxins by a novel plant metabolite, mansonone-D.
Diphtheria
Inhibitory effect of dideoxyforskolin on cell death induced by ricin, modeccin, diphtheria toxin, and Pseudomonas toxin in MDCK cells.
Diphtheria
Intracellular expression of toxic shock syndrome toxin 1 in Saccharomyces cerevisiae.
Diphtheria
Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and pseudomonas toxin.
Diphtheria
Isolation of variants of Chinese hamster ovary cells with abnormally low levels of GSH: decreased ability to cleave endocytosed disulfide bonds.
Diphtheria
Killing of cultured hepatocytes by conjugates of asialofetuin and EGF linked to the A chains of ricin or diphtheria toxin.
Diphtheria
Lipopolyamine treatment increases the efficacy of intoxication with saporin and an anticancer saporin conjugate.
Diphtheria
Methotrexate-poly(lysine) as a selective agent for mutants of Chinese hamster ovary cells defective in endocytosis.
Diphtheria
Methylamine stimulates the action of ricin toxin but inhibits that of diphtheria toxin.
Diphtheria
Monensin intercalation in liposomes: effect on cytotoxicities of ricin, Pseudomonas exotoxin A and diphtheria toxin in CHO cells.
Diphtheria
Mosquito inoculation: an alternative bioassay for toxins.
Diphtheria
Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity.
Diphtheria
Novel blockade of cell surface expression of virus glycoproteins by leucinostatin A.
Diphtheria
Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy.
Diphtheria
Peptide toxins directed at the matrix dissolution systems of cancer cells.
Diphtheria
Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Diphtheria
Potentiation of ricin cytotoxicity by liposomal monensin under in vitro and in vivo conditions.
Diphtheria
Preparation and properties of chimeric toxins prepared from the constituent polypeptides of diphtheria toxin and ricin. Evidence for entry of ricin A-chain via the diphtheria toxin pathway.
Diphtheria
Prospects of Bacterial and Plant Protein-based Immunotoxins for Treatment of Cancer.
Diphtheria
Protective effect of cell-permeable ceramide analogs against modeccin, ricin, Pseudomonas toxin, and diphtheria toxin.
Diphtheria
Rationale for the use of immunotoxins in the treatment of HIV-infected humans.
Diphtheria
Receptor-mediated transport of the hybrid protein ricin-diphtheria toxin fragment A with subsequent ADP-ribosylation of intracellular elongation factor II.
Diphtheria
Recombinant hybrid toxin with dual enzymatic activities. Potential use in preparing highly effective immunotoxins.
Diphtheria
Recovery of function in Chinese hamster ovary cell mutants with temperature-sensitive defects in vacuolar acidification.
Diphtheria
Resistance against ricin-induced apoptosis in a brefeldin A-resistant mutant cell line (BER-40) of Vero cells.
Diphtheria
Ricin cytotoxicity is sensitive to recycling between the endoplasmic reticulum and the Golgi complex.
Diphtheria
Role of caspases in immunotoxin-induced apoptosis of cancer cells.
Diphtheria
Shiga toxin 1 and ricin A chain bind to human polymorphonuclear leucocytes through a common receptor.
Diphtheria
Somatic cell mutants resistant to ricin, diphtheria toxin, and to immunotoxins.
Diphtheria
Specific efflux of glutathione from the basolateral membrane domain in polarized MDCK cells during ricin-induced apoptosis.
Diphtheria
Study of localization of the protein-synthesizing machinery along actin filament bundles.
Diphtheria
Systemic toxicity of diphtheria toxin-related fragments (CRM26, CRM45), a hormone-toxin hybrid protein (TRH-CRM45), and ricin A.
Diphtheria
Targeted toxin therapy for the treatment of cancer.
Diphtheria
Temporal separation of protein toxin translocation from processing events.
Diphtheria
The binding of tritiated elongation-factors 1 and 2 to ribosomes from Krebs II mouse ascites-tumore cells. The influence of various antibiotics and toxins.
Diphtheria
The different behavior of diphtheria toxin, modeccin and ricin in HeLa cells infected with Trypanosoma cruzi.
Diphtheria
The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum.
Diphtheria
The p21 Rho-activating toxin cytotoxic necrotizing factor 1 is endocytosed by a clathrin-independent mechanism and enters the cytosol by an acidic-dependent membrane translocation step.
Diphtheria
The second intron of AGAMOUS drives carpel- and stamen-specific expression sufficient to induce complete sterility in Arabidopsis.
Diphtheria
Toxicity of ricin, diphtheria toxin and alpha-Amanitin for Acanthamoeba castellanii (1983).
Diphtheria
Toxin-antitoxin selection for isolating somatic cell fusion products between any cell types.
Diphtheria
Toxin-induced cell lysis: protection by 3-methyladenine and cycloheximide.
Diphtheria
Translating ribosomes inhibit poliovirus negative-strand RNA synthesis.
Diphtheria
Treatment of FL cells with neuraminidase stimulating the sensitivities to diphtheria toxin and ricin toxin [proceedings]
Diphtheria
Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy.
Diphtheria
[Effect of cytochalasin D, diphtheria toxin, and ricin on the localization of eukaryotic elongation factor 2 along actin filament bundles in fibroblasts]
Diphtheria
[Endosomes and toxin translocation]
Diphtheria
[Features of the structure of catalytic subunits of toxins, inhibiting protein synthesis. I. The effect of pH and interaction with the B-chain of ricin]
Diphtheria
[Mitogenic responsiveness to growth factor and tumor promoters and regulation of cell growth]
Diphtheria
[Production and characteristics of monoclonal antibodies to the diphtheria toxin]
Distemper
Prevalence of enteropathogens and their antibiotic sensitivity pattern in puppies with hemorrhagic gastroenteritis.
DNA Repair-Deficiency Disorders
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy.
Drug-Related Side Effects and Adverse Reactions
Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.
Dry Eye Syndromes
Programmed Death-Ligand 1 (PD-L1) Regulates T cell Chemotaxis in Dry Eye-Associated Corneal Inflammation.
Dysentery
Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery.
Dysentery
Diarrheagenic E. coli in hospitalized patients: special reference to Shiga-like toxin producing Escherichia coli.
Dysentery
Fecal excretion of leukotriene C4 during human disease due to Shigella dysenteriae.
Dysentery
Molecular epidemiologic techniques in analysis of epidemic and endemic Shigella dysenteriae type 1 strains.
Dysentery
O-specific side-chain toxin-protein conjugates as parenteral vaccines for the prevention of shigellosis and related diseases.
Dysentery
Secretory immunoglobulin A response to Shiga toxin in rabbits: kinetics of the initial mucosal immune response and inhibition of toxicity in vitro and in vivo.
Dysentery
Stimulation of gastrointestinal antibody to Shiga toxin by orogastric immunization in mice.
Dysentery
Toll-like receptor 4 facilitates binding of Shiga toxin to colon carcinoma and primary umbilical vein endothelial cells.
Dysentery
[Experimental studies on the toxins of dysentery bacteria. VII. Effect specificity of Flexner endotoxin and Shiga toxin after single injections and in prolonged infusions.]
Dysentery, Bacillary
Antibodies to Shiga toxin in the serum of children with Shigella-associated haemolytic uraemic syndrome.
Dysentery, Bacillary
Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome.
Dysentery, Bacillary
Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection.
Dysentery, Bacillary
Distribution and characterization of Shiga toxin converting temperate phages carried by Shigella flexneri in Hispaniola.
Dysentery, Bacillary
Foodborne disease in Australia: incidence, notifications and outbreaks. Annual report of the OzFoodNet network, 2002.
Dysentery, Bacillary
From lin-benzoguanines to lin-benzohypoxanthines as ligands for Zymomonas mobilis tRNA-guanine transglycosylase: replacement of protein-ligand hydrogen bonding by importing water clusters.
Dysentery, Bacillary
Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis.
Dysentery, Bacillary
Immunological detection assays for recombinant Shiga toxin & Shigella dysenteriae.
Dysentery, Bacillary
Induction of nitric oxide production in mouse macrophages by Shiga toxin.
Dysentery, Bacillary
Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1.
Dysentery, Bacillary
Shigella-induced encephalopathy in an adult.
Dysentery, Bacillary
The association of Shiga toxin and other cytotoxins with the neurologic manifestations of shigellosis.
Dysentery, Bacillary
Towards a vaccine candidate against Shigella dysenteriae 1: expression of the Shiga toxin B-subunit in an attenuated Shigella flexneri aroD carrier strain.
Dyspnea
Clinical and Pathological Findings Associated with Aerosol Exposure of Macaques to Ricin Toxin.
Dyspnea
Ricin poisoning: a comprehensive review.
Dyspnea
Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
Echinococcosis
Enzyme-linked immunosorbent assay for Shiga toxin and Shiga-like toxin II using P1 glycoprotein from hydatid cysts.
Echinococcosis
Innate and adaptive immune responses following PD-L1 blockade in treating chronic murine alveolar echinococcosis.
Echinococcosis
One step high yield affinity purification of shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays.
Echinococcosis
Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies.
Eclampsia
FOCAL OR INSULAR NECROSIS PRODUCED BY THE BACILLUS OF TUBERCULOSIS.
Eczema
Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
Elephantiasis
Association of a PD-L2 Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort.
Encephalitis
Chronic reactive gliosis following regulatory T cell depletion during acute MCMV encephalitis.
Encephalitis
HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor.
Encephalitis
PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis.
Encephalitis
The application of food safety interventions in primary production of beef and lamb: A review.
Encephalitis
[Protective effects of trichosanthin in Herpes simplex virus-1 encephalitis in mice]
Encephalitis, Japanese
Inhibition of Japanese encephalitis virus infection in vitro and in vivo by pokeweed antiviral protein.
Encephalitis, Japanese
Japanese encephalitis virus expands regulatory T cells by increasing the expression of PD-L1 on dendritic cells.
Encephalitis, Tick-Borne
The application of food safety interventions in primary production of beef and lamb: A review.
Encephalitis, Viral
Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1.
Encephalitis, Viral
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.
Encephalitis, Viral
The PD-1: PD-L1 pathway promotes development of brain-resident memory T cells following acute viral encephalitis.
Encephalomyelitis
Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function.
Encephalomyelitis
IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice.
Encephalomyelitis
Immune modulatory mesenchymal stem cells derived from human embryonic stem cells through a trophoblast-like stage.
Encephalomyelitis
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1.
Encephalomyelitis
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
Encephalomyelitis
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses.
Encephalomyelitis, Autoimmune, Experimental
Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function.
Encephalomyelitis, Autoimmune, Experimental
IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice.
Encephalomyelitis, Autoimmune, Experimental
Immune modulatory mesenchymal stem cells derived from human embryonic stem cells through a trophoblast-like stage.
Encephalomyelitis, Autoimmune, Experimental
PD-L1 is increased in the spinal cord and infiltrating lymphocytes in experimental allergic encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
Encephalomyelitis, Autoimmune, Experimental
Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses.
Encephalomyelitis, Venezuelan Equine
A simple and rapid protein array based method for the simultaneous detection of biowarfare agents.
Encephalomyelitis, Venezuelan Equine
Suitability of Commercial Transport Media for Biological Pathogens under Nonideal Conditions.
Endocarditis
Programmed death ligand-1 expression and memory T-cell generation in Coxiella burnetii infection.
Endodermal Sinus Tumor
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.
Endodermal Sinus Tumor
Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Endodermal Sinus Tumor
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Endodermal Sinus Tumor
Serum alpha-fetoprotein subfractions identified by Ricinus communis agglutinin I in hepatic malignancies, yolk sac tumor, benign hepatic diseases, and fetal stage.
Endometrial Neoplasms
?-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
Endometrial Neoplasms
?-Glutamyl cyclotransferase contributes to endometrial carcinoma malignant progression and upregulation of PD-L1 expression during activation of epithelial-mesenchymal transition.
Endometrial Neoplasms
A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
Endometrial Neoplasms
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
Endometrial Neoplasms
Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer.
Endometrial Neoplasms
Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
Endometrial Neoplasms
Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer.
Endometrial Neoplasms
Expression of immune checkpoint molecules in endometrial carcinoma.
Endometrial Neoplasms
Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
Endometrial Neoplasms
Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer.
Endometrial Neoplasms
Expression of programmed death-ligand 1 and hypoxia-inducible factor-1? proteins in endometrial carcinoma.
Endometrial Neoplasms
High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.
Endometrial Neoplasms
Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.
Endometrial Neoplasms
Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas.
Endometrial Neoplasms
Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma.
Endometrial Neoplasms
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.
Endometrial Neoplasms
Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1.
Endometrial Neoplasms
PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.
Endometrial Neoplasms
PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas.
Endometrial Neoplasms
PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Endometrial Neoplasms
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
Endometrial Neoplasms
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Endometrial Neoplasms
PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
Endometrial Neoplasms
PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer.
Endometrial Neoplasms
PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3.
Endometrial Neoplasms
Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Endometrial Neoplasms
Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.
Endometrial Neoplasms
Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
Endometrial Neoplasms
Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma.
Endometrial Neoplasms
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Endometrial Neoplasms
Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer.
Endometrial Neoplasms
T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.
Endometrial Neoplasms
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.
Endometrial Neoplasms
The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
Endometrial Neoplasms
The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
Endometrial Neoplasms
Undifferentiated Endometrial Carcinoma, an Immunohistochemical Study Including PD-L1 Testing of a Series of Cases From a Single Cancer Center.
Endometriosis
Expression of programed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol.
Endometriosis
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Endometriosis
Ovarian endometrioma infiltrating neutrophils orchestrate immunosuppressive microenvironment.
Endometriosis
The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters.
Endotoxemia
Spleen-derived IFN-? induces generation of PD-L1
Enteritis
Detection of VTEC using specific DNA probes and complex typing of Escherichia coli O157.
Enteritis
Immuno-inhibitory PD-L1 can be induced by a Peptidoglycan/NOD2 mediated pathway in primary monocytic cells and is deficient in Crohn's patients with homozygous NOD2 mutations.
Enteritis
Impact of the rpoS genotype for acid resistance patterns of pathogenic and probiotic Escherichia coli.
Enteritis
Intravenous Shiga toxin 2 promotes enteritis and renal injury characterized by polymorphonuclear leukocyte infiltration and thrombosis in Dutch Belted rabbits.
Enteritis
Protection of Mice against Shiga Toxin 2 (Stx2)-Associated Damage by Maternal Immunization with a Brucella Lumazine Synthase-Stx2 B Subunit Chimera.
Enteritis
Role of Shiga-like toxin I in bacterial enteritis: comparison between isogenic Escherichia coli strains induced in rabbits.
Enterocolitis
Anti-Shiga toxin 2 antibodies in enterohemorrhagic Escherichia coli O104:H4 infected patients may predict hemolytic uremic syndrome.
Enterocolitis
Enterocolitis associated with Shiga-like toxin production: an appropriate animal model at last?
Enterocolitis
Increased Expression of Complement Regulators CD55 and CD59 on Peripheral Blood Cells in Patients with EAHEC O104:H4 Infection.
Enterocolitis
Shiga toxin 2-converting bacteriophages associated with clonal variability in Escherichia coli O157:H7 strains of human origin isolated from a single outbreak.
Enterocolitis
[Gastrointestinal complications of the new immune checkpoint inhibitor therapies].
Enzootic Bovine Leukosis
Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte proliferation.
Enzootic Bovine Leukosis
Antiviral activity of shiga toxin requires enzymatic activity and is associated with increased permeability of the target cells.
Enzootic Bovine Leukosis
Differential sensitivity of viruses to the antiviral activity of Shiga toxin 1 A subunit.
Enzootic Bovine Leukosis
In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.
Enzootic Bovine Leukosis
Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.
Enzootic Bovine Leukosis
Shiga toxin 1 targets bovine leukemia virus-expressing cells.
Enzootic Bovine Leukosis
The non-toxic A subunit of Shiga toxin type 1 prevents replication of bovine immunodeficiency virus in infected cells.
Ependymoma
Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?
Ependymoma
PD1 and PD-L1 in ependymoma might not be therapeutic targets.
Ependymoma
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
Ependymoma
The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study.
Ependymoma
Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
Epilepsy
Evidence of syntaxin 1A involvement in migraine susceptibility: a Portuguese study.
Epilepsy
Synergistic association of STX1A and VAMP2 with cryptogenic epilepsy in North Indian population.
Epstein-Barr Virus Infections
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Epstein-Barr Virus Infections
Checkpoint inhibitors in hematological malignancies.
Epstein-Barr Virus Infections
Clinicopathological analysis of programmed cell death-1 and programmed cell death-ligand 1 expression in the tumor microenvironments of diffuse large B-cell lymphomas.
Epstein-Barr Virus Infections
Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Epstein-Barr Virus Infections
Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Epstein-Barr Virus Infections
Clinicopathological Significance of EBV-Infected Gastric Carcinomas: A Meta-Analysis.
Epstein-Barr Virus Infections
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy.
Epstein-Barr Virus Infections
Expression of PD-L1 in EBV-associated malignancies.
Epstein-Barr Virus Infections
Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Epstein-Barr Virus Infections
Integrated pan-cancer map of EBV-associated neoplasms reveals functional host-virus interactions.
Epstein-Barr Virus Infections
Lack of efficacy of radiation therapy plus PD-L1 blockade for Merkel cell carcinoma arising in a patient with chronic active Epstein-Barr virus infection.
Epstein-Barr Virus Infections
Molecular and pathological analyses of gastric stump cancer by next-generation sequencing and immunohistochemistry.
Epstein-Barr Virus Infections
New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
Epstein-Barr Virus Infections
Nivolumab in the Treatment of Hodgkin Lymphoma.
Epstein-Barr Virus Infections
PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
Epstein-Barr Virus Infections
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.
Epstein-Barr Virus Infections
PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
Epstein-Barr Virus Infections
Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
Epstein-Barr Virus Infections
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Epstein-Barr Virus Infections
Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma.
Epstein-Barr Virus Infections
Revisiting the Tissue Microenvironment of Infectious Mononucleosis: Identification of EBV Infection in T Cells and Deep Characterization of Immune Profiles.
Epstein-Barr Virus Infections
RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells.
Epstein-Barr Virus Infections
Targeting the programmed death-1 pathway in lymphoid neoplasms.
Epstein-Barr Virus Infections
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Epstein-Barr Virus Infections
The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer.
Erythema Multiforme
Reduced expression of programmed cell death 1 and programmed cell death ligand 1 in infiltrating inflammatory cells of lichen planus without administration of immune checkpoint inhibitors.
Escherichia coli Infections
Abstracts of the 8th International Symposium on Shiga Toxin (Verocytotoxin) Producing Escherichia coli Infections. May 6-9, 2012. Amsterdam, The Netherlands.
Escherichia coli Infections
An Epidemiologic Surveillance of Shiga-like Toxin-producing Escherichia coli Infection in Argentinean Children: Risk Factors and Serum Shiga-like Toxin 2 Values.
Escherichia coli Infections
Brainstem mechanisms of autonomic dysfunction in encephalopathy-associated Shiga toxin 2 intoxication.
Escherichia coli Infections
Characterization of Shiga toxin -- producing Escherichia coli infections in beef feeder calves and the effectiveness of a prebiotic in alleviating Shiga toxin - producing Escherichia coli infections.
Escherichia coli Infections
Colistin inhibits E. coli O157:H7 Shiga-like toxin release, binds endotoxins and protects Vero cells.
Escherichia coli Infections
Comparative Characterization of Shiga Toxin Type 2 and Subtilase Cytotoxin Effects on Human Renal Epithelial and Endothelial Cells Grown in Monolayer and Bilayer Conditions.
Escherichia coli Infections
Comparative histopathology of intestinal infections.
Escherichia coli Infections
Comparison of a direct fecal Shiga-like toxin assay and sorbitol-MacConkey agar culture for laboratory diagnosis of enterohemorrhagic Escherichia coli infection.
Escherichia coli Infections
Cytotoxic effects of Shiga toxin-2 on human extravillous trophoblast cell lines.
Escherichia coli Infections
Diagnosis of Shiga toxin producing Escherichia coli infection, contribution of genetic amplification technique.
Escherichia coli Infections
Duplication and diversification of a unique chromosomal virulence island hosting the subtilase cytotoxin in Escherichia coli ST58.
Escherichia coli Infections
Enhancement of pentylenetetrazole-induced seizures by Shigella dysenteriae in LPS-resistant C3H/HeJ mice: role of the host response.
Escherichia coli Infections
Enterohemorrhagic Escherichia Coli Infection Stimulates Shiga toxin 1 Macropinocytosis and Transcytosis across Intestinal Epithelial Cells.
Escherichia coli Infections
Frequent loss of Shiga-like toxin genes in clinical isolates of Escherichia coli upon subcultivation.
Escherichia coli Infections
Genetics of hemolytic uremic syndromes.
Escherichia coli Infections
Hemolytic uremic syndrome associated with Shiga toxin producing Escherichia coli infection in a healthy adult woman.
Escherichia coli Infections
Investigation of Encephalopathy Caused by Shiga Toxin 2c-Producing Escherichia coli Infection in Mice.
Escherichia coli Infections
LPS-primed CD11b
Escherichia coli Infections
Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis.
Escherichia coli Infections
National reporting of Shiga-like toxin (verotoxin) producing Escherichia coli infections and associated syndromes.
Escherichia coli Infections
Neurologic manifestations of E coli infection-induced hemolytic-uremic syndrome in adults.
Escherichia coli Infections
Neuropsychological outcome after complicated Shiga toxin-producing Escherichia coli infection.
Escherichia coli Infections
Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome similar to septic shock.
Escherichia coli Infections
Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection.
Escherichia coli Infections
Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
Escherichia coli Infections
Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B.
Escherichia coli Infections
Quantitation of Risk Reduction of E. coli Transmission After Using Antimicrobial Hand Soap.
Escherichia coli Infections
Retinoid levels influence enterohemorrhagic Escherichia coli infection and Shiga toxin 2 susceptibility in mice.
Escherichia coli Infections
Role of Shiga toxin 2 (Stx2)-binding protein, human serum amyloid P component (HuSAP), in Shiga toxin-producing Escherichia coli infections: assumption from in vitro and in vivo study using HuSAP and anti-Stx2 humanized monoclonal antibody TMA-15.
Escherichia coli Infections
Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS).
Escherichia coli Infections
Shiga toxin 2eB-transgenic lettuce vaccine is effective in protecting weaned piglets from edema disease caused by Shiga toxin-producing Escherichia coli infection.
Escherichia coli Infections
Shiga toxin producing Escherichia coli infection: current progress & future challenges.
Escherichia coli Infections
Subtyping Escherichia coli Virulence Genes Isolated from Feces of Beef Cattle and Clinical Cases in Alberta.
Escherichia coli Infections
The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome.
Escherichia coli Infections
Urinary concentrating defect in rats given Shiga toxin: elevation in urinary AQP2 level associated with polyuria.
Escherichia coli Infections
[Shiga toxin producing Escherichia coli infection]
Esophageal Neoplasms
Cautious optimism-the current role of immunotherapy in gastrointestinal cancers.
Esophageal Neoplasms
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.
Esophageal Neoplasms
Clinical significance of soluble forms of immune checkpoint molecules in advanced esophageal cancer.
Esophageal Neoplasms
Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Esophageal Neoplasms
From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer.
Esophageal Neoplasms
Ginsenoside Rh4 suppresses aerobic glycolysis and the expression of PD-L1 via targeting AKT in esophageal cancer.
Esophageal Neoplasms
High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.
Esophageal Neoplasms
IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer.
Esophageal Neoplasms
Immune cell score, PD-L1 expression and prognosis in esophageal cancer.
Esophageal Neoplasms
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Esophageal Neoplasms
MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer.
Esophageal Neoplasms
PD-L1 and Survival in Solid Tumors: A Meta-Analysis.
Esophageal Neoplasms
PD-L1 expression in human cancers and its association with clinical outcomes.
Esophageal Neoplasms
PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy.
Esophageal Neoplasms
PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.
Esophageal Neoplasms
PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Esophageal Neoplasms
Pembrolizumab as a first-line therapy in spinocellular esophageal cancer.
Esophageal Neoplasms
Prognostic and therapeutic molecular markers in the clinical management of esophageal cancer.
Esophageal Neoplasms
Prognostic Impact of PD-1 on Tumor-Infiltrating Lymphocytes in 433 Resected Esophageal Cancers.
Esophageal Neoplasms
Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.
Esophageal Neoplasms
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
Esophageal Neoplasms
The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis.
Esophageal Neoplasms
The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
Esophageal Neoplasms
TRPM8 facilitates proliferation and immune evasion of esophageal cancer cells.
Esophageal Neoplasms
Use of PD-1 and PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US.
Esophageal Squamous Cell Carcinoma
Advances in targeted therapy for esophageal cancer.
Esophageal Squamous Cell Carcinoma
Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF? and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Esophageal Squamous Cell Carcinoma
C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
Esophageal Squamous Cell Carcinoma
Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation.
Esophageal Squamous Cell Carcinoma
Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.
Esophageal Squamous Cell Carcinoma
Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway.
Esophageal Squamous Cell Carcinoma
Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Esophageal Squamous Cell Carcinoma
Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome.
Esophageal Squamous Cell Carcinoma
High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy.
Esophageal Squamous Cell Carcinoma
Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Esophageal Squamous Cell Carcinoma
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study.
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Esophageal Squamous Cell Carcinoma
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Esophageal Squamous Cell Carcinoma
NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Esophageal Squamous Cell Carcinoma
PD-L1 expression at tumor invasive front is associated with EMT and poor prognosis in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy.
Esophageal Squamous Cell Carcinoma
PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma.
Esophageal Squamous Cell Carcinoma
PD-L1 hotspot in tumor-infiltrating lymphocytes of radically treated esophageal squamous cell carcinoma: Pattern of recurrence and long-term clinical outcomes.
Esophageal Squamous Cell Carcinoma
PD-L1 is prognostic factor in esophageal squamous cell carcinoma and is associated with EGFR.
Esophageal Squamous Cell Carcinoma
Pembrolizumab for the treatment of esophageal cancer.
Esophageal Squamous Cell Carcinoma
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Esophageal Squamous Cell Carcinoma
Positive Programmed Cell Death-Ligand 1 Expression Predicts Poor Treatment Outcomes in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy.
Esophageal Squamous Cell Carcinoma
Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.
Esophageal Squamous Cell Carcinoma
Prognostic factor analysis for patient outcome of PD-L1 expression in thoracic oesophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy.
Esophageal Squamous Cell Carcinoma
Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
Esophageal Squamous Cell Carcinoma
Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis.
Esophageal Squamous Cell Carcinoma
Programmed death-1 ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squamous cell carcinoma in smokers.
Esophageal Squamous Cell Carcinoma
Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells.
Esophageal Squamous Cell Carcinoma
Role of PD-L1 in radio-sensitivity of esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
The emerging role of immunotherapy for esophageal cancer.
Esophageal Squamous Cell Carcinoma
The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
Esophageal Squamous Cell Carcinoma
[Clinical relevance of common inhibitory immune checkpoint genes in esophageal squamous cell carcinoma].
Esthesioneuroblastoma, Olfactory
Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.
Exanthema
Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
Exanthema
Risk of dermatologic and mucosal adverse events associated with PD-1/PD-L1 inhibitors in cancer patients: A meta-analysis of randomized controlled trials.
Exanthema
Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Extranodal Extension
Capture of recombinant ricin A chain by a bispecific anti-RTA:anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice.
Extranodal Extension
The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Fasciitis, Necrotizing
Near-fatal poisoning after ricin injection.
Fetal Growth Retardation
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Fibroadenoma
PD-L1 mediated the differentiation of tumor-infiltrating CD19(+) B lymphocytes and T cells in Invasive breast cancer.
Fibromatosis, Aggressive
Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
Fibrosarcoma
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
Fibrosarcoma
Codelivery of a cytotoxin and photosensitiser via a liposomal nanocarrier: a novel strategy for light-triggered cytosolic release.
Fibrosarcoma
Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin.
Fibrosarcoma
Lectin histochemistry of malignant fibrohistiocytic tumors.
Fibrosarcoma
Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract.
Fibrosarcoma
Shock wave permeabilization with ribosome inactivating proteins: a new approach to tumor therapy.
Fibrosarcoma
Status of programmed death-ligand 1 expression in sarcomas.
Fibrosarcoma
Vascular endothelial cells as targets for photochemical internalization (PCI).
Foodborne Diseases
A new alpha-galactosyl-binding protein from the mushroom Lyophyllum decastes.
Foodborne Diseases
Analysis of virulence potential of Escherichia coli O145 isolated from cattle feces and hide samples based on whole genome sequencing.
Foodborne Diseases
Degradation and inactivation of Shiga toxins by nitrogen gas plasma.
Foodborne Diseases
Development and characterization of monoclonal antibodies against Shiga toxin 2 and their application for toxin detection in milk.
Foodborne Diseases
Development of a bivalent food poisoning vaccine: augmented antigenicity of the C-terminus of Clostridium perfringens enterotoxin by fusion with the B subunit of Escherichia coli Shiga toxin 2.
Foodborne Diseases
First Detection of Shiga Toxin-Producing Escherichia coli in Shellfish and Coastal Environments of Morocco.
Foodborne Diseases
Foodborne diseases: Shiga toxin producing E. coli (STEC).
Foodborne Diseases
Foodborne illness: is it on the rise?
Foodborne Diseases
From lin-benzoguanines to lin-benzohypoxanthines as ligands for Zymomonas mobilis tRNA-guanine transglycosylase: replacement of protein-ligand hydrogen bonding by importing water clusters.
Foodborne Diseases
Immunization with BLS-Stx2B chimera totally protects dams from early pregnancy loss induced by Shiga toxin type 2 (Stx2) and confers anti-Stx2 immunity to the offspring.
Foodborne Diseases
Mass spectrometry-based Shiga toxin identification: An optimized approach.
Foodborne Diseases
Molecular Mechanisms Governing "Hair-Trigger" Induction of Shiga Toxin-Encoding Prophages.
Foodborne Diseases
Sensitive detection of active Shiga toxin using low cost CCD based optical detector.
Foodborne Diseases
Shiga Toxin (Verotoxin)-producing ?Escherichia coli and Foodborne Disease: ?A Review.
Foodborne Diseases
Shiga toxin 2-induced intestinal pathology in infant rabbits is A-subunit dependent and responsive to the tyrosine kinase and potential ZAK inhibitor imatinib.
Foodborne Diseases
Shiga toxin-producing Escherichia coli O157:H7 in milk and milk products in Ogun State, Nigeria.
Foodborne Diseases
Shiga-like toxin II-related cytotoxins in Citrobacter freundii strains from humans and beef samples.
Foodborne Diseases
Structure-based design and characterization of novel platforms for ricin and shiga toxin inhibition.
Foodborne Diseases
The Probiotic Escherichia coli Strain Nissle 1917 Combats Lambdoid Bacteriophages stx and ?.
Foodborne Diseases
The synthesis of a multivalent heterobifunctional ligand for specific interaction with Shiga toxin 2 produced by E. coli O157:H7.
Foodborne Diseases
Transcription of the subtilase cytotoxin gene subAB1 in Shiga toxin-producing Escherichia coli is dependent on hfq and hns.
Foodborne Diseases
Virulence factors, serogroups and antimicrobial resistance properties of Escherichia coli strains in fermented dairy products.
Foodborne Diseases
[Isolation, characterization and typing of Escherichia coil 0157:H7 strains from beef products and milk]
Fractures, Spontaneous
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
Furunculosis
Frequencies of PD-1- and PD-L1- positive T CD3+CD4+, T CD3+CD8+ and B CD19+ lymphocytes and its correlations with other immune cells in patients with recurrent furunculosis.
Gallbladder Neoplasms
Association of Immunostaining of Galectin-3 and Sambucus nigra Agglutinin with Invasion, Metastasis and Poor Progression of Gallbladder Adenocarcinoma.
Gallbladder Neoplasms
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression.
Gallbladder Neoplasms
Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy.
Gallbladder Neoplasms
Expression of the RIP-1 gene and its role in growth and invasion of human gallbladder carcinoma.
Gallbladder Neoplasms
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Gallbladder Neoplasms
Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer.
Gallbladder Neoplasms
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer.
Gallbladder Neoplasms
Significant benefit of nivolumab combining radiotherapy in metastatic gallbladder cancer patient with strong PD-L1 expression: a case report.
Ganglion Cysts
GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.
Ganglioneuroblastoma
Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells.
Ganglioneuroblastoma
[Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
Gastritis
Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.
Gastritis
Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection.
Gastritis
PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma.
Gastritis
Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis.
Gastritis
Programmed Death Ligand 1-Expressing Classical Dendritic Cells MitigateHelicobacter-Induced Gastritis.
Gastritis
The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Gastritis, Atrophic
Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.
Gastroenteritis
Escherichia albertii Inactivation following l-Lactic Acid Exposure or Cooking in Ground Beef.
Gastroenteritis
Escherichia albertii Pathogenesis.
Gastroenteritis
Evaluation of castor bean toxicosis in dogs: 98 cases.
Gastroenteritis
Importance of culture confirmation of shiga toxin-producing Escherichia coli infection as illustrated by outbreaks of gastroenteritis--New York and North Carolina, 2005.
Gastroenteritis
Oral immunization with a shiga toxin B subunit: rotavirus NSP4(90) fusion protein protects mice against gastroenteritis.
Gastroenteritis
Prevalence, quantification and isolation of pathogenic shiga toxin Escherichia coli O157:H7 along the production and supply chain of pork around Hubei Province of China.
Gastroenteritis
Sequencing of Escherichia coli O111 O-antigen gene cluster and identification of O111-specific genes.
Gastroenteritis
Shiga-toxigenic Escherichia coli detection in stool samples screened for viral gastroenteritis in Alberta, Canada.
Gastrointestinal Diseases
An orally applicable Shiga toxin-neutralizer functions in the intestine to inhibit the intracellular transport of the toxin.
Gastrointestinal Diseases
Analysis Shiga Toxin-Encoding Bacteriophage in a Rare Strain of Shiga Toxin-Producing Escherichia coli O157:H7 stx2a/stx2c.
Gastrointestinal Diseases
Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionization quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1.
Gastrointestinal Diseases
Development of monoclonal antibodies and immunoassays for sensitive and specific detection of shiga toxin stx2f.
Gastrointestinal Diseases
Frequent loss of Shiga-like toxin genes in clinical isolates of Escherichia coli upon subcultivation.
Gastrointestinal Diseases
Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge.
Gastrointestinal Hemorrhage
Microbiological, biological, and chemical weapons of warfare and terrorism.
Gastrointestinal Neoplasms
Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.
Gastrointestinal Neoplasms
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.
Gastrointestinal Neoplasms
PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Gastrointestinal Neoplasms
PPAR? induces PD-L1 expression in MSS+ colorectal cancer cells.
Gastrointestinal Neoplasms
The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis.
Gastrointestinal Neoplasms
The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
Gastrointestinal Neoplasms
[Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].
Gastrointestinal Stromal Tumors
Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors.
Gastrointestinal Stromal Tumors
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
Gastrointestinal Stromal Tumors
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
Gaucher Disease
Eliglustat prevents Shiga toxin 2 cytotoxic effects in human renal tubular epithelial cells.
Genetic Diseases, Inborn
Human uracil DNA N-glycosidase: studies in normal and repair defective cultured fibroblasts.
Genetic Diseases, Inborn
PD-L1 up-regulation restrains Th17 cell differentiation in STAT3 loss- and STAT1 gain-of-function patients.
Germinoma
Central Nervous System Germinomas Express Programmed Death Ligand 1.
Germinoma
Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance.
Germinoma
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Germinoma
Molecular Pathology and Targeted Therapies for Personalized Management of Central Nervous System Germinoma.
Germinoma
PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Germinoma
Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms.
Gestational Trophoblastic Disease
PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.
Gestational Trophoblastic Disease
PD-L1 Expression in Premalignant and Malignant Trophoblasts From Gestational Trophoblastic Diseases Is Ubiquitous and Independent of Clinical Outcomes.
Gestational Trophoblastic Disease
PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.
Giant Cell Tumor of Bone
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRP? infiltration after denosumab treatment.
Giant Cell Tumors
Expression of PD-L1 in mononuclear cells, multinucleated cells, and foam cells in tenosynovial giant cell tumors.
Giant Cell Tumors
Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone.
Giant Cell Tumors
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRP? infiltration after denosumab treatment.
Glanders
FOCAL OR INSULAR NECROSIS PRODUCED BY THE BACILLUS OF TUBERCULOSIS.
Glioblastoma
?-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion.
Glioblastoma
?-Catenin regulates tumor-derived PD-L1.
Glioblastoma
A new type 1 ribosome-inactivating protein from the seeds of Gypsophila elegans M.Bieb.
Glioblastoma
A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset.
Glioblastoma
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
Glioblastoma
ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Glioblastoma
Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma.
Glioblastoma
Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Glioblastoma
Antitumor activity of the third generation EphA2 CAR-T cells against glioblastoma is associated with interferon gamma induced PD-L1.
Glioblastoma
Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
Glioblastoma
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-? and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Glioblastoma
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
Glioblastoma
CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.
Glioblastoma
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.
Glioblastoma
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Glioblastoma
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Glioblastoma
Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
Glioblastoma
Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.
Glioblastoma
Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.
Glioblastoma
Correction: CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
Glioblastoma
Correlation of immune phenotype with IDH mutation in diffuse glioma.
Glioblastoma
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Glioblastoma
Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma.
Glioblastoma
Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid?Coated Superparamagnetic Iron Oxide.
Glioblastoma
Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.
Glioblastoma
Distinct cellular responses induced by saporin and a trasferrin-saporin conjugate in two different human glioblastoma cell lines.
Glioblastoma
Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model.
Glioblastoma
Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Glioblastoma
EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Glioblastoma
Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas.
Glioblastoma
Extracellular Vesicles Containing PD-L1 Contribute to Immune Evasion in Glioblastoma.
Glioblastoma
Genetic engineering and characterisation of chlorotoxin-fused gelonin for enhanced glioblastoma therapy.
Glioblastoma
Genomic and immunologic correlates of LAG-3 expression in cancer.
Glioblastoma
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Glioblastoma
Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes.
Glioblastoma
Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma.
Glioblastoma
Identifying Cancer Driver lncRNAs Bridged by Functional Effectors through Integrating Multi-omics Data in Human Cancers.
Glioblastoma
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Glioblastoma
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
Glioblastoma
Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
Glioblastoma
Induction of PD-L1 by Nitric Oxide via JNK Activation in A172 Glioblastoma Cells.
Glioblastoma
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3K? inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Glioblastoma
Investigation of The Relationship Between Immune Checkpoints and Mismatch Repair Deficiency in Recurrent and Non-Recurrent Glioblastoma.
Glioblastoma
Lectins as differentiation markers of human gliomas.
Glioblastoma
MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Glioblastoma
Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel.
Glioblastoma
Myeloid-derived suppressive cells promote B cell-mediated immunosuppression via transfer of PD-L1 in glioblastoma.
Glioblastoma
Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Glioblastoma
Neuro-oncology: Glioblastoma prognosis linked to neuronal PD-L1 expression in tumour-adjacent tissue.
Glioblastoma
Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression.
Glioblastoma
PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
Glioblastoma
PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients.
Glioblastoma
PD-L1 expression and prognostic impact in glioblastoma.
Glioblastoma
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients.
Glioblastoma
PD-L1 Expression Correlated with p53 Expression in Pediatric Glioblastoma Multiforme.
Glioblastoma
PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis.
Glioblastoma
PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN Signaling Pathway and Can Be Targeted to Sensitize Glioblastomas to Radiation.
Glioblastoma
PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
Glioblastoma
PD-L1/PD-1 Axis in Glioblastoma Multiforme.
Glioblastoma
PDZ Domain in the Engineering and Production of a Saporin Chimeric Toxin as a tool for targeting cancer cells.
Glioblastoma
Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.
Glioblastoma
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Glioblastoma
Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Glioblastoma
Protein Toxin Chaperoned by LRP-1-Targeted Virus-Mimicking Vesicles Induces High-Efficiency Glioblastoma Therapy In Vivo.
Glioblastoma
Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy.
Glioblastoma
Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD-L1.
Glioblastoma
Targeted therapy of human glioblastoma via delivery of a toxin through a peptide directed to cell surface nucleolin.
Glioblastoma
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.
Glioblastoma
The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis.
Glioblastoma
The splicing FK506-binding protein-51 isoform plays a role in glioblastoma resistance through programmed cell death ligand-1 expression regulation.
Glioblastoma
TLR3 regulates PD-L1 expression in human cytomegalovirus infected glioblastoma.
Glioma
A humanized single-chain Fv fragment with high targeting potential against human malignant gliomas.
Glioma
A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.
Glioma
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
Glioma
ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Glioma
An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.
Glioma
Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Glioma
Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Glioma
Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma.
Glioma
BICD Cargo Adaptor 1 (BICD1) Downregulation Correlates with a Decreased Level of PD-L1 and Predicts a Favorable Prognosis in Patients with IDH1-Mutant Lower-Grade Gliomas.
Glioma
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.
Glioma
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models.
Glioma
CD48 is a key molecule of immunomodulation affecting prognosis in glioma.
Glioma
Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.
Glioma
Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.
Glioma
Comprehensive analysis of PD-L1 expression in glioblastoma multiforme.
Glioma
Correlation of immune phenotype with IDH mutation in diffuse glioma.
Glioma
Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high-grade glioma cell lines derived from glioblastoma.
Glioma
Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model.
Glioma
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors.
Glioma
EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Glioma
Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Glioma
EVA1B to Evaluate the Tumor Immune Microenvironment and Clinical Prognosis in Glioma.
Glioma
Exosomal miR-1246 from glioma patient body fluids drives the differentiation and activation of myeloid-derived suppressor cells.
Glioma
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Glioma
Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas.
Glioma
Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
Glioma
Function of PD-L1 in antitumor immunity of glioma cells.
Glioma
Genetic engineering and characterisation of chlorotoxin-fused gelonin for enhanced glioblastoma therapy.
Glioma
Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Glioma
Glioma-Associated Stromal Cells Stimulate Glioma Malignancy by Regulating the Tumor Immune Microenvironment.
Glioma
Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma.
Glioma
Growth related changes in sugar determinants on the surface of C6 glioma cells in culture: a cytochemical lectin-binding study.
Glioma
High Affinity of Chlorin e6 to Immunoglobulin G for Intraoperative Fluorescence Image-Guided Cancer Photodynamic and Checkpoint Blockade Therapy.
Glioma
Identification of repaglinide as a therapeutic drug for glioblastoma multiforme.
Glioma
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Glioma
Immune Checkpoints and Innovative Therapies in Glioblastoma.
Glioma
In search of a target: PD-1 and PD-L1 profiling across glioma types.
Glioma
Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue.
Glioma
Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Glioma
Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma.
Glioma
Involvement of SNARE Protein Interaction for Non-classical Release of DAMPs/Alarmins Proteins, Prothymosin Alpha and S100A13.
Glioma
Lectin histochemistry of human gliomas.
Glioma
miR-34a attenuates glioma cells progression and chemoresistance via targeting PD-L1.
Glioma
MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Glioma
Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.
Glioma
Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples.
Glioma
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.
Glioma
Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Glioma
Paliperidone Inhibits Glioblastoma Growth in Mouse Brain Tumor Model and Reduces PD-L1 Expression.
Glioma
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Glioma
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients.
Glioma
PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.
Glioma
PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages.
Glioma
PD-L1/PD-1 Axis in Glioblastoma Multiforme.
Glioma
Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Glioma
Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma infiltration.
Glioma
Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.
Glioma
Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.
Glioma
Sensitivity of human glioma cells to cytotoxic heteroconjugates.
Glioma
Shikonin kills glioma cells through necroptosis mediated by RIP-1.
Glioma
Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.
Glioma
The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling.
Glioma
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.
Glioma
The IFN-?/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Glioma
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.
Glioma
The Prognostic and Therapeutic Value of PD-L1 in Glioma.
Glioma
The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis.
Glioma
The relationship between expression of PD-L1 and HIF-1? in glioma cells under hypoxia.
Glioma
The splicing FK506-binding protein-51 isoform plays a role in glioblastoma resistance through programmed cell death ligand-1 expression regulation.
Glioma
TLR3 regulates PD-L1 expression in human cytomegalovirus infected glioblastoma.
Glioma
Trichosanthin suppresses the proliferation of glioma cells by inhibiting LGR5 expression and the Wnt/?-catenin signaling pathway.
Glioma
Triptolide reverses helper T cell inhibition and down-regulates IFN-? induced PD-L1 expression in glioma cell lines.
Glioma
Vascularization of syngenic intracerebral RG2 and F98 rat transplantation tumors. A histochemical and morphometric study by use of ricinus communis agglutinin I.
Glioma
[Small interfering RNA-mediated programmed cell death-ligand 1 silencing in human glioma cells enhances human CD8+ T lymphocyte cytotoxicity in vitro].
Glioma, Subependymal
Therapeutic targets in subependymoma.
Glomerulonephritis
Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice.
Glomerulonephritis
PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis.
Glomerulonephritis
The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis.
Glomerulonephritis
The role of programed death-ligand 1 in renal diseases.
Glucose Intolerance
Search for genetic variants of the SYNTAXIN 1A (STX1A) gene: the -352 A>T variant in the STX1A promoter associates with impaired glucose metabolism in an Italian obese population.
Glycogen Storage Disease Type VI
Vaginal mucositis related to immunotherapy in endometrial cancer.
Gnathostomiasis
Recognition of deglycosylated larval proteins of Gnathostoma spinigerum by a monoclonal antibody and human gnathostomiasis antiserum.
Goiter
Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.
Graft vs Host Disease
A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
Graft vs Host Disease
A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation.
Graft vs Host Disease
An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells.
Graft vs Host Disease
Failure of a CD18/anti-LFA1 monoclonal antibody infusion to prevent graft rejection in leukemic patients receiving T-depleted allogeneic bone marrow transplantation.
Graft vs Host Disease
Immunotoxins in cancer therapy: Review and update.
Graft vs Host Disease
Monoclonal antibody-toxin conjugates reactive against human T lymphocytes. A comparison of antibody linked to intact ricin toxin with antibody linked to ricin A chain.
Graft vs Host Disease
Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation.
Graft vs Host Disease
PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients.
Graft vs Host Disease
PD-L1 Ameliorates Murine Acute Graft-Versus-Host Disease by Suppressing Effector But Not Regulatory T Cells Function.
Graft vs Host Disease
PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
Graft vs Host Disease
PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
Graft vs Host Disease
PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.
Graft vs Host Disease
Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
Graft vs Host Disease
Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study.
Graft vs Host Disease
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
Graft vs Host Disease
Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
Graft vs Host Disease
T-cell depletion with ricin A-chain T101 in allogeneic bone marrow transplantation to prevent severe graft-versus-host disease.
Graft vs Host Disease
The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease.
Graft vs Host Disease
Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
Graft vs Host Disease
Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin.
Graft vs Host Disease
Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Graft vs Host Disease
Unrelated donor bone marrow transplantation for correction of lethal congenital immunodeficiencies.
Graft vs Host Disease
Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease.
Granuloma
Adult pulmonary Langerhans cell histiocytosis might consist of two distinct groups: isolated form and extrapulmonary recidivism type.
Granuloma
Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.
Granuloma
Dendritic cells in chronic mycobacterial granulomas restrict local anti-bacterial T cell response in a murine model.
Granuloma
Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy.
Granuloma
Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.
Granuloma
[Histochemical study using lectin and anti-human von Willebrand factor antibody of oral hemangioma]
Granulomatous Disease, Chronic
Viscum album agglutinin-I (VAA-I) induces apoptosis and degradation of cytoskeletal proteins in human leukemia PLB-985 and X-CGD cells via caspases: lamin B1 is a novel target of VAA-I.
Graves Disease
Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients.
Graves Disease
Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves' Disease and Hashimoto's Thyroiditis in Korean Patients.
Hantavirus Infections
Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.
Hashimoto Disease
Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Hashimoto Disease
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.
Hashimoto Disease
PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
Head and Neck Neoplasms
An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.
Head and Neck Neoplasms
Association of PD-L1 expression in oral squamous cell carcinoma with smoking, sex, and p53 expression.
Head and Neck Neoplasms
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Head and Neck Neoplasms
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Head and Neck Neoplasms
Circulating tumour cell PD-L1 test for head and neck cancers.
Head and Neck Neoplasms
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.
Head and Neck Neoplasms
Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma.
Head and Neck Neoplasms
DUPLICATE: Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Head and Neck Neoplasms
HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Head and Neck Neoplasms
HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Head and Neck Neoplasms
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN? That Induce PD-L1 Expression in Head and Neck Cancer.
Head and Neck Neoplasms
IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer.
Head and Neck Neoplasms
Immuno-regulatory antibodies for the treatment of cancer.
Head and Neck Neoplasms
Induction of resident memory T cells enhances the efficacy of cancer vaccine.
Head and Neck Neoplasms
Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
Head and Neck Neoplasms
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Head and Neck Neoplasms
New technology on the horizon: Fast analytical screening technique FNA (FAST-FNA) enables rapid, multiplex biomarker analysis in head and neck cancers.
Head and Neck Neoplasms
Nivolumab in recurrent/metastatic head and neck cancers.
Head and Neck Neoplasms
Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.
Head and Neck Neoplasms
Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
Head and Neck Neoplasms
PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection.
Head and Neck Neoplasms
PD-L1 expressing circulating tumour cells in head and neck cancers.
Head and Neck Neoplasms
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
Head and Neck Neoplasms
PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells.
Head and Neck Neoplasms
PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.
Head and Neck Neoplasms
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.
Head and Neck Neoplasms
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
Head and Neck Neoplasms
Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis.
Head and Neck Neoplasms
Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.
Head and Neck Neoplasms
Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.
Head and Neck Neoplasms
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Head and Neck Neoplasms
Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
Head and Neck Neoplasms
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Head and Neck Neoplasms
Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers.
Heart Diseases
PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.
Heart Failure
Expression of coinhibitory PD-L1 on CD4?CD25?FOXP3? regulatory T cells is elevated in patients with acute coronary syndrome.
Hemangioblastoma
Comparing the Clinical Performance of the New 19-G ViziShot FLEX and 21- or 22-G ViziShot 2 Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Needles.
Hemangioma
[Histochemical study using lectin and anti-human von Willebrand factor antibody of oral hemangioma]
Hemangioma, Capillary
[Histochemical study using lectin and anti-human von Willebrand factor antibody of oral hemangioma]
Hemangioma, Cavernous
[Histochemical study using lectin and anti-human von Willebrand factor antibody of oral hemangioma]
Hemangiosarcoma
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
Hemangiosarcoma
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.
Hemangiosarcoma
Antiprogrammed cell death protein 1 immunotherapy for angiosarcoma with high programmed death-ligand 1 expression: a case report.
Hemangiosarcoma
Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.
Hemangiosarcoma
IGF2BP3 (IMP3) expression in angiosarcoma, epithelioid hemangioendothelioma, and benign vascular lesions.
Hemangiosarcoma
Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.
Hemangiosarcoma
Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Hemangiosarcoma
Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.
Hemangiosarcoma
Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma.
Hemangiosarcoma
Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
Hemangiosarcoma
Prognostic implications of PD-L1 expression in patients with angiosarcoma.
Hemangiosarcoma
Programmed Cell Death Ligand 1 Expression in Canine Cancer.
Hemangiosarcoma
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Hemangiosarcoma
Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma.
Hemangiosarcoma
Regulation of PD-L1 expression by aPKC? in cutaneous angiosarcoma.
Hematologic Neoplasms
Active Immunotherapy of Cancer.
Hematologic Neoplasms
Biomarkers for checkpoint inhibition in hematologic malignancies.
Hematologic Neoplasms
Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies.
Hematologic Neoplasms
Cell-targeting fusion constructs containing recombinant gelonin.
Hematologic Neoplasms
Checkpoint inhibitors in AML: are we there yet?
Hematologic Neoplasms
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations.
Hematologic Neoplasms
Immune-related adverse events of immune checkpoint inhibitors: a brief review.
Hematologic Neoplasms
Large scale manufacturing of TXU(anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate for clinical trials.
Hematologic Neoplasms
Optimal elimination of leukemic T cells from human bone marrow with T101-ricin A-chain immunotoxin.
Hematologic Neoplasms
PD-L1 Expression in Mastocytosis.
Hematologic Neoplasms
Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.
Hematologic Neoplasms
Preclinical Data Supporting Antitumor Activity of PD-1 Blockade.
Hematologic Neoplasms
Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.
Hematologic Neoplasms
The role of genetic polymorphism within PD-L1 gene in cancer. Review.
Hematologic Neoplasms
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.
Hematologic Neoplasms
Variability of PD-L1 expression in mastocytosis.
Hematuria
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
Hemoglobinuria
Hemoglobinuria for the early identification of STEC-HUS in high-risk children: data from the ItalKid-HUS Network.
Hemolytic-Uremic Syndrome
60Co irradiation of Shiga toxin (Stx)-producing Escherichia coli induces Stx phage.
Hemolytic-Uremic Syndrome
A case of hemolytic-uremic syndrome associated with shiga toxin 2-producing Escherichia coli O121 infection caused by drinking water contaminated with bovine feces.
Hemolytic-Uremic Syndrome
A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model.
Hemolytic-Uremic Syndrome
A New Immunoassay for Detecting All Subtypes of Shiga Toxins Produced by Shiga Toxin-Producing E. coli in Ground Beef.
Hemolytic-Uremic Syndrome
A Novel Mechanism of Bacterial Toxin Transfer within Host Blood Cell-Derived Microvesicles.
Hemolytic-Uremic Syndrome
A Novel Tail-Associated O91-Specific Polysaccharide Depolymerase from Podophage Reveals Lytic Efficacy of Shiga Toxin-Producing E. coli.
Hemolytic-Uremic Syndrome
A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo.
Hemolytic-Uremic Syndrome
A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.
Hemolytic-Uremic Syndrome
Absence of interleukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells.
Hemolytic-Uremic Syndrome
Adaptive mutations and replacements of virulence traits in the Escherichia coli O104:H4 outbreak population.
Hemolytic-Uremic Syndrome
Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.
Hemolytic-Uremic Syndrome
Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection.
Hemolytic-Uremic Syndrome
Advances in pathogenesis and therapy of hemolytic uremic syndrome caused by shiga toxin-2.
Hemolytic-Uremic Syndrome
Affinity-Based Screening of Tetravalent Peptides Identifies Subtype-Selective Neutralizers of Shiga Toxin 2d, a Highly Virulent Subtype, by Targeting a Unique Amino Acid Involved in Its Receptor Recognition.
Hemolytic-Uremic Syndrome
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Hemolytic-Uremic Syndrome
An Epidemiologic Surveillance of Shiga-like Toxin-producing Escherichia coli Infection in Argentinean Children: Risk Factors and Serum Shiga-like Toxin 2 Values.
Hemolytic-Uremic Syndrome
Analysis of urinary Escherichia coli isolates for ability to produce Shiga toxin.
Hemolytic-Uremic Syndrome
Annexin Induces Cellular Uptake of Extracellular Vesicles and Delays Disease in Escherichia coli O157:H7 Infection.
Hemolytic-Uremic Syndrome
Antagonistic effects of probiotic Escherichia coli Nissle 1917 on EHEC strains of serotype O104:H4 and O157:H7.
Hemolytic-Uremic Syndrome
Anti-Shiga toxin 2 antibodies in enterohemorrhagic Escherichia coli O104:H4 infected patients may predict hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods.
Hemolytic-Uremic Syndrome
Antibody responses elicited in mice immunized with Bacillus subtilis vaccine strains expressing Stx2B subunit of enterohaemorragic Escherichia coli O157:H7.
Hemolytic-Uremic Syndrome
Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2.
Hemolytic-Uremic Syndrome
Apoptosis of renal tubular cells in Shiga-toxin-mediated hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionization quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1.
Hemolytic-Uremic Syndrome
Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Attaching-effacing Escherichia coli infections in cattle.
Hemolytic-Uremic Syndrome
Atypical hemolytic uremic syndrome triggered by varicella infection.
Hemolytic-Uremic Syndrome
Biochemical characterization of in-vitro reconstituted biologically active recombinant Shiga toxin.
Hemolytic-Uremic Syndrome
Cattle lack vascular receptors for Escherichia coli O157:H7 Shiga toxins.
Hemolytic-Uremic Syndrome
CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).
Hemolytic-Uremic Syndrome
Characterization of a Shiga toxin 1-neutralizing recombinant Fab fragment isolated by phage display system.
Hemolytic-Uremic Syndrome
Characterization of Rabbit Polyclonal Sera against Recombinant Shiga Toxin and its Subunits for Detection of Stx-Producing E. coli.
Hemolytic-Uremic Syndrome
Characterization of the cytokine immune response in children who have experienced an episode of typical hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
Characterization of urinary tract infection-associated Shiga toxin-producing Escherichia coli.
Hemolytic-Uremic Syndrome
Characterizing the Cattle Gut Microbiome in Farms with a High and Low Prevalence of Shiga Toxin Producing Escherichia coli.
Hemolytic-Uremic Syndrome
Charged and hydrophobic surfaces on the a chain of shiga-like toxin 1 recognize the C-terminal domain of ribosomal stalk proteins.
Hemolytic-Uremic Syndrome
Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides.
Hemolytic-Uremic Syndrome
Chemokine Receptor CCR1 Disruption Limits Renal Damage in a Murine Model of Hemolytic Uremic Syndrome.
Hemolytic-Uremic Syndrome
Clinical Relevance of Shiga Toxin Concentrations in the Blood of Patients With Hemolytic Uremic Syndrome.
Hemolytic-Uremic Syndrome
Clonal relatedness of Shiga-like toxin-producing Escherichia coli O101 strains of human and porcine origin.
Hemolytic-Uremic Syndrome
Cluster of hemolytic-uremic syndrome caused by Shiga toxin-producing Escherichia coli O26:H11.
Hemolytic-Uremic Syndrome
Clustering of post-diarrheal (Shiga toxin-mediated) hemolytic uremic syndrome in families.
Hemolytic-Uremic Syndrome
Combined Action of Shiga Toxin Type 2 and Subtilase Cytotoxin in the Pathogenesis of Hemolytic Uremic Syndrome.
Hemolytic-Uremic Syndrome
Combining Mass Spectrometry, Surface Acoustic Wave Interaction Analysis, and Cell Viability Assays for Characterization of Shiga Toxin Subtypes of Pathogenic Escherichia coli Bacteria.
Hemolytic-Uremic Syndrome
Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis.
Hemolytic-Uremic Syndrome
Comparative toxicity and virulence of Escherichia coli clones expressing variant and chimeric Shiga-like toxin type II operons.
Hemolytic-Uremic Syndrome
Compensatory renal growth protects mice against Shiga toxin 2-induced toxicity.
Hemolytic-Uremic Syndrome
Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Hemolytic-Uremic Syndrome
Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study.
Hemolytic-Uremic Syndrome
Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis.
Hemolytic-Uremic Syndrome
Construction of recombinant Shiga-like toxin-IIv (SLT-IIv) and its use in monitoring the SLT-IIv antibody status of pigs.
Hemolytic-Uremic Syndrome
Contribution of polyunsaturated fatty acids to Shiga toxin cytotoxicity in human renal tubular epithelium-derived cells.
Hemolytic-Uremic Syndrome
Crosstalk between Human Microvascular Endothelial Cells and Tubular Epithelial Cells Modulates Pro-Inflammatory Responses Induced by Shiga Toxin Type 2 and Subtilase Cytotoxin.
Hemolytic-Uremic Syndrome
CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation.
Hemolytic-Uremic Syndrome
Cytokine Production Is Altered in Monocytes from Children with Hemolytic Uremic Syndrome.
Hemolytic-Uremic Syndrome
Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells.
Hemolytic-Uremic Syndrome
Degradation and inactivation of Shiga toxins by nitrogen gas plasma.
Hemolytic-Uremic Syndrome
Demonstration of RNA N-glycosidase activity of a Vero toxin (VT2 variant) produced by Escherichia coli O91:H21 from a patient with the hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Detection of E. coli O157:H7 and Shigella dysenteriae toxins in clinical samples by PCR-ELISA.
Hemolytic-Uremic Syndrome
Detection of Shiga toxin-encoding genes in small community water supplies.
Hemolytic-Uremic Syndrome
Detection of Shiga toxin-producing Escherichia coli by sandwich enzyme-linked immunosorbent assay using chicken egg yolk IgY antibodies.
Hemolytic-Uremic Syndrome
Development and characterization of monoclonal antibodies against Shiga toxin 2 and their application for toxin detection in milk.
Hemolytic-Uremic Syndrome
Development and Evaluation of a Novel VHH-Based Immunocapture Assay for High-Sensitivity Detection of Shiga Toxin Type 2 (Stx2) in Stool Samples.
Hemolytic-Uremic Syndrome
Development and evaluation of enzyme-linked immunosorbent assays for detection of shiga-like toxin I and shiga-like toxin II.
Hemolytic-Uremic Syndrome
Development and Validation of Shiga Toxin-Producing Escherichia coli Immunodiagnostic Assay.
Hemolytic-Uremic Syndrome
Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2.
Hemolytic-Uremic Syndrome
Development of a Mouse Model of Shiga Toxin 2 (STX2) Intoxication for Testing Therapeutic Agents against Hemolytic Uremic Syndrome (HUS).
Hemolytic-Uremic Syndrome
Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS).
Hemolytic-Uremic Syndrome
Development of DNA vaccines against hemolytic-uremic syndrome in a murine model.
Hemolytic-Uremic Syndrome
Dexamethasone prevents motor deficits and neurovascular damage produced by shiga toxin 2 and lipopolysaccharide in the mouse striatum.
Hemolytic-Uremic Syndrome
Dexamethasone rescues neurovascular unit integrity from cell damage caused by systemic administration of shiga toxin 2 and lipopolysaccharide in mice motor cortex.
Hemolytic-Uremic Syndrome
Diagnostic approach to microangiopathic hemolytic disorders.
Hemolytic-Uremic Syndrome
Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2.
Hemolytic-Uremic Syndrome
Dietary choice affects Shiga toxin-producing Escherichia coli (STEC) O157:H7 colonization and disease.
Hemolytic-Uremic Syndrome
Direct cytotoxic action of Shiga toxin on human vascular endothelial cells.
Hemolytic-Uremic Syndrome
Do the A subunits contribute to the differences in the toxicity of Shiga toxin 1 and Shiga toxin 2?
Hemolytic-Uremic Syndrome
Down-regulation of renal klotho expression by Shiga toxin 2.
Hemolytic-Uremic Syndrome
Duration of Fecal Shedding of Shiga Toxin-Producing Escherichia coli O104:H4 in Patients Infected During the 2011 Outbreak in Germany: A Multicenter Study.
Hemolytic-Uremic Syndrome
Effect of TNF-alpha, Shiga toxin and calcium ionophore on Weibel-Palade body content of endothelial cells: possible implications for the hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Effects of azithromycin on shiga toxin production by Escherichia coli and subsequent host inflammatory response.
Hemolytic-Uremic Syndrome
Effects of Escherichia coli subtilase cytotoxin and Shiga toxin 2 on primary cultures of human renal tubular epithelial cells.
Hemolytic-Uremic Syndrome
Effects of human intravenous immune globulin on diarrhea caused by Shiga-like toxin I and Shiga-like toxin II in infant rabbits.
Hemolytic-Uremic Syndrome
Effects of shiga toxin 2 on cellular regeneration mechanisms in primary and three-dimensional cultures of human renal tubular epithelial cells.
Hemolytic-Uremic Syndrome
Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli.
Hemolytic-Uremic Syndrome
Emerging Multidrug-Resistant Hybrid Pathotype Shiga Toxin-Producing Escherichia coli O80 and Related Strains of Clonal Complex 165, Europe.
Hemolytic-Uremic Syndrome
Enhanced virulence of the Escherichia coli O157:H7 spinach-associated outbreak strain in two animal models is associated with higher levels of Stx2 production after induction with ciprofloxacin.
Hemolytic-Uremic Syndrome
Enterobacter cloacae producing a Shiga-like toxin II-related cytotoxin associated with a case of hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in a Shiga toxin independent manner.
Hemolytic-Uremic Syndrome
Environmental Cues Modulate Microglial Cell Behavior Upon Shiga Toxin 2 From Enterohemorrhagic Escherichia coli Exposure.
Hemolytic-Uremic Syndrome
Epidemic Escherichia coli O104:H4: Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction.
Hemolytic-Uremic Syndrome
Epithelial cell signaling responses to enterohemorrhagic Escherichia coli infection.
Hemolytic-Uremic Syndrome
Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms.
Hemolytic-Uremic Syndrome
Escherichia coli O157:H7 and O157:H(-) strains that do not produce Shiga toxin: phenotypic and genetic characterization of isolates associated with diarrhea and hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome.
Hemolytic-Uremic Syndrome
Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells.
Hemolytic-Uremic Syndrome
Extracellular vesicles as mediators of vascular inflammation in kidney disease.
Hemolytic-Uremic Syndrome
Factors associated with the development of renal sequelae in a series of cases with Shiga toxin hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
Failure of manganese to protect from Shiga toxin.
Hemolytic-Uremic Syndrome
First Detection of Shiga Toxin-Producing Escherichia coli in Shellfish and Coastal Environments of Morocco.
Hemolytic-Uremic Syndrome
Genetic makeup of Shiga toxin-producing Escherichia coli in relation to clinical symptoms and duration of shedding: a microarray analysis of isolates from Swedish children.
Hemolytic-Uremic Syndrome
Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge.
Hemolytic-Uremic Syndrome
Genomic Characterization of Two Shiga Toxin-Converting Bacteriophages Induced From Environmental Shiga Toxin-Producing Escherichia coli.
Hemolytic-Uremic Syndrome
Genomic comparison of Escherichia coli O104:H4 isolates from 2009 and 2011 reveals plasmid, and prophage heterogeneity, including shiga toxin encoding phage stx2.
Hemolytic-Uremic Syndrome
Glomerular epithelial cell arachidonate metabolism in Shiga toxin hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection.
Hemolytic-Uremic Syndrome
Hemoglobinuria for the early identification of STEC-HUS in high-risk children: data from the ItalKid-HUS Network.
Hemolytic-Uremic Syndrome
Hemolysin from Shiga toxin-negative Escherichia coli O26 strains injures microvascular endothelium.
Hemolytic-Uremic Syndrome
Hemolytic Uremic Syndrome and Kidney Transplantation: A Case Series and Review of the Literature.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome associated with Escherichia coli O8:H19 and Shiga toxin 2f gene.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome associated with Shiga toxin producing Escherichia coli infection in a healthy adult woman.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome due to shiga-like toxin producing Escherichia coli 048:H21 in South Australia.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin.
Hemolytic-Uremic Syndrome
Hemolytic Uremic Syndrome is associated with dysregulation of Chemokine Receptor expression in Circulating Monocytes.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome revisited: Shiga toxin, factor H, and fibrin generation.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalities.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome-associated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome: an emerging health risk.
Hemolytic-Uremic Syndrome
Hemolytic uremic syndrome: co-infection with two different serotypes of Shiga-like toxin producing Escherichia coli.
Hemolytic-Uremic Syndrome
Heterogeneity in Induction Level, Infection Ability, and Morphology of Shiga Toxin-Encoding Phages (Stx Phages) from Dairy and Human Shiga Toxin-Producing Escherichia coli O26:H11 Isolates.
Hemolytic-Uremic Syndrome
High efficiency generalized transduction in Escherichia coli O157:H7.
Hemolytic-Uremic Syndrome
Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.
Hemolytic-Uremic Syndrome
Human monocytes stimulated by Shiga toxin 1a via globotriaosylceramide release proinflammatory molecules associated with hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Human platelet aggregation is not altered by Shiga toxins 1 or 2.
Hemolytic-Uremic Syndrome
Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo.
Hemolytic-Uremic Syndrome
Human Serum Amyloid P Component Protects against Escherichia coli O157:H7 Shiga Toxin 2 In Vivo: Therapeutic Implications for Hemolytic-Uremic Syndrome.
Hemolytic-Uremic Syndrome
Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls.
Hemolytic-Uremic Syndrome
Identification and distribution of the enterohemorrhagic Escherichia coli factor for adherence (efa1) gene in sorbitol-fermenting Escherichia coli O157: H-.
Hemolytic-Uremic Syndrome
Immune response to Escherichia coli O157:H7 in hemolytic uremic syndrome following salmonellosis.
Hemolytic-Uremic Syndrome
Immunity profiles of wild-type and recombinant shiga-like toxin-encoding bacteriophages and characterization of novel double lysogens.
Hemolytic-Uremic Syndrome
Immunization with BLS-Stx2B chimera totally protects dams from early pregnancy loss induced by Shiga toxin type 2 (Stx2) and confers anti-Stx2 immunity to the offspring.
Hemolytic-Uremic Syndrome
Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of Enterohemorrhagic Escherichia coli O157:H7 infection.
Hemolytic-Uremic Syndrome
Impact of the rpoS genotype for acid resistance patterns of pathogenic and probiotic Escherichia coli.
Hemolytic-Uremic Syndrome
Importance of environmental transmission in cases of EHEC O157 causing hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2.
Hemolytic-Uremic Syndrome
Increased Expression of Complement Regulators CD55 and CD59 on Peripheral Blood Cells in Patients with EAHEC O104:H4 Infection.
Hemolytic-Uremic Syndrome
Increased serum IL-10 and endothelin levels in hemolytic uremic syndrome caused by Escherichia coli O157.
Hemolytic-Uremic Syndrome
Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Hemolytic-Uremic Syndrome
Infectious diarrhea. Pathogenesis and risk factors.
Hemolytic-Uremic Syndrome
Ingested Shiga Toxin 2 (Stx2) Causes Histopathological Changes in Kidney, Spleen, and Thymus Tissues and Mortality in Mice.
Hemolytic-Uremic Syndrome
Inhibitory action of telithromycin against Shiga toxin and endotoxin.
Hemolytic-Uremic Syndrome
Interaction of Shiga toxin 2 with complement regulators of the factor H protein family.
Hemolytic-Uremic Syndrome
Interaction of Shiga Toxin with the A-Domains and Multimers of von Willebrand Factor.
Hemolytic-Uremic Syndrome
Interactions between Shiga toxins and human polymorphonuclear leukocytes.
Hemolytic-Uremic Syndrome
Interactions of Shiga-like toxin with human peripheral blood monocytes.
Hemolytic-Uremic Syndrome
Intestinal organoids model human responses to infection by commensal and Shiga toxin producing Escherichia coli.
Hemolytic-Uremic Syndrome
Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody.
Hemolytic-Uremic Syndrome
Intracerebroventricular administration of Shiga toxin type 2 altered the expression levels of neuronal nitric oxide synthase and glial fibrillary acidic protein in rat brains.
Hemolytic-Uremic Syndrome
Intracerebroventricular administration of Shiga toxin type 2 induces striatal neuronal death and glial alterations: an ultrastructural study.
Hemolytic-Uremic Syndrome
Intracerebroventricular Shiga toxin 2 increases the expression of its receptor globotriaosylceramide and causes dendritic abnormalities.
Hemolytic-Uremic Syndrome
Investigation of enteropathogenic Escherichia coli and Shiga toxin-producingEscherichia coli associated with hemolytic uremic syndrome in ?zmir Province, Turkey.
Hemolytic-Uremic Syndrome
Involvement of high-mobility group box 1 in the pathogenesis of severe hemolytic uremic syndrome in a murine model.
Hemolytic-Uremic Syndrome
Isolation of an Escherichia coli O157:H7 strain producing Shiga toxin 1 but not Shiga toxin 2 from a patient with hemolytic uremic syndrome in Korea.
Hemolytic-Uremic Syndrome
Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance.
Hemolytic-Uremic Syndrome
Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice.
Hemolytic-Uremic Syndrome
Large-scale genome analysis of bovine commensal Escherichia coli reveals that bovine-adapted E. coli lineages are serving as evolutionary sources of the emergence of human intestinal pathogenic strains.
Hemolytic-Uremic Syndrome
Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli.
Hemolytic-Uremic Syndrome
Leukotriene C4 increases the susceptibility of adult mice to Shiga toxin-producing Escherichia coli infection.
Hemolytic-Uremic Syndrome
Lipopolysaccharide upregulates renal shiga toxin receptors in a primate model of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Long-term outcomes of Shiga toxin hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh.
Hemolytic-Uremic Syndrome
LPS-primed CD11b
Hemolytic-Uremic Syndrome
Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review.
Hemolytic-Uremic Syndrome
Management of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Metabolomic analysis of Shiga toxin 2a-induced injury in conditionally immortalized glomerular endothelial cells.
Hemolytic-Uremic Syndrome
Method for the Detection of the Cleaved Form of Shiga Toxin 2a Added to Normal Human Serum.
Hemolytic-Uremic Syndrome
Microbiological and serological control of Escherichia coli O157: H7 in kindergarten staff in Buenos Aires city and suburban areas.
Hemolytic-Uremic Syndrome
Molecular characteristics of eae-positive clinical Shiga toxin-producing Escherichia coli in Sweden.
Hemolytic-Uremic Syndrome
Molecular Characterization of the Enterohemolysin Gene (ehxA) in Clinical Shiga Toxin-Producing Escherichia coli Isolates.
Hemolytic-Uremic Syndrome
Molecular damage and induction of proinflammatory cytokines in human endothelial cells exposed to Shiga toxin 1, Shiga toxin 2, and alpha-sarcin.
Hemolytic-Uremic Syndrome
Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.
Hemolytic-Uremic Syndrome
Mutations in hns reduce the adherence of Shiga toxin-producing E. coli 091:H21 strain B2F1 to human colonic epithelial cells and increase the production of hemolysin.
Hemolytic-Uremic Syndrome
Neurologic manifestations of E coli infection-induced hemolytic-uremic syndrome in adults.
Hemolytic-Uremic Syndrome
Neurological involvement and MRI brain findings in an adult with hemolytic uremic syndrome: A case report.
Hemolytic-Uremic Syndrome
Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins.
Hemolytic-Uremic Syndrome
Nitrobenzylthioinosine (NBT), a nucleoside transport inhibitor, protects against Shiga toxin cytotoxicity in human microvascular endothelial cells.
Hemolytic-Uremic Syndrome
Nontoxigenic sorbitol-fermenting Escherichia coli O157:H- associated with a family outbreak of diarrhoea.
Hemolytic-Uremic Syndrome
Oral intoxication of mice with Shiga toxin type 2a (Stx2a) and protection by anti-Stx2a monoclonal antibody 11E10.
Hemolytic-Uremic Syndrome
Ouabain Protects against Shiga Toxin-Triggered Apoptosis by Reversing the Imbalance between Bax and Bcl-xL.
Hemolytic-Uremic Syndrome
Outbreak of Shiga toxin-producing Escherichia coli (STEC) O104:H4 infection in Germany causes a paradigm shift with regard to human pathogenicity of STEC strains.
Hemolytic-Uremic Syndrome
Overview and Historical Perspectives.
Hemolytic-Uremic Syndrome
p38 mitogen-activated protein kinase mediates lipopolysaccharide and tumor necrosis factor alpha induction of shiga toxin 2 sensitivity in human umbilical vein endothelial cells.
Hemolytic-Uremic Syndrome
Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in Children.
Hemolytic-Uremic Syndrome
Pathogenesis of Shiga-Toxin Producing Escherichia coli.
Hemolytic-Uremic Syndrome
Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Post-traumatic thrombotic microangiopathy: What trauma surgeons need to know?
Hemolytic-Uremic Syndrome
Procalcitonin in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Production of nitric oxide is lower in Shiga toxin-stimulated neutrophils of infants compared to those of children or adults.
Hemolytic-Uremic Syndrome
Promoter Sequence of Shiga Toxin 2 (Stx2) Is Recognized In Vivo, Leading to Production of Biologically Active Stx2.
Hemolytic-Uremic Syndrome
Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Prospective Genomic Characterization of the German Enterohemorrhagic Escherichia coli O104:H4 Outbreak by Rapid Next Generation Sequencing Technology.
Hemolytic-Uremic Syndrome
Protection of human podocytes from Shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P component.
Hemolytic-Uremic Syndrome
Purification and some properties of a Vero toxin from a human strain of Escherichia coli that is immunologically related to Shiga-like toxin II (VT2).
Hemolytic-Uremic Syndrome
Quantitation of Risk Reduction of E. coli Transmission After Using Antimicrobial Hand Soap.
Hemolytic-Uremic Syndrome
Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor.
Hemolytic-Uremic Syndrome
Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli.
Hemolytic-Uremic Syndrome
Recent Updates on Outbreaks of Shiga Toxin-Producing Escherichia coli and Its Potential Reservoirs.
Hemolytic-Uremic Syndrome
Recovery of thalamic microstructural damage after Shiga toxin 2-associated hemolytic-uremic syndrome.
Hemolytic-Uremic Syndrome
Recurrent hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS).
Hemolytic-Uremic Syndrome
Renal prostacyclin biosynthesis in a baboon model of Shiga toxin mediated hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.
Hemolytic-Uremic Syndrome
Response to Shiga toxin 1 and 2 in a baboon model of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells.
Hemolytic-Uremic Syndrome
Safe and effective use of eculizumab in the treatment of severe Shiga toxin Escherichia coli-associated hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Safety and Pharmacokinetics of Chimeric Anti-Shiga Toxin 1 and Anti-Shiga Toxin 2 Monoclonal Antibodies in Healthy Volunteers.
Hemolytic-Uremic Syndrome
Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli.
Hemolytic-Uremic Syndrome
Sequencing of Escherichia coli O111 O-antigen gene cluster and identification of O111-specific genes.
Hemolytic-Uremic Syndrome
Serum insulin-like growth factor-binding protein 2 levels as an indicator for disease severity in enterohemorrhagic Escherichia coli induced hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Sex steroids do not affect shigatoxin cytotoxicity on human renal tubular or glomerular cells.
Hemolytic-Uremic Syndrome
Shiga Toxin (Stx) Classification, Structure, and Function.
Hemolytic-Uremic Syndrome
Shiga toxin (Stx) type 1a reduces the toxicity of the more potent Stx2a in vivo and in vitro.
Hemolytic-Uremic Syndrome
Shiga Toxin (Stx)-Binding Glycosphingolipids of Primary Human Renal Cortical Epithelial Cells (pHRCEpiCs) and Stx-Mediated Cytotoxicity.
Hemolytic-Uremic Syndrome
Shiga toxin 1 causes direct renal injury in rats.
Hemolytic-Uremic Syndrome
Shiga toxin 1 elicits diverse biologic responses in mesangial cells.
Hemolytic-Uremic Syndrome
Shiga toxin 1, as DNA repair inhibitor, synergistically potentiates the activity of the anticancer drug, mafosfamide, on raji cells.
Hemolytic-Uremic Syndrome
Shiga toxin 1-induced inflammatory response in lipopolysaccharide-sensitized astrocytes is mediated by endogenous tumor necrosis factor alpha.
Hemolytic-Uremic Syndrome
Shiga toxin 2 from enterohemorrhagic Escherichia coli induces reactive glial cells and neurovascular disarrangements including edema and lipid peroxidation in the murine brain hippocampus.
Hemolytic-Uremic Syndrome
Shiga toxin 2-specific but not shiga toxin 1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing shiga toxin 1 and shiga toxin 2.
Hemolytic-Uremic Syndrome
Shiga toxin 2a and Enteroaggregative Escherichia coli--a deadly combination.
Hemolytic-Uremic Syndrome
Shiga toxin 2a binds antithrombin and heparin, but does not directly activate platelets.
Hemolytic-Uremic Syndrome
Shiga Toxin 2a-Induced Endothelial Injury in Hemolytic Uremic Syndrome: A Metabolomic Analysis.
Hemolytic-Uremic Syndrome
Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Shiga toxin associated hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.
Hemolytic-Uremic Syndrome
Shiga toxin binds to activated platelets.
Hemolytic-Uremic Syndrome
Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Shiga toxin glycosphingolipid receptors and their lipid membrane ensemble in primary human blood-brain barrier endothelial cells.
Hemolytic-Uremic Syndrome
Shiga toxin induces medullary tubular injury in isolated perfused rat kidneys.
Hemolytic-Uremic Syndrome
Shiga toxin induces superoxide production in polymorphonuclear cells with subsequent impairment of phagocytosis and responsiveness to phorbol esters.
Hemolytic-Uremic Syndrome
Shiga toxin producing Escherichia coli-associated diarrhea and hemolytic uremic syndrome in young children in Romania.
Hemolytic-Uremic Syndrome
Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement.
Hemolytic-Uremic Syndrome
Shiga Toxin Selectively Upregulates Expression of Syndecan-4 and Adhesion Molecule ICAM-1 in Human Glomerular Microvascular Endothelium.
Hemolytic-Uremic Syndrome
Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism.
Hemolytic-Uremic Syndrome
Shiga toxin subtypes display dramatic differences in potency.
Hemolytic-Uremic Syndrome
Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
Hemolytic-Uremic Syndrome
Shiga Toxin Uptake and Sequestration in Extracellular Vesicles Is Mediated by Its B-Subunit.
Hemolytic-Uremic Syndrome
Shiga toxin-1 affects nitric oxide production by human glomerular endothelial and mesangial cells.
Hemolytic-Uremic Syndrome
Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1.
Hemolytic-Uremic Syndrome
Shiga toxin-associated hemolytic uremic syndrome: combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro.
Hemolytic-Uremic Syndrome
Shiga toxin-associated hemolytic uremic syndrome: effect of sodium butyrate on sensitivity of human umbilical vein endothelial cells to Shiga toxin.
Hemolytic-Uremic Syndrome
Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro.
Hemolytic-Uremic Syndrome
Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.
Hemolytic-Uremic Syndrome
Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro.
Hemolytic-Uremic Syndrome
Shiga Toxin-Bearing Microvesicles Exert a Cytotoxic Effect on Recipient Cells Only When the Cells Express the Toxin Receptor.
Hemolytic-Uremic Syndrome
Shiga toxin-converting phages and the emergence of new pathogenic Escherichia coli: a world in motion.
Hemolytic-Uremic Syndrome
Shiga toxin-induced complement-mediated hemolysis and release of complement-coated red blood cell-derived microvesicles in hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Shiga toxin-mediated hemolytic uremic syndrome: time to change the diagnostic paradigm?
Hemolytic-Uremic Syndrome
Shiga toxin-producing Escherichia coli (STEC).
Hemolytic-Uremic Syndrome
Shiga toxin-producing Escherichia coli O157:H7 show an increased pathogenicity in mice after the passage through the gastrointestinal tract of the same host.
Hemolytic-Uremic Syndrome
Shiga toxin-producing Escherichia coli: an overview.
Hemolytic-Uremic Syndrome
Shiga Toxin-Producing Serogroup O91 Escherichia coli Strains Isolated from Food and Environmental Samples.
Hemolytic-Uremic Syndrome
Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells.
Hemolytic-Uremic Syndrome
Shiga-like toxin inhibition of FLICE-like inhibitory protein expression sensitizes endothelial cells to bacterial lipopolysaccharide-induced apoptosis.
Hemolytic-Uremic Syndrome
Silencing of Bak ameliorates apoptosis of human proximal tubular epithelial cells by Escherichia coli-derived Shiga toxin 2.
Hemolytic-Uremic Syndrome
Soluble Toll-Like Receptor 4 Impairs the Interaction of Shiga Toxin 2a with Human Serum Amyloid P Component.
Hemolytic-Uremic Syndrome
Sorbitol-negative phenotype among enterohemorrhagic Escherichia coli strains of different serotypes and from different sources.
Hemolytic-Uremic Syndrome
Southwestern Internal Medicine Conference: Shiga-like toxins in hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura.
Hemolytic-Uremic Syndrome
Spread of a Distinct Stx2-Encoding Phage Prototype among Escherichia coli O104:H4 Strains from Outbreaks in Germany, Norway, and Georgia.
Hemolytic-Uremic Syndrome
Structural basis for the interaction of Shiga toxin 2a with a C-terminal peptide of ribosomal P stalk proteins.
Hemolytic-Uremic Syndrome
Study of regulatory pathway of related molecules in hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Stx1B and Stx2B induce von Willebrand factor secretion from human umbilical vein endothelial cells through different signaling pathways.
Hemolytic-Uremic Syndrome
Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants.
Hemolytic-Uremic Syndrome
Sub-Lethal Dose of Shiga Toxin 2 from Enterohemorrhagic Escherichia coli Affects Balance and Cerebellar Cytoarchitecture.
Hemolytic-Uremic Syndrome
Subcutaneous and intranasal immunization with Stx2B-Tir-Stx1B-Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice.
Hemolytic-Uremic Syndrome
Synthesis and Assessment of Globotriose-Chitosan Conjugate, a Novel Inhibitor of Shiga Toxins Produced by Escherichia coli.
Hemolytic-Uremic Syndrome
Taxonomy Meets Public Health: The Case of Shiga Toxin-Producing Escherichia coli.
Hemolytic-Uremic Syndrome
Thalamic involvement in patients with neurologic impairment due to Shiga toxin 2.
Hemolytic-Uremic Syndrome
The 2011 German Enterohemorrhagic Escherichia Coli O104:H4 Outbreak-The Danger Is Still Out There.
Hemolytic-Uremic Syndrome
The A1 Subunit of Shiga Toxin 2 Has Higher Affinity for Ribosomes and Higher Catalytic Activity than the A1 Subunit of Shiga Toxin 1.
Hemolytic-Uremic Syndrome
The Antibiotic Polymyxin B Impairs the Interactions between Shiga Toxins and Human Neutrophils.
Hemolytic-Uremic Syndrome
The B subunits of Shiga-like toxins induce regulated VWF secretion in a phospholipase D1-dependent manner.
Hemolytic-Uremic Syndrome
The crystal structure of shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor.
Hemolytic-Uremic Syndrome
The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
The effect of shiga toxin on weibel-palade bodies in primary human endothelial cells.
Hemolytic-Uremic Syndrome
The Effects of Shiga Toxin 1, 2 and Their Subunits on Cytokine and Chemokine Expression by Human Macrophage-Like THP-1 Cells.
Hemolytic-Uremic Syndrome
The efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin associated hemolytic uremic syndrome model mice.
Hemolytic-Uremic Syndrome
The hemolytic uremic syndromes.
Hemolytic-Uremic Syndrome
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Hemolytic-Uremic Syndrome
The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection.
Hemolytic-Uremic Syndrome
The Role of the AggR Regulon in the Virulence of the Shiga Toxin-Producing Enteroaggregative Escherichia coli Epidemic O104:H4 Strain in Mice.
Hemolytic-Uremic Syndrome
The role of Tir, EspA, and NleB in the colonization of cattle by Shiga toxin producing Escherichia coli O26:H11.
Hemolytic-Uremic Syndrome
The Shiga toxin 2 B subunit inhibits net fluid absorption in human colon and elicits fluid accumulation in rat colon loops.
Hemolytic-Uremic Syndrome
The Shiga toxin genotype rather than the amount of Shiga toxin or the cytotoxicity of Shiga toxin in vitro correlates with the appearance of the hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
The synthesis of a multivalent heterobifunctional ligand for specific interaction with Shiga toxin 2 produced by E. coli O157:H7.
Hemolytic-Uremic Syndrome
Therapeutic strategies for Shiga toxin-producing Escherichia coli infections.
Hemolytic-Uremic Syndrome
Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Thrombotic microangiopathies: Similar presentations, different therapies.
Hemolytic-Uremic Syndrome
Tissue-resident macrophages mediate neutrophil recruitment and kidney injury in shiga toxin-induced hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Tolerance to lipopolysaccharide (LPS) regulates the endotoxin effects on Shiga toxin-2 lethality.
Hemolytic-Uremic Syndrome
Toll-like receptor 4 facilitates binding of Shiga toxin to colon carcinoma and primary umbilical vein endothelial cells.
Hemolytic-Uremic Syndrome
Towards a vaccine candidate against Shigella dysenteriae 1: expression of the Shiga toxin B-subunit in an attenuated Shigella flexneri aroD carrier strain.
Hemolytic-Uremic Syndrome
Transcription of the subtilase cytotoxin gene subAB1 in Shiga toxin-producing Escherichia coli is dependent on hfq and hns.
Hemolytic-Uremic Syndrome
Tumor necrosis factor-? modifies the effects of Shiga toxin on glial cells.
Hemolytic-Uremic Syndrome
Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511.
Hemolytic-Uremic Syndrome
Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities.
Hemolytic-Uremic Syndrome
Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
Hemolytic-Uremic Syndrome
Upregulation of Shiga Toxin Receptor CD77/Gb3 and Interleukin-1? Expression in the Brain of EHEC Patients with Hemolytic Uremic Syndrome and Neurologic Symptoms.
Hemolytic-Uremic Syndrome
Urinary concentrating defect in rats given Shiga toxin: elevation in urinary AQP2 level associated with polyuria.
Hemolytic-Uremic Syndrome
Use of comparative genomics as a tool to assess the clinical and public health significance of emerging Shiga toxin-producing Escherichia coli serotypes.
Hemolytic-Uremic Syndrome
Use of complement monoclonal antibody eculizumab in Shiga toxin producing Escherichia coli associated hemolytic uremic syndrome: A review of current evidence.
Hemolytic-Uremic Syndrome
Usefulness of serum fibrinogen degradation product-E in sporadic cases of classical hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Virulence gene profiles and population genetic analysis for exploration of pathogenic serogroups of Shiga toxin-producing Escherichia coli.
Hemolytic-Uremic Syndrome
von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome.
Hemolytic-Uremic Syndrome
Why exclude children with Shiga toxin genotype 1 alone from hemolytic uremic syndrome screening?
Hemolytic-Uremic Syndrome
[A case of hemolytic uremic syndrome with hemorrhagic colitis due to Escherichia coli O111 infection]
Hemolytic-Uremic Syndrome
[Cytotoxic effect of Shiga toxin type 2 and its B subunit on human renal tubular epithelial cell cultures]
Hemolytic-Uremic Syndrome
[Enterohemorrhagic Escherichia coli and its infection: from 1977 to 1995]
Hemolytic-Uremic Syndrome
[Evolution and infection biology of hemolytic-uremic syndrome (HUS) associated E. coli (HUSEC)].
Hemolytic-Uremic Syndrome
[Isolation and characterization of Shiga-toxin-producing Escherichia coli from frozen hamburgers and soft cheeses]
Hemolytic-Uremic Syndrome
[Role of the Shiga toxin in the hemolytic uremic syndrome]
Hemolytic-Uremic Syndrome
[Shiga toxin and tetanus toxin as a potential biologic weapon].
Hemolytic-Uremic Syndrome
[Vitrectomy for retinal proliferation in childhood following hemolytic uremic syndrome].
Hemorrhagic Fevers, Viral
Capillary leak syndrome: etiologies, pathophysiology, and management.
Hepatitis
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Hepatitis
Expression of programmed death-1 and its ligands in the liver of biliary atresia.
Hepatitis
Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients.
Hepatitis
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Hepatitis
Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis.
Hepatitis
The extent and duration of acute hepatitis in mice is dominated by the function rather than by the survival of effector CD8 T cells.
Hepatitis A
Detection of hepatitis A virus in seeded oyster digestive tissue by ricin A-linked magnetic separation combined with reverse transcription PCR.
Hepatitis B
2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
Hepatitis B
Anti-Viral Intrahepatic T-Cell Responses can be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B.
Hepatitis B
Effect of Radix Trichosanthis and Trichosanthin on Hepatitis B Virus in HepG2.2.15 Cells.
Hepatitis B
Expression of novel fusion antiviral proteins ricin a chain-pokeweed antiviral proteins (RTA-PAPs) in Escherichia coli and their inhibition of protein synthesis and of hepatitis B virus in vitro.
Hepatitis B
Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters.
Hepatitis B
Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B.
Hepatitis B
Hepatitis B virus-triggered PTEN/?-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Hepatitis B
Inhibition of hepatitis B virus replication by pokeweed antiviral protein in vitro.
Hepatitis B
Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection.
Hepatitis B
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Hepatitis B
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Hepatitis B
Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
Hepatitis B
Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B.
Hepatitis B
Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection.
Hepatitis B
Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Hepatitis B
The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.
Hepatitis B
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance.
Hepatitis B, Chronic
Anti-Viral Intrahepatic T-Cell Responses can be Restored by Blocking Programmed Death-1 Pathway in Chronic Hepatitis B.
Hepatitis B, Chronic
CD4+ T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B.
Hepatitis B, Chronic
HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.
Hepatitis B, Chronic
Intrahepatic Expression of Programmed Death-1 and its Ligands in Patients with HBV-Related Acute-on-Chronic Liver Failure.
Hepatitis B, Chronic
Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection.
Hepatitis B, Chronic
Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B.
Hepatitis B, Chronic
Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B.
Hepatitis B, Chronic
[PD-L1 expression in circulating dendritic cells of patients with chronic hepatitis B]
Hepatitis B, Chronic
[Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B.].
Hepatitis C
Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment.
Hepatitis C
The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.
Hepatitis C
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance.
Hepatitis C, Chronic
PD-L1 Expression on Circulating CD34? Hematopoietic Stem Cells Closely Correlated with T-cell Apoptosis in Chronic Hepatitis C Infected Patients.
Hepatitis E
The application of food safety interventions in primary production of beef and lamb: A review.
Hepatitis, Autoimmune
Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity.
Hepatitis, Autoimmune
End-organ damage in a mouse model of fulminant liver inflammation requires CD4+ T cell production of IFN-gamma but is independent of Fas.
Hepatitis, Autoimmune
Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice.
Hepatitis, Autoimmune
Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response.
Hepatitis, Autoimmune
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.
Hepatitis, Chronic
Serum alpha-fetoprotein subfractions identified by Ricinus communis agglutinin I in hepatic malignancies, yolk sac tumor, benign hepatic diseases, and fetal stage.
Hepatitis, Chronic
[Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B.].
Hepatoblastoma
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Hepatoblastoma
Momordin Ic couples apoptosis with autophagy in human hepatoblastoma cancer cells by reactive oxygen species (ROS)-mediated PI3K/Akt and MAPK signaling pathways.
Herpes Simplex
Inhibition of herpes simplex virus DNA synthesis by pokeweed antiviral protein.
Herpes Simplex
Inhibition of herpes simplex virus multiplication by the pokeweed antiviral protein.
Herpes Simplex
Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies.
Herpes Simplex
Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
Herpes Simplex
Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Herpes Simplex
Purification and partial characterization of another form of the antiviral protein from the seeds of Phytolacca americana L. (pokeweed).
Herpes Simplex
Ricin injection eliminates latent herpes simplex virus in the mouse.
Herpes Simplex
Targeted delivery of DNA encoding cytotoxic proteins through high-affinity fibroblast growth factor receptors.
Herpes Simplex
Trichosanthin affects HSV-1 replication in Hep-2 cells.
Herpes Simplex
[Protective effects of trichosanthin in Herpes simplex virus-1 encephalitis in mice]
Herpes Zoster
Evidence for a role of the major glycoprotein in the structural maintenance of the pig zona pellucida.
Herpes Zoster
Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function.
Histiocytic Necrotizing Lymphadenitis
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Histiocytic Sarcoma
An immunocytochemical study on the distribution of ferritin and other markers in 36 cases of malignant histiocytosis.
Histiocytic Sarcoma
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Histiocytic Sarcoma
Lectin distinction of benign from malignant histiocytes.
Histiocytoma, Benign Fibrous
PD-L1 expression in angiomatoid fibrous histiocytoma.
Histiocytoma, Malignant Fibrous
Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin.
Histiocytoma, Malignant Fibrous
Lectin histochemistry of malignant fibrohistiocytic tumors.
Histiocytosis
Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1.
Histiocytosis
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Histiocytosis, Langerhans-Cell
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Histiocytosis, Sinus
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
HIV Infections
Anti-HIV agent trichosanthin enhances the capabilities of chemokines to stimulate chemotaxis and G protein activation, and this is mediated through interaction of trichosanthin and chemokine receptors.
HIV Infections
CD4 T Follicular Helper and Regulatory Cell Dynamics and Function in HIV Infection.
HIV Infections
Human immunodeficiency virus type 1 (HIV-1) inhibition, DNA-binding, RNA-binding, and ribosome inactivation activities in the N-terminal segments of the plant anti-HIV protein GAP31.
HIV Infections
Increased levels of soluble co-stimulatory molecule PD-L1 (B7-H1) in the plasma of viraemic HIV-1+ individuals.
HIV Infections
Myeloid-Derived Suppressor Cells Associated With Disease Progression in Primary HIV Infection: PD-L1 Blockade Attenuates Inhibition.
HIV Infections
Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8+ T cell function in vitro.
HIV Infections
Role of CD25+ and CD25-T cells in acute HIV infection in vitro.
HIV Infections
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product.
HIV Infections
The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study.
HIV Infections
Trichosanthin treatment of HIV-induced immune dysregulation.
Hodgkin Disease
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.
Hodgkin Disease
A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
Hodgkin Disease
Advances in cancer immunology and cancer immunotherapy.
Hodgkin Disease
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
Hodgkin Disease
Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Hodgkin Disease
Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma.
Hodgkin Disease
Biomarkers for checkpoint inhibition in hematologic malignancies.
Hodgkin Disease
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
Hodgkin Disease
CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.
Hodgkin Disease
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma.
Hodgkin Disease
Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
Hodgkin Disease
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Hodgkin Disease
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy.
Hodgkin Disease
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
Hodgkin Disease
Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Hodgkin Disease
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities.
Hodgkin Disease
Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
Hodgkin Disease
Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab.
Hodgkin Disease
Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Hodgkin Disease
Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
Hodgkin Disease
Experimental therapy in Hodgkin's disease.
Hodgkin Disease
Experimental treatment of human Hodgkin's disease with ricin A-chain immunotoxins.
Hodgkin Disease
Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma.
Hodgkin Disease
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Hodgkin Disease
GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.
Hodgkin Disease
Immune checkpoint inhibitors in the treatment of cancer.
Hodgkin Disease
Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type.
Hodgkin Disease
Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
Hodgkin Disease
Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
Hodgkin Disease
In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins.
Hodgkin Disease
In vivo and in vitro uptake of an anti-CD30/saporin immunotoxin by rat liver parenchymal and nonparenchymal cells.
Hodgkin Disease
Lectin staining of carbohydrates of haemic cells. III. The cells of Hodgkin's disease and other lymphomas.
Hodgkin Disease
Lymphocyte-depleted classic Hodgkin lymphoma with primary extranodal disease: Two cases that highlight the combination of immunodeficiency and immune escape in the pathogenesis.
Hodgkin Disease
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Hodgkin Disease
MGCD0103 induces apoptosis and simultaneously increases the expression of NF-?B and PD-L1 in classical Hodgkin's lymphoma.
Hodgkin Disease
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Hodgkin Disease
PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
Hodgkin Disease
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Hodgkin Disease
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
Hodgkin Disease
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Hodgkin Disease
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Hodgkin Disease
PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance?
Hodgkin Disease
PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
Hodgkin Disease
PD-L1 expression in pediatric Epstein-Barr virus positive classic Hodgkin lymphoma is not associated with 9p24.1 amplification.
Hodgkin Disease
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Hodgkin Disease
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
Hodgkin Disease
PD-L1 Immunohistochemistry Highlights Bone Marrow Involvement by Classic Hodgkin Lymphoma in Staging Biopsies: Implications for Diagnosis and Tumor Microenvironment Alterations.
Hodgkin Disease
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Hodgkin Disease
Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
Hodgkin Disease
Response To: PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
Hodgkin Disease
Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma.
Hodgkin Disease
Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.
Hodgkin Disease
Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma.
Hodgkin Disease
Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.
Hodgkin Disease
Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.
Hodgkin Disease
Syncytial variant of classic Hodgkin lymphoma: Four cases diagnosed with the aid of CD274/programmed cell death ligand 1 immunohistochemistry.
Hodgkin Disease
Targeting immune checkpoints in lymphoma.
Hodgkin Disease
Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
Hodgkin Disease
Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
Hodgkin Disease
The genetics of Hodgkin lymphoma: an overview and clinical implications.
Hodgkin Disease
The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
Hodgkin Disease
Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Hodgkin Disease
Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin.
Hodgkin Disease
Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
Hutchinson's Melanotic Freckle
Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Hydatidiform Mole
Analysis of PD-L1 expression in trophoblastic tissues and tumors.
Hydatidiform Mole
Selective killing of choriocarcinoma cells in vitro by trichosanthin, a plant protein purified from root tubers of the Chinese medicinal herb Trichosanthes kirilowii.
Hydatidiform Mole
Trichosanthin in the treatment of hydatidiform mole. Clinical analysis of 52 cases.
Hydatidiform Mole, Invasive
Selective killing of choriocarcinoma cells in vitro by trichosanthin, a plant protein purified from root tubers of the Chinese medicinal herb Trichosanthes kirilowii.
Hydrocephalus
Induced hydrocephalus in postnatal rats following an intracerebral injection of ricin.
Hyperalgesia
Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia.
Hyperalgesia
Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors.
Hyperalgesia
PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.
Hypercalcemia
Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 Score.
Hyperkalemia
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
Hypersensitivity
Alterations in the rostral ventromedial medulla after the selective ablation of ?-opioid receptor expressing neurons.
Hypersensitivity
Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report.
Hypersensitivity
Descending facilitation from the rostral ventromedial medulla maintains nerve injury-induced central sensitization.
Hypersensitivity
GABA-A receptor activity in the noradrenergic locus coeruleus drives trigeminal neuropathic pain in the rat; contribution of NA?1 receptors in the medial prefrontal cortex.
Hypersensitivity
Human Langerhans cells control Th cells via programmed death-ligand 1 in response to bacterial stimuli and nickel-induced contact allergy.
Hypersensitivity
Human Rhinovirus Infection Enhances the Th2 Environment in Allergic and Non-allergic Patients with Chronic Rhinosinusitis.
Hypersensitivity
Increased cytotoxicity of ricin in a putative Golgi-defective mutant of Chinese hamster ovary cell.
Hypersensitivity
Lowering of trichosanthin immunogenicity by site-specific coupling to dextran.
Hypersensitivity
Mispositioned Neurokinin-1 Receptor-Expressing Neurons Underlie Heat Hyperalgesia in Disabled-1 Mutant Mice.
Hypersensitivity
P75-expressing elements are necessary for anti-allodynic effects of spinal clonidine and neostigmine.
Hypersensitivity
Properties of bromodextran-trichosanthin: a comparison with trichosanthin, an anti-AIDS protein.
Hypersensitivity
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.
Hypersensitivity
Targeting spinal neuropeptide Y1 receptor-expressing interneurons to alleviate chronic pain and itch.
Hypersensitivity
Trichosanthin-stimulated dendritic cells induce a type 2 helper T lymphocyte response through the OX40 ligand.
Hypersensitivity
[An investigation on the allergic reaction to trichosanthin]
Hypersensitivity
[Epidemic of ricin allergy in Dieppe (1963-1965)]
Hypersensitivity
[Intra-amniotic injection of crystal trichosanthin for induction of labour in second trimester pregnancy]
Hypersensitivity
[Investigations of allergy to ricin.]
Hypersensitivity
[Respiratory allergy to ricin in the Marseille region.]
Hypertension
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.
Hypertension
PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
Hypertension, Malignant
Etiology and Outcomes of Thrombotic Microangiopathies.
Hypertension, Malignant
Thrombotic microangiopathy and associated renal disorders.
Hyperthyroidism
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Hyperthyroidism
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
Hypoalbuminemia
Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.
Hypoglycemia
Identification of hypoglycemia in mice as a surrogate marker of ricin toxicosis.
Hypoglycemia
Post-exposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model.
Hypopharyngeal Neoplasms
Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.
Hypopharyngeal Neoplasms
Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer.
Hypophysitis
Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment.
Hypophysitis
Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Hypophysitis
The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events.
Hypotension
Evaluation of castor bean toxicosis in dogs: 98 cases.
Hypotension
Ricin poisoning causing death after ingestion of herbal medicine.
Hypothyroidism
A case of severe Pembrolizumab-induced neutropenia.
Hypothyroidism
A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors.
Hypothyroidism
Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Hypothyroidism
Concanavalin-A, lentil, and ricin lectin affinity binding characteristics of human thyrotropin: differences in the sialylation of thyrotropin in sera of euthyroid, primary, and central hypothyroid patients.
Hypothyroidism
Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials.
Hypothyroidism
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Hypothyroidism
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Hypothyroidism
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
Hypothyroidism
Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab.
Hypothyroidism
Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Idiopathic Pulmonary Fibrosis
PD-L1 on invasive fibroblasts drives fibrosis in a humanized model of idiopathic pulmonary fibrosis.
Ileitis
Induction of the heat shock response prevents tissue injury during acute inflammation of the rat ileum.
Immune System Diseases
Immune checkpoints in sepsis: New hopes and challenges.
Immune System Diseases
Immune disorders in sepsis and their treatment as a significant problem of modern intensive care.
Immune System Diseases
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.
Immune System Diseases
Targeting CD28, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells.
Immunoglobulin G4-Related Disease
IgG4 Related Disease is characterized by the overexpression of Immunomodulatory proteins.
Immunoglobulin G4-Related Disease
The Role of PD-1/PD-Ls in the Pathogenesis of IgG4-RD.
Infarction, Middle Cerebral Artery
PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.
Infections
A case of hemolytic-uremic syndrome associated with shiga toxin 2-producing Escherichia coli O121 infection caused by drinking water contaminated with bovine feces.
Infections
A complex fruit-specific type-2 ribosome-inactivating protein from elderberry (Sambucus nigra) is correctly processed and assembled in transgenic tobacco plants.
Infections
A multivalent peptide library approach identifies a novel Shiga toxin inhibitor that induces aberrant cellular transport of the toxin.
Infections
A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.
Infections
A non-toxic pokeweed antiviral protein mutant inhibits pathogen infection via a novel salicylic acid-independent pathway.
Infections
A Poly-N-acetylglucosamine-Shiga toxin broad-spectrum conjugate vaccine for Shiga toxin-producing Escherichia coli.
Infections
A Potential Inhibitory Profile of Liver CD68+ Cells during HCV Infection as Observed by an Increased CD80 and PD-L1 but Not CD86 Expression.
Infections
A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection.
Infections
A potential therapeutic peptide-based neutralizer that potently inhibits Shiga toxin 2 in vitro and in vivo.
Infections
A practical composite risk score for the development of Haemolytic Uraemic Syndrome from Shiga toxin-producing Escherichia coli.
Infections
A retrograde trafficking inhibitor of ricin and Shiga-like toxins inhibits infection of cells by human and monkey polyomaviruses.
Infections
A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7.
Infections
A translational murine model of sub-lethal intoxication with Shiga toxin 2 reveals novel ultrastructural findings in the brain striatum.
Infections
Abstracts of the 8th International Symposium on Shiga Toxin (Verocytotoxin) Producing Escherichia coli Infections. May 6-9, 2012. Amsterdam, The Netherlands.
Infections
Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells.
Infections
Activation of a prophage-encoded tyrosine kinase by a heterologous infecting phage results in a self-inflicted abortive infection.
Infections
Acute renal tubular necrosis and death of mice orally infected with Escherichia coli strains that produce Shiga-like toxin type II.
Infections
Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection.
Infections
An animal model for the study of neurotoxicity of bacterial products and application of the model to demonstrate that Shiga toxin and lipopolysaccharide cooperate in inducing neurologic disorders.
Infections
An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine.
Infections
An Epidemiologic Surveillance of Shiga-like Toxin-producing Escherichia coli Infection in Argentinean Children: Risk Factors and Serum Shiga-like Toxin 2 Values.
Infections
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Infections
An orally applicable Shiga toxin-neutralizer functions in the intestine to inhibit the intracellular transport of the toxin.
Infections
An unbalanced PD-L1/CD86 ratio in CD14(++)CD16(+) monocytes is correlated with HCV viremia during chronic HCV infection.
Infections
An Update Review on the Anthelmintic Activity of Bitter Gourd, Momordica charantia.
Infections
Analysis of the enterohemorrhagic Escherichia coli O157 DNA region containing lambdoid phage gene p and Shiga-like toxin structural genes.
Infections
Anti-biofilm and Antibacterial Activity of Allium sativum Against Drug Resistant Shiga-Toxin Producing Escherichia coli (STEC) Isolates from Patient Samples and Food Sources.
Infections
Anti-infective mannose receptor immune mechanism in large yellow croaker (Larimichthys crocea).
Infections
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.
Infections
Anti-PD-L1 therapy does not improve survival in a murine model of lethal Staphyloccocus aureus pneumonia.
Infections
Anti-Shiga toxin 2 antibodies in enterohemorrhagic Escherichia coli O104:H4 infected patients may predict hemolytic uremic syndrome.
Infections
Antibiotic-resistant Shiga toxin-producing Escherichia coli: An overview of prevalence and intervention strategies.
Infections
Antibodies to Shiga toxin in the serum of children with Shigella-associated haemolytic uraemic syndrome.
Infections
Antibody response to lipopolysaccharides and recombinant proteins of Shiga toxin (STX)-producing Escherichia coli (STEC) in children with haemolytic uraemic syndrome in Poland.
Infections
Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods.
Infections
Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2.
Infections
Antiviral activity of shiga toxin 1: suppression of bovine leukemia virus-related spontaneous lymphocyte proliferation.
Infections
Antiviral and Antiviroid Activity of MAP-Containing Extracts from Mirabilis jalapa Roots.
Infections
Antiviral and antiviroid activity of MAP-containing extracts from Mirabilis jalapa roots.
Infections
Assessment of physician knowledge and practices concerning Shiga toxin-producing Escherichia coli infection and enteric illness, 2009, Foodborne Diseases Active Surveillance Network (FoodNet).
Infections
Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients.
Infections
Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.
Infections
Associations between the presence of virulence determinants and the epidemiology and ecology of zoonotic E. coli.
Infections
Atypical hemolytic uremic syndrome: from diagnosis to treatment.
Infections
Axonal injury heralds virus-induced demyelination.
Infections
B cells induced by Schistosoma japonicum infection display diverse regulatory phenotypes and modulate CD4+ T cell response.
Infections
Bacillus Calmette-Guérin Induces PD-L1 Expression on Antigen-Presenting Cells via Autocrine and Paracrine Interleukin-STAT3 Circuits.
Infections
Bacterial genetic determinants of non-O157 stec outbreaks and hemolytic-uremic syndrome after infection.
Infections
Beneficial Effects of CpG-Oligodeoxynucleotide Treatment on Trauma and Secondary Lung Infection.
Infections
Bovine ileal intraepithelial lymphocytes represent target cells for Shiga toxin 1 from Escherichia coli.
Infections
Bovine macrophages sense Escherichia coli Shiga toxin 1.
Infections
Brainstem mechanisms of autonomic dysfunction in encephalopathy-associated Shiga toxin 2 intoxication.
Infections
Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
Infections
CD169(+) macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection.
Infections
CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.
Infections
CD4 T Follicular Helper and Regulatory Cell Dynamics and Function in HIV Infection.
Infections
CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1+ viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion.
Infections
Cell Biological Responses after Shiga Toxin-1 Exposure to Primary Human Glomerular Microvascular Endothelial Cells from Pediatric and Adult Origin.
Infections
Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome.
Infections
Characteristics of shiga toxin-producing Escherichia coli isolated from Swiss raw milk cheese within a 3-year monitoring program.
Infections
Characterization of Shiga toxin -- producing Escherichia coli infections in beef feeder calves and the effectiveness of a prebiotic in alleviating Shiga toxin - producing Escherichia coli infections.
Infections
Characterization of single site ricin toxin B chain mutants.
Infections
Characterizing the Escherichia coli O157:H7 proteome including protein associations with higher order assemblies.
Infections
Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides.
Infections
Chronic reactive gliosis following regulatory T cell depletion during acute MCMV encephalitis.
Infections
Clinicopathological evidence of hepatitis B virus infection in the development of gastric adenocarcinoma.
Infections
Cloning a Truncated Fragment (stx2a(1)) of the Shiga-Like Toxin 2A (1) Subunit of EHEC O157:H7: Candidate Immunogen for a Subunit Vaccine.
Infections
Colistin inhibits E. coli O157:H7 Shiga-like toxin release, binds endotoxins and protects Vero cells.
Infections
Colonic hemorrhage produced in mice by a unique vero cell cytotoxin from an Escherichia coli strain that causes hemorrhagic colitis.
Infections
Combinatorial Tim-3 and PD-1 activity sustains antigen-specific Th1 cell numbers during blood-stage malaria.
Infections
Combined Blockade Of Programmed Death-1 And Activation Of CD137 Increase Responses Of Human Liver T Cells Against HBV, But Not HCV.
Infections
Combining Mass Spectrometry, Surface Acoustic Wave Interaction Analysis, and Cell Viability Assays for Characterization of Shiga Toxin Subtypes of Pathogenic Escherichia coli Bacteria.
Infections
Community-wide outbreak of haemolytic uraemic syndrome associated with Shiga toxin 2-producing Escherichia coli O26:H11 in southern Italy, summer 2013.
Infections
Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis.
Infections
Comparative Characterization of Shiga Toxin Type 2 and Subtilase Cytotoxin Effects on Human Renal Epithelial and Endothelial Cells Grown in Monolayer and Bilayer Conditions.
Infections
Comparative histopathology of intestinal infections.
Infections
Comparative phenotypic characterization of hybrid Shiga toxin-producing / uropathogenic Escherichia coli, canonical uropathogenic and Shiga toxin-producing Escherichia coli.
Infections
Comparison of a direct fecal Shiga-like toxin assay and sorbitol-MacConkey agar culture for laboratory diagnosis of enterohemorrhagic Escherichia coli infection.
Infections
Comparison of alteration of cell surface carbohydrates of the chinchilla tubotympanum and colonial opacity phenotype of Streptococcus pneumoniae during experimental pneumococcal otitis media with or without an antecedent influenza A virus infection.
Infections
Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice.
Infections
Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Infections
Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
Infections
Concomitant Mycobacterium tuberculosis infection promotes lung tumor growth through enhancing Treg development.
Infections
Construction of recombinant Shiga-like toxin-IIv (SLT-IIv) and its use in monitoring the SLT-IIv antibody status of pigs.
Infections
Construction of stable LamB-Shiga toxin B subunit hybrids: analysis of expression in Salmonella typhimurium aroA strains and stimulation of B subunit-specific mucosal and serum antibody responses.
Infections
Contact with farming environment as a major risk factor for Shiga toxin (Vero cytotoxin)-producing Escherichia coli O157 infection in humans.
Infections
Continuous surveillance of Shiga toxin-producing Escherichia coli infections by pulsed-field gel electrophoresis shows that most infections are sporadic.
Infections
Contributions of PD-L1 reverse signaling to dendritic cell trafficking.
Infections
Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection.
Infections
CRISPR Screen Reveals that EHEC's T3SS and Shiga Toxin Rely on Shared Host Factors for Infection.
Infections
Crosstalk between Human Microvascular Endothelial Cells and Tubular Epithelial Cells Modulates Pro-Inflammatory Responses Induced by Shiga Toxin Type 2 and Subtilase Cytotoxin.
Infections
Cumulative effect of prophage burden on Shiga toxin production in Escherichia coli.
Infections
Cytotoxic effects of Shiga toxin-2 on human extravillous trophoblast cell lines.
Infections
Design of multifunctional peptides expressing both antimicrobial activity and shiga toxin neutralization activity.
Infections
Detection and characterization of Shiga toxin-producing Escherichia coli in game meat and ready-to-eat meat products.
Infections
Development and characterization of monoclonal antibodies against Shiga toxin 2 and their application for toxin detection in milk.
Infections
Development of a homogeneous time-resolved FRET (HTRF) assay for the quantification of Shiga toxin 2 produced by E. coli.
Infections
Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2.
Infections
Development of a Mouse Model of Shiga Toxin 2 (STX2) Intoxication for Testing Therapeutic Agents against Hemolytic Uremic Syndrome (HUS).
Infections
Development of a Simple Fed-Batch Process for the High-Yield Production of Recombinant Shiga Toxin B-Chain Protein.
Infections
Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS).
Infections
Dextran sulfate sodium colitis facilitates colonization with Shiga-toxin producing E. coli: A novel murine model for the study of Shiga toxicosis.
Infections
Diagnosis of Shiga toxin producing Escherichia coli infection, contribution of genetic amplification technique.
Infections
Different kinetic of antibody responses following infection of newly weaned pigs with an F4 enterotoxigenic Escherichia coli strain or an F18 verotoxigenic Escherichia coli strain.
Infections
Differential induction of Shiga toxin in environmental Escherichia coli O145:H28 strains carrying the same genotype as the outbreak strains.
Infections
Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines.
Infections
Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
Infections
Diversity and host range of Shiga toxin-encoding phage.
Infections
Down-regulation of cytochrome P450 proteins and its activities by Shiga-like toxin II from Escherichia coli O157:H7.
Infections
Duplication and diversification of a unique chromosomal virulence island hosting the subtilase cytotoxin in Escherichia coli ST58.
Infections
Effect of Shiga-like toxin II from Escherichia coli O157:H7 on intestinal clearance of norfloxacin in rats.
Infections
Effects of antimicrobials on Shiga toxin production in high-virulent Shiga toxin-producing Escherichia coli.
Infections
Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli.
Infections
Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model.
Infections
Emergence of Escherichia coli encoding Shiga toxin 2f in human Shiga toxin-producing E. coli (STEC) infections in the Netherlands, January 2008 to December 2011.
Infections
Endogenous glucocorticoids attenuate Shiga toxin-2-induced toxicity in a mouse model of haemolytic uraemic syndrome.
Infections
Enhanced upper genital tract pathologies by blocking Tim-3 and PD-L1 signaling pathways in mice intravaginally infected with Chlamydia muridarum.
Infections
Enhancement of pentylenetetrazole-induced seizures by Shigella dysenteriae in LPS-resistant C3H/HeJ mice: role of the host response.
Infections
Enhancement of susceptibility to Shiga toxin-producing Escherichia coli O157:H7 by protein calorie malnutrition in mice.
Infections
Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection.
Infections
Enterohemorrhagic E. coli (EHEC) pathogenesis.
Infections
Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in a Shiga toxin independent manner.
Infections
Enterohemorrhagic Escherichia coli Hybrid Pathotype O80:H2 as a New Therapeutic Challenge.
Infections
Enterohemorrhagic Escherichia coli in human infection: in vivo evolution of a bacterial pathogen.
Infections
Enterohemorrhagic Escherichia Coli Infection Stimulates Shiga toxin 1 Macropinocytosis and Transcytosis across Intestinal Epithelial Cells.
Infections
Enterohemorrhagic Escherichia coli suppresses inflammatory response to cytokines and its own toxin.
Infections
Epidemic Escherichia coli O104:H4: Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction.
Infections
Epidemic of gastrointestinal tract infection including hemorrhagic colitis attributable to Shiga toxin 1-producing Escherichia coli O118:H2 at a junior high school in Japan.
Infections
Epidemiology of Shiga Toxin-Producing Escherichia coli O157 in the Province of Alberta, Canada, 2009-2016.
Infections
Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms.
Infections
Escherichia coli O157 infection associated with a petting zoo.
Infections
Escherichia coli O157:H7 infections: discordance between filterable fecal shiga toxin and disease outcome.
Infections
Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells.
Infections
Estimation of the amount of internalized ricin that reaches the trans-Golgi network.
Infections
Etiology and Outcomes of Thrombotic Microangiopathies.
Infections
Evaluation of CHROMagar STEC and STEC O104 chromogenic agar media for detection of Shiga Toxin-producing Escherichia coli in stool specimens.
Infections
Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma.
Infections
Evaluation of Recombinant Forms of the Shiga Toxin Variant Stx2eB Subunit and Non-Toxic Mutant Stx2e as Vaccine Candidates against Porcine Edema Disease.
Infections
Expression of Immune Checkpoint Receptors in Placentae With Infectious and Non-Infectious Chronic Villitis.
Infections
Expression of PD-L1 on CD4+CD25+Foxp3+ Regulatory T Cells of Patients with Chronic HBV Infection and Its Correlation with Clinical Parameters.
Infections
Expression of Programmed Death-1 Ligand (PD-L) 1, PD-L2, B7-H3, and Inducible Costimulator Ligand on Human Respiratory Tract Epithelial Cells and Regulation by Respiratory Syncytial Virus and Type 1 and 2 Cytokines.
Infections
Expression of ricin B chain in Spodoptera frugiperda.
Infections
Extracellular vesicles as mediators of vascular inflammation in kidney disease.
Infections
Feline programmed death and its ligand: characterization and changes with feline immunodeficiency virus infection.
Infections
Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome.
Infections
Foodborne disease investigation across Australia: annual report of the OzFoodNet network, 2003.
Infections
Foodborne illness: is it on the rise?
Infections
Frequent loss of Shiga-like toxin genes in clinical isolates of Escherichia coli upon subcultivation.
Infections
From In silico Protein Epitope Density Prediction to Testing Escherichia coli O157:H7 Vaccine Candidates in a Murine Model of Colonization.
Infections
Frontline Science: Anti-PD-L1 protects against infection with common bacterial pathogens after burn injury.
Infections
Gastric eosinophils are detrimental for Helicobacter pylori vaccine efficacy.
Infections
Genetic diversity and virulence potential of shiga toxin-producing Escherichia coli O113:H21 strains isolated from clinical, environmental, and food sources.
Infections
Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.
Infections
Genetics of atypical hemolytic uremic syndrome (aHUS).
Infections
Genetics of hemolytic uremic syndromes.
Infections
Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection.
Infections
Granulocytic myeloid-derived suppressor cells suppress virus-specific CD8(+) T cell responses during acute Friend retrovirus infection.
Infections
H. pylori modulates DC functions via T4SS/TNF?/p38-dependent SOCS3 expression.
Infections
HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection.
Infections
Hemolytic Uremic Syndrome and Kidney Transplantation: A Case Series and Review of the Literature.
Infections
Hemolytic uremic syndrome associated with Shiga toxin producing Escherichia coli infection in a healthy adult woman.
Infections
Hemolytic Uremic Syndrome is associated with dysregulation of Chemokine Receptor expression in Circulating Monocytes.
Infections
Hemorrhagic colitis due to a novel Escherichia coli serotype (O121:H19) in a transplant patient.
Infections
Hepatitis B Virus Infection Alters Gut Microbiota Composition in Mice.
Infections
Hepatitis B virus-triggered PTEN/?-catenin/c-Myc signaling enhances PD-L1 expression to promote immune evasion.
Infections
Highly Pathogenic Clone of Shiga Toxin-Producing Escherichia coli O157:H7, England and Wales.
Infections
Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells.
Infections
HIV-Mediated Phosphatidylinositol 3-Kinase/Serine-Threonine Kinase Activation in APCs Leads to Programmed Death-1 Ligand Upregulation and Suppression of HIV-Specific CD8 T Cells.
Infections
Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications.
Infections
Human Rhinovirus Infection Enhances the Th2 Environment in Allergic and Non-allergic Patients with Chronic Rhinosinusitis.
Infections
Human Serum Amyloid P Component Protects against Escherichia coli O157:H7 Shiga Toxin 2 In Vivo: Therapeutic Implications for Hemolytic-Uremic Syndrome.
Infections
Humoral immune response to Shiga Toxin 2 (Stx2) among Brazilian urban children with hemolytic uremic syndrome and healthy controls.
Infections
Identification and Characterization of Novel Compounds Blocking Shiga Toxin Expression in Escherichia coli O157:H7.
Infections
Identification and characterization of Shiga toxin type 2 variants in Escherichia coli isolates from animals, food, and humans.
Infections
Identification and prevalence of in vivo-induced genes in enterohaemorrhagic Escherichia coli.
Infections
Identification of shiga toxin-producing bacteria by a new immuno-capture toxin gene PCR.
Infections
Identification, Shiga toxin subtypes and prevalence of minor serogroups of Shiga toxin-producing Escherichia coli in feedlot cattle feces.
Infections
IL-21 treatment recovers follicular helper T cells and neutralizing antibody production in respiratory syncytial virus infection.
Infections
IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors.
Infections
ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control.
Infections
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Infections
Immune Suppression by Neutrophils in HIV-1 Infection: Role of PD-L1/PD-1 Pathway.
Infections
Immunobiochemical Reconstruction of Influenza Lung Infection-Melanoma Skin Cancer Interactions.
Infections
Immunoproteomic analysis to identify Shiga toxin-producing Escherichia coli outer membrane proteins expressed during human infection.
Infections
Improved porcine model for Shiga toxin-producing Escherichia coli infection by deprivation of colostrum feeding in newborn piglets.
Infections
In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
Infections
Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on DCs and allows productive infection and robust immune responses.
Infections
Inclusion of PD-L1 into a recombinant profilin antigen enhances immunity against Babesia microti in a murine model.
Infections
Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.
Infections
Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection.
Infections
Increased Expression of Complement Regulators CD55 and CD59 on Peripheral Blood Cells in Patients with EAHEC O104:H4 Infection.
Infections
Increased PD-L1 expression and PD-L1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection.
Infections
Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection.
Infections
Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection.
Infections
Increased serum IL-10 and endothelin levels in hemolytic uremic syndrome caused by Escherichia coli O157.
Infections
Infection and pathogenesis of a murine strain of Escherichia coli with genetically introduced Shiga toxin type I operon in conventional mice.
Infections
Infections in Pediatric Postdiarrheal Hemolytic Uremic Syndrome: Factors Associated With Identifying Shiga Toxin-Producing Escherichia coli.
Infections
Inhibition of Escherichia coli O157:H7 and Salmonella enterica virulence factors by benzyl isothiocyanate.
Infections
Inhibition of HIV-1 Replication by Balsamin, a Ribosome Inactivating Protein of Momordica balsamina.
Infections
Inhibition of PI3K? Enhances Poly I:C-Induced Antiviral Responses and Inhibits Replication of Human Metapneumovirus in Murine Lungs and Human Bronchial Epithelial Cells.
Infections
Inhibition of water absorption and selective damage to human colonic mucosa induced by Shiga toxin-2 are enhanced by Escherichia coli O157:H7 infection.
Infections
Inhibitory potential of strepthonium A against Shiga toxin production in enterohemorrhagic Escherichia coli (EHEC) strain EDL933.
Infections
Innate and adaptive immune responses following PD-L1 blockade in treating chronic murine alveolar echinococcosis.
Infections
Interaction of Shiga toxins with human brain microvascular endothelial cells: cytokines as sensitizing agents.
Infections
Interactions between Shiga toxins and human polymorphonuclear leukocytes.
Infections
Interferon-gamma increases monocyte PD-L1 but does not diminish T-cell activation.
Infections
Intervention with Shiga toxin (Stx) antibody after infection by Stx-producing Escherichia coli.
Infections
Intestinal Clostridium species lower host susceptibility to enterohemorrhagic Escherichia coli O157:H7 infection.
Infections
Intestinal organoids model human responses to infection by commensal and Shiga toxin producing Escherichia coli.
Infections
Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody.
Infections
Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B.
Infections
Intrahepatic PD-1/PD-L1 up-regulation closely correlates with inflammation and virus replication in patients with chronic HBV infection.
Infections
Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.
Infections
Inverse expression of P(k) and Luke blood group antigens on human RBCs.
Infections
Investigation of Encephalopathy Caused by Shiga Toxin 2c-Producing Escherichia coli Infection in Mice.
Infections
Involvement of hypoxia and inflammation in early pregnancy loss mediated by Shiga toxin type 2.
Infections
Isolate independent molecular typing improves the yield of O typing of infections due to Shiga toxin producing Escherichia coli.
Infections
Isolation and Characteristics of Shiga Toxin 2f-Producing Escherichia coli among Pigeons in Kyushu, Japan.
Infections
Isolation and characterization of the Shiga toxin gene (stx)-bearing Escherichia coli O157 and non-O157 from retail meats in Shandong Province, China, and characterization of the O157-derived stx2 phages.
Infections
KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 ?-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression.
Infections
Laboratory Practices and Incidence of Non-O157 Shiga Toxin-producing Escherichia coli Infections.
Infections
Laboratory preparedness for detection and monitoring of Shiga toxin 2-producing Escherichia coli O104:H4 in Europe and response to the 2011 outbreak.
Infections
Lack of PD-L1 expression by iNKT cells improves the course of influenza A infection.
Infections
Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes.
Infections
Lectin/glycan interactions play a role in recognition in a coral/dinoflagellate symbiosis.
Infections
Leishmania Parasites Drive PD-L1 Expression in Mice and Human Neutrophils With Suppressor Capacity.
Infections
Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity.
Infections
Long-term shedding and clonal turnover of enterohemorrhagic Escherichia coli O157 in diarrheal diseases.
Infections
Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B.
Infections
Low risk of hemolytic uremic syndrome after early effective antimicrobial therapy for Shigella dysenteriae type 1 infection in Bangladesh.
Infections
Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
Infections
Low-level release of Shiga-like toxin (verocytotoxin) and endotoxin from enterohemorrhagic Escherichia coli treated with imipenem.
Infections
LPS-primed CD11b
Infections
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
Infections
Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis.
Infections
Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.
Infections
Making the Correct Diagnosis in Thrombotic Microangiopathy: A Narrative Review.
Infections
Manganese blocks intracellular trafficking of Shiga toxin and protects against Shiga toxicosis.
Infections
Mature cystic fibrosis airway neutrophils suppress T cell function: evidence for a role of arginase 1 but not programmed death-ligand 1.
Infections
Metabolic events mediating early killing of host cells infected by Shigella flexneri.
Infections
Metabolism of uracil-containing DNA: degradation of bacteriophage PBS2 DNA in Bacillus subtilis.
Infections
Method for the Detection of the Cleaved Form of Shiga Toxin 2a Added to Normal Human Serum.
Infections
Microbiological and serological control of Escherichia coli O157: H7 in kindergarten staff in Buenos Aires city and suburban areas.
Infections
Modification of fibroblast surface amines alters receptor-mediated cell spreading on protein-coated substrata but not adsorptive endocytosis.
Infections
Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
Infections
Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in chickens infected with Marek's disease virus.
Infections
Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors.
Infections
Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody.
Infections
Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection.
Infections
Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors.
Infections
N-Glycosidase activity in extracts of Bacillus subtilis and its inhibition after infection with bacteriophage PBS2.
Infections
National reporting of Shiga-like toxin (verotoxin) producing Escherichia coli infections and associated syndromes.
Infections
Neonatal Atypical Hemolytic Uremic Syndrome in the Eculizumab Era.
Infections
Neurologic manifestations of E coli infection-induced hemolytic-uremic syndrome in adults.
Infections
Neuropsychological outcome after complicated Shiga toxin-producing Escherichia coli infection.
Infections
Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins.
Infections
Neutralizing antibodies against Shiga-like toxins from Escherichia coli in colostra and sera of cattle.
Infections
New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome.
Infections
New high-affinity monoclonal antibodies against Shiga toxin 1 facilitate the detection of hybrid Stx1/Stx2 in vivo.
Infections
Nitrobenzylthioinosine (NBT), a nucleoside transport inhibitor, protects against Shiga toxin cytotoxicity in human microvascular endothelial cells.
Infections
Non-pathogenic Escherichia coli Enhance Stx2a Production of E. coli O157:H7 Through Both bamA-Dependent and Independent Mechanisms.
Infections
O side chain deficiency enhances sensitivity of Escherichia coli to Shiga toxin 2-converting bacteriophages.
Infections
Occurrence of plasmid-mediated quinolone resistance and virulence genes in avian Escherichia coli isolates from Algeria.
Infections
Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.
Infections
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.
Infections
Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin.
Infections
Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections.
Infections
Ouabain Protects against Shiga Toxin-Triggered Apoptosis by Reversing the Imbalance between Bax and Bcl-xL.
Infections
Overexpression of programmed cell death ligand 1 in patients with CIN and its correlation with human papillomavirus infection and CIN persistence.
Infections
OX40 stimulation and PD-L1 blockade synergistically augment HBV-specific CD4 T cells in patients with HBeAg-negative infection.
Infections
Pathogenesis of Escherichia coli O157:H7 strain 86-24 following oral infection of BALB/c mice with an intact commensal flora.
Infections
Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS.
Infections
Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7.
Infections
Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).
Infections
PD-1 and its ligand PD-L1 are progressively up-regulated on CD4 and CD8 T-cells in HIV-2 infection irrespective of the presence of viremia.
Infections
PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma.
Infections
PD-1 blockade inhibits lymphocyte apoptosis and restores proliferation and anti-viral immune functions of lymphocyte after CP and NCP BVDV infection in vitro.
Infections
PD-1-PD-L1 pathway impairs Th1 immune response in the late stage of infection with Mycobacterium bovis bacillus Calmette-Guerin.
Infections
PD-1/PD-L1 Pathway Modulates Macrophage Susceptibility to Mycobacterium tuberculosis Specific CD8+ T cell Induced Death.
Infections
PD-1hi CD8+ resident memory T cells balance immunity and fibrotic sequelae.
Infections
PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis.
Infections
PD-L1 Dysregulation in COVID-19 Patients.
Infections
PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell response.
Infections
PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
Infections
PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing.
Infections
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.
Infections
PD-L1-expressing dendritic cells contribute to viral resistance during acute HSV-1 infection.
Infections
PD-L1/B7-H1 Inhibits Viral Clearance by Macrophages in HSV-1-Infected Corneas.
Infections
Perspectives on Shiga-like Toxin Infections in Argentina .
Infections
Phage-mediated Shiga toxin (Stx) horizontal gene transfer and expression in non-Shiga toxigenic Enterobacter and Escherichia coli strains.
Infections
Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.
Infections
Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates.
Infections
Pneumococal Surface Protein A (PspA) Regulates Programmed Death Ligand 1 Expression on Dendritic Cells in a Toll-Like Receptor 2 and Calcium Dependent Manner.
Infections
Pokeweed antiviral protein restores levels of cellular APOBEC3G during HIV-1 infection by depurinating Vif mRNA.
Infections
Poliovirus-mediated entry of pokeweed antiviral protein.
Infections
Polymerase Chain Reaction-Based Prevalence of Serogroups of Escherichia coli Known to Carry Shiga Toxin Genes in Feces of Finisher Pigs.
Infections
Porphyromonas gingivalis cell wall components induce PD-L1 expression on human oral carcinoma cells by a RIP2-dependent mechanism.
Infections
Postdiarrheal Shiga toxin-mediated hemolytic uremic syndrome similar to septic shock.
Infections
Posttransplant recurrence of atypical hemolytic uremic syndrome.
Infections
Potential immunosuppressive effects of Escherichia coli O157:H7 experimental infection on the bovine host.
Infections
Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in shiga toxin producing Escherichia coli infection.
Infections
Predicting Host Association for Shiga Toxin-Producing E. coli Serogroups by Machine Learning.
Infections
Prediction of PD-L1 inhibition effects for HIV-infected individuals.
Infections
Prevention of Escherichia coli O157:H7 infection in gnotobiotic mice associated with Bifidobacterium strains.
Infections
Primary Human Derived Blood Outgrowth Endothelial Cells: An Appropriate In Vitro Model to Study Shiga Toxin Mediated Damage of Endothelial Cells.
Infections
Probiotic Escherichia coli Nissle 1917 reduces growth, Shiga toxin expression, release and thus cytotoxicity of enterohemorrhagic Escherichia coli.
Infections
Production of a Shiga-like cytotoxin by Campylobacter.
Infections
Production, characterization and immunodiagnostic application of a monoclonal antibody to Shiga toxin.
Infections
Programmed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4+ T Effector and Regulatory T Cells in Cutaneous Leishmaniasis.
Infections
Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals.
Infections
Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections.
Infections
Programmed Death Ligand 1 Promotes Early-Life Chlamydia Respiratory Infection-Induced Severe Allergic Airway Disease.
Infections
Programmed death ligand 2 regulates arginase induction and modifies Trypanosoma cruzi survival in macrophages during murine experimental infection.
Infections
Programmed death ligand-1 expression and memory T-cell generation in Coxiella burnetii infection.
Infections
Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade.
Infections
Promising Nucleic Acid Lateral Flow Assay Plus PCR for Shiga Toxin-Producing Escherichia coli.
Infections
Promoter Sequence of Shiga Toxin 2 (Stx2) Is Recognized In Vivo, Leading to Production of Biologically Active Stx2.
Infections
Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues.
Infections
Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B.
Infections
Protection against Shiga-Toxigenic Escherichia coli by Non-Genetically Modified Organism Receptor Mimic Bacterial Ghosts.
Infections
Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice.
Infections
Proteomic View of Interactions of Shiga Toxin-Producing Escherichia coli with the Intestinal Environment in Gnotobiotic Piglets.
Infections
Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages.
Infections
Quantitation of Risk Reduction of E. coli Transmission After Using Antimicrobial Hand Soap.
Infections
Rapid and quantitative detection of Shiga toxin1 and Shiga toxin2 based on multiple targets UPT-LF assay.
Infections
Rapid and sensitive detection of Shiga toxin-producing Escherichia coli directly from stool samples by real-time PCR in comparison to culture, enzyme immunoassay and Vero cell cytotoxicity assay.
Infections
Real-time interaction analysis of Shiga toxins and membrane microdomains of primary human brain microvascular endothelial cells.
Infections
Recent progress of Shiga toxin neutralizer for treatment of infections by Shiga toxin-producing Escherichia coli.
Infections
Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity.
Infections
Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1.
Infections
Regulatory elements of stx2 gene and the expression level of Shiga-like toxin 2 in Escherichia coli O157:H7.
Infections
Regulatory NK cells mediated between immunosuppressive monocytes and dysfunctional T cells in chronic HBV infection.
Infections
Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer.
Infections
Relationship between pathogenicity for humans and stx genotype in Shiga toxin-producing Escherichia coli serotype O157.
Infections
Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains.
Infections
Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.
Infections
Respiratory infections regulated blood cells IFN-?-PD-L1 pathway in pediatric asthma.
Infections
Respiratory Syncytial Virus infection is associated with an altered innate immunity and a heightened pro-inflammatory response in the lungs of preterm lambs.
Infections
Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs.
Infections
Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis.
Infections
Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: Effect of viremia levels and antiviral treatment.
Infections
Retinoid levels influence enterohemorrhagic Escherichia coli infection and Shiga toxin 2 susceptibility in mice.
Infections
Ribosome-inactivating activity and cDNA cloning of antiviral protein isoforms of Chenopodium album.
Infections
Riproximin is a recently discovered type II ribosome inactivating protein with potential for treating cancer.
Infections
RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells.
Infections
Role of bacteriophages in STEC infections: new implications for the design of prophylactic and treatment approaches.
Infections
Role of complement in enterohemorrhagic Escherichia coli-Induced hemolytic uremic syndrome.
Infections
Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells.
Infections
Role of Shiga toxin 2 (Stx2)-binding protein, human serum amyloid P component (HuSAP), in Shiga toxin-producing Escherichia coli infections: assumption from in vitro and in vivo study using HuSAP and anti-Stx2 humanized monoclonal antibody TMA-15.
Infections
Role of Shiga/Vero toxins in pathogenesis.
Infections
Role of the Nitric Oxide Reductase NorVW in the Survival and Virulence of Enterohaemorrhagic Escherichia coli during Infection.
Infections
RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity.
Infections
Safe and effective means of detecting and quantitating Shiga-like toxins in attomole amounts.
Infections
Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection.
Infections
Schistosoma mansoni worms induce anergy of T cells via selective up-regulation of programmed death ligand 1 on macrophages.
Infections
Serogroup-specific bacterial engineered glycoproteins as novel antigenic targets for diagnosis of shiga toxin-producing-escherichia coli-associated hemolytic-uremic syndrome.
Infections
Serological and biochemical properties of Shiga-like toxin (verocytotoxin)-producing strains of Escherichia coli, other than O-group 157, from patients in Germany.
Infections
Serum neutrophil gelatinase-associated lipocalin (NGAL) in patients with Shiga toxin mediated haemolytic uraemic syndrome (STEC-HUS).
Infections
Shiga toxin (Stx) type 1a reduces the toxicity of the more potent Stx2a in vivo and in vitro.
Infections
Shiga Toxin (Verotoxin)-Producing Escherichia coli in Japan.
Infections
Shiga toxin 1 causes direct renal injury in rats.
Infections
Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity.
Infections
Shiga Toxin 1-Producing Shigella sonnei Infections, California, United States, 2014-2015.
Infections
Shiga toxin 2 overexpression in Escherichia coli O157:H7 strains associated with severe human disease.
Infections
Shiga toxin 2a binds antithrombin and heparin, but does not directly activate platelets.
Infections
Shiga Toxin 2a Binds to Complement Components C3b and C5 and Upregulates Their Gene Expression in Human Cell Lines.
Infections
Shiga toxin 2eB-transgenic lettuce vaccine is effective in protecting weaned piglets from edema disease caused by Shiga toxin-producing Escherichia coli infection.
Infections
Shiga toxin gene loss and transfer in vitro and in vivo during enterohemorrhagic Escherichia coli O26 infection in humans.
Infections
Shiga toxin in enterohemorrhagic E.coli: regulation and novel anti-virulence strategies.
Infections
Shiga toxin producing Escherichia coli infection: current progress & future challenges.
Infections
Shiga toxin producing Escherichia coli-associated diarrhea and hemolytic uremic syndrome in young children in Romania.
Infections
Shiga toxin producing Escherichia coli: identification of non-O157:H7-Super-Shedding cows and related risk factors.
Infections
Shiga toxin production and translocation during microaerobic human colonic infection with Shiga toxin-producing E.?coli?O157:H7 and O104:H4.
Infections
Shiga Toxin Selectively Upregulates Expression of Syndecan-4 and Adhesion Molecule ICAM-1 in Human Glomerular Microvascular Endothelium.
Infections
Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism.
Infections
Shiga toxin sub-type 2a increases the efficiency of Escherichia coli O157 transmission between animals and restricts epithelial regeneration in bovine enteroids.
Infections
Shiga toxin-glycosphingolipid interaction: Status quo of research with focus on primary human brain and kidney endothelial cells.
Infections
Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview.
Infections
Shiga toxin-induced tumor necrosis factor alpha expression: requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases.
Infections
Shiga toxin-mediated hemolytic uremic syndrome: time to change the diagnostic paradigm?
Infections
Shiga toxin-negative attaching and effacing Escherichia coli: distinct clinical associations with bacterial phylogeny and virulence traits and inferred in-host pathogen evolution.
Infections
Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study.
Infections
Shiga Toxin-Producing Escherichia coli in Feces of Finisher Pigs: Isolation, Identification, and Public Health Implications of Major and Minor Serogroups.
Infections
Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology.
Infections
Shiga toxin-producing Escherichia coli O157:H7 show an increased pathogenicity in mice after the passage through the gastrointestinal tract of the same host.
Infections
Short-tailed stx phages exploit the conserved YaeT protein to disseminate Shiga toxin genes among enterobacteria.
Infections
Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure.
Infections
Soluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic syndrome: a case-control study.
Infections
Sporadic STEC O157 infection: secondary household transmission in Wales.
Infections
Stable Neutralization of a Virulence Factor in Bacteria Using Temperate Phage in the Mammalian Gut.
Infections
Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.
Infections
stx genotype and molecular epidemiological analyses of Shiga toxin-producing Escherichia coli O157:H7/H- in human and cattle isolates.
Infections
Subtyping Escherichia coli Virulence Genes Isolated from Feces of Beef Cattle and Clinical Cases in Alberta.
Infections
T-regulatory cells infected with feline immunodeficiency virus up-regulate programmed death-1 (PD-1).
Infections
Targeting inflammatory demyelinating lesions to sites of Wallerian degeneration.
Infections
The A1 Subunit of Shiga Toxin 2 Has Higher Affinity for Ribosomes and Higher Catalytic Activity than the A1 Subunit of Shiga Toxin 1.
Infections
The Antibiotic Polymyxin B Impairs the Interactions between Shiga Toxins and Human Neutrophils.
Infections
The antimicrobial peptide cathelicidin protects mice from Escherichia coli O157:H7-mediated disease.
Infections
The carrier state of shiga-like toxin II (SLT II) and hemolysin-producing enteroaggregative Escherichia coli strain.
Infections
The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery.
Infections
The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome.
Infections
The effect of surface membrane modifications of fibroblastic cells on the entry process of Trypanosoma cruzi trypomastigotes.
Infections
The Effects of Shiga Toxin 1, 2 and Their Subunits on Cytokine and Chemokine Expression by Human Macrophage-Like THP-1 Cells.
Infections
The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
Infections
The MAP kinase-activated protein kinase 2 (MK2) contributes to the Shiga toxin-induced inflammatory response.
Infections
The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome.
Infections
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance.
Infections
The PD-1/PD-L1 Pathway Affects the Expansion and Function of Cytotoxic CD8+ T Cells During an Acute Retroviral Infection.
Infections
The PD-1: PD-L1 pathway promotes development of brain-resident memory T cells following acute viral encephalitis.
Infections
The PD-1:PD-L1 immune inhibitory checkpoint in
Helicobacter pylori
infection and gastric cancer: a comprehensive review and future perspectives.
Infections
The PD-L1/CD86 ratio is increased in dendritic cells co-infected with porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus, and the PD-L1/PD-1 axis is associated with anergy, apoptosis, and the induction of regulatory T-cells in porcine lymphocytes.
Infections
The Prevalence of Shiga Toxin-1 in Non-Shigella Dysenteriae Isolates Collected from Diarrhea Samples in Patients, Ahvaz, Iran.
Infections
The Regulatory Role of the Oral Commensal Streptococcus mitis on Human Monocytes.
Infections
The role of coagulation and fibrinolysis in the pathogenesis of diarrhea-associated hemolytic uremic syndrome.
Infections
The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection.
Infections
The role of programmed death ligand 1 pathway in persistent biomaterial-associated infections.
Infections
The Shiga toxin 2 production level in enterohemorrhagic Escherichia coli O157:H7 is correlated with the subtypes of toxin-encoding phage.
Infections
The type-1 and type-2 ribosome-inactivating proteins from Iris confer transgenic tobacco plants local but not systemic protection against viruses.
Infections
Therapeutic effect of anti-TNF-alpha antibody and levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection.
Infections
Therapeutic strategies for Shiga toxin-producing Escherichia coli infections.
Infections
Therapeutic use of a receptor mimic probiotic reduces intestinal Shiga toxin levels in a piglet model of hemolytic uremic syndrome.
Infections
Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in children and adolescents.
Infections
ThymicPeptides Reverse Immune Exhaustion in Patients with Reactivated Human Alphaherpesvirus1 Infections.
Infections
TNF contributes to T-cell exhaustion in chronic L. mexicana infections of mice through PD-L1 up-regulation.
Infections
Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis.
Infections
Toll-like receptor 4 facilitates binding of Shiga toxin to colon carcinoma and primary umbilical vein endothelial cells.
Infections
Toxigenic properties and stx phage characterization of Escherichia coli O157 isolated from animal sources in a developing country setting.
Infections
Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response.
Infections
Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli.
Infections
Trichosanthin suppresses the elevation of p38 MAPK, and Bcl-2 induced by HSV-1 infection in Vero cells.
Infections
Tumor localization of oncolytic adenovirus assisted by pH-degradable microgels with JQ1-mediated boosting replication and PD-L1 suppression for enhanced cancer therapy.
Infections
Tumor necrosis factor-? modifies the effects of Shiga toxin on glial cells.
Infections
Type-2 diabetes alters the basal phenotype of human macrophages and diminishes their capacity to respond, internalise, and control Mycobacterium tuberculosis.
Infections
Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
Infections
Upregulation of PD-1 on CD4?CD25? T cells is associated with immunosuppression in liver of mice infected with Echinococcus multilocularis.
Infections
Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-? by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection.
Infections
Urinary concentrating defect in rats given Shiga toxin: elevation in urinary AQP2 level associated with polyuria.
Infections
Usefulness of serum fibrinogen degradation product-E in sporadic cases of classical hemolytic uremic syndrome.
Infections
Varicella Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex 1 in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells and Lung Fibroblasts.
Infections
Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function.
Infections
Verocytotoxin inhibits mitogenesis and protein synthesis in purified human glomerular mesangial cells without affecting cell viability: evidence for two distinct mechanisms.
Infections
Virulence factors of Shiga toxin-producing Escherichia coli and the risk of developing haemolytic uraemic syndrome in Norway, 1992-2013.
Infections
Virulence gene profiles and population genetic analysis for exploration of pathogenic serogroups of Shiga toxin-producing Escherichia coli.
Infections
Waking up T cells to counteract chronic infections.
Infections
Zinc Induces Dendritic Cell Tolerogenic Phenotype and Skews Regulatory T Cell-Th17 Balance.
Infections
[Active etiological surveillance for foodborne diseases in Guangdong province, 2013-2014].
Infections
[Antimicrobial susceptibility of shiga toxin producing E coli (STEC) strains isolated from human infections and food]
Infections
[Cell-cooperation integrated test for the detection of immune reactivity to Shiga-toxin in patients with acute intestine infection]
Infections
[Differences in pattern of pathogenicity genes in Escherichia coli strains producing shiga-like toxin]
Infections
[Epidemiological analysis of Shiga toxin-producing Escherichia coli O157 isolates from familial infection]
Infections
[Escherichia coli O157:H7 strains carrying Shiga toxin 2 variant slt2vha were isolated from Xuzhou City of Jiangsu Province]
Infections
[HBV transinfected enhances the PD-L expression of cytokines stimulating]
Infections
[Identification of Shiga toxin in patients with acute intestinal infections in the presence of mono- and mixed-O-antigens of pathogens].
Infections
[Lysogenic infection of a Shiga toxin 2-converting bacteriophage changes host gene expression, enhances host acid resistance and motility]
Infections
[PD-1/PD-L1 expression and its interaction with interferon-? in Toxoplasma gondii-infected mice at middle and late pregnancy].
Infections
[Risk factors for abundance of shiga toxin producing Escherichia coli in sewage water]
Infections
[Shiga toxin producing Escherichia coli infection]
Infections
[The immunoregulatory functions of exosome derived from mesenchymal stem cells that are genetically modified by adeno-associated virus].
Infections
[The influence of ricin on the course of experimental infections of mice with Trichinella spiralis]
Infertility
Induction of Male Sterility in Tobacco by Anther-Specific Expression of the Gene for Ricin Enzymatic Subunit A Chain RTA.
Infertility
Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility.
Infertility
The second intron of AGAMOUS drives carpel- and stamen-specific expression sufficient to induce complete sterility in Arabidopsis.
Infertility, Male
Induction of Male Sterility in Tobacco by Anther-Specific Expression of the Gene for Ricin Enzymatic Subunit A Chain RTA.
Infertility, Male
Isolation and promoter analysis of anther-specific genes encoding putative arabinogalactan proteins in Malus x domestica.
Infertility, Male
Production of transgenic male sterile tobacco plants with the cDNA encoding a ribosome inactivating protein in Dianthus sinensis L.
Inflammatory Bowel Diseases
Bifidobacterium infantis Induces Protective Colonic PD-L1 and Foxp3 Regulatory T Cells in an Acute Murine Experimental Model of Inflammatory Bowel Disease.
Inflammatory Bowel Diseases
Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics.
Inflammatory Bowel Diseases
Tachykinergic neurotransmission is enhanced in small intestinal circular muscle in a rabbit model of inflammation.
Inflammatory Bowel Diseases
The roles of microbial products in the development of colorectal cancer: a review.
Inflammatory Breast Neoplasms
Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression.
Inflammatory Breast Neoplasms
The combined presence of CD20?+?B cells and PD-L1?+?tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Influenza in Birds
Expression and Immunogenicity of M2e Peptide of Avian Influenza Virus H5N1 Fused to Ricin Toxin B Chain Produced in Duckweed Plants.
Influenza in Birds
Pulmonary endothelium-derived PD-L1 induced by the H9N2 avian influenza virus inhibits the immune response of T cells.
Influenza, Human
Comparison of alteration of cell surface carbohydrates of the chinchilla tubotympanum and colonial opacity phenotype of Streptococcus pneumoniae during experimental pneumococcal otitis media with or without an antecedent influenza A virus infection.
Influenza, Human
Concise and Reliable Syntheses of Glycodendrimers via Self-Activating Click Chemistry: A Robust Strategy for Mimicking Multivalent Glycan-Pathogen Interactions.
Influenza, Human
Expression of pokeweed antiviral protein in mammalian cells activates c-Jun NH2-terminal kinase without causing apoptosis.
Influenza, Human
Glycan-based high-affinity ligands for toxins and pathogen receptors.
Influenza, Human
Glycosylation does not determine segregation of viral envelope proteins in the plasma membrane of epithelial cells.
Influenza, Human
Highly pathological influenza A virus infection is associated with augmented expression of PD-1 by functionally compromised virus-specific CD8+ T cells.
Influenza, Human
Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1.
Influenza, Human
Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies.
Influenza, Human
Inhibition of HIV-1 Replication by Balsamin, a Ribosome Inactivating Protein of Momordica balsamina.
Influenza, Human
Intranasal Immunization with Influenza Virus-Like Particles Containing Membrane-Anchored Cholera Toxin B or Ricin Toxin B Enhances Adaptive Immune Responses and Protection against an Antigenically Distinct Virus.
Influenza, Human
Lack of PD-L1 expression by iNKT cells improves the course of influenza A infection.
Influenza, Human
Modification of fibroblast surface amines alters receptor-mediated cell spreading on protein-coated substrata but not adsorptive endocytosis.
Influenza, Human
Optimization of furin inhibitors to protect against the activation of influenza hemagglutinin H5 and Shiga toxin.
Influenza, Human
PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell response.
Influenza, Human
Quantitative interaction of Ricinus communis agglutinin and concanavalin A with influenza and vesicular stomatitis viruses and virus-infected normal and polyoma-transformed cells.
Influenza, Human
Tissue distribution of human and avian type sialic acid influenza virus receptors in domestic cat.
Influenza, Human
Tissue distribution of sialic acid-linked influenza virus receptors in beagle dogs.
Influenza, Human
Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway.
Influenza, Human
Use of Salmonella for heterologous gene expression and vaccine delivery systems.
Influenza, Human
Viral acute lower respiratory infections impair CD8+ T cells through PD-1.
Insulin Resistance
Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation.
Intestinal Diseases
Escherichia coli serogroup O107/O117 lipopolysaccharide binds and neutralizes Shiga toxin 2.
Ischemic Stroke
PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.
Ischemic Stroke
The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury.
Keratitis, Herpetic
PD-L1-expressing dendritic cells contribute to viral resistance during acute HSV-1 infection.
Keratoacanthoma
Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
Keratoconjunctivitis
Hafnia alvei, a probable cause of diarrhea in humans.
Keratoconus
Glycoconjugate abnormalities in cultured keratoconus stromal cells.
Keratosis, Actinic
Increased PD-L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation.
Kidney Cortex Necrosis
Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice.
Kidney Diseases
Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Kidney Failure, Chronic
Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis.
Kidney Failure, Chronic
Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression.
Kidney Failure, Chronic
The hemolytic uremic syndromes.
Kidney Neoplasms
A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint.
Kidney Neoplasms
A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape.
Kidney Neoplasms
DDX39B Predicts Poor Survival and Associated with Clinical Benefit of Anti-PD-L1 Therapy in ccRCC.
Kidney Neoplasms
Glucose metabolism involved in PD-L1-mediated immune escape in the malignant kidney tumour microenvironment.
Kidney Neoplasms
Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.
Kidney Neoplasms
Immuno-regulatory antibodies for the treatment of cancer.
Kidney Neoplasms
Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus.
Kidney Neoplasms
Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression.
Kidney Neoplasms
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Kidney Neoplasms
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response.
Kidney Neoplasms
PD-L1 status and Immune checkpoint inhibitors in kidney cancer: ignorance, lack of knowledge or both.
Kidney Neoplasms
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay.
Kidney Neoplasms
PD1/PD-L1 axis in uro-oncology.
Kidney Neoplasms
Platelets stimulate programmed death-ligand 1 expression by cancer cells: Inhibition by anti-platelet drugs.
Kidney Neoplasms
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
Kidney Neoplasms
Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting.
Klatskin Tumor
PD-L1 expression in extrahepatic cholangiocarcinoma.
Klatskin Tumor
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Klatskin Tumor
[The Regulation of PD-L1 Expression in the Tumor Microenvironment Associated with Epithelial-Mesenchymal Transformation].
Krukenberg Tumor
PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins.
Laryngeal Neoplasms
Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
Laryngeal Neoplasms
Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration.
Laryngeal Neoplasms
miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression.
Laryngeal Neoplasms
Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
Latent Infection
CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.
Latent Infection
Specific Elimination of Latently HIV-1 Infected Cells Using HIV-1 Protease-Sensitive Toxin Nanocapsules.
Leiomyoma
PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Leiomyosarcoma
Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
Leiomyosarcoma
Correction to: Association of PD-L1 and IDO1 expression with JAK-STAT pathway activation in soft-tissue leiomyosarcoma.
Leiomyosarcoma
Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.
Leiomyosarcoma
Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.
Leiomyosarcoma
Intratumoral immune-biomarkers and mismatch repair status in leiyomyosarcoma -potential predictive markers for adjuvant treatment: a pilot study.
Leiomyosarcoma
Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Leiomyosarcoma
PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Leiomyosarcoma
Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
Leiomyosarcoma
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Leiomyosarcoma
T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study.
Leishmaniasis
PD-L1 May Mediate T-Cell Exhaustion in a Case of Early Diffuse Leishmaniasis Caused by Leishmania (L.) amazonensis.
Leishmaniasis
Structurally optimized analogs of the retrograde trafficking inhibitor Retro-2cycl limit Leishmania infections.
Leishmaniasis, Cutaneous
PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis.
Leishmaniasis, Cutaneous
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Leishmaniasis, Diffuse Cutaneous
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Leishmaniasis, Mucocutaneous
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Leishmaniasis, Visceral
News.
Leishmaniasis, Visceral
PD-1 and PD-L1 regulate cellular immunity in canine visceral leishmaniasis.
Leishmaniasis, Visceral
Regulatory IgDhi B Cells Suppress T Cell Function via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis.
Leishmaniasis, Visceral
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Leukemia
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Leukemia
Adult T cell leukemia: a potential target for ricin A chain immunotoxins.
Leukemia
An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Leukemia
Antitumor effects of abrin and ricin used singly and in combination with cisplatin.
Leukemia
APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells.
Leukemia
Binding and cytotoxic effect of ricin toxin on multivalent hybrid antibody-coated target cells.
Leukemia
Cancer-associated oxidoreductase ERO1-? promotes immune escape through up-regulation of PD-L1 in human breast cancer.
Leukemia
Characterization of a new monoclonal antibody 6G7 that recognizes a unique antigen on myeloid and lymphoid cells.
Leukemia
Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia.
Leukemia
Comparative studies on internalization of gold labelled mistletoe lectin I (MLI), its subunits, and of an immunotoxin into mouse L 1210V leukemia cells.
Leukemia
Comparative studies on internalization of gold-labelled mistletoe lectin I, its subunits, as well as of an immunotoxin in murine L 1210 leukemia cells.
Leukemia
Comparison of the selective cytotoxic effects of immunotoxins containing ricin A chain or pokeweed antiviral protein and anti-Thy 1.1 monoclonal antibodies.
Leukemia
Correlation of PD-L1 surface expression on leukemia cells with the ratio of PD-L1 mRNA variants and with electrophoretic mobility.
Leukemia
Decreased sensitivity of an interferon-resistant subline of murine leukemia L-1210 cells to toxic effects of ricin and abrin.
Leukemia
Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer.
Leukemia
Doxorubicin and ricin, a strongly synergistic combination in mouse leukemia.
Leukemia
Effect of ricin and abrin on survival of L1210 leukemic mice and on leukemic and normal bone-marrow cells.
Leukemia
Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients.
Leukemia
Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Leukemia
Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.
Leukemia
Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin.
Leukemia
Glycosphingolipid expression in acute nonlymphocytic leukemia: common expression of shiga toxin and parvovirus B19 receptors on early myeloblasts.
Leukemia
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations.
Leukemia
High toxic efficiency of ricin immunotoxins specific for the T-cell antigen receptor of a human leukemia T-cell line.
Leukemia
Identification and characterization of a monoclonal antibody that neutralizes ricin toxicity in vitro and in vivo.
Leukemia
IL2 fused to lectin-deficient ricin is toxic to human leukemia cells expressing the IL2 receptor.
Leukemia
Immunotoxin therapy of leptomeningeal neoplasia.
Leukemia
Immunotoxins in cancer therapy: Review and update.
Leukemia
Immunotoxins in the treatment of hematologic malignancies.
Leukemia
Important Chinese herbal remedies.
Leukemia
In vivo follow up of the cytotoxic effect of ricin toxin vectorized by multivalent hybrid antibody on target cells.
Leukemia
In vivo follow-up of the cytotoxic effect of protein A--ricin toxin conjugate, on antibody-coated target cells.
Leukemia
Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein.
Leukemia
Induction of apoptosis by momordin I in promyelocytic leukemia (HL-60) cells.
Leukemia
Internalization and action of an immunotoxin containing mistletoe lectin A-chain.
Leukemia
Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.
Leukemia
Lectin distinction of benign from malignant histiocytes.
Leukemia
Lectinocytochemical detection of apoptotic murine leukemia L1210 cells.
Leukemia
Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.
Leukemia
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Leukemia
Marked difference in the in vivo antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD10). Mechanisms involved in the differential activities of immunotoxins.
Leukemia
MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Leukemia
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Leukemia
Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.
Leukemia
Mutations at the capsid-nucleocapsid cleavage site of gag polyprotein of Moloney murine leukemia virus abolish virus infectivity.
Leukemia
Myeloid precursors and acute myeloid leukemia cells express multiple CD33-related Siglecs.
Leukemia
Nec-1 Enhances Shikonin-Induced Apoptosis in Leukemia Cells by Inhibition of RIP-1 and ERK1/2.
Leukemia
Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy.
Leukemia
PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation.
Leukemia
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
Leukemia
Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma.
Leukemia
Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
Leukemia
Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors:pokeweed antiviral protein or ricin A chain.
Leukemia
Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
Leukemia
Retinoic acid-induced CD38 antigen as a target for immunotoxin-mediated killing of leukemia cells.
Leukemia
Specific destruction of hybridoma cells by antigen-toxin conjugates demonstrate an efficient strategy for targeted drug therapy in leukemias of the B cell lineage.
Leukemia
Specific killing of mouse leukemic cells with ricin A-chain immunotoxin.
Leukemia
Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Leukemia
Synergistic effect of ricin in combination with daunorubicin, cis-dichlorodiammineplatinum(II) and vincristine in systemic L1210 leukemia.
Leukemia
Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
Leukemia
Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications.
Leukemia
The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.
Leukemia
The Effect of Small Molecule Pharmacological Agents on the Triterpenoid Saponin Induced Endolysosomal Escape of Saporin and a Saporin-Based Immunotoxin in Target Human Lymphoma Cells.
Leukemia
The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma.
Leukemia
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
Leukemia
The synthesis and degradation of presumptive messenger RNA in cultured mouse leukemia cells during the inhibition of protein synthesis.
Leukemia
Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen.
Leukemia
Transcriptional network inference and master regulator analysis of the response to ribosome-inactivating proteins in leukemia cells.
Leukemia
Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia.
Leukemia
Transport of ricin A chain after prior treatment of mouse leukemia cells with ricin B chain.
Leukemia
Treatment of leukemia patients with T101 ricin A chain immunotoxins.
Leukemia
Treatment of murine EL4 leukemia in ascitic form with anti-Thy 1.2 specific immunotoxins.
Leukemia
TYchi, a novel chitinase with RNA N-glycosidase and anti-tumor activities.
Leukemia
Variability of PD-L1 expression in mastocytosis.
Leukemia
Viscum album agglutinin-I (VAA-I) induces apoptosis and degradation of cytoskeletal proteins in human leukemia PLB-985 and X-CGD cells via caspases: lamin B1 is a novel target of VAA-I.
Leukemia
Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
Leukemia
[Expression and Significance of PD-L1, HSP90 and HSP90? in Serum of Patients with Acute Leukemia].
Leukemia
[Expression of Programmed Death Ligand-1 (PD-L1) in Human Acute Leukemia and Its Clinical Significance].
Leukemia
[Mechanism of trichosanthin against human leukemia/lymphoma cells in vitro]
Leukemia
[Purification and anti-cancer activity of ricin]
Leukemia
[Relationship of PD-L1 Expression with the Clinical Features and Prognosis of Patients with Primary Acute Leukemia].
Leukemia
[Study on Trichosanthin induced apoptosis of leukemia K562 cells]
Leukemia
[Value of BCL-2 and PD-L1 Combined Detection in Predicting the Prognosis of Primary Acute Leukemia].
Leukemia L1210
Ricin A-chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity.
Leukemia L1210
Target-cell cytotoxicity of a hybrid of Fab' on immunoglobulin and A-chain of ricin.
Leukemia, B-Cell
Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin.
Leukemia, B-Cell
Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
Leukemia, B-Cell
Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
Leukemia, B-Cell
Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
Leukemia, Erythroblastic, Acute
Changes in surface architecture during murine erythroleukemia cell differentiation as detected by lectin binding and agglutination.
Leukemia, Erythroblastic, Acute
Specific destruction of hybridoma cells by antigen-toxin conjugates demonstrate an efficient strategy for targeted drug therapy in leukemias of the B cell lineage.
Leukemia, Erythroblastic, Acute
Wheat germ agglutinin-binding protein changes in highly malignant Friend leukemia cells metastasizing to the liver.
Leukemia, Feline
Identification of a new viral protein containing CAp30 and NCp10 sequences in murine and feline leukemia retroviruses.
Leukemia, Hairy Cell
Immunotoxins in cancer therapy: Review and update.
Leukemia, Lymphocytic, Chronic, B-Cell
Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease.
Leukemia, Lymphocytic, Chronic, B-Cell
B-cell restricted saporin immunotoxins: activity against B-cell lines and chronic lymphocytic leukemia cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Leukemia, Lymphocytic, Chronic, B-Cell
Four ricin chain A-based immunotoxins directed against the common chronic lymphocytic leukemia antigen: in vitro characterization.
Leukemia, Lymphocytic, Chronic, B-Cell
Immunotoxins in cancer therapy: Review and update.
Leukemia, Lymphocytic, Chronic, B-Cell
PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.
Leukemia, Lymphocytic, Chronic, B-Cell
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Leukemia, Lymphocytic, Chronic, B-Cell
Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia
Leukemia, Mast-Cell
Leveraging Siglec-8 endocytic mechanisms to kill human eosinophils and malignant mast cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
[Effect of PD-L1 Blockade on Function of Dendritic Cells Derived from Chronic Myelocytic Leukemia.]
Leukemia, Myeloid
Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias.
Leukemia, Myeloid
Comparison of the apoptosis-inducing abilities of various protein synthesis inhibitors in U937 cells.
Leukemia, Myeloid
Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling.
Leukemia, Myeloid
Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures.
Leukemia, Myeloid
PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation.
Leukemia, Myeloid
Shiga toxin 1 induces apoptosis in the human myelogenous leukemia cell line THP-1 by a caspase-8-dependent, tumor necrosis factor receptor-independent mechanism.
Leukemia, Myeloid
Transcriptional network inference and master regulator analysis of the response to ribosome-inactivating proteins in leukemia cells.
Leukemia, Myeloid, Acute
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
Leukemia, Myeloid, Acute
An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Leukemia, Myeloid, Acute
Attempts to express the A1-GMCSF immunotoxin in the baculovirus expression vector system.
Leukemia, Myeloid, Acute
Correlation of PD-L1 surface expression on leukemia cells with the ratio of PD-L1 mRNA variants and with electrophoretic mobility.
Leukemia, Myeloid, Acute
Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling.
Leukemia, Myeloid, Acute
Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.
Leukemia, Myeloid, Acute
Glycosphingolipid expression in acute nonlymphocytic leukemia: common expression of shiga toxin and parvovirus B19 receptors on early myeloblasts.
Leukemia, Myeloid, Acute
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations.
Leukemia, Myeloid, Acute
Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity.
Leukemia, Myeloid, Acute
Immunotoxins in cancer therapy: Review and update.
Leukemia, Myeloid, Acute
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Leukemia, Myeloid, Acute
PD-L1 (CD274) promoter methylation predicts survival in patients with acute myeloid leukemia.
Leukemia, Myeloid, Acute
PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity.
Leukemia, Myeloid, Acute
Ricin fusion toxin targeted to the human granulocyte-macrophage colony stimulating factor receptor is selectively toxic to acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
Leukemia, Myeloid, Acute
Transcriptional network inference and master regulator analysis of the response to ribosome-inactivating proteins in leukemia cells.
Leukemia, Myeloid, Acute
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.
Leukemia, Myeloid, Acute
[Effect of PD-L1 Expression on Activity of NK Killing AML Cell Lines and Its Mechanisms].
Leukemia, Myeloid, Acute
[Expression and Clinical Significance of PD-L1 and MicroRNA-138-5p in Patients with Acute Myeloid Leukemia].
Leukemia, T-Cell
Adult T cell leukemia: a potential target for ricin A chain immunotoxins.
Leukemia, T-Cell
Complete suppression of in vivo growth of human leukemia cells by specific immunotoxins: nude mouse models.
Leukemia, T-Cell
Effects of mistletoe lectin I on human blood cell lines and peripheral blood cells. Cytotoxicity, apoptosis and induction of cytokines.
Leukemia, T-Cell
Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line.
Leukemia, T-Cell
Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
Leukemia, T-Cell
Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies.
Leukemia, T-Cell
Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Leukemia, T-Cell
Suppression of human T-cell leukemia virus I (HTLV-I) gene expression by pokeweed antiviral protein.
Leukemia, T-Cell
Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
Leukemia-Lymphoma, Adult T-Cell
Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets.
Leukemia-Lymphoma, Adult T-Cell
Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
Leukemia-Lymphoma, Adult T-Cell
Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma.
Leukemia-Lymphoma, Adult T-Cell
Immunotoxins in cancer therapy: Review and update.
Leukemia-Lymphoma, Adult T-Cell
PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.
Leukemia-Lymphoma, Adult T-Cell
PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
Leukocytosis
Complement activation is associated with more severe course of diarrhea-associated hemolytic uremic syndrome, a preliminary study.
Leukodystrophy, Globoid Cell
Fetal globoid cell leukodystrophy.
Leukopenia
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Leukoplakia
Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration.
Leukoplakia, Oral
CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma.
Leukoplakia, Oral
Effect of smoking status and programmed death-ligand 1 expression on the microenvironment and malignant transformation of oral leukoplakia: A retrospective cohort study.
Leukoplakia, Oral
Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Leukoplakia, Oral
PD-1 blockade prevents the progression of oral carcinogenesis.
Lichen Planus
Changes in carbohydrate expression of lichen planus affected oral epithelial cell membranes.
Lichen Planus
Reduced expression of programmed cell death 1 and programmed cell death ligand 1 in infiltrating inflammatory cells of lichen planus without administration of immune checkpoint inhibitors.
Lichen Planus, Oral
Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus.
Lichen Sclerosus et Atrophicus
Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
Lipoma
PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Liposarcoma
Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single Center Experience Over 25 Years and Evaluation of PD-L1 Expression.
Liposarcoma
Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Liposarcoma
Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.
Liposarcoma
Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas.
Liposarcoma
Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.
Liposarcoma
Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression.
Liposarcoma
Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.
Liposarcoma
Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Liposarcoma
PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Liposarcoma
Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
Liposarcoma
Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
Liposarcoma
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Liposarcoma
Status of programmed death-ligand 1 expression in sarcomas.
Liposarcoma, Myxoid
Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas.
Liposarcoma, Myxoid
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Listeriosis
Foodborne disease in Australia: incidence, notifications and outbreaks. Annual report of the OzFoodNet network, 2002.
Liver Cirrhosis
Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Liver Cirrhosis
Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients.
Liver Cirrhosis
Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: relation to treatment response.
Liver Cirrhosis
Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Liver Cirrhosis
Pokeweed antiviral protein attenuates liver fibrosis in mice through regulating Wnt/Jnk mediated glucose metabolism.
Liver Cirrhosis
Serum alpha-fetoprotein subfractions identified by Ricinus communis agglutinin I in hepatic malignancies, yolk sac tumor, benign hepatic diseases, and fetal stage.
Liver Cirrhosis
Visual detection of serum asialohaptoglobin by plasmonic sandwich ELLSA--a new platform for cirrhosis diagnosis.
Liver Diseases
A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction.
Liver Diseases
Activation of the cholinergic anti-inflammatory pathway reduces ricin-induced mortality and organ failure in mice.
Liver Diseases
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.
Liver Diseases
Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.
Liver Diseases
Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases.
Liver Diseases
Gender-related disparities in the frequencies of PD-1 and PD-L1 positive peripheral blood T and B lymphocytes in patients with alcohol-related liver disease: a single center pilot study.
Liver Diseases
Immune tolerance: What is unique about the liver.
Liver Diseases
Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells.
Liver Diseases
Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
Liver Neoplasms
A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma.
Liver Neoplasms
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-infiltrating T cells in Hepatocellular Carcinomas.
Liver Neoplasms
Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8+ T cells in liver cancer.
Liver Neoplasms
Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
Liver Neoplasms
Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Liver Neoplasms
Combination of Balsamin and Flavonoids Induce Apoptotic Effects in Liver and Breast Cancer Cells.
Liver Neoplasms
Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1? and STAT3 (T705) signaling pathways in hepatic cancer.
Liver Neoplasms
Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.
Liver Neoplasms
Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma.
Liver Neoplasms
Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma.
Liver Neoplasms
Inhibition of c-MET upregulates PD-L1 expression in lung adenocarcinoma.
Liver Neoplasms
JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Liver Neoplasms
Modification of ricin and its hepatotoxicity and activity against hepatocellular cancer in mice.
Liver Neoplasms
MYC-Mediated Translation of PD-L1 Promotes Liver Cancer Immune Escape.
Liver Neoplasms
Natural triterpenoid saponin Momordin Ic suppresses HepG2 cell invasion via COX-2 inhibition and PPAR? activation.
Liver Neoplasms
Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
Liver Neoplasms
Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects.
Liver Neoplasms
RIP-1/c-FLIPL Induce Hepatic Cancer Cell Apoptosis Through Regulating Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).
Liver Neoplasms
Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape.
Liver Neoplasms
Role of Matrix Metallopeptidase 12 in the Development of Hepatocellular Carcinoma.
Liver Neoplasms
Serum alpha-fetoprotein subfractions identified by Ricinus communis agglutinin I in hepatic malignancies, yolk sac tumor, benign hepatic diseases, and fetal stage.
Liver Neoplasms
Suppression of hepatoma tumor growth by systemic administration of the phytotoxin gelonin driven by the survivin promoter.
Liver Neoplasms
Suppressive effects of Momordin Ic on HepG2 cell migration and invasion by regulating MMP-9 and adhesion molecules: Involvement of p38 and JNK pathways.
Liver Neoplasms
Synergistic anti-liver cancer effects of curcumin and total ginsenosides.
Liver Neoplasms
Targeted PD-L1 PLGA/liposomes-mediated luteolin therapy for effective liver cancer cell treatment.
Liver Neoplasms
The Immunostimulative Effect and Mechanisms of a Novel Mouse Anti-Human PD-1 Monoclonal Antibody on Jurkat Lymphocytic Cells Cocultured with Hepatoma Cells.
Liver Neoplasms
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.
Liver Neoplasms
[A study of ricinus communis agglutinin I receptors in liver cancer tissues]
Lung Abscess
Lung abscess following bronchoscopy due to multidrug-resistant Capnocytophaga sputigena adjacent to lung cancer with high PD-L1 expression.
Lung Diseases
Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer.
Lung Diseases
Microbiological, biological, and chemical weapons of warfare and terrorism.
Lung Diseases
Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice.
Lung Diseases
Proinflammatory responses of human airway cells to ricin involve stress-activated protein kinases and NF-kappaB.
Lung Diseases, Interstitial
Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling.
Lung Diseases, Interstitial
Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ?50% on first-line pembrolizumab.
Lung Diseases, Interstitial
[Drug-induced interstitial pneumonitis due to avelumab: A case report].
Lung Diseases, Obstructive
PD-L1 inhibitor-induced worsening of eosinophilic obstructive lung disease successfully rescued with anti-interleukin 5 receptor (IL-5R) therapy.
Lung Injury
Aerosolized specific antibody protects mice from lung injury associated with aerosolized ricin exposure.
Lung Injury
Correction: COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
Lung Injury
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
Lung Injury
Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72.
Lung Injury
Necrostatin-1 attenuates lipopolysaccharide-induced acute lung injury in mice.
Lung Injury
Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease.
Lung Injury
Programmed cell death receptor ligand 1 modulates the regulatory T cells' capacity to repress shock/sepsis-induced indirect acute lung injury by recruiting phosphatase SRC homology region 2 domain-containing phosphatase 1.
Lung Injury
Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental animal model of sepsis.
Lung Injury
Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis.
Lung Neoplasms
155P: PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Lung Neoplasms
18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer.
Lung Neoplasms
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Lung Neoplasms
18F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer.
Lung Neoplasms
6P Expression of PD-L1 in lung cancer cells regulates Treg cell differentiation.
Lung Neoplasms
A Case Series of Two Patients Presenting With Pericardial Effusion as First Manifestation of Non-Small Cell Lung Cancer With BRAF Mutation and Expression Of PD-L1.
Lung Neoplasms
A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers.
Lung Neoplasms
A comparability study of natural and deglycosylated PD-L1 levels in lung cancer: evidence from immunohistochemical analysis.
Lung Neoplasms
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
Lung Neoplasms
A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients.
Lung Neoplasms
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland.
Lung Neoplasms
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland.
Lung Neoplasms
A defucosylated anti-PD-L1 monoclonal antibody 13-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Lung Neoplasms
A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Lung Neoplasms
A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Lung Neoplasms
A novel bifunctional anti-PD-L1/TGF-? Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.
Lung Neoplasms
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Lung Neoplasms
A phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer.
Lung Neoplasms
A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker.
Lung Neoplasms
A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer.
Lung Neoplasms
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Lung Neoplasms
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Lung Neoplasms
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.
Lung Neoplasms
A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
Lung Neoplasms
A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Lung Neoplasms
A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project.
Lung Neoplasms
A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Lung Neoplasms
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.
Lung Neoplasms
A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.
Lung Neoplasms
A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
Lung Neoplasms
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFN? signaling in non-small cell lung cancer.
Lung Neoplasms
Accurate PD-L1 Protocols for Non-Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3.
Lung Neoplasms
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Lung Neoplasms
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Lung Neoplasms
Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell-block specimens.
Lung Neoplasms
Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence.
Lung Neoplasms
Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.
Lung Neoplasms
Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy.
Lung Neoplasms
Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors: A protocol for systematic review and meta-analysis.
Lung Neoplasms
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cut-Offs in Non-Small Cell Lung Cancer.
Lung Neoplasms
AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells.
Lung Neoplasms
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution.
Lung Neoplasms
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Lung Neoplasms
Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
Lung Neoplasms
Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.
Lung Neoplasms
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Lung Neoplasms
An anti-mucin immunotoxin BrE-3-ricin A-chain is potently and selectively toxic to human small-cell lung cancer.
Lung Neoplasms
An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
Lung Neoplasms
An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lung Neoplasms
Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review.
Lung Neoplasms
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.
Lung Neoplasms
Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management.
Lung Neoplasms
Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents.
Lung Neoplasms
Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials.
Lung Neoplasms
Anti-PD1 versus anti-PD-L1 immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis.
Lung Neoplasms
Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer.
Lung Neoplasms
Arsenic sulfide reverses cisplatin resistance in non-small cell lung cancer in vitro and in vivo through targeting PD-L1.
Lung Neoplasms
Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
Lung Neoplasms
Aspirin-targeted PD-L1 in lung cancer growth inhibition.
Lung Neoplasms
Assays for predicting and monitoring responses to lung cancer immunotherapy.
Lung Neoplasms
Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Lung Neoplasms
Assessing PD-L1 Expression Level by Radiomic Features From PET/CT in Nonsmall Cell Lung Cancer Patients: An Initial Result.
Lung Neoplasms
Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Lung Neoplasms
Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.
Lung Neoplasms
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
Lung Neoplasms
Assessment of programmed cell death ligand-1 expression with multiple immunohistochemistry antibody clones in non-small cell lung cancer.
Lung Neoplasms
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
Lung Neoplasms
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.
Lung Neoplasms
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Lung Neoplasms
Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
Lung Neoplasms
Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis.
Lung Neoplasms
Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications.
Lung Neoplasms
Association Between PD-L1 Expression and Metabolic Activity on
Lung Neoplasms
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Lung Neoplasms
Association between single nucleotide polymorphism of PD-L1 gene and non-small cell lung cancer susceptibility in a Chinese population.
Lung Neoplasms
Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Lung Neoplasms
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
Lung Neoplasms
Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
Lung Neoplasms
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Lung Neoplasms
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy.
Lung Neoplasms
Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.
Lung Neoplasms
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation.
Lung Neoplasms
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Lung Neoplasms
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lung Neoplasms
Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.
Lung Neoplasms
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Lung Neoplasms
Atypical patterns of response and progression in the era of immunotherapy combinations.
Lung Neoplasms
Augmentation of antiproliferative and antitumor effect on human cancer cells in combined use of electroporation with a plant toxin, saporin.
Lung Neoplasms
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Lung Neoplasms
Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software.
Lung Neoplasms
Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.
Lung Neoplasms
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Lung Neoplasms
Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?
Lung Neoplasms
B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Lung Neoplasms
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation.
Lung Neoplasms
Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Lung Neoplasms
Beyond PD-L1 Markers for Lung Cancer Immunotherapy.
Lung Neoplasms
Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.
Lung Neoplasms
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial.
Lung Neoplasms
Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells.
Lung Neoplasms
Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer.
Lung Neoplasms
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Lung Neoplasms
Biomarkers in immunotherapy: literature review and future directions.
Lung Neoplasms
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
Lung Neoplasms
Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
Lung Neoplasms
Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
Lung Neoplasms
Blockade of PD-1 decreases neutrophilic inflammation and lung damage in experimental COPD.
Lung Neoplasms
Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors.
Lung Neoplasms
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Lung Neoplasms
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Lung Neoplasms
Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers.
Lung Neoplasms
Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Lung Neoplasms
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Lung Neoplasms
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms.
Lung Neoplasms
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lung Neoplasms
CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.
Lung Neoplasms
Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
Lung Neoplasms
CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-?.
Lung Neoplasms
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Lung Neoplasms
CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
Lung Neoplasms
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
Lung Neoplasms
Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer.
Lung Neoplasms
Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer.
Lung Neoplasms
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.
Lung Neoplasms
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Lung Neoplasms
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
Lung Neoplasms
Challenges of PD-L1 testing in non-small cell lung cancer and beyond.
Lung Neoplasms
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
Lung Neoplasms
Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors.
Lung Neoplasms
Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer.
Lung Neoplasms
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Lung Neoplasms
Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
Lung Neoplasms
Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis.
Lung Neoplasms
Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.
Lung Neoplasms
Characterization of PD-L1 protein expression and CD8+ tumor-infiltrating lymphocyte density, and their associations with clinical outcome in small-cell lung cancer.
Lung Neoplasms
Characterization of the immune microenvironment in brain metastases from different solid tumors.
Lung Neoplasms
Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images.
Lung Neoplasms
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Lung Neoplasms
Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-? induced epithelial mesenchymal transition in non-small cell lung cancer.
Lung Neoplasms
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Lung Neoplasms
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Lung Neoplasms
Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1.
Lung Neoplasms
Circular RNA circ_0000284 plays an oncogenic role in the progression of non-small cell lung cancer through the miR-377-3p-mediated PD-L1 promotion.
Lung Neoplasms
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Lung Neoplasms
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Lung Neoplasms
Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics.
Lung Neoplasms
Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
Lung Neoplasms
Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study.
Lung Neoplasms
Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Lung Neoplasms
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.
Lung Neoplasms
Class A CpG oligodeoxynucleotide inhibits IFN-?-induced signaling and apoptosis in lung cancer.
Lung Neoplasms
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ?50.
Lung Neoplasms
Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
Lung Neoplasms
Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis.
Lung Neoplasms
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Lung Neoplasms
Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression.
Lung Neoplasms
Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer.
Lung Neoplasms
Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer.
Lung Neoplasms
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients.
Lung Neoplasms
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Lung Neoplasms
Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
Lung Neoplasms
Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer.
Lung Neoplasms
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Lung Neoplasms
Clinical significance of ? 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Lung Neoplasms
Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
Lung Neoplasms
Clinical significance of PD-L1 expression in patients with surgically resected non-small cell lung cancer.
Lung Neoplasms
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Lung Neoplasms
Clinical significance of PD?L1 and PD?L2 copy number gains in non?small?cell lung cancer.
Lung Neoplasms
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.
Lung Neoplasms
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.
Lung Neoplasms
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ??50%.
Lung Neoplasms
Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
Lung Neoplasms
Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Lung Neoplasms
Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer.
Lung Neoplasms
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
Lung Neoplasms
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Lung Neoplasms
Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
Lung Neoplasms
Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
Lung Neoplasms
CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Lung Neoplasms
CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
Lung Neoplasms
Co-expression of PD-L1 and HIF-1? predicts poor prognosis in Patients with Non-small Cell Lung Cancer after surgery.
Lung Neoplasms
Cochinin B, a novel ribosome-inactivating protein from the seeds of Momordica cochinchinensis.
Lung Neoplasms
Combination of Local Ablative Therapy and Continuation of Immune Checkpoint Inhibitor (ICI) Therapy Provides Durable Treatment Response Past Oligometastatic Progression in NSCLC: A Case Report.
Lung Neoplasms
Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Lung Neoplasms
Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
Lung Neoplasms
Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy.
Lung Neoplasms
Combined Methylome and Transcriptome Analyses Reveals Potential Therapeutic Targets for EGFR Wild Type Lung Cancers with Low PD-L1 Expression.
Lung Neoplasms
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
Lung Neoplasms
Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
Lung Neoplasms
Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ?50% treated with front-line pembrolizumab'.
Lung Neoplasms
Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Lung Neoplasms
Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
Lung Neoplasms
Comparability of PD-L1 immunohistochemistry assays for non-small cell lung cancer: a systematic review.
Lung Neoplasms
Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer.
Lung Neoplasms
Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer.
Lung Neoplasms
Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients.
Lung Neoplasms
Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer.
Lung Neoplasms
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
Lung Neoplasms
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
Lung Neoplasms
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Lung Neoplasms
Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Lung Neoplasms
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer.
Lung Neoplasms
Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
Lung Neoplasms
Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.
Lung Neoplasms
Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
Lung Neoplasms
Comparison of PD-L1 immunohistochemistry assays and response to PD-1/L1 inhibitors in advanced non-small cell lung cancer in clinical practice.
Lung Neoplasms
Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.
Lung Neoplasms
Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer.
Lung Neoplasms
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Lung Neoplasms
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Lung Neoplasms
Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer.
Lung Neoplasms
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.
Lung Neoplasms
Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Lung Neoplasms
Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
Lung Neoplasms
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Lung Neoplasms
Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer.
Lung Neoplasms
Concordance of PD-L1 Expression Detection in Non-Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC).
Lung Neoplasms
Concordance of PD-L1 Status Between Image-Guided Percutaneous Biopsies and Matched Surgical Specimen in Non-Small Cell Lung Cancer.
Lung Neoplasms
Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA
Lung Neoplasms
Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer.
Lung Neoplasms
Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients.
Lung Neoplasms
Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.
Lung Neoplasms
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Lung Neoplasms
Correction of acknowledgments: PD-L1 testing in non-small cell lung cancer: past, present, and future.
Lung Neoplasms
Correction to: High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.
Lung Neoplasms
Correction: PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Lung Neoplasms
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ?50% Expression in Lung Adenocarcinoma.
Lung Neoplasms
Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort.
Lung Neoplasms
Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver.
Lung Neoplasms
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.
Lung Neoplasms
Correlation of
Lung Neoplasms
Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma.
Lung Neoplasms
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
Lung Neoplasms
Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
Lung Neoplasms
Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
Lung Neoplasms
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
Lung Neoplasms
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
Lung Neoplasms
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
Lung Neoplasms
Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Lung Neoplasms
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA.
Lung Neoplasms
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
Lung Neoplasms
Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels.
Lung Neoplasms
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy.
Lung Neoplasms
CT-Based Hand-crafted Radiomic Signatures Can Predict PD-L1 Expression Levels in Non-small Cell Lung Cancer: a Two-Center Study.
Lung Neoplasms
CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays.
Lung Neoplasms
Current PD-L1 immunohistochemistry for non-small cell lung cancer.
Lung Neoplasms
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
Lung Neoplasms
Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years.
Lung Neoplasms
CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Lung Neoplasms
Cytokine and epigenetic regulation of programmed death-ligand 1 in stem cell differentiation and cancer cell plasticity.
Lung Neoplasms
Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer.
Lung Neoplasms
Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
Lung Neoplasms
Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.
Lung Neoplasms
Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer.
Lung Neoplasms
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Lung Neoplasms
Design of PD-L1 inhibitors for lung cancer.
Lung Neoplasms
Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
Lung Neoplasms
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Lung Neoplasms
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
Lung Neoplasms
Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Lung Neoplasms
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Lung Neoplasms
Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1.
Lung Neoplasms
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Lung Neoplasms
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Lung Neoplasms
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
Lung Neoplasms
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
Lung Neoplasms
Diagnostic test accuracy of 18F-FDG PET/CT for prediction of programmed death ligand 1 (PD-L1) expression in solid tumours: a meta-analysis.
Lung Neoplasms
Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials.
Lung Neoplasms
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.
Lung Neoplasms
Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
Lung Neoplasms
Differential Expression of PD-L1 in Central and Peripheral and TTF1-Positive and -Negative Small-Cell Lung Cancer.
Lung Neoplasms
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.
Lung Neoplasms
Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Lung Neoplasms
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression.
Lung Neoplasms
Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27kip1 /CDK4 axis in non-small cell lung cancer.
Lung Neoplasms
Downregulation of NKG2DLs by TGF-? in human lung cancer cells.
Lung Neoplasms
Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report.
Lung Neoplasms
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.
Lung Neoplasms
Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
Lung Neoplasms
Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer.
Lung Neoplasms
Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Lung Neoplasms
Durvalumab Lengthens Survival in Extensive-Stage SCLC.
Lung Neoplasms
Durvalumab Promising for NSCLC.
Lung Neoplasms
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
Lung Neoplasms
Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
Lung Neoplasms
E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Lung Neoplasms
Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features.
Lung Neoplasms
EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Lung Neoplasms
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
Lung Neoplasms
eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA.
Lung Neoplasms
Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
Lung Neoplasms
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.
Lung Neoplasms
Effects of different levels of soluble PD-L1 protein on the growth of Lewis lung cancer transplanted tumor.
Lung Neoplasms
Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer.
Lung Neoplasms
Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Lung Neoplasms
Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
Lung Neoplasms
Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001).
Lung Neoplasms
Efficacy of atezolizumab to treat non-small-cell lung cancer: a meta-analysis based on randomized clinical trials.
Lung Neoplasms
Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Lung Neoplasms
Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Lung Neoplasms
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Lung Neoplasms
Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression ?50.
Lung Neoplasms
Efficiency of Cytology Samples for PD-L1 Evaluation and Comparison with Tissue Samples.
Lung Neoplasms
EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative.
Lung Neoplasms
EGFR mutation status in non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and its correlation with PD-L1 expression: a meta-analysis.
Lung Neoplasms
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Lung Neoplasms
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.
Lung Neoplasms
Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
Lung Neoplasms
Eliminating Radiation Resistance of Non-Small Cell Lung Cancer by Dihydroartemisinin Through Abrogating Immunity Escaping and Promoting Radiation Sensitivity by Inhibiting PD-L1 Expression.
Lung Neoplasms
Elucidation of S-Allylcysteine Role in Inducing Apoptosis by Inhibiting PD-L1 Expression in Human Lung Cancer Cells.
Lung Neoplasms
Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Lung Neoplasms
Emergence of lung cancer with a low PD-L1 expression level after the administration of immune check point inhibitor for lung adenocarcinoma with a high PD-L1 expression level: A case report.
Lung Neoplasms
Emerging Immunotherapies in the Treatment of Non-Small Cell Lung Cancer (NSCLC): The Role of Immune Checkpoint Inhibitors.
Lung Neoplasms
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1? and STAT3.
Lung Neoplasms
Endobronchial ultrasound in diagnosing and staging of lung cancer by Acquire 22G TBNB versus regular 22G TBNA needles: study protocol of a randomised clinical trial.
Lung Neoplasms
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.
Lung Neoplasms
Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report.
Lung Neoplasms
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Lung Neoplasms
Erratum to the importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy.
Lung Neoplasms
Essential preanalytics in PD-L1 immunocytochemistry.
Lung Neoplasms
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
Lung Neoplasms
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.
Lung Neoplasms
Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis.
Lung Neoplasms
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
Lung Neoplasms
Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor.
Lung Neoplasms
Exploring a Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells.
Lung Neoplasms
Expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer.
Lung Neoplasms
Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Lung Neoplasms
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Lung Neoplasms
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Lung Neoplasms
Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer.
Lung Neoplasms
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.
Lung Neoplasms
Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung.
Lung Neoplasms
Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer.
Lung Neoplasms
Expression of PD-L1, cancer stem cell and epithelial-mesenchymal transition phenotype in non-small cell lung cancer.
Lung Neoplasms
Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay.
Lung Neoplasms
Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling.
Lung Neoplasms
Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.
Lung Neoplasms
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
Lung Neoplasms
Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.
Lung Neoplasms
External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different.
Lung Neoplasms
Extracellular vesicles derived from lung cancer cells exposed to intermittent hypoxia upregulate programmed death ligand 1 expression in macrophages.
Lung Neoplasms
EZH2 regulates PD-L1 expression via HIF-1? in non-small cell lung cancer cells.
Lung Neoplasms
Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study.
Lung Neoplasms
Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
Lung Neoplasms
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Lung Neoplasms
Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer.
Lung Neoplasms
First Anti-PD-L1 Drug Approved for NSCLC.
Lung Neoplasms
First-Line Atezolizumab OK'd for SCLC.
Lung Neoplasms
First-line immune checkpoint blockade for advanced non-small-cell lung cancer: Travelling at the speed of light.
Lung Neoplasms
First-line immune checkpoint therapy in metastatic squamous cell lung cancer harboring both EGFR mutation and high expression of PD-L1: A case report.
Lung Neoplasms
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ?50% in a multicenter real-life cohort: The PEMBREIZH study.
Lung Neoplasms
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Lung Neoplasms
First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective.
Lung Neoplasms
First-Line Pembrolizumab Versus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-024 Japan Subset.
Lung Neoplasms
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ?50.
Lung Neoplasms
Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1.
Lung Neoplasms
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ? 50.
Lung Neoplasms
FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells.
Lung Neoplasms
Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.
Lung Neoplasms
Gastrointestinal tract metastasis of lung cancer: The PD-L1 expression and correlated clinicopathological variables.
Lung Neoplasms
Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Lung Neoplasms
Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.
Lung Neoplasms
Genetic variants as predictors of toxicity and response in patients with non-small cell lung cancer undergoing first-line platinum-based chemotherapy: Design of the multicenter PGxLUNG study.
Lung Neoplasms
Genomic amplification of CD274 (PD-L1) in small cell lung cancer.
Lung Neoplasms
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Lung Neoplasms
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
Lung Neoplasms
Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.
Lung Neoplasms
Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
Lung Neoplasms
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report.
Lung Neoplasms
Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
Lung Neoplasms
Harmonization across programmed death ligand 1 (PD-L1) assays for lung cancer by immunohistochemistry using noncontact alternating current electric field mixing.
Lung Neoplasms
Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1.
Lung Neoplasms
Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress.
Lung Neoplasms
Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.
Lung Neoplasms
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.
Lung Neoplasms
Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Lung Neoplasms
Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.
Lung Neoplasms
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma.
Lung Neoplasms
Heterogeneity of PD-L1 Expression in Lung Mixed Adenocarcinomas and Adenosquamous Carcinomas.
Lung Neoplasms
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Lung Neoplasms
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer.
Lung Neoplasms
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.
Lung Neoplasms
Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Lung Neoplasms
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
Lung Neoplasms
High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.
Lung Neoplasms
High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Lung Neoplasms
High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy.
Lung Neoplasms
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Lung Neoplasms
High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer.
Lung Neoplasms
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.
Lung Neoplasms
High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-?B signaling pathway in non-small cell lung cancer cells.
Lung Neoplasms
Higher PD-L1 expression correlates with lymphocyte infiltration in early non-small cell lung cancer.
Lung Neoplasms
Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
Lung Neoplasms
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lung Neoplasms
Histology versus cytology: PD-L1 testing in non-small cell lung cancer.
Lung Neoplasms
HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.
Lung Neoplasms
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Lung Neoplasms
Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer.
Lung Neoplasms
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
Lung Neoplasms
Hypoxia-inducible factor-1? and nuclear factor-?B play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Lung Neoplasms
HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila.
Lung Neoplasms
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.
Lung Neoplasms
Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.
Lung Neoplasms
Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry.
Lung Neoplasms
IFN-?-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Lung Neoplasms
IL-27 induces the expression of IDO and PD-L1 in human cancer cells.
Lung Neoplasms
Imaging of PD-L1 in single cancer cells by SERS-based hyperspectral analysis.
Lung Neoplasms
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1.
Lung Neoplasms
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Lung Neoplasms
Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.
Lung Neoplasms
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
Lung Neoplasms
Immune checkpoint inhibitors in lung cancer: past, present and future.
Lung Neoplasms
Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.
Lung Neoplasms
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
Lung Neoplasms
Immune checkpoints and their inhibition in cancer and infectious diseases.
Lung Neoplasms
Immune checkpoints: A therapeutic target in triple negative breast cancer.
Lung Neoplasms
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.
Lung Neoplasms
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer.
Lung Neoplasms
Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for nonsmall cell lung cancer: Protocol for a systematic review and meta-analysis.
Lung Neoplasms
Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Lung Neoplasms
Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.
Lung Neoplasms
Immunocytochemistry for predictive biomarker testing in lung cancer cytology.
Lung Neoplasms
Immunohistochemical expression of PD-L1 in early and late stage non-small cell lung cancer: Correlation with clinicopathological and molecular features.
Lung Neoplasms
Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Lung Neoplasms
Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities.
Lung Neoplasms
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Lung Neoplasms
Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer.
Lung Neoplasms
Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
Lung Neoplasms
Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer.
Lung Neoplasms
Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma.
Lung Neoplasms
Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.
Lung Neoplasms
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Lung Neoplasms
Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer.
Lung Neoplasms
Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Lung Neoplasms
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials.
Lung Neoplasms
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ?50% treated with front-line pembrolizumab.
Lung Neoplasms
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study).
Lung Neoplasms
Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines.
Lung Neoplasms
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Lung Neoplasms
Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.
Lung Neoplasms
Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Lung Neoplasms
Implementation of PD-L1 analysis among patients with non-small cell lung cancer in a single center.
Lung Neoplasms
Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Lung Neoplasms
Improving our knowledge in PD-L1 testing in lung cancer: the archival sample is 'promoted'!
Lung Neoplasms
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
Lung Neoplasms
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.
Lung Neoplasms
Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
Lung Neoplasms
Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation.
Lung Neoplasms
Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients.
Lung Neoplasms
Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.
Lung Neoplasms
Increased PD-L1 expression in erlotinib-resistant NSCLC cells with
Lung Neoplasms
Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer.
Lung Neoplasms
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Lung Neoplasms
Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients.
Lung Neoplasms
Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
Lung Neoplasms
Inference on covariate effect types for treatment effectiveness in a randomized trial with a binary outcome.
Lung Neoplasms
Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Lung Neoplasms
Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
Lung Neoplasms
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Lung Neoplasms
Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Lung Neoplasms
Inhibition of GFAT1 in lung cancer cells destabilizes PD-L1 protein.
Lung Neoplasms
iNOS Expression by Tumor-Infiltrating Lymphocytes, PD-L1 and Prognosis in Non-Small-Cell Lung Cancer.
Lung Neoplasms
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Lung Neoplasms
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
Lung Neoplasms
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Lung Neoplasms
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
Lung Neoplasms
Interferon-? signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells.
Lung Neoplasms
Interlaboratory-concordance of PD-L1 immunohistochemistry for non-small cell lung cancer.
Lung Neoplasms
Interobserver Reproducibility of PD-L1 Biomarker in Non-small Cell Lung Cancer: A Multi-Institutional Study by 27 Pathologists.
Lung Neoplasms
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.
Lung Neoplasms
Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab.
Lung Neoplasms
Intrathoracic core needle biopsy and repeat biopsy for PD-L1 evaluation in non-small cell lung cancer.
Lung Neoplasms
Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.
Lung Neoplasms
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Lung Neoplasms
Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
Lung Neoplasms
JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers.
Lung Neoplasms
JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Lung Neoplasms
Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker.
Lung Neoplasms
KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.
Lung Neoplasms
KRAS G12V mutation upregulates PD-L1 expression via TGF-?/EMT signaling pathway in human non-small-cell lung cancer.
Lung Neoplasms
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Lung Neoplasms
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (?50%) lung adenocarcinoma.
Lung Neoplasms
Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
Lung Neoplasms
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression.
Lung Neoplasms
Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Lung Neoplasms
Liquid Biopsy and Lung Cancer.
Lung Neoplasms
LncRNA SOX2-OT/miR-30d-5p/PDK1 Regulates PD-L1 Checkpoint Through the mTOR Signaling Pathway to Promote Non-small Cell Lung Cancer Progression and Immune Escape.
Lung Neoplasms
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Lung Neoplasms
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
Lung Neoplasms
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Lung Neoplasms
Lung abscess following bronchoscopy due to multidrug-resistant Capnocytophaga sputigena adjacent to lung cancer with high PD-L1 expression.
Lung Neoplasms
Lung adenocarcinoma with sarcomatoid transformation after tyrosine kinase inhibitor treatment and chemotherapy.
Lung Neoplasms
Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
Lung Neoplasms
Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer.
Lung Neoplasms
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.
Lung Neoplasms
Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Lung Neoplasms
Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature.
Lung Neoplasms
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Lung Neoplasms
Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
Lung Neoplasms
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
Lung Neoplasms
MET is overexpressed in microsatellite instability-high gastric carcinoma.
Lung Neoplasms
MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function.
Lung Neoplasms
MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.
Lung Neoplasms
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
Lung Neoplasms
Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
Lung Neoplasms
MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer.
Lung Neoplasms
MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer.
Lung Neoplasms
Mifepristone Extends Both Length and Quality of Life in a Patient With Advanced Non-small Cell Lung Cancer that Has Progressed Despite Chemotherapy and a Check-point Inhibitor.
Lung Neoplasms
miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway.
Lung Neoplasms
miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1.
Lung Neoplasms
MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression.
Lung Neoplasms
Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer.
Lung Neoplasms
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
Lung Neoplasms
Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis.
Lung Neoplasms
Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.
Lung Neoplasms
Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Lung Neoplasms
Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer.
Lung Neoplasms
Molecular profiling and characteristics of non-small-cell lung cancer patients in Georgia.
Lung Neoplasms
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
Lung Neoplasms
Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
Lung Neoplasms
Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity.
Lung Neoplasms
Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer.
Lung Neoplasms
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Lung Neoplasms
MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.
Lung Neoplasms
MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer.
Lung Neoplasms
Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images.
Lung Neoplasms
Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer.
Lung Neoplasms
Multicentre study on the consistency of PD-L1 immunohistochemistry as predictive test for immunotherapy in non-small cell lung cancer.
Lung Neoplasms
Multiple lung cancers including squamous cell carcinoma with strong PD-L1 expression and adenocarcinoma with EGFR exon 19 deletion: A case report.
Lung Neoplasms
Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage.
Lung Neoplasms
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Lung Neoplasms
Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer.
Lung Neoplasms
MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
Lung Neoplasms
Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway.
Lung Neoplasms
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.
Lung Neoplasms
Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Lung Neoplasms
Nagilactone E increases PD-L1 expression through activation of c-Jun in lung cancer cells.
Lung Neoplasms
Narrative review of the emerging role of molecular biomarkers in guiding the definitive management of unresectable non-small cell lung cancer.
Lung Neoplasms
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
Lung Neoplasms
Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports.
Lung Neoplasms
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Lung Neoplasms
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Lung Neoplasms
New Dancing Couple: PD-L1 and MicroRNA.
Lung Neoplasms
New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Lung Neoplasms
NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Lung Neoplasms
NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Lung Neoplasms
Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ?50.
Lung Neoplasms
Nivolumab plus Carboplatin and Paclitaxel as the First-line Therapy for Advanced Squamous Cell Carcinoma of the Lung with Strong Programmed Death-ligand 1 Expression: A Case Report.
Lung Neoplasms
Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC.
Lung Neoplasms
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Lung Neoplasms
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.
Lung Neoplasms
Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with 89Zr-Df-Atezolizumab.
Lung Neoplasms
Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates.
Lung Neoplasms
Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
Lung Neoplasms
Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
Lung Neoplasms
Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
Lung Neoplasms
Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype.
Lung Neoplasms
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Lung Neoplasms
Oncological outcomes of addition of anti-PD1/PD-L1 to chemotherapy in the therapy of patients with advanced gastric or gastro-oesophageal junction cancer: A meta-analysis.
Lung Neoplasms
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.
Lung Neoplasms
Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
Lung Neoplasms
Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.
Lung Neoplasms
Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.
Lung Neoplasms
Optimizing PD-L1 evaluation on cytological samples from advanced non-small-cell lung cancer.
Lung Neoplasms
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ?50% who progress on first-line immunotherapy: real-world data from a European cohort.
Lung Neoplasms
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ?50%) metastatic NSCLC at US oncology practices.
Lung Neoplasms
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and very high PD-L1 expression.
Lung Neoplasms
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
Lung Neoplasms
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.
Lung Neoplasms
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice.
Lung Neoplasms
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
Lung Neoplasms
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Lung Neoplasms
Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines.
Lung Neoplasms
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis.
Lung Neoplasms
PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer.
Lung Neoplasms
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
Lung Neoplasms
PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer.
Lung Neoplasms
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
Lung Neoplasms
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
Lung Neoplasms
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Lung Neoplasms
PD-L1 ? 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination.
Lung Neoplasms
PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.
Lung Neoplasms
PD-L1 and c-MET expression and survival in patients with small cell lung cancer.
Lung Neoplasms
PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
Lung Neoplasms
PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system
Lung Neoplasms
PD-L1 and Lung Cancer: The Era of Precision-ish Medicine?
Lung Neoplasms
PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Lung Neoplasms
PD-L1 and standardized uptake value expression in lung cancer: a possible connection for efficient early lung cancer treatment.
Lung Neoplasms
PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging.
Lung Neoplasms
PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.
Lung Neoplasms
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs: An Interclone Evaluation by Differently Trained Pathologists.
Lung Neoplasms
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Lung Neoplasms
PD-L1 confers primary resistance to EGFR-TKI in EGFR mutant non-small cell lung cancer via inducing EMT phenotype.
Lung Neoplasms
PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.
Lung Neoplasms
PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy.
Lung Neoplasms
PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer.
Lung Neoplasms
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
Lung Neoplasms
PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8.
Lung Neoplasms
PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.
Lung Neoplasms
PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs.
Lung Neoplasms
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Lung Neoplasms
PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment.
Lung Neoplasms
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
Lung Neoplasms
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.
Lung Neoplasms
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Lung Neoplasms
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Lung Neoplasms
PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.
Lung Neoplasms
PD-L1 expression as a predictor of postoperative recurrence and the association between the PD-L1 expression and EGFR mutations in NSCLC.
Lung Neoplasms
PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer.
Lung Neoplasms
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
Lung Neoplasms
PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
Lung Neoplasms
PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer.
Lung Neoplasms
PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy.
Lung Neoplasms
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer.
Lung Neoplasms
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.
Lung Neoplasms
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Lung Neoplasms
PD-L1 Expression in a Non-Small Cell Lung Cancer Specimen Obtained by EBUS-TBNA.
Lung Neoplasms
PD-L1 expression in cell-blocks of non-small cell lung cancer: The impact of prolonged fixation.
Lung Neoplasms
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Lung Neoplasms
PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer.
Lung Neoplasms
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Lung Neoplasms
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
Lung Neoplasms
PD-L1 expression in human cancers and its association with clinical outcomes.
Lung Neoplasms
PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer.
Lung Neoplasms
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
Lung Neoplasms
PD-L1 Expression in Lung Cancer.
Lung Neoplasms
PD-L1 expression in lung cancer.
Lung Neoplasms
PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer.
Lung Neoplasms
PD-L1 Expression in Non Small Cell Lung Cancer and Prognosis
Lung Neoplasms
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.
Lung Neoplasms
PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain.
Lung Neoplasms
PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays.
Lung Neoplasms
PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis.
Lung Neoplasms
PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
Lung Neoplasms
PD-L1 Expression in Patients with Non-small Cell Lung Cancer.
Lung Neoplasms
PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
Lung Neoplasms
PD-L1 expression in small cell lung cancer.
Lung Neoplasms
PD-L1 Expression in Small Cell Lung Cancer.
Lung Neoplasms
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
Lung Neoplasms
PD-L1 expression in tumour buds of colorectal carcinoma.
Lung Neoplasms
PD-L1 expression is associated with advanced non-small cell lung cancer.
Lung Neoplasms
PD-L1 expression levels on tumor cells affect their immunosuppressive activity.
Lung Neoplasms
PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Lung Neoplasms
PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion.
Lung Neoplasms
PD-L1 Expression on Lung Cancer Stem Cells in Metastatic Lymph Nodes Aspirates.
Lung Neoplasms
PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.
Lung Neoplasms
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Lung Neoplasms
PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
Lung Neoplasms
PD-L1 expression testing in non-small cell lung cancer.
Lung Neoplasms
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
Lung Neoplasms
PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China.
Lung Neoplasms
PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
Lung Neoplasms
PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.
Lung Neoplasms
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Lung Neoplasms
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis.
Lung Neoplasms
PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
Lung Neoplasms
PD-L1 gene expression in Japanese lung cancer patients.
Lung Neoplasms
PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer.
Lung Neoplasms
PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study.
Lung Neoplasms
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Lung Neoplasms
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Lung Neoplasms
PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?
Lung Neoplasms
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Lung Neoplasms
PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
Lung Neoplasms
PD-L1 immunohistochemistry in patients with non-small cell lung cancer.
Lung Neoplasms
PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung Cancers.
Lung Neoplasms
PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.
Lung Neoplasms
PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
Lung Neoplasms
PD-L1 induced by IFN-? from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Lung Neoplasms
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer.
Lung Neoplasms
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Lung Neoplasms
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
Lung Neoplasms
PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
Lung Neoplasms
PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
Lung Neoplasms
PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics.
Lung Neoplasms
PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors.
Lung Neoplasms
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.
Lung Neoplasms
PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.
Lung Neoplasms
PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
Lung Neoplasms
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
Lung Neoplasms
PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.
Lung Neoplasms
PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade.
Lung Neoplasms
PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B.
Lung Neoplasms
PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer.
Lung Neoplasms
PD-L1 promotes tumor growth and progression by activating WIP and ?-catenin signaling pathways and predicts poor prognosis in lung cancer.
Lung Neoplasms
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Lung Neoplasms
PD-L1 protein expression in non-small cell lung cancer based on different immunohistochemical antibodies.
Lung Neoplasms
PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
Lung Neoplasms
PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
Lung Neoplasms
PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
Lung Neoplasms
PD-L1 regulation by SDH5 via ?-catenin/ZEB1 signaling.
Lung Neoplasms
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Lung Neoplasms
PD-L1 Status and Survival in Patients With Lung Cancer.
Lung Neoplasms
PD-L1 Testing and Lack of Benefit to Guide Treatment With Immune Checkpoint Inhibitors in Patients With Non-Small-Cell Lung Cancer.
Lung Neoplasms
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.
Lung Neoplasms
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
Lung Neoplasms
PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.
Lung Neoplasms
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.
Lung Neoplasms
PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth".
Lung Neoplasms
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future.
Lung Neoplasms
PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
Lung Neoplasms
PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
Lung Neoplasms
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
Lung Neoplasms
PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
Lung Neoplasms
Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics.
Lung Neoplasms
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression.
Lung Neoplasms
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ?50%: real-world data.
Lung Neoplasms
Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (? 50%) NSCLC: Real-world Results with Special Focus on PS ? 2, Brain Metastases, and Steroids.
Lung Neoplasms
Pembrolizumab for the treatment of non-small cell lung cancer.
Lung Neoplasms
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Lung Neoplasms
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.
Lung Neoplasms
Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?
Lung Neoplasms
Pembrolizumab in lung cancer: current evidence and future perspectives.
Lung Neoplasms
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Lung Neoplasms
Pembrolizumab Monotherapy for NSCLC Extends Survival.
Lung Neoplasms
Pembrolizumab monotherapy for PD-L1 ?50% non-small cell lung cancer, undisputed first choice?
Lung Neoplasms
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Lung Neoplasms
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ? 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
Lung Neoplasms
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Lung Neoplasms
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Lung Neoplasms
Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report.
Lung Neoplasms
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
Lung Neoplasms
Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effects.
Lung Neoplasms
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Lung Neoplasms
Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer.
Lung Neoplasms
Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells.
Lung Neoplasms
Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.
Lung Neoplasms
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small cell lung cancer with a PD-L1 expression level of???1% by the U.S. Food and Drug Administration.
Lung Neoplasms
Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Lung Neoplasms
Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin.
Lung Neoplasms
Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule.
Lung Neoplasms
POU2F1 induces the immune escape in lung cancer by up-regulating PD-L1.
Lung Neoplasms
Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ?50% on first-line pembrolizumab.
Lung Neoplasms
Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).
Lung Neoplasms
Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Lung Neoplasms
Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
Lung Neoplasms
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
Lung Neoplasms
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Lung Neoplasms
Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Lung Neoplasms
Predictive markers in lung cancer: a few hints for the practicing pathologist.
Lung Neoplasms
Predictive potential and need for standardization of PD-L1 immunohistochemistry.
Lung Neoplasms
Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Lung Neoplasms
Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
Lung Neoplasms
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.
Lung Neoplasms
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Lung Neoplasms
Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis.
Lung Neoplasms
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Lung Neoplasms
Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis.
Lung Neoplasms
Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Lung Neoplasms
Preparation of Programmed Cell Death-Ligand 1 Antibody Nanoparticles Based on Nude Mouse Model and Its Therapeutic Effect on Lung Cancer.
Lung Neoplasms
Preparation of Programmed Death-Ligand 1 Antibody Nanoparticles and Their Lung Cancer Targeting Therapeutic Effects.
Lung Neoplasms
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Lung Neoplasms
Pretreatment lung immune prognostic index as a biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab.
Lung Neoplasms
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
Lung Neoplasms
Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.
Lung Neoplasms
Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance.
Lung Neoplasms
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Lung Neoplasms
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Lung Neoplasms
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.
Lung Neoplasms
Prognostic and predictive role of the tumor immune landscape.
Lung Neoplasms
Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience.
Lung Neoplasms
Prognostic Impact of PD-L2 Expression and Association with PD-L1 in Patients with Small-cell Lung Cancer.
Lung Neoplasms
Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer.
Lung Neoplasms
Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
Lung Neoplasms
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer.
Lung Neoplasms
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
Lung Neoplasms
Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Lung Neoplasms
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
Lung Neoplasms
Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1.
Lung Neoplasms
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours.
Lung Neoplasms
Prognostic value of PD-L1 expression in patients with unresectable stage III non-small cell lung cancer treated with chemoradiotherapy.
Lung Neoplasms
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Lung Neoplasms
Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
Lung Neoplasms
Prognostic value of programmed cell death ligand-1 expression in the tumor-infiltrating immune cells of patients with lung cancer: A meta-analysis.
Lung Neoplasms
Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
Lung Neoplasms
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer.
Lung Neoplasms
Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines.
Lung Neoplasms
Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Lung Neoplasms
Programmed death ligand 1 expression in EBUS aspirates of non-small cell lung cancer: Is interpretation affected by type of fixation?
Lung Neoplasms
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.
Lung Neoplasms
Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer.
Lung Neoplasms
Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.
Lung Neoplasms
Programmed death ligand-1 expression in non-small cell lung cancer.
Lung Neoplasms
Programmed Death Ligand-1 Immunohistochemistry- A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Lung Neoplasms
Programmed death-ligand 1 expression according to epidermal growth factor receptor mutation status in pretreated non-small cell lung cancer.
Lung Neoplasms
Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer.
Lung Neoplasms
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.
Lung Neoplasms
Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
Lung Neoplasms
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
Lung Neoplasms
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Lung Neoplasms
Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
Lung Neoplasms
Promising predictors of checkpoint inhibitor response in NSCLC.
Lung Neoplasms
Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer.
Lung Neoplasms
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
Lung Neoplasms
Prostasin regulates PD-L1 expression in human lung cancer cells.
Lung Neoplasms
Pulmonary Aerosol Delivery of Let-7b microRNA Confers a Striking Inhibitory Effect on Lung Carcinogenesis through Targeting the Tumor Immune Microenvironment.
Lung Neoplasms
Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.
Lung Neoplasms
Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
Lung Neoplasms
Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
Lung Neoplasms
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
Lung Neoplasms
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
Lung Neoplasms
Radiation and immunotherapy: emerging mechanisms of synergy.
Lung Neoplasms
Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
Lung Neoplasms
Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Lung Neoplasms
RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
Lung Neoplasms
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
Lung Neoplasms
Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
Lung Neoplasms
Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
Lung Neoplasms
Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression.
Lung Neoplasms
Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
Lung Neoplasms
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
Lung Neoplasms
Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
Lung Neoplasms
Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel.
Lung Neoplasms
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.
Lung Neoplasms
Regulation of PD-L1 expression by matrix stiffness in lung cancer cells.
Lung Neoplasms
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Lung Neoplasms
Relationship Between Programmed Death-ligand 1 and Clinicopathological Characteristics in Non-small Cell Lung Cancer Patients.
Lung Neoplasms
Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer.
Lung Neoplasms
Relationship Between Tumor Immune Markers and Fluorine-18-?-Methyltyrosine ([18F]FAMT) Uptake in Patients with Lung Cancer.
Lung Neoplasms
Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer.
Lung Neoplasms
Reliability of PD-L1 assays using small tissue samples compared with surgical specimens.
Lung Neoplasms
Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
Lung Neoplasms
Research progress in immune checkpoint inhibitors for lung cancer in China.
Lung Neoplasms
Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression.
Lung Neoplasms
Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells.
Lung Neoplasms
Retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients.
Lung Neoplasms
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Lung Neoplasms
Role of immune-checkpoint inhibitors in lung cancer.
Lung Neoplasms
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.
Lung Neoplasms
Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
Lung Neoplasms
ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1-SHP2 Signaling Pathway in Non-Small Cell Lung Cancer.
Lung Neoplasms
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
Lung Neoplasms
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Lung Neoplasms
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Lung Neoplasms
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1).
Lung Neoplasms
Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors.
Lung Neoplasms
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
Lung Neoplasms
Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.
Lung Neoplasms
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
Lung Neoplasms
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.
Lung Neoplasms
Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy.
Lung Neoplasms
Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
Lung Neoplasms
Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy.
Lung Neoplasms
Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.
Lung Neoplasms
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials.
Lung Neoplasms
SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer.
Lung Neoplasms
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
Lung Neoplasms
Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Lung Neoplasms
Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.
Lung Neoplasms
Simultaneous inhibition of CXCR1/2, TGF-?, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
Lung Neoplasms
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations.
Lung Neoplasms
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Lung Neoplasms
Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer.
Lung Neoplasms
Squamous NSCLC Improves with Atezolizumab Plus Chemo.
Lung Neoplasms
Study: Atezolizumab Improves Survival in SCLC.
Lung Neoplasms
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Lung Neoplasms
Successful immune checkpoint inhibition in an EGFR-mutant lung cancer patient refractory to epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Lung Neoplasms
Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression.
Lung Neoplasms
Successful treatment with nivolumab for lung cancer with low expression of PD-L1 and prominent tumor-infiltrating B cells and immunoglobulin G.
Lung Neoplasms
Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study.
Lung Neoplasms
Suppression of STING associated with LKB1 loss in KRAS-driven lung cancer.
Lung Neoplasms
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Lung Neoplasms
Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Lung Neoplasms
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Lung Neoplasms
Targeted theranostics of lung cancer: PD-L1-guided delivery of gold nanoprisms with chlorin e6 for enhanced imaging and photothermal/ photodynamic therapy.
Lung Neoplasms
Targeting PD-L1 for non-small-cell lung cancer.
Lung Neoplasms
Targeting PD-L1 in non-small cell lung cancer using CAR T cells.
Lung Neoplasms
Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
Lung Neoplasms
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
Lung Neoplasms
Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer.
Lung Neoplasms
The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.
Lung Neoplasms
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
Lung Neoplasms
The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer.
Lung Neoplasms
The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials.
Lung Neoplasms
The association of PD-L1 gene polymorphisms with non-small-cell lung cancer susceptibility and clinical outcomes in a Chinese population.
Lung Neoplasms
The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer.
Lung Neoplasms
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer.
Lung Neoplasms
The clinical significance of soluble PD-1 and PD-L1 in lung cancer.
Lung Neoplasms
The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Lung Neoplasms
The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.
Lung Neoplasms
The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.
Lung Neoplasms
The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lung Neoplasms
The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study.
Lung Neoplasms
The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis.
Lung Neoplasms
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Lung Neoplasms
The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
Lung Neoplasms
The effect of PD-L1 status on survival outcomes in patients with stage II-III non-small cell lung cancer treated with chemotherapy.
Lung Neoplasms
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Lung Neoplasms
The efficacy and safety of anti-PD-1/PD-L1 antibody therapy versus docetaxel for pretreated advanced NSCLC: a meta-analysis.
Lung Neoplasms
The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.
Lung Neoplasms
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Lung Neoplasms
The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
Lung Neoplasms
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Lung Neoplasms
The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
Lung Neoplasms
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.
Lung Neoplasms
The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy.
Lung Neoplasms
The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells.
Lung Neoplasms
The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC.
Lung Neoplasms
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Lung Neoplasms
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ? 50% advanced non-small-cell lung cancer.
Lung Neoplasms
The mechanism of ABL1 upregulating the expression of PD-L1 and the therapeutic effect of PD-L1 and STAT3 inhibitors in lung adenocarcinoma.
Lung Neoplasms
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Lung Neoplasms
The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
Lung Neoplasms
The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer.
Lung Neoplasms
The novel 19G endobronchial USS (EBUS) needle samples processed as tissue "core biopsies" facilitate PD-L1 and other biomarker testing in lung cancer specimens: case report and the view point from the Respiratory Physician and the Pathologist.
Lung Neoplasms
The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.
Lung Neoplasms
The potential predictive value of circulating immune cell ratio and tumor marker in atezolizumab treated advanced non-small cell lung cancer patients.
Lung Neoplasms
The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex.
Lung Neoplasms
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.
Lung Neoplasms
The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
Lung Neoplasms
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis.
Lung Neoplasms
The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
Lung Neoplasms
The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
Lung Neoplasms
The reproducibility of PD-L1 scoring in lung cancer: can the pathologists do better?
Lung Neoplasms
The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience.
Lung Neoplasms
The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Lung Neoplasms
The role of genetic polymorphism within PD-L1 gene in cancer. Review.
Lung Neoplasms
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
Lung Neoplasms
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis.
Lung Neoplasms
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Lung Neoplasms
The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer.
Lung Neoplasms
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Lung Neoplasms
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Lung Neoplasms
The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Lung Neoplasms
The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy.
Lung Neoplasms
The Value of 18F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
Lung Neoplasms
The Value of PD-L1 Expression in Metastatic Lymph Nodes of Advanced Non-Small Cell Lung Cancer.
Lung Neoplasms
The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.
Lung Neoplasms
The Value of PD-L1 Testing in Non-Small-Cell Lung Cancer.
Lung Neoplasms
Three-Drug Regimen Bests Chemo in NSCLC.
Lung Neoplasms
Thymosin ?1 suppresses migration and invasion of PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3-MMP2 signaling.
Lung Neoplasms
Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort.
Lung Neoplasms
Time is up for PD-L1 testing standardization in lung cancer.
Lung Neoplasms
Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
Lung Neoplasms
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients.
Lung Neoplasms
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature.
Lung Neoplasms
Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients.
Lung Neoplasms
Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM.
Lung Neoplasms
Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells.
Lung Neoplasms
Trichosanthin enhances the antitumor effect of gemcitabine in non-small cell lung cancer via inhibition of the PI3K/AKT pathway.
Lung Neoplasms
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.
Lung Neoplasms
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis.
Lung Neoplasms
Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis.
Lung Neoplasms
Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
Lung Neoplasms
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Lung Neoplasms
Tumor immune microenvironment and mutational analysis of tracheal adenoid cystic carcinoma.
Lung Neoplasms
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Lung Neoplasms
Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Lung Neoplasms
Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China.
Lung Neoplasms
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.
Lung Neoplasms
Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.
Lung Neoplasms
Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
Lung Neoplasms
Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells.
Lung Neoplasms
Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers.
Lung Neoplasms
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
Lung Neoplasms
Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Lung Neoplasms
Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Lung Neoplasms
TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC).
Lung Neoplasms
Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature.
Lung Neoplasms
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
Lung Neoplasms
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Lung Neoplasms
Unmasking the expression of PD-L1 in Myeloid Derived Suppressor Cells: A case study in lung cancer to discover new drugs with specific on-target efficacy.
Lung Neoplasms
Up-regulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Lung Neoplasms
Update on Immunohistochemistry for the Diagnosis of Lung Cancer.
Lung Neoplasms
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Lung Neoplasms
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Lung Neoplasms
Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.
Lung Neoplasms
Use of an Additional 19-G EBUS-TBNA Needle Increases the Diagnostic Yield of EBUS-TBNA.
Lung Neoplasms
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Lung Neoplasms
Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer.
Lung Neoplasms
Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer.
Lung Neoplasms
Utility of PD-L1 testing on non-small cell lung cancer cytology specimens: An institutional experience with interobserver variability analysis.
Lung Neoplasms
Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses.
Lung Neoplasms
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
Lung Neoplasms
Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers.
Lung Neoplasms
Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.
Lung Neoplasms
Voluntary wheel running can lead to modulation of immune checkpoint molecule expression.
Lung Neoplasms
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
Lung Neoplasms
YAP regulates PD-L1 expression in human NSCLC cells.
Lung Neoplasms
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
Lung Neoplasms
Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer.
Lung Neoplasms
[A Case of Squamous Cell Lung Cancer in an Elderly Patient with Low PD-L1 Expression Effectively Treated with Nab-Paclitaxel(Nab-PTX)plus Carboplatin (CBDCA)plus Pembrolizumab for a Recurrence after Operation].
Lung Neoplasms
[A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Lung Neoplasms
[Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.]
Lung Neoplasms
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Lung Neoplasms
[Detection of PD-L1 expression in non-small cell lung cancer: current status].
Lung Neoplasms
[Effect of soluble PD-L1 released by lung cancer cells in regulating the function of T lymphocytes].
Lung Neoplasms
[Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
Lung Neoplasms
[Effects of immunohistochemical conditions on the results of PD-L1 (22C3) staining].
Lung Neoplasms
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or ?Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Lung Neoplasms
[Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].
Lung Neoplasms
[Expression and significance of gp96 and immune-related gene CTLA-4, CD8 in lung cancer tissues]
Lung Neoplasms
[Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications].
Lung Neoplasms
[Immuno-Oncology: A Brief Overview].
Lung Neoplasms
[Immunotherapy for lung cancer].
Lung Neoplasms
[Immunotherapy of lung cancer].
Lung Neoplasms
[Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].
Lung Neoplasms
[PD-L1 expression is related with prognosis of small cell lung cancer].
Lung Neoplasms
[Predictive Markers for Treating Efficacy of PD-1/PD-L1 Inhibitors in Patients with Lung Cancer: A Review of the 18th World Conference on Lung Cancer].
Lung Neoplasms
[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
Lung Neoplasms
[Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
Lung Neoplasms
[Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data].
Lung Neoplasms
[Research Progress on Heterogeneity of Tumor Mutation Burden in Patients with ?Non-small Cell Lung Cancer].
Lung Neoplasms
[Status of PD-L1 testing in non-small cell lung cancer in China].
Lung Neoplasms
[Successful Treatment of Squamous Cell Lung Cancer without PD-L1 Expression Using Fourth-Line Nivolumab].
Lung Neoplasms
[The Expression and Biological Significance of PD-L1 on Lung Cancer Cell Lines.]
Lung Neoplasms
[The expression of PD-L1 in the non-small cell lung cancer and the correlation with the novel lung adenocarcinoma classification].
Lung Neoplasms
[Tumor Associated Fibroblasts Promote PD-L1 Expression in Lung Cancer Cells].
Lung Neoplasms
[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Lupus Erythematosus, Cutaneous
De novo subacute cutaneous lupus erythematosus like eruptions in the setting of PD-1 or PD-L1 inhibitor therapy: clinical-pathological correlation.
Lupus Erythematosus, Systemic
A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Increased expression of soluble inducible costimulator ligand (ICOSL) in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
The role and clinical significance of programmed cell death- ligand 1 expressed on CD19+B-cells and subsets in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
TNF-? and TGF-? Counter-Regulate PD-L1 Expression on Monocytes in Systemic Lupus Erythematosus.
Lupus Nephritis
A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus.
Lupus Nephritis
Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1.
Lupus Nephritis
Delivering PD-1 inhibitory signal concomitant with blocking ICOS co-stimulation suppresses lupus-like syndrome in autoimmune BXSB mice.
Lupus Nephritis
PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis.
Lupus Nephritis
The role of programed death-ligand 1 in renal diseases.
Lupus Nephritis
Treatment of lupus nephritis with CD5 PLUS, an immunoconjugate of an anti-CD5 monoclonal antibody and ricin A chain.
Lymphadenitis
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Lymphadenopathy
ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Lymphangioleiomyomatosis
Immune Checkpoint Ligand PD-L1 is Upregulated in Pulmonary Lymphangioleiomyomatosis (LAM).
Lymphatic Metastasis
18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer.
Lymphatic Metastasis
A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis.
Lymphatic Metastasis
A nomogram incorporating PD-L1, NLR, and clinicopathologic features to predict inguinal lymph node metastasis in penile squamous cell carcinoma.
Lymphatic Metastasis
Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Lymphatic Metastasis
Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.
Lymphatic Metastasis
Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Lymphatic Metastasis
Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Lymphatic Metastasis
BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Lymphatic Metastasis
CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC.
Lymphatic Metastasis
Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation.
Lymphatic Metastasis
Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma
Lymphatic Metastasis
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
Lymphatic Metastasis
Clinical retrospective study on the expression of the PD-L1 molecule in sporadic colorectal cancer and its correlation with K-ras gene mutations in Chinese patients.
Lymphatic Metastasis
CLINICAL SIGNIFICANCE OF PD-L1 EXPRESSION IN PARATHYROID CANCER.
Lymphatic Metastasis
Clinical significance of PD-L1 expression in patients with surgically resected non-small cell lung cancer.
Lymphatic Metastasis
Clinical significance of PD?L1 and PD?L2 copy number gains in non?small?cell lung cancer.
Lymphatic Metastasis
Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.
Lymphatic Metastasis
Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.
Lymphatic Metastasis
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Lymphatic Metastasis
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Lymphatic Metastasis
Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis.
Lymphatic Metastasis
Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.
Lymphatic Metastasis
Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression.
Lymphatic Metastasis
CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Lymphatic Metastasis
Co-expression of PD-L1 and HIF-1? predicts poor prognosis in Patients with Non-small Cell Lung Cancer after surgery.
Lymphatic Metastasis
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Lymphatic Metastasis
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
Lymphatic Metastasis
Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
Lymphatic Metastasis
Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
Lymphatic Metastasis
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Lymphatic Metastasis
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Lymphatic Metastasis
Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Lymphatic Metastasis
Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Lymphatic Metastasis
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
Lymphatic Metastasis
Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
Lymphatic Metastasis
Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Lymphatic Metastasis
Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome.
Lymphatic Metastasis
Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.
Lymphatic Metastasis
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Lymphatic Metastasis
Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status.
Lymphatic Metastasis
Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Lymphatic Metastasis
Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.
Lymphatic Metastasis
Expression of programmed death-ligand 1 and hypoxia-inducible factor-1? proteins in endometrial carcinoma.
Lymphatic Metastasis
Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration.
Lymphatic Metastasis
Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Lymphatic Metastasis
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Lymphatic Metastasis
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
Lymphatic Metastasis
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
Lymphatic Metastasis
Gene mutations of esophageal squamous cell carcinoma based on next-generation sequencing.
Lymphatic Metastasis
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Lymphatic Metastasis
High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Lymphatic Metastasis
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
Lymphatic Metastasis
High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.
Lymphatic Metastasis
Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
Lymphatic Metastasis
Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Lymphatic Metastasis
Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Lymphatic Metastasis
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.
Lymphatic Metastasis
Impact of Neoadjuvant Chemotherapy on Concordance of PD-L1 Staining Fidelity between the Primary Tumor and Lymph Node Metastases in Bladder Cancer.
Lymphatic Metastasis
Impact of sidedness of colorectal cancer on tumor immunity.
Lymphatic Metastasis
Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Lymphatic Metastasis
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Lymphatic Metastasis
Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Lymphatic Metastasis
Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Lymphatic Metastasis
Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
Lymphatic Metastasis
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Lymphatic Metastasis
Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects.
Lymphatic Metastasis
MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
Lymphatic Metastasis
Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Lymphatic Metastasis
PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Lymphatic Metastasis
PD-1, PD-L1, and BIM as Predictors of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
Lymphatic Metastasis
PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
Lymphatic Metastasis
PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma.
Lymphatic Metastasis
PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Lymphatic Metastasis
PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Lymphatic Metastasis
PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
Lymphatic Metastasis
PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Lymphatic Metastasis
PD-L1 expression in colon cancer and its relationship with clinical prognosis.
Lymphatic Metastasis
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer.
Lymphatic Metastasis
PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis.
Lymphatic Metastasis
PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
Lymphatic Metastasis
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Lymphatic Metastasis
PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer.
Lymphatic Metastasis
PD-L1 expression is associated with advanced non-small cell lung cancer.
Lymphatic Metastasis
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
Lymphatic Metastasis
PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer.
Lymphatic Metastasis
PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Lymphatic Metastasis
PD-L1 gene expression in Japanese lung cancer patients.
Lymphatic Metastasis
PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay.
Lymphatic Metastasis
PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma.
Lymphatic Metastasis
PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma.
Lymphatic Metastasis
PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
Lymphatic Metastasis
PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.
Lymphatic Metastasis
Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
Lymphatic Metastasis
Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Lymphatic Metastasis
Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
Lymphatic Metastasis
Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer.
Lymphatic Metastasis
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
Lymphatic Metastasis
Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Lymphatic Metastasis
Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.
Lymphatic Metastasis
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.
Lymphatic Metastasis
Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Lymphatic Metastasis
Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.
Lymphatic Metastasis
Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms.
Lymphatic Metastasis
Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
Lymphatic Metastasis
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Lymphatic Metastasis
Programmed cell death ligand-1 and cytotoxic T cell infiltrates in metastatic cutaneous squamous cell carcinoma of the head and neck.
Lymphatic Metastasis
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
Lymphatic Metastasis
Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
Lymphatic Metastasis
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Lymphatic Metastasis
Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin ?4/SNAI1/SIRT3 signaling pathway.
Lymphatic Metastasis
Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?
Lymphatic Metastasis
Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Lymphatic Metastasis
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.
Lymphatic Metastasis
Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
Lymphatic Metastasis
Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma.
Lymphatic Metastasis
Relationship Between Programmed Death-ligand 1 and Clinicopathological Characteristics in Non-small Cell Lung Cancer Patients.
Lymphatic Metastasis
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
Lymphatic Metastasis
Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
Lymphatic Metastasis
ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report.
Lymphatic Metastasis
Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer.
Lymphatic Metastasis
Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Lymphatic Metastasis
Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Lymphatic Metastasis
Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.
Lymphatic Metastasis
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
Lymphatic Metastasis
The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Lymphatic Metastasis
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Lymphatic Metastasis
The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Lymphatic Metastasis
The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Lymphatic Metastasis
The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Lymphatic Metastasis
The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
Lymphatic Metastasis
The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer.
Lymphatic Metastasis
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Lymphatic Metastasis
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Lymphatic Metastasis
The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.
Lymphatic Metastasis
The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.
Lymphatic Metastasis
The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Lymphatic Metastasis
The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma.
Lymphatic Metastasis
The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
Lymphatic Metastasis
Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.
Lymphatic Metastasis
Uncovering PD-L1 and CD8+ TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma.
Lymphatic Metastasis
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Lymphatic Metastasis
Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
Lymphatic Metastasis
Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Lymphatic Metastasis
[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1?Antibody-Safety and Effectiveness of Pirfenidone].
Lymphatic Metastasis
[Expression and significance of PD-L1 in laryngocarcinoma]
Lymphatic Metastasis
[Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].
Lymphatic Metastasis
[Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].
Lymphatic Metastasis
[Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
Lymphatic Metastasis
[Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
Lymphatic Metastasis
[Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
Lymphatic Metastasis
[The clinical significance of the expression of costimulatory molecule PD-L1 in nasopharyngeal carcinoma]
Lymphocytic Choriomeningitis
CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.
Lymphocytic Choriomeningitis
CNS activity of Pokeweed anti-viral protein (PAP) in mice infected with lymphocytic choriomeningitis virus (LCMV).
Lymphocytic Choriomeningitis
PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Lymphocytic Choriomeningitis
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.
Lymphohistiocytosis, Hemophagocytic
Capillary leak syndrome: etiologies, pathophysiology, and management.
Lymphoma
A comparison of established human lymphoma lines by flow cytometry: quantitation of Ricinus communis agglutinin binding and the effect of specific glycosidases.
Lymphoma
A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.
Lymphoma
A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy.
Lymphoma
A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening.
Lymphoma
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Lymphoma
A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.
Lymphoma
Abrus abrin derived peptides induce apoptosis by targeting mitochondria in HeLa cells.
Lymphoma
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Lymphoma
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Lymphoma
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
Lymphoma
An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
Lymphoma
An in vivo model to study immunotoxin-induced vascular leak in human tissue.
Lymphoma
Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest.
Lymphoma
Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis.
Lymphoma
Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-?-associated JAK-STAT pathway.
Lymphoma
Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
Lymphoma
Antitumour effect of abrin on transplanted tumours in mice.
Lymphoma
Application of mid-infrared microscopic imaging for the diagnosis and classification of human lymphomas.
Lymphoma
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Lymphoma
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
Lymphoma
Augmentation of Saporin-Based Immunotoxins for Human Leukaemia and Lymphoma Cells by Triterpenoid Saponins: The Modifying Effects of Small Molecule Pharmacological Agents.
Lymphoma
Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.
Lymphoma
Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma.
Lymphoma
Biomarkers for checkpoint inhibition in hematologic malignancies.
Lymphoma
Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
Lymphoma
Bryodin, a single-chain ribosome-inactivating protein, selectively inhibits the growth of HIV-1-infected cells and reduces HIV-1 production.
Lymphoma
CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.
Lymphoma
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.
Lymphoma
Cell surface receptors and their dynamics on toxin-treated malignant cells.
Lymphoma
Characterization of a new monoclonal antibody 6G7 that recognizes a unique antigen on myeloid and lymphoid cells.
Lymphoma
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Lymphoma
Checkpoint inhibitors in hematological malignancies.
Lymphoma
Checkpoint molecule expression by B and T cell lymphomas in dogs.
Lymphoma
Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
Lymphoma
Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
Lymphoma
Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.
Lymphoma
Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Lymphoma
Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
Lymphoma
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Lymphoma
Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
Lymphoma
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Lymphoma
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy.
Lymphoma
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
Lymphoma
Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
Lymphoma
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
Lymphoma
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
Lymphoma
Cost-effectiveness of precision diagnostic testing for precision medicine approaches against non-small-cell lung cancer: A systematic review.
Lymphoma
Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Lymphoma
Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Lymphoma
Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
Lymphoma
Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma.
Lymphoma
Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Lymphoma
Dynamics of toxin and lectin receptors on a lymphoma cell line and its toxin-resistant variant using ferritin-conjugated, 125I-labeled ligand.
Lymphoma
Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Lymphoma
Evaluation of four CD22 antibodies as ricin A chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas.
Lymphoma
Evaluation of ricin A chain-containing immunotoxins directed against glycolipid and glycoprotein on mouse lymphoma cells.
Lymphoma
Expression of HSP60 in gastric lymphoma treated by a combination of trichosanthin and radiotherapy and its mechanism.
Lymphoma
Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Lymphoma
Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma.
Lymphoma
Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
Lymphoma
Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Lymphoma
Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma.
Lymphoma
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Lymphoma
Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells.
Lymphoma
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Lymphoma
Flower cells of tropical descent: a challenging case of adult T-cell leukemia/lymphoma.
Lymphoma
Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.
Lymphoma
GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.
Lymphoma
Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
Lymphoma
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations.
Lymphoma
High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells.
Lymphoma
High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.
Lymphoma
Human leukocyte antigen class II expression is a good prognostic factor of adult T-cell leukemia/lymphoma.
Lymphoma
Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
Lymphoma
Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
Lymphoma
Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression.
Lymphoma
Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Lymphoma
Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
Lymphoma
Immunotoxins in the treatment of hematologic malignancies.
Lymphoma
Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.
Lymphoma
In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
Lymphoma
Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium.
Lymphoma
Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
Lymphoma
Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab.
Lymphoma
Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.
Lymphoma
Liposome-mediated delivery of ribosome inactivating proteins to cells in vitro.
Lymphoma
LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Lymphoma
Macrophage-histiocytes in malignant lymphoma, small lymphocytic type (well-differentiated lymphocytic lymphoma).
Lymphoma
Mechanism of resistance to ricin toxin in selected mouse lymphoma cell lines.
Lymphoma
Mechanisms in removal of tumor by antibody.
Lymphoma
MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Lymphoma
Molecular Pathology: A Requirement for Precision Medicine in Cancer.
Lymphoma
Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.
Lymphoma
MYC inhibition increases PD-L1 expression induced by IFN-? in hepatocellular carcinoma cells.
Lymphoma
Myeloid loss of Beclin 1 promotes PD-L1hiprecursor B Cell lymphoma development.
Lymphoma
N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.
Lymphoma
NIM-R7, a novel marker for resting B1 and marginal-zone B lymphocytes, is also expressed on activated T and B cells.
Lymphoma
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Lymphoma
NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
Lymphoma
Nodal diffuse large B-cell lymphoma with neoplastic PD-L1 positivity, but without EBV association: Three cases highlighting an aspect of gray zone lymphoma.
Lymphoma
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.
Lymphoma
Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen.
Lymphoma
Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma.
Lymphoma
Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
Lymphoma
Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines.
Lymphoma
PD-1 and PD-L1 Immunohistochemistry as a Diagnostic Tool for Classic Hodgkin Lymphoma in Small-volume Biopsies.
Lymphoma
PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population.
Lymphoma
PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.
Lymphoma
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
Lymphoma
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Lymphoma
PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Lymphoma
PD-L1 expression in anaplastic large cell lymphoma.
Lymphoma
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Lymphoma
PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.
Lymphoma
PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
Lymphoma
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
Lymphoma
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large cell lymphoma.
Lymphoma
PD-L1 is upregulated by EBV-driven LMP1 through NF-?B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Lymphoma
PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.
Lymphoma
PD-L1 Status in Refractory Lymphomas.
Lymphoma
PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.
Lymphoma
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
Lymphoma
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Lymphoma
Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
Lymphoma
Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma.
Lymphoma
Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Lymphoma
Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients.
Lymphoma
Potentiation of antiproliferative effects of monoclonal antibody Lym-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with gamma-interferon and tumor necrosis factor.
Lymphoma
Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-?B, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.
Lymphoma
Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Lymphoma
Preproricin expressed in Nicotiana tabacum cells in vitro is fully processed and biologically active.
Lymphoma
Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Lymphoma
Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.
Lymphoma
Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Lymphoma
Programmed Cell Death Ligand 1 Expression in Canine Cancer.
Lymphoma
Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
Lymphoma
Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Lymphoma
Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
Lymphoma
Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma.
Lymphoma
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Lymphoma
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Lymphoma
Rationale for clinical use of immunotoxins in cancer and autoimmune disease.
Lymphoma
Regulation of Caspase-3 and Bcl-2 Expression in Dalton's Lymphoma Ascites Cells by Abrin.
Lymphoma
Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
Lymphoma
Ricinus communis toxin-mediated inhibition of protein synthesis in cell-free extracts of a toxin-resistant variant mouse lymphoma cell line.
Lymphoma
Role of Immune Microenvironmental Factors for Improving the IPI-related Risk Stratification of Aggressive B Cell Lymphoma.
Lymphoma
Saporin induces multiple death pathways in lymphoma cells with different intensity and timing as compared to ricin.
Lymphoma
Selection and characterization of transferrin receptor mutants using receptor-specific antibodies.
Lymphoma
Several immune escape patterns in non-Hodgkin's lymphomas.
Lymphoma
Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice.
Lymphoma
Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma.
Lymphoma
Synthesis and Preclinical Evaluation of 68Ga-labeled Adnectin, 68Ga-BMS-986192 as a PET Agent for Imaging PD-L1 Expression.
Lymphoma
Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
Lymphoma
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities.
Lymphoma
Targeting immune checkpoints in lymphoma.
Lymphoma
The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin.
Lymphoma
The Effect of Small Molecule Pharmacological Agents on the Triterpenoid Saponin Induced Endolysosomal Escape of Saporin and a Saporin-Based Immunotoxin in Target Human Lymphoma Cells.
Lymphoma
The emerging role of ricin A-chain immunotoxins in leukemia and lymphoma.
Lymphoma
The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.
Lymphoma
The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Lymphoma
The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.
Lymphoma
The Role of Cholesterol on Triterpenoid Saponin-Induced Endolysosomal Escape of a Saporin-Based Immunotoxin.
Lymphoma
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Lymphoma
Transformation of ALK expression and PD-L1 0% to PD-L1 90% only after surgery: the need for rebiopsy in lung cancer patients.
Lymphoma
Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells.
Lymphoma
Update on checkpoint blockade therapy for lymphoma.
Lymphoma
Use of an Additional 19-G EBUS-TBNA Needle Increases the Diagnostic Yield of EBUS-TBNA.
Lymphoma
VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma.
Lymphoma
Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
Lymphoma
[Expression of PD-L1 in lymphoma and its effect on lymphoma proliferation and chemotherapy resistance].
Lymphoma
[Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance].
Lymphoma
[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].
Lymphoma
[Immune-checkpoint and hemopathies].
Lymphoma
[Mechanism of trichosanthin against human leukemia/lymphoma cells in vitro]
Lymphoma
[PD-1/PD-L1 Signaling Pathway and Its Anti-Tumor Effect in Lymphoma -Review].
Lymphoma
[Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].
Lymphoma
[The immune microenvironment in malignant lymphoma].
Lymphoma, B-Cell
A comparison of established human lymphoma lines by flow cytometry: quantitation of Ricinus communis agglutinin binding and the effect of specific glycosidases.
Lymphoma, B-Cell
A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
Lymphoma, B-Cell
A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
Lymphoma, B-Cell
A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.
Lymphoma, B-Cell
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Lymphoma, B-Cell
Adrenal diffuse large B-cell lymphoma with high PD-L1 expression: Two case reports and literature review.
Lymphoma, B-Cell
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma.
Lymphoma, B-Cell
An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
Lymphoma, B-Cell
Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Lymphoma, B-Cell
Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression.
Lymphoma, B-Cell
B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Biomarkers for checkpoint inhibition in hematologic malignancies.
Lymphoma, B-Cell
CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells.
Lymphoma, B-Cell
CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Lymphoma, B-Cell
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.
Lymphoma, B-Cell
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Lymphoma, B-Cell
Checkpoint molecule expression by B and T cell lymphomas in dogs.
Lymphoma, B-Cell
Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.
Lymphoma, B-Cell
Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.
Lymphoma, B-Cell
Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Lymphoma, B-Cell
Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Lymphoma, B-Cell
Clinicopathological analysis of programmed cell death-1 and programmed cell death-ligand 1 expression in the tumor microenvironments of diffuse large B-cell lymphomas.
Lymphoma, B-Cell
Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Lymphoma, B-Cell
Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs.
Lymphoma, B-Cell
Current progress and future perspectives of research on intravascular large B-cell lymphoma.
Lymphoma, B-Cell
Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
Lymphoma, B-Cell
Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Lymphoma, B-Cell
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities.
Lymphoma, B-Cell
Divergence and heterogeneity of neoplastic PD-L1 expression: Two autopsy case reports of intravascular large B-cell lymphoma.
Lymphoma, B-Cell
EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
Lymphoma, B-Cell
Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Lymphoma, B-Cell
Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Lymphoma, B-Cell
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Lymphoma, B-Cell
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
Lymphoma, B-Cell
Gold nanoparticles conjugated with programmed death-ligand 1 antibodies induce apoptosis of SCC-25 oral squamous cell carcinoma cells via programmed death-ligand 1/signal transducer and transcription 3 pathway.
Lymphoma, B-Cell
HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC.
Lymphoma, B-Cell
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Lymphoma, B-Cell
High PD-L1 expression predicts poor prognosis in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
Lymphoma, B-Cell
High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.
Lymphoma, B-Cell
Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.
Lymphoma, B-Cell
Inflamed phenotype of splenic marginal zone B-cell lymphomas with expression of PD-L1 by intratumoral monocytes/macrophages and dendritic cells.
Lymphoma, B-Cell
Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.
Lymphoma, B-Cell
LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Lymphoma, B-Cell
MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
Lymphoma, B-Cell
MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Lymphoma, B-Cell
Nodal diffuse large B-cell lymphoma with neoplastic PD-L1 positivity, but without EBV association: Three cases highlighting an aspect of gray zone lymphoma.
Lymphoma, B-Cell
Novel mechanism of immune evasion in cancer via structural variations of the PD-L1 gene.
Lymphoma, B-Cell
Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen.
Lymphoma, B-Cell
Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.
Lymphoma, B-Cell
Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma.
Lymphoma, B-Cell
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Lymphoma, B-Cell
PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.
Lymphoma, B-Cell
PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS.
Lymphoma, B-Cell
PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
Lymphoma, B-Cell
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Lymphoma, B-Cell
PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories.
Lymphoma, B-Cell
PD-L1 and tumor-associated macrophages in de novo DLBCL.
Lymphoma, B-Cell
PD-L1 expression in B-cell lymphomas and virus-associated malignancies--letter.
Lymphoma, B-Cell
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Lymphoma, B-Cell
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Lymphoma, B-Cell
PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.
Lymphoma, B-Cell
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
Lymphoma, B-Cell
PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
Lymphoma, B-Cell
Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
Lymphoma, B-Cell
Phase I immunotoxin trial in patients with B-cell lymphoma.
Lymphoma, B-Cell
Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
Lymphoma, B-Cell
Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients.
Lymphoma, B-Cell
Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-?B, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.
Lymphoma, B-Cell
Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
Lymphoma, B-Cell
Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.
Lymphoma, B-Cell
Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope.
Lymphoma, B-Cell
Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
Lymphoma, B-Cell
Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
Lymphoma, B-Cell
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Lymphoma, B-Cell
Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
Lymphoma, B-Cell
Response of B-cell lymphoma to a combination of bispecific antibodies and saporin.
Lymphoma, B-Cell
Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma.
Lymphoma, B-Cell
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma.
Lymphoma, B-Cell
Suppression of murine B-cell lymphoma growth by trichosanthin through anti-angiogenesis.
Lymphoma, B-Cell
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
Lymphoma, B-Cell
The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.
Lymphoma, B-Cell
The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.
Lymphoma, B-Cell
Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin.
Lymphoma, B-Cell
Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.
Lymphoma, B-Cell
[Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].
Lymphoma, B-Cell, Marginal Zone
Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma.
Lymphoma, Follicular
An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
Lymphoma, Follicular
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Lymphoma, Follicular
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.
Lymphoma, Follicular
Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma.
Lymphoma, Large B-Cell, Diffuse
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Lymphoma, Large B-Cell, Diffuse
Adrenal diffuse large B-cell lymphoma with high PD-L1 expression: Two case reports and literature review.
Lymphoma, Large B-Cell, Diffuse
An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
Lymphoma, Large B-Cell, Diffuse
B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Biomarkers for checkpoint inhibition in hematologic malignancies.
Lymphoma, Large B-Cell, Diffuse
CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Lymphoma, Large B-Cell, Diffuse
Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.
Lymphoma, Large B-Cell, Diffuse
Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.
Lymphoma, Large B-Cell, Diffuse
Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Lymphoma, Large B-Cell, Diffuse
Clinicopathological analysis of programmed cell death-1 and programmed cell death-ligand 1 expression in the tumor microenvironments of diffuse large B-cell lymphomas.
Lymphoma, Large B-Cell, Diffuse
Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Lymphoma, Large B-Cell, Diffuse
Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Current progress and future perspectives of research on intravascular large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Lymphoma, Large B-Cell, Diffuse
Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities.
Lymphoma, Large B-Cell, Diffuse
EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
Lymphoma, Large B-Cell, Diffuse
Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Lymphoma, Large B-Cell, Diffuse
High PD-L1 expression predicts poor prognosis in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
Lymphoma, Large B-Cell, Diffuse
Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Impact of serum soluble programed death ligand 1 on end of treatment metabolic response of diffuse large B cell lymphoma patients.
Lymphoma, Large B-Cell, Diffuse
Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.
Lymphoma, Large B-Cell, Diffuse
LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Lymphoma, Large B-Cell, Diffuse
MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
Lymphoma, Large B-Cell, Diffuse
Nodal diffuse large B-cell lymphoma with neoplastic PD-L1 positivity, but without EBV association: Three cases highlighting an aspect of gray zone lymphoma.
Lymphoma, Large B-Cell, Diffuse
Novel mechanism of immune evasion in cancer via structural variations of the PD-L1 gene.
Lymphoma, Large B-Cell, Diffuse
Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen.
Lymphoma, Large B-Cell, Diffuse
Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.
Lymphoma, Large B-Cell, Diffuse
PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS.
Lymphoma, Large B-Cell, Diffuse
PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
Lymphoma, Large B-Cell, Diffuse
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Lymphoma, Large B-Cell, Diffuse
PD-L1 and tumor-associated macrophages in de novo DLBCL.
Lymphoma, Large B-Cell, Diffuse
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Lymphoma, Large B-Cell, Diffuse
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
Lymphoma, Large B-Cell, Diffuse
PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients.
Lymphoma, Large B-Cell, Diffuse
Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.
Lymphoma, Large B-Cell, Diffuse
Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope.
Lymphoma, Large B-Cell, Diffuse
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Lymphoma, Large B-Cell, Diffuse
Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
Lymphoma, Large B-Cell, Diffuse
Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma.
Lymphoma, Large B-Cell, Diffuse
Soluble PD-1 but Not PD-L1 Levels Predict Poor Outcome in Patients with High-Risk Diffuse Large B-Cell Lymphoma.
Lymphoma, Large B-Cell, Diffuse
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.
Lymphoma, Large B-Cell, Diffuse
The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis.
Lymphoma, Large B-Cell, Diffuse
Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.
Lymphoma, Large B-Cell, Diffuse
[Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].
Lymphoma, Large-Cell, Anaplastic
A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening.
Lymphoma, Large-Cell, Anaplastic
Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
Lymphoma, Large-Cell, Anaplastic
Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
Lymphoma, Large-Cell, Anaplastic
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Lymphoma, Large-Cell, Anaplastic
Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.
Lymphoma, Large-Cell, Anaplastic
PD-L1 expression in anaplastic large cell lymphoma.
Lymphoma, Large-Cell, Anaplastic
PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma.
Lymphoma, Large-Cell, Anaplastic
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large cell lymphoma.
Lymphoma, Large-Cell, Anaplastic
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Lymphoma, Large-Cell, Anaplastic
[Genetic abnormality and protein expression of C-MYC and PD-L1 in ALK-negative anaplastic large cell lymphoma].
Lymphoma, Mantle-Cell
Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
Lymphoma, Mantle-Cell
PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population.
Lymphoma, Mantle-Cell
Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma.
Lymphoma, Mantle-Cell
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
Lymphoma, Non-Hodgkin
A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Adrenal diffuse large B-cell lymphoma with high PD-L1 expression: Two case reports and literature review.
Lymphoma, Non-Hodgkin
Checkpoint molecule expression by B and T cell lymphomas in dogs.
Lymphoma, Non-Hodgkin
Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
Lymphoma, Non-Hodgkin
Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
Lymphoma, Non-Hodgkin
Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
Lymphoma, Non-Hodgkin
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Lymphoma, Non-Hodgkin
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Lymphoma, Non-Hodgkin
Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
Lymphoma, Non-Hodgkin
Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Lymphoma, Non-Hodgkin
Prognostic value and clinicopathological characteristics of PD-L1 overexpression in non-Hodgkin lymphoma: a meta-analysis.
Lymphoma, Non-Hodgkin
The carriage and delivery of substances to lymphatic tissues by recirculating lymphocytes. I. The concentration of ricin in lymphocyte traffic areas.
Lymphoma, Non-Hodgkin
The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine.
Lymphoma, Non-Hodgkin
The toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials.
Lymphoma, T-Cell
Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-?-associated JAK-STAT pathway.
Lymphoma, T-Cell
Checkpoint molecule expression by B and T cell lymphomas in dogs.
Lymphoma, T-Cell
Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Lymphoma, T-Cell
High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center.
Lymphoma, T-Cell
Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin.
Lymphoma, T-Cell
PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases.
Lymphoma, T-Cell
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Lymphoma, T-Cell, Cutaneous
Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Lymphoma, T-Cell, Cutaneous
Preproricin expressed in Nicotiana tabacum cells in vitro is fully processed and biologically active.
Lymphoma, T-Cell, Peripheral
Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy.
Lymphoma, T-Cell, Peripheral
Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Lymphoma, T-Cell, Peripheral
PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements.
Lymphoma, T-Cell, Peripheral
Prognostic significance of PD-L1 and TLR5 expression in peripheral T-cell lymphomas.
Lymphoma, T-Cell, Peripheral
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Lymphoma, T-Cell, Peripheral
TLR4 expression correlated with PD-L1 expression indicates a poor prognosis in patients with peripheral T-cell lymphomas.
Lymphoma, T-Cell, Peripheral
TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas.
Lymphoproliferative Disorders
Clinicopathological Evaluation of PD1/PD-L1 Axis in Post-Transplant Lymphoproliferative Disorders: Association with EBV, PD-L1 Copy Number Alterations and Outcome.
Lymphoproliferative Disorders
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy.
Lymphoproliferative Disorders
Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Lymphoproliferative Disorders
Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type.
Lymphoproliferative Disorders
PD-L1 and Notch1 expression in KSHV/HHV-8 and EBV associated germinotropic lymphoproliferative disorder: case report and review of the literature.
Lymphoproliferative Disorders
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Macular Degeneration
Alterations in stromal glycoconjugates in macular corneal dystrophy.
Malaria
An additional mechanism of ribosome-inactivating protein cytotoxicity: degradation of extrachromosomal DNA.
Malaria
Important Chinese herbal remedies.
Malaria
PD-L2 Elbows out PD-L1 to Rescue T Cell Immunity to Malaria.
Malaria
Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4(+) T Cell Immunity.
Malaria
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Malaria
Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection.
Malaria, Falciparum
An additional mechanism of ribosome-inactivating protein cytotoxicity: degradation of extrachromosomal DNA.
Malnutrition
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Mastocytoma
Expression of PD-L1 on canine tumor cells and enhancement of IFN-? production from tumor-infiltrating cells by PD-L1 blockade.
Mastocytoma
The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
Mastocytosis
Expression of PD-L1 in mastocytosis.
Mastocytosis
PD-1 Regulates the Growth of Human Mastocytosis Cells.
Mastocytosis
PD-L1 Expression in Mastocytosis.
Mastocytosis
Variability of PD-L1 expression in mastocytosis.
Mastocytosis, Cutaneous
Variability of PD-L1 expression in mastocytosis.
Mastocytosis, Systemic
Variability of PD-L1 expression in mastocytosis.
Measles
CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy.
Medulloblastoma
A humanized single-chain Fv fragment with high targeting potential against human malignant gliomas.
Medulloblastoma
High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma.
Medulloblastoma
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Medulloblastoma
PD-L1 expression in medulloblastoma: an evaluation by subgroup.
Medulloblastoma
Subgroup-specific immune and stromal microenvironment in medulloblastoma.
Melanoma
(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis.
Melanoma
18F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.
Melanoma
89Zr-Labeled Anti-PD-L1 Antibody Fragment for Evaluating In Vivo PD-L1 Levels in Melanoma Mouse Model.
Melanoma
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Melanoma
A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
Melanoma
A focus on PD-L1 in human melanoma.
Melanoma
A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas.
Melanoma
A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients.
Melanoma
A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.
Melanoma
A secondary role for hypoxia and HIF1 in the regulation of (IFN?-induced) PD-L1 expression in melanoma.
Melanoma
A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin.
Melanoma
A tumor-targeted immune checkpoint blocker.
Melanoma
Aberrant glycosylation of ?v?3 integrin is associated with melanoma progression.
Melanoma
Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.
Melanoma
Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.
Melanoma
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Melanoma
Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors.
Melanoma
Adipocytes promote tumor progression and induce PD-L1 expression via TNF-?/IL-6 signaling.
Melanoma
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Melanoma
Administration of Dendritic Cells and Anti-PD-1 Antibody Converts X-ray Irradiated Tumors Into Effective In situ Vaccines.
Melanoma
ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output.
Melanoma
An antimelanoma-barley ribosome inactivating protein conjugate is cytotoxic to melanoma cells in vitro.
Melanoma
An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo.
Melanoma
An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma.
Melanoma
An indirect treatment comparison of the efficacy of pembrolizumab versus competing regimens for the adjuvant treatment of stage III melanoma.
Melanoma
An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
Melanoma
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.
Melanoma
Anti-PD-1 and PD-L1 antibodies in metastatic melanoma.
Melanoma
Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.
Melanoma
Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.
Melanoma
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model.
Melanoma
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
Melanoma
Anticancer Activities of Ricin-Liposome Complexes on SKMEL-28 Cells.
Melanoma
Antiproliferative effect and apoptotic response in vitro of human melanoma cells to liposomes containing the ribosome-inactivating protein luffin.
Melanoma
Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
Melanoma
Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Melanoma
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Melanoma
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Melanoma
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Melanoma
Autocrine down-regulation of basic fibroblast growth factor receptors causes mitotoxin resistance in a human melanoma cell line.
Melanoma
B7-H1 and a Mathematical Model for Cytotoxic T Cell and Tumor Cell Interaction.
Melanoma
Baseline ?-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
Melanoma
BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade.
Melanoma
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors.
Melanoma
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
Melanoma
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
Melanoma
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
Melanoma
Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Melanoma
Black bronchoscopy in a patient with pulmonary malignant melanoma: A case report.
Melanoma
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Melanoma
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Melanoma
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Melanoma
BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells.
Melanoma
Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and ?-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells.
Melanoma
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.
Melanoma
Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
Melanoma
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Melanoma
Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5.
Melanoma
Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma.
Melanoma
CD271 on Melanoma Cell Is an IFN-?-Inducible Immunosuppressive Factor that Mediates Downregulation of Melanoma Antigens.
Melanoma
Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity.
Melanoma
Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy.
Melanoma
Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma.
Melanoma
Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors.
Melanoma
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Melanoma
Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.
Melanoma
Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma.
Melanoma
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Melanoma
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.
Melanoma
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Melanoma
Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Melanoma
Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis.
Melanoma
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Melanoma
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Melanoma
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Melanoma
Clinical Significance of Tumor Microenvironment in Acral Melanoma: A Large Single-Institution Study of Caucasians.
Melanoma
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.
Melanoma
Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients.
Melanoma
Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
Melanoma
Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients.
Melanoma
Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
Melanoma
Colony growth and chemosensitivity in vitro of human melanoma biopsies. Relationship to clinical parameters.
Melanoma
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
Melanoma
Combined SEP and anti-PD-L1 antibody produces a synergistic antitumor effect in B16-F10 melanoma-bearing mice.
Melanoma
Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy.
Melanoma
Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: malignant melanomas.
Melanoma
Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Melanoma
Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition.
Melanoma
Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells.
Melanoma
Correction: Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
Melanoma
Correlation of MET and PD-L1 Expression in Malignant Melanoma.
Melanoma
Corrigendum to "Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy" [Biomaterials 269 (2021) 120604].
Melanoma
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Melanoma
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients.
Melanoma
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
Melanoma
Cytotoxic anti-melanoma drugs suppress the activation of M2 macrophages.
Melanoma
Cytotoxicity of two new ribosome-inactivating proteins, cinnamomin and camphorin, to carcinoma cells.
Melanoma
Deciphering Mechanisms of UVR-Induced Tumoral Immune Checkpoint Regulation against Melanoma.
Melanoma
Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma.
Melanoma
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
Melanoma
Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014.
Melanoma
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
Melanoma
Differential response of human melanoma and Ehrlich ascites cells in vitro to the ribosome-inactivating protein luffin.
Melanoma
Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.
Melanoma
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.
Melanoma
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
Melanoma
Diverse activity of sc-RIP saporin 6 on primary and metastatic melanoma cells in vitro.
Melanoma
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.
Melanoma
Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model.
Melanoma
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Melanoma
Effects of B cell-activating factor on tumor immunity.
Melanoma
Effects of Glutathione Transferase-Targeting Nitrobenzoxadiazole Compounds in Relation to PD-L1 Status in Human Melanoma Cells.
Melanoma
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.
Melanoma
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.
Melanoma
Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
Melanoma
Enzymatic basis for a lectin-resistant phenotype: increase in a fucosyltransferase in mouse melanoma cells.
Melanoma
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Melanoma
Erratum: SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression.
Melanoma
Essential role of HDAC6 in the regulation of PD-L1 in melanoma.
Melanoma
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.
Melanoma
Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance.
Melanoma
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Melanoma
Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.
Melanoma
Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers.
Melanoma
Expression of IL-27 by tumor cells in invascutaneous and metastatic melanomas.
Melanoma
Expression of PD-L1 on canine tumor cells and enhancement of IFN-? production from tumor-infiltrating cells by PD-L1 blockade.
Melanoma
Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.
Melanoma
Frequent PD-L1 Expression in Malignant Melanomas of the Vulva.
Melanoma
Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma.
Melanoma
Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation.
Melanoma
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Melanoma
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Melanoma
Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth.
Melanoma
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
Melanoma
HDAC inhibitors enhance the immunotherapy response of melanoma cells.
Melanoma
High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
Melanoma
High response rate to PD-1 blockade in desmoplastic melanomas.
Melanoma
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.
Melanoma
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Melanoma
Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.
Melanoma
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Melanoma
Human melanoma cell lines showing striking inherent differences in sensitivity to immunotoxins containing holotoxins.
Melanoma
Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97.
Melanoma
Humoral immune response to a ricin A chain immunotoxin in patients with metastatic melanoma.
Melanoma
HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.
Melanoma
Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.
Melanoma
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.
Melanoma
Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.
Melanoma
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Melanoma
IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
Melanoma
Imaging of programmed death ligand-1 (PD-L1): impact of protein concentration on distribution of anti-PD-L1 SPECT agent in an immunocompetent melanoma murine model.
Melanoma
Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma.
Melanoma
Immune checkpoint inhibitors in the treatment of cancer.
Melanoma
Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.
Melanoma
Immune checkpoints and their inhibition in cancer and infectious diseases.
Melanoma
Immune checkpoints: A therapeutic target in triple negative breast cancer.
Melanoma
Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Melanoma
Immune response-associated gene profiling in Japanese melanoma patients using multi-omics analysis.
Melanoma
Immuno-regulatory antibodies for the treatment of cancer.
Melanoma
Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR-?/? Recombinations.
Melanoma
Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Melanoma
Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.
Melanoma
Immunomodulating property of MAPK inhibitors: from translational knowledge to clinical implementation.
Melanoma
Immunomodulatory Protective Effects of Rb9 Cyclic-Peptide in a Metastatic Melanoma Setting and the Involvement of Dendritic Cells.
Melanoma
Immunotherapies and melanoma.
Melanoma
Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Melanoma
Immunotherapy, an evolving approach for the management of triple negative breast cancer: Converting non-responders to responders.
Melanoma
Impact of Interferon-alpha1b (IFN-?1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma.
Melanoma
Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies.
Melanoma
In vitro sensitivity of human melanoma xenografts to cytotoxic drugs. Correlation with in vivo chemosensitivity.
Melanoma
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Melanoma
Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
Melanoma
Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-?B.
Melanoma
Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
Melanoma
Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
Melanoma
Inhibition of xCT suppresses the efficacy of anti-PD-1/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization.
Melanoma
Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma.
Melanoma
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response.
Melanoma
Inter- and intra-patient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumor microenvironment.
Melanoma
Inter- and intra-patient heterogeneity of PD-L1 expression in metastatic melanomas: A retrospective study.
Melanoma
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Melanoma
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Melanoma
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.
Melanoma
Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.
Melanoma
JAK2, PD-L1, and PD-L2 (9p24.1) Amplification in Metastatic Mucosal and Cutaneous Melanomas with Durable Response to Immunotherapy.
Melanoma
Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.
Melanoma
Kinetics of uptake and degradation of an abrin immunotoxin by melanoma cells and studies of the rates of cellular intoxication.
Melanoma
LAG3-PD-1 Combo Impresses in Melanoma.
Melanoma
Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma.
Melanoma
Lectin binding to cutaneous malignant melanoma: HPA is associated with metastasis formation.
Melanoma
Lectin-resistant variants of mouse melanoma cells. I. Altered metastasizing capacity and tumorigenicity.
Melanoma
Lectin-resistant variants of mouse melanoma cells. II. In vitro characteristics.
Melanoma
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Melanoma
Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression.
Melanoma
Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression.
Melanoma
Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8+ T-cell Responses.
Melanoma
Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.
Melanoma
Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
Melanoma
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Melanoma
Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma.
Melanoma
Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Melanoma
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Melanoma
Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
Melanoma
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth.
Melanoma
Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling.
Melanoma
Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPE.
Melanoma
Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Melanoma
Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Melanoma
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
Melanoma
miR-146a Controls Immune Response in the Melanoma Microenvironment.
Melanoma
MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Melanoma
Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
Melanoma
Molecular Pathology: A Requirement for Precision Medicine in Cancer.
Melanoma
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
Melanoma
Monoclonal antibody immunoconjugates in the diagnosis and treatment of advanced melanoma.
Melanoma
Mucosal Melanoma: a Literature Review.
Melanoma
Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot.
Melanoma
Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma.
Melanoma
Multifunctionality of CD8+ T cells and PD-L1 expression as a biomarker of anti-PD-1 antibody efficacy in advanced melanoma.
Melanoma
Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.
Melanoma
New indirect approach to the therapeutic use of immunotoxins.
Melanoma
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Melanoma
Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Melanoma
Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model.
Melanoma
Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity.
Melanoma
Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
Melanoma
Nuclear damage induced by liposomes containing fitc-labelled saporin on human melanoma cells in vitro.
Melanoma
Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.
Melanoma
Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma.
Melanoma
Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.
Melanoma
Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.
Melanoma
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial.
Melanoma
Overall survival and PD-L1 expression in metastasized malignant melanoma.
Melanoma
Pathology-based Biomarkers Useful for Clinical Decisions in Melanoma.
Melanoma
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Melanoma
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
Melanoma
PCC0208025 (BMS202), a small molecule inhibitor of PD-L1, produces an antitumor effect in B16-F10 melanoma-bearing mice.
Melanoma
PD-1 and PD-L1 antibodies for melanoma.
Melanoma
PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges.
Melanoma
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.
Melanoma
PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.
Melanoma
PD-1 checkpoint blockade in advanced melanoma patients: NK cells, monocytic subsets and host PD-L1 expression as predictive biomarker candidates.
Melanoma
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
Melanoma
PD-1 expression on MelanA-reactive T cells increases during progression to metastatic disease.
Melanoma
PD-1, PD-L1, and BIM as Predictors of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
Melanoma
PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma.
Melanoma
PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Melanoma
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Melanoma
PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.
Melanoma
PD-L1 Detection on Circulating Melanoma Cells.
Melanoma
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Melanoma
PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.
Melanoma
PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy.
Melanoma
PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients.
Melanoma
PD-L1 expression by tumor cell-lines: a predictive marker in melanoma.
Melanoma
PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome.
Melanoma
PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.
Melanoma
PD-L1 expression in human cancers and its association with clinical outcomes.
Melanoma
PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract.
Melanoma
PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation.
Melanoma
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Melanoma
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
Melanoma
PD-L1 expression in meningiomas.
Melanoma
PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival.
Melanoma
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.
Melanoma
PD-L1 expression in tumour buds of colorectal carcinoma.
Melanoma
PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Melanoma
PD-L1 expression levels on tumor cells affect their immunosuppressive activity.
Melanoma
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Melanoma
PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.
Melanoma
PD-L1 IHC assays in melanoma.
Melanoma
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
Melanoma
PD-L1 in melanoma: facts and myths.
Melanoma
PD-L1 inhibits acute and chronic pain by suppressing nociceptive neuron activity via PD-1.
Melanoma
PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
Melanoma
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.
Melanoma
PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
Melanoma
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.
Melanoma
PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma.
Melanoma
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Melanoma
PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B.
Melanoma
PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells.
Melanoma
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Melanoma
PD-L1 Studies Across Tumor Types, its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Melanoma
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p.
Melanoma
PD-L1+ regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis.
Melanoma
PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
Melanoma
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.
Melanoma
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.
Melanoma
PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.
Melanoma
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.
Melanoma
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Melanoma
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.
Melanoma
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Melanoma
Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report.
Melanoma
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma.
Melanoma
Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma.
Melanoma
Phospho-?-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2.
Melanoma
Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Melanoma
Potential prognostic value of PD-L1 and NKG2A expression in Indonesian patients with skin nodular melanoma.
Melanoma
PPAR? inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner.
Melanoma
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
Melanoma
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Melanoma
Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases.
Melanoma
Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
Melanoma
Predictive factors for immunotherapy in melanoma.
Melanoma
Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).
Melanoma
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Melanoma
Prevalence of NRAS Mutation, PD-L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas.
Melanoma
Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.
Melanoma
Primary Ovarian Melanoma Arising From a Mature Teratoma With Melanoma In Situ Present in the Ciliated Columnar and Squamous Epithelium in a Patient With Synchronous Skin Basal Cell Carcinoma.
Melanoma
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Melanoma
Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
Melanoma
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma.
Melanoma
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
Melanoma
Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Melanoma
Programmed Cell Death Ligand 1 Expression in Canine Cancer.
Melanoma
Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma.
Melanoma
Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Melanoma
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Melanoma
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Melanoma
Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes.
Melanoma
Purification and characterization of Moschatin, a novel type I ribosome-inactivating protein from the mature seeds of pumpkin (Cucurbita moschata), and preparation of its immunotoxin against human melanoma cells.
Melanoma
Q&A: Suzanne Topalian on immune therapies.
Melanoma
Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Melanoma
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
Melanoma
Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.
Melanoma
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.
Melanoma
RAC1 P29S regulates PD-L1 expression in melanoma.
Melanoma
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Melanoma
Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells.
Melanoma
Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing.
Melanoma
Rational Design of Hyaluronic Acid-Based Copolymer-Mixed Micelle in Combination PD-L1 Immune Checkpoint Blockade for Enhanced Chemo-Immunotherapy of Melanoma.
Melanoma
Recent advances of molecular mechanisms of regulating PD-L1 expression in melanoma.
Melanoma
Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma.
Melanoma
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Melanoma
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Melanoma
RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
Melanoma
Role of lipids in the retrograde pathway of ricin intoxication.
Melanoma
Saporin 6 conjugated to monoclonal antibody selectively kills human melanoma cells.
Melanoma
Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.
Melanoma
Selective Targeting of Cancerous Mitochondria and Suppression of Tumor Growth Using Redox-Active Treatment Adjuvant.
Melanoma
Sensitivity of cancer cell lines to the novel non-toxic type 2 ribosome-inactivating protein nigrin b.
Melanoma
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.
Melanoma
Significance of PD-L1 Expression in Tongue Cancer Development.
Melanoma
Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth.
Melanoma
Single-dose murine monoclonal antibody ricin A chain immunotoxin in the treatment of metastatic melanoma: a phase I trial.
Melanoma
SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression.
Melanoma
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Melanoma
Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.
Melanoma
SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Melanoma
Stable heat-resistant clones selected from wild-type and surface variants of B-16 melanoma.
Melanoma
Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.
Melanoma
Studies on the mechanism of action of abrin-9.2.27 immunotoxin in human melanoma cell lines.
Melanoma
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
Melanoma
Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors.
Melanoma
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma.
Melanoma
Systemic administration of ?-glucan of 200 kDa modulates melanoma microenvironment and suppresses metastatic cancer.
Melanoma
Targeted co-delivery of Trp-2 polypeptide and monophosphoryl lipid A by pH-sensitive poly (?-amino ester) nano-vaccines for melanoma.
Melanoma
Targeted delivery of immunotoxin by antibody to ganglioside GD3: a novel drug delivery route for tumor cells.
Melanoma
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Melanoma
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.
Melanoma
Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Melanoma
Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review.
Melanoma
Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.
Melanoma
The ?9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration.
Melanoma
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
Melanoma
The changes of angiogenesis and immune regulations in stromal microenvironment of cutaneous melanomas.
Melanoma
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Melanoma
The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.
Melanoma
The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors.
Melanoma
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines.
Melanoma
The Efficacy of Anti-PD-L1 Treatment in Melanoma Is Associated with the Expression of the ECM Molecule EMILIN2.
Melanoma
The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.
Melanoma
The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
Melanoma
The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy.
Melanoma
The HLA-DR mediated signalling increases the migration and invasion of melanoma cells, the expression and lipid raft recruitment of adhesion receptors, PD-L1 and signal transduction proteins.
Melanoma
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.
Melanoma
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Melanoma
The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
Melanoma
The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276.
Melanoma
The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Melanoma
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Melanoma
The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases.
Melanoma
The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas.
Melanoma
The role of genetic polymorphism within PD-L1 gene in cancer. Review.
Melanoma
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.
Melanoma
The Use of Cytologic Material in Melanoma for PD-L1 Immunostaining.
Melanoma
Therapy of metastatic malignant melanoma using Xomazyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin.
Melanoma
TNF? blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Melanoma
Towards understanding the role of sialylation in melanoma progression.
Melanoma
TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas.
Melanoma
Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients.
Melanoma
Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways.
Melanoma
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
Melanoma
Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Melanoma
Triple Therapy Better for Advanced Melanoma.
Melanoma
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.
Melanoma
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Melanoma
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.
Melanoma
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Melanoma
Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Melanoma
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
Melanoma
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
Melanoma
Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.
Melanoma
Tumor-Targeted Drug and CpG Delivery System for Phototherapy and Docetaxel-Enhanced Immunotherapy with Polarization toward M1-Type Macrophages on Triple Negative Breast Cancers.
Melanoma
Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.
Melanoma
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
Melanoma
Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity.
Melanoma
Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.
Melanoma
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells.
Melanoma
Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kB contributes to UV radiation-induced immune suppression.
Melanoma
Validated PD-L1 immunohistochemistry assays (E1L3N & SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.
Melanoma
Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma.
Melanoma
Variable indoleamine 2,3-dioxygenase expression in acral / mucosal melanoma and its possible link to immunotherapy.
Melanoma
VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival.
Melanoma
WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma.
Melanoma
YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma.
Melanoma
[Effect of trichosanthin of cell cycle and apoptosis of murine melanoma cells]
Melanoma
[Immuno-Oncology: A Brief Overview].
Melanoma
[Immunotherapies and melanoma].
Melanoma
[Malignant melanoma of the urinary bladder].
Melanoma
[Molecular and immunohistochemical diagnostics in melanoma].
Melanoma
[What's new in oncology?].
Melanoma, Experimental
Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma.
Melanoma, Experimental
Biochemical analysis and antitumour effect of Abrus precatorius agglutinin derived peptides in Ehrlich's ascites and B16 melanoma mice tumour model.
Melanoma, Experimental
Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Melanoma, Experimental
cGAS is essential for the antitumor effect of immune checkpoint blockade.
Melanoma, Experimental
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses.
Melanoma, Experimental
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.
Melanoma, Experimental
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Melanoma, Experimental
Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Melanoma, Experimental
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
Melanoma, Experimental
Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin.
Melanoma, Experimental
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.
Melanoma, Experimental
Voluntary wheel running can lead to modulation of immune checkpoint molecule expression.
Melena
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
Melioidosis
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.
Melioidosis
Programmed death ligand 1 on Burkholderia pseudomallei-infected human polymorphonuclear neutrophils impairs T cell functions.
Memory Disorders
Unusual social behavior in HPC-1/syntaxin1A knockout mice is caused by disruption of the oxytocinergic neural system.
Meningeal Carcinomatosis
Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report.
Meningioma
Checkpoint inhibition in meningiomas.
Meningioma
Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
Meningioma
Efficient ADCC- killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
Meningioma
Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
Meningioma
Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.
Meningioma
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
Meningioma
New molecular targets in meningiomas: the present and the future.
Meningioma
PD-L1 expression in meningiomas.
Meningioma
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
Meningioma
Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression.
Meningioma
Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours.
Meningioma
Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.
Meningioma
Systemic and local immunosuppression in patients with high-grade meningiomas.
Meningitis
An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys.
Meningitis, Cryptococcal
In vitro and in vivo effect of PD-1/PD-L1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis.
Mesothelioma
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Mesothelioma
Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.
Mesothelioma
Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Mesothelioma
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.
Mesothelioma
Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
Mesothelioma
Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
Mesothelioma
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
Mesothelioma
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
Mesothelioma
Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Mesothelioma
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Mesothelioma
Expression status of PD-L1 and B7-H3 in mesothelioma.
Mesothelioma
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
Mesothelioma
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
Mesothelioma
Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma.
Mesothelioma
IFN-? upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1/PD-L1 blockade.
Mesothelioma
IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells.
Mesothelioma
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Mesothelioma
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
Mesothelioma
Malignant mesothelioma clinical trial combines immunotherapy drugs.
Mesothelioma
Malignant mesothelioma effusions are infiltrated by CD3(+) T cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab.
Mesothelioma
Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
Mesothelioma
Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Mesothelioma
P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment.
Mesothelioma
PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study.
Mesothelioma
PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
Mesothelioma
PD-L1 expression in biphasic pleural mesothelioma with histiocytoid morphology and enrichment of CD8+/CD4+ lymphocytes.
Mesothelioma
PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
Mesothelioma
Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types.
Mesothelioma
Prognostic Immune Cell Profiling of Malignant Pleural Effusion Patients by Computerized Immunohistochemical and Transcriptional Analysis.
Mesothelioma
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.
Mesothelioma
Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
Mesothelioma
Prognostic role of PD-L1 in malignant pleural mesothelioma: unraveling the complexity of the tumor microenvironment in mesothelioma.
Mesothelioma
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1.
Mesothelioma
Response to Comment on "Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy".
Mesothelioma
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Mesothelioma
The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3.
Mesothelioma
Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Mesothelioma
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Mesothelioma
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Mesothelioma
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
Mesothelioma
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Mesothelioma
Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
Mesothelioma
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Mesothelioma, Malignant
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Mesothelioma, Malignant
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Mesothelioma, Malignant
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
Mesothelioma, Malignant
Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study.
Mesothelioma, Malignant
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
Mesothelioma, Malignant
Malignant mesothelioma effusions are infiltrated by CD3(+) T cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab.
Mesothelioma, Malignant
Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
Mesothelioma, Malignant
Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Mesothelioma, Malignant
PD-L1 and prognosis in patients with malignant pleural mesothelioma: a meta-analysis and bioinformatics study.
Mesothelioma, Malignant
PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
Mesothelioma, Malignant
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.
Mesothelioma, Malignant
Prognostic role of PD-L1 in malignant pleural mesothelioma: unraveling the complexity of the tumor microenvironment in mesothelioma.
Mesothelioma, Malignant
Remarkable response to nivolumab in sarcomatoid malignant pleural mesothelioma with high PD-L1.
Mesothelioma, Malignant
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Mesothelioma, Malignant
Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
Mesothelioma, Malignant
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Mesothelioma, Malignant
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Mesothelioma, Malignant
Update on Immunohistochemistry for the Diagnosis of Lung Cancer.
Metabolic Syndrome
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.
Migraine Disorders
Analysis of Genetic Variants in SCN1A, SCN2A, KCNK18, TRPA1 and STX1A as a Possible Marker of Migraine.
Migraine Disorders
Association analysis of STX1A gene variants in common forms of migraine.
Migraine Disorders
Contribution of syntaxin 1A to the genetic susceptibility to migraine: a case-control association study in the Spanish population.
Migraine Disorders
Molecular factors in migraine.
Migraine Disorders
PD-L1 and PD-1 expressed in trigeminal ganglia may inhibit pain in an acute migraine model.
Monoclonal Gammopathy of Undetermined Significance
Carbohydrate analysis of immunoglobulin G myeloma proteins by lectin and high performance liquid chromatography: role of glycosyltransferases in the structures.
Monoclonal Gammopathy of Undetermined Significance
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Mouth Neoplasms
Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells.
Mouth Neoplasms
Clinicopathological and prognostic significance of PD-L1 in oral cancer: A preliminary retrospective immunohistochemistry study.
Mouth Neoplasms
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L
Mouth Neoplasms
Enhanced expression of PD-L1 in oral squamous cell carcinoma-derived CD11b(+)Gr-1(+) cells and its contribution to immunosuppressive activity.
Mouth Neoplasms
Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
Mouth Neoplasms
Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
Mouth Neoplasms
Magnetically Navigated Protein Transduction In Vivo using Iron Oxide-Nanogel Chaperone Hybrid.
Mouth Neoplasms
Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1-mediated immunoescape via STING-IFN signaling and extracellular vesicles.
Mouth Neoplasms
Nano-diamino-tetrac (NDAT) inhibits PD-L1 expression which is essential for proliferation in oral cancer cells.
Mouth Neoplasms
PD-L1 expression patterns in oral cancer as an integrated approach for further prognostic classification.
Mouth Neoplasms
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Mouth Neoplasms
Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells.
Mouth Neoplasms
Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-?-modulated microenvironment in vitro, in vivo, and in clinical patients.
mrna n6-methyladenine demethylase deficiency
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.
Mucolipidoses
Effect of the co-existence of galactosyl and phosphomannosyl residues on beta-hexosaminidase on the processing and transport of the enzyme in mucolipidosis I fibroblasts.
Mucolipidoses
Mucolipidosis II-related mutations inhibit the exit from the endoplasmic reticulum and proteolytic cleavage of GlcNAc-1-phosphotransferase precursor protein (GNPTAB).
Mucolipidoses
Mucolipidosis type II and type III: a systematic review of 843 published cases.
Mucolipidoses
Pathogenic variants in GNPTAB and GNPTG encoding distinct subunits of GlcNAc-1-phosphotransferase differentially impact bone resorption in patients with mucolipidosis type II and III.
Mucopolysaccharidosis I
RTB lectin-mediated delivery of lysosomal ?-l-iduronidase mitigates disease manifestations systemically including the central nervous system.
Mucormycosis
Fungal pathogenesis: A new venom.
Mucositis
Immunohistochemical Analysis of Lichenoid Reactions in Patients Treated with Anti-PD-L1 and Anti-PD-1 Therapy.
Multiple Myeloma
A Novel Anti-PD-L1 Antibody Exhibits Antitumor Effects on Multiple Myeloma in Murine Models via Antibody-Dependent Cellular Cytotoxicity.
Multiple Myeloma
An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients.
Multiple Myeloma
Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.
Multiple Myeloma
Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
Multiple Myeloma
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.
Multiple Myeloma
Bone marrow-derived mesenchymal stem cells inhibit CD8+ T cell immune responses via PD-1/PD-L1 pathway in multiple myeloma.
Multiple Myeloma
Carfilzomib-induced atypical haemolytic uraemic syndrome: a diagnostic challenge and therapeutic success.
Multiple Myeloma
Co-immunizing with PD-L1 induces CD8+ DCs-mediated anti-tumor immunity in multiple myeloma.
Multiple Myeloma
Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma.
Multiple Myeloma
Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients.
Multiple Myeloma
Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade.
Multiple Myeloma
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Multiple Myeloma
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.
Multiple Myeloma
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.
Multiple Myeloma
PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGF? Inhibitors.
Multiple Myeloma
PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma.
Multiple Myeloma
PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model.
Multiple Myeloma
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Multiple Myeloma
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.
Multiple Myeloma
Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies.
Multiple Myeloma
Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma.
Multiple Myeloma
Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma.
Multiple Myeloma
Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Multiple Myeloma
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Multiple Myeloma
Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.
Multiple Myeloma
Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Multiple Myeloma
[Correlation of Nucleostemin with Programmed Death-ligand-1 in Multiple Myeloma U266 Cells].
Multiple Sclerosis
Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease.
Multiple Sclerosis
Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis.
Multiple Sclerosis
Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1.
Multiple Sclerosis
The majority of infiltrating CD8 T lymphocytes in multiple sclerosis lesions is insensitive to enhanced PD-L1 levels on CNS cells.
Multiple Sclerosis, Relapsing-Remitting
Regulation of CTLA-4 and PD-L1 Expression in Relapsing-Remitting Multiple Sclerosis Patients after Treatment with Fingolimod, IFN?-1?, Glatiramer Acetate, and Dimethyl Fumarate Drugs.
Muscle Weakness
Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern.
Muscular Atrophy
Quantification of motor neuron loss and muscular atrophy in ricin-induced focal nerve injury.
Muscular Diseases
Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern.
Myasthenia Gravis
Antigen-specific therapy of experimental myasthenia gravis with acetylcholine receptor-gelonin conjugates in vivo.
Myasthenia Gravis
Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer.
Myasthenia Gravis
Novel immunotoxin: A fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis.
Myasthenia Gravis
PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
Myasthenia Gravis
Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates.
Myasthenia Gravis
Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Mycoses
Anti-PD-L1 peptide improves survival in sepsis.
Mycoses
Expression of pokeweed antiviral proteins in creeping bentgrass.
Mycoses
Plant resistance to fungal infection induced by nontoxic pokeweed antiviral protein mutants.
Mycoses
Reduced toxicity and broad spectrum resistance to viral and fungal infection in transgenic plants expressing pokeweed antiviral protein II.
Mycoses
T cells from Programmed Death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection.
Mycoses
Transformation of blackgram (Vigna mungo (L.) Hepper) by barley chitinase and ribosome-inactivating protein genes towards improving resistance to Corynespora leaf spot fungal disease.
Mycosis Fungoides
Pembrolizumab in mycosis fungoides with PD-L1 structural variants.
Myelodysplastic Syndromes
Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.
Myelodysplastic Syndromes
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Myelodysplastic Syndromes
Variability of PD-L1 expression in mastocytosis.
Myocardial Infarction
Expression of coinhibitory PD-L1 on CD4?CD25?FOXP3? regulatory T cells is elevated in patients with acute coronary syndrome.
Myocardial Ischemia
Expression of coinhibitory PD-L1 on CD4?CD25?FOXP3? regulatory T cells is elevated in patients with acute coronary syndrome.
Myocarditis
Autoimmune complications of immunotherapy: pathophysiology and management.
Myocarditis
Cardiotoxicity of immune checkpoint inhibitors.
Myocarditis
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.
Myocarditis
Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms.
Myocarditis
Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice.
Myocarditis
Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3.
Myocarditis
Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation.
Myocarditis
T Cell Checkpoint Regulators in the Heart.
Myocarditis
The heart of the matter: Protection of the myocardium from T cells.
Myositis
A case of severe Pembrolizumab-induced neutropenia.
Myositis
Autoimmune complications of immunotherapy: pathophysiology and management.
Myositis
Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern.
Myositis
Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer.
Myositis
Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan.
Nasal Polyps
Analysis of glycoproteins from nasal polyps and papillomas by affinity chromatography.
Nasal Polyps
Programmed cell death-1 expression correlates with disease severity and IL-5 in chronic rhinosinusitis with nasal polyps.
Nasopharyngeal Carcinoma
Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1.
Nasopharyngeal Carcinoma
Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
EBV-driven LMP1 and IFN-? up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
Nasopharyngeal Carcinoma
Effect of trichosanthin on apoptosis and telomerase activity of nasopharyngeal carcinomas in nude mice.
Nasopharyngeal Carcinoma
Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
Epstein-Barr virus-encoded circular RNA circBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1.
Nasopharyngeal Carcinoma
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Human nasopharyngeal carcinoma can be radiosensitized by trichosanthin via inhibition of the PI3K pathway.
Nasopharyngeal Carcinoma
Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy.
Nasopharyngeal Carcinoma
Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
Momordica Charantia lectin, a type II ribosome inactivating protein, exhibits antitumor activity toward human nasopharyngeal carcinoma cells in vitro and in vivo.
Nasopharyngeal Carcinoma
PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes.
Nasopharyngeal Carcinoma
PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: A substudy of a randomized phase III trial.
Nasopharyngeal Carcinoma
PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
PD-L1 expression in immune cells is a favorable prognostic factor for nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma.
Nasopharyngeal Carcinoma
PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients.
Nasopharyngeal Carcinoma
PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.
Nasopharyngeal Carcinoma
PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.
Nasopharyngeal Carcinoma
Preferential cytotoxicity of the type I ribosome inactivating protein alpha-momorcharin on human nasopharyngeal carcinoma cells under normoxia and hypoxia.
Nasopharyngeal Carcinoma
Prognostic value of immune checkpoint molecules in head and neck cancer: a meta-analysis.
Nasopharyngeal Carcinoma
Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism.
Nasopharyngeal Carcinoma
Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis.
Nasopharyngeal Carcinoma
Trichosanthin down-regulates Notch signaling and inhibits proliferation of the nasopharyngeal carcinoma cell line CNE2 in vitro.
Nasopharyngeal Carcinoma
Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.
Nasopharyngeal Carcinoma
Usefulness of [18F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
[The clinical significance of the expression of costimulatory molecule PD-L1 in nasopharyngeal carcinoma]
Nasopharyngeal Neoplasms
Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
Nasopharyngeal Neoplasms
Durable response to first-line nivolumab in a patient with oligometastatic PD-L1 positive nasopharyngeal cancer.
Nasopharyngeal Neoplasms
Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer.
Neoplasm Metastasis
18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer.
Neoplasm Metastasis
A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway.
Neoplasm Metastasis
A case of multiple synchronously diagnosed brain metastases from alveolar soft part sarcoma without concurrent lung involvement.
Neoplasm Metastasis
A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas.
Neoplasm Metastasis
A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis.
Neoplasm Metastasis
A nomogram incorporating PD-L1, NLR, and clinicopathologic features to predict inguinal lymph node metastasis in penile squamous cell carcinoma.
Neoplasm Metastasis
A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients.
Neoplasm Metastasis
A Staphylococcus aureus Coinfection on a COVID-19 Pneumonia in a Breast Cancer Patient.
Neoplasm Metastasis
A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis.
Neoplasm Metastasis
Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.
Neoplasm Metastasis
Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE.
Neoplasm Metastasis
Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Neoplasm Metastasis
Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.
Neoplasm Metastasis
AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.
Neoplasm Metastasis
An immunohistochemical analysis of CD3, PD-L1, and CTLA-4 expression in carcinosarcomas of the gynecological tract and their metastases.
Neoplasm Metastasis
Analysis of gp74 expression by transformed rat fibroblasts from experimental pulmonary metastases following specific ricin A-chain immunotoxin therapy.
Neoplasm Metastasis
Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature.
Neoplasm Metastasis
Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.
Neoplasm Metastasis
Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases.
Neoplasm Metastasis
Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Neoplasm Metastasis
Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Neoplasm Metastasis
ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma.
Neoplasm Metastasis
ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Neoplasm Metastasis
Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
Neoplasm Metastasis
Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer.
Neoplasm Metastasis
Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications.
Neoplasm Metastasis
Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.
Neoplasm Metastasis
Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
Neoplasm Metastasis
Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Neoplasm Metastasis
Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Neoplasm Metastasis
Association of Immunostaining of Galectin-3 and Sambucus nigra Agglutinin with Invasion, Metastasis and Poor Progression of Gallbladder Adenocarcinoma.
Neoplasm Metastasis
Association of PD-L1 and HIF-1? Coexpression with Poor Prognosis in Hepatocellular Carcinoma.
Neoplasm Metastasis
Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Neoplasm Metastasis
Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Neoplasm Metastasis
Atezolizumab First-Line Combination Therapy: A Review in Metastatic Nonsquamous NSCLC.
Neoplasm Metastasis
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Neoplasm Metastasis
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Neoplasm Metastasis
Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy.
Neoplasm Metastasis
B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
Neoplasm Metastasis
BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Neoplasm Metastasis
Biomimetic Diselenide-Bridged Mesoporous Organosilica Nanoparticles as an X-ray-Responsive Biodegradable Carrier for Chemo-Immunotherapy.
Neoplasm Metastasis
Bone decalcification to assess programmed cell death ligand 1 expression in bone metastases of non-small cell lung cancers.
Neoplasm Metastasis
Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status.
Neoplasm Metastasis
Case series of pleomorphic carcinomas of the lung treated with nivolumab.
Neoplasm Metastasis
CD163(+)CD204(+) tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma.
Neoplasm Metastasis
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
Neoplasm Metastasis
CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC.
Neoplasm Metastasis
Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity.
Neoplasm Metastasis
Characterization and potential role of PD-L1 positive lung cancer stem cells in lymph nodes metastasis.
Neoplasm Metastasis
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Neoplasm Metastasis
Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation.
Neoplasm Metastasis
Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Neoplasm Metastasis
Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
Neoplasm Metastasis
Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma
Neoplasm Metastasis
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis.
Neoplasm Metastasis
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
Neoplasm Metastasis
Clinical retrospective study on the expression of the PD-L1 molecule in sporadic colorectal cancer and its correlation with K-ras gene mutations in Chinese patients.
Neoplasm Metastasis
CLINICAL SIGNIFICANCE OF PD-L1 EXPRESSION IN PARATHYROID CANCER.
Neoplasm Metastasis
Clinical significance of PD-L1 expression in patients with surgically resected non-small cell lung cancer.
Neoplasm Metastasis
Clinical significance of PD?L1 and PD?L2 copy number gains in non?small?cell lung cancer.
Neoplasm Metastasis
Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma.
Neoplasm Metastasis
Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
Neoplasm Metastasis
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Neoplasm Metastasis
Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Neoplasm Metastasis
Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.
Neoplasm Metastasis
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Neoplasm Metastasis
Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma.
Neoplasm Metastasis
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Neoplasm Metastasis
Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis.
Neoplasm Metastasis
Clinicopathological and prognostic values of PD-L1 expression in oesophageal squamous cell carcinoma: a meta-analysis of 31 studies with 5368 patients.
Neoplasm Metastasis
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Neoplasm Metastasis
Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression.
Neoplasm Metastasis
CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Neoplasm Metastasis
CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
Neoplasm Metastasis
Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis.
Neoplasm Metastasis
Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Neoplasm Metastasis
Co-expression of PD-L1 and HIF-1? predicts poor prognosis in Patients with Non-small Cell Lung Cancer after surgery.
Neoplasm Metastasis
Colony growth and chemosensitivity in vitro of human melanoma biopsies. Relationship to clinical parameters.
Neoplasm Metastasis
Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
Neoplasm Metastasis
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Neoplasm Metastasis
Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response.
Neoplasm Metastasis
Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
Neoplasm Metastasis
Comparison of
Neoplasm Metastasis
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
Neoplasm Metastasis
Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Neoplasm Metastasis
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
Neoplasm Metastasis
Comprehensive evaluation of PD-L1 expression in primary and metastatic prostate cancer.
Neoplasm Metastasis
Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases.
Neoplasm Metastasis
Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
Neoplasm Metastasis
Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA
Neoplasm Metastasis
Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Neoplasm Metastasis
Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
Neoplasm Metastasis
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
Neoplasm Metastasis
Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer.
Neoplasm Metastasis
Coordination and Redox Dual-Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy.
Neoplasm Metastasis
Correction to Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis.
Neoplasm Metastasis
Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma.
Neoplasm Metastasis
Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort.
Neoplasm Metastasis
Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.
Neoplasm Metastasis
Correlation of pd-l1 staining in tumor cells and tumor infiltrate between primary tumors and matched metastasis in advanced colorectal cancer patients.
Neoplasm Metastasis
Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer.
Neoplasm Metastasis
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Neoplasm Metastasis
Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.
Neoplasm Metastasis
Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1? and STAT3 (T705) signaling pathways in hepatic cancer.
Neoplasm Metastasis
Cutaneous metastasis of PD-L1 positive ovarian carcinoma.
Neoplasm Metastasis
CXCL6 fuels the growth and metastases of esophageal squamous cell carcinoma cells both in vitro and in vivo through upregulation of PD-L1 via activation of STAT3 pathway.
Neoplasm Metastasis
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Neoplasm Metastasis
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.
Neoplasm Metastasis
Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Neoplasm Metastasis
Differences in lectin binding in tissue sections of human and murine malignant tumors and their metastases.
Neoplasm Metastasis
Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
Neoplasm Metastasis
Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014.
Neoplasm Metastasis
Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation.
Neoplasm Metastasis
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Neoplasm Metastasis
Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Neoplasm Metastasis
Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.
Neoplasm Metastasis
Differential Molecular Expression Patterns Associated with Metastasis in Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Neoplasm Metastasis
Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.
Neoplasm Metastasis
Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer.
Neoplasm Metastasis
Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Neoplasm Metastasis
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis.
Neoplasm Metastasis
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients.
Neoplasm Metastasis
Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Neoplasm Metastasis
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Neoplasm Metastasis
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.
Neoplasm Metastasis
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Neoplasm Metastasis
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
Neoplasm Metastasis
Effect of Acorus calamus L. Polysaccharide on CD274 and CD326 Expression by Lewis Lung Carcinoma Cells in Mice.
Neoplasm Metastasis
Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis.
Neoplasm Metastasis
Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study.
Neoplasm Metastasis
Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer.
Neoplasm Metastasis
Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy.
Neoplasm Metastasis
Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer Patients With Different Metastatic Sites: A Systematic Review and Meta-Analysis.
Neoplasm Metastasis
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.
Neoplasm Metastasis
Efficacy of PD-1 or PD-L1 inhibitors and central nervous system metastases in advanced cancer: a meta-analysis.
Neoplasm Metastasis
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Neoplasm Metastasis
Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
Neoplasm Metastasis
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer.
Neoplasm Metastasis
Endostar blocks the metastasis, invasion and angiogenesis of ovarian cancer cells.
Neoplasm Metastasis
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions.
Neoplasm Metastasis
Enhanced Tumor Retention Effect by Click Chemistry for Improved Cancer Immunochemotherapy.
Neoplasm Metastasis
Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas.
Neoplasm Metastasis
Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.
Neoplasm Metastasis
Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives.
Neoplasm Metastasis
Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Neoplasm Metastasis
Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma.
Neoplasm Metastasis
Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Neoplasm Metastasis
Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome.
Neoplasm Metastasis
Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.
Neoplasm Metastasis
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Neoplasm Metastasis
Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Neoplasm Metastasis
Expression of PDL1 and Her2neu in Gastric and Gastroesophageal Junction Adenocarcinoma.
Neoplasm Metastasis
Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.
Neoplasm Metastasis
Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer.
Neoplasm Metastasis
Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status.
Neoplasm Metastasis
Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.
Neoplasm Metastasis
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma.
Neoplasm Metastasis
Expression of programmed death-ligand 1 and hypoxia-inducible factor-1? proteins in endometrial carcinoma.
Neoplasm Metastasis
Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Neoplasm Metastasis
Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer.
Neoplasm Metastasis
Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.
Neoplasm Metastasis
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
Neoplasm Metastasis
Extracellular vesicles and oncogenic signaling.
Neoplasm Metastasis
FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Neoplasm Metastasis
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Neoplasm Metastasis
Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis.
Neoplasm Metastasis
Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Neoplasm Metastasis
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
Neoplasm Metastasis
Functional Diversity of p53 in Human and Wild Animals.
Neoplasm Metastasis
Gastrointestinal tract metastasis of lung cancer: The PD-L1 expression and correlated clinicopathological variables.
Neoplasm Metastasis
GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer.
Neoplasm Metastasis
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
Neoplasm Metastasis
Gene mutations of esophageal squamous cell carcinoma based on next-generation sequencing.
Neoplasm Metastasis
Genetic alterations in gastric cancer patients according to sex.
Neoplasm Metastasis
Glucose-6-phosphate dehydrogenase correlates with tumor immune activity and programmed death ligand-1 expression in Merkel cell carcinoma.
Neoplasm Metastasis
Heterogeneity in immune marker expression after acquisition of resistance to EGFR kinase inhibitors: analysis of a case with small cell lung cancer transformation.
Neoplasm Metastasis
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma.
Neoplasm Metastasis
Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
Neoplasm Metastasis
Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
Neoplasm Metastasis
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Neoplasm Metastasis
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Neoplasm Metastasis
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer.
Neoplasm Metastasis
HIF1?/PD-L1 axis mediates hypoxia-induced cell apoptosis and tumor progression in follicular thyroid carcinoma.
Neoplasm Metastasis
HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis.
Neoplasm Metastasis
High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Neoplasm Metastasis
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
Neoplasm Metastasis
High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement.
Neoplasm Metastasis
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Neoplasm Metastasis
High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.
Neoplasm Metastasis
High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy.
Neoplasm Metastasis
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.
Neoplasm Metastasis
High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease.
Neoplasm Metastasis
Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Neoplasm Metastasis
Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
Neoplasm Metastasis
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Neoplasm Metastasis
Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Neoplasm Metastasis
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Co-expression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung.
Neoplasm Metastasis
Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Neoplasm Metastasis
Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis.
Neoplasm Metastasis
Identification and characterization of riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana.
Neoplasm Metastasis
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
Neoplasm Metastasis
Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma.
Neoplasm Metastasis
Immune checkpoint analysis in lip cancer.
Neoplasm Metastasis
Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases.
Neoplasm Metastasis
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma.
Neoplasm Metastasis
Immune Contexture of MMR-Proficient Primary Colorectal Cancer and Matched Liver and Lung Metastases.
Neoplasm Metastasis
Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Neoplasm Metastasis
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.
Neoplasm Metastasis
Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.
Neoplasm Metastasis
Immunological differences between primary and metastatic breast cancer.
Neoplasm Metastasis
Impact of Neoadjuvant Chemotherapy on Concordance of PD-L1 Staining Fidelity between the Primary Tumor and Lymph Node Metastases in Bladder Cancer.
Neoplasm Metastasis
Impact of sidedness of colorectal cancer on tumor immunity.
Neoplasm Metastasis
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Neoplasm Metastasis
Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Neoplasm Metastasis
Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma.
Neoplasm Metastasis
Increased expression levels of Syntaxin 1A and Synaptobrevin 2/Vesicle-Associated Membrane Protein-2 are associated with the progression of bladder cancer.
Neoplasm Metastasis
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Neoplasm Metastasis
Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours.
Neoplasm Metastasis
Independent association of PD-L1 expression with non-inactivated VHL clear cell renal cell carcinoma - a finding with therapeutic potential.
Neoplasm Metastasis
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Neoplasm Metastasis
Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression.
Neoplasm Metastasis
Inhibition to Epithelial-Mesenchymal Transition and Metastatic Potential In Colorectal Cancer Cell By Combination of Traditional Chinese Medicine Formulation Jiedu Sangen Decoction and PD-L1 Inhibitor.
Neoplasm Metastasis
Integrative immunologic and genomic characterization of brain metastasis from ovarian/peritoneal cancer.
Neoplasm Metastasis
Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling.
Neoplasm Metastasis
Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Neoplasm Metastasis
Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
Neoplasm Metastasis
Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Neoplasm Metastasis
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy.
Neoplasm Metastasis
Intracranial complete response for non-small-cell lung cancer patient with negative PD-L1 expression of the lung using nivolumab.
Neoplasm Metastasis
Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma.
Neoplasm Metastasis
Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma.
Neoplasm Metastasis
Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin.
Neoplasm Metastasis
Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Neoplasm Metastasis
Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
Neoplasm Metastasis
Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
Neoplasm Metastasis
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Neoplasm Metastasis
Involvement of Cellular Prion Protein in Invasion and Metastasis of Lung Cancer by Inducing Treg Cell Development.
Neoplasm Metastasis
Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.
Neoplasm Metastasis
LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a.
Neoplasm Metastasis
Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.
Neoplasm Metastasis
Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials.
Neoplasm Metastasis
Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report.
Neoplasm Metastasis
Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects.
Neoplasm Metastasis
Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy.
Neoplasm Metastasis
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Neoplasm Metastasis
Mediation of reduction of spontaneous and experimental pulmonary metastases by ricin A-chain immunotoxin 45-2D9-RTA with potentiation by systemic monensin in mice.
Neoplasm Metastasis
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
Neoplasm Metastasis
Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells.
Neoplasm Metastasis
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Neoplasm Metastasis
MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3.
Neoplasm Metastasis
miR-217 inhibits laryngeal cancer metastasis by repressing AEG-1 and PD-L1 expression.
Neoplasm Metastasis
miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1.
Neoplasm Metastasis
Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer.
Neoplasm Metastasis
Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer.
Neoplasm Metastasis
Multiplex immunohistochemistry indicates biomarkers in colorectal cancer.
Neoplasm Metastasis
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Neoplasm Metastasis
Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology.
Neoplasm Metastasis
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Neoplasm Metastasis
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Neoplasm Metastasis
Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Neoplasm Metastasis
Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy.
Neoplasm Metastasis
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.
Neoplasm Metastasis
Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Neoplasm Metastasis
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
Neoplasm Metastasis
Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Neoplasm Metastasis
Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1.
Neoplasm Metastasis
Patterns of disease progression to checkpoint inhibitor immunotherapy in patients with stage IV non-small cell lung cancer.
Neoplasm Metastasis
PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Neoplasm Metastasis
PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate?
Neoplasm Metastasis
PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread.
Neoplasm Metastasis
PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
Neoplasm Metastasis
PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
Neoplasm Metastasis
PD-1 Blockade During Post-partum Involution Reactivates the Anti-tumor Response and Reduces Lymphatic Vessel Density.
Neoplasm Metastasis
PD-1 expression on MelanA-reactive T cells increases during progression to metastatic disease.
Neoplasm Metastasis
PD-1, PD-L1, and BIM as Predictors of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
Neoplasm Metastasis
PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Neoplasm Metastasis
PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
Neoplasm Metastasis
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.
Neoplasm Metastasis
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
Neoplasm Metastasis
PD-L1 and LAG-3 expression in advanced cutaneous squamous cell carcinomas.
Neoplasm Metastasis
PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.
Neoplasm Metastasis
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.
Neoplasm Metastasis
PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
Neoplasm Metastasis
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.
Neoplasm Metastasis
PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Neoplasm Metastasis
PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
Neoplasm Metastasis
PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Neoplasm Metastasis
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Neoplasm Metastasis
PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Neoplasm Metastasis
PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263.
Neoplasm Metastasis
PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
Neoplasm Metastasis
PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy.
Neoplasm Metastasis
PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Neoplasm Metastasis
PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival.
Neoplasm Metastasis
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.
Neoplasm Metastasis
PD-L1 expression in colon cancer and its relationship with clinical prognosis.
Neoplasm Metastasis
PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis.
Neoplasm Metastasis
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer.
Neoplasm Metastasis
PD-L1 Expression in Extramammary Paget Disease: A Case Series.
Neoplasm Metastasis
PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer.
Neoplasm Metastasis
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
Neoplasm Metastasis
PD-L1 expression in malignant salivary gland tumors.
Neoplasm Metastasis
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Neoplasm Metastasis
PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis.
Neoplasm Metastasis
PD-L1 expression in tongue squamous cell carcinoma.
Neoplasm Metastasis
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
Neoplasm Metastasis
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.
Neoplasm Metastasis
PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
Neoplasm Metastasis
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Neoplasm Metastasis
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Neoplasm Metastasis
PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer.
Neoplasm Metastasis
PD-L1 expression is associated with advanced non-small cell lung cancer.
Neoplasm Metastasis
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
Neoplasm Metastasis
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases: Erratum.
Neoplasm Metastasis
PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer.
Neoplasm Metastasis
PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Neoplasm Metastasis
PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Neoplasm Metastasis
PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
Neoplasm Metastasis
PD-L1 gene expression in Japanese lung cancer patients.
Neoplasm Metastasis
PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay.
Neoplasm Metastasis
PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.
Neoplasm Metastasis
PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma.
Neoplasm Metastasis
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer.
Neoplasm Metastasis
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.
Neoplasm Metastasis
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.
Neoplasm Metastasis
PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma.
Neoplasm Metastasis
PD-L1 Overexpression on Tumor-Infiltrating Lymphocytes Related to Better Prognosis of Colorectal Cancer.
Neoplasm Metastasis
PD-L1 Protein Expression and Gene Amplification Correlate with the Clinicopathological Characteristics and Prognosis of Lung Squamous Cell Carcinoma.
Neoplasm Metastasis
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR.
Neoplasm Metastasis
PD-L1+ regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis.
Neoplasm Metastasis
PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
Neoplasm Metastasis
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.
Neoplasm Metastasis
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Neoplasm Metastasis
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer.
Neoplasm Metastasis
PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8+ T cell exhaustion during metastasis.
Neoplasm Metastasis
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
Neoplasm Metastasis
Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report.
Neoplasm Metastasis
Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.
Neoplasm Metastasis
Phospho-?-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2.
Neoplasm Metastasis
Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer.
Neoplasm Metastasis
Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment.
Neoplasm Metastasis
Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals.
Neoplasm Metastasis
PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.
Neoplasm Metastasis
PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma.
Neoplasm Metastasis
Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma.
Neoplasm Metastasis
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
Neoplasm Metastasis
Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Neoplasm Metastasis
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Neoplasm Metastasis
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Neoplasm Metastasis
Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.
Neoplasm Metastasis
Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Neoplasm Metastasis
Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
Neoplasm Metastasis
Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
Neoplasm Metastasis
Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer.
Neoplasm Metastasis
Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
Neoplasm Metastasis
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
Neoplasm Metastasis
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
Neoplasm Metastasis
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients.
Neoplasm Metastasis
Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Neoplasm Metastasis
Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.
Neoplasm Metastasis
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.
Neoplasm Metastasis
Prognostic significance of PD-L1 protein expression and copy number gains in locally advanced cervical cancer.
Neoplasm Metastasis
Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Neoplasm Metastasis
Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.
Neoplasm Metastasis
Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
Neoplasm Metastasis
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours.
Neoplasm Metastasis
Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms.
Neoplasm Metastasis
Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis.
Neoplasm Metastasis
Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
Neoplasm Metastasis
Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
Neoplasm Metastasis
Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma.
Neoplasm Metastasis
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Neoplasm Metastasis
Prognostic value of tumor infiltrating lymphocytes combined with PD-L1 expression for patients with solitary colorectal cancer liver metastasis.
Neoplasm Metastasis
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Neoplasm Metastasis
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Neoplasm Metastasis
Programmed cell death ligand-1 and cytotoxic T cell infiltrates in metastatic cutaneous squamous cell carcinoma of the head and neck.
Neoplasm Metastasis
Programmed cell death protein 1/programmed death ligand 1 but not HER2 is a potential therapeutic target in gastric neuroendocrine carcinoma.
Neoplasm Metastasis
Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome.
Neoplasm Metastasis
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
Neoplasm Metastasis
Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
Neoplasm Metastasis
Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
Neoplasm Metastasis
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Neoplasm Metastasis
Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin ?4/SNAI1/SIRT3 signaling pathway.
Neoplasm Metastasis
Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Neoplasm Metastasis
Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis.
Neoplasm Metastasis
Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer.
Neoplasm Metastasis
Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma.
Neoplasm Metastasis
Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?
Neoplasm Metastasis
Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Neoplasm Metastasis
Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
Neoplasm Metastasis
Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.
Neoplasm Metastasis
Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer.
Neoplasm Metastasis
Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction.
Neoplasm Metastasis
Prostasin regulates PD-L1 expression in human lung cancer cells.
Neoplasm Metastasis
Pulmonary Neuroendocrine Neoplasms Overexpressing Epithelial-Mesenchymal Transition Mechanical Barriers Genes Lack Immune-Suppressive Response and Present an Increased Risk of Metastasis.
Neoplasm Metastasis
PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
Neoplasm Metastasis
Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.
Neoplasm Metastasis
Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
Neoplasm Metastasis
Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy.
Neoplasm Metastasis
Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.
Neoplasm Metastasis
Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
Neoplasm Metastasis
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity.
Neoplasm Metastasis
Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Neoplasm Metastasis
Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines.
Neoplasm Metastasis
Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma.
Neoplasm Metastasis
Relationship Between Programmed Death-ligand 1 and Clinicopathological Characteristics in Non-small Cell Lung Cancer Patients.
Neoplasm Metastasis
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
Neoplasm Metastasis
Relationship with programmed cell death ligand 1 (PD-L1) and DTI features in brain metastases of non-small cell lung cancer; Preliminary study.
Neoplasm Metastasis
RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
Neoplasm Metastasis
Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL.
Neoplasm Metastasis
Rise of PD-L1 expression during metastasis of colorectal cancer: implications for immunotherapy.
Neoplasm Metastasis
Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
Neoplasm Metastasis
Role of TGF-? in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Neoplasm Metastasis
ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report.
Neoplasm Metastasis
Screening for metastatic osteosarcoma biomarkers with a DNA microarray.
Neoplasm Metastasis
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.
Neoplasm Metastasis
Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation.
Neoplasm Metastasis
Serum alpha-fetoprotein subfractions identified by Ricinus communis agglutinin I in hepatic malignancies, yolk sac tumor, benign hepatic diseases, and fetal stage.
Neoplasm Metastasis
Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer.
Neoplasm Metastasis
Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
Neoplasm Metastasis
Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Neoplasm Metastasis
Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Neoplasm Metastasis
Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Neoplasm Metastasis
Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.
Neoplasm Metastasis
Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.
Neoplasm Metastasis
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.
Neoplasm Metastasis
Stage III Non-small Cell Lung Cancer: A UK National Survey of Practice.
Neoplasm Metastasis
Stem cell-released oncolytic herpes simplex virus has therapeutic efficacy in brain metastatic melanomas.
Neoplasm Metastasis
Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
Neoplasm Metastasis
Structures of the oligosaccharide chains of two forms of alpha 1-acid glycoprotein purified from liver metastases of lung, colon, and breast tumors.
Neoplasm Metastasis
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
Neoplasm Metastasis
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
Neoplasm Metastasis
The ?9 Nicotinic Acetylcholine Receptor Mediates Nicotine-Induced PD-L1 Expression and Regulates Melanoma Cell Proliferation and Migration.
Neoplasm Metastasis
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy.
Neoplasm Metastasis
The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Neoplasm Metastasis
The Association of Tumor-Infiltrating Lymphocytes and Programmed Cell Death 1 Expression with the Incidence of Distant Metastasis in Triple-Negative Breast Cancer Subjects in Sanglah General Hospital, Bali, Indonesia.
Neoplasm Metastasis
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Neoplasm Metastasis
The canonical TGF-?/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
Neoplasm Metastasis
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer.
Neoplasm Metastasis
The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Neoplasm Metastasis
The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.
Neoplasm Metastasis
The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.
Neoplasm Metastasis
The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Neoplasm Metastasis
The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer.
Neoplasm Metastasis
The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery.
Neoplasm Metastasis
The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
Neoplasm Metastasis
The current status of checkpoint inhibitors in metastatic bladder cancer.
Neoplasm Metastasis
The expression of programmed death-ligand 1 and its association with histopathological grade, stage of disease, and occurrence of metastasis in breast cancer.
Neoplasm Metastasis
The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer.
Neoplasm Metastasis
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Neoplasm Metastasis
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Neoplasm Metastasis
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Neoplasm Metastasis
The Major Role of NF-?B in the Depth of Invasion on Acral Melanoma by Decreasing CD8+ T Cells.
Neoplasm Metastasis
The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
Neoplasm Metastasis
The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.
Neoplasm Metastasis
The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.
Neoplasm Metastasis
The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.
Neoplasm Metastasis
The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Neoplasm Metastasis
The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma.
Neoplasm Metastasis
The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count.
Neoplasm Metastasis
The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma.
Neoplasm Metastasis
The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasis.
Neoplasm Metastasis
The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
Neoplasm Metastasis
The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
Neoplasm Metastasis
Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting.
Neoplasm Metastasis
Title: Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase 2 KEYNOTE-086 Study.
Neoplasm Metastasis
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Neoplasm Metastasis
Treatment of micrometastases from Lewis lung carcinoma with abrin and cyclophosphamide, given singly and in combination.
Neoplasm Metastasis
Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Neoplasm Metastasis
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.
Neoplasm Metastasis
Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ? 50.
Neoplasm Metastasis
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
Neoplasm Metastasis
Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.
Neoplasm Metastasis
Tumor-induced peripheral immunosuppression promotes brain metastasis in patients with non-small cell lung cancer.
Neoplasm Metastasis
Tumor-infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
Neoplasm Metastasis
Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.
Neoplasm Metastasis
Tumor-specific targeting of pancreatic cancer with Shigatoxin B-subunit.
Neoplasm Metastasis
Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.
Neoplasm Metastasis
Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.
Neoplasm Metastasis
Uncovering PD-L1 and CD8+ TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma.
Neoplasm Metastasis
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Neoplasm Metastasis
Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer.
Neoplasm Metastasis
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.
Neoplasm Metastasis
Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
Neoplasm Metastasis
Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Neoplasm Metastasis
Validated PD-L1 immunohistochemistry assays (E1L3N & SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.
Neoplasm Metastasis
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.
Neoplasm Metastasis
Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy.
Neoplasm Metastasis
YAP/STAT3 promotes the immune escape of larynx carcinoma by activating VEGFR1-TGF? signaling to facilitate PD-L1 expression in M2-like TAMs.
Neoplasm Metastasis
[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1?Antibody-Safety and Effectiveness of Pirfenidone].
Neoplasm Metastasis
[Concomitant use of nivolumab and immunosuppressants in a renal transplant patient].
Neoplasm Metastasis
[Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids].
Neoplasm Metastasis
[Expression and significance of PD-L1 in laryngocarcinoma]
Neoplasm Metastasis
[Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
Neoplasm Metastasis
[Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].
Neoplasm Metastasis
[Expression of Bcl-2, PD-L1 and its clinical significance in colorectal cancer].
Neoplasm Metastasis
[Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].
Neoplasm Metastasis
[Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
Neoplasm Metastasis
[Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
Neoplasm Metastasis
[Immunotherapies - Overview, mode of action and clinical implications].
Neoplasm Metastasis
[Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer].
Neoplasm Metastasis
[Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
Neoplasm Micrometastasis
Treatment of micrometastases from Lewis lung carcinoma with abrin and cyclophosphamide, given singly and in combination.
Neoplasm Micrometastasis
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.
Neoplasm, Residual
A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.
Neoplasm, Residual
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy.
Neoplasm, Residual
Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.
Neoplasm, Residual
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Neoplasm, Residual
Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Neoplasm, Residual
Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.
Neoplasm, Residual
PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Neoplasm, Residual
Platelet-armored nanoplatform to harmonize janus-faced IFN-? against tumor recurrence and metastasis.
Neoplasm, Residual
Prognostic value of proliferation, PD-L1 and nuclear size in patients with superior sulcus tumours treated with chemoradiotherapy and surgery.
Neoplasm, Residual
Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Neoplasm, Residual
Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
Neoplasm, Residual
Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab.
Neoplasm, Residual
Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice.
Neoplasm, Residual
Relationship between Microsatellite Instability, Immune Cells Infiltration, and Expression of Immune Checkpoint Molecules in Ovarian Carcinoma: Immunotherapeutic Strategies for the Future.
Neoplasm, Residual
Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial.
Neoplasm, Residual
[PD-L1 status in breast cancer].
Neoplasms
"Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms.
Neoplasms
"Lazarus response" of nivolumab in a frail patient with non-small-cell lung cancer.
Neoplasms
18F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.
Neoplasms
18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer.
Neoplasms
18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Neoplasms
18F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer.
Neoplasms
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer.
Neoplasms
2,5-dimethylcelecoxib improves immune microenvironment of hepatocellular carcinoma by promoting ubiquitination of HBx-induced PD-L1.
Neoplasms
2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma.
Neoplasms
4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Neoplasms
5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients.
Neoplasms
5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
Neoplasms
89Zr Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression.
Neoplasms
89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Neoplasms
89Zr-Labeled Anti-PD-L1 Antibody Fragment for Evaluating In Vivo PD-L1 Levels in Melanoma Mouse Model.
Neoplasms
9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
Neoplasms
?-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion.
Neoplasms
?-Catenin-driven adrenocortical carcinoma is characterized with immune exclusion.
Neoplasms
?-PD-L1 mAb enhances the abscopal effect of hypo-fractionated radiation by attenuating PD-L1 expression and inducing CD8+ T-cell infiltration.
Neoplasms
?1-Acid Glycoprotein Enhances the Immunosuppressive and Protumor Functions of Tumor-Associated Macrophages.
Neoplasms
?? T Cells Support Pancreatic Oncogenesis by Restraining ?? T Cell Activation.
Neoplasms
?catenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors.
Neoplasms
?v?3-integrin regulates PD-L1 expression and is involved in cancer immune evasion.
Neoplasms
A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma.
Neoplasms
A biologic scaffold-associated type 2 immune microenvironment inhibits tumor formation and synergizes with checkpoint immunotherapy.
Neoplasms
A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
Neoplasms
A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway.
Neoplasms
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Neoplasms
A carrier-free multiplexed gene editing system applicable for suspension cells.
Neoplasms
A Case of a Pathological Complete Response to Neoadjuvant Nivolumab plus Ipilimumab in Periampullary Adenocarcinoma.
Neoplasms
A case of JAK2V617F-positive essential thrombocythemia where allele burden was reduced by a PD-1 inhibitor.
Neoplasms
A case of Langerhans cell sarcoma on the scalp: Whole-exome sequencing reveals a role of ultraviolet in the pathogenesis.
Neoplasms
A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and Immunotherapy.
Neoplasms
A case of solitary paraaortic lymph node recurrence of lung squamous cell carcinoma after resection.
Neoplasms
A case of the third-line treatment of lung adenocarcinoma using nivolumab combined with anlotinib.
Neoplasms
A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer.
Neoplasms
A case report: metastasis of melanoma to the heart in an era of immunotherapy.
Neoplasms
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy.
Neoplasms
A chemical conjugation of JQ-1 and a TLR7 agonist induces tumoricidal effects in a murine model of melanoma via enhanced immunomodulation.
Neoplasms
A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice.
Neoplasms
A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma.
Neoplasms
A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Neoplasms
A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers.
Neoplasms
A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.
Neoplasms
A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Neoplasms
A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma.
Neoplasms
A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.
Neoplasms
A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma.
Neoplasms
A comparative characterization of the circulating miRNome in whole blood and serum of HCC patients.
Neoplasms
A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.
Neoplasms
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
Neoplasms
A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines.
Neoplasms
A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers.
Neoplasms
A comprehensive pan-cancer analysis of CD274 gene amplification, tumor mutation burden, microsatellite instability, and PD-L1 expression in Chinese cancer patients.
Neoplasms
A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma.
Neoplasms
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland.
Neoplasms
A CT-derived deep neural network predicts for programmed death ligand-1 expression status in advanced lung adenocarcinomas.
Neoplasms
A defucosylated anti-PD-L1 monoclonal antibody 13-mG2a-f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Neoplasms
A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer.
Neoplasms
A dynamic mutational landscape associated to an inter-regionally diverse immune response in malignant rhabdoid tumour.
Neoplasms
A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-Like Properties and Invasion in Human Bladder Cancer.
Neoplasms
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
Neoplasms
A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients.
Neoplasms
A flow-proteometric platform for analyzing protein concentration (FAP): Proof of concept for quantification of PD-L1 protein in cells and tissues.
Neoplasms
A fully human monoclonal antibody targeting PD-L1 with potent anti-tumor activity.
Neoplasms
A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity.
Neoplasms
A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
Neoplasms
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Neoplasms
A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Neoplasms
A high number of PD-L1+ CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors.
Neoplasms
A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis.
Neoplasms
A highly stable multifunctional aptamer for enhancing antitumor immunity against hepatocellular carcinoma by blocking dual immune checkpoints.
Neoplasms
A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Neoplasms
A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Neoplasms
A humanized single-chain Fv fragment with high targeting potential against human malignant gliomas.
Neoplasms
A laboratory model of toxin-induced hemolytic uremic syndrome.
Neoplasms
A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages.
Neoplasms
A Matching-Adjusted Indirect Comparison of Pembrolizumab + Chemotherapy vs. Nivolumab + Ipilimumab as First-Line Therapies in Patients with PD-L1 TPS ?1% Metastatic NSCLC.
Neoplasms
A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Neoplasms
A mechanistic systems pharmacology modeling platform to investigate the effect of PD-L1 expression heterogeneity and dynamics on the efficacy of PD-1 and PD-L1 blocking antibodies in cancer.
Neoplasms
A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy.
Neoplasms
A meta-analysis reveals prognostic role of programmed death ligand-1 in Asian patients with non-small cell lung cancer.
Neoplasms
A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes.
Neoplasms
A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints.
Neoplasms
A minimum of 100 tumor cells in a single biopsy sample is required to assess programmed cell death ligand 1 expression in predicting patient response to nivolumab treatment in non-squamous non-small cell lung carcinoma.
Neoplasms
A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer.
Neoplasms
A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer.
Neoplasms
A Multifunctional Nanovaccine based on L-Arginine-Loaded Black Mesoporous Titania: Ultrasound-Triggered Synergistic Cancer Sonodynamic Therapy/Gas Therapy/Immunotherapy with Remarkably Enhanced Efficacy.
Neoplasms
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Neoplasms
A new delivery system for auristatin in STxB-drug conjugate therapy.
Neoplasms
A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1).
Neoplasms
A new immune-nanoplatform for promoting adaptive antitumor immune response.
Neoplasms
A nomogram incorporating PD-L1, NLR, and clinicopathologic features to predict inguinal lymph node metastasis in penile squamous cell carcinoma.
Neoplasms
A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy.
Neoplasms
A noninterventional, multinational study to assess PD-L1 expression in cytological and histological lung cancer specimens.
Neoplasms
A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention.
Neoplasms
A Novel Approach to Detect Programed Death Ligand 1 (PD-L1) Status and Multiple Tumor Mutations Using a Single Non-Small-Cell Lung Cancer (NSCLC) Bronchoscopy Specimen.
Neoplasms
A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling.
Neoplasms
A novel bifunctional anti-PD-L1/TGF-? Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells.
Neoplasms
A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint.
Neoplasms
A NOVEL CARCINOEMBRYONIC ANTIGEN T CELL BISPECIFIC ANTIBODY (CEA TCB) FOR THE TREATMENT OF SOLID TUMORS.
Neoplasms
A novel case of endometrial dedifferentiated adenocarcinoma associated with MLH1 promotor hypermethylation and microsatellite instability.
Neoplasms
A Novel Combination Treatment with Honokiol and Rapamycin Effectively Restricts c-Met-Induced Growth of Renal Cancer Cells, and also Inhibits the Expression of Tumor Cell PD-L1 Involved in Immune Escape.
Neoplasms
A novel histological examination with dynamic 3D reconstruction from multiple immunohistochemically stained sections of a programmed cell death ligand 1-positive colon cancer.
Neoplasms
A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma.
Neoplasms
A Novel Immunotype-based Risk Stratification Model Predicts Postoperative Prognosis and Adjuvant TACE Benefit in Chinese Patients with Hepatocellular Carcinoma.
Neoplasms
A Novel Link between Inflammation and Cancer.
Neoplasms
A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening.
Neoplasms
A novel oncolytic virus engineered with PD-L1 scFv effectively inhibits tumor growth in a mouse model.
Neoplasms
A novel trichosanthin fusion protein with increased cytotoxicity to tumor cells.
Neoplasms
A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases.
Neoplasms
A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.
Neoplasms
A pathological complete response to neoadjuvant chemotherapy and immunotherapy in a non-small cell lung cancer patient.
Neoplasms
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Neoplasms
A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report.
Neoplasms
A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model.
Neoplasms
A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions.
Neoplasms
A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.
Neoplasms
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Neoplasms
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Neoplasms
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
Neoplasms
A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.
Neoplasms
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Neoplasms
A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Neoplasms
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Neoplasms
A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Neoplasms
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Neoplasms
A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74?years old and patients with PS 0 or 1 from 75?years: NEJ039A (trial in progress).
Neoplasms
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tract.
Neoplasms
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Neoplasms
A Pilot Study of Atezolizumab plus Hypofractionated Image-guided Radiotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Neoplasms
A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer.
Neoplasms
A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2.
Neoplasms
A Potent Pan-TGF? Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys.
Neoplasms
A Potential Predictive Biomarker for Miller/Payne Grading: PD-L1 Expression before Neoadjuvant Chemotherapy in Breast Cancer.
Neoplasms
A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4.
Neoplasms
A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with 68Ga-labeled PD-L1 targeted nanobody.
Neoplasms
A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.
Neoplasms
A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
Neoplasms
A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE.
Neoplasms
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
Neoplasms
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1.
Neoplasms
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Neoplasms
A radiosensitivity gene signature and PD-L1 predict the clinical outcomes of patients with lower grade glioma in TCGA.
Neoplasms
A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset.
Neoplasms
A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset.
Neoplasms
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases.
Neoplasms
A Rare Case of Primary Anorectal Melanoma and a Review of the Current Landscape of Therapy.
Neoplasms
A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells.
Neoplasms
A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
Neoplasms
A recycling program that keeps PD-L1 out of the cancer cell's junkyard.
Neoplasms
A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.
Neoplasms
A Remarkable and Durable Response to Sintilimab and Anlotinib in the First-Line Treatment of an Anaplastic Thyroid Carcinoma without Targetable Genomic Alterations: A Case Report.
Neoplasms
A Remarkable Clinical Response to Pembrolizumab in a Rare Spindle Cell Carcinoma of the Lung.
Neoplasms
A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome.
Neoplasms
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Neoplasms
A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
Neoplasms
A secondary role for hypoxia and HIF1 in the regulation of (IFN?-induced) PD-L1 expression in melanoma.
Neoplasms
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.
Neoplasms
A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma.
Neoplasms
A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.
Neoplasms
A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
Neoplasms
A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids.
Neoplasms
A Space-Time Continuum for Immunotherapy Biomarkers in Gastroesophageal Cancer?
Neoplasms
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
Neoplasms
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging.
Neoplasms
A study of PD-L1 expression in intravascular large B cell lymphoma: correlation with clinical and pathological features.
Neoplasms
A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments.
Neoplasms
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
Neoplasms
A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-?.
Neoplasms
A successful pembrolizumab treatment case of lung adenocarcinoma after becoming resistant to ALK-TKI treatment due to G1202R mutation.
Neoplasms
A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice.
Neoplasms
A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.
Neoplasms
A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.
Neoplasms
A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas.
Neoplasms
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Neoplasms
A therapeutic Her2/neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her2/neu-expressing tumor in HLA-A2 transgenic mice.
Neoplasms
A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Neoplasms
A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy.
Neoplasms
A toxin conjugate containing transforming growth factor-alpha and ricin A specifically inhibits growth of A431 human epidermoid cancer cells.
Neoplasms
A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging.
Neoplasms
A tumor extracellular pH-sensitive PD-L1 binding peptide nanoparticle for chemo-immunotherapy of cancer.
Neoplasms
A tumor microenvironment (TME)-responsive nanoplatform for systemic saporin delivery and effective breast cancer therapy.
Neoplasms
A tumor microenvironment responsive biodegradable CaCO3/MnO2- based nanoplatform for the enhanced photodynamic therapy and improved PD-L1 immunotherapy.
Neoplasms
A Tumor-Immune Interaction Model for Synergistic Combinations of Anti PD-L1 and Ionizing Irradiation Treatment.
Neoplasms
A Tumor-Penetrating Nanomedicine Improves the Chemoimmunotherapy of Pancreatic Cancer.
Neoplasms
A Tumor-Peptide-Based Nanoparticle Vaccine Elicits Efficient Tumor Growth Control in Antitumor Immunotherapy.
Neoplasms
A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.
Neoplasms
A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis.
Neoplasms
A-NGR fusion protein induces apoptosis in human cancer cells.
Neoplasms
Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.
Neoplasms
Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1.
Neoplasms
Abrin P2 suppresses proliferation and induces apoptosis of colon cancer cells via mitochondrial membrane depolarization and caspase activation.
Neoplasms
Abrin-a A chain expressed as soluble form in Escherichia coli from a PCR-synthesized gene is catalytically and functionally active.
Neoplasms
Abrogation of IFN-? Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade.
Neoplasms
Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing.
Neoplasms
Abrus abrin derived peptides induce apoptosis by targeting mitochondria in HeLa cells.
Neoplasms
Abrus agglutinin inhibits oral carcinogenesis through inactivation of NRF2 signaling pathway.
Neoplasms
Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFN? signaling in non-small cell lung cancer.
Neoplasms
Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer.
Neoplasms
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
Neoplasms
Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
Neoplasms
Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
Neoplasms
Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis.
Neoplasms
Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Neoplasms
Accurate PD-L1 Protocols for Non-Small Cell Lung Cancer can be Developed for Automated Staining Platforms With Clone 22C3.
Neoplasms
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.
Neoplasms
Acetylcholine promotes the self-renewal and immune escape of CD133+ thyroid cancer cells through activation of CD133-Akt pathway.
Neoplasms
Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.
Neoplasms
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.
Neoplasms
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
Neoplasms
ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Neoplasms
Action of alpha-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines.
Neoplasms
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Neoplasms
Actions of l-thyroxine and Nano-diamino-tetrac (Nanotetrac) on PD-L1 in cancer cells.
Neoplasms
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1.
Neoplasms
Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer.
Neoplasms
Activation of 4-1BBL+ B cells with CD40 agonism and IFN? elicits potent immunity against glioblastoma.
Neoplasms
Activation of beta(2)-adrenoceptor prevents shiga toxin 2-induced TNF-alpha gene transcription.
Neoplasms
Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple-Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy.
Neoplasms
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Neoplasms
Activation of the cholinergic anti-inflammatory pathway reduces ricin-induced mortality and organ failure in mice.
Neoplasms
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Neoplasms
Active Immunotherapy of Cancer.
Neoplasms
Activity and tolerability of maintenance avelumab immunotherapy after first line polychemotherapy including platinum in patients with locally advanced or metastatic squamous cell penile carcinoma: PULSE.
Neoplasms
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Neoplasms
Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma.
Neoplasms
Acute kidney injury as a risk factor for mortality in oncological patients receiving check-point inhibitors.
Neoplasms
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance.
Neoplasms
Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
Neoplasms
Adenocarcinoma of the Lung Mimicking Miliary Tuberculosis.
Neoplasms
Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy.
Neoplasms
Adenovirus infection enhances killing of melanoma cells by a mitotoxin.
Neoplasms
Adequacy of endosonography-derived samples from peribronchial or periesophageal intrapulmonary lesions for the molecular profiling of lung cancer.
Neoplasms
Adequate tumour cellularity is essential for accurate PD-L1 immunohistochemistry assessment on cytology cell-block specimens.
Neoplasms
Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Neoplasms
Adipocytes promote tumor progression and induce PD-L1 expression via TNF-?/IL-6 signaling.
Neoplasms
Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer.
Neoplasms
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Neoplasms
Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non-small Cell Lung Cancer Recurrence.
Neoplasms
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Neoplasms
Adjuvant pembrolizumab in genomically selected high-risk patients with muscle-invasive bladder cancer.
Neoplasms
Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome.
Neoplasms
Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.
Neoplasms
Adoptive immunotherapy of experimental tumors using cytotoxic lymphocytes to carry and deliver toxins.
Neoplasms
Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma.
Neoplasms
Adoptively transferred V?9V?2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model.
Neoplasms
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Neoplasms
ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium.
Neoplasms
Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway.
Neoplasms
Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics.
Neoplasms
Advanced G-CSF-producing non-small cell lung cancer-not otherwise specified, with favourable response to pembrolizumab monotherapy.
Neoplasms
Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.
Neoplasms
Advances in cancer immunology and cancer immunotherapy.
Neoplasms
Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.
Neoplasms
Advances in soft-tissue sarcoma - There are no mistakes, only lessons to learn!
Neoplasms
Advances on Tumor-Targeting Delivery of Cytotoxic Proteins.
Neoplasms
Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Neoplasms
Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer.
Neoplasms
Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
Neoplasms
Aging, Cancer and Immunity.
Neoplasms
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy.
Neoplasms
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cut-Offs in Non-Small Cell Lung Cancer.
Neoplasms
AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma.
Neoplasms
AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells.
Neoplasms
Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer - A comprehensive review from chemotherapy to immunotherapy.
Neoplasms
Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
Neoplasms
ALDH3A1 Overexpression in Melanoma and Lung Tumors Drives Cancer Stem Cell Expansion, Impairing Immune Surveillance through Enhanced PD-L1 Output.
Neoplasms
ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
Neoplasms
Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.
Neoplasms
ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation.
Neoplasms
All in the Levels-Programmed Death-Ligand 1 Expression as a Biomarker for Immune Checkpoint Inhibitor Response in Patients with Gastrointestinal Cancer.
Neoplasms
Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.
Neoplasms
Alterations in composition of immune cells and impairment of anti-tumor immune response in aged oral cancer-bearing mice.
Neoplasms
Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Neoplasms
Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer.
Neoplasms
AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing.
Neoplasms
Amlexanox enhances the antitumor effect of anti-PD-1 antibody.
Neoplasms
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
Neoplasms
An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
Neoplasms
An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
Neoplasms
An Avidity-Based PD-L1 Antagonist Using Nanoparticle-Antibody Conjugates for Enhanced Immunotherapy.
Neoplasms
An effective dendritic cell-based vaccine containing glioma stem-like cell lysate and CpG adjuvant for an orthotopic mouse model of glioma.
Neoplasms
An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.
Neoplasms
An Efficient Combination Immunotherapy for Primary Liver Cancer by Harmonized Activation of Innate and Adaptive Immunity.
Neoplasms
An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.
Neoplasms
An extrauterine extensively metastatic epithelioid trophoblastic tumor responsive to pembrolizumab.
Neoplasms
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Neoplasms
An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Neoplasms
An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles.
Neoplasms
An immunohistochemical analysis of CD3, PD-L1, and CTLA-4 expression in carcinosarcomas of the gynecological tract and their metastases.
Neoplasms
An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
Neoplasms
An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma.
Neoplasms
An Immunosuppressive Role for Eya3 in TNBC.
Neoplasms
An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Neoplasms
An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Neoplasms
An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use.
Neoplasms
An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Neoplasms
An increase of CD8+?T cell infiltration following recurrence is a good prognosticator in HNSCC.
Neoplasms
An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B chain.
Neoplasms
An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
Neoplasms
An innovative NRF2 nano-modulator induces lung cancer ferroptosis and elicits an immunostimulatory tumor microenvironment.
Neoplasms
An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours.
Neoplasms
An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer.
Neoplasms
An optimized protocol for patient-derived xenograft in humanized mice to evaluate the role of IL-34 in immunotherapeutic resistance.
Neoplasms
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION.
Neoplasms
An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.
Neoplasms
An update on immunotherapy options for urothelial cancer.
Neoplasms
An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.
Neoplasms
An update: circulating tumor cells in head and neck cancer.
Neoplasms
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer.
Neoplasms
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.
Neoplasms
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Neoplasms
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Neoplasms
Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis.
Neoplasms
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Neoplasms
Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Neoplasms
Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.
Neoplasms
Analysis of IFN?-Induced Migration of Ovarian Cancer Cells.
Neoplasms
Analysis of Immune Checkpoint Drug Targets and Tumor Proteotypes in Non-Small Cell Lung Cancer.
Neoplasms
Analysis of Immune Microenvironment by Multiplex Immunohistochemistry Staining in Different Oral Diseases and Oral Squamous Cell Carcinoma.
Neoplasms
Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Neoplasms
Analysis of PD-L1 expression in trophoblastic tissues and tumors.
Neoplasms
Analysis of PD-L1 Transcriptional Regulation in Ovarian Cancer Cells by Chromatin Immunoprecipitation.
Neoplasms
Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.
Neoplasms
Analysis of programmed death-ligand 1 expression in primary normal human dermal fibroblasts after DNA damage.
Neoplasms
Analysis of real-world PD-L1 IHC 28-8 and 22C3 pharmDx assay utilisation, turnaround times and analytical concordance across multiple tumour types.
Neoplasms
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Neoplasms
Analysis of the Expression and Regulation of PD-1 Protein on the Surface of Myeloid-Derived Suppressor Cells (MDSCs).
Neoplasms
Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer.
Neoplasms
Analysis of the immune landscape of small bowel neuroendocrine tumors.
Neoplasms
Analysis of the inflammatory tumor microenvironment in meningeal neoplasms.
Neoplasms
Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review.
Neoplasms
Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma.
Neoplasms
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
Neoplasms
Anaplastic variant of diffuse large B-cell lymphoma: Reappraisal as a nodal disease with sinusoidal involvement.
Neoplasms
Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer.
Neoplasms
Androgen receptor affects the response to immune checkpoint therapy by suppressing PD-L1 in hepatocellular carcinoma.
Neoplasms
Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.
Neoplasms
Angiogenesis, programmed death ligand 1 (PD-L1) and immune microenvironment association in laryngeal carcinoma.
Neoplasms
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.
Neoplasms
Angiotensin II contributes to intratumoral immunosuppressionvia induction of PD-L1 expression in non-small cell lung carcinoma.
Neoplasms
Anisodamine inhibits shiga toxin type 2-mediated tumor necrosis factor-alpha production in vitro and in vivo.
Neoplasms
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells.
Neoplasms
Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Neoplasms
Anthocyanins, delphinidin-3-O-glucoside and cyanidin-3-O-glucoside, inhibit immune checkpoints in human colorectal cancer cells in vitro and in silico.
Neoplasms
Anti program death-1/anti program death-ligand 1 in digestive cancers.
Neoplasms
Anti-B16-F10 melanoma activity of a basic fibroblast growth factor-saporin mitotoxin.
Neoplasms
Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Neoplasms
Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors.
Neoplasms
Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
Neoplasms
Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Neoplasms
Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
Neoplasms
Anti-CTLA-4 therapy-associated granuloma annulare in chronic myelomonocytic leukemia.
Neoplasms
Anti-Human Endoglin (hCD105) Immunotoxin-Containing Recombinant Single Chain Ribosome-Inactivating Protein Musarmin 1.
Neoplasms
Anti-inflammatory effect of Viscum album agglutinin-I (VAA-I): induction of apoptosis in activated neutrophils and inhibition of lipopolysaccharide-induced neutrophilic inflammation in vivo.
Neoplasms
Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.
Neoplasms
Anti-PD-1 And Anti-PD-L1 Antibodies as Immunotherapy Against Cancer: A Structural Perspective.
Neoplasms
Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer.
Neoplasms
Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.
Neoplasms
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.
Neoplasms
Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas.
Neoplasms
Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report.
Neoplasms
Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review.
Neoplasms
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Neoplasms
Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
Neoplasms
Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28.
Neoplasms
Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer.
Neoplasms
Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials.
Neoplasms
Anti-PD-1/PD-L1 antibody versus conventional chemotherapy for previously-treated, advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Neoplasms
Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
Neoplasms
Anti-PD-L1 DNA aptamer antagonizes the interaction of PD-1/PD-L1 with antitumor effect.
Neoplasms
Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.
Neoplasms
Anti-PD-L1-modified and ATRA-loaded nanoparticles for immuno-treatment of oral dysplasia and oral squamous cell carcinoma.
Neoplasms
Anti-PD-L1/TGF?R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis.
Neoplasms
Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-?-associated JAK-STAT pathway.
Neoplasms
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations.
Neoplasms
Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports.
Neoplasms
Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential.
Neoplasms
Anti-tumor activity of Escherichia coli Shiga toxin A subunit delivered by SF9 insect cells.
Neoplasms
Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes.
Neoplasms
Anti-Tumor Efficacy of PD-L1 Targeted Alpha-Particle Therapy in a Human Melanoma Xenograft Model.
Neoplasms
Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV.
Neoplasms
Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
Neoplasms
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-infiltrating T cells in Hepatocellular Carcinomas.
Neoplasms
Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
Neoplasms
Antibody formation against the cytotoxic proteins abrin and ricin in humans and mice.
Neoplasms
Antibody-based delivery of tumor necrosis factor (L19-TNF?) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.
Neoplasms
Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Neoplasms
Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression.
Neoplasms
Anticancer Activities and Mechanism of Action of Nagilactones, a Group of Terpenoid Lactones Isolated from Podocarpus Species.
Neoplasms
Anticancer Activities of Hesperidin via Suppression of Up-Regulated Programmed Death-Ligand 1 Expression in Oral Cancer Cells.
Neoplasms
Anticancer Activities of Ricin-Liposome Complexes on SKMEL-28 Cells.
Neoplasms
Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts.
Neoplasms
Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs.
Neoplasms
Anticipating metastasis through electrochemical immunosensing of tumor hypoxia biomarkers.
Neoplasms
Antifade Carbon Dots on a Plasmonic Substrate for Enhanced Protein Detection in Immunotherapy.
Neoplasms
Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells.
Neoplasms
Antiobesity, antioxidant and cytotoxicity activities of newly synthesized chalcone derivatives and their metal complexes.
Neoplasms
Antiproliferative Activity of Chemically Characterized Propolis from Turkey and Its Mechanisms of Action.
Neoplasms
Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells.
Neoplasms
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Neoplasms
Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
Neoplasms
Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
Neoplasms
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
Neoplasms
Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Neoplasms
Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
Neoplasms
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
Neoplasms
Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
Neoplasms
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Neoplasms
Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Neoplasms
Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.
Neoplasms
Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.
Neoplasms
Antitumour effect of abrin on transplanted tumours in mice.
Neoplasms
Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases.
Neoplasms
Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Neoplasms
Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Neoplasms
APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Neoplasms
Apelin and apelin receptor expression in renal cell carcinoma.
Neoplasms
Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects.
Neoplasms
Apoptosis and necroptosis induced by stenodactylin in neuroblastoma cells can be completely prevented through caspase inhibition plus catalase or necrostatin-1.
Neoplasms
Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.
Neoplasms
Applicability and interpretation of HER2/Neu & PD-L1 stains in gastrointestinal tract tumours.
Neoplasms
Application of anti-sialyl Lea monoclonal antibody, KM231, for immunotherapy of cancer.
Neoplasms
Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
Neoplasms
Aralin, a new cytotoxic protein from Aralia elata, inducing apoptosis in human cancer cells.
Neoplasms
Aralin, a type II ribosome-inactivating protein from Aralia elata, exhibits selective anticancer activity through the processed form of a 110-kDa high-density lipoprotein-binding protein: a promising anticancer drug.
Neoplasms
Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?
Neoplasms
Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?
Neoplasms
Are there, or shall we discover, biomarkers to guide PD-1 inhibition?
Neoplasms
ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer.
Neoplasms
ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma.
Neoplasms
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Neoplasms
ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer.
Neoplasms
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation.
Neoplasms
Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors.
Neoplasms
Arsenic trioxide (ATO) induced degradation of Cyclin D1 sensitized PD-1/PD-L1 checkpoint inhibitor in oral and esophageal squamous cell carcinoma.
Neoplasms
Arthritis after cancer immunotherapy: symptom duration and treatment response.
Neoplasms
Articulatin-D induces apoptosis via activation of caspase-8 in acute T-cell leukemia cell line.
Neoplasms
Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer.
Neoplasms
ASO Author Reflections: Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells in Cholangiocarcinoma Patients.
Neoplasms
Assays for predicting and monitoring responses to lung cancer immunotherapy.
Neoplasms
Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Neoplasms
Assessing the Effects of Concurrent vs. Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice.
Neoplasms
Assessing the Impact of Phytochemicals on Immune Checkpoints: Implications for Cancer Immunotherapy.
Neoplasms
Assessment of associations between clinical and immune microenvironmental factors and tumor mutation burden in resected nonsmall cell lung cancer by applying machine learning to whole-slide images.
Neoplasms
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial.
Neoplasms
Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer.
Neoplasms
Assessment of Immunological Features in Muscle-Invasive Bladder Cancer Prognosis Using Ensemble Learning.
Neoplasms
Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
Neoplasms
Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
Neoplasms
Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.
Neoplasms
Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Cancer Patients Receiving PD-1/PD-L1 Blockade Therapies.
Neoplasms
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
Neoplasms
Assessment of Programmed Death-Ligand 1 (PD-L1) Immunohistochemical Expression on Cytology Specimens in Non-Small Cell Lung Carcinoma: A Comparative Study With Paired Surgical Specimens.
Neoplasms
Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Neoplasms
Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
Neoplasms
Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland.
Neoplasms
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Neoplasms
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Neoplasms
Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
Neoplasms
Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer.
Neoplasms
Association Between Clinicopathological Features and Programmed Death Ligand 1 Expression in Non-small Cell Lung Cancer.
Neoplasms
Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer.
Neoplasms
Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1.
Neoplasms
Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer.
Neoplasms
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Neoplasms
Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies.
Neoplasms
Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
Neoplasms
Association between PD-L1 expression and driven gene status in NSCLC: A meta-analysis.
Neoplasms
Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis.
Neoplasms
Association between PD-L1 expression and initial brain metastasis in patients with non-small cell lung cancer and its clinical implications.
Neoplasms
Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma.
Neoplasms
Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Neoplasms
Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma.
Neoplasms
Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer.
Neoplasms
Association between PD-L1 status and immune checkpoint inhibitor response in advanced malignancies: a systematic review and meta-analysis of overall survival data.
Neoplasms
Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.
Neoplasms
Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.
Neoplasms
Association Between Programmed Death Ligand 1 Expression in Patients With Basal Cell Carcinomas and the Number of Treatment Modalities.
Neoplasms
Association Between Programmed Death-Ligand 1 Expression and Clinicopathological Characteristics, Structural Recurrence, and Biochemical Recurrence/Persistent Disease in Medullary Thyroid Carcinoma.
Neoplasms
Association Between Programmed Death-Ligand 1 Expression and the Vascular Endothelial Growth Factor Pathway in Angiosarcoma.
Neoplasms
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Neoplasms
Association Between RBC Antigen Allo-Antibodies and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Treatment for Advanced Cancers.
Neoplasms
Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Neoplasms
Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours.
Neoplasms
Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
Neoplasms
Association of AXL and PD-L1 expression with clinical outcomes in patients with advanced renal cell carcinoma treated with PD-1 blockade.
Neoplasms
Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer.
Neoplasms
Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer.
Neoplasms
Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
Neoplasms
Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma.
Neoplasms
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.
Neoplasms
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
Neoplasms
Association of increased B7 protein expression by infiltrating immune cells with progression of gastric carcinogenesis.
Neoplasms
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Neoplasms
Association of Long Noncoding RNA Biomarkers With Clinical Immune Subtype and Prediction of Immunotherapy Response in Patients With Cancer.
Neoplasms
Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Neoplasms
Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Neoplasms
Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer.
Neoplasms
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Neoplasms
Association of PD-L1 and HIF-1? Coexpression with Poor Prognosis in Hepatocellular Carcinoma.
Neoplasms
Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors.
Neoplasms
Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis.
Neoplasms
Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
Neoplasms
Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.
Neoplasms
Association of PD-L1 gene rs4143815 C>G polymorphism and human cancer susceptibility: A systematic review and meta-analysis.
Neoplasms
Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens.
Neoplasms
Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
Neoplasms
Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
Neoplasms
Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma.
Neoplasms
Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Neoplasms
Association of Programmed Death 1 Protein Ligand (PD-L1) Expression With Prognosis in Merkel Cell Carcinoma.
Neoplasms
Association of programmed death ligand 1 expression with prognosis among patients with ten uncommon advanced cancers.
Neoplasms
Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.
Neoplasms
Association of Programmed Death Ligand-1 Overexpression with the Grade and Stage of Oral Squamous Cell Carcinoma.
Neoplasms
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.
Neoplasms
Association of Serum Anti-PCSK9 Antibody Levels with Favorable Postoperative Prognosis in Esophageal Cancer.
Neoplasms
Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials.
Neoplasms
Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Neoplasms
Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab.
Neoplasms
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Neoplasms
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma.
Neoplasms
Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy.
Neoplasms
Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.
Neoplasms
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation.
Neoplasms
Associations among pretreatment tumor necrosis and the expression of HIF-1? and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.
Neoplasms
Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response.
Neoplasms
Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial.
Neoplasms
Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in
Neoplasms
Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.
Neoplasms
Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Neoplasms
Atezolizumab and granzyme B as immunotoxin against PD-L1 antigen; an insilico study.
Neoplasms
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
Neoplasms
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Neoplasms
Atezolizumab Extends Survival for Breast Cancer.
Neoplasms
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
Neoplasms
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Neoplasms
Atezolizumab for the treatment of breast cancer.
Neoplasms
Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial).
Neoplasms
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
Neoplasms
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
Neoplasms
Atezolizumab in invasive and metastatic urothelial carcinoma.
Neoplasms
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Neoplasms
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance.
Neoplasms
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Neoplasms
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.
Neoplasms
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation.
Neoplasms
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Neoplasms
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Neoplasms
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study.
Neoplasms
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39).
Neoplasms
Atezolizumab-induced type 1 diabetes mellitus in a patient with metastatic renal cell carcinoma.
Neoplasms
Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.
Neoplasms
Atezolizumab: A Review in Previously Treated Advanced Non-Small Cell Lung Cancer.
Neoplasms
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.
Neoplasms
Atomic resolution structure of cucurmosin, a novel type 1 ribosome-inactivating protein from the sarcocarp of Cucurbita moschata.
Neoplasms
Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells.
Neoplasms
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Neoplasms
Augmentation of antiproliferative and antitumor effect on human cancer cells in combined use of electroporation with a plant toxin, saporin.
Neoplasms
Augmented inhibition of tumor cell proliferation in combined use of electroporation with a plant toxin, saporin.
Neoplasms
Aurora A Inhibition Eliminates Myeloid Cell-Mediated Immunosuppression and Enhances the Efficacy of Anti-PD-L1 Therapy in Breast Cancer.
Neoplasms
Author Correction: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Neoplasms
Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.
Neoplasms
Author Correction: Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
Neoplasms
Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy.
Neoplasms
Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy.
Neoplasms
Autologous bone marrow transplantation (ABMT) in the treatment of cancer.
Neoplasms
Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial.
Neoplasms
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
Neoplasms
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma.
Neoplasms
Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer.
Neoplasms
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer.
Neoplasms
Autophagy controls programmed death-ligand 1 expression on cancer cells (Review).
Neoplasms
Autophagy inhibition enhances PD-L1 expression in gastric cancer.
Neoplasms
Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy.
Neoplasms
Autopsy case report of intravascular large B-cell lymphoma with neoplastic PD-L1 expression.
Neoplasms
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer.
Neoplasms
Avelumab and other recent advances in Merkel cell carcinoma.
Neoplasms
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
Neoplasms
Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
Neoplasms
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
Neoplasms
Avelumab inducing hypothyroidism and hypoadrenalism: A case report and review of literature.
Neoplasms
Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101.
Neoplasms
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Neoplasms
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study.
Neoplasms
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells.
Neoplasms
Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity.
Neoplasms
B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer.
Neoplasms
B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.
Neoplasms
B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
Neoplasms
B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction.
Neoplasms
B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.
Neoplasms
B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
Neoplasms
B7x-from bench to bedside.
Neoplasms
Bacterial Outer Membrane Vesicles Presenting Programmed Death 1 for Improved Cancer Immunotherapy via Immune Activation and Checkpoint Inhibition.
Neoplasms
Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.
Neoplasms
Baicalin triggers apoptosis, inhibits migration, and enhances anti-tumor immunity in colorectal cancer via TLR4/NF-?B signaling pathway.
Neoplasms
Balsamin induces apoptosis in breast cancer cells via DNA fragmentation and cell cycle arrest.
Neoplasms
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.
Neoplasms
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade.
Neoplasms
Base excision repair regulates PD-L1 expression in cancer cells.
Neoplasms
Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade.
Neoplasms
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation.
Neoplasms
Baseline HBV-DNA load plus AST/ALT ratio predicts prognosis of HBV-related hepatocellular carcinoma after hepatectomy: A multicentre study.
Neoplasms
Baseline modified Glasgow prognostic score associated with survival in metastatic urothelial cell carcinoma treated with immune checkpoint inhibitors.
Neoplasms
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors.
Neoplasms
Basis of PD1/PD-L1 Therapies.
Neoplasms
Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5.
Neoplasms
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Neoplasms
beta-Momorcharin, a plant glycoprotein, inhibits synthesis of macromolecules in embryos, splenocytes and tumor cells.
Neoplasms
Beyond Blocking: Engineering RNAi-Mediated Targeted Immune Checkpoint Nanoblocker Enables T-Cell-Independent Cancer Treatment.
Neoplasms
Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
Neoplasms
Beyond PD-L1 Markers for Lung Cancer Immunotherapy.
Neoplasms
Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
Neoplasms
Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Neoplasms
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.
Neoplasms
Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy.
Neoplasms
Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer.
Neoplasms
Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
Neoplasms
Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells.
Neoplasms
Bifunctional and Bioreducible Dendrimer Bearing a Fluoroalkyl Tail for Efficient Protein Delivery Both In Vitro and In Vivo.
Neoplasms
Bifunctional Therapeutic Peptide Assembled Nanoparticles Exerting Improved Activities of Tumor Vessel Normalization and Immune Checkpoint Inhibition.
Neoplasms
Bilberry anthocyanin extracts enhance anti-PD-L1 efficiency by modulating gut microbiota.
Neoplasms
BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Neoplasms
Binding and cytotoxicity of Ricinus communis lectins to HeLa cells, Sarcoma 180 ascites tumor cells and erythrocytes.
Neoplasms
Binding of a type 1 RIP and of its chimeric variant to phospholipid bilayers: evidence for a link between cytotoxicity and protein/membrane interactions.
Neoplasms
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Neoplasms
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in patients with human papillomavirus-associated malignancies.
Neoplasms
Biochemical analysis and antitumour effect of Abrus precatorius agglutinin derived peptides in Ehrlich's ascites and B16 melanoma mice tumour model.
Neoplasms
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.
Neoplasms
Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy: (Trends in Biochemical Sciences 43, 1014-1032; 2018).
Neoplasms
Biological and antipathogenic activities of ribosome-inactivating proteins from Phytolacca dioica L.
Neoplasms
Biological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancer.
Neoplasms
Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.
Neoplasms
Biomarker for personalized immunotherapy.
Neoplasms
Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells.
Neoplasms
Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study).
Neoplasms
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Neoplasms
Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer.
Neoplasms
Biomarkers for checkpoint inhibition in hematologic malignancies.
Neoplasms
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
Neoplasms
Biomarkers for hepatocellular carcinoma: What's new on the horizon?
Neoplasms
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
Neoplasms
Biomarkers for immune checkpoint inhibitors in advanced nonsmall cell lung cancer.
Neoplasms
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1.
Neoplasms
Biomarkers for Immunotherapy: Current Developments and Challenges.
Neoplasms
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Neoplasms
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Neoplasms
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
Neoplasms
Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer.
Neoplasms
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Neoplasms
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Neoplasms
Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Neoplasms
Biomarkers in immunotherapy: literature review and future directions.
Neoplasms
Biomarkers in melanoma: where are we now?
Neoplasms
Biomarkers of immune checkpoint inhibitor efficacy in cancer.
Neoplasms
Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
Neoplasms
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.
Neoplasms
Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
Neoplasms
Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective.
Neoplasms
Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma.
Neoplasms
Biomarkers that may predict response to immunotherapy in ovarian malignancies.
Neoplasms
Biomimetic Diselenide-Bridged Mesoporous Organosilica Nanoparticles as an X-ray-Responsive Biodegradable Carrier for Chemo-Immunotherapy.
Neoplasms
Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
Neoplasms
Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing.
Neoplasms
Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232.
Neoplasms
Bispecific antibodies in cancer immunotherapy.
Neoplasms
Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Neoplasms
Bispecific Antibody PD-L1 x CD3 Boosts the Anti-Tumor Potency of the Expanded V?2V?2 T Cells.
Neoplasms
Bispecific antibody that binds carcinoembryonic antigen and ricin toxin A chain cytotoxic for gastrointestinal tract tumor cells.
Neoplasms
Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
Neoplasms
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Neoplasms
Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumour macrophages partially through interleukin 10.
Neoplasms
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Neoplasms
Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors.
Neoplasms
Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.
Neoplasms
Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapy.
Neoplasms
Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice.
Neoplasms
Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes.
Neoplasms
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
Neoplasms
Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization.
Neoplasms
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.
Neoplasms
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
Neoplasms
Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer.
Neoplasms
Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.
Neoplasms
Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Neoplasms
Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.
Neoplasms
Blocking effect of human serum but not of cerebrospinal fluid on ricin A chain immunotoxin potentiation by monensin or carrier protein-monensin conjugates.
Neoplasms
Blocking exposed PD-L1 elicited by nanosecond pulsed electric field reverses dysfunction of CD8+ T cells in liver cancer.
Neoplasms
Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors.
Neoplasms
Blocking of checkpoint receptor PD-L1 aggravates osteoarthritis in macrophage-dependent manner in the mice model.
Neoplasms
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy.
Neoplasms
Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Neoplasms
Blocking PD-L1 for anti-liver cancer immunity: USP22 represents a critical cotarget.
Neoplasms
Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine.
Neoplasms
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.
Neoplasms
Blocking Triggering Receptor Expressed on Myeloid Cells-1-Positive Tumor-Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti-Programmed Cell Death Ligand 1 Resistance in Liver Cancer.
Neoplasms
Blocking Wnt/?-catenin Signal Amplifies Anti-PD-1 Therapeutic Efficacy by Inhibiting Tumor Growth, Migration, and Promoting Immune Infiltration in Glioblastomas.
Neoplasms
Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer.
Neoplasms
Blood-based PD-L1 analysis in tumor-derived extracellular vesicles: Applications for optimal use of anti-PD-1/PD-L1 axis inhibitors.
Neoplasms
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
Neoplasms
Both T cell priming in lymph node and CXCR3-dependent migration are the key events for predicting the response of atezolizumab.
Neoplasms
BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts.
Neoplasms
Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status.
Neoplasms
BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer.
Neoplasms
BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.
Neoplasms
BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.
Neoplasms
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells.
Neoplasms
Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages.
Neoplasms
Breast cancer-associated macrophages promote tumorigenesis by suppressing succinate dehydrogenase in tumor cells.
Neoplasms
Brief report: efficacy of immune checkpoint inhibitors in KRAS-mutant Non-small cell lung cancer (NSCLC).
Neoplasms
Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1? in cancer.
Neoplasms
Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and ?-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells.
Neoplasms
Bryodin, a ribosome-inactivating protein from the roots of Bryonia dioica L. (white bryony).
Neoplasms
BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.
Neoplasms
BTLA identifies dysfunctional PD-1-expressing CD4(+) T cells in human hepatocellular carcinoma.
Neoplasms
BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer.
Neoplasms
Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
Neoplasms
BUB1B Overexpression Is an Independent Prognostic Marker and Associated with CD44, p53, and PD-L1 in Renal Cell Carcinoma.
Neoplasms
Bulnesia sarmientoi Supercritical Fluid Extract Exhibits Necroptotic Effects and Anti-Metastatic Activity on Lung Cancer Cells.
Neoplasms
Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Neoplasms
Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.
Neoplasms
C-Myc regulates PD-L1 expression in esophageal squamous cell carcinoma.
Neoplasms
CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 Treatment.
Neoplasms
Camptothecin Induces PD-L1 and Immunomodulatory Cytokines in Colon Cancer Cells.
Neoplasms
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial.
Neoplasms
Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Neoplasms
Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?
Neoplasms
Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?
Neoplasms
Cancer biomarkers for targeted therapy.
Neoplasms
Cancer cell CCR2 orchestrates suppression of the adaptive immune response.
Neoplasms
Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA.
Neoplasms
Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy.
Neoplasms
Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.
Neoplasms
Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
Neoplasms
Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.
Neoplasms
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Neoplasms
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Neoplasms
Cancer neoantigens as potential targets for immunotherapy.
Neoplasms
Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
Neoplasms
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Neoplasms
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Neoplasms
Cancer-associated fibroblasts promote PD-L1 expression in mice cancer cells via secreting CXCL5.
Neoplasms
Cancer-associated oxidoreductase ERO1-? promotes immune escape through up-regulation of PD-L1 in human breast cancer.
Neoplasms
Cancer-educated mesenchymal stem cells promote the survival of cancer cells at primary and distant metastatic sites via the expansion of bone marrow-derived-PMN-MDSCs.
Neoplasms
Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation.
Neoplasms
Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Neoplasms
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Neoplasms
Capture of recombinant ricin A chain by a bispecific anti-RTA:anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice.
Neoplasms
CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.
Neoplasms
Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential.
Neoplasms
Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
Neoplasms
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Neoplasms
Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Neoplasms
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer.
Neoplasms
Carcinogenesis response modulation induced by gelonin encapsulated in liposome.
Neoplasms
Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review.
Neoplasms
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors.
Neoplasms
Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes.
Neoplasms
Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations-A Report of a Stunning Success in a 37-Year-Old Patient.
Neoplasms
Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma.
Neoplasms
Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Neoplasms
Case Report: Therapeutic Response to Chemo-Immunotherapy in an Advanced Large Cell Lung Carcinoma Patient With Low Values of Multiple Predictive Biomarkers.
Neoplasms
Case series of pleomorphic carcinomas of the lung treated with nivolumab.
Neoplasms
Case-control study of PD-1, PD-L1 and B7-H3 expression in lung cancer patients with and without human immunodeficiency virus (HIV) infection.
Neoplasms
Casp8 acts through A20 to inhibit PD-L1 expression: The mechanism and its implication in immunotherapy.
Neoplasms
Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review.
Neoplasms
Cationic folate-mediated liposomal delivery of bis-arylidene oxindole induces efficient melanoma tumor regression.
Neoplasms
CCR5 antagonism by maraviroc inhibits Hodgkin lymphoma microenvironment interactions and xenograft growth.
Neoplasms
CD122-selective IL-2 complexes reduce immunosuppression, promote Treg fragility, and sensitize tumor response to PD-L1 blockade.
Neoplasms
CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN-?.
Neoplasms
CD147-mediated glucose metabolic regulation contributes to the predictive role of 18 F-FDG PET/CT imaging for EGFR-TKI treatment sensitivity in NSCLC.
Neoplasms
CD163+ tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes.
Neoplasms
CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma.
Neoplasms
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Neoplasms
CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.
Neoplasms
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
Neoplasms
CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance.
Neoplasms
CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
Neoplasms
CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma.
Neoplasms
CD30L/CD30 signaling regulates the formation of the tumor immune microenvironment and inhibits intestinal tumor development of colitis-associated colon cancer in mice.
Neoplasms
CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.
Neoplasms
CD39: the potential target in small cell lung cancer.
Neoplasms
CD4+ T cell exhaustion leads to adoptive transfer therapy failure which can be prevented by immune checkpoint blockade.
Neoplasms
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.
Neoplasms
CD40-mediated immune cell activation enhances response to anti-PD1 in murine intrahepatic cholangiocarcinoma.
Neoplasms
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
Neoplasms
CD44, a marker of cancer stem cells, is positively correlated with PD-L1 expression and immune cells infiltration in lung adenocarcinoma.
Neoplasms
CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises.
Neoplasms
CD68-positive tumour associated macrophages, PD-L1 expression, and EBV latent infection in a high HIV-prevalent South African cohort of Hodgkin lymphoma patients.
Neoplasms
CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.
Neoplasms
CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.
Neoplasms
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
Neoplasms
CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma.
Neoplasms
CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
Neoplasms
CD8+ T Cell Infiltration Predicts Chemoradiosensitivity in Nasopharyngeal or Oropharyngeal Cancer.
Neoplasms
CD8+ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival.
Neoplasms
CD8+ Tumour-Infiltrating Lymphocytes and Tumour Microenvironment Immune Types as Biomarkers for Immunotherapy in Sinonasal Intestinal-Type Adenocarcinoma.
Neoplasms
CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Neoplasms
CD8+/FOXP3+ Ratio and PD-L1 Expression Associated With Survival in pT3N0M0 Stage Esophageal Squamous Cell Cancer.
Neoplasms
CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.
Neoplasms
CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC.
Neoplasms
CDK4 Inhibitors Thwart Immunity by Inhibiting Phospho-RB-NF-?B Complexes.
Neoplasms
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity.
Neoplasms
Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity.
Neoplasms
CDK5 Promotes Tumor Immune Evasion via PD-L1 Upregulation.
Neoplasms
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1.
Neoplasms
Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy.
Neoplasms
CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis.
Neoplasms
Cell Block as a Surrogate for Programmed Death-Ligand 1 Staining Testing in Patients of Non-Small Cell Lung Cancer.
Neoplasms
Cell by cell immuno- and cancer marker profiling of non-small cell lung cancer tissue: Checkpoint marker expression on CD103+, CD4+ T-cells predicts circulating tumor cells.
Neoplasms
Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.
Neoplasms
Cell growth regulation in epithelial ovarian cancer.
Neoplasms
Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy.
Neoplasms
Cell stemness, epithelial-to-mesenchymal transition, and immunoevasion: Intertwined aspects in cancer metastasis.
Neoplasms
Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer.
Neoplasms
Cell-targeting fusion constructs containing recombinant gelonin.
Neoplasms
Cellular energy dependent agglutination of rat ascites tumor cells mediated by concanavalin A and Ricinus communis agglutinin.
Neoplasms
Cellular Expression of PD-L1 in the Peripheral Blood of Lung Cancer Patients is Associated with Worse Survival.
Neoplasms
Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas.
Neoplasms
Central Nervous System Germinomas Express Programmed Death Ligand 1.
Neoplasms
Cerenkov luminescence imaging is an effective preclinical tool for assessing colorectal cancer PD-L1 levels in vivo.
Neoplasms
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Neoplasms
Cervical cancer patients that respond to chemoradiation therapy display an intense tumor infiltrating immune profile before treatment.
Neoplasms
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders.
Neoplasms
Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency.
Neoplasms
Change in nomenclature for the immunologic synapse from Troxis Necrosis to trogocytosis.
Neoplasms
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
Neoplasms
Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer.
Neoplasms
Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer.
Neoplasms
Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Neoplasms
Changes in the therapeutic landscape of oesophago-gastric cancers.
Neoplasms
Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas.
Neoplasms
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
Neoplasms
Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer.
Neoplasms
Changing paradigm in advanced and metastatic non-small cell lung cancer.
Neoplasms
Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.
Neoplasms
Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients.
Neoplasms
Characteristics of mismatch repair deficiency in sarcomas.
Neoplasms
Characteristics of non-small-cell lung cancer with interstitial pneumonia: variation in cancer location, histopathology, and frequency of postoperative acute exacerbations in interstitial pneumonia.
Neoplasms
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
Neoplasms
Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding.
Neoplasms
Characterization of a toxic lectin in Iscador, a mistletoe preparation with alleged cancerostatic properties.
Neoplasms
Characterization of CD66b and its relationship between immune checkpoints and their synergistic impact in the prognosis of surgically resected lung adenocarcinoma.
Neoplasms
Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity.
Neoplasms
Characterization of immune infiltration in sarcomatoid hepatocellular carcinoma.
Neoplasms
Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Neoplasms
Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer.
Neoplasms
Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.
Neoplasms
Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Neoplasms
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
Neoplasms
Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
Neoplasms
Characterization of recombinant and plant-derived mistletoe lectin and their B-chains.
Neoplasms
Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Neoplasms
Characterization of the anti-PD-1 antibody REGN2810 and its antitumor activity in human PD-1 knock-in mice.
Neoplasms
Characterization of the immune microenvironment in brain metastases from different solid tumors.
Neoplasms
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma (HCC).
Neoplasms
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients.
Neoplasms
Characterization of the immune microenvironment of NSCLC by multispectral analysis of multiplex immunofluorescence images.
Neoplasms
Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Neoplasms
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Neoplasms
Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
Neoplasms
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Neoplasms
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
Neoplasms
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Neoplasms
Checkpoint inhibition for advanced mucosal melanoma.
Neoplasms
Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
Neoplasms
Checkpoint inhibitor immunotherapy in kidney cancer.
Neoplasms
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
Neoplasms
Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Neoplasms
Checkpoint inhibitors in AML: are we there yet?
Neoplasms
Checkpoint inhibitors in hematological malignancies.
Neoplasms
Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Neoplasms
Checkpoint molecule expression by B and T cell lymphomas in dogs.
Neoplasms
Checkpoint molecule PD-1-assisted CD8+ T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Neoplasms
Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade.
Neoplasms
Chemo-immunotherapy as first-line treatment for small-cell lung cancer.
Neoplasms
Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
Neoplasms
Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
Neoplasms
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
Neoplasms
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells.
Neoplasms
Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma.
Neoplasms
Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation.
Neoplasms
Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-? induced epithelial mesenchymal transition in non-small cell lung cancer.
Neoplasms
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-?B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
Neoplasms
Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells.
Neoplasms
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Neoplasms
Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer.
Neoplasms
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.
Neoplasms
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Neoplasms
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Neoplasms
Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth.
Neoplasms
Chimeric PD-1:28 Receptor Upgrades Low-Avidity T cells and Restores Effector Function of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
Neoplasms
Chimeric protein: abrin B chain-trypsin inhibitor conjugate as a new antitumor agent.
Neoplasms
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver.
Neoplasms
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
Neoplasms
Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma.
Neoplasms
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Neoplasms
Chronic Inflammation Promotes CSN5-Mediated PD-L1 Stabilization.
Neoplasms
Cigarette Smoke-Induced Emphysema Exhausts Early Cytotoxic CD8+ T Cell Responses against Nascent Lung Cancer Cells.
Neoplasms
CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches.
Neoplasms
Circular RNA CHST15 Sponges miR-155-5p and miR-194-5p to Promote the Immune Escape of Lung Cancer Cells Mediated by PD-L1.
Neoplasms
Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
Neoplasms
Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-small-cell Lung Cancer.
Neoplasms
Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels.
Neoplasms
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.
Neoplasms
Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
Neoplasms
Circulating MicroRNAs and Extracellular Vesicle-Containing MicroRNAs as Response Biomarkers of Anti-programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC.
Neoplasms
Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab.
Neoplasms
Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study.
Neoplasms
Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
Neoplasms
Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study.
Neoplasms
Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Neoplasms
Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors.
Neoplasms
Circulating tumour cell PD-L1 test for head and neck cancers.
Neoplasms
Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer.
Neoplasms
Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
Neoplasms
Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1/PD-L1 inhibitors than the parental drug.
Neoplasms
Cisplatin promotes the expression level of PD-L1 in the microenvironment of hepatocellular carcinoma through YAP1.
Neoplasms
Cisplatin remodels the tumor immune microenvironment via the transcription factor EB in ovarian cancer.
Neoplasms
Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles.
Neoplasms
Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma.
Neoplasms
Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression.
Neoplasms
Classification of Non-Small Cell Lung Cancer's Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade.
Neoplasms
Classifying Cancers Based on T-cell Infiltration and PD-L1.
Neoplasms
Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Neoplasms
CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage.
Neoplasms
Click Reaction-Assisted Peptide Immune Checkpoint Blockade for Solid Tumor Treatment.
Neoplasms
Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
Neoplasms
Clinical Activity of an hTERT-Specific Cancer Vaccine (Vx-001) in "Immune Desert" NSCLC.
Neoplasms
Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Neoplasms
Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung.
Neoplasms
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy.
Neoplasms
Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies.
Neoplasms
Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis.
Neoplasms
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
Neoplasms
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
Neoplasms
Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer.
Neoplasms
Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Neoplasms
Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment-Current Progress, Strategy, and Future Perspective.
Neoplasms
Clinical and treatment course of lung carcinoma from adult-onset recurrent respiratory papillomatosis with lung involvement: A case report.
Neoplasms
Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma.
Neoplasms
Clinical applications of PD-L1 bioassays for cancer immunotherapy.
Neoplasms
Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series.
Neoplasms
Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression.
Neoplasms
Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
Neoplasms
Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.
Neoplasms
Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
Neoplasms
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis.
Neoplasms
Clinical evaluation of a laboratory-developed test using clone E1L3N for the detection of PD-L1 expression status in non-small cell lung cancer.
Neoplasms
Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Neoplasms
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
Neoplasms
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.
Neoplasms
Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer.
Neoplasms
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy.
Neoplasms
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
Neoplasms
Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.
Neoplasms
Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.
Neoplasms
Clinical implication of programmed cell death-1 ligand-1 expression in tonsillar squamous cell carcinoma in association with intratumoral heterogeneity, human papillomavirus, and epithelial-to-mesenchymal transition.
Neoplasms
Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Neoplasms
Clinical implications of WNT/?-catenin signaling for hepatocellular carcinoma.
Neoplasms
Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC).
Neoplasms
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Neoplasms
Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.
Neoplasms
Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Neoplasms
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Neoplasms
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
Neoplasms
Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab.
Neoplasms
Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer.
Neoplasms
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.
Neoplasms
Clinical relevance and prognostic significance of PD-1/PD-Ls in non-metastatic bladder cancer: A role for PD-L2.
Neoplasms
Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma.
Neoplasms
Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer.
Neoplasms
Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma.
Neoplasms
Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Neoplasms
Clinical Relevance of PD-L1 Expression and CD8+ T Cells' Infiltration in Patients With Lung Invasive Mucinous Adenocarcinoma.
Neoplasms
Clinical relevance of PD-L1 expression in gallbladder cancer: a potential target for therapy.
Neoplasms
Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma.
Neoplasms
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.
Neoplasms
Clinical response of a patient to anti-PD-1 immunotherapy and the immune landscape of testicular germ cell tumors.
Neoplasms
Clinical retrospective study on the expression of the PD-L1 molecule in sporadic colorectal cancer and its correlation with K-ras gene mutations in Chinese patients.
Neoplasms
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Neoplasms
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
Neoplasms
Clinical significance of ? 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Neoplasms
Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.
Neoplasms
Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.
Neoplasms
Clinical significance of PD-1 and PD-L1 molecules in patients with diffuse large B-cell lymphoma, not otherwise specified: Correlation with clinical and pathological findings.
Neoplasms
Clinical significance of PD-L1 (CD274) enhanced expression in cervical squamous cell carcinoma.
Neoplasms
Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients.
Neoplasms
Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.
Neoplasms
Clinical significance of PD-L1 expression in patients with surgically resected non-small cell lung cancer.
Neoplasms
Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Neoplasms
Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Neoplasms
Clinical significance of PD?L1 and PD?L2 copy number gains in non?small?cell lung cancer.
Neoplasms
Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Neoplasms
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Neoplasms
Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma.
Neoplasms
Clinical Significance of Programmed Death Ligand?1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.
Neoplasms
Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
Neoplasms
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.
Neoplasms
Clinical significance of signal regulatory protein alpha (SIRP?) expression in esophageal squamous cell carcinoma.
Neoplasms
Clinical significance of T cell clonality and expression levels of immune-related genes in endometrial cancer.
Neoplasms
Clinical Significance of Tumor and Immune Cell PD-L1 Expression in Gastric Adenocarcinoma.
Neoplasms
Clinical Significance of Tumor Microenvironment in Acral Melanoma: A Large Single-Institution Study of Caucasians.
Neoplasms
Clinical significance of tumor-associated immune cells in patients with oral squamous cell carcinoma.
Neoplasms
Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
Neoplasms
Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer.
Neoplasms
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.
Neoplasms
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.
Neoplasms
Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
Neoplasms
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma.
Neoplasms
Clinical, Genetic and Innate Immunity Characteristics of Melanoma in Organ Transplant Recipients.
Neoplasms
Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Neoplasms
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Neoplasms
Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.
Neoplasms
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
Neoplasms
Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26?year experience from an academic medical center in Brazil.
Neoplasms
Clinicopathologic characteristics and novel biomarkers of aggressive B-cell lymphomas in the nasopharynx.
Neoplasms
Clinicopathologic correlates of MYD88 L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.
Neoplasms
Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: A report from India.
Neoplasms
Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non-Small Cell Lung Cancer.
Neoplasms
Clinicopathologic Features and Immune Microenvironment of Non-Small-cell Lung Cancer With Primary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Neoplasms
Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1.
Neoplasms
Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
Neoplasms
Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Neoplasms
Clinicopathologic implications of the miR-197/PD-L1 axis in oral squamous cell carcinoma.
Neoplasms
Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Neoplasms
Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
Neoplasms
Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Neoplasms
Clinicopathological analysis of neoplastic PD-L1-positive EBV+ diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort.
Neoplasms
Clinicopathological analysis of PD-L2 expression in colorectal cancer.
Neoplasms
Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
Neoplasms
Clinicopathological analysis of programmed cell death-1 and programmed cell death-ligand 1 expression in the tumor microenvironments of diffuse large B-cell lymphomas.
Neoplasms
Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.
Neoplasms
Clinicopathological and genomic correlates of Programmed Cell Death Ligand 1 (PD-L1) expression in nonsquamous non-small cell lung cancer.
Neoplasms
Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings.
Neoplasms
Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
Neoplasms
Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas.
Neoplasms
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.
Neoplasms
Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene.
Neoplasms
Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma.
Neoplasms
Clinicopathological and prognostic significance of PD-1/PD-L1 axis expression in patients with tongue squamous cell carcinoma.
Neoplasms
Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a meta-analysis.
Neoplasms
Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis.
Neoplasms
Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Neoplasms
Clinicopathological and prognostic significance of PD-L1 in oral cancer: A preliminary retrospective immunohistochemistry study.
Neoplasms
Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis.
Neoplasms
Clinicopathological and prognostic significance of programmed cell death ligand 1 expression in patients diagnosed with breast cancer: meta-analysis.
Neoplasms
Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Neoplasms
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Neoplasms
Clinicopathological and prognostic significance of programmed death ligand 1 expression in Korean melanoma patients.
Neoplasms
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Neoplasms
Clinicopathological and prognostic significance of programmed death ligant-1 expression in gastric cancer: a meta-analysis.
Neoplasms
Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Neoplasms
Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.
Neoplasms
Clinicopathological associations and prognostic values of IDH1 gene mutation, MGMT gene promoter methylation, and PD-L1 expressions in high-grade glioma treated with standard treatment.
Neoplasms
Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.
Neoplasms
Clinicopathological Correlates of ?? T Cell Infiltration in Triple-Negative Breast Cancer.
Neoplasms
Clinicopathological correlation of PD-L1 and TET1 expression with tumor-infiltrating lymphocytes in non-small cell lung cancer.
Neoplasms
Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
Neoplasms
Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?
Neoplasms
Clinicopathological Evaluation of PD1/PD-L1 Axis in Post-Transplant Lymphoproliferative Disorders: Association with EBV, PD-L1 Copy Number Alterations and Outcome.
Neoplasms
Clinicopathological evidence of hepatitis B virus infection in the development of gastric adenocarcinoma.
Neoplasms
Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer.
Neoplasms
Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
Neoplasms
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Neoplasms
Clinicopathological features of PD-L1 expression with MMR, EBV status and cancer genome alterations in MGC.
Neoplasms
Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Neoplasms
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
Neoplasms
Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Neoplasms
Clinicopathological Features, Surgical Outcomes, Oncogenic Status and PD-L1 Expression of Pulmonary Pleomorphic Carcinoma.
Neoplasms
Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Neoplasms
Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
Neoplasms
Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.
Neoplasms
Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression.
Neoplasms
Clinicopathological significance of the expression of PD-L1 in non-small cell lung cancer.
Neoplasms
Clinicopathological significance of the immunologic signature (PDL1, FOXP3+ Tregs, TILs) in early stage triple-negative breast cancer treated with neoadjuvant chemotherapy.
Neoplasms
Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
Neoplasms
Clonal Expansion of Tumor-Infiltrating T Cells and Analysis of the Tumor Microenvironment within Esophageal Squamous Cell Carcinoma Relapsed after Definitive Chemoradiation Therapy.
Neoplasms
Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain.
Neoplasms
Cloning, expression of the abrin-a A-chain in Escherichia coli and measurement of the biological activities in vitro.
Neoplasms
CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Neoplasms
CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Neoplasms
CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Neoplasms
CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
Neoplasms
CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas.
Neoplasms
CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients.
Neoplasms
CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors.
Neoplasms
CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
Neoplasms
Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.
Neoplasms
Co-application of ricin A chain and a recombinant adenovirus expressing ricin B chain as a novel approach for cancer therapy.
Neoplasms
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy.
Neoplasms
Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis.
Neoplasms
Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Neoplasms
Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
Neoplasms
Co-expression of NGF and PD-L1 on tumor-associated immune cells in the microenvironment of Merkel cell carcinoma.
Neoplasms
Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
Neoplasms
Co-expression of PD-L1 and HIF-1? predicts poor prognosis in Patients with Non-small Cell Lung Cancer after surgery.
Neoplasms
Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
Neoplasms
Co-inhibition of the TGF-? pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy.
Neoplasms
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
Neoplasms
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Neoplasms
Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer.
Neoplasms
Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice.
Neoplasms
Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice.
Neoplasms
Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
Neoplasms
Coinhibitory molecule PD-1 as a therapeutic target in the microenvironment of Multiple Myeloma.
Neoplasms
Colony growth and chemosensitivity in vitro of human melanoma biopsies. Relationship to clinical parameters.
Neoplasms
Combination cancer immunotherapies tailored to the tumour microenvironment.
Neoplasms
Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.
Neoplasms
Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle.
Neoplasms
Combination immunotherapy with ?-CTLA-4 and ?-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.
Neoplasms
Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check.
Neoplasms
Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
Neoplasms
Combination of Balsamin and Flavonoids Induce Apoptotic Effects in Liver and Breast Cancer Cells.
Neoplasms
Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies.
Neoplasms
Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade.
Neoplasms
Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Neoplasms
Combination of Cytokine-Induced Killer Cells and Programmed Cell Death-1 Blockade Works Synergistically to Enhance Therapeutic Efficacy in Metastatic Renal Cell Carcinoma and Non-Small Cell Lung Cancer.
Neoplasms
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.
Neoplasms
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.
Neoplasms
Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma.
Neoplasms
Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Neoplasms
Combination of radiotherapy and vaccination overcome checkpoint blockade resistance.
Neoplasms
Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Neoplasms
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Neoplasms
Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Neoplasms
Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma.
Neoplasms
Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
Neoplasms
Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.
Neoplasms
Combination therapy with dendritic cell vaccine and programmed death ligand 1 immune checkpoint inhibitor for hepatocellular carcinoma in an orthotopic mouse model.
Neoplasms
Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Neoplasms
Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
Neoplasms
Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer.
Neoplasms
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Neoplasms
Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy.
Neoplasms
Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma.
Neoplasms
Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment.
Neoplasms
Combinatorially Designed Lipid-like Nanoparticles for Intracellular Delivery of Cytotoxic Protein for Cancer Therapy.
Neoplasms
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.
Neoplasms
Combined antitumor therapy with the chemotherapeutic drug doxorubicin and an anti-transferrin receptor immunotoxin: in vitro and in vivo studies.
Neoplasms
Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes.
Neoplasms
Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Neoplasms
Combined Blockade Of Programmed Death-1 And Activation Of CD137 Increase Responses Of Human Liver T Cells Against HBV, But Not HCV.
Neoplasms
Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer.
Neoplasms
Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times.
Neoplasms
Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.
Neoplasms
Combined immunochemotherapy of human solid tumors in nude mice.
Neoplasms
Combined Inhibition of TGF-? Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Neoplasms
Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients.
Neoplasms
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Neoplasms
Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.
Neoplasms
Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
Neoplasms
Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8+ T Cells.
Neoplasms
Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Neoplasms
Combining Magnetic Resonance Imaging with Systemic Monocyte Evaluation for the Implementation of GBM Management.
Neoplasms
Combining mannose receptor mediated nanovaccines and gene regulated PD-L1 blockade for boosting cancer immunotherapy.
Neoplasms
Combining PD-L1 Expression and Standardized Uptake Values in FDG-PET/CT Can Predict Prognosis in Patients With Resectable Non-Small-Cell Lung Cancer.
Neoplasms
Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response.
Neoplasms
Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.
Neoplasms
Comment on 'Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ?50% treated with front-line pembrolizumab'.
Neoplasms
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Neoplasms
Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer.
Neoplasms
Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.
Neoplasms
Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
Neoplasms
Comparative Analysis of Programmed Cell Death Ligand 1 Assays in Renal Cell Carcinoma.
Neoplasms
Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Neoplasms
Comparative genomic profiling of glandular bladder tumours.
Neoplasms
Comparative Impact of PD-1 and PD-L1 Inhibitors on Advanced Esophageal or Gastric/Gastroesophageal Junction Cancer Treatment: A Systematic Review and Meta-Analysis.
Neoplasms
Comparative molecular profiling of HPV-induced squamous cell carcinomas.
Neoplasms
Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer.
Neoplasms
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
Neoplasms
Comparative study on modeccin- and phytohemagglutinin (PHA)-induced secretion of cytokines and nitric oxide (NO) in RAW264.7 cells.
Neoplasms
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Neoplasms
Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer.
Neoplasms
Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
Neoplasms
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis.
Neoplasms
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Neoplasms
Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
Neoplasms
Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Neoplasms
Comparison of laboratory-developed test & validated assay of programmed death ligand-1 immunohistochemistry in non-small-cell lung carcinoma.
Neoplasms
Comparison of microbial and transient expression (tobacco plants and plant-cell packs) for the production and purification of the anticancer mistletoe lectin viscumin.
Neoplasms
Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.
Neoplasms
Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas.
Neoplasms
Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma.
Neoplasms
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
Neoplasms
Comparison of PD-L1 Scores in Primary Kidney Tumors Versus Accompanying Venous Tumor Thrombi: Retrospective, Comparative, Monocentric Study in Treatment-Naive Patients.
Neoplasms
Comparison of Programmed Death Ligand-1 Immunohistochemical Staining Between Endobronchial Ultrasound Transbronchial Needle Aspiration and Resected Lung Cancer Specimens.
Neoplasms
Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.
Neoplasms
Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer.
Neoplasms
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
Neoplasms
Comparison of the cellular internalization of antibodies used either as immunotoxins or in ADEPT.
Neoplasms
Comparison of the cytotoxic effect of hormonotoxins prepared with the use of heterobifunctional cross-linking agents N-succinimidyl 3-(2-pyridyldithio)propionate and N-succinimidyl 6-[3-(2-pyridyldithio)propionamido]hexanoate.
Neoplasms
Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Neoplasms
Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
Neoplasms
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Neoplasms
Comparison of tumor cell numbers and 22C3 PD-L1 expression between cryobiopsy and transbronchial biopsy with endobronchial ultrasonography-guide sheath for lung cancer.
Neoplasms
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients.
Neoplasms
Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: malignant melanomas.
Neoplasms
Complete remission of chemo-refractory multiple-metastatic upper tract urothelial carcinoma by autologous formalin-fixed tumor vaccine.
Neoplasms
Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report.
Neoplasms
Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials.
Neoplasms
Complete response to perioperative treatment using nivolumab for metastatic renal cell carcinoma: A case report.
Neoplasms
Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.
Neoplasms
Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas.
Neoplasms
Comprehensive analyses of the heterogeneity and prognostic significance of tumor-infiltrating immune cells in non-small-cell lung cancer: Development and validation of an individualized prognostic model.
Neoplasms
Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.
Neoplasms
Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.
Neoplasms
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy.
Neoplasms
Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma.
Neoplasms
Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
Neoplasms
Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.
Neoplasms
Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Neoplasms
Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
Neoplasms
Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores.
Neoplasms
Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model.
Neoplasms
Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Neoplasms
Comprehensive genomic profiling of histologic subtypes of urethral carcinomas.
Neoplasms
Comprehensive Genomic Profiling of Rare Tumors in China: Routes to Immunotherapy.
Neoplasms
Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.
Neoplasms
Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer.
Neoplasms
Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA.
Neoplasms
Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma.
Neoplasms
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.
Neoplasms
Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma.
Neoplasms
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Neoplasms
Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
Neoplasms
Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component.
Neoplasms
Comprehensive molecular profiling of advanced/metastatic olfactory neuroblastomas.
Neoplasms
Comprehensive molecular profiling of pulmonary pleomorphic carcinoma.
Neoplasms
Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Neoplasms
Comprehensive screening for PD-L1 expression in thyroid cancer.
Neoplasms
Computational design of a synthetic PD-1 agonist.
Neoplasms
Computational measurement of tumor immune microenvironment in gastric adenocarcinomas.
Neoplasms
Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models.
Neoplasms
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
Neoplasms
Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Neoplasms
Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.
Neoplasms
Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases.
Neoplasms
Concordance of PD-L1 Expression Between Core Biopsy and Resection Specimens of Non-Small Cell Lung Cancer.
Neoplasms
Concordance of PD-L1 Expression Detection in Non-Small Cell Lung Cancer (NSCLC) Tissue Biopsy Specimens Between OncoTect iO Lung Assay and Immunohistochemistry (IHC).
Neoplasms
Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
Neoplasms
Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
Neoplasms
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
Neoplasms
Concurrent Control of KSHV Life Cycle through Chromatin Modulation and Host Hedgehog Signaling: A New Prospect to the Therapeutic Potential of Lipoxin A4.
Neoplasms
Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer.
Neoplasms
Consistency Analysis of Programmed Death-Ligand 1 Expression between Primary and Metastatic Non-Small Cell Lung Cancer: A Retrospective Study.
Neoplasms
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Neoplasms
Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration Rates.
Neoplasms
Constructing a better binding peptide for drug delivery targeting the interleukin-4 receptor.
Neoplasms
Construction and characterization of gelonin and saporin plasmids for toxic gene-based cancer therapy.
Neoplasms
Construction and validation of a Sambucus nigra biosensor for cancer-associated STn antigen.
Neoplasms
Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using Escherichia coli host cell machinery.
Neoplasms
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
Neoplasms
Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy.
Neoplasms
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis.
Neoplasms
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.
Neoplasms
Contributions of PD-L1 reverse signaling to dendritic cell trafficking.
Neoplasms
Contributions of T cell dysfunction to the resistance against anti-PD-1 therapy in oral carcinogenesis.
Neoplasms
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
Neoplasms
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
Neoplasms
Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy.
Neoplasms
Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties.
Neoplasms
Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models.
Neoplasms
Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
Neoplasms
Cooperativity of HOXA5 and STAT3 Is Critical for HDAC8 Inhibition-Mediated Transcriptional Activation of PD-L1 in Human Melanoma Cells.
Neoplasms
Coordination and Redox Dual-Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy.
Neoplasms
Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy.
Neoplasms
Correction for Vannini et al., ?v?3-integrin regulates PD-L1 expression and is involved in cancer immune evasion.
Neoplasms
Correction of arginine metabolism with sepiapterin-the precursor of nitric oxide synthase cofactor BH4-induces immunostimulatory-shift of breast cancer.
Neoplasms
Correction to Co-Delivery of Trichosanthin and Albendazole by Nano-Self-Assembly for Overcoming Tumor Multidrug-Resistance and Metastasis.
Neoplasms
Correction to: Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Neoplasms
Correction: Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma.
Neoplasms
Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Neoplasms
Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.
Neoplasms
Correction: THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy.
Neoplasms
Correlate tumor mutation burden with immune signatures in human cancers.
Neoplasms
Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.
Neoplasms
Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma.
Neoplasms
Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model.
Neoplasms
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ?50% Expression in Lung Adenocarcinoma.
Neoplasms
Correlation Between Dual-Time-Point FDG PET and Tumor Microenvironment Immune Types in Non-Small Cell Lung Cancer.
Neoplasms
Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Neoplasms
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma.
Neoplasms
Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: A real-world study of a large Chinese cohort.
Neoplasms
Correlation between PD-L1 expression ON CTCs and prognosis of patients with cancer: a systematic review and meta-analysis.
Neoplasms
Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Neoplasms
Correlation between the expression of folate receptor alpha (FR?) and clinicopathological features in patients with lung adenocarcinoma.
Neoplasms
Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors.
Neoplasms
Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.
Neoplasms
Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC.
Neoplasms
Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.
Neoplasms
Correlation of genomic alterations and PD-L1 expression in thymoma.
Neoplasms
Correlation of immune phenotype with IDH mutation in diffuse glioma.
Neoplasms
Correlation of MET and PD-L1 Expression in Malignant Melanoma.
Neoplasms
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.
Neoplasms
Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder.
Neoplasms
Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer.
Neoplasms
Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients.
Neoplasms
Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma.
Neoplasms
Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically resected pulmonary adenocarcinoma.
Neoplasms
Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
Neoplasms
Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma.
Neoplasms
Correlation of pd-l1 staining in tumor cells and tumor infiltrate between primary tumors and matched metastasis in advanced colorectal cancer patients.
Neoplasms
Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial.
Neoplasms
Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer.
Neoplasms
Correlation of tumor microenvironment from biopsy and resection specimens in untreated colorectal cancer patients: a surprising lack of agreement.
Neoplasms
Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.
Neoplasms
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Neoplasms
Corrigendum to "Rapid PD-L1 detection in tumors with PET using a highly specific peptide" [Biochemical and Biophysical Research Communications 483/1 (2017) 258-263].
Neoplasms
Corrigendum: CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.
Neoplasms
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong.
Neoplasms
Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
Neoplasms
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores.
Neoplasms
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
Neoplasms
Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
Neoplasms
Cost-effectiveness of Pembrolizumab versus Carboplatin-based Chemotherapy as First-line Treatment of PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States.
Neoplasms
Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA.
Neoplasms
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
Neoplasms
Costimulation, coinhibition and cancer.
Neoplasms
Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma?
Neoplasms
Could the PD-1 Pathway Be a Potential Target for Treating Small Intestinal Adenocarcinoma?
Neoplasms
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Neoplasms
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.
Neoplasms
Craniopharyngiomas: A clinicopathological and molecular study of 52 cases - Experience in the Complejo Hospitalario de Toledo and Hospital Universitario 12 de Octubre (Madrid).
Neoplasms
Cripto-1 as a Potential Target of Cancer Stem Cells for Immunotherapy.
Neoplasms
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.
Neoplasms
CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.
Neoplasms
Critical appraisal of PD-L1 reflex diagnostic testing: current standards and future opportunities.
Neoplasms
Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model.
Neoplasms
Crizotinib-induced immunogenic cell death in non-small cell lung cancer.
Neoplasms
Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.
Neoplasms
Cross-Link-Functionalized Nanoparticles for Rapid Excretion in Nanotheranostic Applications.
Neoplasms
Cross-talk between the pathways leading to the induction of apoptosis and the secretion of tumor necrosis factor-alpha in ricin-treated RAW 264.7 cells.
Neoplasms
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy.
Neoplasms
Crystal structure of mistletoe lectin I from Viscum album.
Neoplasms
Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Neoplasms
CTC immune escape mediated by PD-L1.
Neoplasms
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients.
Neoplasms
CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
Neoplasms
CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells.
Neoplasms
Curcumol inhibits the expression of programmed cell death-ligand 1 through crosstalk between hypoxia-inducible factor-1? and STAT3 (T705) signaling pathways in hepatic cancer.
Neoplasms
Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs.
Neoplasms
Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Neoplasms
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Neoplasms
Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
Neoplasms
Current Landscape of Personalized Therapy.
Neoplasms
Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors.
Neoplasms
Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer.
Neoplasms
Current state of immunotherapy for non-small cell lung cancer.
Neoplasms
Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
Neoplasms
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.
Neoplasms
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
Neoplasms
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.
Neoplasms
Current understanding of cancer-intrinsic PD-L1: regulation of expression and its protumoral activity.
Neoplasms
Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors.
Neoplasms
Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy.
Neoplasms
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
Neoplasms
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Neoplasms
CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways.
Neoplasms
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Neoplasms
CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers.
Neoplasms
CXCR4 Inhibition Counteracts Immunosuppressive Properties of Metastatic NSCLC Stem Cells.
Neoplasms
CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice.
Neoplasms
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Neoplasms
Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner.
Neoplasms
Cytokine and epigenetic regulation of programmed death-ligand 1 in stem cell differentiation and cancer cell plasticity.
Neoplasms
Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment.
Neoplasms
Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas.
Neoplasms
Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Neoplasms
Cytology for PD-L1 testing: A systematic review.
Neoplasms
Cytology samples and molecular biomarker testing in lung cancer-advantages and challenges.
Neoplasms
Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Neoplasms
Cytomembranic PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma.
Neoplasms
Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma.
Neoplasms
Cytotoxic activity of chimeric protein PD-L4UWSCI(tr) does not appear be affected by specificity of inhibition mediated by anti-protease WSCI domain.
Neoplasms
Cytotoxic activity of lutropin-gelonin conjugate in mouse Leydig tumor cells: potentiation of the hormonotoxin activity by different drugs.
Neoplasms
Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
Neoplasms
Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells.
Neoplasms
Cytotoxic effect of Shiga toxin-1 on human proximal tubule cells.
Neoplasms
Cytotoxic effect of the immunotoxin constructed of the ribosome-inactivating protein curcin and the monoclonal antibody against Her2 receptor on tumor cells.
Neoplasms
Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer.
Neoplasms
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.
Neoplasms
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy.
Neoplasms
Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.
Neoplasms
Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Neoplasms
Cytotoxicity of an ebulin l-anti-human CD105 immunotoxin on mouse fibroblasts (L929) and rat myoblasts (L6E9) cells expressing human CD105.
Neoplasms
Cytotoxicity of streptavidin-blocked biotinyl-ricin is retrieved by in vitro immunotargeting via biotinyl monoclonal antibody.
Neoplasms
Cytotoxicity of VEGF121/rGel on Vascular Endothelial Cells Resulting in Inhibition of Angiogenesis is Mediated via VEGFR-2.
Neoplasms
DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.
Neoplasms
Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer.
Neoplasms
Decreased levels of circulating cytokines VEGF, TNF-? and IL-15 indicate PD-L1 overexpression in tumours of primary breast cancer patients.
Neoplasms
Decursin promotes HIF-1? proteasomal degradation and immune responses in hypoxic tumour microenvironment.
Neoplasms
Deep learning for in vivo near-infrared imaging.
Neoplasms
Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies.
Neoplasms
Defining the immunogram of breast cancer: a focus on clinical trials.
Neoplasms
Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer.
Neoplasms
Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103+ dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity.
Neoplasms
Deletion of the RNA regulator HuR in tumor-associated microglia and macrophages stimulates anti-tumor immunity and attenuates glioma growth.
Neoplasms
Delivery of ribosome-inactivating protein toxin into cancer cells with shock waves.
Neoplasms
Delivery of ricin and abrin A-chains to human carcinoma cells in culture following covalent linkage to monoclonal antibody LICR-LOND-Fib 75.
Neoplasms
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.
Neoplasms
Dendritic cells with an increased PD-L1 by TGF-? induce T cell anergy for the cytotoxicity of hepatocellular carcinoma cells.
Neoplasms
Dendritic-Cell PD-L1 Mediates CD8+ T Cell-Dependent Antitumor Immunity.
Neoplasms
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
Neoplasms
Depletion of liver and splenic macrophages reduces the lethality of Shiga toxin-2 in a mouse model.
Neoplasms
Depression promotes lung carcinoma progression by regulating the tumor microenvironment in tumor-bearing models of C57BL/6J mice.
Neoplasms
Design and Discovery of Natural Cyclopeptide Skeleton Based Programmed Death Ligand 1 Inhibitor as Immune Modulator for Cancer Therapy.
Neoplasms
Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Neoplasms
Designing and Analyzing the Structure of DT-STXB Fusion Protein as an Anti-tumor Agent: An in Silico Approach.
Neoplasms
Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression.
Neoplasms
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.
Neoplasms
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L
Neoplasms
Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
Neoplasms
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Neoplasms
Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder.
Neoplasms
Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy.
Neoplasms
Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
Neoplasms
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.
Neoplasms
Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
Neoplasms
Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
Neoplasms
Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1.
Neoplasms
Deubiquitination and Stabilization of PD-L1 by CSN5.
Neoplasms
Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma.
Neoplasms
Developing a Bright NIR-II Fluorophore with Fast Renal Excretion and Its Application in Molecular Imaging of Immune Checkpoint PD-L1.
Neoplasms
Developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation.
Neoplasms
Development and Analytical Validation of a Reverse Transcription Droplet Digital PCR (RT-ddPCR) Assay for PD-L1 Transcripts in Circulating Tumor Cells.
Neoplasms
Development and validation of a novel clinical fluorescence in situ hybridization assay to detect JAK2 and PD-L1 amplification: a fluorescence in situ hybridization assay for JAK2 and PD-L1 amplification.
Neoplasms
Development and validation of a novel pseudogene pair-based prognostic signature for prediction of overall survival in patients with hepatocellular carcinoma.
Neoplasms
Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy.
Neoplasms
Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis.
Neoplasms
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
Neoplasms
Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma.
Neoplasms
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Neoplasms
Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab.
Neoplasms
Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.
Neoplasms
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Neoplasms
Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue.
Neoplasms
Development of a severe combined immunodeficiency (SCID) mouse model consisting of highly disseminated human B-cell leukemia/lymphoma, cure of the tumors by systemic administration of immunotoxin, and development/application of a clonotype-specific polymerase chain reaction-based assay.
Neoplasms
Development of amino- and dimethylcarbamate-substituted resorcinol as programmed cell death-1 (PD-1) inhibitor.
Neoplasms
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
Neoplasms
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
Neoplasms
Development of Immunotherapy Combination Strategies in Cancer.
Neoplasms
Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Neoplasms
Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Neoplasms
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
Neoplasms
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
Neoplasms
Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Neoplasms
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
Neoplasms
Development of [18F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide.
Neoplasms
Development, characterization and anti-tumor effect of a sequential sustained-release preparation containing ricin and cobra venom cytotoxin.
Neoplasms
Dexamethasone enhances trichosanthin-induced apoptosis in the HepG2 hepatoma cell line.
Neoplasms
DHA-SBT-1214 Taxoid Nanoemulsion and Anti-PD-L1 Antibody Combination Therapy Enhances Anti-Tumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model.
Neoplasms
Diabetes mellitus type 2 is associated with increased tumor expression of programmed death-ligand 1 (PD-L1) in surgically resected non-small cell lung cancer-A matched case-control study.
Neoplasms
Diagnosis of immunomarkers in vivo via multiplexed surface enhanced Raman spectroscopy with gold nanostars.
Neoplasms
Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report.
Neoplasms
Diagnostic test accuracy of 18F-FDG PET/CT for prediction of programmed death ligand 1 (PD-L1) expression in solid tumours: a meta-analysis.
Neoplasms
Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Neoplasms
Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases.
Neoplasms
Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma.
Neoplasms
Diagnostic yield of endobronchial ultrasound-guided transbronchial needle aspiration to assess tumor-programmed cell death ligand-1 expression in mediastinal lymph nodes metastasized from non-small cell lung cancer.
Neoplasms
Dianthin and Its Potential in Targeted Tumor Therapies.
Neoplasms
Differences in histological features and PD-L1 expression between sporadic microsatellite instability and Lynch-syndrome-associated disease in Japanese patients with colorectal cancer.
Neoplasms
Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.
Neoplasms
Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma.
Neoplasms
Differences in lectin binding in tissue sections of human and murine malignant tumors and their metastases.
Neoplasms
Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors.
Neoplasms
Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Neoplasms
Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
Neoplasms
Different expression of BRAFV600E, ALK and PD-L1 in melanoma in children and adolescents: a nationwide retrospective study in Finland in 1990-2014.
Neoplasms
Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
Neoplasms
Different patterns of treatment-related adverse events of programmed cell death-1 and its ligand-1 inhibitors in different cancer types: A meta-analysis and systemic review of clinical trials.
Neoplasms
Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer.
Neoplasms
Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
Neoplasms
Differential effects of abrin on normal and tumor cells.
Neoplasms
Differential effects of CD20+?B cells and PD-L1+?immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients.
Neoplasms
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.
Neoplasms
Differential Expression and Clinicopathological Significance of HER2, Indoleamine 2,3-Dioxygenase and PD-L1 in Urothelial Carcinoma of the Bladder.
Neoplasms
Differential expression and significance of PD-L1, IDO-1 and B7-H4 in human lung cancer.
Neoplasms
Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression.
Neoplasms
Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade.
Neoplasms
Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation.
Neoplasms
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.
Neoplasms
Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
Neoplasms
Differential Expression of PD-L1 in Central and Peripheral and TTF1-Positive and -Negative Small-Cell Lung Cancer.
Neoplasms
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Neoplasms
Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Neoplasms
Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.
Neoplasms
Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.
Neoplasms
Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Neoplasms
Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.
Neoplasms
Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma.
Neoplasms
Differential Molecular Expression Patterns Associated with Metastasis in Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Neoplasms
Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer.
Neoplasms
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Neoplasms
Differential response of human melanoma and Ehrlich ascites cells in vitro to the ribosome-inactivating protein luffin.
Neoplasms
Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
Neoplasms
Differential toxicity profile of ricin isoforms correlates with their glycosylation levels.
Neoplasms
Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors.
Neoplasms
Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Neoplasms
Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.
Neoplasms
Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas.
Neoplasms
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.
Neoplasms
Digital quantitative assessment of PD-L1 using digital spatial profiling.
Neoplasms
Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life.
Neoplasms
Diphtheria fusion protein therapy of chemoresistant malignancies.
Neoplasms
Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
Neoplasms
Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas.
Neoplasms
Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions.
Neoplasms
Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
Neoplasms
Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis.
Neoplasms
Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer.
Neoplasms
Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
Neoplasms
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Neoplasms
Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
Neoplasms
Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.
Neoplasms
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
Neoplasms
Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Neoplasms
Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Neoplasms
Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice.
Neoplasms
Distinct Biomarker Profiles and TCR Sequence Diversity Characterize the Response to PD-L1 Blockade in a Mouse Melanoma Model.
Neoplasms
Distinct contribution of PD-L1 suppression by spatial expression of PD-L1 on tumor and non-tumor cells.
Neoplasms
Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
Neoplasms
Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGF?/PD-L1 blockade-treated squamous cell carcinoma.
Neoplasms
Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Neoplasms
Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of Vater.
Neoplasms
Distinct Molecular Landscape of Epstein-Barr Virus Associated Pulmonary Lymphoepithelioma-Like Carcinoma Revealed by Genomic Sequencing.
Neoplasms
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic.
Neoplasms
Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors.
Neoplasms
Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients.
Neoplasms
Distribution and Expression of Programmed Death Ligand -1 (PD-L1) in Non-Small Cell Carcinomas of the Lung in a Tertiary Care Centre in South India.
Neoplasms
Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Neoplasms
Distribution of tumor-infiltrating-T-lymphocytes and possible tumor-escape mechanisms avoiding immune cell attack in locally advanced adenocarcinomas of the esophagus.
Neoplasms
Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma.
Neoplasms
Disulfonated tetraphenyl chlorin (TPCS(2a)), a novel photosensitizer developed for clinical utilization of photochemical internalization.
Neoplasms
Divergence and heterogeneity of neoplastic PD-L1 expression: Two autopsy case reports of intravascular large B-cell lymphoma.
Neoplasms
DNA Damage and Cancer Immunotherapy: A STING in the Tale.
Neoplasms
DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU).
Neoplasms
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.
Neoplasms
DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients.
Neoplasms
DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel.
Neoplasms
DNA polymerase-associated lectin (DPAL) and its binding to the galactose-containing glycoconjugate of the replication complex.
Neoplasms
DNA Repair and Signaling in Immune-Related Cancer Therapy.
Neoplasms
DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection.
Neoplasms
Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?
Neoplasms
Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
Neoplasms
Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?
Neoplasms
Does the immune system naturally protect against cancer?
Neoplasms
Domain Adaptation-Based Deep Learning for Automated Tumor Cell (TC) Scoring and Survival Analysis on PD-L1 Stained Tissue Images.
Neoplasms
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
Neoplasms
Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma.
Neoplasms
Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27kip1 /CDK4 axis in non-small cell lung cancer.
Neoplasms
Downregulation of CYLD promotes IFN-? mediated PD-L1 expression in thymic epithelial tumors.
Neoplasms
Downregulation of PD-L1 via amide analogues of brefelamide: Alternatives to antibody-based cancer immunotherapy.
Neoplasms
Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model.
Neoplasms
Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Neoplasms
Doxorubicin inhibits miR-140 expression and upregulates PD-L1 expression in HCT116 cells, opposite to its effects on MDA-MB-231 cells.
Neoplasms
Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells.
Neoplasms
Dramatic response to anti-PD-1 therapy in a patient of squamous cell carcinoma of thymus with multiple lung metastases.
Neoplasms
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer.
Neoplasms
Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
Neoplasms
Dramatic Responses of Recurrent Upper Urinary Tract Urothelial Carcinoma Harboring FGFR3 and TP53 Activating Mutations to Pembrolizumab in Combination with Erdafitinib: A Case Report.
Neoplasms
Driver Mutation Analysis and PD-L1 Expression in Synchronous Double Primary Lung Cancer.
Neoplasms
Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells.
Neoplasms
Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Neoplasms
Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation.
Neoplasms
Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Neoplasms
Dual faces of IFN-? in cancer progression: a role of PD-L1 induction in the determination of pro- and anti-tumor immunity.
Neoplasms
Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells.
Neoplasms
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
Neoplasms
Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion.
Neoplasms
Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Neoplasms
Dual-Sensitive PEG-Sheddable Nanodrug Hierarchically Incorporating PD-L1 Antibody and Zinc Phthalocyanine for Improved Immuno-Photodynamic Therapy.
Neoplasms
Durable Complete Remission of PD-L1 Positive NUT Carcinoma Treated With Concurrent Chemotherapy and Radiation.
Neoplasms
Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.
Neoplasms
Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade.
Neoplasms
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.
Neoplasms
Durable Response to Immunotherapy With Antiangiogenic Drug in Large-Cell Lung Carcinoma With Multiple Fulminant Postoperative Metastases: A Case Report.
Neoplasms
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer.
Neoplasms
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report.
Neoplasms
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Neoplasms
Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.
Neoplasms
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ?25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Neoplasms
Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Neoplasms
Durvalumab for the treatment of non-small cell lung cancer.
Neoplasms
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Neoplasms
Durvalumab in non-small-cell lung cancer patients: current developments.
Neoplasms
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Neoplasms
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Neoplasms
Durvalumab-associated vasculitis presenting as 'the blue toe syndrome'.
Neoplasms
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
Neoplasms
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy.
Neoplasms
Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy.
Neoplasms
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Neoplasms
Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment.
Neoplasms
Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
Neoplasms
Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer.
Neoplasms
Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling.
Neoplasms
Early T Cell Signalling Is Reversibly Altered in PD-1 T Lymphocytes Infiltrating Human Tumors.
Neoplasms
EBUS in optimizing non-small cell lung cancer diagnosis and treatment.
Neoplasms
EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer.
Neoplasms
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
Neoplasms
EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non-Small Cell Lung Cancer.
Neoplasms
EBV Positivity and Programmed Death-ligand 1 Expression in Diffuse Large B-cell Lymphoma: A Systematic Review.
Neoplasms
EBV-driven LMP1 and IFN-? up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
Neoplasms
EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency.
Neoplasms
EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment.
Neoplasms
Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Neoplasms
Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Neoplasms
Educational video: the role of PD-L1 in the local tumour microenvironment.
Neoplasms
eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA.
Neoplasms
Effect and biomarker of Nivolumab for non-small-cell lung cancer.
Neoplasms
Effect of a monoclonal anti-carcinoembryonic antigen antibody-ricin A-chain conjugate on human carcinoembryonic antigen-producing tumor cells.
Neoplasms
Effect of Acorus calamus L. Polysaccharide on CD274 and CD326 Expression by Lewis Lung Carcinoma Cells in Mice.
Neoplasms
Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer.
Neoplasms
Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
Neoplasms
Effect of crystalline abrin on the biosynthesis of protein, RNA, and DNA in experimental tumors.
Neoplasms
Effect of crystalline ricin on the biosynthesis of protein, RNA, and DNA in experimental tumor cells.
Neoplasms
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Neoplasms
Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo.
Neoplasms
Effect of interstitial chemotherapy with ricin temperature-responsive gel for anti-breast cancer and immune regulation in rat.
Neoplasms
Effect of metabolic inhibitors on the agglutination of tumor cells by concanavalin A and Ricinus communis agglutinin.
Neoplasms
Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.
Neoplasms
Effect of neoadjuvant chemotherapy (NAC) on programmed cell death ligand (PD-L1) in patients of carcinoma breast: A prospective study in Indian tertiary care setting.
Neoplasms
Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Neoplasms
Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer.
Neoplasms
Effect of Primary Systemic Therapy on PD-1, PD-L1, and PD-L2 mRNA Expression in Advanced Breast Cancer.
Neoplasms
Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment.
Neoplasms
Effect of ricin or ricin A-chain encapsulated in anti-carcinoembryonic antigen (CEA) antibody-bearing liposomes on CEA-producing tumor cells.
Neoplasms
Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen.
Neoplasms
Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
Neoplasms
Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden.
Neoplasms
Effects of Bacillus subtilis iturin A on HepG2 cells in vitro and vivo.
Neoplasms
Effects of BCL-2 overexpression on the sensitivity of MCF-7 breast cancer cells to ricin, diphtheria and Pseudomonas toxin and immunotoxins.
Neoplasms
Effects of D-galactose and its derivatives on the growth of tumor cells in the presence of ricin.
Neoplasms
Effects of different levels of soluble PD-L1 protein on the growth of Lewis lung cancer transplanted tumor.
Neoplasms
Effects of gelonin immunoconjugate of monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vitro.
Neoplasms
Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer.
Neoplasms
Effects of mistletoe lectin I and ionizing radiation on the glucose and thymidine uptake in tumour cells in vitro.
Neoplasms
Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer.
Neoplasms
Effects of retinoids and phorbol esters on the sensitivity of different cell lines to the polypeptide toxins modeccin, abrin, ricin and diphtheria toxin.
Neoplasms
Effects of ricin A chain conjugates of monoclonal antibodies to human alpha-fetoprotein and placental alkaline phosphatase on antigen-producing tumor cells in culture.
Neoplasms
Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Effects of Tussilago farfara L. Polysaccharides on the Expression of PD-1 (CD279) and PD-L1 (CD274) in Peripheral Blood and Tumor Tissue Lymphocytes in Mice with Lewis Lung Carcinoma.
Neoplasms
Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Neoplasms
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy.
Neoplasms
Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Neoplasms
Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
Neoplasms
Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Neoplasms
Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Neoplasms
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.
Neoplasms
Efficacy and safety of Nivolumab in non-small cell lung cancer patients in Tel-Aviv tertiary medical center: Facing the reality.
Neoplasms
Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Neoplasms
Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study.
Neoplasms
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Neoplasms
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study.
Neoplasms
Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
Neoplasms
Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review.
Neoplasms
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Neoplasms
Efficacy and Selectivity of FGF2-Saporin Cytosolically Delivered by PCI in Cells Overexpressing FGFR1.
Neoplasms
Efficacy and Treatment Strategies in Advanced Cancers with Liver Metastasis Receiving Atezolizumab Therapy.
Neoplasms
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors.
Neoplasms
Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression.
Neoplasms
Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Neoplasms
Efficacy of immune checkpoint inhibitors in the treatment of non-small cell lung cancer patients with different genes mutation: A meta-analysis.
Neoplasms
Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases.
Neoplasms
Efficacy of Liposomal Monensin on the Enhancement of the Antitumour Activity of Liposomal Ricin in Human Epidermoid Carcinoma (KB) Cells.
Neoplasms
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
Neoplasms
Efficacy of PD-1 or PD-L1 inhibitors and central nervous system metastases in advanced cancer: a meta-analysis.
Neoplasms
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis.
Neoplasms
Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.
Neoplasms
Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Neoplasms
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
Neoplasms
Efficacy, Safety and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma.
Neoplasms
Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial.
Neoplasms
Efficiency of Cytology Samples for PD-L1 Evaluation and Comparison with Tissue Samples.
Neoplasms
Efficient ADCC- killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK.
Neoplasms
Efficient antiproliferative and antiangiogenic effects on human ovarian cancer growth by gene transfer of attenuated mutants of Shiga-like toxin I.
Neoplasms
Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapy.
Neoplasms
Efficient Inhibition of Ovarian Cancer by Gelonin Toxin Gene Delivered by Biodegradable Cationic Heparin-polyethyleneimine Nanogels.
Neoplasms
Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy.
Neoplasms
Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6.
Neoplasms
Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy.
Neoplasms
Efficiently restoring the tumoricidal immunity against resistant malignancies via an immune nanomodulator.
Neoplasms
EGFR activation induced Snail-dependent EMT and myc-dependent PD-L1 in human salivary adenoid cystic carcinoma cells.
Neoplasms
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
Neoplasms
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.
Neoplasms
EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Neoplasms
EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer.
Neoplasms
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Neoplasms
EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
Neoplasms
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer.
Neoplasms
eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
Neoplasms
Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
Neoplasms
Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells.
Neoplasms
Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
Neoplasms
Eliminating Radiation Resistance of Non-Small Cell Lung Cancer by Dihydroartemisinin Through Abrogating Immunity Escaping and Promoting Radiation Sensitivity by Inhibiting PD-L1 Expression.
Neoplasms
Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates.
Neoplasms
Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin.
Neoplasms
Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Neoplasms
Elucidation of S-Allylcysteine Role in Inducing Apoptosis by Inhibiting PD-L1 Expression in Human Lung Cancer Cells.
Neoplasms
Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Neoplasms
Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma.
Neoplasms
Emerging biomarkers for immune checkpoint inhibition in lung cancer.
Neoplasms
Emerging biomarkers for PD-1 pathway cancer therapy.
Neoplasms
Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
Neoplasms
Emerging Multimodality Approaches to Treat Localized Esophageal Cancer.
Neoplasms
Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Neoplasms
Emerging role of PD-L1 modification in cancer immunotherapy.
Neoplasms
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.
Neoplasms
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1? and STAT3.
Neoplasms
Endobronchial ultrasound in diagnosing and staging of lung cancer by Acquire 22G TBNB versus regular 22G TBNA needles: study protocol of a randomised clinical trial.
Neoplasms
Endocytosis and intracellular transport of the glycolipid-binding ligand Shiga toxin in polarized MDCK cells.
Neoplasms
Endocytosis of immunotoxin-791T/36-RTA by tumor cells in relation to its cytotoxic action.
Neoplasms
Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
Neoplasms
Endothelial heterogeneity in Shiga toxin receptors and responses.
Neoplasms
Endothelial progenitor cells accelerate endothelial regeneration in an in vitro model of Shigatoxin-2a-induced injury via soluble growth factors.
Neoplasms
ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer.
Neoplasms
Engagement of T Cell-Expressed PD-L1 Weakens Antitumor Immunity.
Neoplasms
Engineered scPDL1-DM1 drug conjugate with improved in vitro analysis to target PD-L1 positive cancer cells and intracellular trafficking studies in cancer therapy.
Neoplasms
Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD-L1 Expression for Circumventing Immune Resistance of Cancer.
Neoplasms
Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
Neoplasms
Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1.
Neoplasms
Engineering universal cells that evade immune detection.
Neoplasms
Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.
Neoplasms
Enhanced anticancer effect of MAP30-S3 by cyclosproin A through endosomal escape.
Neoplasms
Enhanced Antitumor Immunity via Endocrine Therapy Prevents Mammary Tumor Relapse and Increases Immune Checkpoint Blockade Sensitivity.
Neoplasms
Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Neoplasms
Enhanced cytotoxic activity of a bifunctional chimeric protein containing a type 1 ribosome-inactivating protein and a serine protease inhibitor.
Neoplasms
Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization.
Neoplasms
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
Neoplasms
Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin.
Neoplasms
Enhanced expression of PD-L1 in oral squamous cell carcinoma-derived CD11b(+)Gr-1(+) cells and its contribution to immunosuppressive activity.
Neoplasms
Enhanced expression of programmed death-1 (PD-1)/PD-L1 in salivary glands of patients with Sjögren's syndrome.
Neoplasms
Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Neoplasms
Enhanced Immunotherapeutic Efficacy of Anti-PD-L1 Antibody in Combination with an EP4 Antagonist.
Neoplasms
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.
Neoplasms
Enhanced killing of human epidermoid carcinoma (KB) cells by treatment with ricin encapsulated into sterically stabilized liposomes in combination with monensin.
Neoplasms
Enhanced PD-L1 expression on tumor cells in primary cutaneous large T-cell lymphoma with CD30 expression as classic Hodgkin lymphoma mimics: A report of lymph node lesions of two cases.
Neoplasms
Enhanced photodynamic destruction of a transplantable fibrosarcoma using photochemical internalisation of gelonin.
Neoplasms
Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.
Neoplasms
Enhanced response to PD-L1 silencing by modulation of TME via balancing glucose metabolism and robust co-delivery of siRNA/Resveratrol with dual-responsive polyplexes.
Neoplasms
Enhanced Safety and Antitumor Efficacy of Switchable Dual Chimeric Antigen Receptor-Engineered T Cells against Solid Tumors through a Synthetic Bifunctional PD-L1-Blocking Peptide.
Neoplasms
Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolane.
Neoplasms
Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
Neoplasms
Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells.
Neoplasms
Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
Neoplasms
Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.
Neoplasms
Enhancing potency of liposomal monensin on ricin cytotoxicity in mouse macrophage tumor cells.
Neoplasms
Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.
Neoplasms
Enlightening the Immune Mechanism of the Abscopal Effect in a Murine HCC Model and Overcoming the Late Resistance With Anti-PD-L1.
Neoplasms
Enrichment of circulating tumor-derived extracellular vesicles from human plasma.
Neoplasms
Enteric plexus neuropathy associated with PD-L1 blockade in a patient with small-cell lung cancer.
Neoplasms
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy.
Neoplasms
Entry of diphtheria toxin into cells: possible existence of cellular factor(s) for entry of diphtheria toxin into cells was studied in somatic cell hybrids and hybrid toxins.
Neoplasms
Enzyme-responsive micellar JQ1 induces enhanced BET protein inhibition and immunotherapy of malignant tumors.
Neoplasms
EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.
Neoplasms
EpCAM signaling promotes tumor progression and protein stability of PD-L1 through the EGFR pathway.
Neoplasms
Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
Neoplasms
Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
Neoplasms
Epigenetic and Genetic Regulation of PDCD1 Gene in Cancer Immunology.
Neoplasms
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Neoplasms
Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Neoplasms
Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types.
Neoplasms
Epigenetic regulation of immune checkpoints and T cell exhaustion markers in tumor-infiltrating T cells of colorectal cancer patients.
Neoplasms
Epigenetic regulators of programmed death-ligand 1 expression in human cancers.
Neoplasms
Epigenetic treatment-mediated modulation of PD-L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD-L1 reverse signaling.
Neoplasms
Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma.
Neoplasms
Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer.
Neoplasms
Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma.
Neoplasms
Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma.
Neoplasms
Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer.
Neoplasms
Epithelial-to-Mesenchymal Transition Contributes to Immunosuppression in Breast Carcinomas.
Neoplasms
Epstein-Barr Virus Positive B-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract.
Neoplasms
Epstein-Barr virus-encoded circular RNA circBART2.2 promotes immune escape of nasopharyngeal carcinoma by regulating PD-L1.
Neoplasms
Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Neoplasms
ER? is a negative regulator of PD-L1 gene transcription in breast cancer.
Neoplasms
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
Neoplasms
Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity.
Neoplasms
Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer.
Neoplasms
ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma.
Neoplasms
ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma.
Neoplasms
Erratum for the Research Article: "Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy" by M. Mayoux, A. Roller, V. Pulko, S. Sammicheli, S. Chen, E. Sum, C. Jost, M. F. Fransen, R. B. Buser, M. Kowanetz, K. Rommel, I. Matos, S. Colombetti, A. Belousov, V. Karanikas, F. Ossendorp, P. S. Hegde, D. S. Chen, P. Umana, M. Perro, C. Klein, W. Xu.
Neoplasms
Erratum to "The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma" [Lung Cancer 132 (June) (2019) 36-38].
Neoplasms
Erratum: SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression.
Neoplasms
Esophageal, gastric cancer and immunotherapy: small steps in the right direction?
Neoplasms
Essential preanalytics in PD-L1 immunocytochemistry.
Neoplasms
Essential role of HDAC6 in the regulation of PD-L1 in melanoma.
Neoplasms
Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.
Neoplasms
Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-? to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Neoplasms
Ethanol extract of Chaenomeles speciosa Nakai induces apoptosis in cancer cells and suppresses tumor growth in mice.
Neoplasms
Etiology and Outcomes of Thrombotic Microangiopathies.
Neoplasms
EUS fine-needle pancreatic core biopsy can determine eligibility for tumor-agnostic immunotherapy.
Neoplasms
EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
Neoplasms
Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent.
Neoplasms
Evaluating PD-L1 in Head & Neck Squamous Cell Carcinoma: concordance between 22C3 PharmaDx and SP263 assays on whole sections from a multicenter study.
Neoplasms
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.
Neoplasms
Evaluation of an online training tool for scoring programmed cell death ligand-1 (PD-L1) diagnostic tests for lung cancer.
Neoplasms
Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors.
Neoplasms
Evaluation of Combination Strategies for the A2AR Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model.
Neoplasms
Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas.
Neoplasms
Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
Neoplasms
Evaluation of monoclonal antibody DF3 conjugated with ricin as a specific immunotoxin for in vitro purging of human bone marrow.
Neoplasms
Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Neoplasms
Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes.
Neoplasms
Evaluation of PD-L1 and PD-1 expression in aggressive eyelid sebaceous gland carcinoma and its clinical significance.
Neoplasms
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Neoplasms
Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma.
Neoplasms
Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.
Neoplasms
Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
Neoplasms
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
Neoplasms
Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+?and FOXP3+?immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Neoplasms
Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.
Neoplasms
Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Neoplasms
Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Neoplasms
Evaluation of Riproximin binding properties reveals a novel mechanism for cellular targeting.
Neoplasms
Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer.
Neoplasms
Evaluation of the role of Shiga and Shiga-like toxins in mediating direct damage to human vascular endothelial cells.
Neoplasms
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma.
Neoplasms
Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations.
Neoplasms
Evolution of delayed resistance to immunotherapy in a melanoma responder.
Neoplasms
Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.
Neoplasms
Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy.
Neoplasms
Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8+ T cells from negative regulation by local IFN-?.
Neoplasms
Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.
Neoplasms
Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy.
Neoplasms
Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical Carcinoma.
Neoplasms
Exceptional response to nivolumab of a heavily pre-treated patient with metastatic renal-cell cancer: from a case report to molecular investigation and future perspectives.
Neoplasms
ExoHCR: a sensitive assay to profile PD-L1 level on tumor exosomes for immunotherapeutic prognosis.
Neoplasms
Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients.
Neoplasms
Exosomal miRNA-16-5p Derived From M1 Macrophages Enhances T Cell-Dependent Immune Response by Regulating PD-L1 in Gastric Cancer.
Neoplasms
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Neoplasms
Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.
Neoplasms
Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer.
Neoplasms
Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.
Neoplasms
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies.
Neoplasms
Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.
Neoplasms
Exosomes Produced by Mesenchymal Stem Cells Drive Differentiation of Myeloid Cells into Immunosuppressive M2-Polarized Macrophages in Breast Cancer.
Neoplasms
Exosomes: Powerful weapon for cancer nano-immunoengineering.
Neoplasms
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Neoplasms
Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Neoplasms
Experimental therapy in Hodgkin's disease.
Neoplasms
Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.
Neoplasms
Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers.
Neoplasms
Expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer.
Neoplasms
Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis.
Neoplasms
Expression and clinical significance of PD-L1 and BRAF expression in nasopharyngeal carcinoma.
Neoplasms
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Neoplasms
Expression and clinical significance of programmed death ligand 1 in nasopharyngeal carcinoma.
Neoplasms
Expression and clinical value of PD-L1 which is regulated by BRD4 in tongue squamous cell carcinoma.
Neoplasms
Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
Neoplasms
Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.
Neoplasms
Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma.
Neoplasms
Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Neoplasms
Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma.
Neoplasms
Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas.
Neoplasms
Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma.
Neoplasms
Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study.
Neoplasms
Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
Neoplasms
Expression of alpha 2,6-sialylated sugar chains in normal and neoplastic colon tissues. Detection by digoxigenin-conjugated Sambucus nigra agglutinin.
Neoplasms
Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
Neoplasms
Expression of cancer cell-intrinsic PD-1 associates with PD-L1 and p-S6 and predicts a good prognosis in nasopharyngeal carcinoma.
Neoplasms
Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease.
Neoplasms
Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer.
Neoplasms
Expression of immune checkpoint molecules in endometrial carcinoma.
Neoplasms
Expression of immune checkpoint PD-1 in non-small cell lung cancer is associated with tumor cell DNA-dependent protein kinase.
Neoplasms
Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Neoplasms
Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Neoplasms
Expression of Immune Response Markers in Arab Patients With Lung Cancer.
Neoplasms
Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma.
Neoplasms
Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS.
Neoplasms
Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
Neoplasms
Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients.
Neoplasms
Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma.
Neoplasms
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Neoplasms
Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study.
Neoplasms
Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.
Neoplasms
Expression of PD-1 and PD-L1 in poorly differentiated neuroendocrine carcinomas of the digestive system: a potential target for anti-PD-1/PD-L1 therapy.
Neoplasms
Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.
Neoplasms
Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer.
Neoplasms
Expression of PD-1 and PD-Ls in Kaposi's sarcoma and regulation by oncogenic herpesvirus lytic reactivation.
Neoplasms
Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Neoplasms
Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Neoplasms
Expression of PD-1/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients.
Neoplasms
Expression of PD-1/PD-L1 in children's classical Hodgkin lymphomas.
Neoplasms
Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Neoplasms
Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters.
Neoplasms
Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome.
Neoplasms
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Neoplasms
Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival.
Neoplasms
Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.
Neoplasms
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Neoplasms
Expression of PD-L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion.
Neoplasms
Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Neoplasms
Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Neoplasms
Expression of PD-L1 for predicting response to immune checkpoint inhibitors in metastatic urothelial carcinoma: a systematic review and meta-analysis.
Neoplasms
Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung.
Neoplasms
Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression.
Neoplasms
Expression of PD-L1 in EBV-associated malignancies.
Neoplasms
Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Neoplasms
Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
Neoplasms
Expression of PD-L1 in medullary thyroid carcinoma-a new therapeutic target?
Neoplasms
Expression of PD-L1 in mononuclear cells, multinucleated cells, and foam cells in tenosynovial giant cell tumors.
Neoplasms
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Neoplasms
Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer.
Neoplasms
Expression of PD-L1 Is Associated with Inflammatory Microenvironment in Surgical Specimens of Non-Small Cell Lung Cancer.
Neoplasms
Expression of PD-L1 on canine tumor cells and enhancement of IFN-? production from tumor-infiltrating cells by PD-L1 blockade.
Neoplasms
Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.
Neoplasms
Expression of PD-L1 on Monocytes Is a Novel Predictor of Prognosis in Natural Killer/T-Cell Lymphoma.
Neoplasms
Expression of PD-L1, cancer stem cell and epithelial-mesenchymal transition phenotype in non-small cell lung cancer.
Neoplasms
Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
Neoplasms
Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
Neoplasms
Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus.
Neoplasms
Expression of PD-L1/PD-L2 is associated with high proliferation index of Ki-67 but not with TP53 overexpression in chondrosarcoma.
Neoplasms
Expression of programed death-1 (PD-1) and its ligand PD-L1 is upregulated in endometriosis and promoted by 17beta-estradiol.
Neoplasms
Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
Neoplasms
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Neoplasms
Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma.
Neoplasms
Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Neoplasms
Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte Infiltration in Olfactory Neuroblastoma.
Neoplasms
Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
Neoplasms
Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay.
Neoplasms
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Neoplasms
Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis.
Neoplasms
Expression of programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand (PD-L1) in adenocarcinomas of the gastroesophageal junction change significantly after neoadjuvant treatment.
Neoplasms
Expression of Programmed Cell Death Proteins in Kaposi Sarcoma and Cutaneous Angiosarcoma.
Neoplasms
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Neoplasms
Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Neoplasms
Expression of programmed cell death-ligand 1 in primary testicular diffuse large B cell lymphoma: A retrospective study.
Neoplasms
Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes.
Neoplasms
Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice.
Neoplasms
Expression of programmed death ligand (PD-L1) in different tumors. Comparison of several current available antibody clones and antibody profiling.
Neoplasms
Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer.
Neoplasms
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.
Neoplasms
Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status.
Neoplasms
Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
Neoplasms
Expression of Programmed Death Ligand 1 Is Associated with the Prognosis of Intrahepatic Cholangiocarcinoma.
Neoplasms
Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
Neoplasms
Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance.
Neoplasms
Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
Neoplasms
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
Neoplasms
Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma.
Neoplasms
Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer.
Neoplasms
Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.
Neoplasms
Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
Neoplasms
Expression of programmed death-ligand 1 and hypoxia-inducible factor-1? proteins in endometrial carcinoma.
Neoplasms
Expression of Programmed Death-Ligand 1 and Programmed Death-1 in Patients with Extramammary Paget's Disease.
Neoplasms
Expression of Programmed Death-Ligand 1 in Cutaneous Squamous Cell Carcinoma Arising in Sun-Exposed and Nonsun-Exposed Skin.
Neoplasms
Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration.
Neoplasms
Expression of programmed death-ligand 1 protein in pulmonary squamous cell carcinoma correlates with tumour necrosis but not with tumour differentiation.
Neoplasms
Expression of Receptor Tyrosine Kinases on Peripheral Blood Mononuclear Cells and Tumor-Infiltrating Lymphocytes in Patients with Renal Cell Carcinoma and Healthy Donors.
Neoplasms
Expression of scavenger receptor MARCO defines a targetable tumor-associated macrophage subset in non-small cell lung cancer.
Neoplasms
Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.
Neoplasms
Expression of STING and PD-L1 in colorectal cancer and their correlation with clinical prognosis.
Neoplasms
Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma.
Neoplasms
Expression of the Immune Checkpoints LAG-3 and PD-L1 in High-grade Serous Ovarian Carcinoma: Relationship to Tumor-associated Lymphocytes and Germline BRCA Status.
Neoplasms
Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors.
Neoplasms
Expression of the RIP-1 gene and its role in growth and invasion of human gallbladder carcinoma.
Neoplasms
Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy.
Neoplasms
Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognosticator in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Neoplasms
Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Neoplasms
Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Neoplasms
Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer.
Neoplasms
Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: comparison between primary tumors and metastases.
Neoplasms
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Neoplasms
Expression profile and in vitro blockade of PD-1 in HPV-negative head and neck squamous cell carcinoma.
Neoplasms
Expression status of PD-L1 and B7-H3 in mesothelioma.
Neoplasms
Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas.
Neoplasms
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
Neoplasms
External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different.
Neoplasms
Extracellular acidity in tumor tissue upregulates programmed cell death protein 1 expression on tumor cells via proton-sensing G protein-coupled receptors.
Neoplasms
Extracellular and nuclear PD-L1 in modulating cancer immunotherapy.
Neoplasms
Extracellular vesicles and oncogenic signaling.
Neoplasms
Extracellular Vesicles Secreted by Tumor Cells Promote the Generation of Suppressive Monocytes.
Neoplasms
Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A.
Neoplasms
Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression.
Neoplasms
Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.
Neoplasms
EZH2 regulates PD-L1 expression via HIF-1? in non-small cell lung cancer cells.
Neoplasms
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.
Neoplasms
Factors associated with immunotherapy selection in patients with advanced melanoma.
Neoplasms
Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Neoplasms
Fading With Time of PD-L1 Immunoreactivity in Non-Small Cells Lung Cancer Tissues: A Methodological Study.
Neoplasms
FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma.
Neoplasms
Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1.
Neoplasms
Fatal immune-related hepatitis with intrahepatic cholestasis and pneumonia associated with camrelizumab: A case report and literature review.
Neoplasms
Fatty Acid Oxidation Controls CD8+ Tissue-Resident Memory T-cell Survival in Gastric Adenocarcinoma.
Neoplasms
Fatty acid synthase inhibitor orlistat impairs cell growth and down-regulates PD-L1 expression of a human T-cell leukemia line.
Neoplasms
Favorable Disease-free Survival Associated with Programmed Death Ligand 1 Expression in Patients with Surgically Resected Small-cell Lung Cancer.
Neoplasms
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations.
Neoplasms
Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma.
Neoplasms
Fc?R interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.
Neoplasms
Fc?R-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
Neoplasms
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Neoplasms
FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1.
Neoplasms
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
Neoplasms
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Neoplasms
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.
Neoplasms
FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer.
Neoplasms
FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer.
Neoplasms
Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer.
Neoplasms
Feasibility study of cryobiopsy for practical pathological diagnosis of primary lung cancer including immunohistochemical assessment.
Neoplasms
Ferrimagnetic Vortex Nanoring-Mediated Mild Magnetic Hyperthermia Imparts Potent Immunological Effect for Treating Cancer Metastasis.
Neoplasms
Few-Layer Bismuthene for Checkpoint Knockdown Enhanced Cancer Immunotherapy with Rapid Clearance and Sequentially Triggered One-for-All Strategy.
Neoplasms
Fewer actionable mutations but higher tumor mutational burden characterizes NSCLC in black patients at an urban academic medical center.
Neoplasms
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Neoplasms
FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.
Neoplasms
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study.
Neoplasms
Finding the hot spot: identifying immune sensitive gastrointestinal tumors.
Neoplasms
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.
Neoplasms
First line Immunotherapy for Non-Small Cell Lung Cancer.
Neoplasms
First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
Neoplasms
First-in-human study of 89Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
Neoplasms
First-in-Human Study of the Biodistribution and Pharmacokinetics of 89Zr-CX-072, a Novel Immunopet Tracer Based on an Anti-PD-L1 Probody.
Neoplasms
First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
Neoplasms
First-Line Immune Checkpoint Inhibition for Advanced Non-Small-Cell Lung Cancer: State of the Art and Future Directions.
Neoplasms
First-line immunotherapy for patients with advanced stage or metastatic non-small cell lung cancer
finally what threshold of PD-L1 expression on tumor cells?
Neoplasms
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis.
Neoplasms
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Neoplasms
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Neoplasms
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Neoplasms
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Neoplasms
First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1.
Neoplasms
First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ?50% in a multicenter real-life cohort: The PEMBREIZH study.
Neoplasms
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Neoplasms
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Neoplasms
First-Line Pembrolizumab Versus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-024 Japan Subset.
Neoplasms
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ?50.
Neoplasms
First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Neoplasms
Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP).
Neoplasms
Five cases of BRAF V600E-mutant lung adenocarcinoma with high expression of programmed death ligand 1.
Neoplasms
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ? 50.
Neoplasms
Five-Year Overall Survival for Patients With Advanced Non?Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Neoplasms
Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1-Mediated Immune Evasion in Prostate Cancer.
Neoplasms
Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-?.
Neoplasms
Flow cytometry detection of cell type-specific expression of programmed death receptor ligand-1 (PD-L1) in colorectal cancer specimens.
Neoplasms
Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer.
Neoplasms
Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer.
Neoplasms
Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma.
Neoplasms
Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer.
Neoplasms
Folate receptor mediated targeted delivery of ricin entrapped into sterically stabilized liposomes to human epidermoid carcinoma (KB) cells: effect of monensin intercalated into folate-tagged liposomes.
Neoplasms
Follicular helper T cell exhaustion induced by PD-L1 expression in hepatocellular carcinoma results in impaired cytokine expression and B cell help, and is associated with advanced tumor stages.
Neoplasms
Fordin: A novel type I ribosome inactivating protein from Vernicia fordii modulates multiple signaling cascades leading to anti-invasive and pro-apoptotic effects in cancer cells in vitro.
Neoplasms
Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade.
Neoplasms
Formulation and Cytotoxicity of Ribosome-Inactivating Protein Mirabilis Jalapa L. Nanoparticles Using Alginate-Low Viscosity Chitosan Conjugated with Anti-Epcam Antibodies in the T47D Breast Cancer Cell Line.
Neoplasms
Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma.
Neoplasms
FOXP3 infiltrating lymphocyte density and PD-L1 expression in operable non-small cell lung carcinoma.
Neoplasms
FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells.
Neoplasms
Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Neoplasms
Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1? and STAT3.
Neoplasms
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.
Neoplasms
Frequency and clinicopathologic associations of DNA mismatch repair protein deficiency in ampullary carcinoma: Routine testing is indicated.
Neoplasms
Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis.
Neoplasms
Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
Neoplasms
Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Neoplasms
Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
Neoplasms
Frequent expression of PD-L1 on circulating breast cancer cells.
Neoplasms
Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.
Neoplasms
Frequent PD-L1 Expression in Malignant Melanomas of the Vulva.
Neoplasms
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
Neoplasms
Frequent PD-L1 expression in testicular germ cell tumors.
Neoplasms
Frizzled-7 promoter is highly active in tumors and promoter-driven Shiga-like toxin I inhibits hepatocellular carcinoma growth.
Neoplasms
From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer.
Neoplasms
From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway.
Neoplasms
From the Hellstrom paradox toward cancer cure.
Neoplasms
From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC.
Neoplasms
Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Neoplasms
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models.
Neoplasms
Function of follicular helper T cell is impaired and correlates with survival time in non-small cell lung cancer.
Neoplasms
Function of PD-L1 in antitumor immunity of glioma cells.
Neoplasms
Functional CD3+CD8+PD1- T Cell Accumulation and PD-L1 Expression Increases During Tumor Invasion in DCIS of the Breast.
Neoplasms
Functional Diversity of p53 in Human and Wild Animals.
Neoplasms
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Neoplasms
Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Neoplasms
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.
Neoplasms
Functionally impaired follicular helper T cells induce regulatory B cells and CD14+ human leukocyte antigen-DR- cell differentiation in non-small cell lung cancer.
Neoplasms
Functions of Immune Checkpoint Molecules Beyond Immune Evasion.
Neoplasms
Further report on therapeutic effect of abrin and ricin on human cancers.
Neoplasms
Fusion of gelonin and anti-insulin-like growth factor-1 receptor (IGF-1R) affibody for enhanced brain cancer therapy.
Neoplasms
Galectin-9 in non-small cell lung cancer.
Neoplasms
Gastric adenocarcinomas express the glycosphingolipid Gb3/CD77: Targeting of gastric cancer cells with Shiga toxin B-subunit.
Neoplasms
Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis.
Neoplasms
Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
Neoplasms
Gastric Carcinomas With Lymphoid Stroma: An Evaluation of the Histopathologic and Molecular Features.
Neoplasms
Gastritis cystica profunda is associated with aberrant p53 and Epstein-Barr virus in gastric cancer: A clinicopathological, immunohistochemical and in situ hybridization study.
Neoplasms
Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes.
Neoplasms
Gastrointestinal tract metastasis of lung cancer: The PD-L1 expression and correlated clinicopathological variables.
Neoplasms
Gated Resonance Energy Transfer (gRET) Controlled by Programmed Death Protein Ligand 1.
Neoplasms
GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma - assessing tumor and T cell interaction.
Neoplasms
GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.
Neoplasms
Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
Neoplasms
Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer.
Neoplasms
Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy.
Neoplasms
Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.
Neoplasms
Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients.
Neoplasms
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
Neoplasms
Gene expression profiles reveal key genes for early diagnosis and treatment of adamantinomatous craniopharyngioma.
Neoplasms
Gene expression profiling by targeted RNA sequencing in pathological stage I lung adenocarcinoma with a solid component.
Neoplasms
Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set.
Neoplasms
Gene mutations of esophageal squamous cell carcinoma based on next-generation sequencing.
Neoplasms
Gene Regulatory Network Rewiring in the Immune Cells Associated with Cancer.
Neoplasms
Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
Neoplasms
Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
Neoplasms
Generation of the tumor-suppressive secretome from tumor cells.
Neoplasms
Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer.
Neoplasms
Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation.
Neoplasms
Genetic alterations in gastric cancer patients according to sex.
Neoplasms
Genetic and immune profiling for potential therapeutic targets in adult human craniopharyngioma.
Neoplasms
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
Neoplasms
Genetic engineering and characterisation of chlorotoxin-fused gelonin for enhanced glioblastoma therapy.
Neoplasms
Genetic engineering cellular vesicles expressing CD64 as checkpoint antibody carrier for cancer immunotherapy.
Neoplasms
Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression.
Neoplasms
Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.
Neoplasms
Genetic Variants and Tumor Immune Microenvironment: Clues for Targeted Therapies in Inflammatory Breast Cancer (IBC).
Neoplasms
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Neoplasms
Genetically-engineered protein prodrug-like nanoconjugates for tumor-targeting biomimetic delivery via a SHEATH strategy.
Neoplasms
Genome-Wide Profiling of Human Papillomavirus DNA Integration into Human Genome and Its Influence on PD-L1 Expression in Chinese Uygur Cervical Cancer Women.
Neoplasms
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Neoplasms
Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib.
Neoplasms
Genomic and immunologic characterization of INI1-deficient pediatric cancers.
Neoplasms
Genomic and immunologic correlates of LAG-3 expression in cancer.
Neoplasms
Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
Neoplasms
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early-Invasive Lung Adenocarcinoma.
Neoplasms
Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Neoplasms
Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1.
Neoplasms
Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.
Neoplasms
Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis.
Neoplasms
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
Neoplasms
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
Neoplasms
Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
Neoplasms
Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.
Neoplasms
Ginsenoside Rh4 suppresses aerobic glycolysis and the expression of PD-L1 via targeting AKT in esophageal cancer.
Neoplasms
Glial Cell Expression of PD-L1.
Neoplasms
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Neoplasms
Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Neoplasms
Glioma Dual-Targeting Nanohybrid Protein Toxin Constructed by Intein-Mediated Site-Specific Ligation for Multistage Booster Delivery.
Neoplasms
Global PD-L1 Signals and Tumor-Infiltrating Lymphocytes: Markers of Immunogenicity in Different Subsets of Merkel Cell Carcinoma and Potential Therapeutic Implications.
Neoplasms
Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer.
Neoplasms
Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun Signaling in Renal Cancer.
Neoplasms
Glycan profiling of endometrial cancers using lectin microarray.
Neoplasms
Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer.
Neoplasms
Glyco-Engineered Anti-Human Programmed Death-Ligand 1 Antibody Mediates Stronger CD8 T Cell Activation Than Its Normal Glycosylated and Non-Glycosylated Counterparts.
Neoplasms
Glycogen Metabolism Predicts the Efficacy of Immunotherapy for Urothelial Carcinoma.
Neoplasms
Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
Neoplasms
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
Neoplasms
Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance.
Neoplasms
GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.
Neoplasms
GOLM1 upregulates expression of PD-L1 through EGFR/STAT3 pathway in hepatocellular carcinoma.
Neoplasms
Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells.
Neoplasms
Graft PD-L1 expression as a marker for transplant rejection following anti-PD1 immunotherapy for recurrent liver tumors.
Neoplasms
Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth.
Neoplasms
H3K4me3 mediates the NF-?B p50 homodimer binding to the pdcd1 promoter to activate PD-1 transcription in T cells.
Neoplasms
Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients.
Neoplasms
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.
Neoplasms
HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines.
Neoplasms
HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
Neoplasms
HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
Neoplasms
HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC.
Neoplasms
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Neoplasms
HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
Neoplasms
HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.
Neoplasms
Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer.
Neoplasms
Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.
Neoplasms
Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Neoplasms
Hepatobiliary cancers and immunotherapy: where are we now and where are we heading?
Neoplasms
Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors.
Neoplasms
Hepatoid adenocarcinoma of lung: A diagnostic challenge - Series of six cases with histopathological, predictive molecular and PD.L1 assessment.
Neoplasms
HER2-targeted antibody-drug conjugate induces host immunity against cancer stem cells.
Neoplasms
Herbal Medicines Attenuate PD-L1 Expression to Induce Anti-Proliferation in Obesity-Related Cancers.
Neoplasms
Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Neoplasms
Heterogeneity and prognosis of programmed cell death-ligand 1 expression in the circulating tumor cells of non-small cell lung cancer.
Neoplasms
Heterogeneity in immune marker expression after acquisition of resistance to EGFR kinase inhibitors: analysis of a case with small cell lung cancer transformation.
Neoplasms
Heterogeneity in PD-L1 expression in malignant peritoneal mesothelioma with systemic or intraperitoneal chemotherapy.
Neoplasms
Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma.
Neoplasms
Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy.
Neoplasms
Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma.
Neoplasms
Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
Neoplasms
Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas.
Neoplasms
Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
Neoplasms
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Neoplasms
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Neoplasms
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer.
Neoplasms
Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer.
Neoplasms
Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
Neoplasms
Heterogeneous components of lung adenocarcinomas confer distinct EGFR mutation and PD-L1 expression.
Neoplasms
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy.
Neoplasms
Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Neoplasms
Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections.
Neoplasms
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin.
Neoplasms
HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma.
Neoplasms
HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Neoplasms
HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer.
Neoplasms
HIF1?/PD-L1 axis mediates hypoxia-induced cell apoptosis and tumor progression in follicular thyroid carcinoma.
Neoplasms
HIF1A expression correlates with increased tumor immune and stromal signatures and aggressive phenotypes in human cancers.
Neoplasms
High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes.
Neoplasms
High co-expression of PD-L1 and HIF-1? correlates with tumour necrosis in pulmonary pleomorphic carcinoma.
Neoplasms
High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.
Neoplasms
High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
Neoplasms
High expression levels of TLR9 and PD-L1 indicates a poor prognosis in patients with angioimmunoblastic T-cell lymphoma: a retrospective study of 88 cases in a single center.
Neoplasms
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Neoplasms
High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation.
Neoplasms
High expression of PD-1 and PD-L1 in ocular adnexal sebaceous carcinoma.
Neoplasms
High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations.
Neoplasms
High Expression of PD-L1 and PD-L2 in Ophthalmic Sebaceous Carcinoma: The Case for a Clinical Trial of Checkpoint Inhibitors.
Neoplasms
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation.
Neoplasms
High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition.
Neoplasms
High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma.
Neoplasms
High Immunoexpression of COX-2 as a Metastatic Risk Factor in ccRCC without PD-L1 Involvement.
Neoplasms
High level of programmed death ligand 1 (PD-L1) predicts longer survival in patients with resectable small cell lung cancer.
Neoplasms
High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells.
Neoplasms
High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study.
Neoplasms
High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
Neoplasms
High PD-1 expression level is associated with an unfavorable prognosis in patients with cervical adenocarcinoma.
Neoplasms
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Neoplasms
High PD-L1 expression correlates with primary resistance to EGFR-TKIs in treatment naïve advanced EGFR-mutant lung adenocarcinoma patients.
Neoplasms
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Neoplasms
High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.
Neoplasms
High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer.
Neoplasms
High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers.
Neoplasms
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer.
Neoplasms
High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy.
Neoplasms
High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
Neoplasms
High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Neoplasms
High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations.
Neoplasms
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.
Neoplasms
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients.
Neoplasms
High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma.
Neoplasms
High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
Neoplasms
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Neoplasms
High response rate to PD-1 blockade in desmoplastic melanomas.
Neoplasms
High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer.
Neoplasms
High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer.
Neoplasms
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy.
Neoplasms
High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
Neoplasms
High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease.
Neoplasms
High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas.
Neoplasms
High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system.
Neoplasms
High-affinity human PD-L1 variants attenuate the suppression of T cell activation.
Neoplasms
High-affinity PD-1 molecules deliver improved interaction with PD-L1 and PD-L2.
Neoplasms
High-Affinity PD-1 Protein Has Potential.
Neoplasms
High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies.
Neoplasms
High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling.
Neoplasms
High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research.
Neoplasms
High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.
Neoplasms
Higher PD-L1 Immunohistochemical Detection Signal in Frozen Compared to Matched Paraffin-Embedded Formalin-Fixed Tissues.
Neoplasms
Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Neoplasms
Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.
Neoplasms
Higher Tumor Mutation Burden and Higher PD-L1 Activity Predicts the Efficacy of Immune Checkpoint Inhibitor Treatment in a Patient With Four Lung Cancers. A Case Report.
Neoplasms
Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
Neoplasms
Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer.
Neoplasms
Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
Neoplasms
Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens.
Neoplasms
HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity.
Neoplasms
Histiocytic and dendritic cell neoplasms: Reappraisal of a Japanese series based on t(14;18) and neoplastic PD-L1 expression.
Neoplasms
Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study.
Neoplasms
Histological differentiation impacts the tumor immune microenvironment in gastric carcinoma: Relation to the immune cycle.
Neoplasms
Histology-specific FGFR2 alterations and FGFR2-TACC2 fusion in mixed adenoid cystic and neuroendocrine small cell carcinoma of the uterine cervix.
Neoplasms
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Neoplasms
Histone deacetylase 6 inhibition in urothelial cancer as a potential new strategy for cancer treatment.
Neoplasms
Histone H2AX suppresses translocations in lymphomas of E?-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genes.
Neoplasms
Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
Neoplasms
Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles of tumour micro environmental factors for CD274 expression.
Neoplasms
Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.
Neoplasms
HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
Neoplasms
HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.
Neoplasms
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
Neoplasms
HLA loss of heterozygosity-mediated discordant responses to immune checkpoint blockade in squamous cell lung cancer with renal metastasis.
Neoplasms
HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients.
Neoplasms
HNC0014, a Multi-Targeted Small-Molecule, Inhibits Head and Neck Squamous Cell Carcinoma by Suppressing c-Met/STAT3/CD44/PD-L1 Oncoimmune Signature and Eliciting Antitumor Immune Responses.
Neoplasms
HNRNPL affects the proliferation and apoptosis of colorectal cancer cells by regulating PD-L1.
Neoplasms
Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Neoplasms
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
Neoplasms
Hormonotoxins: synthesis, characterization and bioefficacy of some defined disulfide linked conjugates of ovine LH with a ribosome inactivating protein, gelonin.
Neoplasms
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Neoplasms
How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy.
Neoplasms
How microRNAs affect the PD-L1 and its synthetic pathway in cancer.
Neoplasms
How to Make the Best Use of Immunotherapy as First-Line Treatment for Advanced/Metastatic Non-Small-Cell Lung Cancer.
Neoplasms
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Neoplasms
Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497/PD-L1 pathway.
Neoplasms
HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins.
Neoplasms
Human Biofield Therapy and the Growth of Mouse Lung Carcinoma.
Neoplasms
Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds.
Neoplasms
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Neoplasms
Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.
Neoplasms
Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.
Neoplasms
Human Immune System Increases Breast Cancer-Induced Osteoblastic Bone Growth in a Humanized Mouse Model without Affecting Normal Bone.
Neoplasms
Human Leukocyte Antigen Class I and Programmed Death-Ligand 1 Co-expression Is an Independent Poor Prognostic Factor in Adenocarcinoma of the Lung.
Neoplasms
Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma: An Adaptive Immune Evasion Strategy Most Common in Microsatellite Instable Tumors.
Neoplasms
Human leukocyte antigen class II expression is a good prognostic factor of adult T-cell leukemia/lymphoma.
Neoplasms
Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I-III small cell lung cancer.
Neoplasms
Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas.
Neoplasms
Human lung cancer-derived immunosuppressive plasmacytoid dendritic cells release IL-1? in an AIM2 inflammasome-dependent manner.
Neoplasms
Human nasopharyngeal carcinoma can be radiosensitized by trichosanthin via inhibition of the PI3K pathway.
Neoplasms
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.
Neoplasms
Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells.
Neoplasms
Human papillomavirus E7 oncoprotein expression by keratinocytes alters the cytotoxic mechanisms used by CD8 T cells.
Neoplasms
Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro.
Neoplasms
Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer.
Neoplasms
Human V?9V?2 T cells exert anti-tumor activity independently of PD-L1 expression in tumor cells.
Neoplasms
HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
Neoplasms
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Neoplasms
Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy.
Neoplasms
Hyperprogression after anti-programmed cell death ligand-1 therapy in a patient with recurrent metastatic urothelial bladder carcinoma following first-line cisplatin-based chemotherapy: a case report.
Neoplasms
Hyperprogression on immunotherapy with complete response to chemotherapy in a NSCLC patient with high PD-L1 and STK11: A case report.
Neoplasms
Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.
Neoplasms
Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.
Neoplasms
Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Neoplasms
Hypoxia-inducible factor-1? and nuclear factor-?B play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Neoplasms
Hypoxia-related lncRNAs to build prognostic classifier and reveal the immune characteristics of EGFR wild type and low expression of PD-L1 squamous and adenocarcinoma NSCLC.
Neoplasms
HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila.
Neoplasms
Icaritin promotes tumor T-cell infiltration and induces antitumor immunity in mice.
Neoplasms
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.
Neoplasms
Identification and characterization of an alternative cancer-derived PD-L1 splice variant.
Neoplasms
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Neoplasms
Identification and characterization of riproximin, a new type II ribosome-inactivating protein with antineoplastic activity from Ximenia americana.
Neoplasms
Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.
Neoplasms
Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Neoplasms
Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors.
Neoplasms
Identification and validation of significant gene mutations to predict clinical benefit of immune checkpoint inhibitors in lung adenocarcinoma.
Neoplasms
Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.
Neoplasms
Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.
Neoplasms
Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes.
Neoplasms
Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer.
Neoplasms
Identification of chemical compounds regulating PD-L1 by introducing HiBiT-tagged cells.
Neoplasms
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Neoplasms
Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics.
Neoplasms
Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer.
Neoplasms
Identification of gastric cancer subtypes based on pathway clustering.
Neoplasms
Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment.
Neoplasms
Identification of JAK2 and FOXM1 expression as novel candidate biomarkers for predicting the benefit of immunotherapy in lung squamous cell carcinoma.
Neoplasms
Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas.
Neoplasms
Identification of molecular signatures associated with early relapse after complete resection of lung adenocarcinomas.
Neoplasms
Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry.
Neoplasms
Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.
Neoplasms
Identification of Prostaglandin F2 Receptor Negative Regulator (PTGFRN) as an internalizable target in cancer cells for antibody-drug conjugate development.
Neoplasms
Identification of STXBP6-IRF1 positive feedback loop in regulation of PD-L1 in cancer.
Neoplasms
Identification of targets for prostate cancer immunotherapy.
Neoplasms
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN? That Induce PD-L1 Expression in Head and Neck Cancer.
Neoplasms
Identification of vitamin B6 as a PD-L1 suppressor and an adjuvant for cancer immunotherapy.
Neoplasms
Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer.
Neoplasms
Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer.
Neoplasms
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
Neoplasms
IFN-? from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Neoplasms
IFN-? Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
Neoplasms
IFN-? treatment protocol for MHC-Ilo/PD-L1+ pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential.
Neoplasms
IFN-?-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
Neoplasms
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Neoplasms
IFN?-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin.
Neoplasms
IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.
Neoplasms
IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
Neoplasms
IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4(+) T cells and promoting CTL persistence in a murine model of plasmacytoma.
Neoplasms
IL-10 suppresses IFN-?-mediated signaling in lung adenocarcinoma.
Neoplasms
IL-1? Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
Neoplasms
IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models.
Neoplasms
IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer.
Neoplasms
IL-27 induces the expression of IDO and PD-L1 in human cancer cells.
Neoplasms
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Neoplasms
IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Neoplasms
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
Neoplasms
IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors.
Neoplasms
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Neoplasms
Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients.
Neoplasms
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma.
Neoplasms
Imaging of PD-L1 in single cancer cells by SERS-based hyperspectral analysis.
Neoplasms
Imaging of programmed death ligand-1 (PD-L1): impact of protein concentration on distribution of anti-PD-L1 SPECT agent in an immunocompetent melanoma murine model.
Neoplasms
Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer.
Neoplasms
Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model.
Neoplasms
Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response.
Neoplasms
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer.
Neoplasms
Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Neoplasms
Immune biomarkers in thymic epithelial tumors: expression patterns, prognostic value and comparison of diagnostic tests for PD-L1.
Neoplasms
Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Neoplasms
Immune Cell Infiltrates and Neutrophil-to-Lymphocyte Ratio in Relation to Response to Chemotherapy and Prognosis in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas.
Neoplasms
Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors.
Neoplasms
Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma.
Neoplasms
Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
Neoplasms
Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer.
Neoplasms
Immune checkpoint analysis in lip cancer.
Neoplasms
Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
Neoplasms
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
Neoplasms
Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients.
Neoplasms
Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
Neoplasms
Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Neoplasms
Immune checkpoint blockade in ovarian cancer.
Neoplasms
Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.
Neoplasms
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Neoplasms
Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.
Neoplasms
Immune Checkpoint Dysfunction in Medium and Large Vessel Vasculitis.
Neoplasms
Immune checkpoint expression in HNSCC patients before and after definitive chemoradiotherapy.
Neoplasms
Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Neoplasms
Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
Neoplasms
Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
Neoplasms
Immune checkpoint inhibition for the treatment of mesothelioma.
Neoplasms
Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?
Neoplasms
Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages.
Neoplasms
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Neoplasms
Immune checkpoint inhibitors and small cell lung cancer: what's new?
Neoplasms
Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application.
Neoplasms
Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
Neoplasms
Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review.
Neoplasms
Immune checkpoint inhibitors for the management of advanced non-small-cell lung carcinoma: a meta-analysis.
Neoplasms
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: Emerging Mechanisms and Perspectives.
Neoplasms
Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities.
Neoplasms
Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer.
Neoplasms
Immune Checkpoint Inhibitors in Locally Advanced, Unresectable, and Metastatic Upper Gastrointestinal Malignancies.
Neoplasms
Immune checkpoint inhibitors in lung cancer: past, present and future.
Neoplasms
Immune checkpoint inhibitors in lymphoma: challenges and opportunities.
Neoplasms
Immune checkpoint inhibitors in non-small cell lung cancer - towards daily practice.
Neoplasms
Immune checkpoint inhibitors in NSCLC.
Neoplasms
Immune Checkpoint Inhibitors in Oral Cavity Squamous Cell Carcinoma and Oral Potentially Malignant Disorders: A Systematic Review.
Neoplasms
Immune Checkpoint Inhibitors in the Management of Lung Cancer.
Neoplasms
Immune checkpoint inhibitors in the management of malignancies in transplant recipients.
Neoplasms
Immune checkpoint inhibitors in the treatment of cancer.
Neoplasms
Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing.
Neoplasms
Immune checkpoint inhibitors in Wilms' tumor and Neuroblastoma: What now?
Neoplasms
Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma: A case report.
Neoplasms
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics.
Neoplasms
Immune Checkpoint Inhibitors-Related Cardiotoxicity.
Neoplasms
Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Neoplasms
Immune Checkpoint Ligand PD-L1 is Upregulated in Pulmonary Lymphangioleiomyomatosis (LAM).
Neoplasms
Immune Checkpoint Ligand Reverse Signaling: Looking Back to Go Forward in Cancer Therapy.
Neoplasms
Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
Neoplasms
Immune Checkpoint Markers in Neuroendocrine Carcinoma of the Digestive System.
Neoplasms
Immune checkpoint modulation for non-small cell lung cancer.
Neoplasms
Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
Neoplasms
Immune Checkpoint Molecules in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.
Neoplasms
Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy.
Neoplasms
Immune Checkpoint Molecules-Inherited Variations as Markers for Cancer Risk.
Neoplasms
Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.
Neoplasms
Immune checkpoint regulator PD-L1 expression on tumor cells by contacting CD11b positive bone marrow derived stromal cells.
Neoplasms
Immune checkpoint status and tumor microenvironment in vulvar squamous cell carcinoma.
Neoplasms
Immune checkpoint: The novel target for antitumor therapy.
Neoplasms
Immune checkpoints and their inhibition in cancer and infectious diseases.
Neoplasms
Immune checkpoints in aggressive breast cancer subtypes.
Neoplasms
Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.
Neoplasms
Immune checkpoints: A therapeutic target in triple negative breast cancer.
Neoplasms
Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
Neoplasms
Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients.
Neoplasms
Immune Contexture of MMR-Proficient Primary Colorectal Cancer and Matched Liver and Lung Metastases.
Neoplasms
Immune determinants of Barrett's progression to esophageal adenocarcinoma.
Neoplasms
Immune environment in serrated lesions of the Colon: intraepithelial lymphocyte density, PD-1, and PD-L1 expression correlate with serrated neoplasia pathway progression.
Neoplasms
Immune Escape Mediated by Exosomal PD-L1 in Cancer.
Neoplasms
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
Neoplasms
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.
Neoplasms
Immune evasion-related extranodal large B-cell lymphoma: A report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma.
Neoplasms
Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.
Neoplasms
Immune expression in children with Wilms tumor: a pilot study.
Neoplasms
Immune gene expression profiles in high-grade urothelial carcinoma of the bladder: a NanoString study.
Neoplasms
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.
Neoplasms
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
Neoplasms
Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients.
Neoplasms
Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors.
Neoplasms
Immune landscape in Burkitt lymphoma reveals M2-macrophage polarization and correlation between PD-L1 expression and non-canonical EBV latency program.
Neoplasms
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Neoplasms
Immune mediated colitis caused by lung cancer treatment with atezolizumab.
Neoplasms
Immune microenvironment and expression of PD-L1, PD-1, cancer testis antigen PRAME and MHC I in salivary duct carcinoma.
Neoplasms
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study.
Neoplasms
Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
Neoplasms
Immune modulation in cancer with antibodies.
Neoplasms
Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment.
Neoplasms
Immune Oncology Biomarkers in Lung Cancer: an Overview.
Neoplasms
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
Neoplasms
Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Neoplasms
Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens.
Neoplasms
Immune profiling and immunotherapeutic targets in pancreatic cancer.
Neoplasms
Immune Profiling of Advanced Thyroid Cancers Using Fluorescent Multiplex Immunohistochemistry.
Neoplasms
Immune profiling of NF1-associated tumors reveals histologic subtype distinctions and heterogeneity: implications for immunotherapy.
Neoplasms
Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression.
Neoplasms
Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response.
Neoplasms
Immune regulation of canine tumour and macrophage PD-L1 expression.
Neoplasms
Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities.
Neoplasms
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
Neoplasms
Immune response regulation in the tumor microenvironment by hypoxia.
Neoplasms
Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression.
Neoplasms
Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity.
Neoplasms
Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses.
Neoplasms
Immune targets in the tumor microenvironment treated by radiotherapy.
Neoplasms
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.
Neoplasms
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.
Neoplasms
Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
Neoplasms
Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Neoplasms
Immune-Derived PD-L1 Gene Expression Defines a Subgroup of Stage II/III Colorectal Cancer Patients with Favorable Prognosis Who May Be Harmed by Adjuvant Chemotherapy.
Neoplasms
Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.
Neoplasms
Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer.
Neoplasms
Immune-Related Adverse Events From Immune Checkpoint Inhibitors.
Neoplasms
Immune-related adverse events of checkpoint inhibitors.
Neoplasms
Immune-related adverse events of immune checkpoint inhibitors: a brief review.
Neoplasms
Immune-related alopecia (areata and universalis-type) in cancer patients receiving immune checkpoint inhibitors.
Neoplasms
Immune-resistant mechanisms in cancer immunotherapy.
Neoplasms
Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles.
Neoplasms
IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
Neoplasms
Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Neoplasms
Immuno-Oncology: Emerging Targets and Combination Therapies.
Neoplasms
Immuno-PET imaging of 68Ga-labeled nanobody Nb109 for dynamic monitoring the PD-L1 expression in cancers.
Neoplasms
Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.
Neoplasms
Immuno-regulatory antibodies for the treatment of cancer.
Neoplasms
Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma.
Neoplasms
Immunoaffinity microflow liquid chromatography/tandem mass spectrometry for the quantitation of PD1 and PD-L1 in human tumor tissues.
Neoplasms
Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-?-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA.
Neoplasms
Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients.
Neoplasms
Immunogenetics of glioblastoma: the future of personalized patient management.
Neoplasms
Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus.
Neoplasms
Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1.
Neoplasms
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Neoplasms
Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
Neoplasms
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Neoplasms
Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer.
Neoplasms
Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
Neoplasms
Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
Neoplasms
Immunohistochemical Analysis of Foxp3(+), CD4(+), CD8(+) Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma.
Neoplasms
Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Neoplasms
Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of
Neoplasms
Immunohistochemical assessment of the diagnostic utility of PD-L1: a preliminary analysis of anti-PD-L1 antibody (SP142) for lymphoproliferative diseases with tumour and non-malignant Hodgkin-Reed-Sternberg (HRS)-like cells.
Neoplasms
Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases.
Neoplasms
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance.
Neoplasms
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Neoplasms
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial.
Neoplasms
Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.
Neoplasms
Immunologic and gene expression profiles of spontaneous canine oligodendrogliomas.
Neoplasms
Immunologic and immunogenomic aspects of tumor progression.
Neoplasms
Immunologic impact of chemoradiation in cervical cancer and how immune cell infiltration could lead toward personalized treatment.
Neoplasms
Immunological differences between primary and metastatic breast cancer.
Neoplasms
Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer.
Neoplasms
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.
Neoplasms
Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment.
Neoplasms
Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.
Neoplasms
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.
Neoplasms
Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments.
Neoplasms
Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment.
Neoplasms
Immunomodulatory Molecules On Lung Cancer Stem Cells From Lymph Nodes Aspirates.
Neoplasms
Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
Neoplasms
Immunopathologic Stratification of Colorectal Cancer for Checkpoint Blockade Immunotherapy.
Neoplasms
Immunophenotype of Vestibular Schwannomas.
Neoplasms
Immunophenotypes Based on the Tumor Immune Microenvironment Allow for Unsupervised Penile Cancer Patient Stratification.
Neoplasms
Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
Neoplasms
Immunoprofiles of colorectal cancer from Lynch syndrome.
Neoplasms
Immunoprofiling as a predictor of patient's response to cancer therapy-promises and challenges.
Neoplasms
Immunoprofiling: An Encouraging Method for Predictive Factors Examination in Lung Cancer Patients Treated with Immunotherapy.
Neoplasms
Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer.
Neoplasms
Immunosuppression Factors PD-1, PD-L1, and IDO1 and Colorectal Cancer.
Neoplasms
Immunosuppressive B cells expressing PD-1/PD-L1 in solid tumors: A mini review.
Neoplasms
Immunosuppressive Phenotype of Esophagus Tumors Stroma.
Neoplasms
Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung.
Neoplasms
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
Neoplasms
Immunotherapeutic Approaches to the Management of Head and Neck Cancer.
Neoplasms
Immunotherapies for Lung Cancer.
Neoplasms
Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells.
Neoplasms
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
Neoplasms
Immunotherapy combinations for the treatment of patients with solid tumors.
Neoplasms
Immunotherapy for Esophageal and Gastric Cancer.
Neoplasms
Immunotherapy for head and neck cancer: Recent advances and future directions.
Neoplasms
Immunotherapy for Localized Prostate Cancer: The Next Frontier?
Neoplasms
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives.
Neoplasms
Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance.
Neoplasms
Immunotherapy for small cell lung cancer: mechanisms of resistance.
Neoplasms
Immunotherapy for squamous cell carcinoma of the head and neck.
Neoplasms
Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer.
Neoplasms
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
Neoplasms
Immunotherapy for thymoma.
Neoplasms
Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis.
Neoplasms
Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance.
Neoplasms
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
Neoplasms
Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.
Neoplasms
Immunotherapy in melanoma: Recent advances and future directions.
Neoplasms
Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities.
Neoplasms
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Neoplasms
Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.
Neoplasms
Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Neoplasms
Immunotherapy in NSCLC: A Promising and Revolutionary Weapon.
Neoplasms
Immunotherapy in previously treated non-small cell lung cancer (NSCLC).
Neoplasms
Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Neoplasms
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
Neoplasms
Immunotherapy in triple-negative breast cancer.
Neoplasms
Immunotherapy of experimental animal tumors with antitumor antibodies conjugated to diphtheria toxin or ricin.
Neoplasms
Immunotherapy Toxicity.
Neoplasms
Immunotherapy toxicity. Diagnosis and treatment.
Neoplasms
Immunotherapy utilizing the combination of natural killer- and antibody dependent cellular cytotoxicity (ADCC)-mediating agents with poly (ADP-ribose) polymerase (PARP) inhibition.
Neoplasms
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors.
Neoplasms
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Neoplasms
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.
Neoplasms
Immunotherapy: a new treatment paradigm in bladder cancer.
Neoplasms
Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.
Neoplasms
Immunotherapy: New insights in breast cancer treatment.
Neoplasms
Immunotoxin construction with a ribosome-inactivating protein from barley.
Neoplasms
Immunotoxin therapy of leptomeningeal neoplasia.
Neoplasms
Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer.
Neoplasms
Immunotoxins and other conjugates containing saporin-s6 for cancer therapy.
Neoplasms
Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
Neoplasms
Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.
Neoplasms
Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome.
Neoplasms
Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates.
Neoplasms
Immunotoxins: is there a clinical value?
Neoplasms
Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Neoplasms
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study.
Neoplasms
Impact of antiretroviral drugs on PD-L1 expression and copy number gains with clinical outcomes in HIV-positive and -negative locally advanced cervical cancers.
Neoplasms
Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Neoplasms
Impact of copy number variant and single nucleotide polymorphism of the programmed death-ligand 1 gene, programmed death-ligand 1 protein expression and therapy regimens on overall survival in a large group of Caucasian patients with non-small cell lung carcinoma.
Neoplasms
Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.
Neoplasms
Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
Neoplasms
Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones.
Neoplasms
Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Neoplasms
Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Neoplasms
Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association with Vascular Formation.
Neoplasms
Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes.
Neoplasms
Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation.
Neoplasms
Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.
Neoplasms
Impact of Mistletoe Triterpene Acids on the Uptake of Mistletoe Lectin by Cultured Tumor Cells.
Neoplasms
Impact of Neoadjuvant Chemotherapy on Concordance of PD-L1 Staining Fidelity between the Primary Tumor and Lymph Node Metastases in Bladder Cancer.
Neoplasms
Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study.
Neoplasms
Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8+ Tumor-Infiltrating Lymphocytes in Non-Small Cell Lung Cancer.
Neoplasms
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
Neoplasms
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
Neoplasms
Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Neoplasms
Impact of PD-L1 Protein Expression on Renal Cell Carcinoma Histo-differentiation.
Neoplasms
Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.
Neoplasms
Impact of PD-L1, transforming growth factor-? expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors.
Neoplasms
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ?50% treated with front-line pembrolizumab.
Neoplasms
Impact of pre-therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV-specific T-cell therapy.
Neoplasms
Impact of sidedness of colorectal cancer on tumor immunity.
Neoplasms
Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines.
Neoplasms
Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Neoplasms
Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
Neoplasms
Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms.
Neoplasms
Impaired Tumor-infiltrating T Cells in Patients with COPD Impacts Lung Cancer Response to PD-1 Blockade.
Neoplasms
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Neoplasms
Imperfect Predictors for Lung Cancer Immunotherapy-A Field for Further Research.
Neoplasms
Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation.
Neoplasms
Implication of CD69+ CD103+ tissue-resident-like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma.
Neoplasms
Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
Neoplasms
Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Neoplasms
Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma.
Neoplasms
Implications of the tumor immune microenvironment for staging and therapeutics.
Neoplasms
Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence.
Neoplasms
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Neoplasms
Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?
Neoplasms
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Neoplasms
Improved pharmacokinetics and tumor localization of immunotoxins constructed with the Mr 30,000 form of ricin A chain.
Neoplasms
Improved Synthesis and In Vitro Evaluation of an Aptamer Ribosomal Toxin Conjugate.
Neoplasms
Improvement of an enzyme linked lectin assay to determine recombinant mistletoe lectin I.
Neoplasms
Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand
Neoplasms
Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
Neoplasms
In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
Neoplasms
In silico and in vitro studies reveal complement system drives coagulation cascade in SARS-CoV-2 pathogenesis.
Neoplasms
In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model.
Neoplasms
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Neoplasms
In situ Tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas.
Neoplasms
In Situ Vaccination after Accelerated Hypofractionated Radiation and Surgery in a Mesothelioma Mouse Model.
Neoplasms
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.
Neoplasms
In tumor cells, thyroid hormone analogues non-immunologically regulate PD-L1 and PD-1 accumulation that is anti-apoptotic.
Neoplasms
In vitro and in vivo cytotoxic activity of native and ricin conjugated monoclonal antibodies to HBs antigen for Alexander primary liver cell carcinoma cells and tumours.
Neoplasms
In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC).
Neoplasms
In vitro and in vivo efficacy of heat shock protein specific immunotoxins on human tumor cells.
Neoplasms
In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
Neoplasms
In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins.
Neoplasms
In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1.
Neoplasms
In vitro-induced M2 type macrophages induces the resistance of prostate cancer cells to cytotoxic action of NK cells.
Neoplasms
In Vivo Antitumor Effects of MK615 Led by PD-L1 Downregulation.
Neoplasms
In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with 89Zr-labeled avelumab.
Neoplasms
In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.
Neoplasms
In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Neoplasms
In vivo Imaging of the Programmed Death Ligand 1 by (18)F Positron Emission Tomography.
Neoplasms
In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles.
Neoplasms
In vivo potentiation of ricin toxicity by monensin delivered through liposomes.
Neoplasms
In vivo studies of whole ricin monoclonal antibody immunoconjugates for the treatment of murine tumours.
Neoplasms
In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
Neoplasms
In vivo tumor targeting by the B-subunit of shiga toxin.
Neoplasms
In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy.
Neoplasms
Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma.
Neoplasms
Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
Neoplasms
Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers.
Neoplasms
Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma.
Neoplasms
Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation.
Neoplasms
Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Neoplasms
Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
Neoplasms
Increased CD3+ T cells with a low FOXP3+/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients.
Neoplasms
Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.
Neoplasms
Increased cFLIP expression in thymic epithelial tumors blocks autophagy via NF-?B signalling.
Neoplasms
Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.
Neoplasms
Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Neoplasms
Increased expression levels of Syntaxin 1A and Synaptobrevin 2/Vesicle-Associated Membrane Protein-2 are associated with the progression of bladder cancer.
Neoplasms
Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1/Anti-CTLA4 antibodies and shorter survival.
Neoplasms
Increased expression of PD-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk HPV-related cervical intraepithelial neoplasia.
Neoplasms
Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study.
Neoplasms
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Neoplasms
Increased Expression of Programmed Death Ligand 1 in Hepatocellular Carcinoma of Patients with Hepatitis B Virus Pre-S2 Mutant.
Neoplasms
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment.
Neoplasms
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma.
Neoplasms
Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment.
Neoplasms
Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy.
Neoplasms
Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.
Neoplasms
Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-?-PD-L1 pathway.
Neoplasms
Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC.
Neoplasms
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Neoplasms
Increased PD-L1 Expression in Breast and Colon Cancer Stem Cells.
Neoplasms
Increased PD-L1 Expression in Human Skin Acutely and Chronically Exposed to UV Irradiation.
Neoplasms
Increased programmed death ligand (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) expression is associated with metastasis and poor prognosis in malignant canine mammary gland tumours.
Neoplasms
Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients.
Neoplasms
Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection.
Neoplasms
Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma.
Neoplasms
Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200.
Neoplasms
Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors.
Neoplasms
Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas.
Neoplasms
Independent association of PD-L1 expression with non-inactivated VHL clear cell renal cell carcinoma - a finding with therapeutic potential.
Neoplasms
Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer.
Neoplasms
Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.
Neoplasms
Indirect comparison between immunotherapy alone and immunotherapy plus chemotherapy as first-line treatment for advanced non-small cell lung cancer: a systematic review.
Neoplasms
Individualizing renal cell carcinoma treatment through biomarkers discovery in the era of immune checkpoint inhibitors: where do we stand?
Neoplasms
Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Neoplasms
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool.
Neoplasms
Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas.
Neoplasms
Indoleamine 2,3-Dioxygenase-1 Expression in Adrenocortical Carcinoma.
Neoplasms
Indoleamine-2,3-Dioxygenase in Non-Small Cell Lung Cancer: A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1.
Neoplasms
Induced apoptotic action of recombinant trichosanthin in human stomach adenocarcinoma MCG803 cells.
Neoplasms
Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment.
Neoplasms
Inducing Tumor Suppressive Microenvironments through Genome Edited CD47-/- Syngeneic Cell Vaccination.
Neoplasms
Induction of antitumor immunity by tumor cells treated with abrin.
Neoplasms
Induction of apoptosis of human brain microvascular endothelial cells by shiga toxin 1.
Neoplasms
Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium.
Neoplasms
Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer.
Neoplasms
Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients.
Neoplasms
Induction of resident memory T cells enhances the efficacy of cancer vaccine.
Neoplasms
Induction of T cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinoma.
Neoplasms
Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3K? inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Neoplasms
Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
Neoplasms
Infiltration of CD8+ FOXP3+ T cells, CD8+ T cells, and FOXP3+ T cells in non-small cell lung cancer microenvironment.
Neoplasms
Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.
Neoplasms
Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression.
Neoplasms
Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Neoplasms
Inflammation and Cancer: What Can We Therapeutically Expect from Checkpoint Inhibitors?
Neoplasms
Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors.
Neoplasms
Inflammation induced PD-L1-specific T cells.
Neoplasms
Inflammatory Serum Biomarkers in Colorectal Cancer in Kazakhstan Population.
Neoplasms
Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
Neoplasms
Influence of Nivolumab for Intercellular Adhesion Force between a T Cell and a Cancer Cell Evaluated by AFM Force Spectroscopy.
Neoplasms
Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma.
Neoplasms
Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours.
Neoplasms
Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.
Neoplasms
Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing.
Neoplasms
Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Neoplasms
Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.
Neoplasms
Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Neoplasms
Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity.
Neoplasms
Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
Neoplasms
Inhibition of Immunosuppressive Tumors by Polymer-Assisted Inductions of Immunogenic Cell Death and Multivalent PD-L1 Crosslinking.
Neoplasms
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Neoplasms
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.
Neoplasms
Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced ?-TrCP degradation.
Neoplasms
Inhibition of mutant KRAS-driven overexpression of ARF6 and MYC by an eIF4A inhibitor drug improves the effects of anti-PD-1 immunotherapy for pancreatic cancer.
Neoplasms
Inhibition of p38 mitogen-activated protein kinase ameliorates cytokine up-regulated shigatoxin-1 toxicity in human brain microvascular endothelial cells.
Neoplasms
Inhibition of PAI-1 Blocks PD-L1 Endocytosis and Improves the Response of Melanoma Cells to Immune Checkpoint Blockade.
Neoplasms
Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
Neoplasms
Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.
Neoplasms
Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
Neoplasms
Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners.
Neoplasms
Inhibitory effect of abrin and ricin on the growth of transplantable murine tumors and of abrin on human cancers in nude mice.
Neoplasms
Inhibitory effect of abrin on Ehrlich ascites tumor.
Neoplasms
Inhibitory Effect of Anoectochilus formosanus Extract on Hyperglycemia-Related PD-L1 Expression and Cancer Proliferation.
Neoplasms
Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer.
Neoplasms
Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.
Neoplasms
Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.
Neoplasms
Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression.
Neoplasms
Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
Neoplasms
Innate vs. Adaptive: PD-L1-mediated immune resistance by melanoma.
Neoplasms
iNOS Expression by Tumor-Infiltrating Lymphocytes, PD-L1 and Prognosis in Non-Small-Cell Lung Cancer.
Neoplasms
Insights into the mechanism of cell death induced by saporin delivered into cancer cells by an antibody fusion protein targeting the transferrin receptor 1.
Neoplasms
Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PD-L1) production and transport in colon cancer stem cells.
Neoplasms
Integrated Analysis of Genomic and Immunological Features in Lung Adenocarcinoma With Micropapillary Component.
Neoplasms
Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma.
Neoplasms
Integrated Analysis of the Immune Infiltrates and PD-L1 Expression of N6-Methyladenosine-Related Long Non-Coding RNAs in Colorectal Cancer.
Neoplasms
Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer.
Neoplasms
Integrated CT imaging and tissue immune features disclose a radio-immune signature with high prognostic impact on surgically resected NSCLC.
Neoplasms
Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma.
Neoplasms
Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Neoplasms
Integrated pan-cancer map of EBV-associated neoplasms reveals functional host-virus interactions.
Neoplasms
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.
Neoplasms
Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer.
Neoplasms
Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer.
Neoplasms
Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer.
Neoplasms
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Neoplasms
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients.
Neoplasms
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response.
Neoplasms
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.
Neoplasms
Integrative Analysis and Machine Learning based Characterization of Single Circulating Tumor Cells.
Neoplasms
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Neoplasms
Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.
Neoplasms
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Neoplasms
Integrative immunologic and genomic characterization of brain metastasis from ovarian/peritoneal cancer.
Neoplasms
Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma.
Neoplasms
Integrin ?v?3-targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy.
Neoplasms
Integrin ?v?8-expressing tumor cells evade host immunity by regulating TGF-? activation in immune cells.
Neoplasms
Inter- and intra-patient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumor microenvironment.
Neoplasms
Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Neoplasms
Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Neoplasms
Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer.
Neoplasms
Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.
Neoplasms
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
Neoplasms
Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.
Neoplasms
Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study.
Neoplasms
Interferon Gamma Induces Changes in Natural Killer (NK) Cell Ligand Expression and Alters NK Cell-Mediated Lysis of Pediatric Cancer Cell Lines.
Neoplasms
Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
Neoplasms
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Neoplasms
Interferon Gamma-Induced Interferon Regulatory Factor 1 Activates Transcription of HHLA2 and Induces Immune Escape of Hepatocellular Carcinoma Cells.
Neoplasms
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Neoplasms
Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Neoplasms
Interferon-? induced PD-L1 expression and soluble PD-L1 production in gastric cancer.
Neoplasms
Interferon-? signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells.
Neoplasms
Interferon-?-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression.
Neoplasms
Interferon-?-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway.
Neoplasms
Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells.
Neoplasms
Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Neoplasms
Interleukin-17 promotes nitric oxide-dependent expression of PD-L1 in mesenchymal stem cells.
Neoplasms
Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea.
Neoplasms
Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.
Neoplasms
Interobserver Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in NSCLC.
Neoplasms
Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging.
Neoplasms
Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
Neoplasms
Interstitial chemotherapy using thermosensitive gel-coated ricin in nude mice bearing a human hepatoma.
Neoplasms
Interstitial chemotherapy with ricin-loaded thermosensitive hydrogel in pancreatic cancer xenograft.
Neoplasms
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer.
Neoplasms
Intracellular drug delivery: Potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy.
Neoplasms
Intracellular Protein Delivery System Using a Target-Specific Repebody and Translocation Domain of Bacterial Exotoxin.
Neoplasms
Intracellular re-localisation by photochemical internalisation enhances the cytotoxic effect of gelonin--quantitative studies in normal rat liver.
Neoplasms
Intralesional interleukin-2: A novel option to maximize response to systemic immune checkpoint therapy in loco-regional metastatic melanoma.
Neoplasms
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Neoplasms
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients.
Neoplasms
Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma.
Neoplasms
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.
Neoplasms
Intratumoral administration of mRNA encoding a fusokine consisting of IFN-? and the ectodomain of the TGF-? receptor II potentiates antitumor immunity.
Neoplasms
Intratumoral CD3 and CD8 T-Cell Densities Associated with Relapse Free Survival in HCC.
Neoplasms
Intratumoral Copper Modulates PD-L1 Expression and Influences Tumor Immune Evasion.
Neoplasms
Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
Neoplasms
Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1.
Neoplasms
Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma.
Neoplasms
Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
Neoplasms
Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
Neoplasms
Intratumoral Heterogeneity in PD-L1 Immunoreactivity is Associated with Variation in Non-Small Cell Lung Carcinoma Histotype.
Neoplasms
Intratumoral heterogeneity of programmed cell death ligand-1 expression is common in lung cancer.
Neoplasms
Intratumoral immune cells expressing PD-1/PD-L1 and their prognostic implications in cancer: a meta-analysis.
Neoplasms
Intratumoral immune-biomarkers and mismatch repair status in leiyomyosarcoma -potential predictive markers for adjuvant treatment: a pilot study.
Neoplasms
Intratumour therapy of solid tumours with ricin-antibody conjugates.
Neoplasms
Intratumoural immune cell landscape in germinoma reveals multipotent lineages and exhibits prognostic significance.
Neoplasms
Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
Neoplasms
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Neoplasms
Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
Neoplasms
Intravital Imaging of Adoptive T-Cell Morphology, Mobility and Trafficking Following Immune Checkpoint Inhibition in a Mouse Melanoma Model.
Neoplasms
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma.
Neoplasms
Intron 4-5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance.
Neoplasms
Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Uterine Cervix: Clinicopathological and Molecular Characteristics With Special Emphasis on the First Description of Consistent Programmed Death-ligand 1 (PD-L1) Over-expression.
Neoplasms
Inverse correlation between PD-L1 expression and LGR5 expression in tumor budding of stage II/III colorectal cancer.
Neoplasms
Inverse correlation of soluble programmed cell death-1 ligand-1 (sPD-L1) with eosinophil count and clinical severity in allergic rhinitis patients.
Neoplasms
Inverse Relationship Between Alzheimer's Disease and Cancer: How Immune Checkpoints Might Explain the Mechanisms Underlying Age-Related Diseases.
Neoplasms
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Neoplasms
Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.
Neoplasms
Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy.
Neoplasms
Investigation on the effects of soluble programmed death-1 (sPD-1) enhancing anti-tumor immune response.
Neoplasms
Involvement of Cellular Prion Protein in Invasion and Metastasis of Lung Cancer by Inducing Treg Cell Development.
Neoplasms
Involvement of extracellular vesicles in the macrophage-tumor cell communication in head and neck squamous cell carcinoma.
Neoplasms
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Neoplasms
Involvement of prohibitin upregulation in abrin-triggered apoptosis.
Neoplasms
Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
Neoplasms
Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study.
Neoplasms
Ipilimumab in melanoma.
Neoplasms
IRE1? regulates macrophage polarization, PD-L1 expression, and tumor survival.
Neoplasms
IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell.
Neoplasms
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
Neoplasms
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Neoplasms
Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer.
Neoplasms
Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?
Neoplasms
Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor.
Neoplasms
Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
Neoplasms
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Neoplasms
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Neoplasms
ITM2A as a Tumor Suppressor and Its Correlation With PD-L1 in Breast Cancer.
Neoplasms
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.
Neoplasms
JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers.
Neoplasms
JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management.
Neoplasms
Joint association of patients' sex and PD-L1 expression with overall survival benefits and tumor-immune microenvironment in immune checkpoint inhibitors for cancers.
Neoplasms
JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Neoplasms
JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Neoplasms
JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial.
Neoplasms
Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Neoplasms
KALRN mutations promote antitumor immunity and immunotherapy response in cancer.
Neoplasms
KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Neoplasms
KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1-49.
Neoplasms
Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker.
Neoplasms
Keytruda Crosses First-Line Finish Line First.
Neoplasms
Kinetic study of the cytotoxic effect of alpha-sarcin, a ribosome inactivating protein from Aspergillus giganteus, on tumour cell lines: protein biosynthesis inhibition and cell binding.
Neoplasms
KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity.
Neoplasms
Knockdown of Chitinase 3-Like-1 Inhibits Cell Proliferation, Promotes Apoptosis, and Enhances Effect of Anti-Programmed Death Ligand 1 (PD-L1) in Diffuse Large B Cell Lymphoma Cells.
Neoplasms
Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.
Neoplasms
KPNB1 Inhibitor Importazole Reduces Ionizing Radiation-Increased Cell Surface PD-L1 Expression by Modulating Expression and Nuclear Import of IRF1.
Neoplasms
KPNB1-mediated nuclear translocation of PD-L1 promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signaling pathway.
Neoplasms
KRAS expression is a prognostic indicator and associated with immune infiltration in breast cancer.
Neoplasms
KRAS G12D mutation predicts lower TMB and drives immune suppression in lung adenocarcinoma.
Neoplasms
KRAS G12V mutation upregulates PD-L1 expression via TGF-?/EMT signaling pathway in human non-small-cell lung cancer.
Neoplasms
KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas.
Neoplasms
KSHV infection skews macrophage polarisation towards M2-like/TAM and activates Ire1 ?-XBP1 axis up-regulating pro-tumorigenic cytokine release and PD-L1 expression.
Neoplasms
Label-free and specific detection of soluble programmed death ligand-1 using a localized surface plasmon resonance biosensor based on excessively tilted fiber gratings.
Neoplasms
Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
Neoplasms
LAG-3 antagonists by cancer treatment: a patent review.
Neoplasms
LAG-3 expression in the inflammatory microenvironment of glioma.
Neoplasms
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
Neoplasms
LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.
Neoplasms
LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
Neoplasms
Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
Neoplasms
Landscape of current and future therapies of Merkel cell carcinoma.
Neoplasms
Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers.
Neoplasms
Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: A case report.
Neoplasms
Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.
Neoplasms
Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.
Neoplasms
Lazarus-type tumour response to therapy with nivolumab for sarcomatoid carcinomas of the lung.
Neoplasms
LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
Neoplasms
Lectin binding to human gastric adenocarcinomas and adjacent tissues.
Neoplasms
Lectins as differentiation markers of human gliomas.
Neoplasms
Lectins: reliable differentiation markers in human oligodendrogliomas.
Neoplasms
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
Neoplasms
Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Neoplasms
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.
Neoplasms
Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma.
Neoplasms
Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells.
Neoplasms
LIN28/let-7/PD-L1 Pathway as a Target for Cancer Immunotherapy.
Neoplasms
LINC00116 enhances cervical cancer tumorigenesis through miR-106a/c-Jun pathway.
Neoplasms
LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a.
Neoplasms
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Neoplasms
Lineage-Specific Alterations in Gynecologic Neoplasms with Choriocarcinomatous Differentiation: Implications for Origin and Therapeutics.
Neoplasms
Liothyronine could block the programmed death-ligand 1 (PDL1) activity: an e-Pharmacophore modeling and virtual screening study.
Neoplasms
Lipid Metabolism in Tumor-Infiltrating T Cells.
Neoplasms
Lipopolyamine treatment increases the efficacy of intoxication with saporin and an anticancer saporin conjugate.
Neoplasms
Liposomal nanohybrid cerasomes targeted to PD-L1 enable dual-modality imaging and improve antitumor treatments.
Neoplasms
Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies.
Neoplasms
Listeria-based hepatocellular carcinoma vaccine facilitates anti-PD-1 therapy by regulating macrophage polarization.
Neoplasms
Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients.
Neoplasms
Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation.
Neoplasms
Liver metastases and the efficacy of the PD-1 or PD-L1 inhibitors in cancer: a meta-analysis of randomized controlled trials.
Neoplasms
LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
Neoplasms
LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
Neoplasms
LncRNA KCNQ1OT1 Secreted by Tumor Cell-Derived Exosomes Mediates Immune Escape in Colorectal Cancer by Regulating PD-L1 Ubiquitination via MiR-30a-5p/USP22.
Neoplasms
LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Neoplasms
LncRNA MIAT correlates with immune infiltrates and drug reactions in hepatocellular carcinoma.
Neoplasms
Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma.
Neoplasms
Local targeting of NAD+ salvage pathway alters the immune tumor microenvironment and enhances checkpoint immunotherapy in glioblastoma.
Neoplasms
Localization of PD-L1 on single cancer cells by iSERS microscopy with Au/Au core/satellite nanoparticles.
Neoplasms
Locally advanced undifferentiated sarcomatoid carcinoma of the right maxillary sinus with PDCD6-TERT fusion: A rare case report.
Neoplasms
Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils.
Neoplasms
Long Noncoding RNAs Control the Modulation of Immune Checkpoint Molecules in Cancer.
Neoplasms
Long-distance modulation of bystander tumor cells by CD8+ T cell-secreted IFN?.
Neoplasms
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Neoplasms
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
Neoplasms
Long-term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer.
Neoplasms
Long-term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PD-L1 expression.
Neoplasms
Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report.
Neoplasms
Long-term survival of a patient with programmed death ligand 1-negative lung adenocarcinoma and oligoprogressive disease treated with nivolumab and stereotactic body radiation therapy.
Neoplasms
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Neoplasms
Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Neoplasms
Loss of DNA mismatch repair proteins in prostate cancer.
Neoplasms
Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer.
Neoplasms
Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma.
Neoplasms
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
Neoplasms
Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
Neoplasms
Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
Neoplasms
Loss of tumor intrinsic PD-L1 confers resistance to drug-induced apoptosis in human colon cancer.
Neoplasms
Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
Neoplasms
Low CD8? T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44?/CD133? Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer.
Neoplasms
Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis.
Neoplasms
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Neoplasms
Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma.
Neoplasms
Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma.
Neoplasms
Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression.
Neoplasms
Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy.
Neoplasms
Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.
Neoplasms
Low-dose Diosbulbin-B (DB) activates tumor-intrinsic PD-L1/NLRP3 signaling pathway mediated pyroptotic cell death to increase cisplatin-sensitivity in gastric cancer (GC).
Neoplasms
LRP11 activates ?-catenin to induce PD-L1 expression in prostate cancer.
Neoplasms
Lung Adenocarcinoma Harboring EGFR Kinase Domain Duplication (EGFR-KDD) Confers Sensitivity to Osimertinib and Nivolumab: A Case Report.
Neoplasms
Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy.
Neoplasms
Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
Neoplasms
Lung and lymph node metastases from hepatocellular carcinoma: Comparison of pathological aspects.
Neoplasms
Lung Carcinoma Predictive Biomarker Testing by Immunoperoxidase Stains in Cytology and Small Biopsy Specimens: Advantages and Limitations.
Neoplasms
Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
Neoplasms
Lymph nodes may be a source for immunetherapy in gastric cancer.
Neoplasms
Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8+ T-cell Responses.
Neoplasms
Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes.
Neoplasms
Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.
Neoplasms
Lymphocyte targeted ricin as a potential therapy for lymphoid malignancy. I. Targeting efficiency.
Neoplasms
Lymphocyte-C-reactive protein ratio as a prognostic marker associated with the tumor immune microenvironment in intrahepatic cholangiocarcinoma.
Neoplasms
Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.
Neoplasms
Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer.
Neoplasms
Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Neoplasms
Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth.
Neoplasms
Lysosomal Acid Lipase Deficiency Controls T- and B-Regulatory Cell Homeostasis in the Lymph Nodes of Mice with Human Cancer Xenotransplants.
Neoplasms
Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy.
Neoplasms
Lysyl Oxidase-Like 4 Fosters an Immunosuppressive Microenvironment During Hepatocarcinogenesis.
Neoplasms
M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer.
Neoplasms
M2-Like TAMs Function Reversal Contributes to Breast Cancer Eradication by Combination Dual Immune Checkpoint Blockade and Photothermal Therapy.
Neoplasms
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma.
Neoplasms
m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer.
Neoplasms
M7824, a novel bifunctional anti-PD-L1/TGF? Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine.
Neoplasms
Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer.
Neoplasms
Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
Neoplasms
Macrophage polarity in cancer: A review.
Neoplasms
Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway.
Neoplasms
Macrophage-histiocytes in malignant lymphoma, small lymphocytic type (well-differentiated lymphocytic lymphoma).
Neoplasms
Macrophages in Oral Carcinomas: Relationship with Cancer Stem Cell Markers and PD-L1 Expression.
Neoplasms
Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Neoplasms
Magnetic Resonance Colonography Enables the Efficacy Assessment of Immune Checkpoint Inhibitors in an Orthotopic Colorectal Cancer Mouse Model.
Neoplasms
Magnetically Navigated Protein Transduction In Vivo using Iron Oxide-Nanogel Chaperone Hybrid.
Neoplasms
Maintenance avelumab for metastatic urothelial cancer: a new standard of care.
Neoplasms
Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin.
Neoplasms
Majority of B2M-Mutant and -Deficient Colorectal Carcinomas Achieve Clinical Benefit From Immune Checkpoint Inhibitor Therapy and Are Microsatellite Instability-High.
Neoplasms
Malignant mesothelioma clinical trial combines immunotherapy drugs.
Neoplasms
Malignant mesothelioma effusions are infiltrated by CD3(+) T cells highly expressing PD-L1 and the PD-L1(+) tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab.
Neoplasms
Malignant pleural effusion as a predictor of the efficacy of anti-PD-1 antibody in patients with non-small cell lung cancer.
Neoplasms
Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intra-tumor heterogeneity over time.
Neoplasms
Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.
Neoplasms
Mammary-tumor-educated B cells acquire LAP/TGF-? and PD-L1 expression and suppress anti-tumor immune responses.
Neoplasms
Management of Immune-Related Dermatitis and Mucositis Associated With Pembrolizumab in Metastatic Human Papillomavirus-Associated Squamous Cell Carcinoma of the Oropharynx.
Neoplasms
Management trends and outcomes of pineal germinoma in a multi-institutional Australian cohort.
Neoplasms
Managing immune checkpoint-blocking antibody side effects.
Neoplasms
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Neoplasms
Manipulating immune system using nanoparticles for an effective cancer treatment: Combination of targeted therapy and checkpoint blockage miRNA.
Neoplasms
MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells.
Neoplasms
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.
Neoplasms
Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma.
Neoplasms
Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients.
Neoplasms
mDKN-01, a Novel Anti-DKK1 mAb, Enhances Innate Immune Responses in the Tumor Microenvironment.
Neoplasms
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma.
Neoplasms
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Neoplasms
MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma.
Neoplasms
Measurement of kinetic binding constants of a panel of anti-saporin antibodies using a resonant mirror biosensor.
Neoplasms
Measurement of Protein-Protein Interactions through Microscale Thermophoresis (MST).
Neoplasms
Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.
Neoplasms
Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Neoplasms
Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC.
Neoplasms
Mechanism of PKM2 affecting cancer immunity and metabolism in Tumor Microenvironment.
Neoplasms
Mechanisms Controlling PD-L1 Expression in Cancer.
Neoplasms
Mechanisms in removal of tumor by antibody.
Neoplasms
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.
Neoplasms
Mechanisms Of Hypoxia-Induced Immune Escape In Cancer And Their Regulation By Nitric Oxide.
Neoplasms
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Neoplasms
Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells.
Neoplasms
Mechanisms of Resistance to PD-1 Checkpoint Blockade.
Neoplasms
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
Neoplasms
Mechanisms regulating PD-L1 expression on tumor and immune cells.
Neoplasms
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Neoplasms
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Neoplasms
Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases.
Neoplasms
Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
Neoplasms
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.
Neoplasms
Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Neoplasms
Melanoma: prognostic factors and factors predictive of response to therapy.
Neoplasms
Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
Neoplasms
Membrane destabilization by ricin.
Neoplasms
Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study.
Neoplasms
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
Neoplasms
Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells.
Neoplasms
Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
Neoplasms
Merkel Cell Carcinoma of Unknown Primary: Immunohistochemical and Molecular Analyses Reveal Distinct UV-Signature/MCPyV-Negative and High Immunogenicity/MCPyV-Positive Profiles.
Neoplasms
Merkel Cell Carcinoma: An Update and Immunotherapy.
Neoplasms
Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma.
Neoplasms
Mesencephalic astrocyte-derived neurotrophic factor is secreted from interferon-?-activated tumor cells through ER calcium depletion.
Neoplasms
Mesenchymal stem cells induce PD-L1 expression through the secretion of CCL5 in breast cancer cells.
Neoplasms
Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
Neoplasms
Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression.
Neoplasms
Met inhibition revokes IFN?-induction of PD-1 ligands in MET-amplified tumours.
Neoplasms
MET is overexpressed in microsatellite instability-high gastric carcinoma.
Neoplasms
MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function.
Neoplasms
MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.
Neoplasms
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.
Neoplasms
Metabolic modulation via mTOR pathway and anti-angiogenesis remodels tumor microenvironment using PD-L1-targeting codelivery.
Neoplasms
Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.
Neoplasms
Metabolomic analysis of Shiga toxin 2a-induced injury in conditionally immortalized glomerular endothelial cells.
Neoplasms
Metaplastic breast cancer: an old histotype but a current therapeutic problem.
Neoplasms
Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.
Neoplasms
Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes.
Neoplasms
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.
Neoplasms
Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab.
Neoplasms
Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells.
Neoplasms
Metastatic Syringocystadenocarcinoma Papilliferum: A Case Report, Tumor Genomic Profiling, and Literature Review.
Neoplasms
Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells.
Neoplasms
Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
Neoplasms
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Neoplasms
Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1.
Neoplasms
Method for the Instant In-Flight Manufacture of Black Phosphorus to Assemble Core@Shell Nanocomposites for Targeted Photoimmunotherapy.
Neoplasms
Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
Neoplasms
Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus.
Neoplasms
Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.
Neoplasms
Microneedles loaded with anti-PD-1-cisplatin nanoparticles for synergistic cancer immuno-chemotherapy.
Neoplasms
Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1.
Neoplasms
MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Neoplasms
MicroRNA-138-5p Suppresses Non-small Cell Lung Cancer Cells by Targeting PD-L1/PD-1 to Regulate Tumor Microenvironment.
Neoplasms
MicroRNA-155 induction via TNF-? and IFN-? suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells.
Neoplasms
MicroRNA-155-5p suppresses PD-L1 expression in lung adenocarcinoma.
Neoplasms
MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
Neoplasms
MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer.
Neoplasms
MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT.
Neoplasms
MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3.
Neoplasms
MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer.
Neoplasms
MicroRNA-4458 Regulates PD-L1 Expression to Enhance Anti-tumor Immunity in NSCLC via Targeting STAT3.
Neoplasms
MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer.
Neoplasms
MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer.
Neoplasms
Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
Neoplasms
Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer.
Neoplasms
Microsatellite instability and mismatch repair protein expressions in lymphocyte-predominant breast cancer.
Neoplasms
Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Neoplasms
Microsatellite Instability as a Predictor of Outcomes in Colorectal Cancer in the Era of Immune-Checkpoint Inhibitors.
Neoplasms
Microsatellite instability in Japanese female patients with triple-negative breast cancer.
Neoplasms
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Neoplasms
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
Neoplasms
miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer.
Neoplasms
miR-140-3p Suppresses Cell Growth And Induces Apoptosis In Colorectal Cancer By Targeting PD-L1.
Neoplasms
miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway.
Neoplasms
miR-142-5p regulates tumor cell PD-L1 expression and enhances anti-tumor immunity.
Neoplasms
miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Neoplasms
MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
Neoplasms
MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
Neoplasms
miR-375 inhibits IFN-?-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
Neoplasms
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint.
Neoplasms
MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression.
Neoplasms
MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Neoplasms
miREIA - an immunoassay method in assessment of microRNA levels in tumor tissue-pilot study. The impact of miR-93-5p, miR-142-5p and IFN? on PD-L1 level in colorectal cancer.
Neoplasms
miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
Neoplasms
miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.
Neoplasms
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.
Neoplasms
Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.
Neoplasms
Mismatch repair status and high expression of PD-L1 in nasopharyngeal carcinoma.
Neoplasms
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Neoplasms
Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Neoplasms
Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis.
Neoplasms
Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer.
Neoplasms
Mitosis in Cancer Cell Increases Immune Resistance via High Expression of HLA-G and PD-L1.
Neoplasms
Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer.
Neoplasms
MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer.
Neoplasms
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Neoplasms
MLLT6 maintains PD-L1 expression and mediates tumor immune resistance.
Neoplasms
MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Neoplasms
Modeling tumor immunity of mouse glioblastoma by exhausted CD8
Neoplasms
Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli.
Neoplasms
Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.
Neoplasms
Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy.
Neoplasms
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.
Neoplasms
Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Neoplasms
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments.
Neoplasms
Modulation of the PD-1/PD-L1 immune checkpoint axis during inflammation-associated lung tumorigenesis.
Neoplasms
Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features.
Neoplasms
Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Neoplasms
Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
Neoplasms
Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals.
Neoplasms
Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.
Neoplasms
Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.
Neoplasms
Molecular Characterization of Appendiceal Goblet Cell Carcinoid.
Neoplasms
Molecular characterization of cancers with NTRK gene fusions.
Neoplasms
Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
Neoplasms
Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in chickens infected with Marek's disease virus.
Neoplasms
Molecular Characterization of the Recombinant A-chain of a Type II Ribosome-Inactivating Protein (RIP) from Viscum album coloratum and Structural Basis on its Ribosome-Inactivating Activity and the Sugar-binding Properties of the B-chain.
Neoplasms
Molecular characterization, biological function, tumor microenvironment association and clinical significance of m6A regulators in lung adenocarcinoma.
Neoplasms
Molecular determinants of response to PD-L1 blockade across tumor types.
Neoplasms
Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Neoplasms
Molecular differences across invasive lung adenocarcinoma morphological subgroups.
Neoplasms
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
Neoplasms
Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.
Neoplasms
Molecular dynamics simulations elucidate conformational selection and induced fit mechanisms in the binding of PD-1 and PD-L1.
Neoplasms
Molecular events in the pathogenesis of vulvar squamous cell carcinoma.
Neoplasms
Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer.
Neoplasms
Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Neoplasms
Molecular Heterogeneity of High Grade Colorectal Adenocarcinoma.
Neoplasms
Molecular Imaging and the PD-L1 Pathway: From Bench to Clinic.
Neoplasms
Molecular imaging of PD-L1 expression and dynamics with the adnectin-based PET tracer 18F-BMS-986192.
Neoplasms
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
Neoplasms
Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises.
Neoplasms
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.
Neoplasms
Molecular pathology of lung cancer: current status and perspectives.
Neoplasms
Molecular Pathology: A Requirement for Precision Medicine in Cancer.
Neoplasms
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.
Neoplasms
Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer.
Neoplasms
Molecular profile of non-small cell lung cancer in northeastern Brazil.
Neoplasms
Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer.
Neoplasms
Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.
Neoplasms
Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy.
Neoplasms
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Neoplasms
Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases.
Neoplasms
Molecular Profiling Reveals Limited Targetable Biomarkers in Neuroendocrine Carcinoma of the Cervix.
Neoplasms
Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Neoplasms
Molecular Targeted Agent and Immune Checkpoint Inhibitor Co-Loaded Thermosensitive Hydrogel for Synergistic Therapy of Rectal Cancer.
Neoplasms
Molecular tumor targeting of gelonin by fusion with F3 peptide.
Neoplasms
Momordin Ic couples apoptosis with autophagy in human hepatoblastoma cancer cells by reactive oxygen species (ROS)-mediated PI3K/Akt and MAPK signaling pathways.
Neoplasms
Momordins inhibit both AP-1 function and cell proliferation.
Neoplasms
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
Neoplasms
Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Neoplasms
Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Neoplasms
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
Neoplasms
Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
Neoplasms
Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity.
Neoplasms
Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy.
Neoplasms
Monoclonal Antibody L
Neoplasms
Monoclonal antibody-ricin or ricin A chain hybrids: kinetic analysis of cell killing for tumor therapy.
Neoplasms
Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer.
Neoplasms
Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
Neoplasms
Mouse embryonic development and tumor cell growth under the influence of recombinant trichosanthin (a ribosome inactivating protein) and its muteins.
Neoplasms
Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity.
Neoplasms
Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment.
Neoplasms
mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand for PD-L1).
Neoplasms
mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Neoplasms
mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.
Neoplasms
MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
Neoplasms
mTOR Inhibition Increases Transcription Factor E3 (TFE3) Activity and Modulates Programmed Death-Ligand 1 (PD-L1) Expression in Translocation Renal Cell Carcinoma.
Neoplasms
mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?
Neoplasms
MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a Bicistronic Expression Plasmid Generates Specific Immune Responses and Antitumour Effects in a Murine Colorectal Carcinoma Model.
Neoplasms
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Neoplasms
MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer.
Neoplasms
Mucin-type sialyl-Tn antigen is associated with PD-L1 expression and predicts poor clinical prognosis in breast cancer.
Neoplasms
Multi-Field-of-View Deep Learning Model Predicts Nonsmall Cell Lung Cancer Programmed Death-Ligand 1 Status from Whole-Slide Hematoxylin and Eosin Images.
Neoplasms
Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer.
Neoplasms
Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE.
Neoplasms
Multicenter French harmonization study for PD-L1 IHC testing in non-small cell lung cancer.
Neoplasms
Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.
Neoplasms
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Neoplasms
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.
Neoplasms
Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma.
Neoplasms
Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment.
Neoplasms
Multifunctional Nanoregulator Reshapes Immune Microenvironment and Enhances Immune Memory for Tumor Immunotherapy.
Neoplasms
Multifunctionality of CD8+ T cells and PD-L1 expression as a biomarker of anti-PD-1 antibody efficacy in advanced melanoma.
Neoplasms
Multimodal detection of PD-L1: reasonable biomarkers for immune checkpoint inhibitor.
Neoplasms
Multimodal Molecular Imaging Detects Early Responses to Immune Checkpoint Blockade.
Neoplasms
Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.
Neoplasms
Multiplatform molecular profiling identifies potentially targetable biomarkers in malignant phyllodes tumors of the breast.
Neoplasms
Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
Neoplasms
Multiple Immune-Suppressive Mechanisms in Fibrolamellar Carcinoma.
Neoplasms
Multiplex immune protein profiling of fine-needle aspirates from patients with non-small-cell lung cancer reveals signatures associated with PD-L1 expression and tumor stage.
Neoplasms
Multiplex Immuno-LC-MS-PRM Quantitation of CD8A, CD4, LAG3, PD1, PD-L1 and PD-L2 in Frozen Human Tissues.
Neoplasms
Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
Neoplasms
Multiplex Immunohistochemistry for Image Analysis of Tertiary Lymphoid Structures in Cancer.
Neoplasms
Multiplex immunohistochemistry indicates biomarkers in colorectal cancer.
Neoplasms
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Neoplasms
Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy.
Neoplasms
Multiplex Three-Dimensional Mapping of Macromolecular Drug Distribution in the Tumor Microenvironment.
Neoplasms
Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities in Craniopharyngioma.
Neoplasms
Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ.
Neoplasms
Multiregion Sequencing Reveals the Genetic Heterogeneity and Evolutionary History of Osteosarcoma and Matched Pulmonary Metastases.
Neoplasms
Multispecific Platinum(IV) Complex Deters Breast Cancer via Interposing Inflammation and Immunosuppression as an Inhibitor of COX-2 and PD-L1.
Neoplasms
Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma.
Neoplasms
Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Neoplasms
Multistage Cooperative Nanodrug Combined with PD-L1 for Enhancing Antitumor Chemoimmunotherapy.
Neoplasms
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer.
Neoplasms
Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors.
Neoplasms
Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Neoplasms
Mutational burden, MHC-I expression and immune infiltration as limiting factors for in situ vaccination by TNF? and IL-12 gene electrotransfer.
Neoplasms
Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2.
Neoplasms
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer.
Neoplasms
MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
Neoplasms
MYC inhibition increases PD-L1 expression induced by IFN-? in hepatocellular carcinoma cells.
Neoplasms
MYC regulates the antitumor immune response through CD47 and PD-L1.
Neoplasms
MYC: Master Regulator of Immune Privilege.
Neoplasms
Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing.
Neoplasms
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Neoplasms
Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
Neoplasms
Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.
Neoplasms
N-acetylgalactosamine, N-acetylglucosamine and sialic acid expression in primary breast cancers.
Neoplasms
N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells.
Neoplasms
N-glycosylation and ubiquitinylation of PD-L1 do not restrict interaction with BMS-202: A molecular modeling study.
Neoplasms
N-glycosylation of PD-1 promotes binding of camrelizumab.
Neoplasms
N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.
Neoplasms
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion.
Neoplasms
Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Neoplasms
Nano-diamino-tetrac (NDAT) inhibits PD-L1 expression which is essential for proliferation in oral cancer cells.
Neoplasms
Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice.
Neoplasms
Nanomedicine-combined immunotherapy for cancer.
Neoplasms
Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Neoplasms
Nanoparticle Conjugation Stabilizes and Multimerizes ?-Hairpin Peptides To Effectively Target PD-1/PD-L1 ?-Sheet-Rich Interfaces.
Neoplasms
Nanosac, a Noncationic and Soft Polyphenol Nanocapsule, Enables Systemic Delivery of siRNA to Solid Tumors.
Neoplasms
Nanoscale reduced graphene oxide-mediated photothermal therapy together with IDO inhibition and PD-L1 blockade synergistically promote antitumor immunity.
Neoplasms
Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity.
Neoplasms
Nanozyme-assisted sensitive profiling of exosomal proteins for rapid cancer diagnosis.
Neoplasms
Nature of lectin-induced alteration of potassium transfer in Ehrlich ascites tumor cells.
Neoplasms
NCCN Guidelines Updates: New Immunotherapy Strategies for Improving Outcomes in Non-Small Cell Lung Cancer.
Neoplasms
NDAT Targets PI3K-Mediated PD-L1 Upregulation to Reduce Proliferation in Gefitinib-Resistant Colorectal Cancer.
Neoplasms
Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma.
Neoplasms
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.
Neoplasms
Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice.
Neoplasms
Near-Infrared-II Nanoparticles for Cancer Imaging of Immune Checkpoint Programmed Death-Ligand 1 and Photodynamic/Immune Therapy.
Neoplasms
Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Neoplasms
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
Neoplasms
Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy.
Neoplasms
Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.
Neoplasms
Negative regulation of T-cell function by PD-1.
Neoplasms
NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Neoplasms
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial.
Neoplasms
Neoadjuvant checkpoint blockade for cancer immunotherapy.
Neoplasms
Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
Neoplasms
Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression.
Neoplasms
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
Neoplasms
Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma.
Neoplasms
Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?
Neoplasms
Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer.
Neoplasms
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
Neoplasms
Neoadjuvant Immunotherapy of Oral Squamous Cell Carcinoma: Case Report and Assessment of Histological Response.
Neoplasms
Neoadjuvant Interferons: Critical for effective PD-1 based immunotherapy in TNBC.
Neoplasms
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 Trial.
Neoplasms
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
Neoplasms
Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.
Neoplasms
Neuroendocrine tumours and their microenvironment.
Neoplasms
Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
Neoplasms
Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort.
Neoplasms
Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab.
Neoplasms
New antibody approaches to lymphoma therapy.
Neoplasms
New Dancing Couple: PD-L1 and MicroRNA.
Neoplasms
New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.
Neoplasms
New emerging targets in cancer immunotherapy: the role of VISTA.
Neoplasms
New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.
Neoplasms
New Frontiers for Molecular Pathology.
Neoplasms
New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.
Neoplasms
New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression.
Neoplasms
New Method Enables Design of Protein Drugs That Covalently Bind Targets.
Neoplasms
New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles.
Neoplasms
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.
Neoplasms
Next generation predictive biomarkers for immune checkpoint inhibition.
Neoplasms
Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
Neoplasms
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors.
Neoplasms
NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma.
Neoplasms
NFATc1 is Suppressed in Tumor Microenvironment of Hodgkin Lymphoma.
Neoplasms
NFE2L2/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy.
Neoplasms
NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Neoplasms
Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Neoplasms
Nimesulide inhibits IFN-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells by COX-2 and PGE2 independent mechanisms.
Neoplasms
Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies.
Neoplasms
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Neoplasms
Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ?50.
Neoplasms
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Neoplasms
Nivolumab in melanoma.
Neoplasms
Nivolumab in metastatic melanoma: good efficacy and tolerability in elderly patients.
Neoplasms
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Neoplasms
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.
Neoplasms
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.
Neoplasms
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Neoplasms
Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy-free, first-line treatment for PD-L1-positive non-small cell lung cancer.
Neoplasms
Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.
Neoplasms
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Neoplasms
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Neoplasms
Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.
Neoplasms
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Neoplasms
Nivolumab-Induced Impressive Response of Refractory Pulmonary Sarcomatoid Carcinoma with Brain Metastasis.
Neoplasms
Nivolumab/Ipilimumab Combo Yields Durable Efficacy in Advanced NSCLC.
Neoplasms
NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27.
Neoplasms
NK Cells Respond to Checkpoint Blockade.
Neoplasms
NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy?
Neoplasms
NK-1-receptor-mediated lesion of spinal post-synaptic dorsal column neurons might improve intractable visceral pain of cancer origin.
Neoplasms
NLRP3 inflammasome upregulates PD-L1 expression and contributes to immune suppression in lymphoma.
Neoplasms
NME4 modulates PD-L1 expression via the STAT3 signaling pathway in squamous cell carcinoma.
Neoplasms
Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Neoplasms
Non-coding RNA and immune-checkpoint inhibitors: friends or foes?
Neoplasms
Non-cytomembrane PD-L1: An atypical target for cancer.
Neoplasms
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Neoplasms
Non-invasive assessment of tumor PD-L1 status with circulating tumor cells.
Neoplasms
Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model.
Neoplasms
Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Neoplasms
Non-Small Cell Lung Cancer in the Era of Personalized Medicine: Molecular Tests that Matter.
Neoplasms
Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Neoplasms
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.
Neoplasms
Non-viral nano-immunotherapeutics targeting tumor microenvironmental immune cells.
Neoplasms
Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics.
Neoplasms
Noninvasive detection of PD-L1 on circulating tumor cells in patient blood samples.
Neoplasms
Noninvasive evaluation of PD-L1 expression using Copper 64 labeled peptide WL12 by micro-PET imaging in Chinese hamster ovary cell tumor model.
Neoplasms
Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT.
Neoplasms
Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with 89Zr-Df-Atezolizumab.
Neoplasms
Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy.
Neoplasms
Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies.
Neoplasms
Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates.
Neoplasms
Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study.
Neoplasms
Norepinephrine Enhances Aerobic Glycolysis and May Act as a Predictive Factor for Immunotherapy in Gastric Cancer.
Neoplasms
Novel anti-PD-L1 peptide selected from combinatorial phage library inhibits tumor cell growth and restores T-cell activity.
Neoplasms
Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
Neoplasms
Novel circulating tumor cell-based blood test for the assessment of PD-L1 protein expression in treatment-naïve, newly diagnosed patients with non-small cell lung cancer.
Neoplasms
Novel cucurmosin-based immunotoxin targeting programmed cell death 1-ligand 1 with high potency against human tumor in vitro and in vivo.
Neoplasms
Novel genetic characteristics in low-grade fetal adenocarcinoma of the lung.
Neoplasms
Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.
Neoplasms
Novel mechanism of immune evasion in cancer via structural variations of the PD-L1 gene.
Neoplasms
Novel multiplex droplet digital PCR assay for scoring PD-L1 in non-small cell lung cancer biopsy specimens.
Neoplasms
Novel multitarget inhibitors with antiangiogenic and immunomodulator properties.
Neoplasms
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Neoplasms
Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype.
Neoplasms
Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer.
Neoplasms
Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.
Neoplasms
Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression.
Neoplasms
Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A review update of Patent Literature.
Neoplasms
Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
Neoplasms
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.
Neoplasms
Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
Neoplasms
Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma.
Neoplasms
Novel Treatment of Melanoma: Combined Parasite-Derived Peptide GK-1 and Anti-Programmed Death Ligand 1 Therapy.
Neoplasms
Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.
Neoplasms
NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Neoplasms
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.
Neoplasms
Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy.
Neoplasms
Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.
Neoplasms
Nuclear localization of PD-L1: artifact or reality?
Neoplasms
O.03: Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression.
Neoplasms
ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.
Neoplasms
Odontogenic tumor with combined characteristics of adenomatoid odontogenic and calcifying epithelial odontogenic tumors.
Neoplasms
Off-label use of common predictive biomarkers in gastrointestinal malignancies: a critical appraisal.
Neoplasms
Oleic acid and oleoylethanolamide decrease interferon-?-induced expression of PD-L1 and induce apoptosis in human lung carcinoma cells.
Neoplasms
Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors.
Neoplasms
On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment.
Neoplasms
Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion.
Neoplasms
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Neoplasms
Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.
Neoplasms
Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma.
Neoplasms
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.
Neoplasms
Oncology meets immunology: the cancer-immunity cycle.
Neoplasms
Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
Neoplasms
Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8+ PD-1- tumor-infiltrating T cells in PD-L1-enriched tumor microenvironment.
Neoplasms
Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Neoplasms
Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
Neoplasms
Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer.
Neoplasms
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors.
Neoplasms
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
Neoplasms
Oncosuppressive role of MicroRNA-205-3p in gastric cancer through inhibition of proliferation and induction of senescence: Oncosuppressive role of MicroRNA-205 in gastric cancer.
Neoplasms
One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging.
Neoplasms
Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
Neoplasms
Optimal elimination of leukemic T cells from human bone marrow with T101-ricin A-chain immunotoxin.
Neoplasms
Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods.
Neoplasms
Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations.
Neoplasms
Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.
Neoplasms
Optimal timing of PD-1 blockade in combination with oncolytic virus therapy.
Neoplasms
Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera.
Neoplasms
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.
Neoplasms
Optimized PD-L1 scoring of gastric cancer.
Neoplasms
Optimizing immunotherapy for gynecologic cancers.
Neoplasms
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
Neoplasms
Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer.
Neoplasms
Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma.
Neoplasms
Orexin A Suppresses the Expression of Exosomal PD-L1 in Colon Cancer and Promotes T Cell Activity by Inhibiting JAK2/STAT3 Signaling Pathway.
Neoplasms
Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
Neoplasms
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Neoplasms
Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Neoplasms
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.
Neoplasms
Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review.
Neoplasms
Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ?50%) metastatic NSCLC at US oncology practices.
Neoplasms
Outcomes of Programmed Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(PD-L1) Inhibitor Therapy in HIV Patients with Advanced Cancer.
Neoplasms
Outcomes to first-line pembrolizumab in patients with PD-L1-high (?50%) non-small cell lung cancer and a poor performance status.
Neoplasms
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.
Neoplasms
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
Neoplasms
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma.
Neoplasms
Ovarian Cancer Immunotherapy and Personalized Medicine.
Neoplasms
Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
Neoplasms
Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
Neoplasms
Overall survival and PD-L1 expression in metastasized malignant melanoma.
Neoplasms
Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction.
Neoplasms
Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.
Neoplasms
Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
Neoplasms
Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Neoplasms
Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications.
Neoplasms
Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment.
Neoplasms
Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD-L1 and predicts poor prognosis in B-cell lymphoma.
Neoplasms
Overexpression of MERTK receptor tyrosine kinase in epithelial cancer cells drives efferocytosis in a gain-of-function capacity.
Neoplasms
Overexpression of PD-L1 and PD-L2 is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Neoplasms
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.
Neoplasms
Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors.
Neoplasms
Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.
Neoplasms
Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK/T cell lymphoma and predict poor response rate.
Neoplasms
Overexpression of transposable elements is associated with immune evasion and poor outcome in colorectal cancer.
Neoplasms
Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Neoplasms
OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers.
Neoplasms
P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment.
Neoplasms
P1GF-saporin fusion protein: a potential anti-angiogenic agent.
Neoplasms
p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer.
Neoplasms
p38 mitogen-activated protein kinase mediates lipopolysaccharide and tumor necrosis factor alpha induction of shiga toxin 2 sensitivity in human umbilical vein endothelial cells.
Neoplasms
Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx.
Neoplasms
Pan-cancer analysis of ARID1A Alterations as Biomarkers for Immunotherapy Outcomes.
Neoplasms
Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.
Neoplasms
Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
Neoplasms
Pan-cancer analysis of ligand-receptor crosstalk in the tumor microenvironment.
Neoplasms
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration.
Neoplasms
Pan-cancer landscape of CD274 (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression.
Neoplasms
Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti-PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer.
Neoplasms
Panaxadiol inhibits programmed cell death-ligand 1 expression and tumour proliferation via hypoxia-inducible factor (HIF)-1? and STAT3 in human colon cancer cells.
Neoplasms
Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 Score.
Neoplasms
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Neoplasms
Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo.
Neoplasms
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Neoplasms
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression.
Neoplasms
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3.
Neoplasms
Partial absence of PD-1 expression by tumor-infiltrating EBV-specific CD8+ T cells in EBV-driven lymphoepithelioma-like carcinoma.
Neoplasms
Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS.
Neoplasms
Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
Neoplasms
Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases.
Neoplasms
Pathological Findings of the Host Immune Reaction in the Tumor Microenvironment of Gastroenteropancreatic Neuroendocrine Neoplasms.
Neoplasms
Pathological roles of c-Met in bladder cancer: Association with cyclooxygenase-2, heme oxygenase-1, vascular endothelial growth factor-A and programmed death ligand 1.
Neoplasms
Pathological significance of abnormal recepteur d'origine nantais and programmed death ligand 1 expression in colorectal cancer.
Neoplasms
Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
Neoplasms
Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
Neoplasms
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.
Neoplasms
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.
Neoplasms
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Neoplasms
Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
Neoplasms
Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.
Neoplasms
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
Neoplasms
Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Neoplasms
Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors.
Neoplasms
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma.
Neoplasms
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Neoplasms
PCC0208018 exerts antitumor effects by activating effector T cells.
Neoplasms
PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters.
Neoplasms
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Neoplasms
PD-1 and its ligands are important immune checkpoints in cancer.
Neoplasms
PD-1 and PD-L1 antibodies in cancer: current status and future directions.
Neoplasms
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.
Neoplasms
PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer.
Neoplasms
PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Neoplasms
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Neoplasms
PD-1 and PD-L1 expression in 132 recurrent nasopharyngeal carcinoma: the correlation with anemia and outcomes.
Neoplasms
PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Neoplasms
PD-1 and PD-L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics.
Neoplasms
PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer.
Neoplasms
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Neoplasms
PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread.
Neoplasms
PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus.
Neoplasms
PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.
Neoplasms
PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection.
Neoplasms
PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
Neoplasms
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Neoplasms
PD-1 and PD-L1 in neoplastic cells and the tumor microenvironment of Merkel cell carcinoma.
Neoplasms
PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: Dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer.
Neoplasms
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
Neoplasms
PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer: a systematic review.
Neoplasms
PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.
Neoplasms
PD-1 and PD-L1 Up-regulation Promotes T-cell Apoptosis in Gastric Adenocarcinoma.
Neoplasms
PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
Neoplasms
PD-1 as a potential target in cancer therapy.
Neoplasms
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Neoplasms
PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRP? axis in HPV negative head and neck squamous cell carcinoma.
Neoplasms
PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy.
Neoplasms
PD-1 Blockade During Post-partum Involution Reactivates the Anti-tumor Response and Reduces Lymphatic Vessel Density.
Neoplasms
PD-1 Blockade in Anaplastic Thyroid Carcinoma.
Neoplasms
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Neoplasms
PD-1 blockade induces responses by inhibiting adaptive immune resistance.
Neoplasms
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.
Neoplasms
PD-1 blockade inhibits osteoclast formation and murine bone cancer pain.
Neoplasms
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Neoplasms
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises.
Neoplasms
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
Neoplasms
PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma.
Neoplasms
PD-1 expression by canine T cells and functional effects of PD-1 blockade.
Neoplasms
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity.
Neoplasms
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
Neoplasms
PD-1 expression is elevated in monocytes from hepatocellular carcinoma patients and contributes to CD8 T cell suppression.
Neoplasms
PD-1 expression on MelanA-reactive T cells increases during progression to metastatic disease.
Neoplasms
PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
Neoplasms
PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research.
Neoplasms
PD-1 Inhibitors in the Advanced Esophageal Cancer.
Neoplasms
PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications.
Neoplasms
PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Neoplasms
PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Neoplasms
PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients.
Neoplasms
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade.
Neoplasms
PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.
Neoplasms
PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.
Neoplasms
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
Neoplasms
PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications.
Neoplasms
PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma.
Neoplasms
PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.
Neoplasms
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Neoplasms
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
Neoplasms
PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.
Neoplasms
PD-1/PD-L1 Axis in Lung Cancer.
Neoplasms
PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection.
Neoplasms
PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake.
Neoplasms
PD-1/PD-L1 blockade enhances T cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors.
Neoplasms
PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Neoplasms
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Neoplasms
PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Neoplasms
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Neoplasms
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
Neoplasms
PD-1/PD-L1 Blockade: Prospectives for immunotherapy in Cancer and Autoimmunity.
Neoplasms
PD-1/PD-L1 co-inhibition shapes anticancer T cell immunodominance: facing the consequences of an immunological ménage à trois.
Neoplasms
PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.
Neoplasms
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.
Neoplasms
PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Neoplasms
PD-1/PD-L1 expression in chromophobe renal cell carcinoma: An immunological exception?
Neoplasms
PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.
Neoplasms
PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
Neoplasms
PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Neoplasms
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
Neoplasms
PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
Neoplasms
PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy.
Neoplasms
PD-1/PD-L1 in cardiovascular disease.
Neoplasms
PD-1/PD-L1 in disease.
Neoplasms
PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways.
Neoplasms
PD-1/PD-L1 interactions inhibit anti-tumor immune responses in a murine acute myeloid leukemia model.
Neoplasms
PD-1/PD-L1 pathway and angiogenesis dual recognizable nanoparticles for enhancing chemotherapy of malignant cancer.
Neoplasms
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Neoplasms
PD-1/PD-L1 Pathway in Breast Cancer.
Neoplasms
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer.
Neoplasms
PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.
Neoplasms
PD-1/PD-L1 pathway: current researches in cancer.
Neoplasms
PD-1/PD-L1-associated immunoarchitectural patterns stratify pancreatic cancer patients into prognostic/predictive subgroups.
Neoplasms
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Neoplasms
PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Neoplasms
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas.
Neoplasms
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Neoplasms
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.
Neoplasms
PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy.
Neoplasms
PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers.
Neoplasms
PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study.
Neoplasms
PD-L1 ? 50% lung cancer refractory to PD-1 inhibition: the role of salvage chemo-immunotherapy combination.
Neoplasms
PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.
Neoplasms
PD-L1 and c-MET expression and survival in patients with small cell lung cancer.
Neoplasms
PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.
Neoplasms
PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
Neoplasms
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.
Neoplasms
PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system
Neoplasms
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.
Neoplasms
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study.
Neoplasms
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.
Neoplasms
PD-L1 and IAPs co-operate to protect tumors from cytotoxic lymphocyte-derived TNF.
Neoplasms
PD-L1 and IDO Expression in Cervical and Vulvar Invasive and Intraepithelial Squamous Neoplasias: Implications for Combination Immunotherapy.
Neoplasms
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
Neoplasms
PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS.
Neoplasms
PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Neoplasms
PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies.
Neoplasms
PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer.
Neoplasms
PD-L1 and intratumoral immune response in breast cancer.
Neoplasms
PD-L1 and LAG-3 expression in advanced cutaneous squamous cell carcinomas.
Neoplasms
PD-L1 and miR-34a are Prognostic Factors for Primary Gastric Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.
Neoplasms
PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas.
Neoplasms
PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.
Neoplasms
PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.
Neoplasms
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Neoplasms
PD-L1 and PD-L2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications.
Neoplasms
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.
Neoplasms
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Neoplasms
PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Neoplasms
PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications.
Neoplasms
PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories.
Neoplasms
PD-L1 and Survival in Solid Tumors: A Meta-Analysis.
Neoplasms
PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
Neoplasms
PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.
Neoplasms
PD-L1 and tumor-associated macrophages in de novo DLBCL.
Neoplasms
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells.
Neoplasms
PD-L1 aptamer isolation via Modular-SELEX and its applications in cancer cell detection and tumor tissue section imaging.
Neoplasms
PD-L1 as a biomarker of response to immune-checkpoint inhibitors.
Neoplasms
PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.
Neoplasms
PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.
Neoplasms
PD-L1 Assessment for Targeted Therapy Testing in Cancer: Urgent Need For Realistic Economic and Practice Expectations.
Neoplasms
PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.
Neoplasms
PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface.
Neoplasms
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Neoplasms
PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.
Neoplasms
PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.
Neoplasms
PD-L1 blockade enhances anti-tumor efficacy of NK cells.
Neoplasms
PD-L1 blockade for cancer treatment: MEDI4736.
Neoplasms
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.
Neoplasms
PD-L1 Blockade Therapy: Location, Location, Location.
Neoplasms
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models.
Neoplasms
PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Neoplasms
PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
Neoplasms
PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation.
Neoplasms
PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.
Neoplasms
PD-L1 controls cancer pyroptosis.
Neoplasms
PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.
Neoplasms
PD-L1 correlated gene expression profiles and tumor infiltrating lymphocytes in pancreatic cancer.
Neoplasms
PD-L1 degradation is regulated by electrostatic membrane association of its cytoplasmic domain.
Neoplasms
PD-L1 degradation pathway and immunotherapy for cancer.
Neoplasms
PD-L1 detection in histology specimens and matched pleural fluid cell blocks of patients with NSCLC.
Neoplasms
PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
Neoplasms
PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer.
Neoplasms
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response.
Neoplasms
PD-L1 Detection-Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology.
Neoplasms
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
Neoplasms
PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.
Neoplasms
PD-L1 disruption by CRISPR/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Neoplasms
PD-L1 Distribution and Perspective for Cancer Immunotherapy-Blockade, Knockdown, or Inhibition.
Neoplasms
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.
Neoplasms
PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
Neoplasms
PD-L1 expressing circulating tumour cells in head and neck cancers.
Neoplasms
PD-L1 expression according to the EGFR status in primary lung adenocarcinoma.
Neoplasms
PD-L1 Expression Affects Neoantigen Presentation.
Neoplasms
PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy.
Neoplasms
PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies.
Neoplasms
PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
Neoplasms
PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
Neoplasms
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.
Neoplasms
PD-L1 Expression and CD8(+) T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer.
Neoplasms
PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis.
Neoplasms
PD-L1 Expression and CD8+ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer.
Neoplasms
PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors.
Neoplasms
PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma.
Neoplasms
PD-L1 expression and CD8-positive T cells are associated with favorable survival in HER2-positive invasive breast cancer.
Neoplasms
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
Neoplasms
PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients.
Neoplasms
PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate.
Neoplasms
PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity.
Neoplasms
PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study.
Neoplasms
PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Neoplasms
PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Neoplasms
PD-L1 expression and infiltration by CD4+ and FoxP3+ T cells are increased in Xp11 translocation renal cell carcinoma and indicate poor prognosis.
Neoplasms
PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
Neoplasms
PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
Neoplasms
PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
Neoplasms
PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation.
Neoplasms
PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Neoplasms
PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment.
Neoplasms
PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
Neoplasms
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.
Neoplasms
PD-L1 expression and prognostic impact in glioblastoma.
Neoplasms
PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer.
Neoplasms
PD-L1 Expression and Survival among Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy.
Neoplasms
PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva.
Neoplasms
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Neoplasms
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.
Neoplasms
PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Neoplasms
PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Neoplasms
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
Neoplasms
PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.
Neoplasms
PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients.
Neoplasms
PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old.
Neoplasms
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.
Neoplasms
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.
Neoplasms
PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Neoplasms
PD-L1 expression and tumor-infiltrating lymphocytes: Revisiting the antitumor immune response potential in breast cancer.
Neoplasms
PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.
Neoplasms
PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare.
Neoplasms
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.
Neoplasms
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.
Neoplasms
PD-L1 Expression Associated with Epstein-Barr Virus Status and Patients' Survival in a Large Cohort of Gastric Cancer Patients in Northern Brazil.
Neoplasms
PD-L1 expression at tumor invasive front is associated with EMT and poor prognosis in esophageal squamous cell carcinoma.
Neoplasms
PD-L1 expression by immunohistochemistry in salivary duct carcinoma.
Neoplasms
PD-L1 Expression by Neurons Nearby Tumors Indicates Better Prognosis in Glioblastoma Patients.
Neoplasms
PD-L1 expression by tumor cell-lines: a predictive marker in melanoma.
Neoplasms
PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC).
Neoplasms
PD-L1 expression can be regarded as prognostic factor for survival of non-small cell lung cancer patients after chemoradiotherapy.
Neoplasms
PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Neoplasms
PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
Neoplasms
PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma.
Neoplasms
PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer.
Neoplasms
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Neoplasms
PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
Neoplasms
PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
Neoplasms
PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
Neoplasms
PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-? leads to poor pancreatic cancer prognosis.
Neoplasms
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections.
Neoplasms
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
Neoplasms
PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome.
Neoplasms
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Neoplasms
PD-L1 expression in angiomatoid fibrous histiocytoma.
Neoplasms
PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
Neoplasms
PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy.
Neoplasms
PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Neoplasms
PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.
Neoplasms
PD-L1 expression in bone marrow plasma cells as a biomarker to predict multiple myeloma prognosis: developing a nomogram-based prognostic model.
Neoplasms
PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.
Neoplasms
PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival.
Neoplasms
PD-L1 Expression in Carcinosarcomas of the Gynecologic Tract: A Potentially Actionable Biomarker.
Neoplasms
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Neoplasms
PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer.
Neoplasms
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Neoplasms
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases.
Neoplasms
PD-L1 expression in colon cancer and its relationship with clinical prognosis.
Neoplasms
PD-L1 expression in colorectal cancer and its relationship with TLR-4 expression.
Neoplasms
PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments.
Neoplasms
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes.
Neoplasms
PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation.
Neoplasms
PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis.
Neoplasms
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer.
Neoplasms
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
Neoplasms
PD-L1 Expression in Endocervical Adenocarcinoma: Correlation With Patterns of Tumor Invasion, CD8+ Tumor-infiltrating Lymphocytes, and Clinical Outcomes.
Neoplasms
PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Neoplasms
PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.
Neoplasms
PD-L1 expression in extrahepatic cholangiocarcinoma.
Neoplasms
PD-L1 Expression in Extramammary Paget Disease: A Case Series.
Neoplasms
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
Neoplasms
PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3.
Neoplasms
PD-L1 Expression in Glioblastoma, the Clinical and Prognostic Significance: A Systematic Literature Review and Meta-Analysis.
Neoplasms
PD-L1 expression in HNPCC-associated colorectal cancer.
Neoplasms
PD-L1 expression in HPV-independent cervical adenocarcinoma and its prognostic significance.
Neoplasms
PD-L1 Expression in Human Breast Cancer Stem Cells Is Epigenetically Regulated through Posttranslational Histone Modifications.
Neoplasms
PD-L1 expression in human cancers and its association with clinical outcomes.
Neoplasms
PD-L1 expression in inflammatory myofibroblastic tumors.
Neoplasms
PD-L1 expression in large cell neuroendocrine carcinoma of the lung.
Neoplasms
PD-L1 expression in liver metastasis: its clinical significance and discordance with primary tumor in colorectal cancer.
Neoplasms
PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.
Neoplasms
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
Neoplasms
PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer.
Neoplasms
PD-L1 expression in malignant salivary gland tumors.
Neoplasms
PD-L1 Expression in Mastocytosis.
Neoplasms
PD-L1 expression in medulloblastoma: an evaluation by subgroup.
Neoplasms
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.
Neoplasms
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
Neoplasms
PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes.
Neoplasms
PD-L1 expression in meningiomas.
Neoplasms
PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays.
Neoplasms
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
Neoplasms
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Neoplasms
PD-L1 expression in neuroendocrine tumors of the lung.
Neoplasms
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.
Neoplasms
PD-L1 expression in non-small cell lung cancer: heterogeneity by pathologic types, tissue sampling and metastasis.
Neoplasms
PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Neoplasms
PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
Neoplasms
PD-L1 expression in nonclear-cell renal cell carcinoma.
Neoplasms
PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study.
Neoplasms
PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component.
Neoplasms
PD-L1 expression in papillary renal cell carcinoma.
Neoplasms
PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study.
Neoplasms
PD-L1 Expression in Patients with Non-small Cell Lung Cancer.
Neoplasms
PD-L1 Expression in Pediatric Low-Grade Gliomas Is Independent of BRAF V600E Mutational Status.
Neoplasms
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
Neoplasms
PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements.
Neoplasms
PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis.
Neoplasms
PD-L1 expression in recurrent head and neck squamous cell carcinoma.
Neoplasms
PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.
Neoplasms
PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
Neoplasms
PD-L1 expression in sebaceous carcinomas.
Neoplasms
PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
Neoplasms
PD-L1 expression in small cell neuroendocrine carcinomas.
Neoplasms
PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung.
Neoplasms
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.
Neoplasms
PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival.
Neoplasms
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Neoplasms
PD-L1 expression in triple-negative breast cancer.
Neoplasms
PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Neoplasms
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
Neoplasms
PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
Neoplasms
PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Neoplasms
PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
Neoplasms
PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma.
Neoplasms
PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma.
Neoplasms
PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
Neoplasms
PD-L1 expression in tumour buds of colorectal carcinoma.
Neoplasms
PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma.
Neoplasms
PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
Neoplasms
PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents.
Neoplasms
PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
Neoplasms
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness.
Neoplasms
PD-L1 expression increased by IFN-? via JAK2-STAT1 signaling and predicts a poor survival in colorectal cancer.
Neoplasms
PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed.
Neoplasms
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Neoplasms
PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma.
Neoplasms
PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
Neoplasms
PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers.
Neoplasms
PD-L1 Expression Is an Independent Marker for Lymph Node Metastasis in Middle Eastern Endometrial Cancer.
Neoplasms
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma.
Neoplasms
PD-L1 Expression Is Associated with Deficient Mismatch Repair and Poor Prognosis in Middle Eastern Colorectal Cancers.
Neoplasms
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Neoplasms
PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis.
Neoplasms
PD-L1 expression is associated with p16
Neoplasms
PD-L1 Expression is Associated With Poor Prognosis in Renal Cell Carcinoma.
Neoplasms
PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.
Neoplasms
PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
Neoplasms
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Neoplasms
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Neoplasms
PD-L1 Expression is Highly Associated with Tumor-Associated Macrophage Infiltration in Nasopharyngeal Carcinoma.
Neoplasms
PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases.
Neoplasms
PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma.
Neoplasms
PD-L1 expression levels on tumor cells affect their immunosuppressive activity.
Neoplasms
PD-L1 Expression of Lung Cancer Cells, Unlike Infiltrating Immune Cells, Is Stable and Unaffected by Therapy During Brain Metastasis.
Neoplasms
PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
Neoplasms
PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion.
Neoplasms
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Neoplasms
PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.
Neoplasms
PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients.
Neoplasms
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
Neoplasms
PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy.
Neoplasms
PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
Neoplasms
PD-L1 expression on routine samples of non-small cell lung cancer: results and critical issues from a 1-year experience of a centralised laboratory.
Neoplasms
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.
Neoplasms
PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
Neoplasms
PD-L1 Expression on Tumor Cells Is Associated With a Poor Outcome in a Cohort of Caucasian Nasopharyngeal Carcinoma Patients.
Neoplasms
PD-L1 Expression On tumor Cells Was Associated With Unfavorable Prognosis In Esophageal Squamous Cell Carcinoma.
Neoplasms
PD-L1 expression on tumor or stromal cells of nodal cytotoxic T-cell lymphoma: A clinicopathological study of 50 cases.
Neoplasms
PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer.
Neoplasms
PD-L1 Expression Patterns in Microsatellite Instability-High Intestinal Adenocarcinoma Subtypes.
Neoplasms
PD-L1 expression patterns in oral cancer as an integrated approach for further prognostic classification.
Neoplasms
PD-L1 expression patterns in tumour cells and their association with CD8+ tumour infiltrating lymphocytes in clear cell renal cell carcinoma.
Neoplasms
PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins.
Neoplasms
PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
Neoplasms
PD-L1 Expression Promotes Epithelial to Mesenchymal Transition in Human Esophageal Cancer.
Neoplasms
PD-L1 Expression Reveals Significant Association With Squamous Differentiation in Upper Tract Urothelial Carcinoma.
Neoplasms
PD-L1 expression testing in non-small cell lung cancer.
Neoplasms
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
Neoplasms
PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.
Neoplasms
PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases.
Neoplasms
PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China.
Neoplasms
PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Neoplasms
PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
Neoplasms
PD-L1 Expression, T-lymphocyte Subpopulations and Langerhans Cells in Cutaneous Squamous Cell Carcinoma and Precursor Lesions.
Neoplasms
PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.
Neoplasms
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Neoplasms
PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
Neoplasms
PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
Neoplasms
PD-L1 gene expression in Japanese lung cancer patients.
Neoplasms
PD-L1 immune suppression in cancer: Tumor cells or host cells?
Neoplasms
PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
Neoplasms
PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study.
Neoplasms
PD-L1 Immunohistochemical Detection in Tumor Cells and Tumor Microenvironment: Main Considerations on the Use of Tissue Micro Arrays.
Neoplasms
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Neoplasms
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
Neoplasms
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project.
Neoplasms
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
Neoplasms
PD-L1 Immunohistochemistry Highlights Bone Marrow Involvement by Classic Hodgkin Lymphoma in Staging Biopsies: Implications for Diagnosis and Tumor Microenvironment Alterations.
Neoplasms
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Neoplasms
PD-L1 Immunohistochemistry-Discrepant Results Between Synchronous Tumor Samples May Cause More Treatment Choice Dilemmas Than Molecular Heterogeneity in Patients With Advanced Non-Small Cell Lung Cancers.
Neoplasms
PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters.
Neoplasms
PD-L1 in Breast Cancer: Comparative Analysis of Three Different Antibodies.
Neoplasms
PD-L1 in Combination with CD8+TIL and HIF-1? are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma.
Neoplasms
PD-L1 in Cytological Samples: A Review and a Practical Approach.
Neoplasms
PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT.
Neoplasms
PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay.
Neoplasms
PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability.
Neoplasms
PD-L1 in squamous cell carcinoma of the oral tongue shows gender-specific association with prognosis.
Neoplasms
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy.
Neoplasms
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
Neoplasms
PD-L1 induced by IFN-? from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Neoplasms
PD-L1 Induces Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells Through Activation of the PI3K/AKT Pathway.
Neoplasms
PD-L1 Induction by Cancer-Associated Fibroblast-Derived Factors in Lung Adenocarcinoma Cells.
Neoplasms
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer.
Neoplasms
PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells.
Neoplasms
PD-L1 inhibition with MPDL3280A for solid tumors.
Neoplasms
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Neoplasms
PD-L1 inhibitors in the pipeline: Promise and progress.
Neoplasms
PD-L1 instead of PD-1 status is associated with the clinical features in human primary prostate tumors.
Neoplasms
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Neoplasms
PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1.
Neoplasms
PD-L1 is a novel direct target of HIF-1?, and its blockade under hypoxia enhanced MDSC-mediated T cell activation.
Neoplasms
PD-L1 is a positive prognostic factor in squamous cell carcinoma of the nasal vestibule.
Neoplasms
PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3.
Neoplasms
PD-L1 Is an Independent Prognostic Marker in Middle Eastern PTC and Its Expression Is Upregulated by BRAFV600E Mutation.
Neoplasms
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.
Neoplasms
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Neoplasms
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
Neoplasms
PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy.
Neoplasms
PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-? and Can Be Expressed in the Tumor Microenvironment.
Neoplasms
PD-L1 is overexpressed on breast cancer stem cells through notch3/mTOR axis.
Neoplasms
PD-L1 is prognostic factor in esophageal squamous cell carcinoma and is associated with EGFR.
Neoplasms
PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival.
Neoplasms
PD-L1 is upregulated by EBV-driven LMP1 through NF-?B pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
Neoplasms
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
Neoplasms
PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
Neoplasms
PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
Neoplasms
PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry.
Neoplasms
PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity.
Neoplasms
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.
Neoplasms
PD-L1 mediated the differentiation of tumor-infiltrating CD19(+) B lymphocytes and T cells in Invasive breast cancer.
Neoplasms
PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.
Neoplasms
PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer.
Neoplasms
PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma.
Neoplasms
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade.
Neoplasms
PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.
Neoplasms
PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction.
Neoplasms
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Neoplasms
PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.
Neoplasms
PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
Neoplasms
PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
Neoplasms
PD-L1 overexpression is partially regulated by EGFR/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer.
Neoplasms
PD-L1 Overexpression on Tumor-Infiltrating Lymphocytes Related to Better Prognosis of Colorectal Cancer.
Neoplasms
PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells.
Neoplasms
PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.
Neoplasms
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
Neoplasms
PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions.
Neoplasms
PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B.
Neoplasms
PD-L1 Positivity Associated with Presence of Tertiary Lymphoid Structures and High-Stage Disease in Upper Tract Urothelial Carcinoma.
Neoplasms
PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer.
Neoplasms
PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Neoplasms
PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance.
Neoplasms
PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
Neoplasms
PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation.
Neoplasms
PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells.
Neoplasms
PD-L1 promotes tumor growth and progression by activating WIP and ?-catenin signaling pathways and predicts poor prognosis in lung cancer.
Neoplasms
PD-L1 protein expression and copy number gains in HIV-positive locally advanced cervical cancer.
Neoplasms
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.
Neoplasms
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes.
Neoplasms
PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer.
Neoplasms
PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
Neoplasms
PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
Neoplasms
PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.
Neoplasms
PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
Neoplasms
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR.
Neoplasms
PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.
Neoplasms
PD-L1 regulation by SDH5 via ?-catenin/ZEB1 signaling.
Neoplasms
PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Neoplasms
PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation.
Neoplasms
PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
Neoplasms
PD-L1 Status in Refractory Lymphomas.
Neoplasms
PD-L1 Studies Across Tumor Types, its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Neoplasms
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
Neoplasms
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Neoplasms
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee.
Neoplasms
PD-L1 Testing in Cancer: Challenges in Companion Diagnostic Development.
Neoplasms
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
Neoplasms
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.
Neoplasms
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future.
Neoplasms
PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer.
Neoplasms
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
Neoplasms
PD-L1 testing, fit for routine evaluation? From a patholo?gist's point of view.
Neoplasms
PD-L1 Tumor Cell Expression in Upper Tract Urothelial Carcinomas is Associated With Higher Pathologic Stage.
Neoplasms
PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
Neoplasms
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Neoplasms
PD-L1 upregulation is associated with activation of the DNA double-strand break repair pathway in patients with colitic cancer.
Neoplasms
PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?
Neoplasms
PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients.
Neoplasms
PD-L1+ dendritic cells in the tumor microenvironment correlate with good prognosis and CD8+ T cell infiltration in colon cancer.
Neoplasms
PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity.
Neoplasms
PD-L1+ regulatory B cells act as a T cell suppressor in a PD-L1-dependent manner in melanoma patients with bone metastasis.
Neoplasms
PD-L1+ tumor-associated macrophages and PD-1+ tumor-infiltrating lymphocytes predict survival in primary testicular lymphoma.
Neoplasms
PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.
Neoplasms
PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma.
Neoplasms
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Neoplasms
PD-L1, Galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.
Neoplasms
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.
Neoplasms
PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: Expression in Brain Metastases Compared to Corresponding Extracranial Tumors.
Neoplasms
PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
Neoplasms
PD-L1, RB1 and mismatch repair protein immunohistochemical expression in neuroendocrine carcinoma, small cell type of the uterine cervix.
Neoplasms
PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer.
Neoplasms
PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study.
Neoplasms
PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis.
Neoplasms
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Neoplasms
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Neoplasms
PD-L1-specific T cells.
Neoplasms
PD-L1-targeted microbubbles loaded with docetaxel produce a synergistic effect for the treatment of lung cancer under ultrasound irradiation.
Neoplasms
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity.
Neoplasms
PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas.
Neoplasms
PD-L1/PD-1 Axis in Glioblastoma Multiforme.
Neoplasms
PD-L1/PD-1 check-point in gastric carcinoma with lymphoid stroma case report with immunochemical study.
Neoplasms
PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
Neoplasms
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.
Neoplasms
PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.
Neoplasms
PD-L1/PD1 Expression, Composition of Tumor-Associated Immune Infiltrate, and HPV Status in Conjunctival Squamous Cell Carcinoma.
Neoplasms
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Neoplasms
PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro.
Neoplasms
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab.
Neoplasms
PD-L2 based immune signature confers poor prognosis in HNSCC.
Neoplasms
PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
Neoplasms
PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Neoplasms
PD-L2: A prognostic marker in chromophobe renal cell carcinoma?
Neoplasms
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL).
Neoplasms
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay.
Neoplasms
PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
Neoplasms
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.
Neoplasms
PD1 blockage delays murine squamous cell carcinoma development.
Neoplasms
PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood.
Neoplasms
PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Neoplasms
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer.
Neoplasms
PD1/PD-L1 axis in uro-oncology.
Neoplasms
PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Neoplasms
PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
Neoplasms
PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8+ T cell exhaustion during metastasis.
Neoplasms
PDZ Domain in the Engineering and Production of a Saporin Chimeric Toxin as a tool for targeting cancer cells.
Neoplasms
Pegylated Engineered IL2 plus Anti-PD-1 Monoclonal Antibody: The Nectar Comes from the Combination.
Neoplasms
Pegylated Interleukin-10: Clinical Development of an Immunoregulatory Cytokine for Use in Cancer Therapeutics.
Neoplasms
PEGylation of alpha-momorcharin: synthesis and characterization of novel anti-tumor conjugates with therapeutic potential.
Neoplasms
Pembro Ups Survival in PD-L1-positive HNSCC.
Neoplasms
Pembrolizumab and atezolizumab in triple-negative breast cancer.
Neoplasms
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ?50%: real-world data.
Neoplasms
Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer.
Neoplasms
Pembrolizumab as first-line treatment for metastatic uveal melanoma.
Neoplasms
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Neoplasms
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis.
Neoplasms
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
Neoplasms
Pembrolizumab for Previously Treated, PD-L1-expressing Advanced NSCLC: Real-world Time on Treatment and Overall Survival.
Neoplasms
Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma: Findings of the Phase 1b KEYNOTE-028 Study.
Neoplasms
Pembrolizumab for the treatment of non-small cell lung cancer.
Neoplasms
Pembrolizumab for the treatment of non-small-cell lung cancer.
Neoplasms
Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy.
Neoplasms
Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid.
Neoplasms
Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review.
Neoplasms
Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer.
Neoplasms
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial.
Neoplasms
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Neoplasms
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Neoplasms
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.
Neoplasms
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Neoplasms
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study.
Neoplasms
Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Neoplasms
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.
Neoplasms
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Neoplasms
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.
Neoplasms
Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial.
Neoplasms
Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
Neoplasms
Pembrolizumab Outperforms Docetaxel for NSCLC.
Neoplasms
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Neoplasms
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Neoplasms
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Neoplasms
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Neoplasms
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Neoplasms
Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ? 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
Neoplasms
Pembrolizumab plus platinum-based chemotherapy for unfavorable cancer of unknown primary site: Case report.
Neoplasms
Pembrolizumab Shows Promise for NSCLC.
Neoplasms
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Neoplasms
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Neoplasms
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Neoplasms
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Neoplasms
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
Neoplasms
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Neoplasms
Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study.
Neoplasms
Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.
Neoplasms
Pembrolizumab-induced necrotizing myositis in a patient with metastatic non-small-cell lung cancer: a case report.
Neoplasms
Pembrolizumab-Induced Thyroiditis.
Neoplasms
Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer.
Neoplasms
Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer.
Neoplasms
Pentamethylquercetin Inhibits Hepatocellular Carcinoma Progression and Adipocytes-induced PD-L1 Expression via IFN-? Signaling.
Neoplasms
Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy.
Neoplasms
Peptide toxins directed at the matrix dissolution systems of cancer cells.
Neoplasms
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.
Neoplasms
Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Neoplasms
Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer.
Neoplasms
Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer.
Neoplasms
Peptide-based PET quantifies target engagement of PD-L1 therapeutics.
Neoplasms
Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Performance of Ventana SP263 PD-L1 assay in endobronchial ultrasound guided-fine-needle aspiration derived non-small-cell lung carcinoma samples.
Neoplasms
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy.
Neoplasms
Peripheral Versus Intraparenchymal Papillary Thyroid Microcarcinoma: Different Morphologies and PD-L1 Expression.
Neoplasms
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma.
Neoplasms
Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.
Neoplasms
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.
Neoplasms
Personalized Immuno-oncology.
Neoplasms
Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Neoplasms
Personalized Vaccine Induces Antitumor Activity.
Neoplasms
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma.
Neoplasms
Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.
Neoplasms
PET imaging of tumor PD-L1 expression with a highly specific non-blocking nanobody.
Neoplasms
PET/CT Imaging of 89Zr-N-sucDf-Pembrolizumab in Healthy Cynomolgus Monkeys.
Neoplasms
Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression.
Neoplasms
Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics.
Neoplasms
Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer.
Neoplasms
Pharmacokinetics of an antibody-ricin conjugate administered intraperitoneally to mice.
Neoplasms
Pharmacokinetics of natural mistletoe lectins after subcutaneous injection.
Neoplasms
Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
Neoplasms
Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model.
Neoplasms
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma.
Neoplasms
Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.
Neoplasms
Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New.
Neoplasms
Pharmacological studies of ricin in mice and humans.
Neoplasms
Pharmacological suppression of B7-H4 glycosylation restores antitumor immunity in immune-cold breast cancers.
Neoplasms
Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research.
Neoplasms
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.
Neoplasms
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers.
Neoplasms
Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma.
Neoplasms
Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
Neoplasms
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? and PD-L1, in patients with pretreated biliary tract cancer.
Neoplasms
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Neoplasms
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Neoplasms
Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.
Neoplasms
Phase I study of the plant protein ricin.
Neoplasms
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
Neoplasms
Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma.
Neoplasms
Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8(+) T-cell Infiltration.
Neoplasms
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF?, in Advanced Solid Tumors.
Neoplasms
Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).
Neoplasms
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.
Neoplasms
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Neoplasms
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).
Neoplasms
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Neoplasms
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Neoplasms
Phorbol myristate acetate selectively stimulates apical endocytosis via protein kinase C in polarized MDCK cells.
Neoplasms
Phosphatidylserine Sensing by TAM Receptors Regulates AKT-dependent Chemoresistance and PD-L1 Expression.
Neoplasms
Phospho-?-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2.
Neoplasms
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-?B Activation and PD-L1 Expression.
Neoplasms
Phosphorylation of HSF1 by PIM2 induces PD-L1 expression and promotes tumor growth in breast cancer.
Neoplasms
Photo-Enhanced CRISPR/Cas9 System Enables Robust PD-L1 Gene Disruption in Cancer Cells and Cancer Stem-Like Cells for Efficient Cancer Immunotherapy.
Neoplasms
Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer.
Neoplasms
Photodynamic therapy synergizes with PD-L1 checkpoint blockade for immunotherapy of CRC by multifunctional nanoparticles.
Neoplasms
Photothermal-Activatable Fe3O4 Superparticle Nanodrug Carriers with PD-L1 Immune Checkpoint Blockade for Anti-metastatic Cancer Immunotherapy.
Neoplasms
Photothermal-Chemotherapy Integrated Nanoparticles with Tumor Microenvironment Response Enhanced the Induction of Immunogenic Cell Death for Colorectal Cancer Efficient Treatment.
Neoplasms
Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
Neoplasms
Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.
Neoplasms
Pilot Study of the Performance of 19-G Needle in Endobronchial Ultrasound-guided Transbronchial Aspiration for the Diagnosis and Testing of Molecular Markers in Lung Cancer.
Neoplasms
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
Neoplasms
Pirfenidone reduces immune-suppressive capacity of cancer-associated fibroblasts through targeting CCL17 and TNF-beta.
Neoplasms
Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer.
Neoplasms
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer.
Neoplasms
PKC inhibition is involved in trichosanthin-induced apoptosis in human chronic myeloid leukemia cell line K562.
Neoplasms
PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.
Neoplasms
Plant galactolipid dLGG suppresses lung metastasis of melanoma through deregulating TNF-?-mediated pulmonary vascular permeability and circulating oxylipin dynamics in mice.
Neoplasms
Plant lectins: Targeting programmed cell death pathways as antitumor agents.
Neoplasms
Plant ribosome-inactivating proteins type II induce the unfolded protein response in human cancer cells.
Neoplasms
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
Neoplasms
Plasma levels of soluble programmed death ligand 1 (sPD-L1) in WHO II/III nasopharyngeal carcinoma (NPC): A preliminary study.
Neoplasms
Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade.
Neoplasms
Plasmacytoid urothelial carcinoma (UC) are luminal tumors with similar CD8+ Tcell density and PD-L1 protein expression on immune cells as compared to conventional UC.
Neoplasms
Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors.
Neoplasms
Platelets stimulate programmed death-ligand 1 expression by cancer cells: Inhibition by anti-platelet drugs.
Neoplasms
Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: Preclinical and clinical studies and mechanism of action.
Neoplasms
Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report.
Neoplasms
Platycodin D triggers the extracellular release of programed death Ligand-1 in lung cancer cells.
Neoplasms
Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
Neoplasms
PLGA Nanoparticles Codelivering siRNAs against Programmed Cell Death Protein-1 and Its Ligand Gene for Suppression of Colon Tumor Growth.
Neoplasms
Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy.
Neoplasms
Pokeweed antiviral protein: ribosome inactivation and therapeutic applications.
Neoplasms
POLE Score: a comprehensive profiling of programmed death 1 ligand 1 expression in pancreatic ductal adenocarcinoma.
Neoplasms
POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure.
Neoplasms
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.
Neoplasms
Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Neoplasms
Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.
Neoplasms
Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity.
Neoplasms
Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies.
Neoplasms
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.
Neoplasms
Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
Neoplasms
Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.
Neoplasms
Population Modeling of Tumor Kinetics and Overall Survival to Identify Prognostic and Predictive Biomarkers of Efficacy for Durvalumab in Patients With Urothelial Carcinoma.
Neoplasms
Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
Neoplasms
Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study.
Neoplasms
Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin.
Neoplasms
Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma.
Neoplasms
Positive Surgical Margin, HPV Persistence, and Expression of Both TPX2 and PD-L1 Are Associated with Persistence/Recurrence of Cervical Intraepithelial Neoplasia after Cervical Conization.
Neoplasms
Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer.
Neoplasms
Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake Correlates with KRAS and EMT Gene Signatures in Operable Esophageal Adenocarcinoma.
Neoplasms
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy.
Neoplasms
Posttranscriptional Control of PD-L1 Expression by 17?-Estradiol via PI3K/Akt Signaling Pathway in ER?-Positive Cancer Cell Lines.
Neoplasms
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.
Neoplasms
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
Neoplasms
Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model.
Neoplasms
Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.
Neoplasms
Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer.
Neoplasms
Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
Neoplasms
Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects.
Neoplasms
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer.
Neoplasms
Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy.
Neoplasms
Potential of new therapies like anti-PD1 in kidney cancer.
Neoplasms
Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date.
Neoplasms
Potential predictive biomarkers other than PD-L1 in tumor immunotherapy.
Neoplasms
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
Neoplasms
Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
Neoplasms
Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma.
Neoplasms
Potential therapeutic applications of plant toxin-ricin in cancer: challenges and advances.
Neoplasms
Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
Neoplasms
Potentiation of ricin A immunotoxin by monoclonal antibody targeted monensin containing small unilamellar vesicles.
Neoplasms
Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice.
Neoplasms
PPAR? induces PD-L1 expression in MSS+ colorectal cancer cells.
Neoplasms
Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.
Neoplasms
Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-?B, JAK1/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma.
Neoplasms
Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor immune cell composition.
Neoplasms
Pre-existing interstitial lung disease does not affect prognosis in non-small cell lung cancer patients with PD-L1 expression ?50% on first-line pembrolizumab.
Neoplasms
Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Neoplasms
Precision medicine in immune checkpoint blockade therapy for non-small cell lung cancer.
Neoplasms
Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
Neoplasms
Preclinical development and characterisation of 99mTc-NM-01 for SPECT/CT imaging of human PD-L1.
Neoplasms
Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma.
Neoplasms
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
Neoplasms
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
Neoplasms
Preclinical PET imaging with the novel human antibody 89Zr-DFO-REGN3504 sensitively detects PD-L1 expression in tumors and normal tissues.
Neoplasms
Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Neoplasms
Predicting PD-L1 expression on human cancer cells using next-generation sequencing information in computational simulation models.
Neoplasms
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Neoplasms
Predicting Treatment Response Based on RNA Expression in Large Datasets.
Neoplasms
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
Neoplasms
Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Neoplasms
Predictive and Prognostic Role of PD-L1 in Urothelial Carcinoma Patients with Anti-PD-1/PD-L1 Therapy: A Systematic Review and Meta-Analysis.
Neoplasms
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
Neoplasms
Predictive biomarkers and tumor microenvironment in female genital melanomas: a multi-institutional study of 55 cases.
Neoplasms
Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Neoplasms
Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
Neoplasms
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Neoplasms
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies.
Neoplasms
Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives.
Neoplasms
Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
Neoplasms
Predictive biomarkers for tumor immune checkpoint blockade.
Neoplasms
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
Neoplasms
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC.
Neoplasms
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Neoplasms
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Neoplasms
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Neoplasms
Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
Neoplasms
Predictive factors for immunotherapy in melanoma.
Neoplasms
Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
Neoplasms
Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis.
Neoplasms
Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM).
Neoplasms
Predictive potential and need for standardization of PD-L1 immunohistochemistry.
Neoplasms
Predictive Potential of PD-L1, TYMS, and DCC Expressions in Treatment Outcome of Colorectal Carcinoma.
Neoplasms
Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.
Neoplasms
Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.
Neoplasms
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab.
Neoplasms
Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
Neoplasms
Predictive value of CD8/FOXP3 ratio combined with PD-L1 expression for radiosensitivity in patients with squamous cell carcinoma of the larynx receiving definitive radiation therapy.
Neoplasms
Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Neoplasms
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Neoplasms
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Neoplasms
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Neoplasms
Predictive value of WHO classification for PD-L1 and Her2/Neu expression and distinct associations with protein expression based classification in gastric carcinoma.
Neoplasms
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
Neoplasms
Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Neoplasms
Predictors for the clinical benefit of anti-PD-1/PD-L1 therapy in advanced gastroesophageal cancer: a meta-analysis of clinical trials.
Neoplasms
Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.
Neoplasms
Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
Neoplasms
Predominance of M1 subtype among tumor-associated macrophages in phenotypically aggressive sporadic vestibular schwannoma.
Neoplasms
Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Neoplasms
Preparation and biological characterization of conjugates consisting of ricin and a tumor-specific non-internalizing MAb.
Neoplasms
Preparation of antibody (IgG)-ricin A-chain conjugate and its biologic activity.
Neoplasms
Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
Neoplasms
Preparation of cytotoxic antibody-toxin conjugates.
Neoplasms
Preparation of engineered extracellular vesicles with full-length functional PD-1 membrane proteins by baculovirus expression system.
Neoplasms
Preparation of Programmed Cell Death-Ligand 1 Antibody Nanoparticles Based on Nude Mouse Model and Its Therapeutic Effect on Lung Cancer.
Neoplasms
Preparation of Programmed Death-Ligand 1 Antibody Nanoparticles and Their Lung Cancer Targeting Therapeutic Effects.
Neoplasms
Preparation, Biosafety, and Cytotoxicity Studies of a Newly Tumor-Microenvironment-Responsive Biodegradable Mesoporous Silica Nanosystem Based on Multimodal and Synergistic Treatment.
Neoplasms
Preproricin expressed in Nicotiana tabacum cells in vitro is fully processed and biologically active.
Neoplasms
Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series.
Neoplasms
Presence of high-endothelial venules correlates with a favorable immune microenvironment in oral squamous cell carcinoma.
Neoplasms
Present potential of immunotoxins.
Neoplasms
Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC.
Neoplasms
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.
Neoplasms
Prevalence and clinical patterns of ocular complications associated with anti-PD-1/PD-L1 anticancer immunotherapy.
Neoplasms
Prevalence and Heterogeneity of PD-L1 Expression by 22C3 Assay in Routine Population-Based and Reflexive Clinical Testing in Lung Cancer.
Neoplasms
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
Neoplasms
Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
Neoplasms
Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
Neoplasms
Prevalence of NRAS Mutation, PD-L1 Expression and Amplification, and Overall Survival Analysis in 36 Primary Vaginal Melanomas.
Neoplasms
Prevalence of PD-L1 expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis.
Neoplasms
Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
Neoplasms
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Neoplasms
Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer.
Neoplasms
Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors.
Neoplasms
Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis.
Neoplasms
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
Neoplasms
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Neoplasms
Prevention and Inhibition of TC-1 Cell Growth in Tumor Bearing Mice by HPV16 E7 Protein in Fusion with Shiga Toxin B-Subunit from shigella dysenteriae.
Neoplasms
Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics.
Neoplasms
Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.
Neoplasms
Primary CNS lymphoma commonly expresses immune response biomarkers.
Neoplasms
Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review.
Neoplasms
Primary pleural epithelioid angiosarcoma treated successfully with anti-PD-1 therapy: A rare case report.
Neoplasms
Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report.
Neoplasms
Primary pulmonary lymphoepithelioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden.
Neoplasms
Primary pulmonary lymphoepithelioma-like carcinoma with positive expression of Epstein-Barr virus and PD-L1: A case report.
Neoplasms
Primary pulmonary lymphoepithelioma-like carcinoma.
Neoplasms
Primary pulmonary melanoma: a report of two cases.
Neoplasms
Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression.
Neoplasms
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Neoplasms
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
Neoplasms
Primary Sequence and 3D Structure Prediction of the Plant Toxin Stenodactylin.
Neoplasms
Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.
Neoplasms
Priming is key to effective incorporation of image-guided thermal ablation into immunotherapy protocols.
Neoplasms
Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types.
Neoplasms
Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice.
Neoplasms
Probody therapeutic design of 89Zr-CX-072 promotes accumulation in PD-L1 expressing tumors compared to normal murine lymphoid tissue.
Neoplasms
Prodrug-Based Versatile Nanomedicine with Simultaneous Physical and Physiological Tumor Penetration for Enhanced Cancer Chemo-Immunotherapy.
Neoplasms
Prodrug-Like, PEGylated Protein Toxin Trichosanthin for Reversal of Chemoresistance.
Neoplasms
Product review: avelumab, an anti-PD-L1 antibody.
Neoplasms
Production of aralin, a selective cytotoxic lectin against human transformed cells, in callus culture of Aralia elata.
Neoplasms
Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.
Neoplasms
Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.
Neoplasms
Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Neoplasms
Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy.
Neoplasms
Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland.
Neoplasms
Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer.
Neoplasms
Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
Neoplasms
Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer.
Neoplasms
Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis.
Neoplasms
Prognostic and clinicopathological roles of programmed death-ligand 1 (PD-L1) expression in thymic epithelial tumors: A meta-analysis.
Neoplasms
Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
Neoplasms
Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Neoplasms
Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis.
Neoplasms
Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.
Neoplasms
Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis.
Neoplasms
Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis.
Neoplasms
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Neoplasms
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.
Neoplasms
Prognostic and predictive markers for the new immunotherapies.
Neoplasms
Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review.
Neoplasms
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.
Neoplasms
Prognostic and predictive role of the tumor immune landscape.
Neoplasms
Prognostic and Predictive Significance of PD-L1 Expression in Non-Small Cell Lung Cancer Patients: A Single-Center Experience.
Neoplasms
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
Neoplasms
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT).
Neoplasms
Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma.
Neoplasms
Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.
Neoplasms
Prognostic and Therapeutic Implications of Immune Classification by CD8+ Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma.
Neoplasms
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Neoplasms
Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Neoplasms
Prognostic factor analysis for patient outcome of PD-L1 expression in thoracic oesophageal squamous cell carcinoma.
Neoplasms
Prognostic Impact of Adenosine Receptor 2 (A2aR) and Programmed Cell Death Ligand 1 (PD-L1) Expression in Colorectal Cancer.
Neoplasms
Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer.
Neoplasms
Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
Neoplasms
Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics.
Neoplasms
Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
Neoplasms
Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.
Neoplasms
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study.
Neoplasms
Prognostic Impact of PD-1 on Tumor-Infiltrating Lymphocytes in 433 Resected Esophageal Cancers.
Neoplasms
Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung.
Neoplasms
Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.
Neoplasms
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.
Neoplasms
Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma.
Neoplasms
Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking.
Neoplasms
Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Neoplasms
Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma.
Neoplasms
Prognostic impact of programmed cell death ligand 1 expression on long-term oncologic outcomes in colorectal cancer.
Neoplasms
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Neoplasms
Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
Neoplasms
Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC.
Neoplasms
Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes.
Neoplasms
Prognostic Impact of YKL-40 Immunohistochemical Expression in Patients with Colorectal Cancer.
Neoplasms
Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Neoplasms
Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
Neoplasms
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Neoplasms
Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.
Neoplasms
Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: a systematic review and meta-analysis.
Neoplasms
Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
Neoplasms
Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
Neoplasms
Prognostic markers in salivary gland cancer and their impact on survival.
Neoplasms
Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
Neoplasms
Prognostic Prediction, Immune Microenvironment, and Drug Resistance Value of Collagen Type I Alpha 1 Chain: From Gastrointestinal Cancers to Pan-Cancer Analysis.
Neoplasms
Prognostic Relevance of CD4+, CD8+ and FOXP3+ TILs in Oral Squamous Cell Carcinoma and Correlations with PD-L1 and Cancer Stem Cell Markers.
Neoplasms
Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy.
Neoplasms
Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Neoplasms
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach.
Neoplasms
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Neoplasms
Prognostic relevance of programmed death-ligand 1 expression and microsatellite status in small bowel adenocarcinoma.
Neoplasms
Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Neoplasms
Prognostic Role and Clinical Significance of Tumor-Infiltrating Lymphocyte (TIL) and Programmed Death Ligand 1 (PD-L1) Expression in Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis Study.
Neoplasms
Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma.
Neoplasms
Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma.
Neoplasms
Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone.
Neoplasms
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis.
Neoplasms
Prognostic role of PD-L1 in malignant pleural mesothelioma: unraveling the complexity of the tumor microenvironment in mesothelioma.
Neoplasms
Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.
Neoplasms
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
Neoplasms
Prognostic Role of Programmed Cell Death 1 Ligand 1 in Resectable Pleural Mesothelioma.
Neoplasms
Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma.
Neoplasms
Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis.
Neoplasms
Prognostic Role of Programmed Death Ligand-1 on Tumor-Infiltrating Immune Cells in "High-Risk" Patients Following Radical Cystectomy: A Retrospective Cohort Study.
Neoplasms
Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: a meta-analysis.
Neoplasms
Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Neoplasms
Prognostic role of stromal tumor-infiltrating lymphocytes in locally advanced upper tract urothelial carcinoma: A retrospective multicenter study (TSU-02 study).
Neoplasms
Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
Neoplasms
Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis.
Neoplasms
Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
Neoplasms
Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis.
Neoplasms
Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
Neoplasms
Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Neoplasms
Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Neoplasms
Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.
Neoplasms
Prognostic significance of PD-L1 and PD-L2 in breast cancer.
Neoplasms
Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma.
Neoplasms
Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Neoplasms
Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma.
Neoplasms
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer.
Neoplasms
Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.
Neoplasms
Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis.
Neoplasms
Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
Neoplasms
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Neoplasms
Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.
Neoplasms
Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma.
Neoplasms
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases.
Neoplasms
Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Neoplasms
Prognostic significance of PD-L1 protein expression and copy number gains in locally advanced cervical cancer.
Neoplasms
Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
Neoplasms
Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer: A Meta-Analysis.
Neoplasms
Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Neoplasms
Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
Neoplasms
Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Neoplasms
Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer: A meta-analysis of the literature.
Neoplasms
Prognostic significance of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in uterine carcinosarcoma.
Neoplasms
Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Neoplasms
Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients.
Neoplasms
Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary.
Neoplasms
Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma.
Neoplasms
Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.
Neoplasms
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
Neoplasms
Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression.
Neoplasms
Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma.
Neoplasms
Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma.
Neoplasms
Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Neoplasms
Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment.
Neoplasms
Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.
Neoplasms
Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy.
Neoplasms
Prognostic value of CD8CD45RO tumor infiltrating lymphocytes in patients with extrahepatic cholangiocarcinoma.
Neoplasms
Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma.
Neoplasms
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Neoplasms
Prognostic value of PD -L1 expression in patients with primary solid tumors.
Neoplasms
Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.
Neoplasms
Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Neoplasms
Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies.
Neoplasms
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours.
Neoplasms
Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms.
Neoplasms
Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.
Neoplasms
Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
Neoplasms
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Neoplasms
Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.
Neoplasms
Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma.
Neoplasms
Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
Neoplasms
Prognostic Value of PD-L1, PD-1 and CD8A in Canine Diffuse Large B-Cell Lymphoma Detected by RNAscope.
Neoplasms
Prognostic value of programed death ligand 1 in patients with solid tumors: A meta-analysis.
Neoplasms
Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
Neoplasms
Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
Neoplasms
Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.
Neoplasms
Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Neoplasms
Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer.
Neoplasms
Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma.
Neoplasms
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Neoplasms
Prognostic value of proliferation, PD-L1 and nuclear size in patients with superior sulcus tumours treated with chemoradiotherapy and surgery.
Neoplasms
Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients.
Neoplasms
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.
Neoplasms
Prognostic value of tumor infiltrating lymphocytes combined with PD-L1 expression for patients with solitary colorectal cancer liver metastasis.
Neoplasms
Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer.
Neoplasms
Prognostic Value of Tumor Proportion Score in Salivary Gland Carcinoma.
Neoplasms
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
Neoplasms
Prognostic Value of Vimentin Is Associated With Immunosuppression in Metastatic Renal Cell Carcinoma.
Neoplasms
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.
Neoplasms
Programmable Unlocking Nano-Matryoshka-CRISPR Precisely Reverses Immunosuppression to Unleash Cascade Amplified Adaptive Immune Response.
Neoplasms
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Neoplasms
Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status.
Neoplasms
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.
Neoplasms
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases.
Neoplasms
Programmed Cell Death Ligand 1 (PD-L1) Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
Neoplasms
Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas.
Neoplasms
Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
Neoplasms
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
Neoplasms
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Neoplasms
Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Neoplasms
Programmed Cell Death Ligand 1 Expression in Canine Cancer.
Neoplasms
Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma.
Neoplasms
Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
Neoplasms
Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
Neoplasms
Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
Neoplasms
Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced NSCLC and Response to Osimertinib Versus Comparator in FLAURA.
Neoplasms
Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer.
Neoplasms
Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
Neoplasms
Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies.
Neoplasms
Programmed cell death ligand-1 and cytotoxic T cell infiltrates in metastatic cutaneous squamous cell carcinoma of the head and neck.
Neoplasms
Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark.
Neoplasms
Programmed cell death ligand-1 expression in gastroenteropancreatic neuroendocrine tumors.
Neoplasms
Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma.
Neoplasms
Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis.
Neoplasms
Programmed cell death ligand-1-mediated enhancement of hexokinase 2 expression is inversely related to T-cell effector gene expression in non-small-cell lung cancer.
Neoplasms
Programmed cell death ligands expression drives immune tolerogenesis across the diverse subtypes of neuroendocrine tumours.
Neoplasms
Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines.
Neoplasms
Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma.
Neoplasms
Programmed Cell Death Protein Ligand-1 Silencing with Polyethylenimine-Dermatan Sulfate Complex for Dual Inhibition of Melanoma Growth.
Neoplasms
Programmed cell death-ligand 1 expression and efficacy of cisplatin-based chemotherapy in lung cancer: A sub-analysis of data from the two Okayama Lung Cancer Study Group prospective feasibility studies.
Neoplasms
Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy.
Neoplasms
Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
Neoplasms
Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.
Neoplasms
Programmed cell death-ligand 1 expression in stromal immune cells is a marker of breast cancer outcome.
Neoplasms
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
Neoplasms
Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Neoplasms
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
Neoplasms
Programmed Cell Death-Ligand 1 Expression Status in Urothelial Carcinoma According to Clinical and Pathological Factors: A Multi-Institutional Retrospective Study.
Neoplasms
PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Neoplasms
Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Neoplasms
Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Nagasaki Transplant Group.
Neoplasms
Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
Neoplasms
Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Neoplasms
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Neoplasms
Programmed Death Ligand 1 (PD-L1) Expression in Epithelial
Ovarian Cancer: A Comparison of Type I and Type II Tumors
Neoplasms
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Neoplasms
Programmed death ligand 1 (PD-L1) expression in parathyroid tumors.
Neoplasms
Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma.
Neoplasms
Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study.
Neoplasms
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Neoplasms
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction.
Neoplasms
Programmed death ligand 1 and CD8+ immune cell infiltrates in resected primary tracheal malignant neoplasms.
Neoplasms
Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the Pleura.
Neoplasms
Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma.
Neoplasms
Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
Neoplasms
Programmed Death Ligand 1 Expression and Related Markers in Pleuropulmonary Blastoma.
Neoplasms
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
Neoplasms
Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
Neoplasms
Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features.
Neoplasms
Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer.
Neoplasms
Programmed death ligand 1 expression in esophageal cancer following definitive chemoradiotherapy: Prognostic significance and association with inflammatory biomarkers.
Neoplasms
Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
Neoplasms
Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses.
Neoplasms
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.
Neoplasms
Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition.
Neoplasms
Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma.
Neoplasms
Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability.
Neoplasms
Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer.
Neoplasms
Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Neoplasms
Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.
Neoplasms
Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin ?4/SNAI1/SIRT3 signaling pathway.
Neoplasms
Programmed death ligand 1 protein expression, histological tumour differentiation and intratumoural heterogeneity in pulmonary adenocarcinoma.
Neoplasms
Programmed Death Ligand 1 Testing of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non-Small Cell Lung Cancer.
Neoplasms
Programmed death ligand 1/indoleamine 2,3-dioxygenase 1 expression and tumor-infiltrating lymphocyte status in renal cell carcinoma with sarcomatoid changes and rhabdoid features.
Neoplasms
Programmed Death Ligand 1: A Poor Prognostic Marker in Endometrial Carcinoma.
Neoplasms
Programmed Death Ligand 1: A Step Toward Immunoscore for Esophageal Cancer.
Neoplasms
Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
Neoplasms
Programmed death ligand 2 in cancer-induced immune suppression.
Neoplasms
Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Neoplasms
Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Neoplasms
Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression.
Neoplasms
Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers.
Neoplasms
Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer.
Neoplasms
Programmed Death Ligand-1 (PD-L1) regulated by NRF- 2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Neoplasms
Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).
Neoplasms
Programmed death ligand-1 expression as immunotherapeutic target in sinonasal cancer.
Neoplasms
Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges.
Neoplasms
Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.
Neoplasms
Programmed death ligand-1 expression in non-small cell lung cancer.
Neoplasms
Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort.
Neoplasms
Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma.
Neoplasms
Programmed Death Ligand-1 Immunohistochemistry- A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Neoplasms
Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Neoplasms
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer.
Neoplasms
Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Neoplasms
Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications.
Neoplasms
Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma.
Neoplasms
Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer.
Neoplasms
Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
Neoplasms
Programmed death-1 and PD-1 ligand-1 expression in early onset gastric carcinoma and correlation with clinicopathological characteristics.
Neoplasms
Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Neoplasms
Programmed death-1 ligands and tumor infiltrating T lymphocytes in primary and lymph node metastasis of esophageal cancer patients.
Neoplasms
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Neoplasms
Programmed death-1 receptor (PD-1) and PD-ligand-1 (PD-L1) expression in non-small cell lung cancer and the immune-suppressive effect of anaerobic glycolysis.
Neoplasms
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
Neoplasms
Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma
Neoplasms
Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.
Neoplasms
Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
Neoplasms
Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
Neoplasms
Programmed Death-Ligand 1 (PD-L1) Expression Is Induced by Insulin in Pancreatic Ductal Adenocarcinoma Cells Pointing to Its Role in Immune Checkpoint Control.
Neoplasms
Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas.
Neoplasms
Programmed death-ligand 1 (PD-L1) may play a role in malignant glioma infiltration.
Neoplasms
Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients.
Neoplasms
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
Neoplasms
Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget's Disease.
Neoplasms
Programmed death-ligand 1 and survival in colorectal cancers: A meta-analysis.
Neoplasms
Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC.
Neoplasms
Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis.
Neoplasms
Programmed death-ligand 1 expression and its correlation with clinicopathological parameters in gallbladder cancer.
Neoplasms
Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma.
Neoplasms
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Neoplasms
Programmed death-ligand 1 expression and T790M status in EGFR-mutant non-small cell lung cancer.
Neoplasms
Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in colorectal adenocarcinoma.
Neoplasms
Programmed Death-Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Temporal Bone Squamous Cell Carcinoma.
Neoplasms
Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients.
Neoplasms
Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
Neoplasms
Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
Neoplasms
Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?
Neoplasms
Programmed Death-Ligand 1 Expression in Non-Small Cell Lung Carcinoma Biopsies and Its Association with Tumor Infi ltrat ing Lymphocytes and the Degree of Desmoplasia.
Neoplasms
Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Neoplasms
Programmed death-ligand 1 expression in rectal cancer.
Neoplasms
Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma.
Neoplasms
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.
Neoplasms
Programmed death-ligand 1 expression is associated with fibrosarcomatous transformation of dermatofibrosarcoma protuberans.
Neoplasms
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Neoplasms
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Neoplasms
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Neoplasms
Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
Neoplasms
Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas.
Neoplasms
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
Neoplasms
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Neoplasms
Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer.
Neoplasms
Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma.
Neoplasms
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Neoplasms
Programmed death-ligand 1 positivity can predict improved survival and a lower risk of brain metastasis in patients with resectable small cell lung cancer.
Neoplasms
Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression.
Neoplasms
Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
Neoplasms
Programming the immune checkpoint to treat hematologic malignancies.
Neoplasms
Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion.
Neoplasms
Progress and challenges of immunotherapy in triple-negative breast cancer.
Neoplasms
Progress for Immunotherapy in Inflammatory Breast Cancer and Emerging Barriers to Therapeutic Efficacy.
Neoplasms
Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers.
Neoplasms
Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes.
Neoplasms
Proinflammatory S100A8 Induces PD-L1 Expression in Macrophages, Mediating Tumor Immune Escape.
Neoplasms
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.
Neoplasms
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.
Neoplasms
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report.
Neoplasms
Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.
Neoplasms
Promising potential of a 18F-labelled small-molecular radiotracer to evaluate PD-L1 expression in tumors by PET imaging.
Neoplasms
Promising predictors of checkpoint inhibitor response in NSCLC.
Neoplasms
Promotion effects of DEHP on hepatocellular carcinoma models: up-regulation of PD-L1 by activating the JAK2/STAT3 pathway.
Neoplasms
Proposed mechanisms for the extracellular release of PD-L1 by the anticancer saponin platycodin D.
Neoplasms
Prospective evaluation of EBUS-TBNA specimens for programmed death-ligand 1 expression in non-small cell lung cancer patients: a pilot study.
Neoplasms
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
Neoplasms
Prospects for targeting PD-1 and PD-L1 in various tumor types.
Neoplasms
Prostasin regulates PD-L1 expression in human lung cancer cells.
Neoplasms
Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
Neoplasms
Protein Barcodes Enable High-Dimensional Single-Cell CRISPR Screens.
Neoplasms
Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
Neoplasms
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma.
Neoplasms
Protein Footprinting and X-ray Crystallography Reveal the Interaction of PD-L1 and a Macrocyclic Peptide.
Neoplasms
Protein Kinase D3 Promotes the Reconstruction of OSCC Immune Escape Niche Via Regulating MHC-I and Immune Inhibit Molecules Expression.
Neoplasms
Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti-tumor immunity in non-small cell lung cancer.
Neoplasms
Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.
Neoplasms
Proteomic analysis uncovers common effects of IFN-? and IL-27 on the HLA class I antigen presentation machinery in human cancer cells.
Neoplasms
Proximity ligation assay mediated rolling circle amplification strategy for in situ amplified imaging of glycosylated PD-L1.
Neoplasms
Pseudogene MSTO2P enhances hypoxia-induced osteosarcoma malignancy by upregulating PD-L1.
Neoplasms
PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models.
Neoplasms
Pulmonary Adenocarcinoma Mimicking Desquamative Interstitial Pneumonia: Report of 2 Cases With Genetic Analysis.
Neoplasms
Pulmonary Aerosol Delivery of Let-7b microRNA Confers a Striking Inhibitory Effect on Lung Carcinogenesis through Targeting the Tumor Immune Microenvironment.
Neoplasms
Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype.
Neoplasms
Purification and partial characterization of a ribosome-inactivating protein from the latex of Euphorbia trigona Miller with cytotoxic activity toward human cancer cell lines.
Neoplasms
Purification, characterization and molecular cloning of trichoanguin, a novel type I ribosome-inactivating protein from the seeds of Trichosanthes anguina.
Neoplasms
PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
Neoplasms
Pyruvate Kinase M2 Is Required for the Expression of the Immune Checkpoint PD-L1 in Immune Cells and Tumors.
Neoplasms
Q&A: Suzanne Topalian on immune therapies.
Neoplasms
Quantification Analysis and In Vitro Anti-Inflammatory Effects of 20-Hydroxyecdysone, Momordin Ic, and Oleanolic Acid from the Fructus of Kochia scoparia.
Neoplasms
Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
Neoplasms
Quantification of PD-L1 expression with [18F]BMS-986192 PET/CT in patients with advanced stage non-small-cell lung cancer.
Neoplasms
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges.
Neoplasms
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer.
Neoplasms
Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
Neoplasms
Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy.
Neoplasms
Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Neoplasms
Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray.
Neoplasms
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
Neoplasms
Quantitative Evaluation of Tumor Early Response to a Vascular-Disrupting Agent with Dynamic PET.
Neoplasms
Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Neoplasms
Quantitative Systems Pharmacology Modeling of PBMC-Humanized Mouse to Facilitate Preclinical Immuno-oncology Drug Development.
Neoplasms
Quetiapine-induced thrombotic microangiopathy in a patient on maintenance dialysis.
Neoplasms
Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway.
Neoplasms
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Neoplasms
Radiation and immunotherapy: emerging mechanisms of synergy.
Neoplasms
Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Neoplasms
Radiation Therapy Plus Anti-Programmed Death Ligand 1 Immunotherapy: A Review on Overall Survival.
Neoplasms
Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing.
Neoplasms
Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions.
Neoplasms
Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy.
Neoplasms
Radioimmunoassays of abrin and ricin in blood.
Neoplasms
Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features.
Neoplasms
Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Neoplasms
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms.
Neoplasms
Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy.
Neoplasms
Radiotherapy enhances responses of lung cancer to CTLA-4 blockade.
Neoplasms
Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.
Neoplasms
Radiotherapy Upregulates Programmed Death Ligand-1 through the Pathways Downstream of Epidermal Growth Factor Receptor in Glioma.
Neoplasms
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
Neoplasms
Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy.
Neoplasms
Rapid and Long-term Response of Pulmonary Pleomorphic Carcinoma to Nivolumab: A Case Report.
Neoplasms
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.
Neoplasms
Rapid PD-L1 detection in tumors with PET using a highly specific peptide.
Neoplasms
Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data.
Neoplasms
Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi).
Neoplasms
RAS and PD-L1: A Masters' Liaison in Cancer Immune Evasion.
Neoplasms
Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
Neoplasms
Rational combination of cancer immunotherapy in melanoma.
Neoplasms
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.
Neoplasms
Rational Design of Hyaluronic Acid-Based Copolymer-Mixed Micelle in Combination PD-L1 Immune Checkpoint Blockade for Enhanced Chemo-Immunotherapy of Melanoma.
Neoplasms
Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy.
Neoplasms
RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
Neoplasms
Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.
Neoplasms
Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors.
Neoplasms
Rationale for immunotoxin therapy of metastatic prostate carcinoma formatted as a multi-stage delivery system.
Neoplasms
Rationally designed peptide-conjugated gold/platinum nanosystem with active tumor-targeting for enhancing tumor photothermal-immunotherapy.
Neoplasms
Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression.
Neoplasms
Re: PD-L1 Expression in Tumor Cells and the Immunologic Milieu of Bladder Carcinomas: A Pathologic Review of 165 Cases.
Neoplasms
Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a Molecular Subtype Approach to Bladder Cancer is Also Needed.
Neoplasms
Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1.
Neoplasms
Reactive versus Constitutive: Reconcile the Controversial Results about the Prognostic Value of PD-L1 Expression in cancer.
Neoplasms
Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients.
Neoplasms
Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non-Small-Cell Lung Cancer and High PD-L1 Tumor Expression.
Neoplasms
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices.
Neoplasms
Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
Neoplasms
Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
Neoplasms
Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.
Neoplasms
Real-World Prevalence of PD-L1 Expression Among Tumor Samples From Patients With Non-Small-Cell Lung Cancer.
Neoplasms
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.
Neoplasms
Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status.
Neoplasms
Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel.
Neoplasms
Reappraisal of the incidence, various types and risk factors of malignancies in patients with dermatomyositis and polymyositis in Taiwan.
Neoplasms
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Neoplasms
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.
Neoplasms
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies.
Neoplasms
Recent advances in the management of anaplastic thyroid cancer.
Neoplasms
Recent advances in the management of gastric adenocarcinoma patients.
Neoplasms
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy.
Neoplasms
Recent Findings in the Posttranslational Modifications of PD-L1.
Neoplasms
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression.
Neoplasms
RECK expression is associated with angiogenesis and immunogenic Tumor Microenvironment in Hepatocellular Carcinoma, and is a prognostic factor for better survival.
Neoplasms
Recognition and killing of tumour cells expressing heat shock protein 65 kD with immunotoxins containing saporin.
Neoplasms
Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
Neoplasms
Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation.
Neoplasms
Recombinant Orthopoxvirus Primes Colon Cancer for Checkpoint Inhibitor and Cross-Primes T Cells for Antitumor and Antiviral Immunity.
Neoplasms
Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Neoplasms
Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain.
Neoplasms
Recombinant VAA-I from Viscum album induces apoptotic cell death of hepatocellular carcinoma SMMC7721 cells.
Neoplasms
Rectosigmoid-Junction Squamous Cell Carcinoma With pMMR/MSS Achieved a Partial Response Following PD-1 Blockade Combined With Chemotherapy: A Case Report.
Neoplasms
Recurrent genetic alterations and biomarker expression in primary and metastatic squamous cell carcinomas of the vulva.
Neoplasms
Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8(+) T cells.
Neoplasms
Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy.
Neoplasms
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Neoplasms
Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review.
Neoplasms
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery.
Neoplasms
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity.
Neoplasms
Regulating Glucose Metabolism with Prodrug Nanoparticles for Promoting Photoimmunotherapy of Pancreatic Cancer.
Neoplasms
Regulation and Function of the PD-L1 Checkpoint.
Neoplasms
Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins.
Neoplasms
Regulation of Caspase-3 and Bcl-2 Expression in Dalton's Lymphoma Ascites Cells by Abrin.
Neoplasms
Regulation of cytotoxic T-cell responses by p53 in cancer.
Neoplasms
Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.
Neoplasms
Regulation of innate and adaptive antitumor immunity by IAP antagonists.
Neoplasms
Regulation of PD-L1 expression by aPKC? in cutaneous angiosarcoma.
Neoplasms
Regulation of PD-L1 expression by matrix stiffness in lung cancer cells.
Neoplasms
Regulation of PD-L1 Expression by NF-?B in Cancer.
Neoplasms
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Neoplasms
Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy.
Neoplasms
Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling.
Neoplasms
Regulation of PD-L1 expression in response to DNA damage in cancer cells: Implications for precision medicine.
Neoplasms
Regulation of PD-L1 expression in the tumor microenvironment.
Neoplasms
Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
Neoplasms
Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs.
Neoplasms
Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-?.
Neoplasms
Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Neoplasms
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion.
Neoplasms
Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice.
Neoplasms
Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Neoplasms
Regulation of sister chromatid cohesion by nuclear PD-L1.
Neoplasms
Regulatory (FoxP3+) T cells and TGF-? predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer.
Neoplasms
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Neoplasms
Regulatory mechanisms of PD-L1 expression in cancer cells.
Neoplasms
Reinforcing the Combinational Immuno-Oncotherapy of Switching "Cold" Tumor to "Hot" by Responsive Penetrating Nanogels.
Neoplasms
Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy.
Neoplasms
Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma.
Neoplasms
Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer.
Neoplasms
Relationship between IL-10 and PD-L1 in esophageal carcinoma tissues and IL-10 down-regulates PD-L1 expression via Met signaling pathway.
Neoplasms
Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer.
Neoplasms
Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer.
Neoplasms
Relationship Between PD-L1 Expression and CD8+ T-cell Immune Responses in Hepatocellular Carcinoma.
Neoplasms
Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma.
Neoplasms
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Neoplasms
Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients.
Neoplasms
Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis.
Neoplasms
Relationship Between Programmed Death-ligand 1 and Clinicopathological Characteristics in Non-small Cell Lung Cancer Patients.
Neoplasms
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden, and PD-L1 expression in cancer patients.
Neoplasms
Relationship between SP142 PD-L1 Expression and 18F-FDG Uptake in Non-Small-Cell Lung Cancer.
Neoplasms
Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
Neoplasms
Relationship between the immune microenvironment of different locations in a primary tumour and clinical outcomes of oesophageal squamous cell carcinoma.
Neoplasms
Relationship Between Tumor Immune Markers and Fluorine-18-?-Methyltyrosine ([18F]FAMT) Uptake in Patients with Lung Cancer.
Neoplasms
Relationship of hypothyroidism and immune response to pegylated IL-10/nivolumab.
Neoplasms
Relationship of Metabolic Alterations and PD-L1 Expression in Cisplatin Resistant Lung Cancer.
Neoplasms
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
Neoplasms
Relationship of Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) Polymorphisms with Overall Cancer Susceptibility: An Updated Meta-Analysis of 28 Studies with 60 612 Subjects.
Neoplasms
Relationship of the Breast Ductal Carcinoma In Situ Immune Microenvironment with Clinicopathological and Genetic Features.
Neoplasms
Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model.
Neoplasms
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Neoplasms
Relationship of tumor PD-L1 expression with EGFR wild-type status and poor prognosis in lung adenocarcinoma.
Neoplasms
Relationships between apparent diffusion coefficient (ADC) histogram analysis parameters and PD-L 1-expression in head and neck squamous cell carcinomas: a preliminary study.
Neoplasms
Relative Efficacy of Checkpoint Inhibitors for Advanced NSCLC According to Programmed Death-Ligand-1 Expression: A Systematic Review and Network Meta-Analysis.
Neoplasms
Relaxin gene delivery modulates macrophages to resolve cancer fibrosis and synergizes with immune checkpoint blockade therapy.
Neoplasms
Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node-positive study.
Neoplasms
Reliability of a single-region sample to evaluate tumor immune microenvironment in hepatocellular carcinoma.
Neoplasms
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
Neoplasms
Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
Neoplasms
Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report.
Neoplasms
Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.
Neoplasms
Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti-Programmed Death-Ligand 1 Immunotherapy.
Neoplasms
Removal of N-Linked Glycosylation Enhances PD-L1 Detection in Colon Cancer: Validation Research Based on Immunohistochemistry Analysis.
Neoplasms
Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
Neoplasms
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.
Neoplasms
Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD-L1.
Neoplasms
Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
Neoplasms
Reprogramming the T cell response to cancer by simultaneous, nanoparticle-mediated PD-L1 inhibition and immunogenic cell death.
Neoplasms
Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy.
Neoplasms
Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells.
Neoplasms
Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade.
Neoplasms
Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity.
Neoplasms
Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC).
Neoplasms
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors.
Neoplasms
Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated PD-L1 attenuation and chemotherapeutics-induced immunogenic cell death.
Neoplasms
Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma.
Neoplasms
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors.
Neoplasms
Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Neoplasms
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma.
Neoplasms
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Neoplasms
Respiratory hyperoxia reverses immunosuppression by regulating myeloid-derived suppressor cells and PD-L1 expression in a triple-negative breast cancer mouse model.
Neoplasms
Response of primary human mammary tumor cell cultures to a monoclonal antibody-recombinant ricin A chain immunotoxin.
Neoplasms
Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review.
Neoplasms
Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Neoplasms
Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice.
Neoplasms
Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study.
Neoplasms
Response to immunotherapy in a patient with anaplastic thyroid cancer: A case report.
Neoplasms
Response to Letter to the Editor Titled "The Impact of Patient Characteristics on Tumor Cell PD-L1 Expression in NSCLC Patients".
Neoplasms
Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors.
Neoplasms
Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.
Neoplasms
Response to Pembrolizumab in Advanced Anal Squamous Cell Carcinoma With High TMB and PD-L1 and PD-L2 Amplification.
Neoplasms
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden.
Neoplasms
Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.
Neoplasms
Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors.
Neoplasms
Restoring Immune Function of Tumor-Specific CD4+ T Cells during Recurrence of Melanoma.
Neoplasms
Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.
Neoplasms
Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
Neoplasms
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
Neoplasms
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
Neoplasms
Resveratrol antagonizes thyroid hormone-induced expression of checkpoint and proliferative genes in oral cancer cells.
Neoplasms
Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity.
Neoplasms
Rethinking medulloblastoma from a targeted therapeutics perspective.
Neoplasms
Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer.
Neoplasms
Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models.
Neoplasms
Retreatment with anti-PD-1 antibody in non-small cell lung cancer patients previously treated with anti-PD-L1 antibody.
Neoplasms
Retrograde delivery of photosensitizer (TPPp-O-beta-GluOH)3 selectively potentiates its photodynamic activity.
Neoplasms
Retrospective analysis of antitumor effects and biomarkers for nivolumab in NSCLC patients with EGFR mutations.
Neoplasms
Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.
Neoplasms
Retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients.
Neoplasms
Retrospective analysis of the prognostic value of PD-L1 expression and 18F-FDG PET/CT metabolic parameters in colorectal cancer.
Neoplasms
Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species.
Neoplasms
Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree).
Neoplasms
Ribosome-inactivating proteins: from plant defense to tumor attack.
Neoplasms
Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro.
Neoplasms
Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.
Neoplasms
Ricin A-chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity.
Neoplasms
Ricin and lentil lectin-affinity chromatography reveals oligosaccharide heterogeneity of thyrotropin secreted by 12 human pituitary tumors.
Neoplasms
Ricin and Ricinus communis in pharmacology and toxicology-from ancient use and "Papyrus Ebers" to modern perspectives and "poisonous plant of the year 2018".
Neoplasms
Ricin B-like lectin orthologues from two mushrooms, Hericium erinaceus and Stereum hirsutum, enable recognition of highly fucosylated N-glycans.
Neoplasms
Ricin induces the production of tumour necrosis factor-alpha and interleukin-1 beta by human peripheral-blood mononuclear cells.
Neoplasms
Ricin-mediated cell-lysis and apoptosis of drug sensitive and resistant tumor-cells.
Neoplasms
Ricin. Mechanisms of cytotoxicity.
Neoplasms
Ricin: An Ancient Story for a Timeless Plant Toxin.
Neoplasms
Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.
Neoplasms
RIP-1/c-FLIPL Induce Hepatic Cancer Cell Apoptosis Through Regulating Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL).
Neoplasms
Riproximin is a recently discovered type II ribosome inactivating protein with potential for treating cancer.
Neoplasms
Riproximin modulates multiple signaling cascades leading to cytostatic and apoptotic effects in human breast cancer cells.
Neoplasms
Rise of PD-L1 expression during metastasis of colorectal cancer: implications for immunotherapy.
Neoplasms
RNA Expression Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder Reveals a Basal-Like Molecular Subtype.
Neoplasms
RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.
Neoplasms
RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue.
Neoplasms
RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis.
Neoplasms
Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
Neoplasms
Role of BCLAF-1 in PD-L1 stabilization in response to ionizing irradiation.
Neoplasms
Role of Checkpoint Inhibition in Localized Bladder Cancer.
Neoplasms
Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer.
Neoplasms
Role of HPV status and PD-L1 expression in prognosis of laryngeal squamous cell carcinoma.
Neoplasms
Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data.
Neoplasms
Role of Immune Microenvironment in Gastrointestinal Stromal Tumors.
Neoplasms
Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Neoplasms
Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer.
Neoplasms
Role of monensin PLGA polymer nanoparticles and liposomes as potentiator of ricin A immunotoxins in vitro.
Neoplasms
Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma.
Neoplasms
Role of PD-1 in Immunity and Diseases.
Neoplasms
Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Neoplasms
Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer.
Neoplasms
Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers.
Neoplasms
Role of PD-L1 in Gut Mucosa Tolerance and Chronic Inflammation.
Neoplasms
Role of programmed cell death ligand-1 expression on prognostic and overall survival of breast cancer: A systematic review and meta-analysis.
Neoplasms
Role of programmed death-ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma.
Neoplasms
Role of TGF-? in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Neoplasms
Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations.
Neoplasms
Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer.
Neoplasms
Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression.
Neoplasms
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
Neoplasms
Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
Neoplasms
Roles of gamma interferon and tumor necrosis factor-alpha in shiga toxin lethality.
Neoplasms
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
Neoplasms
Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer.
Neoplasms
ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer.
Neoplasms
ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report.
Neoplasms
RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Neoplasms
Ruxolitinib reverses checkpoint inhibition by reducing programmed cell death ligand-1 (PD-L1) expression and increases anti-tumour effects of T cells in multiple myeloma.
Neoplasms
SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1.
Neoplasms
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
Neoplasms
Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.
Neoplasms
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Neoplasms
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Neoplasms
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.
Neoplasms
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Neoplasms
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
Neoplasms
Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
Neoplasms
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Neoplasms
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.
Neoplasms
Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
Neoplasms
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Neoplasms
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients.
Neoplasms
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Neoplasms
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors.
Neoplasms
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
Neoplasms
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Neoplasms
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Neoplasms
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Neoplasms
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Neoplasms
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors.
Neoplasms
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF? and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Neoplasms
Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Neoplasms
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.
Neoplasms
Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Neoplasms
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial.
Neoplasms
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
Neoplasms
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Neoplasms
Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression.
Neoplasms
Saporin as a novel suicide gene in anticancer gene therapy.
Neoplasms
Saporin Conjugated Monoclonal Antibody to the Transcobalamin Receptor TCblR/CD320 Is Effective in Targeting and Destroying Cancer Cells.
Neoplasms
Saporin induces multiple death pathways in lymphoma cells with different intensity and timing as compared to ricin.
Neoplasms
Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model.
Neoplasms
Saporin, a ribosome-inactivating protein used to prepare immunotoxins, induces cell death via apoptosis.
Neoplasms
Saporin-S6: A Useful Tool in Cancer Therapy.
Neoplasms
Sarcoidosis and Cancer: A Complex Relationship.
Neoplasms
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
Neoplasms
Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors.
Neoplasms
Screening and characterization of a novel high-efficiency tumor-homing cell-penetrating peptide from the buffalo cathelicidin family.
Neoplasms
Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1.
Neoplasms
Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots.
Neoplasms
Screening of MSI detection loci and their heterogeneity in East Asian colorectal cancer patients.
Neoplasms
Searching for the real function of mTOR signaling in the regulation of PD-L1 expression.
Neoplasms
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.
Neoplasms
Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Neoplasms
Seed- and Soil-Dependent Differences in Murine Breast Tumor Microenvironments Dictate Anti-PD-L1 IgG Delivery and Therapeutic Efficacy.
Neoplasms
Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.
Neoplasms
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Neoplasms
Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-? and PD-L1.
Neoplasms
Selective CXCR4+ Cancer Cell Targeting and Potent Antineoplastic Effect by a Nanostructured Version of Recombinant Ricin.
Neoplasms
Selective Cytotoxicity to HER2 Positive Breast Cancer Cells by Saporin-Loaded Nanobody-Targeted Polymeric Nanoparticles in Combination with Photochemical Internalization.
Neoplasms
Selective killing of tumor cells in vitro by an immunotoxin composed of ricin and monoclonal antibody against Ia antigen.
Neoplasms
Selective Suppression of Cell Growth and Programmed Cell Death-Ligand 1 Expression in HT1080 Fibrosarcoma Cells by Low Molecular Weight Fucoidan Extract.
Neoplasms
Selective Targeting of Cancerous Mitochondria and Suppression of Tumor Growth Using Redox-Active Treatment Adjuvant.
Neoplasms
Selective uptake of ricin A-chain by hepatic non-parenchymal cells in vitro. Importance of mannose oligosaccharides in the toxin.
Neoplasms
Self-Assembly of Extracellular Vesicle-like Metal-Organic Framework Nanoparticles for Protection and Intracellular Delivery of Biofunctional Proteins.
Neoplasms
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
Neoplasms
Senescence, immune microenvironment, and vascularization in cardiac myxomas.
Neoplasms
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.
Neoplasms
Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines.
Neoplasms
Sensitivity of cancer cell lines to the novel non-toxic type 2 ribosome-inactivating protein nigrin b.
Neoplasms
Sensitization of AIDS related non-Hodgkin's B lymphoma cell lines to cytotoxic drugs toxins by interferon-gamma.
Neoplasms
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-?Gal and MVA-MUC1 (TG4010) in a murine tumor model.
Neoplasms
Sequential and Timely Combination of a Cancer Nanovaccine with Immune Checkpoint Blockade Effectively Inhibits Tumor Growth and Relapse.
Neoplasms
Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Neoplasms
Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicity-From Case Report to Mouse Model Validation.
Neoplasms
Sequential MR Image-Guided Local Immune Checkpoint Blockade Cancer Immunotherapy Using Ferumoxytol Capped Ultralarge Pore Mesoporous Silica Carriers after Standard Chemotherapy.
Neoplasms
Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial.
Neoplasms
Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy.
Neoplasms
Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
Neoplasms
Serum alpha-fetoprotein subfractions identified by Ricinus communis agglutinin I in hepatic malignancies, yolk sac tumor, benign hepatic diseases, and fetal stage.
Neoplasms
Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes.
Neoplasms
Serum insulin-like growth factor-binding protein 2 levels as an indicator for disease severity in enterohemorrhagic Escherichia coli induced hemolytic uremic syndrome.
Neoplasms
Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.
Neoplasms
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Neoplasms
Serum levels of soluble programmed death-ligand 1 (sPD-L1): A possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma.
Neoplasms
Serum PD-1/PD-L1 Levels, Tumor Expression and PD-L1 Somatic Mutations in HER2-Positive and Triple Negative Normal-Like Feline Mammary Carcinoma Subtypes.
Neoplasms
Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
Neoplasms
Several immune escape patterns in non-Hodgkin's lymphomas.
Neoplasms
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Neoplasms
Shedding light on the molecular determinants of response to anti-PD-1 therapy.
Neoplasms
Shiga toxin 1 induces apoptosis in the human myelogenous leukemia cell line THP-1 by a caspase-8-dependent, tumor necrosis factor receptor-independent mechanism.
Neoplasms
Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity.
Neoplasms
Shiga toxin 1-induced inflammatory response in lipopolysaccharide-sensitized astrocytes is mediated by endogenous tumor necrosis factor alpha.
Neoplasms
Shiga Toxin 2a-Induced Endothelial Injury in Hemolytic Uremic Syndrome: A Metabolomic Analysis.
Neoplasms
Shiga toxin and its use in targeted cancer therapy and imaging.
Neoplasms
Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome.
Neoplasms
Shiga toxin receptor Gb3Cer/CD77: tumor-association and promising therapeutic target in pancreas and colon cancer.
Neoplasms
Shiga toxin type 1 activates tumor necrosis factor-alpha gene transcription and nuclear translocation of the transcriptional activators nuclear factor-kappaB and activator protein-1.
Neoplasms
Shiga toxin-1 regulation of cytokine production by human glomerular epithelial cells.
Neoplasms
Shiga toxin-associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro.
Neoplasms
Shiga Toxins Activate the NLRP3 Inflammasome Pathway To Promote Both Production of the Proinflammatory Cytokine Interleukin-1? and Apoptotic Cell Death.
Neoplasms
Shiga-like toxin II derived from Escherichia coli O157:H7 modifies renal handling of levofloxacin in rats.
Neoplasms
Shock wave permeabilization with ribosome inactivating proteins: a new approach to tumor therapy.
Neoplasms
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Neoplasms
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma.
Neoplasms
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Neoplasms
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
Neoplasms
SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells.
Neoplasms
Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.
Neoplasms
Siglec-15 as an emerging target for next-generation cancer immunotherapy.
Neoplasms
Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy.
Neoplasms
Signal transducer and activator of transcription 3 signaling in tumor immune evasion.
Neoplasms
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.
Neoplasms
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response.
Neoplasms
Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
Neoplasms
Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.
Neoplasms
Significance of PD-L1 clones and C-MET expression in hepatocellular carcinoma.
Neoplasms
Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
Neoplasms
Significance of PD-L1 Expression in Tongue Cancer Development.
Neoplasms
Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer.
Neoplasms
Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Neoplasms
Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.
Neoplasms
Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth.
Neoplasms
Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes.
Neoplasms
Silencing PD-1 and PD-L1: the potential of PolyPurine Reverse Hoogsteen hairpins for the elimination of tumor cells.
Neoplasms
Silencing Signal Transducer and Activator of Transcription 3 (STAT3) and Use of Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody Induces Immune Response and Anti-Tumor Activity.
Neoplasms
Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism.
Neoplasms
Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.
Neoplasms
Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma.
Neoplasms
Simultaneous blockade of multiple immune inhibitory checkpoints enhance anti-tumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Neoplasms
Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release.
Neoplasms
Simultaneous inhibition of CXCR1/2, TGF-?, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
Neoplasms
Simultaneous targeting of TGF-?/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion.
Neoplasms
Single administration of avelumab induced a complete response in thyroid transcription factor 1-positive combined Merkel cell carcinoma.
Neoplasms
Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Neoplasms
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.
Neoplasms
Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells.
Neoplasms
Single-cell transcriptomics reveals the effect of PD-L1/TGF-? blockade on the tumor microenvironment.
Neoplasms
Single-Dose Anti-PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses.
Neoplasms
siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions.
Neoplasms
Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry.
Neoplasms
Size Matters: Dissecting Key Parameters for Panel-Based Tumor Mutational Burden (TMB) Analysis.
Neoplasms
Small angle neutron scattering as sensitive tool to detect ligand-dependent shape changes in a plant lectin with beta-trefoil folding and their dependence on the nature of the solvent.
Neoplasms
Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas.
Neoplasms
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1.
Neoplasms
Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy.
Neoplasms
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
Neoplasms
Smoking Induced Extracellular Vesicles Release and Their Distinct Properties in Non-Small Cell Lung Cancer.
Neoplasms
SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression.
Neoplasms
Soft tissue sarcoma with additional anaplastic components. A clinicopathologic and immunohistochemical study of 27 cases.
Neoplasms
Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Neoplasms
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.
Neoplasms
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy.
Neoplasms
Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.
Neoplasms
Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.
Neoplasms
Soluble PD-L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma.
Neoplasms
Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.
Neoplasms
Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours.
Neoplasms
Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Neoplasms
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.
Neoplasms
Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis.
Neoplasms
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.
Neoplasms
Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type.
Neoplasms
Somatic mutations and immune checkpoint biomarkers.
Neoplasms
Somatic mutations in renal cell carcinomas from Chinese patients revealed by whole exome sequencing.
Neoplasms
Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin.
Neoplasms
Sorting nexin 6 interacts with Cullin3 and regulates programmed death ligand 1 expression.
Neoplasms
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Neoplasms
SOX2 immunity and tissue resident memory in children and young adults with glioma.
Neoplasms
SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3.
Neoplasms
Spatial and phenotypic immune profiling of metastatic colon cancer.
Neoplasms
Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
Neoplasms
Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy.
Neoplasms
Spatial distribution of immune checkpoint proteins in histological subtypes of lung adenocarcinoma.
Neoplasms
Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer.
Neoplasms
Spatial UMAP and image-cytometry for topographic immuno-oncology biomarker discovery.
Neoplasms
Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas.
Neoplasms
Spatiotemporal Changes in Checkpoint Molecule Expression.
Neoplasms
sPD-L1 Expression is Associated with Immunosuppression and Infectious Complications in Patients with Acute Pancreatitis.
Neoplasms
Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.
Neoplasms
Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
Neoplasms
Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression.
Neoplasms
Spectroscopic characterization of gelonin--assignments secondary structure and thermal denaturation.
Neoplasms
Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development.
Neoplasms
Spontaneous pathological complete regression of high-grade triple-negative breast cancer with axillary metastasis.
Neoplasms
Spontaneous remission of advanced progressive poorly differentiated non-small cell lung cancer: a case report and review of literature.
Neoplasms
Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.
Neoplasms
Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab.
Neoplasms
STAG2 loss-of-function mutation induces PD-L1 expression in U2OS cells.
Neoplasms
Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment.
Neoplasms
Standardizing immunohistochemistry methodology for evaluation of PD-1 and PDL-1 expression in upper tract urothelial carcinoma.
Neoplasms
STAT1 as a potential prognosis marker for poor outcomes of early stage colorectal cancer with microsatellite instability.
Neoplasms
STAT1 deficiency supports PD-1/PD-L1 signaling resulting in dysfunctional TNF? mediated immune responses in a model of NSCLC.
Neoplasms
STAT3 Activation and Oncogenesis in Lymphoma.
Neoplasms
STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer.
Neoplasms
State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.
Neoplasms
Status of programmed death-ligand 1 expression in sarcomas.
Neoplasms
Stereotactic Body Radiotherapy Is Effective in Modifying the Tumor Genome and Tumor Immune Microenvironment in Non-Small Cell Lung Cancer or Lung Metastatic Carcinoma.
Neoplasms
STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer.
Neoplasms
STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.
Neoplasms
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
Neoplasms
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
Neoplasms
STINGing the Tumor's immune evasion mechanism.
Neoplasms
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Neoplasms
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Neoplasms
Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review.
Neoplasms
Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins.
Neoplasms
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Neoplasms
Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients.
Neoplasms
Stromal cell PD-L1 inhibits CD8+ T-cell antitumor immune responses and promotes colon cancer.
Neoplasms
Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.
Neoplasms
Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
Neoplasms
Stromal PD-1+ tumor-associated macrophages predict poor prognosis in lung adenocarcinoma.
Neoplasms
Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
Neoplasms
Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Neoplasms
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy.
Neoplasms
Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab.
Neoplasms
Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Neoplasms
Structure and properties of ricin the toxic protein of Ricinus communis
Neoplasms
Structure-Activity Relationship of Transfection-Modulating Saponins - A Pursuit for the Optimal Gene Trafficker.
Neoplasms
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion.
Neoplasms
Studies of abrin toxic action on tumor cells by immunoelectron microscopy.
Neoplasms
Studies on the antitumor lectins isolated from the seeds of Ricinus communis (castor bean).
Neoplasms
Studies on the mechanism of action of abrin-9.2.27 immunotoxin in human melanoma cell lines.
Neoplasms
Studies on the mechanisms of abortion induction by Trichosanthin.
Neoplasms
Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Neoplasms
Study on the Expression Levels and Clinical Significance of PD-1 and PD-L1 in Plasma of NSCLC Patients.
Neoplasms
Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Neoplasms
Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports.
Neoplasms
Subversion of NK-cell and TNF? Immune Surveillance Drives Tumor Recurrence.
Neoplasms
Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy.
Neoplasms
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
Neoplasms
Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.
Neoplasms
Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
Neoplasms
Successful implementation of genomically based treatment of chemotherapy refractory peripheral T-cell lymphoma (PTCL).
Neoplasms
Successful response to monotherapy of immune checkpoint inhibitor in intrahepatic cholangiocarcinoma with high tumor mutational burden and PD-L1 expression.
Neoplasms
Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report.
Neoplasms
Successful treatment of a patient with non-small cell lung cancer and interstitial lung disease with durvalumab: a case report.
Neoplasms
Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
Neoplasms
Successful Treatment of Afatinib-Refractory Non-Small Cell Lung Cancer with Uncommon Complex EGFR Mutations Using Pembrolizumab: A Case Report.
Neoplasms
Successful treatment of disseminated human Hodgkin's disease in SCID mice with deglycosylated ricin A-chain immunotoxins.
Neoplasms
Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade.
Neoplasms
Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa.
Neoplasms
Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study.
Neoplasms
Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
Neoplasms
Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
Neoplasms
Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody.
Neoplasms
Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
Neoplasms
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.
Neoplasms
Suppression of hepatoma tumor growth by systemic administration of the phytotoxin gelonin driven by the survivin promoter.
Neoplasms
Suppression of metastatic murine ovarian cancer cells by transduced embryonic progenitor cells.
Neoplasms
Suppression of murine B-cell lymphoma growth by trichosanthin through anti-angiogenesis.
Neoplasms
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.
Neoplasms
Supramolecularly Engineered Circular Bivalent Aptamer for Enhanced Functional Protein Delivery.
Neoplasms
Surgical resection of small cell lung carcinoma: prognostic factors and the tumor microenvironment.
Neoplasms
Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
Neoplasms
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Neoplasms
Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC.
Neoplasms
Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells.
Neoplasms
Sustained low-level expression of interferon-gamma promotes tumor development: potential insights in tumor prevention and tumor immunotherapy.
Neoplasms
Sustained partial remission of a metastatic NEN using off-label immunotherapy with pembrolizumab.
Neoplasms
Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with CSMD3 mutation.
Neoplasms
Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade.
Neoplasms
Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.
Neoplasms
Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.
Neoplasms
Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma.
Neoplasms
Synergistic Antitumor Activity from Two-Stage Delivery of Targeted Toxins and Endosome-Disrupting Nanoparticles.
Neoplasms
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
Neoplasms
Synergistic effect of meta-tetra(hydroxyphenyl)chlorin-based photodynamic therapy followed by cisplatin on malignant Hep-2 cells.
Neoplasms
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1.
Neoplasms
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Neoplasms
Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin.
Neoplasms
Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Neoplasms
Syngeneic tobacco carcinogen-induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden.
Neoplasms
Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Neoplasms
Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[c][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with In Vivo Antitumor Activity.
Neoplasms
Synthesis and Preclinical Evaluation of 68Ga-labeled Adnectin, 68Ga-BMS-986192 as a PET Agent for Imaging PD-L1 Expression.
Neoplasms
Synthesis and properties of a mitochondrial peripheral benzodiazepine receptor conjugate.
Neoplasms
Synthesis of Multifunctional Nanoparticles for the Combination of Photodynamic Therapy and Immunotherapy.
Neoplasms
Systematic Analysis of Splice-Site-Creating Mutations in Cancer.
Neoplasms
Systematic construction and validation of an immune prognostic model for lung adenocarcinoma.
Neoplasms
Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.
Neoplasms
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Neoplasms
Systematic identification of the cancer pathways and molecules related with breast cancer immunogenicity.
Neoplasms
Systematic review of neoadjuvant therapy by Immune checkpoint inhibitors before radical cystectomy: where do we stand?
Neoplasms
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Neoplasms
Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC).
Neoplasms
Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy.
Neoplasms
Systemic and local immunosuppression in patients with high-grade meningiomas.
Neoplasms
Systemic immune-inflammation index in germ-cell tumours.
Neoplasms
Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Neoplasms
Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer-May Cold Tumors Simply Be Too Hot?
Neoplasms
Systemic Interferon-? Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.
Neoplasms
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.
Neoplasms
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Neoplasms
Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
Neoplasms
T cell coinhibition and immunotherapy in human breast cancer.
Neoplasms
T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer.
Neoplasms
T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN-? Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma.
Neoplasms
T cell membrane cloaking tumor microenvironment-responsive nanoparticles with a smart "membrane escape mechanism" for enhanced immune-chemotherapy of melanoma.
Neoplasms
T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.
Neoplasms
T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival.
Neoplasms
T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.
Neoplasms
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Neoplasms
T-cell programming in pancreatic adenocarcinoma: a review.
Neoplasms
T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.
Neoplasms
T-Cell-Derived Nanovesicles for Cancer Immunotherapy.
Neoplasms
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
Neoplasms
T-Cell-Mimicking Nanoparticles for Cancer Immunotherapy.
Neoplasms
Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.
Neoplasms
Tailing effect of PD-1 antibody results in the eradication of unresectable multiple primary lung cancer presenting as ground-glass opacities: a case report.
Neoplasms
Tandem-Multimeric F3-Gelonin Fusion Toxins for Enhanced Anti-Cancer Activity for Prostate Cancer Treatment.
Neoplasms
Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Neoplasms
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities.
Neoplasms
Targeted and intracellular delivery of protein therapeutics by a boronated polymer for the treatment of bone tumors.
Neoplasms
Targeted co-delivery of Trp-2 polypeptide and monophosphoryl lipid A by pH-sensitive poly (?-amino ester) nano-vaccines for melanoma.
Neoplasms
Targeted delivery of IL2 to the tumor stroma potentiates the action of immune checkpoint inhibitors by preferential activation of NK and CD8+ T cells.
Neoplasms
Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies.
Neoplasms
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Neoplasms
Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?
Neoplasms
Targeted Protein Degradation through Cytosolic Delivery of Monobody Binders Using Bacterial Toxins.
Neoplasms
Targeted Shiga toxin-drug conjugates prepared via Cu-free click chemistry.
Neoplasms
Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Neoplasms
Targeted therapy of human glioblastoma via delivery of a toxin through a peptide directed to cell surface nucleolin.
Neoplasms
Targeted Therapy Recommendations for Therapy Refractory Solid Tumors-Data from the Real-World Precision Medicine Platform MONDTI.
Neoplasms
Targeted toxin therapy for the treatment of cancer.
Neoplasms
Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b.
Neoplasms
Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells.
Neoplasms
Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma.
Neoplasms
Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy.
Neoplasms
Targeting cancer cells with transferrin conjugates containing the non-toxic type 2 ribosome-inactivating proteins nigrin b or ebulin l.
Neoplasms
Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation.
Neoplasms
Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma.
Neoplasms
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
Neoplasms
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs.
Neoplasms
Targeting EGFR in Esophagogastric Cancer.
Neoplasms
Targeting glycosylated PD-1 induces potent anti-tumor immunity.
Neoplasms
Targeting IFN? to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance.
Neoplasms
Targeting immune checkpoints in gynecologic cancer: updates & perspectives for pathologists.
Neoplasms
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer.
Neoplasms
Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
Neoplasms
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Neoplasms
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Neoplasms
Targeting of a developmentally regulated epitope of CD43 for the treatment of acute leukemia.
Neoplasms
Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
Neoplasms
Targeting PD-1/PD-L1 interactions for cancer immunotherapy.
Neoplasms
Targeting PD-L1 for cancer cell detection.
Neoplasms
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
Neoplasms
Targeting PD-L1 Protein: Translation, Modification and Transport
Neoplasms
Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.
Neoplasms
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Neoplasms
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy.
Neoplasms
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
Neoplasms
Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy.
Neoplasms
Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression.
Neoplasms
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy.
Neoplasms
Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer.
Neoplasms
Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy.
Neoplasms
Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Neoplasms
Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma.
Neoplasms
Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities.
Neoplasms
Targeting the programmed cell death-1 pathway in breast and ovarian cancer.
Neoplasms
Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.
Neoplasms
Targeting the programmed death-1 pathway in lymphoid neoplasms.
Neoplasms
Targeting the TGF? pathway with galunisertib, a TGF?RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Neoplasms
Targeting the tumor microenvironment with interferon-? bridges innate and adaptive immune responses.
Neoplasms
Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity.
Neoplasms
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment.
Neoplasms
Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.
Neoplasms
TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis.
Neoplasms
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer.
Neoplasms
Temporal evolution of PD-L1 expression in patients with non-small cell lung cancer.
Neoplasms
Temporal expression of circulating miRNA after severe injury.
Neoplasms
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
Neoplasms
Temporary inhibition of Moloney-murine sarcoma virus (M-MSV) induced-tumours by adoptive transfer of ricin-treated T-lymphocytes.
Neoplasms
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Neoplasms
TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.
Neoplasms
TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1.
Neoplasms
TGF-? Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma.
Neoplasms
TGF-beta: a master immune regulator.
Neoplasms
TGF? attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Neoplasms
TGF? Blockade Augments PD-1 Inhibition to Promote T-Cell Mediated Regression of Pancreatic Cancer.
Neoplasms
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
Neoplasms
Th1high in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC.
Neoplasms
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy.
Neoplasms
The ?133p53? isoform promotes an immunosuppressive environment leading to aggressive prostate cancer.
Neoplasms
The anthelmintic flubendazole blocks human melanoma growth and metastasis and suppresses programmed cell death protein-1 and myeloid-derived suppressor cell accumulation.
Neoplasms
The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3.
Neoplasms
The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.
Neoplasms
The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP.
Neoplasms
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients.
Neoplasms
The antileukemic efficacy of an immunotoxin composed of a monoclonal anti-Thy-1 antibody disulfide linked to the ribosome-inactivating protein gelonin.
Neoplasms
The antitumor activity and preliminary modeling on the potential mechanism of action of human peroxiredoxin-5.
Neoplasms
The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade.
Neoplasms
The application and mechanism of PD pathway blockade for cancer therapy.
Neoplasms
The aryl hydrocarbon receptor suppresses immunity to oral squamous cell carcinoma through immune checkpoint regulation.
Neoplasms
The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma.
Neoplasms
The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
Neoplasms
The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Neoplasms
The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Neoplasms
The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Neoplasms
The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers.
Neoplasms
The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer.
Neoplasms
The AURORA of a New Way to Value Myeloid Immunosuppression in Cancer.
Neoplasms
The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
Neoplasms
The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial.
Neoplasms
The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.
Neoplasms
The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-L1.
Neoplasms
The binding of abrin and ricin by Ehrlich ascites tumor cells.
Neoplasms
The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling.
Neoplasms
The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer.
Neoplasms
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Neoplasms
The Cancer Omics Atlas: an integrative resource for cancer omics annotations.
Neoplasms
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Neoplasms
The Cellular and Chemical Biology of Endocytic Trafficking and Intracellular Delivery-The GL-Lect Hypothesis.
Neoplasms
The Challenge for Development of Valuable Immuno-oncology Biomarkers.
Neoplasms
The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: pharmacokinetics and biodistribution of two divalent, ricin-based immunotoxins in xenografted athymic mice.
Neoplasms
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
Neoplasms
The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.
Neoplasms
The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer.
Neoplasms
The clinical application of camrelizumab on advanced hepatocellular carcinoma.
Neoplasms
The clinical benefits of immune checkpoint inhibitor for thymic carcinomas ?experience of single public hospital in Japan?.
Neoplasms
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
Neoplasms
The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer.
Neoplasms
The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte.
Neoplasms
The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
Neoplasms
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer.
Neoplasms
The clinical significance of HERV-H LTR -associating 2 expression in cervical adenocarcinoma.
Neoplasms
The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression.
Neoplasms
The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Neoplasms
The clinical utility of PD-L1 testing in selecting non-small cell lung cancer patients for PD1/PD-L1-directed therapy.
Neoplasms
The Clinicopathological and Molecular Associations of PD-L1 Expression in Non-small Cell Lung Cancer: Analysis of a Series of 10,005 Cases Tested with the 22C3 Assay.
Neoplasms
The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.
Neoplasms
The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients.
Neoplasms
The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
Neoplasms
The clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis.
Neoplasms
The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Neoplasms
The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis.
Neoplasms
The Clinicopathological Characteristics And Genetic Alterations of Signet-ring Cell Carcinoma in Gastric Cancer.
Neoplasms
The Clinicopathological Features and Genetic Alterations in Epstein-Barr Virus-Associated Gastric Cancer Patients after Curative Surgery.
Neoplasms
The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer.
Neoplasms
The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Neoplasms
The Co-Expression of Programmed Death-Ligand 1 (PD-L1) in Untreated EGFR-Mutated Metastatic Lung Adenocarcinoma.
Neoplasms
The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Neoplasms
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Neoplasms
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Neoplasms
The combined presence of CD20?+?B cells and PD-L1?+?tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
Neoplasms
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
Neoplasms
The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma.
Neoplasms
The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.
Neoplasms
The conundrum of the Epstein-Barr virus-associated gastric carcinoma in the Americas.
Neoplasms
The correlation and overlaps between PD-L1 expression and classical genomic aberrations in Chinese lung adenocarcinoma patients: a single center case series.
Neoplasms
The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma.
Neoplasms
The current status of checkpoint inhibitors in metastatic bladder cancer.
Neoplasms
The cutting-edge progress of immune-checkpoint blockade in lung cancer.
Neoplasms
The cytotoxic effects of abrin and ricin on Ehrlich ascites tumor cells.
Neoplasms
The daily practice reality of PD-L1 (CD274) evaluation in non-small cell lung cancer: A retrospective study.
Neoplasms
The density and spatial tissue distribution of CD8+ and CD163+ immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors.
Neoplasms
The design of high affinity human PD-1 mutants by using molecular dynamics simulations (MD).
Neoplasms
The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis.
Neoplasms
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells.
Neoplasms
The development of immunotherapy in older adults: New treatments, new toxicities?
Neoplasms
The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis.
Neoplasms
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia.
Neoplasms
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer.
Neoplasms
The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial.
Neoplasms
The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Neoplasms
The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice.
Neoplasms
The effect of AZT and chloroquine on the activities of ricin and a saporin-transferrin chimeric toxin.
Neoplasms
The effect of intestinal flora on immune checkpoint inhibitors in tumor treatment: a narrative review.
Neoplasms
The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
Neoplasms
The effect of PD-L1 status on survival outcomes in patients with stage II-III non-small cell lung cancer treated with chemotherapy.
Neoplasms
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.
Neoplasms
The effect of shiga toxin and sonicates of Shigella isolates from children with neurologic manifestation on neuroblastoma cell lines.
Neoplasms
The effect of specific glycosidases on Ricinus communis agglutinin binding to cell surfaces of two tumor sublines. A comparative flow-cytometric study.
Neoplasms
The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.
Neoplasms
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Neoplasms
The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.
Neoplasms
The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.
Neoplasms
The Efficacy of Anti-PD-L1 Treatment in Melanoma Is Associated with the Expression of the ECM Molecule EMILIN2.
Neoplasms
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
Neoplasms
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer.
Neoplasms
The elevated glutaminolysis of bladder cancer and T cells in a simulated tumor microenvironment contributes to the up-regulation of PD-L1 expression by interferon-?.
Neoplasms
The Enhanced Inhibitory Effect of Estrogen on PD-L1 Expression Following Nrf2 Deficiency in the AOM/DSS Model of Colitis-Associated Cancer.
Neoplasms
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.
Neoplasms
The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.
Neoplasms
The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.
Neoplasms
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.
Neoplasms
The evolving role of microsatellite instability in colorectal cancer: A review.
Neoplasms
The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma.
Neoplasms
The evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer.
Neoplasms
The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.
Neoplasms
The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
Neoplasms
The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer.
Neoplasms
The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
Neoplasms
The Expression of PD-L1 and B7-H4 in Thymic Epithelial Tumor and Its Relationship With Tumor Immune-Infiltrating Cells.
Neoplasms
The expression of PD-L1 in salivary gland carcinomas.
Neoplasms
The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
Neoplasms
The expression of programmed death-ligand 1 in patients with invasive breast cancer.
Neoplasms
The Expression of Three Negative Co-Stimulatory B7 Family Molecules in Small Cell Lung Cancer and Their Effect on Prognosis.
Neoplasms
The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy.
Neoplasms
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.
Neoplasms
The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysis.
Neoplasms
The extracts of Astragalus membranaceus overcome tumor immune tolerance by inhibition of tumor programmed cell death protein ligand-1 expression.
Neoplasms
The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
Neoplasms
The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.
Neoplasms
The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
Neoplasms
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China.
Neoplasms
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.
Neoplasms
The future of cancer treatment: will it include immunotherapy?
Neoplasms
The future of radiation-induced abscopal response: beyond conventional radiotherapy approaches.
Neoplasms
The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
Neoplasms
The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers.
Neoplasms
The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
Neoplasms
The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer.
Neoplasms
The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.
Neoplasms
The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
Neoplasms
The Identification of Immunological Biomarkers in Kidney Cancers.
Neoplasms
The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas.
Neoplasms
The IFN-?/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Neoplasms
The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.
Neoplasms
The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200.
Neoplasms
The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
Neoplasms
The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer.
Neoplasms
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.
Neoplasms
The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Neoplasms
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Neoplasms
The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
Neoplasms
The immune landscape of the microenvironment of thyroid cancer is closely related to differentiation status.
Neoplasms
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative Chemotherapy.
Neoplasms
The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy.
Neoplasms
The immune microenvironment of breast ductal carcinoma in situ.
Neoplasms
The Immune Microenvironment of Chordomas: An Immunohistochemical Analysis.
Neoplasms
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade.
Neoplasms
The immune microenvironment of uterine adenosarcomas.
Neoplasms
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Neoplasms
The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Neoplasms
The immunological activity of plant toxins used in the preparation of immunotoxins--II. The immunodepressive activity of gelonin.
Neoplasms
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Neoplasms
The Immunoscore is a Superior Prognostic Tool in Stages II and III Colorectal Cancer and is Significantly Correlated with Programmed Death-Ligand 1 (PD-L1) Expression on Tumor-Infiltrating Mononuclear Cells.
Neoplasms
The impact of host immune cells on the development of neurofibromatosis type 1: The abnormal immune system provides an immune microenvironment for tumorigenesis.
Neoplasms
The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab.
Neoplasms
The Impact of Nrf2 Silencing on Nrf2-PD-L1 Axis to Overcome Oxaliplatin Resistance and Migration in Colon Cancer Cells.
Neoplasms
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
Neoplasms
The impact of PD-L1?N-linked glycosylation on cancer therapy and clinical diagnosis.
Neoplasms
The impact of programmed cell death-ligand 1 (PD-L1) and CD8 expression in grade 3 endometrial carcinomas.
Neoplasms
The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Neoplasms
The importance of histological patterns on PD-L1 staining heterogeneity: Should we use pattern-based approach for selecting tumor samples for PD-L1 testing in lung adenocarcinomas?
Neoplasms
The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma.
Neoplasms
The inhibitory effect of crystalline ricin in Ehrlich ascites tumor.
Neoplasms
The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells.
Neoplasms
The innate immune effector ISG12a promotes cancer immunity by suppressing the canonical Wnt/?-catenin signaling pathway.
Neoplasms
The InSituPlex® Staining Method for Multiplexed Immunofluorescence Cell Phenotyping and Spatial Profiling of Tumor FFPE Samples.
Neoplasms
The interaction of Ricinus communis agglutinin with normal and tumor cell surfaces.
Neoplasms
The Interplay Between the DNA Damage Response, RNA Processing and Extracellular Vesicles.
Neoplasms
The intracellular signalosome of PD-L1 in cancer cells.
Neoplasms
The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma.
Neoplasms
The intrinsic role and mechanism of tumor expressed-CD38 on lung adenocarcinoma progression.
Neoplasms
The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines.
Neoplasms
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
Neoplasms
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy.
Neoplasms
The lactate receptor GPR81 promotes breast cancer growth via a paracrine mechanism involving antigen-presenting cells in the tumor microenvironment.
Neoplasms
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.
Neoplasms
The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review.
Neoplasms
The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
Neoplasms
The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma.
Neoplasms
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Neoplasms
The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Neoplasms
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Neoplasms
The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors.
Neoplasms
The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
Neoplasms
The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.
Neoplasms
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ? 50% advanced non-small-cell lung cancer.
Neoplasms
The mechanism of ABL1 upregulating the expression of PD-L1 and the therapeutic effect of PD-L1 and STAT3 inhibitors in lung adenocarcinoma.
Neoplasms
The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
Neoplasms
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Neoplasms
The mechanisms tumor cells utilize to evade the host's immune system.
Neoplasms
The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma.
Neoplasms
The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
Neoplasms
The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy.
Neoplasms
The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.
Neoplasms
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Neoplasms
The modulation of PD-L1 induced by the oncogenic HBXIP for breast cancer growth.
Neoplasms
The Multiple Faces of Programmed Cell Death Ligand 1 Expression in Malignant and Nonmalignant Cells.
Neoplasms
The mutational profile and infiltration pattern of murine MLH1-/- tumors - concurrences, disparities and cell line establishment for functional analysis.
Neoplasms
The neoadjuvant paradigm reinvigorated: a review of pre-surgical immunotherapy in HNSCC.
Neoplasms
The neuropilin 2 isoform NRP2b uniquely supports TGF?-mediated progression in lung cancer.
Neoplasms
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Neoplasms
The next-generation BET inhibitor, PLX51107, delays melanoma growth in a CD8-mediated manner.
Neoplasms
The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1/PD-1: A future perspective for a combined gastric cancer therapy?
Neoplasms
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice.
Neoplasms
The Pattern and Clinicopathological Correlates of PD-L1 Expression in Cutaneous Squamous Cell Carcinoma.
Neoplasms
The PD-1 Interactome.
Neoplasms
The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
Neoplasms
The PD-1/PD-L1 axis may be aberrantly activated in occupational cholangiocarcinoma.
Neoplasms
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.
Neoplasms
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
Neoplasms
The PD-1:PD-L1 axis in Inflammatory Arthritis.
Neoplasms
The PD-L1 metabolic interactome intersects with choline metabolism and inflammation.
Neoplasms
The PD-L1- and IL6-mediated dampening of the IL27/STAT1 anticancer responses are prevented by ?-PD-L1 or ?-IL6 antibodies.
Neoplasms
The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity in Cancer.
Neoplasms
The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.
Neoplasms
The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients.
Neoplasms
The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis.
Neoplasms
The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay.
Neoplasms
The polymorphism rs975484 in the protein arginine methyltransferase 1 gene modulates expression of immune checkpoint genes in hepatocellular carcinoma.
Neoplasms
The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.
Neoplasms
The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer.
Neoplasms
The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Neoplasms
The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Neoplasms
The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Neoplasms
The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.
Neoplasms
The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.
Neoplasms
The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.
Neoplasms
The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis.
Neoplasms
The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population.
Neoplasms
The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
Neoplasms
The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Neoplasms
The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: a meta-analysis.
Neoplasms
The Prognostic and Therapeutic Value of PD-L1 in Glioma.
Neoplasms
The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Neoplasms
The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.
Neoplasms
The prognostic role of soluble transforming growth factor-? and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
Neoplasms
The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma.
Neoplasms
The prognostic significance of PD-L1 expression on tumor and immune cells in Merkel cell carcinoma.
Neoplasms
The prognostic significance of PD-L1 in bladder cancer.
Neoplasms
The prognostic significance of pdl1 and foxp3 expressions in tumor cells and the tumor microenvironment of ovarian epithelial tumors.
Neoplasms
The prognostic value and pathobiological significance of Glasgow microenvironment score in gastric cancer.
Neoplasms
The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3.
Neoplasms
The Prognostic Value of Immune Factors in the Tumor Microenvironment of Penile Squamous Cell Carcinoma.
Neoplasms
The Prognostic Value of Measuring PD-L1 mRNA Expression Levels in Surgically Resected Non-Small Cell Lung Cancer.
Neoplasms
The prognostic value of PD-L1 expression in upper tract urothelial carcinoma varies according to platelet count.
Neoplasms
The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma.
Neoplasms
The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette-Guérin immunotherapy: Current status.
Neoplasms
The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma.
Neoplasms
The Programmed Cell Death Ligand-1/Programmed Cell Death-1 Pathway Mediates Pregnancy-Induced Analgesia via Regulating Spinal Inflammatory Cytokines.
Neoplasms
The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma.
Neoplasms
The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.
Neoplasms
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Neoplasms
The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy.
Neoplasms
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability
Neoplasms
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.
Neoplasms
The relationship between expression of PD-L1 and HIF-1? in glioma cells under hypoxia.
Neoplasms
The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
Neoplasms
The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.
Neoplasms
The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History.
Neoplasms
The Relationship Between Tumor-Stroma Ratio, the Immune Microenvironment, and Survival in Patients With Spinal Chordoma.
Neoplasms
The relationships between PD-L1 expression, CD8+ TILs and clinico-histomorphological parameters in malignant melanomas.
Neoplasms
The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
Neoplasms
The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia.
Neoplasms
The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.
Neoplasms
The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer.
Neoplasms
The role of exosomal PD-L1 in tumor immunotherapy.
Neoplasms
The role of exosomal PD-L1 in tumor progression and immunotherapy.
Neoplasms
The role of genetic polymorphism within PD-L1 gene in cancer. Review.
Neoplasms
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Neoplasms
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes.
Neoplasms
The role of immunotherapy for management of advanced thymic epithelial tumors: a narrative review.
Neoplasms
The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.
Neoplasms
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Neoplasms
The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer.
Neoplasms
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy.
Neoplasms
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Neoplasms
The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury.
Neoplasms
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer.
Neoplasms
The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppression.
Neoplasms
The Role of PD-L1 Testing in Advanced Genitourinary Malignancies.
Neoplasms
The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
Neoplasms
The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene.
Neoplasms
The role of S100A9 in the interaction between pancreatic ductal adenocarcinoma cells and stromal cells.
Neoplasms
The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma.
Neoplasms
The role of TNF-? in chordoma progression and inflammatory pathways.
Neoplasms
The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
Neoplasms
The roles of microbial products in the development of colorectal cancer: a review.
Neoplasms
The roles of PD-1/PD-L1 and its signalling pathway in gastrointestinal tract cancers.
Neoplasms
The roles of programmed death ligand 1 in virus-associated cancers.
Neoplasms
The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3.
Neoplasms
The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma.
Neoplasms
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Neoplasms
The significance of lectin receptors in the kidney and in hypernephroma (renal adenocarcinoma).
Neoplasms
The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma.
Neoplasms
The significance of Siglec-15 expression in resectable non-small cell lung cancer.
Neoplasms
The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Neoplasms
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Neoplasms
The splicing FK506-binding protein-51 isoform plays a role in glioblastoma resistance through programmed cell death ligand-1 expression regulation.
Neoplasms
The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?
Neoplasms
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Neoplasms
The suppressive effect of co-inhibiting PD-1 and CTLA-4 expression on H22 hepatomas in mice.
Neoplasms
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
Neoplasms
The synthesis and degradation of presumptive messenger RNA in cultured mouse leukemia cells during the inhibition of protein synthesis.
Neoplasms
The Targeting Effect of Cetuximab Combined with PD-L1 Blockade against EGFR-Expressing Tumors in a Tailored CD16-CAR T-Cell Reporter System.
Neoplasms
The Triple Positivity for EBV, PD-1, and PD-L1 Identifies a Very High Risk Classical Hodgkin Lymphoma.
Neoplasms
The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
Neoplasms
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort.
Neoplasms
The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Neoplasms
The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer.
Neoplasms
The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation.
Neoplasms
The unusual stability of saporin, a candidate for the synthesis of immunotoxins.
Neoplasms
The up-regulation of PD-L1 promotes the resistant response in non-small cell lung cancer patients with neo-adjuvant chemotherapy.
Neoplasms
The Upregulation of Immune Checkpoint Ligand PD-L1 in Tumor Microenvironment.
Neoplasms
The use of miR122 and its target sequence in adeno-associated virus-mediated trichosanthin gene therapy.
Neoplasms
The use of Shiga-like toxin 1 in cancer therapy.
Neoplasms
The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma.
Neoplasms
The utility of evaluating mismatch repair proteins in endometrial carcinoma: an experience from a tertiary referral centre in North India.
Neoplasms
The value of maspin and PD-L1 expression and peritumoral lymphocytic infiltration in breast tumors.
Neoplasms
The Value of PD-L1 Expression as Predictive Biomarker in Metastatic Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
Neoplasms
The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis.
Neoplasms
The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy.
Neoplasms
The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors.
Neoplasms
The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.
Neoplasms
The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity.
Neoplasms
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.
Neoplasms
Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer.
Neoplasms
Therapeutic Approaches With Immune Checkpoint Inhibitors in Head and Neck Cancers and the Role of PD-L1 as a Biomarker.
Neoplasms
Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
Neoplasms
Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
Neoplasms
Therapeutic Development of Immune Checkpoint Inhibitors.
Neoplasms
Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting.
Neoplasms
Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice.
Neoplasms
Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.
Neoplasms
Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.
Neoplasms
Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma.
Neoplasms
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Neoplasms
Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
Neoplasms
Therapeutic landscape of metaplastic breast cancer.
Neoplasms
Therapeutic PD-1 Pathway Blockade Augments with other Modalities of Immunotherapy to Prevent Immune Decline in Ovarian Cancer.
Neoplasms
Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling.
Neoplasms
Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles.
Neoplasms
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
Neoplasms
Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive.
Neoplasms
Therapeutic targets in subependymoma.
Neoplasms
Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort.
Neoplasms
Thermosensitive liposomes for triggered release of cytotoxic proteins.
Neoplasms
Thorough survey and analysis of pulmonary lymphoepithelioma-like carcinoma in Macau and multimodality treatment for advanced disease.
Neoplasms
Thymic tumors and immune checkpoint inhibitors.
Neoplasms
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Neoplasms
TIGIT-Fc Promotes Antitumor Immunity.
Neoplasms
TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Neoplasms
TILs Immunophenotype in Breast Cancer Predicts Local Failure and Overall Survival: Analysis in a Large Radiotherapy Trial with Long-Term Follow-Up.
Neoplasms
TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer.
Neoplasms
TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer.
Neoplasms
Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
Neoplasms
Time-sequential change in immune-related gene expression after irradiation in glioblastoma: next-generation sequencing analysis.
Neoplasms
Tiragolumab Impresses in Multiple Trials.
Neoplasms
Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer.
Neoplasms
Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients.
Neoplasms
Title: Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase 2 KEYNOTE-086 Study.
Neoplasms
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Neoplasms
TLR9 expression is associated with PD-L1 expression and indicates a poor prognosis in patients with peripheral T-cell lymphomas.
Neoplasms
TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Neoplasms
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Neoplasms
Tn Antigen Expression Defines an Immune Cold Subset of Mismatch-Repair Deficient Colorectal Cancer.
Neoplasms
Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients.
Neoplasms
Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature.
Neoplasms
Tofacitinib overcomes an IFN?-induced decrease in NK cell-mediated cytotoxicity via the regulation of immune-related molecules in LC-2/ad.
Neoplasms
Topical Delivery of Nivolumab, a Therapeutic Antibody, by Fractional Laser and Pneumatic Injection.
Neoplasms
Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies.
Neoplasms
Toxic proteins application in cancer therapy.
Neoplasms
Toxicities of trichosanthin and alpha-momorcharin, abortifacient proteins from Chinese medicinal plants, on cultured tumor cell lines.
Neoplasms
TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas.
Neoplasms
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.
Neoplasms
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Neoplasms
Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients.
Neoplasms
Traditional Chinese medicine Bu-Shen-Jian-Pi-Fang attenuates glycolysis and immune escape in clear cell renal cell carcinoma: results based on network pharmacology.
Neoplasms
Trailblazing perspectives on targeting breast cancer stem cells.
Neoplasms
Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma.
Neoplasms
Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
Neoplasms
Transcriptional Profiling of Advanced Urothelial Cancer Predicts Prognosis and Response to Immunotherapy.
Neoplasms
Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways.
Neoplasms
Transcriptome Related to Avoiding Immune Destruction in Nasopharyngeal Cancer in Indonesian Patients Using Next-Generation Sequencing.
Neoplasms
Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia.
Neoplasms
Transformation of a cold to hot tumor and a durable response to immunotherapy in a patient with non-small cell lung cancer after chemoradiotherapy: a case report.
Neoplasms
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
Neoplasms
Transforming growth factor beta orchestrates PD-L1 enrichment in tumor derived exosomes and mediates CD8 T cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Neoplasms
Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.
Neoplasms
Transition of the programmed death 1 pathway from the primary colorectal cancer to its corresponding pulmonary metastasis.
Neoplasms
Transition state analogues rescue ribosomes from saporin-L1 ribosome inactivating protein.
Neoplasms
Translation control of the immune checkpoint in cancer and its therapeutic targeting.
Neoplasms
Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
Neoplasms
Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma.
Neoplasms
Translational Nanomedicine Boosts Anti-PD1 Therapy to Eradicate Orthotopic PTEN-Negative Glioblastoma.
Neoplasms
TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity.
Neoplasms
Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN? secretion.
Neoplasms
Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Neoplasms
Treatment of atypical pulmonary carcinoid with combination ipilimumab and nivolumab.
Neoplasms
Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Neoplasms
Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1.
Neoplasms
Treatment of Metastatic Extramammary Paget Disease with Combination Ipilimumab and Nivolumab: A Case Report.
Neoplasms
Treatment of metastatic placental site trophoblastic tumor with surgery, chemotherapy, immunotherapy and coil embolization of multiple pulmonary arteriovenous fistulate.
Neoplasms
Treatment of micrometastases from Lewis lung carcinoma with abrin and cyclophosphamide, given singly and in combination.
Neoplasms
Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody.
Neoplasms
Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
Neoplasms
Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Neoplasms
Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE-028 trial.
Neoplasms
Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
Neoplasms
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
Neoplasms
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.
Neoplasms
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
Neoplasms
Trichomicin Suppresses Colorectal Cancer via Comprehensive Regulation of IL-6 and TNF? in Tumor Cells, TAMs, and CAFs.
Neoplasms
Trichosanthin cooperates with Granzyme B to restrain tumor formation in tongue squamous cell carcinoma.
Neoplasms
Trichosanthin down-regulated p210Bcr-Abl and enhanced imatinib-induced growth arrest in chronic myelogenous leukemia cell line K562.
Neoplasms
Trichosanthin down-regulates Notch signaling and inhibits proliferation of the nasopharyngeal carcinoma cell line CNE2 in vitro.
Neoplasms
Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM.
Neoplasms
Trichosanthin enhances sensitivity of non-small cell lung cancer (NSCLC) TRAIL-resistance cells.
Neoplasms
Trichosanthin increases Granzyme B penetration into tumor cells by upregulation of CI-MPR on the cell surface.
Neoplasms
Trichosanthin induced apoptosis in HL-60 cells via mitochondrial and endoplasmic reticulum stress signaling pathways.
Neoplasms
Trichosanthin inhibits cervical cancer by regulating oxidative stress-induced apoptosis.
Neoplasms
Trichosanthin reduces the viability of SU?DHL?2 cells via the activation of the extrinsic and intrinsic apoptotic pathways.
Neoplasms
Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
Neoplasms
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
Neoplasms
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression.
Neoplasms
Triple Therapy Better for Advanced Melanoma.
Neoplasms
Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-?-modulated microenvironment in vitro, in vivo, and in clinical patients.
Neoplasms
Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
Neoplasms
TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
Neoplasms
Truncations of gelonin lead to a reduction in its cytotoxicity.
Neoplasms
TUBB3 Is Associated with High-Grade Histology, Poor Prognosis, p53 Expression, and Cancer Stem Cell Markers in Clear Cell Renal Cell Carcinoma.
Neoplasms
Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review.
Neoplasms
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.
Neoplasms
Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis.
Neoplasms
Tumor Burden Affects Efficacy of Combination Immunotherapy.
Neoplasms
Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer.
Neoplasms
Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Neoplasms
Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin.
Neoplasms
Tumor cell membrane-based peptide delivery system targeting the tumor microenvironment for cancer immunotherapy and diagnosis.
Neoplasms
Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer.
Neoplasms
Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy.
Neoplasms
Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness.
Neoplasms
Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells.
Neoplasms
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
Neoplasms
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.
Neoplasms
Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Neoplasms
Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.
Neoplasms
Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.
Neoplasms
Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
Neoplasms
Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.
Neoplasms
Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Neoplasms
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma.
Neoplasms
Tumor delivery of ultrasound contrast agents using shiga toxin B subunit.
Neoplasms
Tumor Endothelial Cell-Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway.
Neoplasms
Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
Neoplasms
Tumor exosomes block dendritic cells maturation to decrease the T cell immune response.
Neoplasms
Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease.
Neoplasms
Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.
Neoplasms
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Neoplasms
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells.
Neoplasms
Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer.
Neoplasms
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Neoplasms
Tumor immune microenvironment and immune checkpoint inhibitors in esophageal squamous cell carcinoma.
Neoplasms
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
Neoplasms
Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
Neoplasms
Tumor immune response and immunotherapy in gastric cancer.
Neoplasms
Tumor immunity is related to 18 F-FDG uptake in thymic epithelial tumor.
Neoplasms
Tumor Infiltrating Lymphocytes and Macrophages Improve Survival in Microsatellite Unstable Colorectal Cancer.
Neoplasms
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Neoplasms
Tumor infiltrating lymphocytes and PD-L1 expression in pre- and post-treatment breast cancers in the SWOG S0800 Phase II neoadjuvant chemotherapy trial.
Neoplasms
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.
Neoplasms
Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma.
Neoplasms
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus.
Neoplasms
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Neoplasms
Tumor localization of oncolytic adenovirus assisted by pH-degradable microgels with JQ1-mediated boosting replication and PD-L1 suppression for enhanced cancer therapy.
Neoplasms
Tumor Lymphatic Function Regulates Tumor Inflammatory and Immunosuppressive Microenvironments.
Neoplasms
Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ? 50.
Neoplasms
Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
Neoplasms
Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.
Neoplasms
Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations.
Neoplasms
Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Neoplasms
Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status.
Neoplasms
Tumor microenvironment in giant cell tumor of bone: evaluation of PD-L1 expression and SIRP? infiltration after denosumab treatment.
Neoplasms
Tumor microenvironment predicts local tumor extensiveness in PD-L1 positive nasopharyngeal cancer.
Neoplasms
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Neoplasms
Tumor microenvironment-responsive prodrug nanoplatform via co-self-assembly of photothermal agent and IDO inhibitor for enhanced tumor penetration and cancer immunotherapy.
Neoplasms
Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy.
Neoplasms
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.
Neoplasms
Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma.
Neoplasms
Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer.
Neoplasms
Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors.
Neoplasms
Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
Neoplasms
Tumor mutation burden: from comprehensive mutational screening to the clinic.
Neoplasms
Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer.
Neoplasms
Tumor mutational burden analysis of 2,000 Japanese cancer genomes using whole exome and targeted gene panel sequencing.
Neoplasms
Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China.
Neoplasms
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Neoplasms
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Neoplasms
Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB2 harmonization project comparing three NGS panels.
Neoplasms
Tumor mutational burden on cytological samples: A pilot study.
Neoplasms
Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.
Neoplasms
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients.
Neoplasms
Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma.
Neoplasms
Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.
Neoplasms
Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin.
Neoplasms
Tumor necrosis factor-? modifies the effects of Shiga toxin on glial cells.
Neoplasms
Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects.
Neoplasms
Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor.
Neoplasms
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.
Neoplasms
Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Neoplasms
Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma.
Neoplasms
Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab.
Neoplasms
Tumor PD-L1 expression is correlated with increased TILs and poor prognosis in penile squamous cell carcinoma.
Neoplasms
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
Neoplasms
Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage ("SEE") Signal to Facilitate the Elimination of "Cold, Non-Responsive" Low PD-L1-Expressing Tumors by PD-L1 Blockade.
Neoplasms
Tumor PD-L1 status and CD8
Neoplasms
Tumor perfusion enhancement by ultrasound stimulated microbubbles potentiates PD-L1 blockade of MC38 colon cancer in mice.
Neoplasms
Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.
Neoplasms
Tumor regression after combination of radiation and PD-1 antibody nivolumab treatment in a patient with metastatic mediastinal leiomyosarcoma: a case report.
Neoplasms
Tumor stromal type is associated with stromal PD-L1 expression and predicts outcomes in breast cancer.
Neoplasms
Tumor suppressive activity of miR-424-5p in breast cancer cells through targeting PD-L1 and modulating PTEN/PI3K/AKT/mTOR signaling pathway.
Neoplasms
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Neoplasms
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.
Neoplasms
Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy.
Neoplasms
Tumor-Associated CD163+ M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer.
Neoplasms
Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
Neoplasms
Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression.
Neoplasms
Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors.
Neoplasms
Tumor-associated macrophages (TAMs)-derived osteopontin (OPN) upregulates PD-L1 expression and predicts poor prognosis in non-small cell lung cancer (NSCLC).
Neoplasms
Tumor-Associated Macrophages and the Tumor Immune Microenvironment of Primary and Recurrent Epithelial Ovarian Cancer (EOC).
Neoplasms
Tumor-Associated Macrophages Enhance Tumor Hypoxia and Aerobic Glycolysis.
Neoplasms
Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-? signaling.
Neoplasms
Tumor-derived exosomes encapsulating miR-34a promote apoptosis and inhibit migration and tumor progression of colorectal cancer cells under in vitro condition.
Neoplasms
Tumor-derived exosomes in the PD-1/PD-L1 axis: Significant regulators as well as promising clinical targets.
Neoplasms
Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma.
Neoplasms
Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer.
Neoplasms
Tumor-derived TGF-? and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor.
Neoplasms
Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy.
Neoplasms
Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: A pilot study.
Neoplasms
Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.
Neoplasms
Tumor-Infiltrating and Peripheral Blood T Cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma.
Neoplasms
Tumor-infiltrating CD8+ T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells.
Neoplasms
Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Neoplasms
Tumor-infiltrating T cells and PD-L1 expression in childhood malignant extracranial germ-cell tumors.
Neoplasms
Tumor-infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
Neoplasms
Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.
Neoplasms
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
Neoplasms
Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma.
Neoplasms
Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T cell exhaustion in reducing T cell responses.
Neoplasms
Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy.
Neoplasms
Tumor-Targeted Drug Conjugates as an Emerging Novel Therapeutic Approach in Small Cell Lung Cancer (SCLC).
Neoplasms
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Neoplasms
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1.
Neoplasms
Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant.
Neoplasms
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.
Neoplasms
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
Neoplasms
Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Neoplasms
Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.
Neoplasms
Tumour necrosis factor alpha is not an essential component of verotoxin 1-induced toxicity in mice.
Neoplasms
Tumour PD-L1 Expression in Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Neoplasms
Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway.
Neoplasms
Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer.
Neoplasms
Tumour-Infiltrating Lymphocytes (TILs) and PD-L1 Expression Correlate with Lymph Node Metastasis, High-Grade Transformation and Shorter Metastasis-Free Survival in Patients with Acinic Cell Carcinoma (AciCC) of the Salivary Glands.
Neoplasms
Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer.
Neoplasms
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
Neoplasms
Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.
Neoplasms
Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.
Neoplasms
Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors.
Neoplasms
Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade.
Neoplasms
Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.
Neoplasms
Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature.
Neoplasms
Type I? phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-?B.
Neoplasms
U.S. Food and Drug Administration Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Neoplasms
Ubiquitin C-terminal hydrolase L1 promotes expression of programmed cell death-ligand 1 in non-small-cell lung cancer cells.
Neoplasms
Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells.
Neoplasms
Uncovering PD-L1 and CD8+ TILS Expression and Clinical Implication in Cervical Squamous Cell Carcinoma.
Neoplasms
Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process.
Neoplasms
Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
Neoplasms
Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry.
Neoplasms
Understanding PD-L1 Testing in Breast Cancer: A Practical Approach.
Neoplasms
Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy.
Neoplasms
Undifferentiated carcinoma of the transverse colon with rhabdoid features that developed during treatment of non-small cell lung carcinoma with pembrolizumab: a case report.
Neoplasms
Undifferentiated colonic neoplasm with SMARCA4 germline gene mutation and loss of SMARCA4 protein expression: a case report and literature review.
Neoplasms
Undifferentiated Endometrial Carcinoma, an Immunohistochemical Study Including PD-L1 Testing of a Series of Cases From a Single Cancer Center.
Neoplasms
Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells.
Neoplasms
Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells.
Neoplasms
Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies.
Neoplasms
Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer.
Neoplasms
Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1/PD-L1 blockade.
Neoplasms
Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.
Neoplasms
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells.
Neoplasms
Up-regulation of S100A4 expression by HBx protein promotes proliferation of hepatocellular carcinoma cells and its correlation with clinical survival.
Neoplasms
Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice.
Neoplasms
Update on checkpoint blockade therapy for lymphoma.
Neoplasms
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Neoplasms
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
Neoplasms
Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study.
Neoplasms
Updates in Lung Cancer Cytopathology.
Neoplasms
Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.
Neoplasms
Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target.
Neoplasms
Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia
Neoplasms
Upregulation of Oxidative stress-responsive 1(OXSR1) Predicts Poor Prognosis and Promotes Hepatocellular Carcinoma Progression.
Neoplasms
Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
Neoplasms
Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.
Neoplasms
Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions.
Neoplasms
Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma.
Neoplasms
Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Neoplasms
Uptake of adriamycin by sarcoma transplants in the rat kidney: effects of renal arterial vs systemic constant rate infusion and of combination with ricin.
Neoplasms
Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma.
Neoplasms
Urachal cancer-current concepts of a rare cancer.
Neoplasms
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Neoplasms
Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Neoplasms
Use of ribosome-inactivating proteins from sambucus for the construction of immunotoxins and conjugates for cancer therapy.
Neoplasms
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
Neoplasms
Use of the 22C3 anti-programmed death ligand 1 antibody to determine programmed death ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Neoplasms
Usefulness of 18F-FDG PET/CT in treatment-naive patients with thymic squamous cell carcinoma.
Neoplasms
Usefulness of abrin as a positive control for the human tumor clonogenic assay.
Neoplasms
Usefulness of [18F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma.
Neoplasms
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.
Neoplasms
Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD-L1 expression and enhancing T-lymphocyte tumor-killing activity.
Neoplasms
Uterine Cellular Blue Nevus Arising in Mullerian and Pelvic Dendritic Melanocytosis: Case Report of a Rare Phenomenon to Be Distinguished From Uterine Melanoma.
Neoplasms
Utility of PD-L1 immunocytochemistry using body-fluid cell blocks in patients with non-small-cell lung cancer.
Neoplasms
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.
Neoplasms
V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
Neoplasms
Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models.
Neoplasms
Validated PD-L1 immunohistochemistry assays (E1L3N & SP142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system.
Neoplasms
Validation and characterisation of prognostically significant PD-L1+ immune cells in HPV+ oropharyngeal squamous cell carcinoma.
Neoplasms
Validation of a radiomic approach to decipher NSCLC immune microenvironment in surgically resected patients.
Neoplasms
Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry.
Neoplasms
Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues.
Neoplasms
Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer.
Neoplasms
Value of 18F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers.
Neoplasms
Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage Melanoma.
Neoplasms
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.
Neoplasms
Variability of PD-L1 expression in mastocytosis.
Neoplasms
Variable indoleamine 2,3-dioxygenase expression in acral / mucosal melanoma and its possible link to immunotherapy.
Neoplasms
Variant CD44 expression is enriching for a cell population with cancer stem cell-like characteristics in human lung adenocarcinoma.
Neoplasms
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Neoplasms
Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer.
Neoplasms
Vascular endothelial growth factor A amplification in colorectal cancer is associated with reduced M1 and M2 macrophages and diminished PD-1-expressing lymphocytes.
Neoplasms
Vascular targeting of ocular neovascularization with a vascular endothelial growth factor121/gelonin chimeric protein.
Neoplasms
Vascularization of syngenic intracerebral RG2 and F98 rat transplantation tumors. A histochemical and morphometric study by use of ricinus communis agglutinin I.
Neoplasms
VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models.
Neoplasms
VEGF-A Is Associated With the Degree of TILs and PD-L1 Expression in Primary Breast Cancer.
Neoplasms
Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study.
Neoplasms
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.
Neoplasms
Vincristine upregulates PD-L1 and increases the efficacy of PD-L1 blockade therapy in diffuse large B-cell lymphoma.
Neoplasms
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses.
Neoplasms
Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma.
Neoplasms
Virotherapy with a Semliki Forest Virus-based Vector encoding IL-12 synergizes with PD-1/PD-L1 Blockade.
Neoplasms
Virtual Screening and In Vitro Evaluation of PD-1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products.
Neoplasms
Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy.
Neoplasms
Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy.
Neoplasms
VISTA Is an Immune Checkpoint Molecule for Human T Cells.
Neoplasms
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Neoplasms
Vitamin D Supplementation Regulates Postoperative Serum Levels of PD-L1 in Patients with Digestive Tract Cancer and Improves Survivals in the Highest Quintile of PD-L1: A Post Hoc Analysis of the AMATERASU Randomized Controlled Trial.
Neoplasms
Voluntary wheel running can lead to modulation of immune checkpoint molecule expression.
Neoplasms
Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets.
Neoplasms
Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
Neoplasms
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Neoplasms
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers.
Neoplasms
Western Blot as a Support Technique for Immunohistochemistry to Detect Programmed Cell Death Ligand 1 Expression.
Neoplasms
What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer?
Neoplasms
What does PD-L1 positive or negative mean?
Neoplasms
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.
Neoplasms
Whole exome sequencing of a gut-associated lymphoid tissue neoplasm points to precursor or early form of sporadic colon carcinoma.
Neoplasms
Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
Neoplasms
Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors.
Neoplasms
WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
Neoplasms
WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype.
Neoplasms
WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression.
Neoplasms
X-ray sequence and crystal structure of luffaculin 1, a novel type 1 ribosome-inactivating protein.
Neoplasms
X-ray structure of gelonin at 1.8 A resolution.
Neoplasms
XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
Neoplasms
YAP regulates PD-L1 expression in human NSCLC cells.
Neoplasms
YAP/TAZ Signaling and Resistance to Cancer Therapy.
Neoplasms
YIV-906 potentiated anti-PD1 action against hepatocellular carcinoma by enhancing adaptive and innate immunity in the tumor microenvironment.
Neoplasms
YTHDF1 and YTHDF2 are associated with better patient survival and an inflamed tumor-immune microenvironment in non-small-cell lung cancer.
Neoplasms
YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
Neoplasms
Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer.
Neoplasms
ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma.
Neoplasms
["Immunotherapy in head and neck squamous cell carcinoma"].
Neoplasms
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab.
Neoplasms
[30- and 90-day Lethality in Patients with Stage IV Lung Cancer Depending on the Primary Therapy].
Neoplasms
[A Study of Biomarkers in Immuno-Oncology - Correlation between Gut Microbiome Composition and the Effects of Immune Checkpoint Inhibitors].
Neoplasms
[Advances in Oncology 2019].
Neoplasms
[Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer].
Neoplasms
[Advances of the Correlation between Driver Gene Status and Immunotherapy ?in Non-small Cell Lung Cancer].
Neoplasms
[An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function].
Neoplasms
[Anti-PD-1 Antibody Drugs - Potential of Plasma PD-L1 Protein as a Biomarker].
Neoplasms
[Assessment of PD-L1 expression using the neural network analysis algorithm in non-small cell lung carcinoma biopsy specimens].
Neoplasms
[Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Neoplasms
[Autograft of bone marrow treated by immunotoxin T 101 for the treatment of T-cell leukemia and lymphoma. Initial clinical cases]
Neoplasms
[Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
Neoplasms
[Blockade of programmed death-ligand 1 attenuates indirect acute lung injury in mice through targeting endothelial cells but not epithelial cells].
Neoplasms
[Blocking programmed death-ligand 1 attenuates maturation inhibition of dendritic cells by co-cultured breast cancer cells].
Neoplasms
[Bone Morphogenetic Proteins from CT26 Regulate the Expression of PD-L1 in Murine Dendritic Cells and Macrophages].
Neoplasms
[CD45RO? Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Neoplasms
[Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].
Neoplasms
[Clinical Analysis of Primary Pulmonary Lymphoepithelioma-like Carcinoma in 8 Patients].
Neoplasms
[Clinical pathologic characteristics of extranodal follicular dendritic cell sarcoma].
Neoplasms
[Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis].
Neoplasms
[Consensus on the immunohistochemical tests of PD-L1 in solid tumors (2021 version)].
Neoplasms
[Consistency analysis of immunohistochemistry staining for different PD-L1 antibodies in the cancer cells of non-small cell lung cancer].
Neoplasms
[Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
Neoplasms
[Construction of a novel lentiviral vector knocking down PD-1 via microRNA and its application in CAR-T cells].
Neoplasms
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Neoplasms
[Current landscape of biomarker development for immune checkpoint inhibitors targeting PD-1/PD-L1 pathway in oncology].
Neoplasms
[Current Status and Future Direction of Cancer Genomic Medicine].
Neoplasms
[Current Status of Checkpoint Inhibitors in the Treatment of Esophageal and Gastric Tumors - Overview of Studies].
Neoplasms
[Effect of recombinant trichosanthin on proliferation of human cevical cancer Caski cells].
Neoplasms
[Effectiveness of Atezolizumab Combination Therapy for PD-L1(SP142)Positive Lung and Breast Double Cancer-A Case Report].
Neoplasms
[Effects of immunohistochemical conditions on the results of PD-L1 (22C3) staining].
Neoplasms
[Effects of interstitial chemotherapy using thermosensitive gel-coated ricin on hepatoma H22-bearing mice.]
Neoplasms
[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Neoplasms
[Enhancing Antitumor Effects Using Hyperthermia(Including Immune Checkpoint Inhibitor)].
Neoplasms
[Eukaryotic expression and functional characterization of PD-1 extracellular domain]
Neoplasms
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or ?Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Neoplasms
[Expert consensus on PD-L1 expression testing in non-small-cell lung cancer in China].
Neoplasms
[Expression and Clinical Significance of PD-1 and PD-L1 in Pulmonary Carcinoids].
Neoplasms
[Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Neoplasms
[Expression and significance of PD-L1 in laryngocarcinoma]
Neoplasms
[Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
Neoplasms
[Expression of galectin-3 and Sambucus nigra agglutinin and its clinicopathological significance in benign and malignant lesions of breast]
Neoplasms
[Expression of PD-1/PD-L1 in lung adenocarcinoma and correlation with epidermal growth factor receptor mutation status].
Neoplasms
[Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
Neoplasms
[First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
Neoplasms
[Gastrointestinal complications of the new immune checkpoint inhibitor therapies].
Neoplasms
[Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
Neoplasms
[Immune Characteristics of Small Cell Lung Cancer].
Neoplasms
[Immune-checkpoint and hemopathies].
Neoplasms
[Immuno-Oncology: A Brief Overview].
Neoplasms
[Immuno-ricin A chain specific for gastric cancer: internalization and its significance]
Neoplasms
[Immunotherapy and non-small cell lung cancer : a (r)evolution].
Neoplasms
[Immunotherapy for Bladder Cancer].
Neoplasms
[Immunotherapy for head and neck squamous cell carcinoma].
Neoplasms
[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].
Neoplasms
[Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
Neoplasms
[Impact of molecular targeting therapy on tumor immunity].
Neoplasms
[Impact of PD-L1 status on the long-term outcomes of radical treatment of patients with prostate cancer].
Neoplasms
[Impact of the use of systemic corticosteroid therapy on the effectiveness of immune checkpoint inhibitors].
Neoplasms
[Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
Neoplasms
[In vitro and in vivo antitumor activity of monoclonal anti-MM46 antibody-ricin A chain conjugate]
Neoplasms
[Inflammatory and immune biomarkers of radiation response].
Neoplasms
[Influence of genetic variation of programmed death-ligand 1 (PD-L1) on the prognosis of patients with non-small cell lung cancer who received platinum-based adjuvant chemotherapy].
Neoplasms
[Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].
Neoplasms
[Late-Onset Acute Pneumonitis Caused by Pembrolizumab Used to Treat Postoperative Recurrence of Squamous Cell Carcinoma-A Case Report].
Neoplasms
[Management of toxicities from immunotherapy].
Neoplasms
[Medical treatment of metastatic kidney cancer: targeting the tumor micro-environment].
Neoplasms
[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]
Neoplasms
[Merkel-cell carcinoma].
Neoplasms
[Microbiota, cancer and immune therapy].
Neoplasms
[MiR-140-3p Downregulation in Association with PDL-1 Overexpression in Many Cancers: A Review from the Literature Using Predictive Bioinformatics Tools].
Neoplasms
[Modern concepts of systemic treatment for adjuvant and palliative treatment of locally advanced or metastasized esophageal cancer].
Neoplasms
[Molecular and immunohistochemical diagnostics in melanoma].
Neoplasms
[Molecular docking study and experimental evaluation of potential CTLA-4 binding peptides].
Neoplasms
[Myocarditis: Uncommon but severe toxicity of immune checkpoint inhibitors].
Neoplasms
[Novel miRNAs as Potential Regulators of PD-1/PD-L1 Immune Checkpoint, and Prognostic Value of MIR9-1 and MIR124-2 Methylation in Ovarian Cancer].
Neoplasms
[PD-1/PD-L1 Signaling Pathway and Its Anti-Tumor Effect in Lymphoma -Review].
Neoplasms
[PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
Neoplasms
[PD-L1 status in breast cancer].
Neoplasms
[Possibilities of immune checkpoint inhibitor therapy for patients with metastatic non-small cell lung cancer].
Neoplasms
[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Neoplasms
[Predictive biomarkers of response to immune checkpoint inhibitors].
Neoplasms
[Predictive diagnostics of the programmed cell death receptor 1 (PD-1) - programmed cell death ligand 1 (PD-L1) inhibitory therapies].
Neoplasms
[Predictive Markers for Treating Efficacy of PD-1/PD-L1 Inhibitors in Patients with Lung Cancer: A Review of the 18th World Conference on Lung Cancer].
Neoplasms
[Predictive markers of immunotherapy of cancer, practical issues of PD-L1 testing].
Neoplasms
[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
Neoplasms
[Preparation and anti-tumor activity of monoclonal antibody against ascitic mammary tumor MM46 cells]
Neoplasms
[Present and Future of Efficacy Biomarkers in Immune Checkpoint Inhibitors ?of Small-cell Lung Cancer].
Neoplasms
[Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
Neoplasms
[Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].
Neoplasms
[Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
Neoplasms
[Progression of immunotherapy in gastric cancer].
Neoplasms
[Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data].
Neoplasms
[Pulmonary Adenocarcinoma Responding to Fourth-Line S-1 Monotherapy-A Case Report].
Neoplasms
[Pulmonary mucosa-associated lymphoid tissue lymphoma concurrent with lung squamous cell carcinoma: a case report and literature review].
Neoplasms
[Purification and anti-cancer activity of ricin]
Neoplasms
[Qiyusanlong decoction inhibits the level of PD-1/PD-L1 in mice bearing Lewis lung carcinoma].
Neoplasms
[Radiotherapy and PD-L1 Expression].
Neoplasms
[Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Neoplasms
[Regulation of PD-L1 by MicroRNA in Mismatch Repair Deficient-Colorectal Cancer].
Neoplasms
[Regulatory Mechanisms of PD-L1 Expression and Its Role in Immune Evasion].
Neoplasms
[Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
Neoplasms
[Renal Cancer Tissue after Nivolumab/Ipilimumab Combination Therapy for Metastatic Renal Cell Carcinoma].
Neoplasms
[Research Progress on the Mechanism and Clinical Data of Cereblon ?in Reversing the Resistance of Lung Cancer to PD-1 Antibody by T cells].
Neoplasms
[Ribosome Inactivation and the Integrity of the Intestinal Epithelial Barrier].
Neoplasms
[Self defense instead of offense - Immunotherapy in lung cancer].
Neoplasms
[Stimulatory and inhibitory signaling pathways of the T cell-APC interaction and the effect of TLR agonists on APCs].
Neoplasms
[Study Progression on Non-small Cell Lung Cancer with EGFR Mutation ?Treated by Immune Checkpoint Inhibitors].
Neoplasms
[Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].
Neoplasms
[Systemic Treatment of Malignant Pleural Mesothelioma].
Neoplasms
[Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].
Neoplasms
[The effect of the plant toxin ricin on the cellular structure of human hypophyseal tumors]
Neoplasms
[The Expression and Biological Significance of PD-L1 on Lung Cancer Cell Lines.]
Neoplasms
[The Immune Checkpoints Inhibitors for Head and Neck Cancer].
Neoplasms
[The Mechanism of HLA Class I and PD-L1 Expression of Cancer Cells in Tumor Microenvironment].
Neoplasms
[The Mechanism of PD-L1 Expression and the Development of Biomarker of Anti-PD-1/Anti-PD-L1 Monoclonal Antibody from the Viewpoint of IFN-?].
Neoplasms
[The quantity and distribution of specific glycoproteins in gastric carcinoma]
Neoplasms
[The Regulation of PD-L1 Expression in the Tumor Microenvironment Associated with Epithelial-Mesenchymal Transformation].
Neoplasms
[The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response].
Neoplasms
[Thoracic oncology and tumor mutational burden: Towards new challenges for the pathologist?]
Neoplasms
[Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma].
Neoplasms
[Treatment of malignant trophoblastic neoplasia with trichosanthin]
Neoplasms
[Treatment of non-small cell lung cancer].
Neoplasms
[Trichosanthin has potent inhibiting activity of protein synthesis in a cell-free system and its antibody-conjugate exhibits potentiated cytotoxicity to tumor cells in vitro]
Neoplasms
[Urachal cancer - current concepts of a rare cancer (German version)].
Neoplasms, Germ Cell and Embryonal
Clinical response of a patient to anti-PD-1 immunotherapy and the immune landscape of testicular germ cell tumors.
Neoplasms, Germ Cell and Embryonal
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Neoplasms, Germ Cell and Embryonal
Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Neoplasms, Germ Cell and Embryonal
Frequent PD-L1 expression in testicular germ cell tumors.
Neoplasms, Germ Cell and Embryonal
Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors.
Neoplasms, Germ Cell and Embryonal
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Neoplasms, Glandular and Epithelial
Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.
Neoplasms, Glandular and Epithelial
Pathology of thymoma-where are we today?
Neoplasms, Glandular and Epithelial
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.
Neoplasms, Squamous Cell
CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Neoplasms, Squamous Cell
CD8+/FOXP3+ Ratio and PD-L1 Expression Associated With Survival in pT3N0M0 Stage Esophageal Squamous Cell Cancer.
Neoplasms, Squamous Cell
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.
Neoplasms, Squamous Cell
Clinical significance of PD-L1 (CD274) enhanced expression in cervical squamous cell carcinoma.
Neoplasms, Squamous Cell
Clinical significance of PD-L1 expression in patients with surgically resected non-small cell lung cancer.
Neoplasms, Squamous Cell
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy.
Neoplasms, Squamous Cell
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Neoplasms, Squamous Cell
Genomic and immunologic correlates of LAG-3 expression in cancer.
Neoplasms, Squamous Cell
PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.
Neoplasms, Squamous Cell
PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Neoplasms, Squamous Cell
Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.
Neoplastic Cells, Circulating
A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry.
Neoplastic Cells, Circulating
Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Cancer Patients Receiving PD-1/PD-L1 Blockade Therapies.
Neoplastic Cells, Circulating
Biomarkers in melanoma: where are we now?
Neoplastic Cells, Circulating
Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
Neoplastic Cells, Circulating
Circulating tumor cells counts are associated with CD8+ T cell levels in programmed death-ligand 1-negative non-small cell lung cancer patients after radiotherapy: A retrospective study.
Neoplastic Cells, Circulating
Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
Neoplastic Cells, Circulating
Circulating tumour cell PD-L1 test for head and neck cancers.
Neoplastic Cells, Circulating
Clinical Relevance of Immune Checkpoints on Circulating Tumor Cells in Breast Cancer.
Neoplastic Cells, Circulating
Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.
Neoplastic Cells, Circulating
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Neoplastic Cells, Circulating
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors.
Neoplastic Cells, Circulating
Development and Analytical Validation of a Reverse Transcription Droplet Digital PCR (RT-ddPCR) Assay for PD-L1 Transcripts in Circulating Tumor Cells.
Neoplastic Cells, Circulating
Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells.
Neoplastic Cells, Circulating
Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy.
Neoplastic Cells, Circulating
Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
Neoplastic Cells, Circulating
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
Neoplastic Cells, Circulating
Expression and analysis of PD-L1 in peripheral blood circulating tumor cells of lung cancer.
Neoplastic Cells, Circulating
Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients.
Neoplastic Cells, Circulating
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
Neoplastic Cells, Circulating
Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors.
Neoplastic Cells, Circulating
Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer.
Neoplastic Cells, Circulating
Immunomagnetic isolation of circulating melanoma cells and detection of PD-L1 status.
Neoplastic Cells, Circulating
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.
Neoplastic Cells, Circulating
Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?
Neoplastic Cells, Circulating
Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Neoplastic Cells, Circulating
Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
Neoplastic Cells, Circulating
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.
Neoplastic Cells, Circulating
Non-invasive assessment of tumor PD-L1 status with circulating tumor cells.
Neoplastic Cells, Circulating
Noninvasive detection of PD-L1 on circulating tumor cells in patient blood samples.
Neoplastic Cells, Circulating
PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system
Neoplastic Cells, Circulating
PD-L1 expressing circulating tumour cells in head and neck cancers.
Neoplastic Cells, Circulating
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Neoplastic Cells, Circulating
PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer.
Neoplastic Cells, Circulating
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Neoplastic Cells, Circulating
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Neoplastic Cells, Circulating
PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer.
Neoplastic Cells, Circulating
PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
Neoplastic Cells, Circulating
Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
Neoplastic Cells, Circulating
Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
Neoplastic Cells, Circulating
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Neoplastic Cells, Circulating
Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma.
Neoplastic Cells, Circulating
Programmed cell death ligands expression drives immune tolerogenesis across the diverse subtypes of neuroendocrine tumours.
Neoplastic Cells, Circulating
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
Neoplastic Cells, Circulating
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
Neoplastic Cells, Circulating
Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy.
Neoplastic Cells, Circulating
Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Neoplastic Cells, Circulating
Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC).
Neoplastic Cells, Circulating
Trailblazing perspectives on targeting breast cancer stem cells.
Neoplastic Processes
[PD-L1 : a natural immunosuppressor related to carcinogenesis. A pathologist's point of view].
Nephritis
Anti-programmed cell death 1 antibody reduces CD4+PD-1+ T cells and relieves the lupus-like nephritis of NZB/W F1 mice.
Nephritis
Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
Nephritis
The role of programed death-ligand 1 in renal diseases.
Nephritis
Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Nephritis
[Effects of pokeweed antiviral protein on nephrotoxic serum nephritis accelerated by rabbit IgG in mice]
Nephritis, Interstitial
Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1.
Nervous System Diseases
An animal model for the study of neurotoxicity of bacterial products and application of the model to demonstrate that Shiga toxin and lipopolysaccharide cooperate in inducing neurologic disorders.
Nervous System Diseases
Expression of Shiga toxin 2e glycosphingolipid receptors of primary porcine brain endothelial cells and toxin-mediated breakdown of the blood-brain barrier.
Nervous System Diseases
Promiscuous Shiga toxin 2e and its intimate relationship to Forssman.
Neural Tube Defects
Inhibitory effect of ricin on the development of preimplantation mouse embryos.
Neuralgia
Facilitation of neuropathic pain by the NPY Y1 receptor-expressing subpopulation of excitatory interneurons in the dorsal horn.
Neuralgia
Inhibition of TRPV1 by SHP-1 in nociceptive primary sensory neurons is critical in PD-L1 analgesia.
Neuralgia
PD-L1 Improves Motor Function and Alleviates Neuropathic Pain in Male Mice After Spinal Cord Injury by Inhibiting MAPK Pathway.
Neurilemmoma
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Neurilemmoma
Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.
Neurilemmoma
PD-1/PD-L1 negative schwannoma mimicking obstructive bronchial malignancy: A case report.
Neurilemmoma
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
Neuroblastoma
Analysis of lectin-specific cell surface glycoprotein on neuroblastoma cells.
Neuroblastoma
Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
Neuroblastoma
Apoptosis and necroptosis induced by stenodactylin in neuroblastoma cells can be completely prevented through caspase inhibition plus catalase or necrostatin-1.
Neuroblastoma
Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Neuroblastoma
Binding of peanut agglutinin to neuroblastomas and ganglioneuromas: a marker for differentiation of neuroblasts into ganglion cells.
Neuroblastoma
Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells.
Neuroblastoma
Differences in the redistribution of concanavalin A and wheat germ agglutinin binding sites on mouse neuroblastoma cells.
Neuroblastoma
DNA polymerase-associated lectin (DPAL) and its binding to the galactose-containing glycoconjugate of the replication complex.
Neuroblastoma
Effects of programmed death ligand 1 on the prognosis of neuroblastoma: A protocol for systematic review and meta analysis.
Neuroblastoma
Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma.
Neuroblastoma
Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
Neuroblastoma
Inhibition of human neuroblastoma DNA polymerase activities by plant lectins and toxins.
Neuroblastoma
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Neuroblastoma
Metabolic discrimination of select list agents by monitoring cellular responses in a multianalyte microphysiometer.
Neuroblastoma
PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Neuroblastoma
PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance.
Neuroblastoma
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma.
Neuroblastoma
PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective.
Neuroblastoma
Potential role of the PD-L1 expression and tumor-infiltrating lymphocytes on neuroblastoma.
Neuroblastoma
Prediction of PD-L1 Expression in Neuroblastoma via Computational Modeling.
Neuroblastoma
Presidential address. The role of neuronal golgi apparatus in a centripetal membrane vesicular traffic.
Neuroblastoma
The effect of shiga toxin and sonicates of Shigella isolates from children with neurologic manifestation on neuroblastoma cell lines.
Neuroblastoma
The Herpes Simplex Virus 1 Latency-Associated Transcript Promotes Functional Exhaustion of Virus-Specific CD8+ T Cells in Latently Infected Trigeminal Ganglia: a Novel Immune Evasion Mechanism.
Neuroblastoma
The nuclear pore complex protein p62 is one of several sialic acid-containing proteins of the nuclear envelope.
Neuroblastoma
The use of lectins and cholera toxin for the detection of surface carbohydrates of cultured neurons and neuroblastoma.
Neuroblastoma
TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells.
Neuroblastoma
[Expression and significance of programmed cell death ligand-1 in neuroblastoma tissues].
Neurodegenerative Diseases
Enhanced Expression of PD-L1 on Microglia After Surgical Brain Injury Exerts Self-Protection from Inflammation and Promotes Neurological Repair.
Neuroectodermal Tumors, Primitive
Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Neuroectodermal Tumors, Primitive
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors.
Neuroectodermal Tumors, Primitive
Programmed cell death ligands expression drives immune tolerogenesis across the diverse subtypes of neuroendocrine tumours.
Neuroendocrine Tumors
Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.
Neuroendocrine Tumors
Association Between PD-L1 Expression and Metabolic Activity on
Neuroendocrine Tumors
Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
Neuroendocrine Tumors
Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors.
Neuroendocrine Tumors
Molecular Characterization of Appendiceal Goblet Cell Carcinoid.
Neuroendocrine Tumors
Pancreatic Neuroendocrine Tumor With Humoral Hypercalcemia and High Tumor PD-L1 Score.
Neuroendocrine Tumors
PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours.
Neuroendocrine Tumors
PD-L1 expression in neuroendocrine tumors of the lung.
Neuroendocrine Tumors
PD-L1 Is Preferentially Expressed in PIT-1 Positive Pituitary Neuroendocrine Tumours.
Neuroendocrine Tumors
Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Neuroendocrine Tumors
Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors.
Neuroendocrine Tumors
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours.
Neuroendocrine Tumors
Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
Neuroendocrine Tumors
Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
Neuroendocrine Tumors
The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
Neurofibroma
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
Neurofibroma, Plexiform
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
Neurofibromatoses
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.
Neurofibrosarcoma
Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.
Neurofibrosarcoma
Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
Neurofibrosarcoma
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Neurofibrosarcoma
Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic target.
Neuroinflammatory Diseases
Brain-Resident T Cells Following Viral Infection.
Neuroinflammatory Diseases
Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1.
Neuroinflammatory Diseases
Neuroprotective effects of the anti-inflammatory compound triflusal on ischemia-like neurodegeneration in mouse hippocampal slice cultures occur independent of microglia.
Neuroinflammatory Diseases
Nitrosative damage during retrovirus infection-induced neuropathic pain.
Neuroinflammatory Diseases
The PD-1: PD-L1 pathway promotes development of brain-resident memory T cells following acute viral encephalitis.
Neurologic Manifestations
A translational murine model of sub-lethal intoxication with Shiga toxin 2 reveals novel ultrastructural findings in the brain striatum.
Neurologic Manifestations
Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7.
Neurologic Manifestations
The association of Shiga toxin and other cytotoxins with the neurologic manifestations of shigellosis.
Neurologic Manifestations
The effect of shiga toxin and sonicates of Shigella isolates from children with neurologic manifestation on neuroblastoma cell lines.
Neurologic Manifestations
Upregulation of Shiga Toxin Receptor CD77/Gb3 and Interleukin-1? Expression in the Brain of EHEC Patients with Hemolytic Uremic Syndrome and Neurologic Symptoms.
Neuroma
Attempts to prevent equine post neurectomy neuroma formation through retrograde transport of two neurotoxins, doxorubicin and ricin.
Neuroma
Effects of retrograde axonal transport of Ricinus communis agglutinin I on neuroma formation.
Neuroma
Experimental treatment of neuromas in the rat by retrograde axoplasmic transport of ricin with selective destruction of ganglion cells.
Neuroma
Reduction of experimental neuroma formation with ricin.
Neuromuscular Diseases
Differential mechanisms are required for phrenic long-term facilitation over the course of motor neuron loss following CTB-SAP intrapleural injections.
Neuromuscular Diseases
Divergent receptor utilization is necessary for phrenic long-term facilitation over the course of motor neuron loss following CTB-SAP intrapleural injections.
Neutropenia
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Nevus
Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Nevus, Pigmented
Correlation of MET and PD-L1 Expression in Malignant Melanoma.
Noma
Substantial increase of the inhibitory activity of Mirabilis antiviral protein by an elimination of the disulfide bond with genetic engineering.
Non-alcoholic Fatty Liver Disease
Lymphocyte profile and immune checkpoint expression in drug-induced liver injury: an immunophenotyping study.
non-specific serine/threonine protein kinase deficiency
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Obesity
Adipocytes promote tumor progression and induce PD-L1 expression via TNF-?/IL-6 signaling.
Obesity
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Obesity
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ? 50%: a multicenter study with external validation.
Obesity
Diet-induced obesity precipitates kidney dysfunction and alters inflammatory mediators in mice treated with Shiga Toxin 2.
Obesity
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.
Obesity
Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor immune cell composition.
Oligodendroglioma
Lectins: reliable differentiation markers in human oligodendrogliomas.
Ophthalmia, Sympathetic
PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation.
Oropharyngeal Neoplasms
Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.
Oropharyngeal Neoplasms
PD-L1 expression in anogenital and oropharyngeal squamous cell carcinomas associated with different clinicopathological features, HPV status and prognosis: a meta-analysis.
Oropharyngeal Neoplasms
Prognostic impact of PD-L1 in oropharyngeal cancer after primary curative radiotherapy and relation to HPV and tobacco smoking.
Oropharyngeal Neoplasms
Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.
Osteoarthritis
Blocking of checkpoint receptor PD-L1 aggravates osteoarthritis in macrophage-dependent manner in the mice model.
Osteoarthritis
Imbalanced cellular metabolism compromises cartilage homeostasis and joint function in a mouse model of mucolipidosis type III gamma.
Osteoarthritis
Mucolipidosis type III, a series of adult patients.
Osteochondroma
PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Osteosarcoma
A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors.
Osteosarcoma
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells.
Osteosarcoma
Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Osteosarcoma
Autophagy inhibitor enhance ZnPc/BSA nanoparticle induced photodynamic therapy by suppressing PD-L1 expression in osteosarcoma immunotherapy.
Osteosarcoma
Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate.
Osteosarcoma
Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations-A Report of a Stunning Success in a 37-Year-Old Patient.
Osteosarcoma
Characterization of PD-1/PD-L1 Immune Checkpoint Expression in Osteosarcoma.
Osteosarcoma
Checkpoint Blockade in Combination With Doxorubicin Augments Tumor Cell Apoptosis in Osteosarcoma.
Osteosarcoma
Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers.
Osteosarcoma
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions.
Osteosarcoma
Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas.
Osteosarcoma
Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Osteosarcoma
Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers.
Osteosarcoma
FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity.
Osteosarcoma
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Osteosarcoma
High linear energy transfer carbon-ion irradiation upregulates PD-L1 expression more significantly than X-rays in human osteosarcoma U2OS cells.
Osteosarcoma
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma.
Osteosarcoma
Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
Osteosarcoma
In vitro and in vivo cytotoxicity of an anti-osteosarcoma immunotoxin containing pokeweed antiviral protein.
Osteosarcoma
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy.
Osteosarcoma
LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a.
Osteosarcoma
LRP8 activates STAT3 to induce PD-L1 expression in osteosarcoma.
Osteosarcoma
MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling.
Osteosarcoma
MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.
Osteosarcoma
NGS-analysis to the rescue: dual checkpoint inhibition in metastatic osteosarcoma - a case report and review of the literature.
Osteosarcoma
Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Osteosarcoma
PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Osteosarcoma
PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate?
Osteosarcoma
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
Osteosarcoma
PD-L1 and IDO1 expression and tumor-infiltrating lymphocytes in osteosarcoma patients: comparative study of primary and metastatic lesions.
Osteosarcoma
Profiling targetable immune checkpoints in osteosarcoma.
Osteosarcoma
Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis.
Osteosarcoma
Pseudogene MSTO2P enhances hypoxia-induced osteosarcoma malignancy by upregulating PD-L1.
Osteosarcoma
Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.
Osteosarcoma
Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines.
Osteosarcoma
Sunitinib inhibits PD-L1 expression in osteosarcoma by targeting STAT3 and remodels the immune system in tumor-bearing mice.
Osteosarcoma
Targeted and intracellular delivery of protein therapeutics by a boronated polymer for the treatment of bone tumors.
Osteosarcoma
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.
Osteosarcoma
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1.
Osteosarcoma
Water extract of sporoderm-broken spores of Ganoderma lucidum enhanced pd-l1 antibody efficiency through downregulation and relieved complications of pd-l1 monoclonal antibody.
Ovarian Cysts
The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
Ovarian Diseases
The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
Ovarian Hyperstimulation Syndrome
Capillary leak syndrome: etiologies, pathophysiology, and management.
Ovarian Neoplasms
Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8+ T cell function and survival through elevation of PD-L1.
Ovarian Neoplasms
Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer.
Ovarian Neoplasms
Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
Ovarian Neoplasms
Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.
Ovarian Neoplasms
An Immunophenotyping of Ovarian Cancer With Clinical and Immunological Significance.
Ovarian Neoplasms
Analysis of IFN?-Induced Migration of Ovarian Cancer Cells.
Ovarian Neoplasms
Analysis of PD-L1 Transcriptional Regulation in Ovarian Cancer Cells by Chromatin Immunoprecipitation.
Ovarian Neoplasms
Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.
Ovarian Neoplasms
Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
Ovarian Neoplasms
Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer.
Ovarian Neoplasms
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.
Ovarian Neoplasms
ARID1A mutation/ARID1A loss is associated with a high immunogenic profile in clear cell ovarian cancer.
Ovarian Neoplasms
Association between PD-L1 expression and 18F-FDG uptake in ovarian cancer.
Ovarian Neoplasms
Associations between DNA Damage and PD-L1 Expression in Ovarian Cancer, a Potential Biomarker for Clinical Response.
Ovarian Neoplasms
Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Ovarian Neoplasms
Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.
Ovarian Neoplasms
BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.
Ovarian Neoplasms
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Ovarian Neoplasms
BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.
Ovarian Neoplasms
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Ovarian Neoplasms
Characterization of immunotoxins active against ovarian cancer cell lines.
Ovarian Neoplasms
Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-?B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer.
Ovarian Neoplasms
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Ovarian Neoplasms
Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
Ovarian Neoplasms
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Ovarian Neoplasms
Comprehensive genomic analysis of microenvironment phenotypes in ovarian cancer.
Ovarian Neoplasms
Correction to: Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
Ovarian Neoplasms
Correction to: Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils.
Ovarian Neoplasms
Correction: Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
Ovarian Neoplasms
Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer.
Ovarian Neoplasms
DNA damage response and PD-1/PD-L1 pathway in ovarian cancer.
Ovarian Neoplasms
Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature.
Ovarian Neoplasms
Efficient antiproliferative and antiangiogenic effects on human ovarian cancer growth by gene transfer of attenuated mutants of Shiga-like toxin I.
Ovarian Neoplasms
Efficient Inhibition of Ovarian Cancer by Gelonin Toxin Gene Delivered by Biodegradable Cationic Heparin-polyethyleneimine Nanogels.
Ovarian Neoplasms
Endocytosis of immunotoxin-791T/36-RTA by tumor cells in relation to its cytotoxic action.
Ovarian Neoplasms
Endostar blocks the metastasis, invasion and angiogenesis of ovarian cancer cells.
Ovarian Neoplasms
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Ovarian Neoplasms
Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer.
Ovarian Neoplasms
Expression of Concern: PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.
Ovarian Neoplasms
Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
Ovarian Neoplasms
Expression of STAT1 is positively correlated with PD-L1 in human ovarian cancer.
Ovarian Neoplasms
Extracellular acidity in tumor tissue upregulates programmed cell death protein 1 expression on tumor cells via proton-sensing G protein-coupled receptors.
Ovarian Neoplasms
Flow Cytometry Analysis of Surface PD-L1 Expression Induced by IFN? and Romidepsin in Ovarian Cancer Cells.
Ovarian Neoplasms
HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression.
Ovarian Neoplasms
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Ovarian Neoplasms
Identifying markers of immune response in ovarian cancer: does PD-L1 expression meet the mark?
Ovarian Neoplasms
IFN-? from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
Ovarian Neoplasms
Immune checkpoint blockade in ovarian cancer.
Ovarian Neoplasms
Immunoblotting Analysis of Intracellular PD-L1 Levels in Interferon-?-Treated Ovarian Cancer Cells Stably Transfected with Bcl3 shRNA.
Ovarian Neoplasms
Impact of PD-L1 and T-cell inflamed gene expression profile on survival in advanced ovarian cancer.
Ovarian Neoplasms
Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200.
Ovarian Neoplasms
Infiltration of T cells promotes the metastasis of ovarian cancer cells via the modulation of metastasis-related genes and PD-L1 expression.
Ovarian Neoplasms
Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1.
Ovarian Neoplasms
Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils.
Ovarian Neoplasms
Long non-coding RNA SNHG12 promotes immune escape of ovarian cancer cells through their crosstalk with M2 macrophages.
Ovarian Neoplasms
Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Ovarian Neoplasms
Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells.
Ovarian Neoplasms
MiR-200c-3p Contrasts PD-L1 Induction by Combinatorial Therapies and Slows Proliferation of Epithelial Ovarian Cancer through Downregulation of ?-Catenin and c-Myc.
Ovarian Neoplasms
MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells.
Ovarian Neoplasms
Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
Ovarian Neoplasms
Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
Ovarian Neoplasms
Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.
Ovarian Neoplasms
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3.
Ovarian Neoplasms
PD-1 and PD-L1 expression on the prognosis of ovarian cancer.
Ovarian Neoplasms
PD-L1 blockade enhances anti-tumor efficacy of NK cells.
Ovarian Neoplasms
PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics.
Ovarian Neoplasms
PD-L1 disruption by CRISPR/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
Ovarian Neoplasms
PD-L1 expression in human cancers and its association with clinical outcomes.
Ovarian Neoplasms
PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Ovarian Neoplasms
PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases.
Ovarian Neoplasms
PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction.
Ovarian Neoplasms
PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.
Ovarian Neoplasms
Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: a systematic review, meta-analysis and bioinformatics study.
Ovarian Neoplasms
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Ovarian Neoplasms
Prognostic significance of PD-1 and PD-L1 positive tumor-infiltrating immune cells in ovarian carcinoma.
Ovarian Neoplasms
Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis.
Ovarian Neoplasms
Prognostic value of tumor PD-L1 expression combined with CD8(+) tumor infiltrating lymphocytes in high grade serous ovarian cancer.
Ovarian Neoplasms
Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Ovarian Neoplasms
Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
Ovarian Neoplasms
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.
Ovarian Neoplasms
Reactive versus Constitutive: Reconcile the Controversial Results about the Prognostic Value of PD-L1 Expression in cancer.
Ovarian Neoplasms
SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance.
Ovarian Neoplasms
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Ovarian Neoplasms
Suppression of metastatic murine ovarian cancer cells by transduced embryonic progenitor cells.
Ovarian Neoplasms
Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
Ovarian Neoplasms
Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer.
Ovarian Neoplasms
Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES).
Ovarian Neoplasms
Targeted apoptosis in ovarian cancer cells through mitochondrial dysfunction in response to Sambucus nigra agglutinin.
Ovarian Neoplasms
Targeting the programmed cell death-1 pathway in breast and ovarian cancer.
Ovarian Neoplasms
The BRCA1 Methylation and PD-L1 Expression in Sporadic Ovarian Cancer.
Ovarian Neoplasms
The increase of circulating PD-L1-expressing CD68(+) macrophage in ovarian cancer.
Ovarian Neoplasms
The possible regulatory effect of the PD-1/PD-L1 signaling pathway on Tregs in ovarian cancer.
Ovarian Neoplasms
The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.
Ovarian Neoplasms
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Ovarian Neoplasms
The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Ovarian Neoplasms
Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells.
Ovarian Neoplasms
Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer.
Ovarian Neoplasms
Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma.
Ovarian Neoplasms
Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion.
Ovarian Neoplasms
Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma.
Ovarian Neoplasms
Unusual Ovarian Cancer Relapse Managed by Nivolumab in a Long-term Surviving Patient with PD-L1 Mutation.
Ovarian Neoplasms
VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.
Ovarian Neoplasms
[pemetrexed + sildenafil], via autophagy-dependent HDAC down-regulation, enhances the immunotherapy response of NSCLC cells.
Overweight
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Paget Disease, Extramammary
Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease.
Paget Disease, Extramammary
Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.
Paget Disease, Extramammary
Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A.
Paget Disease, Extramammary
Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.
Paget Disease, Extramammary
PD-L1 Expression in Extramammary Paget Disease: A Case Series.
Paget's Disease, Mammary
Expression of PD-1 and PD-L1 in Extramammary Paget Disease: Implications for Immune-Targeted Therapy.
Pancreatic Diseases
Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.
Pancreatic Neoplasms
A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway.
Pancreatic Neoplasms
Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts.
Pancreatic Neoplasms
ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer.
Pancreatic Neoplasms
Augmentation of antiproliferative and antitumor effect on human cancer cells in combined use of electroporation with a plant toxin, saporin.
Pancreatic Neoplasms
c-Met and PD-L1 on Circulating Exosomes as Diagnostic and Prognostic Markers for Pancreatic Cancer.
Pancreatic Neoplasms
Characterization of B cell-mediated PD-1/PD-L1 interaction in pancreatic cancer patients.
Pancreatic Neoplasms
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
Pancreatic Neoplasms
Co-inhibition of the TGF-? pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy.
Pancreatic Neoplasms
Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle.
Pancreatic Neoplasms
Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Pancreatic Neoplasms
Concurrent Injection of Unlabeled Antibodies Allows Positron Emission Tomography Imaging of Programmed Cell Death Ligand 1 Expression in an Orthotopic Pancreatic Tumor Model.
Pancreatic Neoplasms
Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progress.
Pancreatic Neoplasms
Engagement of T Cell-Expressed PD-L1 Weakens Antitumor Immunity.
Pancreatic Neoplasms
Epigenetic regulation of PD-L1 expression and pancreatic cancer response to checkpoint immunotherapy.
Pancreatic Neoplasms
Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.
Pancreatic Neoplasms
Far upstream element-binding protein 1 is up-regulated in pancreatic cancer and modulates immune response by increasing programmed death ligand 1.
Pancreatic Neoplasms
Gastric adenocarcinomas express the glycosphingolipid Gb3/CD77: Targeting of gastric cancer cells with Shiga toxin B-subunit.
Pancreatic Neoplasms
Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer.
Pancreatic Neoplasms
HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer.
Pancreatic Neoplasms
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Pancreatic Neoplasms
Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells.
Pancreatic Neoplasms
IFN-? Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
Pancreatic Neoplasms
IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models.
Pancreatic Neoplasms
IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Pancreatic Neoplasms
Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status.
Pancreatic Neoplasms
Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.
Pancreatic Neoplasms
Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
Pancreatic Neoplasms
Internal enhancement of DNA damage by a novel bispecific antibody-drug conjugate-like therapeutics via blockage of mTOR and PD-L1 signal pathways in pancreatic cancer.
Pancreatic Neoplasms
Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice.
Pancreatic Neoplasms
LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis.
Pancreatic Neoplasms
Low CD8? T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44?/CD133? Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer.
Pancreatic Neoplasms
MicroRNA-519 inhibits hypoxia-induced tumorigenesis of pancreatic cancer by regulating immune checkpoint PD-L1.
Pancreatic Neoplasms
miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer.
Pancreatic Neoplasms
Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Pancreatic Neoplasms
Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells.
Pancreatic Neoplasms
NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1.
Pancreatic Neoplasms
Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
Pancreatic Neoplasms
Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Pancreatic Neoplasms
PD-L1 correlated gene expression profiles and tumor infiltrating lymphocytes in pancreatic cancer.
Pancreatic Neoplasms
PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-? leads to poor pancreatic cancer prognosis.
Pancreatic Neoplasms
PD-L1 expression in human cancers and its association with clinical outcomes.
Pancreatic Neoplasms
PD-L1 Expression in Pancreatic Cancer.
Pancreatic Neoplasms
PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer.
Pancreatic Neoplasms
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Pancreatic Neoplasms
PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells.
Pancreatic Neoplasms
PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of ?-catenin and PD-L1.
Pancreatic Neoplasms
Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.
Pancreatic Neoplasms
Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer.
Pancreatic Neoplasms
Prognostic value of PD-L1 expression in patients with pancreatic cancer: A PRISMA-compliant meta-analysis.
Pancreatic Neoplasms
Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis.
Pancreatic Neoplasms
Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer.
Pancreatic Neoplasms
Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL.
Pancreatic Neoplasms
RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.
Pancreatic Neoplasms
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Pancreatic Neoplasms
Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human Pancreatic Cancer.
Pancreatic Neoplasms
Shikonin-mediated PD-L1 degradation suppresses immune evasion in pancreatic cancer by inhibiting NF-?B/STAT3 and NF-?B/CSN5 signaling pathways.
Pancreatic Neoplasms
Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer.
Pancreatic Neoplasms
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Pancreatic Neoplasms
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
Pancreatic Neoplasms
The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
Pancreatic Neoplasms
The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation.
Pancreatic Neoplasms
The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines.
Pancreatic Neoplasms
The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion.
Pancreatic Neoplasms
The Potential of CAR T Cell Therapy in Pancreatic Cancer.
Pancreatic Neoplasms
The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer.
Pancreatic Neoplasms
The ribosome inhibiting protein riproximin shows antineoplastic activity in experimental pancreatic cancer liver metastasis.
Pancreatic Neoplasms
Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
Pancreatic Neoplasms
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
Pancreatic Neoplasms
Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer.
Pancreatic Neoplasms
WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
Pancreatitis
Autoimmune Pancreatitis Type 2: Diagnostic Utility of PD-L1 Immunohistochemistry.
Pancreatitis
Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation.
Pancreatitis, Chronic
Autoimmune Pancreatitis Type 2: Diagnostic Utility of PD-L1 Immunohistochemistry.
Pancytopenia
A Staphylococcus aureus Coinfection on a COVID-19 Pneumonia in a Breast Cancer Patient.
Papilloma
Analysis of glycoproteins from nasal polyps and papillomas by affinity chromatography.
Papilloma
Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma.
Papilloma
Colloid cyst of the third ventricle. A comparative immunohistochemical study of neuraxis cysts and choroid plexus epithelium.
Papilloma
Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma.
Papilloma
Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis.
Papilloma
Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T-cells And PD-1/PD-L1/L2 Expression.
Papilloma
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Papilloma
New developments in the management of head and neck cancer - impact of pembrolizumab.
Papilloma
PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
Papilloma
PD-L1 expression and CD8+ infiltration shows heterogeneity in juvenile recurrent respiratory papillomatosis.
Papilloma
Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date.
Papilloma
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
Papilloma
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
Papilloma
The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis.
Papilloma
TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Papilloma
[The Clinical Significance of HPV L1/PD-L1 Tests Combined with Colposcopy for Cervical Precancerous Lesions and Cervical Cancer].
Papilloma, Choroid Plexus
Colloid cyst of the third ventricle. A comparative immunohistochemical study of neuraxis cysts and choroid plexus epithelium.
Papillomavirus Infections
Age and Mutations as Predictors of the Response to Immunotherapy in Head and Neck Squamous Cell Cancer.
Papillomavirus Infections
Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients.
Papillomavirus Infections
Clinical significance of PD-L1 (CD274) enhanced expression in cervical squamous cell carcinoma.
Papillomavirus Infections
CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways.
Papillomavirus Infections
Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma.
Papillomavirus Infections
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma.
Papillomavirus Infections
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
Papillomavirus Infections
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Papillomavirus Infections
Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer.
Papillomavirus Infections
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration.
Papillomavirus Infections
PD-1 and PD-L1 Expression Predicts Radiosensitivity and Clinical Outcomes in Head and Neck Cancer and is Associated with HPV Infection.
Papillomavirus Infections
PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma.
Papillomavirus Infections
[Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis].
Paralysis
Cross-protection against challenge by intravenous Escherichia coli verocytotoxin 1 (VT1) in rabbits immunized with VT2 toxoid.
Paralysis
Localization of intravenously administered verocytotoxins (Shiga-like toxins) 1 and 2 in rabbits immunized with homologous and heterologous toxoids and toxin subunits.
Paralysis
Shiga Toxin 2 Affects the Central Nervous System through Receptor Globotriaosylceramide Localized to Neurons.
Paralysis
Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities.
Paramyxoviridae Infections
Viral acute lower respiratory infections impair CD8+ T cells through PD-1.
Paraplegia
Schwann cells are removed from the spinal cord after effecting recovery from paraplegia.
Paraproteinemias
Carbohydrate analysis of immunoglobulin G myeloma proteins by lectin and high performance liquid chromatography: role of glycosyltransferases in the structures.
Paraproteinemias
PD-L1-PD-1 Pathway in the Pathophysiology of Multiple Myeloma.
Parathyroid Neoplasms
CLINICAL SIGNIFICANCE OF PD-L1 EXPRESSION IN PARATHYROID CANCER.
Paratuberculosis
The application of food safety interventions in primary production of beef and lamb: A review.
Paratuberculosis
Upregulation of PD-L1 Expression by Prostaglandin E2 and the Enhancement of IFN-? by Anti-PD-L1 Antibody Combined With a COX-2 Inhibitor in Mycoplasma bovis Infection.
Pemphigoid, Bullous
A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.
Pemphigoid, Bullous
Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1.
Pemphigoid, Bullous
PD-L1 positive macrophages were increased in a case of pembrolizumab-induced bullous pemphigoid.
Penile Neoplasms
A nomogram incorporating PD-L1, NLR, and clinicopathologic features to predict inguinal lymph node metastasis in penile squamous cell carcinoma.
Penile Neoplasms
Defining the Tumor Microenvironment of Penile Cancer by Means of the Cancer Immunogram.
Penile Neoplasms
Expression of Programmed Death Ligand 1 in Penile Cancer is of Prognostic Value and Associated with HPV Status.
Penile Neoplasms
PD-L1 Expression in Men with Penile Cancer and its Association with Clinical Outcomes.
Penile Neoplasms
PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?
Penile Neoplasms
Penile cancer: Prognostic value of PD-L1 status.
Penile Neoplasms
Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review.
Penile Neoplasms
[Systemic treatment of locally advanced or metastatic penile cancer].
Periapical Periodontitis
CAMPANELLIProgrammed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis.
Pericardial Effusion
A Case Series of Two Patients Presenting With Pericardial Effusion as First Manifestation of Non-Small Cell Lung Cancer With BRAF Mutation and Expression Of PD-L1.
Pericarditis
[Pericardial Fenestration and Multidisciplinary Treatment to Improve the Prognosis of the Malignant Pericarditis Due to Lung Cancer].
Periodontitis
Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis.
Periodontitis
Overexpression of PD-L1 in gingival basal keratinocytes reduces periodontal inflammation in a ligature-induced periodontitis model.
Periodontitis
PD-L1 correlates with chemokines and cytokines in gingival crevicular fluid from healthy and diseased sites in subjects with periodontitis.
Periodontitis
Porphyromonas gingivalis cell wall components induce PD-L1 expression on human oral carcinoma cells by a RIP2-dependent mechanism.
Periodontitis
Serum proteins associated with periodontitis relapse post-surgery: A pilot study.
Periodontitis
The implication of the PD-1/PD-L1 checkpoint in chronic periodontitis suggests novel therapeutic opportunities with natural products.
Periodontitis
[Temporal expression of PD-1 and PD-L1 during the development of experimental periodontitis in rats and its implications].
Peripheral Nerve Injuries
Complement and clusterin in the injured nervous system.
Peripheral Nerve Injuries
Inflammation and nerve injury induce expression of pancreatitis-associated protein-II in primary sensory neurons.
Peripheral Nervous System Diseases
Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis.
Peritoneal Neoplasms
Adenovirus-Mediated Inducible Expression of a PD-L1 Blocking Antibody in Combination with Macrophage Depletion Improves Survival in a Mouse Model of Peritoneal Carcinomatosis.
Peritonitis
Evaluation of the anti-inflammatory activity of riparin II (O-methil-N-2-hidroxi-benzoyl tyramine) in animal models.
Persistent Infection
A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRP? expression.
Persistent Infection
CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.
Persistent Infection
Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance.
Persistent Infection
EBV up-regulates PD-L1 on the surface of primary monocytes by increasing ROS and activating TLR signaling and STAT3.
Persistent Infection
Identification and characterization of bovine programmed death-ligand 2.
Persistent Infection
Modeling tumor immunity of mouse glioblastoma by exhausted CD8
Persistent Infection
Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
Persistent Infection
PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment.
Persistent Infection
PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.
Persistent Infection
PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells.
Persistent Infection
PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade.
Persistent Infection
PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell response.
Persistent Infection
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.
Persistent Infection
Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.
Persistent Infection
Programmed Death Ligand 1-Expressing Classical Dendritic Cells MitigateHelicobacter-Induced Gastritis.
Persistent Infection
Programmed death-ligand 1 expression in swine chronic infections and enhancement of interleukin-2 production via programmed death-1/programmed death-ligand 1 blockade.
Persistent Infection
Salmonella induces PD-L1 expression in B cells.
Persistent Infection
The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion.
Persistent Infection
Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.
Pheochromocytoma
In 'undifferentiated' PC12 cells, GERL is not segregated from the Golgi apparatus.
Pheochromocytoma
Studies on the interaction of dopamine beta-hydroxylase from various sources with phytohaemagglutinins.
Pituitary ACTH Hypersecretion
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
Pituitary ACTH Hypersecretion
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Pituitary Neoplasms
Analysis of COX-2, PD-L1 and ARG1 expression in human pituitary adenoma.
Pituitary Neoplasms
Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor.
Pituitary Neoplasms
Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
Pituitary Neoplasms
Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression.
Pituitary Neoplasms
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Pituitary Neoplasms
MSH6/2 and PD-L1 Expressions Are Associated with Tumor Growth and Invasiveness in Silent Pituitary Adenoma Subtypes.
Pituitary Neoplasms
Ricin and lentil lectin-affinity chromatography reveals oligosaccharide heterogeneity of thyrotropin secreted by 12 human pituitary tumors.
Pituitary Neoplasms
Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease.
Pituitary Neoplasms
The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy.
Pituitary Neoplasms
The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Plague
Biological and chemical terrorism: recognition and management.
Plague
Bioterrorism for the respiratory physician.
Plague
Issues in preparedness for biologic terrorism: a perspective for critical care nursing.
Plague
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.
Plague
Strategies for the prevention of a successful biological warfare aerosol attack.
Plague
[Bioterrorism and pathogenic microorganisms].
Plant Diseases
Pokeweed Antiviral Protein: Its Cytotoxicity Mechanism and Applications in Plant Disease Resistance.
Plasmablastic Lymphoma
PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
Plasmacytoma
Expression of immunoglobulin heavy chain-ricin A chain fusions in mammalian cells.
Plasmacytoma
N-linked oligosaccharides of the murine transferrin receptor from a plasmacytoma cell line. Comparison with total cellular N-glycans.
Pleural Effusion
Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
Pleural Effusion
Correlation of programmed death-ligand 1 expression with gene expression and clinicopathological parameters in Indian patients with non-small cell lung cancer.
Pleural Effusion
Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer.
Pleural Effusion
Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor.
Pleural Effusion
High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer.
Pleural Effusion
Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.
Pleural Effusion
Increased soluble and membrane-bound PD-L1 contributes to immune regulation and disease progression in patients with tuberculous pleural effusion.
Pleural Effusion
PD-1/PD-L1 Pathway Modulates Macrophage Susceptibility to Mycobacterium tuberculosis Specific CD8+ T cell Induced Death.
Pleural Effusion
PD-L1 expression in pleural effusions of pulmonary adenocarcinoma and survival prediction: a controlled study by pleural biopsy.
Pleural Effusion
PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion.
Pleural Effusion
PD-L1 induced by IFN-? from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.
Pleural Effusion
Th1/Th2 Imbalance and Elevated PD-L1 in Pleural Effusion Predict the Risk of Multi-Drug Resistant Tuberculous Pleuritis.
Pleural Effusion
Use of the 22C3 anti-programmed death ligand 1 antibody to determine programmed death ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Pleural Effusion
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients.
Pleural Effusion
[Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Pleural Effusion, Malignant
Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study.
Pleural Effusion, Malignant
Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples.
Pleural Effusion, Malignant
PD-L1 expression in malignant pleural effusion samples and its correlation with oncogene mutations in non-small cell lung cancer.
Pleural Effusion, Malignant
PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion.
Pleural Effusion, Malignant
PD-L1 lineage-specific quantification in malignant pleural effusions of lung adenocarcinoma by flow cytometry.
Pleural Effusion, Malignant
Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
Pleural Effusion, Malignant
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
Pleurisy
PD-1/PD-L1 Pathway Modulates Macrophage Susceptibility to Mycobacterium tuberculosis Specific CD8+ T cell Induced Death.
Pleurisy
Th1/Th2 Imbalance and Elevated PD-L1 in Pleural Effusion Predict the Risk of Multi-Drug Resistant Tuberculous Pleuritis.
Pleurisy
Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
Pneumococcal Infections
The thrombotic microangiopathies.
Pneumococcal Infections
Thrombotic microangiopathy and associated renal disorders.
Pneumonia
A "crazy paving" pattern on CT scan in a patient treated with Pembrolizumab.
Pneumonia
Acute-Onset Pneumonitis while Administering the First Dose of Durvalumab.
Pneumonia
An intranasally administered monoclonal antibody cocktail abrogates ricin toxin-induced pulmonary tissue damage and inflammation.
Pneumonia
Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Negative Patient With Refractory Metastatic Esophageal Squamous Cell Carcinoma: A Case Report and Literature Review.
Pneumonia
Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.
Pneumonia
Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
Pneumonia
Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration Rates.
Pneumonia
Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection.
Pneumonia
Correction: COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
Pneumonia
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.
Pneumonia
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study.
Pneumonia
Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.
Pneumonia
FOCAL OR INSULAR NECROSIS PRODUCED BY THE BACILLUS OF TUBERCULOSIS.
Pneumonia
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
Pneumonia
Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
Pneumonia
Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
Pneumonia
Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Pneumonia
Inhibition of PI3K? Enhances Poly I:C-Induced Antiviral Responses and Inhibits Replication of Human Metapneumovirus in Murine Lungs and Human Bronchial Epithelial Cells.
Pneumonia
Lack of PD-L1 expression by iNKT cells improves the course of influenza A infection.
Pneumonia
Pneumonitis From Anti-PD-1/ PD-L1 Therapy.
Pneumonia
Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
Pneumonia
Programmed Death Ligand 1 Promotes Early-Life Chlamydia Respiratory Infection-Induced Severe Allergic Airway Disease.
Pneumonia
Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice.
Pneumonia
Pulmonary inflammation triggered by ricin toxin requires macrophages and IL-1 signaling.
Pneumonia
Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Pneumonia
Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Pneumonia
Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.
Pneumonia
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Pneumonia
Stimulation of pneumovirus-specific CD8(+) T-cells using a non-toxic recombinant ricin delivery system.
Pneumonia
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Pneumonia
[Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].
Pneumonia
[The expression and clinical significance of serum soluble programmed cell death ligand-1 in adult patients with community-acquired pneumonia].
Pneumonia, Mycoplasma
Lectin Microarray Combined with Mass Spectrometry Identifies Haptoglobin-Related Protein (HPR) as a Potential Serologic Biomarker for Separating Nonbacterial Pneumonia from Bacterial Pneumonia in Childhood.
Pneumothorax
Adult pulmonary Langerhans cell histiocytosis might consist of two distinct groups: isolated form and extrapulmonary recidivism type.
Polycystic Ovary Syndrome
Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome.
Polycythemia Vera
Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5.
Polyuria
Urinary concentrating defect in rats given Shiga toxin: elevation in urinary AQP2 level associated with polyuria.
Porcine Reproductive and Respiratory Syndrome
PD-L1 expression is increased in monocyte derived dendritic cells in response to porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus infections.
Pre-Eclampsia
Decreased expression of ligands of placental immune checkpoint inhibitors in uncomplicated and preeclamptic oocyte donation pregnancies.
Pre-Eclampsia
Maternal soluble PD-1 levels are significantly increased in women with preeclampsia.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
A Comparison of the Anti-Tumor Effects of a Chimeric versus Murine Anti-CD19 Immunotoxins on Human B Cell Lymphoma and Pre-B Acute Lymphoblastic Leukemia Cell Lines.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Myeloid loss of Beclin 1 promotes PD-L1hiprecursor B Cell lymphoma development.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
An immunotoxin with therapeutic potential in T cell leukemia: WT1-ricin A.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Corrigendum: CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Immunotoxins in cancer therapy: Review and update.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Influence of cytotoxicity enhancers in combination with human serum on the activity of CD22-recombinant ricin A against B cell lines, chronic and acute lymphocytic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: potentiation by chloroquine.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Marked difference in the in vivo antitumor efficacy between two immunotoxins targeted to different epitopes of common acute lymphoblastic leukemia antigen (CD10). Mechanisms involved in the differential activities of immunotoxins.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal antibody-ricin conjugate cytotoxic to cells expressing the common acute lymphoblastic leukemia antigen (CALLA).
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Ricin A immunotoxins of IgG and Fab of anti-CALLA monoclonal antibody: effect of water soluble long-chain SPDP on conjugate yield, immunoselectivity and cytotoxicity.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Chrysophanol suppresses growth and metastasis of T cell acute lymphoblastic leukemia via miR-9/PD-L1 axis.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
Pregnancy, Ectopic
Ectopic pregnancy treated with trichosanthin. Clinical analysis of 71 patients.
Pregnancy, Ectopic
Ribosome-inactivating Proteins from Root Tubers and Seeds of Trichosan-thes kirilowii and Other Trichosanthes Species.
Pregnancy, Ectopic
Trichosanthin, a Chinese Medicine for the Medical Treatment of Ectopic Pregnancy With High Levels of ?-hCG.
Pregnancy, Tubal
Trichosanthin injection in tubal pregnancy.
Primary Myelofibrosis
PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients.
Primary Myelofibrosis
PD-L1 Immunohistochemistry Highlights Bone Marrow Involvement by Classic Hodgkin Lymphoma in Staging Biopsies: Implications for Diagnosis and Tumor Microenvironment Alterations.
Prostatic Hyperplasia
Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
Prostatic Neoplasms
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
Prostatic Neoplasms
An update: circulating tumor cells in head and neck cancer.
Prostatic Neoplasms
Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Prostatic Neoplasms
Analysis of urinary PSA glycosylation is not indicative of high-risk prostate cancer.
Prostatic Neoplasms
Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
Prostatic Neoplasms
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.
Prostatic Neoplasms
Cancer immunotherapy using PolyPurine Reverse Hoogsteen hairpins targeting the PD-1/PD-L1 pathway in human tumor cells.
Prostatic Neoplasms
Cell membrane and nuclear expression of programmed death ligand-1 in prostate needle biopsy tissue in prostate cancer patients undergoing primary radiation therapy.
Prostatic Neoplasms
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Prostatic Neoplasms
Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer.
Prostatic Neoplasms
Comprehensive evaluation of PD-L1 expression in primary and metastatic prostate cancer.
Prostatic Neoplasms
Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.
Prostatic Neoplasms
CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Prostatic Neoplasms
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.
Prostatic Neoplasms
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients.
Prostatic Neoplasms
Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Prostatic Neoplasms
eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
Prostatic Neoplasms
Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Prostatic Neoplasms
Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8+ tumor-associated lymphocytes and poor prognosis in prostate cancer.
Prostatic Neoplasms
Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.
Prostatic Neoplasms
Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Prostatic Neoplasms
Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance.
Prostatic Neoplasms
Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics.
Prostatic Neoplasms
Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer.
Prostatic Neoplasms
Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
Prostatic Neoplasms
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.
Prostatic Neoplasms
Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer.
Prostatic Neoplasms
Immunotherapy for Localized Prostate Cancer: The Next Frontier?
Prostatic Neoplasms
Inflammatory cytokines IL-17 and TNF-? up-regulate PD-L1 expression in human prostate and colon cancer cells.
Prostatic Neoplasms
Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells.
Prostatic Neoplasms
JQ1, a BET-bromodomain inhibitor, inhibits human cancer growth and suppresses PD-L1 expression.
Prostatic Neoplasms
LncRNA KCNQ1OT1 sponges miR-15a to promote immune evasion and malignant progression of prostate cancer via up-regulating PD-L1.
Prostatic Neoplasms
LRP11 activates ?-catenin to induce PD-L1 expression in prostate cancer.
Prostatic Neoplasms
MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
Prostatic Neoplasms
MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.
Prostatic Neoplasms
Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation.
Prostatic Neoplasms
News.
Prostatic Neoplasms
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
Prostatic Neoplasms
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.
Prostatic Neoplasms
PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.
Prostatic Neoplasms
PD-L1 Expression and CD8(+) T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer.
Prostatic Neoplasms
PD-L1 Expression in De Novo Metastatic Castration-sensitive Prostate Cancer.
Prostatic Neoplasms
PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.
Prostatic Neoplasms
PD-L1 inhibitors for the treatment of prostate cancer.
Prostatic Neoplasms
PD-L1 is highly expressed in Enzalutamide resistant prostate cancer.
Prostatic Neoplasms
PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Prostatic Neoplasms
Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients.
Prostatic Neoplasms
Programmed death ligand 1 expression in prostate cancer cells is associated with deep changes of the tumor inflammatory infiltrate composition.
Prostatic Neoplasms
Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
Prostatic Neoplasms
Prostate cancer: PD-L1 expression is common and indicates poor prognosis.
Prostatic Neoplasms
Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Prostatic Neoplasms
Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells.
Prostatic Neoplasms
Sex Hormones and Anticancer Immunity.
Prostatic Neoplasms
SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells.
Prostatic Neoplasms
Specific zinc finger-induced methylation of PD-L1 promoter inhibits its expression.
Prostatic Neoplasms
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
Prostatic Neoplasms
Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model.
Prostatic Neoplasms
The anti-cancerous activity of recombinant trichosanthin on prostate cancer cell PC3.
Prostatic Neoplasms
The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis.
Prostatic Neoplasms
The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients.
Prostatic Neoplasms
The effect of monensin and chloroquine on the endocytosis and toxicity of chimeric toxins.
Prostatic Neoplasms
The expression of PD-L1 in patients with castrate prostate cancer treated with enzalutamide.
Prostatic Neoplasms
The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer.
Prostatic Neoplasms
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer.
Prostatic Neoplasms
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Prostatic Neoplasms
The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer.
Prostatic Neoplasms
[Mechanism of trichosanthin inducing apoptosis of mouse prostatic cancer RM-1 cells in vitro]
Protein Deficiency
Correlation of mismatch repair protein deficiency, PD-L1 and CD8 expression in high-grade urothelial carcinoma of the bladder.
Protein Deficiency
Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
Protein Deficiency
Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
Protein Deficiency
PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinoma and Tumor-associated Immune Cells: Differences Between MLH1 Methylated and Nonmethylated Subgroups.
Protein-Energy Malnutrition
An interventional approach to block brain damage caused by Shiga toxin-producing Escherichia coli infection, by use of a combination of phosphodiesterase inhibitors.
Proteinuria
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
Proteinuria
Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.
Proteinuria
Microalbuminuria and early renal response to lethal dose Shiga toxin type 2 in rats.
Proteinuria
Programmed Death-Ligand 1 Expression Potentiates the Immune Modulatory Function Of Myeloid-Derived Suppressor Cells in Systemic Lupus Erythematosus.
Pruritus
Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
Psoriasis
Circulating CD14+HLA-DR-/low Myeloid-Derived Suppressor Cells as Potential Biomarkers for the Identification of Psoriasis TCM Blood-Heat Syndrome and Blood-Stasis Syndrome.
Pulmonary Blastoma
Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression.
Pulmonary Disease, Chronic Obstructive
Blockade of PD-1 decreases neutrophilic inflammation and lung damage in experimental COPD.
Pulmonary Disease, Chronic Obstructive
Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series.
Pulmonary Disease, Chronic Obstructive
Dysregulation of Antiviral Function of CD8(+) T Cells in the Chronic Obstructive Pulmonary Disease Lung. Role of the PD-1-PD-L1 Axis.
Pulmonary Disease, Chronic Obstructive
Imbalance of dendritic cell co-stimulation in COPD.
Pulmonary Disease, Chronic Obstructive
Importance of validating antibody panels: Anti-PD-L1 clone binds AF700 fluorophore.
Pulmonary Disease, Chronic Obstructive
Inhibition of PI3K? Enhances Poly I:C-Induced Antiviral Responses and Inhibits Replication of Human Metapneumovirus in Murine Lungs and Human Bronchial Epithelial Cells.
Pulmonary Disease, Chronic Obstructive
Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism.
Pulmonary Disease, Chronic Obstructive
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Pulmonary Disease, Chronic Obstructive
Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma.
Pulmonary Disease, Chronic Obstructive
Upregulation of PD-L1 predicts poor prognosis and is associated with miR-191-5p dysregulation in colon adenocarcinoma.
Pulmonary Edema
Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin.
Pulmonary Edema
Pulmonary gene expression profiling of inhaled ricin.
Pulmonary Edema
[Blockade of programmed death-ligand 1 attenuates indirect acute lung injury in mice through targeting endothelial cells but not epithelial cells].
Pulmonary Embolism
The association between pulmonary embolism and the cancer-related genomic alterations in patients with NSCLC.
Pulmonary Emphysema
Imbalance of dendritic cell co-stimulation in COPD.
Pulmonary Emphysema
PD-L1, FGFR1, PIK3CA, PTEN, and p16 expression in pulmonary emphysema and chronic obstructive pulmonary disease with resected lung squamous cell carcinoma.
Pulmonary Fibrosis
Clinical and Pathological Findings Associated with Aerosol Exposure of Macaques to Ricin Toxin.
Purpura, Thrombocytopenic, Idiopathic
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.
Purpura, Thrombotic Thrombocytopenic
Diagnostic approach to microangiopathic hemolytic disorders.
Purpura, Thrombotic Thrombocytopenic
Immunity profiles of wild-type and recombinant shiga-like toxin-encoding bacteriophages and characterization of novel double lysogens.
Purpura, Thrombotic Thrombocytopenic
Post-traumatic thrombotic microangiopathy: What trauma surgeons need to know?
Purpura, Thrombotic Thrombocytopenic
Southwestern Internal Medicine Conference: Shiga-like toxins in hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura.
Purpura, Thrombotic Thrombocytopenic
Thrombotic microangiopathies: Similar presentations, different therapies.
Purpura, Thrombotic Thrombocytopenic
Thrombotic microangiopathy and associated renal disorders.
Purpura, Thrombotic Thrombocytopenic
[Isolation and characterization of Shiga-toxin-producing Escherichia coli from frozen hamburgers and soft cheeses]
Purpura, Thrombotic Thrombocytopenic
[Shiga toxin and tetanus toxin as a potential biologic weapon].
Q Fever
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.
Q Fever
Programmed death ligand-1 expression and memory T-cell generation in Coxiella burnetii infection.
Q Fever
Strategies for the prevention of a successful biological warfare aerosol attack.
Rabies
Expression of Rabies Glycoprotein and Ricin Toxin B Chain (RGP-RTB) Fusion Protein in Tomato Hairy Roots: A Step Towards Oral Vaccination for Rabies.
rbr-type e3 ubiquitin transferase deficiency
RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis.
Rectal Neoplasms
Clinical complete regression after local radiotherapy combined with chemotherapy for stage IV rectal cancer: A case report.
Rectal Neoplasms
Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Rectal Neoplasms
Expression of PD-L1 and SOX2 during rectal tumourigenesis: Potential mechanisms for immune escape and tumour cell invasion.
Rectal Neoplasms
Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis.
Rectal Neoplasms
Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.
Rectal Neoplasms
Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Rectal Neoplasms
Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
Rectal Neoplasms
Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Rectal Neoplasms
Prognostic Utility of CDX2 and PD-L1 in Rectal Cancer.
Rectal Neoplasms
Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.
Rectal Neoplasms
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Rectal Neoplasms
The Protein Secretome Is Altered in Rectal Cancer Tissue Compared to Normal Rectal Tissue, and Alterations in the Secretome Induce Enhanced Innate Immune Responses.
Rectal Neoplasms
The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation.
Rectal Neoplasms
Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy.
Rectal Neoplasms
Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Renal Insufficiency
A Novel Mechanism of Bacterial Toxin Transfer within Host Blood Cell-Derived Microvesicles.
Renal Insufficiency
Absence of interleukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome.
Renal Insufficiency
Antibiotic-resistant Shiga toxin-producing Escherichia coli: An overview of prevalence and intervention strategies.
Renal Insufficiency
Biochemical characterization of in-vitro reconstituted biologically active recombinant Shiga toxin.
Renal Insufficiency
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
Renal Insufficiency
Detection of Shiga toxin-encoding genes in small community water supplies.
Renal Insufficiency
Down-regulation of renal klotho expression by Shiga toxin 2.
Renal Insufficiency
RAB5A and TRAPPC6B are novel targets for Shiga toxin 2a inactivation in kidney epithelial cells.
Renal Insufficiency
Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.
Renal Insufficiency
Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli.
Renal Insufficiency
Shiga toxin 2 targets the murine renal collecting duct epithelium.
Renal Insufficiency
Shiga toxin pathogenesis: kidney complications and renal failure.
Renal Insufficiency
Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells.
Renal Insufficiency
The ability of an attaching and effacing pathogen to trigger localized actin assembly contributes to virulence by promoting mucosal attachment.
Renal Insufficiency, Chronic
Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma.
Renal Insufficiency, Chronic
The Prevalence of Shiga Toxin-producing Escherichia Coli in Patients with Gastroenteritis in Iran, Systematic Review and Meta-analysis.
Reoviridae Infections
Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.
Reperfusion Injury
The role of programed death-ligand 1 in renal diseases.
Reperfusion Injury
Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Respiratory Distress Syndrome
At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer.
Respiratory Distress Syndrome
Disease-modifying treatment of chemical threat agent-induced acute lung injury.
Respiratory Distress Syndrome
Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin.
Respiratory Distress Syndrome
Pathophysiological profile of awake and anesthetized pigs following systemic exposure to the highly lethal ricin toxin.
Respiratory Distress Syndrome
Proinflammatory responses of human airway cells to ricin involve stress-activated protein kinases and NF-kappaB.
Respiratory Distress Syndrome
Pulmonary inflammation triggered by ricin toxin requires macrophages and IL-1 signaling.
Respiratory Distress Syndrome
Role of apoptotic signaling pathways in regulation of inflammatory responses to ricin in primary murine macrophages.
Respiratory Distress Syndrome
TRAIL (CD253) Sensitizes Human Airway Epithelial Cells to Toxin-Induced Cell Death.
Respiratory Distress Syndrome
Treatments for Pulmonary Ricin Intoxication: Current Aspects and Future Prospects.
Respiratory Insufficiency
A novel swine model of ricin-induced acute respiratory distress syndrome.
Respiratory Insufficiency
Antibody/doxycycline combined therapy for pulmonary ricinosis: Attenuation of inflammation improves survival of ricin-intoxicated mice.
Respiratory Insufficiency
Mass spectrometric detection of ricin and its activity in food and clinical samples.
Respiratory Insufficiency
Total Body Irradiation Mitigates Inflammation and Extends the Therapeutic Time Window for Anti-Ricin Antibody Treatment against Pulmonary Ricinosis in Mice.
Respiratory Syncytial Virus Infections
Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection.
Retinoblastoma
CDK4 Inhibitors Thwart Immunity by Inhibiting Phospho-RB-NF-?B Complexes.
Retinoblastoma
Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma.
Retroviridae Infections
A Combination of Anti-PD-L1 Treatment and Therapeutic Vaccination Facilitates Improved Retroviral Clearance via Reactivation of Highly Exhausted T Cells.
Rhabdomyosarcoma
Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.
Rhabdomyosarcoma
HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells.
Rhabdomyosarcoma
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers.
Rhabdomyosarcoma
PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Rhabdomyosarcoma
PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.
Rhabdomyosarcoma
Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
Rhabdomyosarcoma
Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
Rhabdomyosarcoma
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
Rhabdomyosarcoma
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Rhabdomyosarcoma
Programmed death ligand 1 expression in bladder rhabdomyosarcoma and its association with clinicopathological features.
Rhabdomyosarcoma
Removal of N-glycans from cell surface proteins induces apoptosis by reducing intracellular glutathione levels in the rhabdomyosarcoma cell line S4MH.
Rhabdomyosarcoma
Status of programmed death-ligand 1 expression in sarcomas.
Rhabdomyosarcoma
The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.
Rhabdomyosarcoma, Alveolar
PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Rheumatoid Nodule
Polymorphisms of genes for programmed cell death 1 ligands in patients with rheumatoid arthritis.
Rhinitis, Allergic
The blockade of PD-1/PD-L1 pathway promotes the apoptosis of CD19+ CD25+ Bregs and suppresses the secretion of IL-10 in patients with allergic rhinitis.
Rhinitis, Allergic
The relationship between B7 homologous 1 with interleukin-4, interleukin-17 and interferon gamma in patients with allergic rhinitis.
Rhinitis, Allergic
[Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
ribonuclease e deficiency
Influence of RNase E deficiency on the production of stx2-bearing phages and Shiga toxin in an RNase E-inducible strain of enterohaemorrhagic Escherichia coli (EHEC) O157:H7.
rrna n-glycosylase deficiency
Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy.
rrna n-glycosylase deficiency
Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans.
rrna n-glycosylase deficiency
Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.
rrna n-glycosylase deficiency
Haploidentical mixed chimerism cures autoimmunity in established type 1 diabetic mice.
rrna n-glycosylase deficiency
Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8+ T-cell Responses.
rrna n-glycosylase deficiency
Novel Role for PD-1:PD-L1 as Mediator of Pulmonary Vascular Endothelial Cell Functions in Pathogenesis of Indirect ARDS in Mice.
rrna n-glycosylase deficiency
Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen.
rrna n-glycosylase deficiency
PD-L1 Deficiency within Islets Reduces Allograft Survival in Mice.
rrna n-glycosylase deficiency
PD-L1 Expression Affects Neoantigen Presentation.
rrna n-glycosylase deficiency
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.
rrna n-glycosylase deficiency
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells.
rrna n-glycosylase deficiency
Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease.
rrna n-glycosylase deficiency
Programmed Death-1 Restrains the Germinal Center in Type 1 Diabetes.
rrna n-glycosylase deficiency
Role of PD-L1 and PD-L2 in allergic diseases and asthma.
rrna n-glycosylase deficiency
T Cell Checkpoint Regulators in the Heart.
rrna n-glycosylase deficiency
Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
rrna n-glycosylase deficiency
The PD-1/PD-L1 Pathway Affects the Expansion and Function of Cytotoxic CD8+ T Cells During an Acute Retroviral Infection.
Salivary Gland Neoplasms
Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
Salmonella Infections
Foodborne disease in Australia: incidence, notifications and outbreaks. Annual report of the OzFoodNet network, 2002.
Sarcoidosis
Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T-cell proliferative capacity.
Sarcoidosis
Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy.
Sarcoidosis
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Sarcoidosis
Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
Sarcoidosis, Pulmonary
Ultrastructural localization of anionic sites and lectin-binding sites in sarcoid human alveolar macrophages during interaction with T-lymphocytes.
Sarcoma
A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
Sarcoma
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
Sarcoma
A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes.
Sarcoma
A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging.
Sarcoma
Action of alpha-momorcharin, a ribosome inactivating protein, on cultured tumor cell lines.
Sarcoma
An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B chain.
Sarcoma
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.
Sarcoma
Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial.
Sarcoma
Blockade of VEGFR and PD-L1 Inhibits Alveolar Soft-Part Sarcoma.
Sarcoma
Characteristics of mismatch repair deficiency in sarcomas.
Sarcoma
Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.
Sarcoma
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Sarcoma
Circumvention of resistance to photodynamic therapy in doxorubicin-resistant sarcoma by photochemical internalization of gelonin.
Sarcoma
Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Sarcoma
Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Sarcoma
Construction of anti-hPD-L1 HCAb Nb6 and in situ 124I labeling for noninvasive detection of PD-L1 expression in human bone sarcoma.
Sarcoma
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Sarcoma
Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas.
Sarcoma
Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis.
Sarcoma
Endocytosis of immunotoxin-791T/36-RTA by tumor cells in relation to its cytotoxic action.
Sarcoma
Evaluation of PD1 and PD-L1 expression in high-grade sarcomas of the limbs in the adults: possible implications of immunotherapy.
Sarcoma
Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.
Sarcoma
Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders.
Sarcoma
Follicular dendritic cell sarcoma: clinicopathologic study of 15 cases with emphasis on novel expression of MDM2, somatostatin receptor 2A, and PD-L1.
Sarcoma
Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
Sarcoma
Histiocytic and dendritic cell neoplasms: Reappraisal of a Japanese series based on t(14;18) and neoplastic PD-L1 expression.
Sarcoma
Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers.
Sarcoma
Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma.
Sarcoma
Integrative assessment of clinicopathological parameters and the expression of PD-L1, PD-L2 and PD-1 in tumor cells of retroperitoneal sarcoma.
Sarcoma
Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study.
Sarcoma
KRAS G12V mutation upregulates PD-L1 expression via TGF-?/EMT signaling pathway in human non-small-cell lung cancer.
Sarcoma
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Sarcoma
Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression.
Sarcoma
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy.
Sarcoma
Molecular Characteristics of Genes and the Immune Microenvironment of a Rare Chest Malignant Tumor (Pulmonary Clear Cell Sarcoma): A Case Report.
Sarcoma
Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.
Sarcoma
Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.
Sarcoma
Neoplastic PD-L1 expression on interdigitating dendritic cell sarcoma: A supplementary study of a case report.
Sarcoma
Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Sarcoma
Pathologic complete response to preoperative immunotherapy in a lung adenocarcinoma patient with bone metastasis: A case report.
Sarcoma
PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Sarcoma
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma.
Sarcoma
PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue - prognostic implications and rationale for immunotherapy.
Sarcoma
PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis.
Sarcoma
PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.
Sarcoma
PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.
Sarcoma
Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ?50%: real-world data.
Sarcoma
Photochemical internalization enhances the cytotoxic effect of the protein toxin gelonin and transgene expression in sarcoma cells.
Sarcoma
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Sarcoma
Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
Sarcoma
Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
Sarcoma
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment.
Sarcoma
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Sarcoma
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
Sarcoma
Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.
Sarcoma
Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis.
Sarcoma
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Sarcoma
Programmed Cell Death Ligand 1 Expression in Canine Cancer.
Sarcoma
Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Sarcoma
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Sarcoma
Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Sarcoma
Response to anti-PD1 immunotherapy in patients with metastatic cutaneous sarcoma: case reports and literature review.
Sarcoma
Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.
Sarcoma
Status of programmed death-ligand 1 expression in sarcomas.
Sarcoma
Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade.
Sarcoma
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Sarcoma
Temporary inhibition of Moloney-murine sarcoma virus (M-MSV) induced-tumours by adoptive transfer of ricin-treated T-lymphocytes.
Sarcoma
The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Sarcoma
The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
Sarcoma
The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer.
Sarcoma
Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas.
Sarcoma
Turning 'Cold' tumors 'Hot': immunotherapies in sarcoma.
Sarcoma
Uptake of adriamycin by sarcoma transplants in the rat kidney: effects of renal arterial vs systemic constant rate infusion and of combination with ricin.
Sarcoma 180
Binding and cytotoxicity of Ricinus communis lectins to HeLa cells, Sarcoma 180 ascites tumor cells and erythrocytes.
Sarcoma 180
Chimeric protein: abrin B chain-trypsin inhibitor conjugate as a new antitumor agent.
Sarcoma, Alveolar Soft Part
Blockade of VEGFR and PD-L1 Inhibits Alveolar Soft-Part Sarcoma.
Sarcoma, Alveolar Soft Part
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Sarcoma, Clear Cell
Molecular Characteristics of Genes and the Immune Microenvironment of a Rare Chest Malignant Tumor (Pulmonary Clear Cell Sarcoma): A Case Report.
Sarcoma, Ewing
Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).
Sarcoma, Ewing
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
Sarcoma, Ewing
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Sarcoma, Experimental
[Necrosing or clastic effects of ricin on different organs and on experimental sarcomas.]
Sarcoma, Kaposi
Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Sarcoma, Kaposi
PD-1 and PD-L1 expression in Kaposi sarcoma: A comparative study according to the pathological stage and clinical characteristics.
Sarcoma, Kaposi
PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma.
Sarcoma, Kaposi
Stage-related PD-L1 expression in Kaposi sarcoma tumor microenvironment.
Sarcoma, Synovial
Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens.
Sarcoma, Synovial
Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma.
Sarcoma, Synovial
Photochemical internalization enhances the cytotoxic effect of the protein toxin gelonin and transgene expression in sarcoma cells.
Sarcoma, Synovial
Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma.
Sarcoma, Synovial
Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Sciatica
Detoxification of Abrus precatorius L. seeds by Ayurvedic Shodhana process and anti-inflammatory potential of the detoxified extract.
Scoliosis
Mutation Analysis of 16 Mucolipidosis II and III Alpha/Beta Chinese Children Revealed Genotype-Phenotype Correlations.
Scrapie
Detection, quantification, and glycotyping of prion protein in specifically activated enzyme-linked immunosorbent assay plates.
Scrapie
Involvement of Cellular Prion Protein in Invasion and Metastasis of Lung Cancer by Inducing Treg Cell Development.
Scrapie
Specific proteins associated with Creutzfeldt-Jakob disease and scrapie share antigenic and carbohydrate determinants.
Seizures
An animal model for the study of neurotoxicity of bacterial products and application of the model to demonstrate that Shiga toxin and lipopolysaccharide cooperate in inducing neurologic disorders.
Seizures
Antisocial and seizure susceptibility phenotypes in an animal model of epilepsy are normalized by impairment of brain corticotropin-releasing factor.
Seizures
Enhancement of pentylenetetrazole-induced seizures by Shigella dysenteriae in LPS-resistant C3H/HeJ mice: role of the host response.
Seizures
Increased susceptibility to generalized seizures after immunolesions of the basal forebrain cholinergic neurons in rats.
Seizures
Olfactory neophobia and seizure susceptibility phenotypes in an animal model of epilepsy are normalized by impairment of brain corticotropin releasing factor.
Seizures
Pancreatitis-associated protein-I and pancreatitis-associated protein-III expression in a rat model of kainic acid-induced seizure.
Seizures
Shiga Toxin Mediated Neurologic Changes in Murine Model of Disease.
Seizures
Transplant of GABAergic precursors restores hippocampal inhibitory function in a mouse model of seizure susceptibility.
Seminoma
Characterization and distribution of sialic acids in human testicular seminoma.
Seminoma
Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling.
Seminoma
Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
Seminoma
Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
Seminoma
Frequent PD-L1 expression in testicular germ cell tumors.
Seminoma
Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Seminoma
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Sepsis
A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis.
Sepsis
A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction.
Sepsis
A Novel Role for Programmed Cell Death Receptor Ligand-1 (PD-L1) in Sepsis-Induced Intestinal Dysfunction.
Sepsis
Anti-PD-L1 peptide improves survival in sepsis.
Sepsis
Association between elevation of plasma biomarkers and monocyte dysfunction and their combination in predicting sepsis: An observational single-centre cohort study.
Sepsis
Beneficial Effects of CpG-Oligodeoxynucleotide Treatment on Trauma and Secondary Lung Infection.
Sepsis
Capillary leak syndrome: etiologies, pathophysiology, and management.
Sepsis
Changes in the PD-1 and PD-L1 expressions of splenic dendritic cells in multiple-organ dysfunction syndrome mice and their significance.
Sepsis
Detection of E. coli O157:H7 and Shigella dysenteriae toxins in clinical samples by PCR-ELISA.
Sepsis
Effect of PD-1: PD-L1 in Invariant Natural Killer T Cell Emigration and Chemotaxis Following Sepsis.
Sepsis
Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.
Sepsis
Frontline Science: Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1.
Sepsis
Glutamine Administration in Early or Late Septic Phase Downregulates Lymphocyte PD-1/PD-L1 Expression and the Inflammatory Response in Mice With Polymicrobial Sepsis.
Sepsis
Immune checkpoints in sepsis: New hopes and challenges.
Sepsis
Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression.
Sepsis
Increased percentage of PD-L1+ natural killer cells predicts poor prognosis in sepsis patients: a prospective observational cohort study.
Sepsis
Integrin and PD-1 Ligand Expression on Circulating Extracellular Vesicles in Systemic Inflammatory Response Syndrome and Sepsis.
Sepsis
Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1.
Sepsis
Lactate up-regulates the expression of PD-L1 in kidney and causes immunosuppression in septic Acute Renal Injury.
Sepsis
Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.
Sepsis
MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice.
Sepsis
Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study.
Sepsis
Oxygen Saturation on Admission Is a Predictive Biomarker for PD-L1 Expression on Circulating Monocytes and Impaired Immune Response in Patients With Sepsis.
Sepsis
PD-1 blockade improves Kupffer cell bacterial clearance in acute liver injury.
Sepsis
PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction.
Sepsis
Predictive Value of Soluble Programmed Death-1 for Severe Sepsis and Septic Shock During the First Week in an Intensive Care Unit.
Sepsis
Proof of concept study of mass cytometry in septic shock patients reveals novel immune alterations.
Sepsis
Serum-soluble PD-L1 may be a potential diagnostic biomarker in sepsis.
Sepsis
Shiga toxin producing E coli bloodstream infection secondary to Strongyloides penetration through intestinal mucosa.
Sepsis
Tolerizing CTL by Sustained Hepatic PD-L1 Expression Provides a New Therapy Approach in Mouse Sepsis.
Sepsis
Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental animal model of sepsis.
Sepsis
Upregulated PD-L1 delays human neutrophil apoptosis and promotes lung injury in an experimental mouse model of sepsis.
Sepsis
[Effect of autophagy on expression of neutrophil programmed death ligand-1 in mice with sepsis].
Sepsis
[Role and application of programmed death protein 1 (PD-1) and its ligand PD-L1 in immune cell dysfunction in sepsis: An update].
Severe Combined Immunodeficiency
Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model.
Severe Combined Immunodeficiency
Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
Severe Combined Immunodeficiency
Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Shock, Septic
Monocyte programmed death ligand-1 expression after 3-4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study.
Shock, Septic
Myeloid loss of Beclin 1 promotes PD-L1hiprecursor B Cell lymphoma development.
Shock, Septic
Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients.
Shock, Septic
Sepsis in PD-1 light.
Shock, Septic
Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin.
Shock, Septic
Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients.
Silicosis
Downregulation of the PD-1/PD-Ls pathway in peripheral cells correlates with asbestosis severity.
Sinusitis
Reduced sialylation of glycoproteins in nasal glands of patients with chronic sinusitis.
Skin Neoplasms
Histopathologic PD-L1 Tumor Expression and Prognostic Significance in Nonmelanoma Skin Cancers: A Systematic Review.
Skin Neoplasms
Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
Skin Neoplasms
PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer: a systematic review.
Skin Neoplasms
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
Sleep Wake Disorders
Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity.
Small Cell Lung Carcinoma
An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
Small Cell Lung Carcinoma
Cochinin B, a novel ribosome-inactivating protein from the seeds of Momordica cochinchinensis.
Small Cell Lung Carcinoma
Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
Small Cell Lung Carcinoma
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
Small Cell Lung Carcinoma
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.
Small Cell Lung Carcinoma
Cytotoxic activity of ricin A chain immunotoxins recognising cluster 1, w4 and 5A antigens associated with human small cell lung cancer.
Small Cell Lung Carcinoma
Digital Pathology and PD-L1 Testing in Non Small Cell Lung Cancer: A Workshop Record.
Small Cell Lung Carcinoma
Durvalumab Lengthens Survival in Extensive-Stage SCLC.
Small Cell Lung Carcinoma
Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).
Small Cell Lung Carcinoma
First-Line Atezolizumab OK'd for SCLC.
Small Cell Lung Carcinoma
Genomic amplification of CD274 (PD-L1) in small cell lung cancer.
Small Cell Lung Carcinoma
Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Small Cell Lung Carcinoma
Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer.
Small Cell Lung Carcinoma
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit.
Small Cell Lung Carcinoma
Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
Small Cell Lung Carcinoma
Molecular and biological properties of an abrin A chain immunotoxin designed for therapy of human small cell lung cancer.
Small Cell Lung Carcinoma
Monoclonal antibodies recognising the cluster 2 antigen associated with human small cell lung cancer mediate the toxic effects of ricin A chain in an indirect assay of immunotoxin cytotoxicity.
Small Cell Lung Carcinoma
PD-L1 and c-MET expression and survival in patients with small cell lung cancer.
Small Cell Lung Carcinoma
PD-L1 expression by two complementary diagnostic assays and mRNA in situ hybridization in small cell lung cancer.
Small Cell Lung Carcinoma
PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.
Small Cell Lung Carcinoma
PD-L1 Expression in Non Small Cell Lung Cancer and Prognosis
Small Cell Lung Carcinoma
PD-L1 expression in small cell lung cancer.
Small Cell Lung Carcinoma
Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?
Small Cell Lung Carcinoma
Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule.
Small Cell Lung Carcinoma
Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis.
Small Cell Lung Carcinoma
Prognostic value of PD-L1 expression in bronchopulmonary neuroendocrine tumours.
Small Cell Lung Carcinoma
Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells.
Small Cell Lung Carcinoma
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Small Cell Lung Carcinoma
Selective cytotoxic effects of a ricin A chain immunotoxin made with the monoclonal antibody SWA11 recognising a human small cell lung cancer antigen.
Small Cell Lung Carcinoma
Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.
Small Cell Lung Carcinoma
Study: Atezolizumab Improves Survival in SCLC.
Small Cell Lung Carcinoma
Suitability of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration versus Paired Transbronchial Biopsy Specimens for Evaluating Programmed Death Ligand-1 Expression in Stage III and IV Lung Cancer: A Comparative Retrospective Study.
Small Cell Lung Carcinoma
Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.
Small Cell Lung Carcinoma
The clinical impact of three validated PD-L1 immunohistochemistry assays as a prognostic factor in small cell lung cancer.
Small Cell Lung Carcinoma
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Small Cell Lung Carcinoma
[Immunotherapy of lung cancer].
Small Cell Lung Carcinoma
[PD-L1 expression is related with prognosis of small cell lung cancer].
Small Cell Lung Carcinoma
[Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data].
Smallpox
Biological and chemical terrorism: recognition and management.
Smallpox
Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library.
Smallpox
Issues in preparedness for biologic terrorism: a perspective for critical care nursing.
Smallpox
Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.
Smoldering Multiple Myeloma
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.
Smoldering Multiple Myeloma
PD-L1, LAG3, and HLA-DR are increasingly expressed during smoldering myeloma progression.
Smooth Muscle Tumor
PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
Sphingolipidoses
Influence of length and conformation of saccharide head groups on the mechanics of glycolipid membranes: Unraveled by off-specular neutron scattering.
Spinal Cord Diseases
CRMP5-IgG-Associated Paraneoplastic Myelopathy With PD-L1 Inhibitor Therapy.
Spinal Cord Injuries
Cerebrospinal fluid-contacting neurons affect the expression of endogenous neural progenitor cells and the recovery of neural function after spinal cord injury.
Spinal Cord Injuries
PD-L1 Improves Motor Function and Alleviates Neuropathic Pain in Male Mice After Spinal Cord Injury by Inhibiting MAPK Pathway.
Spinal Cord Injuries
[Establishment of PD-L1 transgenic mouse model and recovery of the motion after spinal cord injury].
Squamous Cell Carcinoma of Head and Neck
A correlative analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 expression in oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
An increase of CD8+?T cell infiltration following recurrence is a good prognosticator in HNSCC.
Squamous Cell Carcinoma of Head and Neck
An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.
Squamous Cell Carcinoma of Head and Neck
An update: circulating tumor cells in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Squamous Cell Carcinoma of Head and Neck
Assessment of PD-L1 mRNA and protein expression in non-small cell lung cancer, head and neck squamous cell carcinoma and urothelial carcinoma tissue specimens using RNAScope and immunohistochemistry.
Squamous Cell Carcinoma of Head and Neck
Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Association of PD-L1 expression in oral squamous cell carcinoma with smoking, sex, and p53 expression.
Squamous Cell Carcinoma of Head and Neck
Associations among pretreatment tumor necrosis and the expression of HIF-1? and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.
Squamous Cell Carcinoma of Head and Neck
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Squamous Cell Carcinoma of Head and Neck
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Biological predictors of radiosensitivity in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Biomarkers for immunotherapy response in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
Squamous Cell Carcinoma of Head and Neck
Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
CD163(+)CD204(+) tumor-associated macrophages contribute to T cell regulation via interleukin-10 and PD-L1 production in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
Squamous Cell Carcinoma of Head and Neck
CD317 Signature in Head and Neck Cancer Indicates Poor Prognosis.
Squamous Cell Carcinoma of Head and Neck
CD44+ cells in head and neck squamous cell carcinoma suppress T cell-mediated immunity by selective constitutive and inducible expression of PD-L1.
Squamous Cell Carcinoma of Head and Neck
CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC.
Squamous Cell Carcinoma of Head and Neck
Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study.
Squamous Cell Carcinoma of Head and Neck
Challenges facing pathologists evaluating PD-L1 in head & neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
Checkpoint cluster: biomarkers of response.
Squamous Cell Carcinoma of Head and Neck
Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Clinical comments on prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma (OSCC).
Squamous Cell Carcinoma of Head and Neck
Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.
Squamous Cell Carcinoma of Head and Neck
Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
CMTM4 regulates epithelial-mesenchymal transition and PD-L1 expression in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC).
Squamous Cell Carcinoma of Head and Neck
Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Squamous Cell Carcinoma of Head and Neck
Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States.
Squamous Cell Carcinoma of Head and Neck
Determining PD-L1 expression in head and neck squamous cell carcinoma using immunohistochemistry.
Squamous Cell Carcinoma of Head and Neck
Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
Squamous Cell Carcinoma of Head and Neck
Development and Analytical Validation of a Reverse Transcription Droplet Digital PCR (RT-ddPCR) Assay for PD-L1 Transcripts in Circulating Tumor Cells.
Squamous Cell Carcinoma of Head and Neck
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Differential localization of PD-L1 and Akt-1 involvement in radioresistant and radiosensitive cell lines of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Digital Pathology Scoring of Immunohistochemical Staining Reliably Identifies Prognostic Markers and Anatomical Associations in a Large Cohort of Oral Cancers.
Squamous Cell Carcinoma of Head and Neck
DNA damage response- and JAK-dependent regulation of PD-L1 expression in head and neck squamous cell carcinoma (HNSCC) cells exposed to 5-fluorouracil (5-FU).
Squamous Cell Carcinoma of Head and Neck
Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?
Squamous Cell Carcinoma of Head and Neck
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ?25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Squamous Cell Carcinoma of Head and Neck
Dynamic host immune response in virus-associated cancers.
Squamous Cell Carcinoma of Head and Neck
Enhanced programmed death 1 (PD-1) and PD-1 ligand (PD-L1) expression in patients with actinic cheilitis and oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Epithelial-mesenchymal transition gene signature is associated with prognosis and tumor microenvironment in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Evaluating PD-L1 in Head & Neck Squamous Cell Carcinoma: concordance between 22C3 PharmaDx and SP263 assays on whole sections from a multicenter study.
Squamous Cell Carcinoma of Head and Neck
Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Exceptional response to cetuximab monotherapy in a patient with metastatic oropharyngeal squamous cell carcinoma: a molecular insight.
Squamous Cell Carcinoma of Head and Neck
Expression and phosphorylation of Stathmin 1 indicate poor survival in head and neck squamous cell carcinoma and associate with immune suppression.
Squamous Cell Carcinoma of Head and Neck
Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
Squamous Cell Carcinoma of Head and Neck
Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer.
Squamous Cell Carcinoma of Head and Neck
Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Squamous Cell Carcinoma of Head and Neck
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
GDNF secreted by nerves enhances PD-L1 expression via JAK2-STAT1 signaling activation in HNSCC.
Squamous Cell Carcinoma of Head and Neck
Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells.
Squamous Cell Carcinoma of Head and Neck
HBD3 Induces PD-L1 Expression on Head and Neck Squamous Cell Carcinoma Cell Lines.
Squamous Cell Carcinoma of Head and Neck
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments.
Squamous Cell Carcinoma of Head and Neck
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.
Squamous Cell Carcinoma of Head and Neck
HNC0014, a Multi-Targeted Small-Molecule, Inhibits Head and Neck Squamous Cell Carcinoma by Suppressing c-Met/STAT3/CD44/PD-L1 Oncoimmune Signature and Eliciting Antitumor Immune Responses.
Squamous Cell Carcinoma of Head and Neck
HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas.
Squamous Cell Carcinoma of Head and Neck
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Identification and characterization of an alternative cancer-derived PD-L1 splice variant.
Squamous Cell Carcinoma of Head and Neck
IFN-?-related mRNA profile predicts clinical response to PD-1 blockade.
Squamous Cell Carcinoma of Head and Neck
IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
Immune Cell Infiltrates and Neutrophil-to-Lymphocyte Ratio in Relation to Response to Chemotherapy and Prognosis in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas.
Squamous Cell Carcinoma of Head and Neck
Immune Checkpoint Inhibition in Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
Immune checkpoint inhibitors in the treatment of cancer.
Squamous Cell Carcinoma of Head and Neck
Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients.
Squamous Cell Carcinoma of Head and Neck
Immune Infiltrates of m6A RNA Methylation-Related lncRNAs and Identification of PD-L1 in Patients With Primary Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Immune microenvironment and expression of PD-L1, PD-1, cancer testis antigen PRAME and MHC I in salivary duct carcinoma.
Squamous Cell Carcinoma of Head and Neck
Immunohistochemical Analysis of Foxp3(+), CD4(+), CD8(+) Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Immunotherapy for head and neck cancer: Recent advances and future directions.
Squamous Cell Carcinoma of Head and Neck
Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.
Squamous Cell Carcinoma of Head and Neck
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis.
Squamous Cell Carcinoma of Head and Neck
Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study.
Squamous Cell Carcinoma of Head and Neck
Increased PD-L1 expression in radioresistant HNSCC cell lines after irradiation affects cell proliferation due to inactivation of GSK-3beta.
Squamous Cell Carcinoma of Head and Neck
Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Squamous Cell Carcinoma of Head and Neck
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Squamous Cell Carcinoma of Head and Neck
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Karyopherin-?1 Regulates Radioresistance and Radiation-Increased Programmed Death-Ligand 1 Expression in Human Head and Neck Squamous Cell Carcinoma Cell Lines.
Squamous Cell Carcinoma of Head and Neck
Lactate induces PD-L1 in HRASG12V-positive oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Lactoferricin B reverses cisplatin resistance in head and neck squamous cell carcinoma cells through targeting PD-L1.
Squamous Cell Carcinoma of Head and Neck
Letter to the Editor regarding, "The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis".
Squamous Cell Carcinoma of Head and Neck
Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
Squamous Cell Carcinoma of Head and Neck
METTL3 Intensifies the Progress of Oral Squamous Cell Carcinoma via Modulating the m6A Amount of PRMT5 and PD-L1.
Squamous Cell Carcinoma of Head and Neck
Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral ?? T cell equilibrium via tumor-derived exosomes.
Squamous Cell Carcinoma of Head and Neck
Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
miR-375 inhibits IFN-?-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
Squamous Cell Carcinoma of Head and Neck
Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages.
Squamous Cell Carcinoma of Head and Neck
Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck.
Squamous Cell Carcinoma of Head and Neck
PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
Squamous Cell Carcinoma of Head and Neck
PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRP? axis in HPV negative head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 and MRN synergy in platinum-based chemoresistance of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 evaluation in head and neck squamous cell carcinoma: Insights regarding specimens, heterogeneity and therapy.
Squamous Cell Carcinoma of Head and Neck
PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression correlated with p53 expression in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression in recurrent head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival.
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 Expression in Tumor Cells Is an Independent Unfavorable Prognostic Factor in Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression is associated with epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression is associated with p16
Squamous Cell Carcinoma of Head and Neck
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients.
Squamous Cell Carcinoma of Head and Neck
PD-L1 Immunohistochemistry Assay Concordance in Urothelial Carcinoma of the Bladder and Hypopharyngeal Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 in Combination with CD8+TIL and HIF-1? are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1 Influences Cell Spreading, Migration and Invasion in Head and Neck Cancer Cells.
Squamous Cell Carcinoma of Head and Neck
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Squamous Cell Carcinoma of Head and Neck
PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance.
Squamous Cell Carcinoma of Head and Neck
PD-L1 Testing and Squamous Cell Carcinoma of the Head and Neck: A Multicenter Study on the Diagnostic Reproducibility of Different Protocols.
Squamous Cell Carcinoma of Head and Neck
PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
PD1 expression and correlation with its ligands in oral cancer specimens and peripheral blood.
Squamous Cell Carcinoma of Head and Neck
Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective.
Squamous Cell Carcinoma of Head and Neck
Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
PKD3 promotes metastasis and growth of oral squamous cell carcinoma through positive feedback regulation with PD-L1 and activation of ERK-STAT1/3-EMT signalling.
Squamous Cell Carcinoma of Head and Neck
Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma.
Squamous Cell Carcinoma of Head and Neck
Predictive value of CD8/FOXP3 ratio combined with PD-L1 expression for radiosensitivity in patients with squamous cell carcinoma of the larynx receiving definitive radiation therapy.
Squamous Cell Carcinoma of Head and Neck
Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Prognostic and clinicopathological significance of PD-L1 overexpression in oral squamous cell carcinoma: A systematic review and comprehensive meta-analysis.
Squamous Cell Carcinoma of Head and Neck
Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment.
Squamous Cell Carcinoma of Head and Neck
Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Squamous Cell Carcinoma of Head and Neck
Prognostic Relevance of CD4+, CD8+ and FOXP3+ TILs in Oral Squamous Cell Carcinoma and Correlations with PD-L1 and Cancer Stem Cell Markers.
Squamous Cell Carcinoma of Head and Neck
Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials.
Squamous Cell Carcinoma of Head and Neck
Prognostic Significance of PD-L1 Expression and Its Tumor-Intrinsic Functions in Hypopharyngeal Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Squamous Cell Carcinoma of Head and Neck
Prognostic value of the association between MHC class I downregulation and PD-L1 upregulation in head and neck squamous cell carcinoma patients.
Squamous Cell Carcinoma of Head and Neck
Programmed death ligand-1 expression is associated with stage and histological grade of parotid carcinoma.
Squamous Cell Carcinoma of Head and Neck
Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Squamous Cell Carcinoma of Head and Neck
Regulation of PD-L1 expression in a high-grade invasive human oral squamous cell carcinoma microenvironment.
Squamous Cell Carcinoma of Head and Neck
Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage.
Squamous Cell Carcinoma of Head and Neck
Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Relationships between apparent diffusion coefficient (ADC) histogram analysis parameters and PD-L 1-expression in head and neck squamous cell carcinomas: a preliminary study.
Squamous Cell Carcinoma of Head and Neck
Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
Squamous Cell Carcinoma of Head and Neck
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Squamous Cell Carcinoma of Head and Neck
Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report.
Squamous Cell Carcinoma of Head and Neck
Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Squamous Cell Carcinoma of Head and Neck
Role of HPV status and PD-L1 expression in prognosis of laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Squamous Cell Carcinoma of Head and Neck
Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Spatial proximity between T and PD-L1 expressing cells as a prognostic biomarker for oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Squamous Cell Carcinoma of Head and Neck
Synergy of Radiotherapy and a Cancer Vaccine for the Treatment of HPV-Associated Head and Neck Cancer.
Squamous Cell Carcinoma of Head and Neck
Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
The 5-Ws of immunotherapy in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
The different role of PD-L1 in head and neck squamous cell carcinomas: A meta-analysis.
Squamous Cell Carcinoma of Head and Neck
The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
The genetic landscape of programmed death ligand-1 (PD-L1) alterations in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Squamous Cell Carcinoma of Head and Neck
The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
Squamous Cell Carcinoma of Head and Neck
The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Squamous Cell Carcinoma of Head and Neck
The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus-Associated Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
Squamous Cell Carcinoma of Head and Neck
The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
TIGIT/CD155 blockade enhances anti-PD-L1 therapy in head and neck squamous cell carcinoma by targeting myeloid-derived suppressor cells.
Squamous Cell Carcinoma of Head and Neck
TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Squamous Cell Carcinoma of Head and Neck
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Translational Insights and New Therapeutic Perspectives in Head and Neck Tumors.
Squamous Cell Carcinoma of Head and Neck
Trial watch: TLR3 agonists in cancer therapy.
Squamous Cell Carcinoma of Head and Neck
Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Tumor PD-L1 status and CD8
Squamous Cell Carcinoma of Head and Neck
Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1.
Squamous Cell Carcinoma of Head and Neck
[Bioinformatics analysis of programmed cell death ligand 1 co-expression genes and their regulatory network in head and neck squamous cell carcinoma].
Squamous Cell Carcinoma of Head and Neck
[Clinicopathological and prognostic significance of PD-L1 expression in oral squamous cell carcinoma: a meta analysis].
Starvation
Acid adaptation and starvation effects on Shiga toxin production by Escherichia coli O157:H7.
Starvation
Changes in Gene Transcription Induced by Hydrogen Peroxide Treatment of Verotoxin-Producing Escherichia coli O157:H7 and Non-O157 Serotypes on Romaine Lettuce.
Starvation
Lysozyme association with circulating RNA, extracellular vesicles, and chronic stress.
Starvation
The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling.
Stomach Diseases
Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis.
Stomach Diseases
Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry.
Stomach Neoplasms
5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients.
Stomach Neoplasms
A gene polymorphism in PD-L1 promoter region is not associated with PD-L1 expression and patients' survival in gastric cancer.
Stomach Neoplasms
A polymorphism in the promoter region of PD-L1 serves as a binding-site for SP1 and is associated with PD-L1 overexpression and increased occurrence of gastric cancer.
Stomach Neoplasms
A Preclinical Human-Derived Autologous Gastric Cancer Organoid/Immune Cell Co-Culture Model to Predict the Efficacy of Targeted Therapies.
Stomach Neoplasms
Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing.
Stomach Neoplasms
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
Stomach Neoplasms
AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in Gastric Cancer.
Stomach Neoplasms
Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer.
Stomach Neoplasms
Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Stomach Neoplasms
Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Stomach Neoplasms
APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Stomach Neoplasms
Appropriate PD-L1 Cutoff Value for Gastric Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
Stomach Neoplasms
ASO Author Reflections: The Prognostic Role of Exosomal PD-L1 in Patients with Gastric Cancer.
Stomach Neoplasms
Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer.
Stomach Neoplasms
Association between PD-L1 Expression on Tumour-Infiltrating Lymphocytes and Overall Survival in Patients with Gastric Cancer.
Stomach Neoplasms
Association of PD-L1 gene rs4143815 C>G polymorphism and human cancer susceptibility: A systematic review and meta-analysis.
Stomach Neoplasms
Associations of Epstein-Barr Virus-Positive Gastric Adenocarcinoma with Circulating Mediators of Inflammation and Immune Response.
Stomach Neoplasms
Autophagy inhibition enhances PD-L1 expression in gastric cancer.
Stomach Neoplasms
Banxia Xiexin Decoction Inhibits the Expression of PD-L1 Through Multi-Target and Multi-Pathway Regulation of Major Oncogenes in Gastric Cancer.
Stomach Neoplasms
Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.
Stomach Neoplasms
Chemoradiation induces upregulation of immunogenic cell death-related molecules together with increased expression of PD-L1 and galectin-9 in gastric cancer.
Stomach Neoplasms
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Stomach Neoplasms
Circulating PD-L1 is associated with T cell infiltration and predicts prognosis in patients with CRLM following hepatic resection.
Stomach Neoplasms
Clinic-Pathological Characteristics and Prognostic Value of PD-L1 and HER2 in Gastric Cancer.
Stomach Neoplasms
Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients.
Stomach Neoplasms
Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer.
Stomach Neoplasms
Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.
Stomach Neoplasms
Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.
Stomach Neoplasms
CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients.
Stomach Neoplasms
Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Stomach Neoplasms
Combined prognostic effect of PD-L1 expression and immunoscore in microsatellite-unstable advanced gastric cancers.
Stomach Neoplasms
Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens.
Stomach Neoplasms
Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer.
Stomach Neoplasms
CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.
Stomach Neoplasms
CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
Stomach Neoplasms
Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.
Stomach Neoplasms
Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.
Stomach Neoplasms
Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer.
Stomach Neoplasms
Digital image analysis in pathologist-selected regions of interest predicts survival more accurately than whole-slide analysis: a direct comparison study in 153 gastric carcinomas.
Stomach Neoplasms
Discordancy and changes in the pattern of programmed death ligand 1 expression before and after platinum-based chemotherapy in metastatic gastric cancer.
Stomach Neoplasms
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
Stomach Neoplasms
Effect of anti-PD-1 antibody, nivolumab on early gastric cancer.
Stomach Neoplasms
EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.
Stomach Neoplasms
Exosomal miRNA-16-5p Derived From M1 Macrophages Enhances T Cell-Dependent Immune Response by Regulating PD-L1 in Gastric Cancer.
Stomach Neoplasms
Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.
Stomach Neoplasms
Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer.
Stomach Neoplasms
Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer.
Stomach Neoplasms
Expression patterns of programmed death-1 and programmed death-1 ligand-1 on T cells in gastric cancer.
Stomach Neoplasms
Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1.
Stomach Neoplasms
Extracellular Vesicles From Gastric Cancer Cells Induce PD-L1 Expression on Neutrophils to Suppress T-Cell Immunity.
Stomach Neoplasms
FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Stomach Neoplasms
Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.
Stomach Neoplasms
Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times.
Stomach Neoplasms
Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.
Stomach Neoplasms
GARP Correlates With Tumor-Infiltrating T-Cells and Predicts the Outcome of Gastric Cancer.
Stomach Neoplasms
Gastric adenocarcinomas express the glycosphingolipid Gb3/CD77: Targeting of gastric cancer cells with Shiga toxin B-subunit.
Stomach Neoplasms
Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis.
Stomach Neoplasms
Genes Involved in the PD-L1 Pathway Might Associate with Radiosensitivity of Patients with Gastric Cancer.
Stomach Neoplasms
Glycoprofiling of Early Gastric Cancer Using Lectin Microarray Technology.
Stomach Neoplasms
Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer.
Stomach Neoplasms
Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids.
Stomach Neoplasms
Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections.
Stomach Neoplasms
High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features.
Stomach Neoplasms
Higher postoperative plasma EV PD-L1 predicts poor survival in patients with gastric cancer.
Stomach Neoplasms
Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression.
Stomach Neoplasms
Human Leukocyte Antigen Class I Deficiency in Gastric Carcinoma: An Adaptive Immune Evasion Strategy Most Common in Microsatellite Instable Tumors.
Stomach Neoplasms
Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications.
Stomach Neoplasms
Identification of functional methylated CpG loci in PD-L1 promoter as the novel epigenetic biomarkers for primary gastric cancer.
Stomach Neoplasms
IFN? induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
Stomach Neoplasms
Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma.
Stomach Neoplasms
Immunochemotherapy benefits in gastric cancer patients stratified by programmed death-1 ligand-1.
Stomach Neoplasms
Immunoclassification characterized by CD8 and PD-L1 expression is associated with the clinical outcome of gastric cancer patients.
Stomach Neoplasms
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial.
Stomach Neoplasms
Increased Programmed Death-Ligand 1 is an Early Epithelial Cell Response to Helicobacter pylori Infection.
Stomach Neoplasms
Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis.
Stomach Neoplasms
Inhibition of NF-?B is required for oleanolic acid to downregulate PD-L1 by promoting DNA demethylation in gastric cancer cells.
Stomach Neoplasms
Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer.
Stomach Neoplasms
Interferon-? induced PD-L1 expression and soluble PD-L1 production in gastric cancer.
Stomach Neoplasms
Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients.
Stomach Neoplasms
Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
Stomach Neoplasms
Investigation on potential biomarkers of hyperprogressive disease (HPD) triggered by immune checkpoint inhibitors (ICIs).
Stomach Neoplasms
Is high serum programmed death ligand 1 level a risk factor for poor survival in patients with gastric cancer?
Stomach Neoplasms
Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.
Stomach Neoplasms
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
Stomach Neoplasms
Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications.
Stomach Neoplasms
LncRNA SNHG15 Contributes to Immuno-Escape of Gastric Cancer Through Targeting miR141/PD-L1.
Stomach Neoplasms
LPS promotes the expression of PD-L1 in gastric cancer cells through NF-?B activation.
Stomach Neoplasms
Lymph nodes may be a source for immunetherapy in gastric cancer.
Stomach Neoplasms
MicroRNA-200c Nanoparticles Sensitized Gastric Cancer Cells to Radiotherapy by Regulating PD-L1 Expression and EMT.
Stomach Neoplasms
MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer.
Stomach Neoplasms
Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer.
Stomach Neoplasms
Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer: Post Hoc Analysis of the CLASSIC Randomized Controlled study.
Stomach Neoplasms
miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer.
Stomach Neoplasms
miR-502-5p affects gastric cancer progression by targeting PD-L1.
Stomach Neoplasms
MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression.
Stomach Neoplasms
Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1/PD- L1-dependent T cell immunization.
Stomach Neoplasms
Molecular and pathological features in patients with gastric cancer in Argentina. Association between Epstein Barr Virus, MSI, PD-L1 expression and T-cells infiltration.
Stomach Neoplasms
Molecular features and translational outlook for Epstein-Barr virus-associated gastric cancer.
Stomach Neoplasms
Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment.
Stomach Neoplasms
Multi-layered control of PD-L1 expression in Epstein-Barr virus-associated gastric cancer.
Stomach Neoplasms
Mutations Defining Patient Cohorts With Elevated PD-L1 Expression in Gastric Cancer.
Stomach Neoplasms
Optimized PD-L1 scoring of gastric cancer.
Stomach Neoplasms
Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications.
Stomach Neoplasms
Pathological Complete Response After a Single Dose of Anti-PD-1 Therapy in Combination with Chemotherapy as a First-Line Setting in an Unresectable Locally Advanced Gastric Cancer with PD-L1 Positive and Microsatellite Instability.
Stomach Neoplasms
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.
Stomach Neoplasms
PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.
Stomach Neoplasms
PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice.
Stomach Neoplasms
PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
Stomach Neoplasms
PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis.
Stomach Neoplasms
PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer.
Stomach Neoplasms
PD-L1 and Survival in Solid Tumors: A Meta-Analysis.
Stomach Neoplasms
PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability.
Stomach Neoplasms
PD-L1 Expression and CD8+ T Cell Infiltration Predict a Favorable Prognosis in Advanced Gastric Cancer.
Stomach Neoplasms
PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
Stomach Neoplasms
PD-L1 Expression Associated with Epstein-Barr Virus Status and Patients' Survival in a Large Cohort of Gastric Cancer Patients in Northern Brazil.
Stomach Neoplasms
PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Stomach Neoplasms
PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays.
Stomach Neoplasms
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
Stomach Neoplasms
PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
Stomach Neoplasms
PD-L1 expression in human cancers and its association with clinical outcomes.
Stomach Neoplasms
PD-L1 expression in paired biopsies and surgical specimens in gastric adenocarcinoma: A digital image analysis study.
Stomach Neoplasms
PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers.
Stomach Neoplasms
PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
Stomach Neoplasms
PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer.
Stomach Neoplasms
PD-L1 Expression Is Regulated By NF-?B During EMT Signaling In Gastric Carcinoma.
Stomach Neoplasms
PD-L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer.
Stomach Neoplasms
PD-L1 is an independent prognostic predictor in gastric cancer of Western patients.
Stomach Neoplasms
PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells.
Stomach Neoplasms
PD-L1 monoclonal antibody-decorated nanoliposomes loaded with Paclitaxel and P-gp transport inhibitor for the synergistic chemotherapy against multidrug resistant gastric cancers.
Stomach Neoplasms
PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms.
Stomach Neoplasms
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Stomach Neoplasms
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
Stomach Neoplasms
PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.
Stomach Neoplasms
PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer.
Stomach Neoplasms
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.
Stomach Neoplasms
Peripheral blood T lymphocytes are downregulated by the PD-1/PD-L1 axis in advanced gastric cancer.
Stomach Neoplasms
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors.
Stomach Neoplasms
Poor Clinical Outcomes and Immunoevasive Contexture in Intratumoral IL-10-Producing Macrophages Enriched Gastric Cancer Patients.
Stomach Neoplasms
Predictive relevance of PD-L1 expression with pre-existing TILs in gastric cancer.
Stomach Neoplasms
Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Stomach Neoplasms
Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Stomach Neoplasms
Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
Stomach Neoplasms
Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
Stomach Neoplasms
Prognostic and predictive values of PD-L1 expression in patients with digestive system cancer: a meta-analysis.
Stomach Neoplasms
Prognostic role of ARID1A negative expression in gastric cancer.
Stomach Neoplasms
Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
Stomach Neoplasms
Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Stomach Neoplasms
Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis.
Stomach Neoplasms
Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
Stomach Neoplasms
Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis.
Stomach Neoplasms
Prognostic significance of soluble forms of immune checkpoint PD-1/PDL1 receptor and ligand in blood plasma of gastric cancer patients.
Stomach Neoplasms
Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma.
Stomach Neoplasms
Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
Stomach Neoplasms
Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.
Stomach Neoplasms
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability.
Stomach Neoplasms
Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group.
Stomach Neoplasms
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Stomach Neoplasms
Programmed death-ligand 1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer.
Stomach Neoplasms
Programmed death-ligand 1 monoclonal antibody-linked immunoliposomes for synergistic efficacy of miR-130a and oxaliplatin in gastric cancers.
Stomach Neoplasms
Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
Stomach Neoplasms
Prominent PD-L1-positive M2 macrophage infiltration in gastric cancer with hyper-progression after anti-PD-1 therapy: A case report.
Stomach Neoplasms
Protective role of astragaloside IV in gastric cancer through regulation of microRNA-195-5p-mediated PD-L1.
Stomach Neoplasms
Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma.
Stomach Neoplasms
PTEN Protein Loss and Loss-of-Function Mutations in Gastric Cancers: The Relationship with Microsatellite Instability, EBV, HER2, and PD-L1 Expression.
Stomach Neoplasms
Receptor-interacting protein-1 promotes the growth and invasion in gastric cancer.
Stomach Neoplasms
Regulatory T cells and M2 macrophages present diverse prognostic value in gastric cancer patients with different clinicopathologic characteristics and chemotherapy strategies.
Stomach Neoplasms
Relationship between Helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer.
Stomach Neoplasms
Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer.
Stomach Neoplasms
Relationship between the expressions of PD-L1 and tumour-associated fibroblasts in gastric cancer.
Stomach Neoplasms
Research progress of PD-1/PD-L1 immunotherapy in gastrointestinal tumors.
Stomach Neoplasms
Role of PD-L1 Expression during the Progression of Submucosal Gastric Cancer.
Stomach Neoplasms
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF? and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Stomach Neoplasms
Safety of pembrolizumab in recurrent or advanced gastric cancer expressing PD-L1 refractory to platinum and fluoropyrimidine.
Stomach Neoplasms
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432.
Stomach Neoplasms
Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
Stomach Neoplasms
Serum alpha-fetoprotein subfractions identified by Ricinus communis agglutinin I in hepatic malignancies, yolk sac tumor, benign hepatic diseases, and fetal stage.
Stomach Neoplasms
Shiga-like toxin I exerts specific and potent anti-tumour efficacy against gastric cancer cell proliferation when driven by tumour-preferential Frizzled-7 promoter.
Stomach Neoplasms
Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer.
Stomach Neoplasms
Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Stomach Neoplasms
Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type.
Stomach Neoplasms
Targeted anti-tumor agents and their cytotoxicity on gastric cancer cells in vitro.
Stomach Neoplasms
The clinical significance of PD-L1 in advanced gastric cancer is dependent on ARID1A mutations and ATM expression.
Stomach Neoplasms
The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients.
Stomach Neoplasms
The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Stomach Neoplasms
The Emerging Role of Liquid Biopsy in Gastric Cancer.
Stomach Neoplasms
The killing effect of novel bi-specific Trop2/PD-L1 CAR-T cell targeted gastric cancer.
Stomach Neoplasms
The PD-1:PD-L1 immune inhibitory checkpoint in
Helicobacter pylori
infection and gastric cancer: a comprehensive review and future perspectives.
Stomach Neoplasms
The prediction of survival of patients with gastric cancer with PD-L1 expression using contrast-enhanced ultrasonography.
Stomach Neoplasms
The Prognostic Value of Pre-treatment Hemoglobin (Hb) in Patients With Advanced or Metastatic Gastric Cancer Treated With Immunotherapy.
Stomach Neoplasms
The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability
Stomach Neoplasms
The Right Treatment of the Right Patient: Integrating Genetic Profiling Into Clinical Decision Making in Advanced Gastric Cancer in Asia.
Stomach Neoplasms
Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
Stomach Neoplasms
Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
Stomach Neoplasms
Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status.
Stomach Neoplasms
Tumor Mutational Burden Determined by Panel Sequencing Predicts Survival After Immunotherapy in Patients With Advanced Gastric Cancer.
Stomach Neoplasms
Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-? signaling.
Stomach Neoplasms
Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer.
Stomach Neoplasms
Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer.
Stomach Neoplasms
Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer.
Stomach Neoplasms
What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
Stomach Neoplasms
[Expression level and prognostic value of PD-L1 in microsatellite instability-high gastric cancer].
Stomach Neoplasms
[Immuno-ricin A chain specific for gastric cancer: internalization and its significance]
Stomach Neoplasms
[Progression of immunotherapy in gastric cancer].
Stomach Neoplasms
[Relationship between PD-L1 protein expression and gene amplification in gastric cancer tissues].
Stomach Neoplasms
[The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.]
Stomach Ulcer
Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use.
Stomach Ulcer
Prevalence of programmed death-1 ligand-1 (PD-L1) and infiltrating lymphocytes in human gastric carcinogenesis.
Stomach Ulcer
The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Stomach Ulcer
Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry.
Stroke
PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
Stroke
PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation.
Stroke
Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.
Superinfection
Shiga toxin-producing Escherichia coli strains from cattle as a source of the Stx2a bacteriophages present in enteroaggregative Escherichia coli O104:H4 strains.
Synovitis
Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis.
Tachycardia
Clinical and Pathological Findings Associated with Aerosol Exposure of Macaques to Ricin Toxin.
Tachycardia, Ventricular
Targeted ablation of cardiac sympathetic neurons reduces the susceptibility to ischemia-induced sustained ventricular tachycardia in conscious rats.
Tarsal Tunnel Syndrome
Combined tarsal and carpal tunnel syndrome in mucolipidosis type III. A case study and review.
Tauopathies
Key role of the CCR2-CCL2 axis in disease modification in a mouse model of tauopathy.
Tauopathies
PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model.
Teratocarcinoma
Mutants of embryonal carcinoma cells defective in the expression of embryoglycan.
Teratocarcinoma
Potentiation of PD-L1 blockade with a potency-matched dual cytokine-antibody fusion protein leads to cancer eradication in BALB/c-derived tumors but not in other mouse strains.
Teratocarcinoma
Saporin toxins directed to basic fibroblast growth factor receptors effectively target human ovarian teratocarcinoma in an animal model.
Teratoma
Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.
Teratoma
Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
Teratoma
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
Teratoma
XCL1 expression correlates with CD8-positive T cells infiltration and PD-L1 expression in squamous cell carcinoma arising from mature cystic teratoma of the ovary.
Testicular Neoplasms
Frequent PD-L1 expression in testicular germ cell tumors.
Testicular Neoplasms
Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors.
Testicular Neoplasms
Testicular cancer: PD-L1: a promising target for TGCTs.
Tetanus
Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery.
Tetanus
Bacterial toxins: friends or foes?
Tetanus
Fluorescence emission and polarization analyses for evaluating binding of ruthenium metalloglycoclusters to lectins and tetanus toxin C-fragment.
Tetanus
Fluorescence emission and polarization for analyzing binding of ruthenium metalloglycocluster to lectin and tetanus toxin C-fragment.
Tetanus
Mosquito inoculation: an alternative bioassay for toxins.
Tetanus
Multireactive human monoclonal antibodies.
Tetanus
Protein biotoxins of military significance.
Tetanus
Retrograde axonal transport of specific macromolecules as a tool for characterizing nerve terminal membranes.
Tetanus
Selective abrogation of antigen-specific human B cell responses by antigen-ricin conjugates.
Tetanus
The heavy chain of tetanus toxin can mediate the entry of cytotoxic gelonin into intact cells.
Tetanus
The threat of mid-spectrum chemical warfare agents.
Thrombocytopenia
A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor.
Thrombocytopenia
Absence of interleukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome.
Thrombocytopenia
Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
Thrombocytopenia
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Thrombocytopenia
Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome.
Thrombocytopenia
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
Thrombocytopenia
Chemokine Receptor CCR1 Disruption Limits Renal Damage in a Murine Model of Hemolytic Uremic Syndrome.
Thrombocytopenia
Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Thrombocytopenia
Detection of E. coli O157:H7 and Shigella dysenteriae toxins in clinical samples by PCR-ELISA.
Thrombocytopenia
Development and Evaluation of a Novel VHH-Based Immunocapture Assay for High-Sensitivity Detection of Shiga Toxin Type 2 (Stx2) in Stool Samples.
Thrombocytopenia
Development of a Mouse Model of Shiga Toxin 2 (STX2) Intoxication for Testing Therapeutic Agents against Hemolytic Uremic Syndrome (HUS).
Thrombocytopenia
Epithelial cell signaling responses to enterohemorrhagic Escherichia coli infection.
Thrombocytopenia
Genetics of hemolytic uremic syndromes.
Thrombocytopenia
Human platelet aggregation is not altered by Shiga toxins 1 or 2.
Thrombocytopenia
Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo.
Thrombocytopenia
Immune Thrombocytopenia Induced by Immune Checkpoint Inhibitors in Solid Cancer: Case Report and Literature Review.
Thrombocytopenia
Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Thrombocytopenia
Ingested Shiga Toxin 2 (Stx2) Causes Histopathological Changes in Kidney, Spleen, and Thymus Tissues and Mortality in Mice.
Thrombocytopenia
Intramuscular Ricin Poisoning of Mice Leads to Widespread Damage in the Heart, Spleen, and Bone Marrow.
Thrombocytopenia
Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice.
Thrombocytopenia
Norovirus: a novel etiologic agent in hemolytic uremic syndrome in an infant.
Thrombocytopenia
Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome.
Thrombocytopenia
Postoperative hemolytic uremic syndrome with renal cortical necrosis following laparoscopic hemicolectomy.
Thrombocytopenia
Quantification and prognostic value of programmed cell death ligand-1 expression in dogs with diffuse large B-cell lymphoma.
Thrombocytopenia
Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.
Thrombocytopenia
Shiga toxin binds human platelets via globotriaosylceramide (Pk antigen) and a novel platelet glycosphingolipid.
Thrombocytopenia
Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.
Thrombocytopenia
Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction.
Thrombocytopenia
Shiga toxin-producing Escherichia coli O157:H7 show an increased pathogenicity in mice after the passage through the gastrointestinal tract of the same host.
Thrombocytopenia
Shiga toxins stimulate secretion of interleukin-8 from intestinal epithelial cells.
Thrombocytopenia
The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome.
Thrombocytosis
Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
Thrombosis
A laboratory model of toxin-induced hemolytic uremic syndrome.
Thrombosis
Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis.
Thrombosis
Anti-programmed cell death ligand 1-based immunotherapy in recurrent hepatocellular carcinoma with inferior vena cava tumor thrombus and metastasis: Three case reports.
Thrombosis
Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1.
Thrombosis
Intravenous Shiga toxin 2 promotes enteritis and renal injury characterized by polymorphonuclear leukocyte infiltration and thrombosis in Dutch Belted rabbits.
Thrombosis
Isolation and Characterization of Shiga Toxin-Associated Microvesicles.
Thrombosis
Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma.
Thrombosis
Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus.
Thrombosis
Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model.
Thrombosis
Role of nitric oxide in a toxin-induced model of haemolytic uraemic syndrome.
Thrombosis
Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement.
Thrombosis
Shiga toxins, glycosphingolipid diversity, and endothelial cell injury.
Thrombosis
The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
Thrombotic Microangiopathies
A laboratory model of toxin-induced hemolytic uremic syndrome.
Thrombotic Microangiopathies
Activated Prothrombin Complex Concentrate-Induced Atypical Hemolytic Uremic Syndrome Treated with Eculizumab.
Thrombotic Microangiopathies
An Atypical Case of Shiga Toxin Producing-Escherichia Coli Hemolytic and Uremic Syndrome (STEC-HUS) in a Lung Transplant Recipient.
Thrombotic Microangiopathies
Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis.
Thrombotic Microangiopathies
Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli.
Thrombotic Microangiopathies
Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo.
Thrombotic Microangiopathies
Interaction of Shiga Toxin with the A-Domains and Multimers of von Willebrand Factor.
Thrombotic Microangiopathies
Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.
Thrombotic Microangiopathies
Role of nitric oxide in a toxin-induced model of haemolytic uraemic syndrome.
Thrombotic Microangiopathies
Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy.
Thrombotic Microangiopathies
Shiga toxin associated hemolytic uremic syndrome.
Thrombotic Microangiopathies
Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice.
Thrombotic Microangiopathies
The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome.
Thrombotic Microangiopathies
Thrombotic microangiopathies: Similar presentations, different therapies.
Thrombotic Microangiopathies
Unusual severe case of hemolytic uremic syndrome due to Shiga toxin 2d-producing E. coli O80:H2.
Thrombotic Microangiopathies
[Globosides as key players in the pathophysiology of Shiga toxin-associated acute kidney failure and Fabry disease].
Thymoma
A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma.
Thymoma
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Thymoma
Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma.
Thymoma
Clinicopathologic Features of Thymoma With the Expression of Programmed Death Ligand 1.
Thymoma
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors.
Thymoma
Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma.
Thymoma
Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Thymoma
Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors.
Thymoma
Correlation of genomic alterations and PD-L1 expression in thymoma.
Thymoma
Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma.
Thymoma
Downregulation of CYLD promotes IFN-? mediated PD-L1 expression in thymic epithelial tumors.
Thymoma
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Thymoma
Expression of PD-1 and PD-L1 in thymic epithelial neoplasms.
Thymoma
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Thymoma
Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma.
Thymoma
Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
Thymoma
Impact of PD-L1, transforming growth factor-? expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors.
Thymoma
Interferon sensitive and insensitive MHC variants of a murine thymoma differentially resistant to methotrexate-containing antibody-directed liposomes and immunotoxin.
Thymoma
Pathology of thymoma-where are we today?
Thymoma
PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms.
Thymoma
PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis.
Thymoma
PD-L1 immuno-expression assay in thymomas: Study of 84 cases and review of literature.
Thymoma
PD-L1, PD-1, CD4, and CD8 expression in neoplastic and nonneoplastic thymus.
Thymoma
Perspective of Immune Checkpoint Inhibitors in Thymic Carcinoma.
Thymoma
Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
Thymoma
Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses.
Thymoma
Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression.
Thymoma
Tumor immunity is related to 18 F-FDG uptake in thymic epithelial tumor.
Thymoma
[A Case of Recurrent Thymoma Treated with Pembrolizumab as the Fifth-Line Chemotherapy].
Thymus Hyperplasia
PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus.
Thyroid Cancer, Papillary
Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer.
Thyroid Cancer, Papillary
Comprehensive screening for PD-L1 expression in thyroid cancer.
Thyroid Cancer, Papillary
CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers.
Thyroid Cancer, Papillary
Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer.
Thyroid Cancer, Papillary
Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer.
Thyroid Cancer, Papillary
In papillary thyroid carcinoma, expression by immunohistochemistry of BRAF V600E, PD-L1, and PD-1 is closely related.
Thyroid Cancer, Papillary
Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Thyroid Cancer, Papillary
PD-1, CTLA4, PD-L1 and PD-L2 DNA methylation in papillary thyroid carcinoma.
Thyroid Cancer, Papillary
PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.
Thyroid Cancer, Papillary
PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study.
Thyroid Cancer, Papillary
PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid carcinoma.
Thyroid Cancer, Papillary
PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Thyroid Cancer, Papillary
Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Thyroid Cancer, Papillary
Programmed Death-Ligand 1 Expression and Its Correlation with Lymph Node Metastasis in Papillary Thyroid Carcinoma.
Thyroid Cancer, Papillary
Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Thyroid Cancer, Papillary
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Thyroid Carcinoma, Anaplastic
Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Thyroid Carcinoma, Anaplastic
Comprehensive screening for PD-L1 expression in thyroid cancer.
Thyroid Carcinoma, Anaplastic
CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers.
Thyroid Carcinoma, Anaplastic
Expression of PD-1 and PD-L1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study.
Thyroid Carcinoma, Anaplastic
HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
Thyroid Carcinoma, Anaplastic
PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Thyroid Diseases
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
Thyroid Neoplasms
Androgen Activity Is Associated With PD-L1 Downregulation in Thyroid Cancer.
Thyroid Neoplasms
Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.
Thyroid Neoplasms
Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer.
Thyroid Neoplasms
Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
Thyroid Neoplasms
Comprehensive screening for PD-L1 expression in thyroid cancer.
Thyroid Neoplasms
Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer.
Thyroid Neoplasms
Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer.
Thyroid Neoplasms
EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
Thyroid Neoplasms
FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale.
Thyroid Neoplasms
HIF1?/PD-L1 axis mediates hypoxia-induced cell apoptosis and tumor progression in follicular thyroid carcinoma.
Thyroid Neoplasms
Immune Landscape of Thyroid Cancers: New Insights.
Thyroid Neoplasms
Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Thyroid Neoplasms
PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications.
Thyroid Neoplasms
PD-1/PD-L1 expressions in medullary thyroid carcinoma: Clinicopathologic and prognostic analysis of Chinese population.
Thyroid Neoplasms
PD-L1 and IDO1 Are Expressed in Poorly Differentiated Thyroid Carcinoma.
Thyroid Neoplasms
PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
Thyroid Neoplasms
PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
Thyroid Neoplasms
Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.
Thyroid Neoplasms
PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER.
Thyroid Neoplasms
Programmed Death-Ligand 1 (PD-L1) Is a Potential Biomarker of Disease-Free Survival in Papillary Thyroid Carcinoma: a Systematic Review and Meta-Analysis of PD-L1 Immunoexpression in Follicular Epithelial Derived Thyroid Carcinoma.
Thyroid Neoplasms
Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions.
Thyroid Neoplasms
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
Thyroid Neoplasms
THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy.
Thyroid Neoplasms
The clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis.
Thyroid Neoplasms
Very low expression of PD-L1 in medullary thyroid carcinoma.
Thyroid Nodule
Programmed Death - Ligand 1 Expression Distinguishes Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma from Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features.
Thyroid Nodule
Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
Thyroiditis
Association between programmed cell death ligand 1 expression and thyroid cancer: A meta-analysis.
Thyroiditis
Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Thyroiditis
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Thyroiditis
Pembrolizumab-Induced Thyroiditis Shows PD-L1Expressing Histiocytes and Infiltrating T Cells in Thyroid Tissue - A Case Report.
Thyroiditis
Programmed Cell Death-Ligand 1 (PD-L1) gene Single Nucleotide Polymorphism in Graves' Disease and Hashimoto's Thyroiditis in Korean Patients.
Thyroiditis
Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.
Thyroiditis
The clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis.
Thyroiditis
Thyroid dysfunction and survival in cancer patients treated with immune checkpoint inhibitors: analyses from a large single tertiary cancer center database.
Thyroiditis, Autoimmune
PD-L1 expression in papillary thyroid cancer with and without lymphocytic thyroiditis: a cross sectional study.
Thyroiditis, Autoimmune
Reduced expression of PD-L1 in autoimmune thyroiditis attenuate trophoblast invasion through ERK/MMP pathway.
Thyrotoxicosis
Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade.
Thyrotoxicosis
Pathogenic role of asialo human chorionic gonadotropin in gestational thyrotoxicosis.
Thyrotoxicosis
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Tics
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study.
Tics
PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.
Tongue Neoplasms
Significance of PD-L1 Expression in Tongue Cancer Development.
Tonsillar Neoplasms
PD-L1 expression in tonsillar cancer is associated with human papillomavirus positivity and improved survival: implications for anti-PD1 clinical trials.
Toxemia
Improved porcine model for Shiga toxin-producing Escherichia coli infection by deprivation of colostrum feeding in newborn piglets.
Toxemia
Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin.
Toxemia
Shiga toxin 2eB-transgenic lettuce vaccine is effective in protecting weaned piglets from edema disease caused by Shiga toxin-producing Escherichia coli infection.
Toxemia
Toxemia as a stimulation factor in the production of antibodies; studies on precipitin production in the dog; the use of ricin.
Toxoplasmosis, Ocular
CD4 T-cell suppression by cells from Toxoplasma gondii-infected retinas is mediated by surface protein PD-L1.
Tremor
Impaired and spared cholinergic functions in the hippocampus after lesions of the medial septum/vertical limb of the diagonal band with 192 IgG-saporin.
Triple Negative Breast Neoplasms
A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors.
Triple Negative Breast Neoplasms
A novel ternary heterostructure with dramatic SERS activity for evaluation of PD-L1 expression at the single-cell level.
Triple Negative Breast Neoplasms
A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
A pragmatic adaptive enrichment design for selecting the right target population for cancer immunotherapies.
Triple Negative Breast Neoplasms
An Fc-free EGFR-specific 4-1BB-agonistic Trimerbody Displays Broad Antitumor Activity in Humanized Murine Cancer Models without Toxicity.
Triple Negative Breast Neoplasms
Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
Triple Negative Breast Neoplasms
Assessment of PD-L1 expression and tumor-infiltrating lymphocytes (TILs) across molecular subtypes of triple-negative breast cancer.
Triple Negative Breast Neoplasms
Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Triple Negative Breast Neoplasms
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Triple Negative Breast Neoplasms
Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer.
Triple Negative Breast Neoplasms
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Triple Negative Breast Neoplasms
BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?
Triple Negative Breast Neoplasms
Cancer-associated oxidoreductase ERO1-? promotes immune escape through up-regulation of PD-L1 in human breast cancer.
Triple Negative Breast Neoplasms
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
Triple Negative Breast Neoplasms
Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity.
Triple Negative Breast Neoplasms
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Triple Negative Breast Neoplasms
Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
Triple Negative Breast Neoplasms
Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy.
Triple Negative Breast Neoplasms
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
Triple Negative Breast Neoplasms
Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells.
Triple Negative Breast Neoplasms
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
Triple Negative Breast Neoplasms
Comparison of three FDA-approved diagnostic immunohistochemistry assays of PD-L1 in triple-negative breast carcinoma.
Triple Negative Breast Neoplasms
Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
Triple Negative Breast Neoplasms
Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
Triple Negative Breast Neoplasms
Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.
Triple Negative Breast Neoplasms
Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan.
Triple Negative Breast Neoplasms
Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system.
Triple Negative Breast Neoplasms
Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.
Triple Negative Breast Neoplasms
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.
Triple Negative Breast Neoplasms
Determining PD-L1 Status in Patients with Triple-Negative Breast Cancer: Lessons Learned from IMpassion130.
Triple Negative Breast Neoplasms
Differential Prognostic Impact of Strong PD-L1 Expression and 18F-FDG Uptake in Triple-negative Breast Cancer.
Triple Negative Breast Neoplasms
Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Efficiently restoring the tumoricidal immunity against resistant malignancies via an immune nanomodulator.
Triple Negative Breast Neoplasms
EP4 as a Therapeutic Target for Aggressive Human Breast Cancer.
Triple Negative Breast Neoplasms
Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
Triple Negative Breast Neoplasms
Erratum: The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
Triple Negative Breast Neoplasms
Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer.
Triple Negative Breast Neoplasms
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Triple Negative Breast Neoplasms
Expression of PD-L1 using SP142 CDx in triple negative breast cancer.
Triple Negative Breast Neoplasms
Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
Triple Negative Breast Neoplasms
FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1.
Triple Negative Breast Neoplasms
GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
Triple Negative Breast Neoplasms
Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade.
Triple Negative Breast Neoplasms
Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
Triple Negative Breast Neoplasms
High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
Triple Negative Breast Neoplasms
Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Triple Negative Breast Neoplasms
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
Triple Negative Breast Neoplasms
Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from PD-L1 inhibition in women with early triple-negative breast cancer.
Triple Negative Breast Neoplasms
Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
Triple Negative Breast Neoplasms
Immunotherapy for early breast cancer: too soon, too superficial, or just right?
Triple Negative Breast Neoplasms
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Triple Negative Breast Neoplasms
Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging.
Triple Negative Breast Neoplasms
Intrapatient Tumor Heterogeneity in IHC Interpretation Using PD-L1 IHC 22C3 pharmDx.
Triple Negative Breast Neoplasms
Investigation of the Effect of PD-L1 Blockade on Triple Negative Breast Cancer Cells Using Fourier Transform Infrared Spectroscopy.
Triple Negative Breast Neoplasms
JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Triple Negative Breast Neoplasms
JQ1-Loaded Polydopamine Nanoplatform Inhibits c-MYC/Programmed Cell Death Ligand 1 to Enhance Photothermal Therapy for Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
Triple Negative Breast Neoplasms
MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression.
Triple Negative Breast Neoplasms
Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer.
Triple Negative Breast Neoplasms
MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
Triple Negative Breast Neoplasms
Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Next-Generation Sequencing-Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer: Potential Implications for Clinical Management.
Triple Negative Breast Neoplasms
Novel RAF/MEK inhibitor CH5126766/VS-6766 has efficacy in combination with eribulin for the treatment of triple-negative breast cancer.
Triple Negative Breast Neoplasms
NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Oncolytic poxvirus CF33-hNIS-?F14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Triple Negative Breast Neoplasms
PD-L1 and intratumoral immune response in breast cancer.
Triple Negative Breast Neoplasms
PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.
Triple Negative Breast Neoplasms
PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.
Triple Negative Breast Neoplasms
PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy.
Triple Negative Breast Neoplasms
PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.
Triple Negative Breast Neoplasms
PD-L1 expression in triple-negative breast cancer.
Triple Negative Breast Neoplasms
PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Triple Negative Breast Neoplasms
PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
Triple Negative Breast Neoplasms
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
PD-L1 Inhibitor Improves Survival in TNBC.
Triple Negative Breast Neoplasms
PD-L1 Protein Expression in Middle Eastern Breast Cancer Predicts Favorable Outcome in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.
Triple Negative Breast Neoplasms
PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Triple Negative Breast Neoplasms
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Triple Negative Breast Neoplasms
PD-L1 testing based on the SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion.
Triple Negative Breast Neoplasms
PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.
Triple Negative Breast Neoplasms
PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer.
Triple Negative Breast Neoplasms
Pembrolizumab in the preoperative setting of triple-negative breast cancer: safety and efficacy.
Triple Negative Breast Neoplasms
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Triple Negative Breast Neoplasms
Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment.
Triple Negative Breast Neoplasms
Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside.
Triple Negative Breast Neoplasms
Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression.
Triple Negative Breast Neoplasms
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies.
Triple Negative Breast Neoplasms
Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.
Triple Negative Breast Neoplasms
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer.
Triple Negative Breast Neoplasms
Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
Triple Negative Breast Neoplasms
Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer.
Triple Negative Breast Neoplasms
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type.
Triple Negative Breast Neoplasms
Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer.
Triple Negative Breast Neoplasms
Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.
Triple Negative Breast Neoplasms
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.
Triple Negative Breast Neoplasms
Respiratory hyperoxia reverses immunosuppression by regulating myeloid-derived suppressor cells and PD-L1 expression in a triple-negative breast cancer mouse model.
Triple Negative Breast Neoplasms
Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Triple Negative Breast Neoplasms
Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Triple Negative Breast Neoplasms
Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer.
Triple Negative Breast Neoplasms
The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Triple Negative Breast Neoplasms
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Triple Negative Breast Neoplasms
The cost-effectiveness of atezolizumab in first-line for metastatic triple negative breast cancer is heavily linked to PD-L1 level.
Triple Negative Breast Neoplasms
The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Triple Negative Breast Neoplasms
The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.
Triple Negative Breast Neoplasms
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Triple Negative Breast Neoplasms
The stabilization of PD-L1 by the endoplasmic reticulum stress protein GRP78 in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
Triple Negative Breast Neoplasms
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
Triple Negative Breast Neoplasms
Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3.
Triple Negative Breast Neoplasms
Type I? phosphatidylinositol phosphate kinase regulates PD-L1 expression by activating NF-?B.
Triple Negative Breast Neoplasms
Understanding PD-L1 Testing in Breast Cancer: A Practical Approach.
Triple Negative Breast Neoplasms
WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
Triple Negative Breast Neoplasms
[Blocking programmed death-ligand 1 attenuates maturation inhibition of dendritic cells by co-cultured breast cancer cells].
Triple Negative Breast Neoplasms
[Immunohistochemical study of MSI markers in breast cancer].
Triple Negative Breast Neoplasms
[PD-L1 status in breast cancer].
Triple Negative Breast Neoplasms
[The first experience of PD-L1 testing of triple negative breast cancer with marker SP142 in Russia].
Trophoblastic Neoplasms
Analysis of PD-L1 expression in trophoblastic tissues and tumors.
Trophoblastic Neoplasms
PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.
Trophoblastic Neoplasms
Selective killing of choriocarcinoma cells in vitro by trichosanthin, a plant protein purified from root tubers of the Chinese medicinal herb Trichosanthes kirilowii.
Trophoblastic Neoplasms
Studies on the mechanisms of abortion induction by Trichosanthin.
Trypanosomiasis, African
Trypanosoma brucei glycoproteins contain novel giant poly-N-acetyllactosamine carbohydrate chains.
Tuberculosis
BioHealthBase: informatics support in the elucidation of influenza virus host pathogen interactions and virulence.
Tuberculosis
Circulating HLA-DR+CD4+ effector memory T cells resistant to CCR5 and PD-L1 mediated suppression compromise regulatory T cell function in tuberculosis.
Tuberculosis
Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy.
Tuberculosis
FOCAL OR INSULAR NECROSIS PRODUCED BY THE BACILLUS OF TUBERCULOSIS.
Tuberculosis
IL-1?, But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to Mycobacterium tuberculosis.
Tuberculosis
Lower IL-7 Receptor Expression of Monocytes Impairs Antimycobacterial Effector Functions in Patients with Tuberculosis.
Tuberculosis
Morphoproteomics Identifies the Foamy Alveolar Macrophage as an M2 Phenotype with PD-L1 Expression in the Early Lesion of Post-Primary Tuberculosis: Implications for Host Immune Surveillance and Therapy.
Tuberculosis
Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors.
Tuberculosis
PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment.
Tuberculosis
Role played by the programmed death-1-programmed death ligand pathway during innate immunity against Mycobacterium tuberculosis.
Tuberculosis
The characteristic profiles of PD-1 and PD-L1 expressions and dynamic changes during treatment in active tuberculosis.
Tuberculosis, Lymph Node
Comparing the Clinical Performance of the New 19-G ViziShot FLEX and 21- or 22-G ViziShot 2 Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Needles.
Tularemia
A biolayer interferometry-based assay for rapid and highly sensitive detection of biowarfare agents.
Tularemia
Issues in preparedness for biologic terrorism: a perspective for critical care nursing.
Tularemia
Strategies for the prevention of a successful biological warfare aerosol attack.
Tularemia
[Bioterrorism and pathogenic microorganisms].
Typhoid Fever
FOCAL OR INSULAR NECROSIS PRODUCED BY THE BACILLUS OF TUBERCULOSIS.
Typhoid Fever
Foodborne disease in Australia: incidence, notifications and outbreaks. Annual report of the OzFoodNet network, 2002.
ulp1 peptidase deficiency
SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance.
Uremia
Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome.
Ureteral Obstruction
Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Urinary Bladder Neoplasms
A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Urinary Bladder Neoplasms
A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-Like Properties and Invasion in Human Bladder Cancer.
Urinary Bladder Neoplasms
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.
Urinary Bladder Neoplasms
A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Urinary Bladder Neoplasms
Advances in cancer immunology and cancer immunotherapy.
Urinary Bladder Neoplasms
Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis.
Urinary Bladder Neoplasms
Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival.
Urinary Bladder Neoplasms
Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?
Urinary Bladder Neoplasms
Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
Urinary Bladder Neoplasms
Bacillus Calmette-Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer.
Urinary Bladder Neoplasms
BCMab1-Ra, a novel immunotoxin that BCMab1 antibody coupled to Ricin A chain, can eliminate bladder tumor.
Urinary Bladder Neoplasms
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Urinary Bladder Neoplasms
Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumour macrophages partially through interleukin 10.
Urinary Bladder Neoplasms
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Urinary Bladder Neoplasms
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Urinary Bladder Neoplasms
Clinical Factors Predict Atezolizumab Response.
Urinary Bladder Neoplasms
Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC).
Urinary Bladder Neoplasms
Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.
Urinary Bladder Neoplasms
Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.
Urinary Bladder Neoplasms
Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability.
Urinary Bladder Neoplasms
Concordance of PD-L1 expression in matched urothelial bladder cancer specimens.
Urinary Bladder Neoplasms
Concordance study of PD-L1 expression in primary and metastatic bladder carcinomas: comparison of four commonly used antibodies and RNA expression.
Urinary Bladder Neoplasms
Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
Urinary Bladder Neoplasms
Correction to: CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling.
Urinary Bladder Neoplasms
COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells.
Urinary Bladder Neoplasms
CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling.
Urinary Bladder Neoplasms
Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder.
Urinary Bladder Neoplasms
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Urinary Bladder Neoplasms
DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
Urinary Bladder Neoplasms
Effect of lectins on KK-47 bladder cancer cell line.
Urinary Bladder Neoplasms
Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer.
Urinary Bladder Neoplasms
Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin.
Urinary Bladder Neoplasms
Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer.
Urinary Bladder Neoplasms
Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.
Urinary Bladder Neoplasms
First-Line Atezolizumab Effective in Bladder Cancer.
Urinary Bladder Neoplasms
Genentech's PD-L1 agent approved for bladder cancer.
Urinary Bladder Neoplasms
Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
Urinary Bladder Neoplasms
High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy.
Urinary Bladder Neoplasms
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Urinary Bladder Neoplasms
Immune checkpoints and their inhibition in cancer and infectious diseases.
Urinary Bladder Neoplasms
Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder.
Urinary Bladder Neoplasms
Impact of Neoadjuvant Chemotherapy on Concordance of PD-L1 Staining Fidelity between the Primary Tumor and Lymph Node Metastases in Bladder Cancer.
Urinary Bladder Neoplasms
Increased expression levels of Syntaxin 1A and Synaptobrevin 2/Vesicle-Associated Membrane Protein-2 are associated with the progression of bladder cancer.
Urinary Bladder Neoplasms
Increased PD-L1 expression in high-grade bladder cancer with squamous cell differentiation in Bulgarian and French patients' samples.
Urinary Bladder Neoplasms
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients.
Urinary Bladder Neoplasms
Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy.
Urinary Bladder Neoplasms
Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.
Urinary Bladder Neoplasms
Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Urinary Bladder Neoplasms
Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer.
Urinary Bladder Neoplasms
Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer.
Urinary Bladder Neoplasms
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays.
Urinary Bladder Neoplasms
Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
Urinary Bladder Neoplasms
PD-1 and PD-L1 are more highly expressed in high-grade bladder cancer than in low-grade cases: PD-L1 might function as a mediator of stage progression in bladder cancer.
Urinary Bladder Neoplasms
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Urinary Bladder Neoplasms
PD-L1 assessment in urothelial carcinoma: a practical approach.
Urinary Bladder Neoplasms
PD-L1 expression and clinical outcomes in patients with advanced urothelial carcinoma treated with checkpoint inhibitors: A meta-analysis.
Urinary Bladder Neoplasms
PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
Urinary Bladder Neoplasms
PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy.
Urinary Bladder Neoplasms
PD-L1 expression in bladder cancer: Which scoring algorithm in what tissue?
Urinary Bladder Neoplasms
PD-L1 expression in human cancers and its association with clinical outcomes.
Urinary Bladder Neoplasms
PD-L1 expression in tumor cells and the immunologic milieu of bladder carcinomas: a pathologic review of 165 cases.
Urinary Bladder Neoplasms
PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy.
Urinary Bladder Neoplasms
PD-L1 expression in tumour buds of colorectal carcinoma.
Urinary Bladder Neoplasms
PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays.
Urinary Bladder Neoplasms
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Urinary Bladder Neoplasms
PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.
Urinary Bladder Neoplasms
PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium.
Urinary Bladder Neoplasms
Positive Ki-67 and PD-L1 expression in post-neoadjuvant chemotherapy muscle-invasive bladder cancer is associated with shorter overall survival: a retrospective study.
Urinary Bladder Neoplasms
Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy.
Urinary Bladder Neoplasms
Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis.
Urinary Bladder Neoplasms
Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
Urinary Bladder Neoplasms
Prognostic significance of the Ki67 index and programmed death-ligand 1 expression after radical cystectomy in patients with muscle-invasive bladder cancer.
Urinary Bladder Neoplasms
Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma.
Urinary Bladder Neoplasms
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
Urinary Bladder Neoplasms
Programmed Death-Ligand 1 Expression in Muscle-Invasive Bladder Cancer Cystectomy Specimens and Lymph Node Metastasis: A Reliable Treatment Selection Biomarker?
Urinary Bladder Neoplasms
Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression.
Urinary Bladder Neoplasms
Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.
Urinary Bladder Neoplasms
Re: Pooja Ghatalia, Matthew Zibelman, Daniel M. Geynisman, Elizabeth Plimack. Approved Checkpoint Inhibitors in Bladder Cancer: Which Drug Should Be Used When? Ther Adv Med Oncol 2018;10:1758835918788310: Knowing PD-L1 Status is Not Enough: Applying a Molecular Subtype Approach to Bladder Cancer is Also Needed.
Urinary Bladder Neoplasms
Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy.
Urinary Bladder Neoplasms
RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis.
Urinary Bladder Neoplasms
Role of Checkpoint Inhibition in Localized Bladder Cancer.
Urinary Bladder Neoplasms
Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Urinary Bladder Neoplasms
Role of immunotherapy in bladder cancer.
Urinary Bladder Neoplasms
Role of Ki-67, MRE11, and PD-L1 as Predictive Biomarkers for Recurrence Pattern in Muscle-invasive Bladder Cancer.
Urinary Bladder Neoplasms
RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Urinary Bladder Neoplasms
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
Urinary Bladder Neoplasms
Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates.
Urinary Bladder Neoplasms
Sexual Dimorphism in Outcomes of Non-muscle-invasive Bladder Cancer: A Role of CD163+ Macrophages, B cells, and PD-L1 Immune Checkpoint.
Urinary Bladder Neoplasms
Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.
Urinary Bladder Neoplasms
Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Urinary Bladder Neoplasms
Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.
Urinary Bladder Neoplasms
The elevated glutaminolysis of bladder cancer and T cells in a simulated tumor microenvironment contributes to the up-regulation of PD-L1 expression by interferon-?.
Urinary Bladder Neoplasms
The emerging role of immunotherapy in advanced urothelial cancers.
Urinary Bladder Neoplasms
The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.
Urinary Bladder Neoplasms
The prognostic significance of PD-L1 in bladder cancer.
Urinary Bladder Neoplasms
The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette-Guérin immunotherapy: Current status.
Urinary Bladder Neoplasms
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder.
Urinary Bladder Neoplasms
The role of genetic polymorphism within PD-L1 gene in cancer. Review.
Urinary Bladder Neoplasms
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Urinary Bladder Neoplasms
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer.
Urinary Bladder Neoplasms
The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.
Urinary Bladder Neoplasms
Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Urinary Bladder Neoplasms
Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.
Urinary Bladder Neoplasms
Toxicity of ribosome-inactivating proteins-containing immunotoxins to a human bladder carcinoma cell line.
Urinary Bladder Neoplasms
Unusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancer.
Urinary Bladder Neoplasms
Using adaptive genetic algorithms combined with high sensitivity single cell-based technology to detect bladder cancer in urine and provide a potential noninvasive marker for response to anti-PD1 immunotherapy.
Urinary Bladder Neoplasms
[Immunohistochemical study of the MSI phenotype of urothelial bladder cancer].
Urinary Tract Infections
Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection.
Urinary Tract Infections
Comparative phenotypic characterization of hybrid Shiga toxin-producing / uropathogenic Escherichia coli, canonical uropathogenic and Shiga toxin-producing Escherichia coli.
Urologic Diseases
Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder.
Uterine Cervical Neoplasms
'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment.
Uterine Cervical Neoplasms
A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers.
Uterine Cervical Neoplasms
A novel dendritic cell targeting HPV16 E7 synthetic vaccine in combination with PD-L1 blockade elicits therapeutic antitumor immunity in mice.
Uterine Cervical Neoplasms
Analysis of radiotherapy-induced alteration of CD8+ T cells and PD-L1 expression in patients with uterine cervical squamous cell carcinoma.
Uterine Cervical Neoplasms
Changes of CD68, CD163, and PD-L1 tumor expression during high-dose-rate and pulsed-dose-rate brachytherapy for cervical cancer.
Uterine Cervical Neoplasms
Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types.
Uterine Cervical Neoplasms
Clinical significance of PD-L1 (CD274) enhanced expression in cervical squamous cell carcinoma.
Uterine Cervical Neoplasms
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data.
Uterine Cervical Neoplasms
Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
Uterine Cervical Neoplasms
Correction: Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
Uterine Cervical Neoplasms
Corrigendum to "IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway" [Biomed. Pharmacother. 123 (2020) 109790].
Uterine Cervical Neoplasms
CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways.
Uterine Cervical Neoplasms
Diagnostic Value of Vaginal Microecology, Serum miR-18a, and PD-L1 for Identifying HPV-Positive Cervical Cancer.
Uterine Cervical Neoplasms
Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway.
Uterine Cervical Neoplasms
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial.
Uterine Cervical Neoplasms
Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells.
Uterine Cervical Neoplasms
Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.
Uterine Cervical Neoplasms
Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity.
Uterine Cervical Neoplasms
Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer.
Uterine Cervical Neoplasms
Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.
Uterine Cervical Neoplasms
Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression.
Uterine Cervical Neoplasms
Expressions of programmed death (PD)-1 and PD-1 ligand (PD-L1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status.
Uterine Cervical Neoplasms
Genome-Wide Profiling of Human Papillomavirus DNA Integration into Human Genome and Its Influence on PD-L1 Expression in Chinese Uygur Cervical Cancer Women.
Uterine Cervical Neoplasms
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.
Uterine Cervical Neoplasms
Genomic stratification based on radiosensitivity and PD-L1 for tailoring therapeutic strategies in cervical cancer.
Uterine Cervical Neoplasms
Identifying Rational Candidates for Immunotherapy Targeting PD-1/PD-L1 in Cervical Cancer.
Uterine Cervical Neoplasms
IFI16 promotes cervical cancer progression by upregulating PD-L1 in immunomicroenvironment through STING-TBK1-NF-kB pathway.
Uterine Cervical Neoplasms
Immune checkpoint inhibitors in the treatment of cancer.
Uterine Cervical Neoplasms
Increase in cytosolic calcium maintains plasma membrane integrity through the formation of microtubule ring structure in apoptotic cervical cancer cells induced by trichosanthin.
Uterine Cervical Neoplasms
Induction of antitumor immunity against cervical cancer by protein HPV-16 E7 in fusion with ricin B chain in tumor-bearing mice.
Uterine Cervical Neoplasms
LINC00116 enhances cervical cancer tumorigenesis through miR-106a/c-Jun pathway.
Uterine Cervical Neoplasms
LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer.
Uterine Cervical Neoplasms
Mechanism of ricin-induced apoptosis in human cervical cancer cells.
Uterine Cervical Neoplasms
MiR-374b increases the CIK expression and mediates biological function changes in cervical cancer cells by targeting the PD-1/PD-L1 signaling pathway.
Uterine Cervical Neoplasms
Mixed and nonvaccine high risk HPV types are associated with higher mortality in Black women with cervical cancer.
Uterine Cervical Neoplasms
Morphological changes of ricin toxin-induced apoptosis in human cervical cancer cells.
Uterine Cervical Neoplasms
Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.
Uterine Cervical Neoplasms
Pattern of disease and response to pembrolizumab in recurrent cervical cancer.
Uterine Cervical Neoplasms
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
Uterine Cervical Neoplasms
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Uterine Cervical Neoplasms
PD-L1 Expression Correlates With Tumor Infiltrating Lymphocytes And Response To Neoadjuvant Chemotherapy In Cervical Cancer.
Uterine Cervical Neoplasms
PD-L1 Expression Correlates With Young Age and CD8+ TIL Density in Poorly Differentiated Cervical Squamous Cell Carcinoma.
Uterine Cervical Neoplasms
PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
Uterine Cervical Neoplasms
PD-L1 protein expression and copy number gains in HIV-positive locally advanced cervical cancer.
Uterine Cervical Neoplasms
PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Uterine Cervical Neoplasms
Pembrolizumab for advanced cervical cancer: safety and efficacy.
Uterine Cervical Neoplasms
Pembrolizumab OK'd for Cervical Cancer.
Uterine Cervical Neoplasms
Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research.
Uterine Cervical Neoplasms
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.
Uterine Cervical Neoplasms
Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy.
Uterine Cervical Neoplasms
Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.
Uterine Cervical Neoplasms
PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.
Uterine Cervical Neoplasms
Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Uterine Cervical Neoplasms
Prognostic significance of PD-L1 protein expression and copy number gains in locally advanced cervical cancer.
Uterine Cervical Neoplasms
Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin ?4/SNAI1/SIRT3 signaling pathway.
Uterine Cervical Neoplasms
Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study.
Uterine Cervical Neoplasms
Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Uterine Cervical Neoplasms
Smac is another pathway in the anti-tumour activity of Trichosanthin and reverses Trichosanthin resistance in CaSki cervical cancer cells.
Uterine Cervical Neoplasms
Synergistic anti-tumor effect of anti-PD-L1 antibody cationic microbubbles for delivery of the miR-34a gene combined with ultrasound on cervical carcinoma.
Uterine Cervical Neoplasms
Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout.
Uterine Cervical Neoplasms
The co-expression of CBX8 and PD-L1 and prognostic value in cervical cancer.
Uterine Cervical Neoplasms
The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Uterine Cervical Neoplasms
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Uterine Cervical Neoplasms
The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.
Uterine Cervical Neoplasms
The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies.
Uterine Cervical Neoplasms
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.
Uterine Cervical Neoplasms
Trichosanthin inhibits cervical cancer by regulating oxidative stress-induced apoptosis.
Uterine Cervical Neoplasms
Trichosanthin inhibits DNA methyltransferase and restores methylation-silenced gene expression in human cervical cancer cells.
Uterine Cervical Neoplasms
Trichosanthin inhibits the proliferation of cervical cancer cells and downregulates STAT-5/C-myc signaling pathway.
Uterine Cervical Neoplasms
Tumor-Associated CD163+ M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer.
Uterine Cervical Neoplasms
Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment.
Uterine Cervical Neoplasms
Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy.
Uterine Cervical Neoplasms
Usnic acid suppresses cervical cancer cell proliferation by inhibiting PD-L1 expression and enhancing T-lymphocyte tumor-killing activity.
Uterine Cervical Neoplasms
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
Uterine Cervical Neoplasms
[Effect of recombinant trichosanthin on proliferation of human cevical cancer Caski cells].
Uterine Cervical Neoplasms
[The Clinical Significance of HPV L1/PD-L1 Tests Combined with Colposcopy for Cervical Precancerous Lesions and Cervical Cancer].
Uterine Cervicitis
[The Clinical Significance of HPV L1/PD-L1 Tests Combined with Colposcopy for Cervical Precancerous Lesions and Cervical Cancer].
Uveitis
Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition.
Vaccinia
By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
Vaccinia
Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check.
Vaccinia
Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library.
Vaccinia
Optical microchip array biosensor for multiplexed detection of bio-hazardous agents.
Vaccinia
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy.
Vaccinia
Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.
Vascular Diseases
Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome.
Vasculitis
Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection.
Vasculitis
Effects of Escherichia coli Shiga-like toxins (verotoxins) in pigs.
Vasculitis
Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a Tox- mutant of Shigella dysenteriae 1.
Vasculitis
The immunoinhibitory PD-1/PD-L1 pathway in inflammatory blood vessel disease.
Vasospasm, Intracranial
PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage.
Vesicular Stomatitis
A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection.
Vesicular Stomatitis
A single mutation in Chinese hamster ovary cells impairs both Golgi and endosomal functions.
Vesicular Stomatitis
A subclass of cell surface carbohydrates revealed by a CHO mutant with two glycosylation mutations.
Vesicular Stomatitis
Estimation of the amount of internalized ricin that reaches the trans-Golgi network.
Vesicular Stomatitis
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
Vesicular Stomatitis
Quantitative interaction of Ricinus communis agglutinin and concanavalin A with influenza and vesicular stomatitis viruses and virus-infected normal and polyoma-transformed cells.
Vesicular Stomatitis
Roles of ARFRP1 (ADP-ribosylation factor-related protein 1) in post-Golgi membrane trafficking.
Vesicular Stomatitis
Selective effects of calcium chelators on anterograde and retrograde protein transport in the cell.
Vesicular Stomatitis
Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures.
Viremia
Major depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV disease.
Viremia
PD-1 and its ligand PD-L1 are progressively up-regulated on CD4 and CD8 T-cells in HIV-2 infection irrespective of the presence of viremia.
Viremia
PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia.
Viremia
Responsiveness of HIV-specific CD4 T cells to PD-1 blockade.
Viremia
Successful Vaccination Induces Multifunctional Memory T-Cell Precursors Associated With Early Control of Hepatitis C Virus.
Virus Diseases
Alpha-momorcharin enhances Nicotiana benthamiana resistance to tobacco mosaic virus infection through modulation of reactive oxygen species.
Virus Diseases
Atypical hemolytic uremic syndrome triggered by varicella infection.
Virus Diseases
Broad-spectrum virus resistance in transgenic plants expressing pokeweed antiviral protein.
Virus Diseases
C-terminal deletion mutant of pokeweed antiviral protein inhibits viral infection but does not depurinate host ribosomes.
Virus Diseases
CD4 T Cell Depletion Substantially Augments the Rescue Potential of PD-L1 Blockade for Deeply Exhausted CD8 T Cells.
Virus Diseases
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance.
Virus Diseases
Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma.
Virus Diseases
Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma.
Virus Diseases
Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.
Virus Diseases
Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection.
Virus Diseases
Correction: PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+ T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+ T Cells.
Virus Diseases
Correlation between the activities of five ribosome-inactivating proteins in depurination of tobacco ribosomes and inhibition of tobacco mosaic virus infection.
Virus Diseases
Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system.
Virus Diseases
Expression and secretion of Mirabilis antiviral protein in Escherichia coli and its inhibition of in vitro eukaryotic and prokaryotic protein synthesis.
Virus Diseases
Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1.
Virus Diseases
IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection.
Virus Diseases
Increase of cells expressing PD-L1 in bovine leukemia virus infection and enhancement of anti-viral immune responses in vitro via PD-L1 blockade.
Virus Diseases
Inhibition of herpes simplex virus DNA synthesis by pokeweed antiviral protein.
Virus Diseases
Inhibition of HIV-1 Replication by Balsamin, a Ribosome Inactivating Protein of Momordica balsamina.
Virus Diseases
Inhibition of Japanese encephalitis virus infection in vitro and in vivo by pokeweed antiviral protein.
Virus Diseases
Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism.
Virus Diseases
Lipidoid Nanoparticles Containing PD-L1 siRNA Delivered In Vivo Enter Kupffer Cells and Enhance NK and CD8(+) T Cell-mediated Hepatic Antiviral Immunity.
Virus Diseases
Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy.
Virus Diseases
Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells.
Virus Diseases
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.
Virus Diseases
New developments in the management of head and neck cancer - impact of pembrolizumab.
Virus Diseases
Oncolytic poxvirus CF33-hNIS-?F14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Virus Diseases
Overcoming CD4 Th1 Cell Fate Restrictions to Sustain Antiviral CD8 T Cells and Control Persistent Virus Infection.
Virus Diseases
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration.
Virus Diseases
PD-1 and its ligands in T-cell immunity.
Virus Diseases
PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells.
Virus Diseases
PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Virus Diseases
PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell response.
Virus Diseases
PD-L1 expression is increased in monocyte derived dendritic cells in response to porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus infections.
Virus Diseases
PD-L1 has distinct functions in hematopoietic and nonhematopoietic cells in regulating T cell responses during chronic infection in mice.
Virus Diseases
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.
Virus Diseases
Plant Ribosome-Inactivating Proteins: Progesses, Challenges and Biotechnological Applications (and a Few Digressions).
Virus Diseases
Pokeweed antiviral protein: ribosome inactivation and therapeutic applications.
Virus Diseases
Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma.
Virus Diseases
Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells in vitro.
Virus Diseases
Pulmonary endothelium-derived PD-L1 induced by the H9N2 avian influenza virus inhibits the immune response of T cells.
Virus Diseases
Relationship of programmed death ligand-1 expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma: A meta-analysis.
Virus Diseases
Role of Matrix Metallopeptidase 12 in the Development of Hepatocellular Carcinoma.
Virus Diseases
Rotavirus infection of MA104 cells is inhibited by Ricinus lectin and separately expressed single binding domains.
Virus Diseases
Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.
Virus Diseases
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Virus Diseases
The PD-1/PD-L1 Axis and Virus Infections: A Delicate Balance.
Virus Diseases
The PD-1: PD-L1 pathway promotes development of brain-resident memory T cells following acute viral encephalitis.
Virus Diseases
The PD-L1/CD86 ratio is increased in dendritic cells co-infected with porcine circovirus type 2 and porcine reproductive and respiratory syndrome virus, and the PD-L1/PD-1 axis is associated with anergy, apoptosis, and the induction of regulatory T-cells in porcine lymphocytes.
Virus Diseases
Tissue-specific differences in PD-1 and PD-L1 expression during chronic viral infection: implications for CD8 T-cell exhaustion.
Vitiligo
PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin.
Vitiligo
Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo.
Vitreoretinopathy, Proliferative
Selective inhibition of growing pigment epithelial cells by a receptor-directed immunotoxin.
Vitreoretinopathy, Proliferative
The antiproliferative effect of a transferrin-toxin on human retinal pigment epithelial cells and rabbit fibroblasts.
Vulvar Neoplasms
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.
Vulvar Neoplasms
Looking past PD-L1: expression of immune checkpoint TIM-3 and its ligand galectin-9 in cervical and vulvar squamous neoplasia.
Vulvar Neoplasms
PD-L1 receptor expression in vulvar carcinomas is HPV-independent.
Vulvar Neoplasms
Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology.
Warts
Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts.
Warts
Macrophages participate in the immunosuppression of condyloma acuminatum through the PD-1/PD-L1 signaling pathway.
Waterborne Diseases
Surface water of a perennial river exhibits multi-antimicrobial resistant shiga toxin and enterotoxin producing Escherichia coli.
Whooping Cough
Bacteria and their toxins tamed for immunotherapy.
Whooping Cough
Bacterial type AB? enterotoxins--structure, function and mechanism of action.
Whooping Cough
Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines.
Whooping Cough
Monoclonal antibodies and toxins--a perspective on function and isotype.
Williams Syndrome
Detection of an atypical 7q11.23 deletion in Williams syndrome patients which does not include the STX1A and FZD3 genes.
Williams Syndrome
Intelligence in Williams Syndrome is related to STX1A, which encodes a component of the presynaptic SNARE complex.
Williams Syndrome
Refinement of the genomic structure of STX1A and mutation analysis in nondeletion Williams syndrome patients.
Wilms Tumor
Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells.
Wilms Tumor
EV PD-L1 Contributes to Immunosuppressive CD8+ T Cells in Peripheral Blood of Pediatric Wilms Tumor.
Xeroderma Pigmentosum
Human uracil DNA N-glycosidase: studies in normal and repair defective cultured fibroblasts.
Yellow Fever
The limited knowledge of placental damage due to neglected infections: ongoing problems in Latin America.
Yersinia Infections
Foodborne disease in Australia: incidence, notifications and outbreaks. Annual report of the OzFoodNet network, 2002.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.